PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	ROTHWELL, PM				ROTHWELL, PM			IS THE EVIDENCE FOR HOMEOPATHT REPRODUCIBLE	LANCET			English	Letter											ROTHWELL, PM (corresponding author), WESTERN GEN HOSP, DEPT CLIN NEUROSCI, CREWE RD, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.		Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211				REILLY D, 1994, LANCET, V344, P1601, DOI 10.1016/S0140-6736(94)90407-3	1	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 28	1995	345	8944					251	251		10.1016/S0140-6736(95)90246-5	http://dx.doi.org/10.1016/S0140-6736(95)90246-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7734017				2022-12-28	WOS:A1995QD53200030
J	KAHN, MF				KAHN, MF			IS THE EVIDENCE FOR HOMEOPATHT REPRODUCIBLE	LANCET			English	Letter											KAHN, MF (corresponding author), HOP BICHAT, SERV RHUMATOL, 46 RUE HENRI HUCHARD, F-75018 PARIS, FRANCE.		Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211				MAYAUX MJ, 1988, LANCET, V1, P528; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157	2	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 28	1995	345	8944					251	251		10.1016/S0140-6736(95)90246-5	http://dx.doi.org/10.1016/S0140-6736(95)90246-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7734017				2022-12-28	WOS:A1995QD53200032
J	AULAS, JJ				AULAS, JJ			IS THE EVIDENCE FOR HOMEOPATHT REPRODUCIBLE	LANCET			English	Letter											AULAS, JJ (corresponding author), REVUE PRESCRIRE, F-75527 PARIS 11, FRANCE.		Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211					0	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 28	1995	345	8944					251	251		10.1016/S0140-6736(95)90246-5	http://dx.doi.org/10.1016/S0140-6736(95)90246-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7734017				2022-12-28	WOS:A1995QD53200031
J	ALLABY, MAK				ALLABY, MAK			CONTRACEPTIVE SERVICES FOR TEENAGERS - DO WE NEED FAMILY-PLANNING CLINICS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine whether the effectiveness of contraceptive services for teenagers is related to the balance of service provision between general practitioners and specialist family planning services. Design-Cross sectional study with routinely collected data from family planning clinics and family health services authorities and published data on births and abortions. Setting-Eight health districts in the former Oxford region. Subjects-Girls aged under 16 and women aged 16-19 who attended a contraceptive service during 1991-2 or who gave birth or had an abortion during 1990-2. Main outcome measures-Attenders at family planning clinics as a percentage of all users of contraceptive services. The conception rate:uptake of contraceptive services ratio was used as a measure of effectiveness. Results-In comparisons between districts the percentage of all users of contraceptive services who attended a clinic varied fi om 38% (95% confidence interval 28% to 48%) to 79% (72% to 86%) among 13-15 year olds and from 14% (12% to 15%) to 44% (42% to 46%) among women aged 16-19 years. The conception rate:uptake of contraceptive services ratio varied twofold in the older age group and more than threefold in the younger age group. It was lowest in districts where clinic attenders comprised a large percentage of all users of contraceptive services. Conclusion-Contraceptive services for teenagers may be more effective in districts where clinics play a large part in delivering the service, particularly for girls aged under 16.			ALLABY, MAK (corresponding author), NORTHAMPTONSHIRE HLTH AUTHOR,DEPT PUBL HLTH MED,NORTHAMPTON NN1 5DN,ENGLAND.							ALLEN I, 1991, FAMILY PLANNING PREG; IBBOTSON S, 1992, BRIT MED J, V305, P835, DOI 10.1136/bmj.305.6857.835-b; JARMAN B, 1984, BRIT MED J, V289, P1587, DOI 10.1136/bmj.289.6458.1587; ROXBY M, 1992, HLTH NEEDS ASSESSMEN; SHEPHERD M, 1988, CONSUMER PREFERENCES; 1992, GUIDELINES REVIEWING; 1992, ABORTION STATISTICS; 1992, HLTH NATION STRATEGY; 1992, FM1 OFF POP CENS SUR; 1990, FM1 OFF POP CENS SUR; 1990, ABORTION STATISTICS; 1994, 37 FAC PUBL HLTH MED; 1991, ABORTION STATISTICS; 1991, FM1 OFF POP CENS SUR	14	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 24	1995	310	6995					1641	1643		10.1136/bmj.310.6995.1641	http://dx.doi.org/10.1136/bmj.310.6995.1641			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RF698	7795452	Green Published			2022-12-28	WOS:A1995RF69800024
J	NUNDY, S; BHUTANI, LK; NATH, I; MEHRA, NK; ANTIA, NH				NUNDY, S; BHUTANI, LK; NATH, I; MEHRA, NK; ANTIA, NH			LEPROSY - REPORT OF A MEETING OF PHYSICIANS AND SCIENTISTS AT THE ALL-INDIA-INSTITUTE-OF-MEDICAL-SCIENCES, NEW-DELHI	LANCET			English	Discussion							T-CELL RESPONSES; MYCOBACTERIUM-LEPRAE; LEPROMATOUS LEPROSY; PROTEIN ANTIGENS; INTERLEUKIN-2; MONOCYTES; PROFILES; LESIONS		FDN RES COMMUNITY HLTH, BOMBAY 400018, MAHARASHTRA, INDIA; ALL INDIA INST MED SCI, DEPT DERMATOL & VENEROL, NEW DELHI, INDIA; ALL INDIA INST MED SCI, DEPT HISTOCOMPATIBIL & IMMUNOGENET, NEW DELHI, INDIA; ALL INDIA INST MED SCI, DEPT BIOTECHNOL, NEW DELHI 110029, INDIA	All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi								Antia N H, 1980, Lepr India, V52, P48; ANTIA NH, 1989, HAND, V1, P139; AROLKAR S, IN PRESS LEPR REV; BRITTON WJ, 1993, T ROY SOC TROP MED H, V87, P508, DOI 10.1016/0035-9203(93)90066-Y; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CONVIT J, 1992, LANCET, V339, P446, DOI 10.1016/0140-6736(92)91056-E; KAPALAN G, 1956, P NATL ACAD SCI USA, V86, P8073; KAPLAN G, 1989, J EXP MED, V169, P893, DOI 10.1084/jem.169.3.893; KIKUCHI I, 1986, LEPR REV S, V52, P139; LAAL S, 1991, P NATL ACAD SCI USA, V88, P1054, DOI 10.1073/pnas.88.3.1054; LAAL S, 1985, INFECT IMMUN, V50, P887, DOI 10.1128/IAI.50.3.887-892.1985; MEHRA NK, 1994, HUM IMMUNOL, V39, P202, DOI 10.1016/0198-8859(94)90261-5; MEHRA NK, 1990, TROP MED PARASITOL, V41, P352; MEHRA NK, IN PRESS INT J LEPR; MEHRA V, 1992, J EXP MED, V175, P275, DOI 10.1084/jem.175.1.275; MISRA N, IN PRESS INT J LEPR; MITTAL A, 1989, CLIN EXP IMMUNOL, V76, P233; MUTIS T, 1993, J IMMUNOL, V150, P4641; NARAYANAN RB, 1983, CLIN EXP IMMUNOL, V55, P623; NATH I, 1984, CLIN EXP IMMUNOL, V58, P531; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SAMPAIO EP, 1991, J EXP MED, V173, P699, DOI 10.1084/jem.173.3.699; SELA S, 1991, INFECT IMMUN, V59, P4117, DOI 10.1128/IAI.59.11.4117-4124.1991; SHETTY VP, 1992, LEPROSY REV, V63, P329; SINGH S, 1994, INFECT IMMUN, V62, P86, DOI 10.1128/IAI.62.1.86-90.1994; VANEDEN W, 1980, J INFECT DIS, V141, P1694; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582; YOUNG DB, 1992, MOL MICROBIOL, V6, P133, DOI 10.1111/j.1365-2958.1992.tb01994.x; YOUNG RA, 1985, NATURE, V316, P450, DOI 10.1038/316450a0	29	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 18	1995	345	8951					697	703						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM732	7794340				2022-12-28	WOS:A1995QM73200012
J	HOWARDS, SS				HOWARDS, SS			CURRENT CONCEPTS - TREATMENT OF MALE-INFERTILITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CLOMIPHENE CITRATE; INTRAUTERINE INSEMINATION; VIBRATORY STIMULATION; OLIGOSPERMIC MEN; THERAPY; OLIGOZOOSPERMIA; TAMOXIFEN; PLACEBO; TRIAL; DELTA-1-TESTOLACTONE				HOWARDS, SS (corresponding author), UNIV VIRGINIA HOSP, DEPT UROL, HLTH SCI CTR BOX 422, CHARLOTTESVILLE, VA 22908 USA.							ABEL BJ, 1982, BRIT J UROL, V54, P780, DOI 10.1111/j.1464-410X.1982.tb13647.x; [Anonymous], 1989, Int J Androl, V12, P254; AUGER J, 1995, NEW ENGL J MED, V332, P281, DOI 10.1056/NEJM199502023320501; AULITZKY W, 1989, INT J ANDROL, V12, P265, DOI 10.1111/j.1365-2605.1989.tb01313.x; BECKERMAN H, 1993, PARAPLEGIA, V31, P689, DOI 10.1038/sc.1993.111; BELKER AM, 1987, UROL CLIN N AM, V14, P597; BELKER AM, 1991, J UROLOGY, V145, P505, DOI 10.1016/S0022-5347(17)38381-7; BRIGANTE C, 1985, Acta Europaea Fertilitatis, V16, P361; BRINDLEY GS, 1981, PARAPLEGIA, V19, P299, DOI 10.1038/sc.1981.57; BUVAT J, 1983, FERTIL STERIL, V39, P700; CHARNY CW, 1979, FERTIL STERIL, V32, P551; CHARNY CW, 1978, FERTIL STERIL, V29, P64; CHARNY CW, 1959, FERTIL STERIL, V10, P557; CHEHVAL MJ, 1979, FERTIL STERIL, V31, P666; CLARK RV, 1989, J ANDROL, V10, P240; COLLINS JA, 1993, HUM REPROD, V8, P592, DOI 10.1093/oxfordjournals.humrep.a138102; DEMOUZON J, 1993, FERTIL STERIL, V59, P587; Denil J, 1992, Acta Urol Belg, V60, P15; DODSON WC, 1991, FERTIL STERIL, V55, P457; DONY JMJ, 1986, ANDROLOGIA, V18, P69; FAUSER BCJM, 1985, ANDROLOGIA, V17, P143; FINKEL DM, 1985, NEW ENGL J MED, V313, P651, DOI 10.1056/NEJM198509123131102; FOSS GL, 1973, J REPROD FERTIL, V32, P167; FOWLER JE, 1991, INFERTILITY MALE, P297; HENDRY WF, 1990, LANCET, V335, P85, DOI 10.1016/0140-6736(90)90548-J; HOMONNAI ZT, 1978, GYNECOL OBSTET INVES, V9, P244, DOI 10.1159/000300991; Howards SS, 1992, INFERTIL REPROD MED, V3, P429; JUNGCK EC, 1964, FERTIL STERIL, V15, P40; KEOGH E J, 1976, P452; LAMENSDORF H, 1975, FERTIL STERIL, V26, P469; MARGALIOTH EJ, 1983, FERTIL STERIL, V39, P841; MICIC S, 1985, J UROLOGY, V133, P221, DOI 10.1016/S0022-5347(17)48889-6; NEUMANN PJ, 1994, NEW ENGL J MED, V331, P239, DOI 10.1056/NEJM199407283310406; NEWTON R, 1980, FERTIL STERIL, V34, P399; NOCI I, 1985, ARCH ANDROLOGY, V15, P83, DOI 10.3109/01485018508986896; PALTI Z, 1970, FERTIL STERIL, V21, P838; PAULSON D F, 1977, Urology, V9, P419, DOI 10.1016/0090-4295(77)90220-5; PROCTOR KG, 1983, J UROLOGY, V129, P837, DOI 10.1016/S0022-5347(17)52390-3; PUSCH HH, 1986, ANDROLOGIA, V18, P201; RONNBERG L, 1980, ANDROLOGIA, V12, P261; ROSS LS, 1980, FERTIL STERIL, V33, P618; ROWE PJ, 1992, INT J ANDROL, V15, P299; ROWLEY MJ, 1972, FERTIL STERIL, V23, P498; SCHELLEN TM, 1972, FERTIL STERIL, V23, P712; SCHELLEN TM, 1974, FERTIL STERIL, V25, P407; SCHLEGEL PN, 1993, J UROLOGY, V150, P1165, DOI 10.1016/S0022-5347(17)35715-4; SCHOPOHL J, 1991, FERTIL STERIL, V56, P1143; SCHWARZSTEIN L, 1975, FERTIL STERIL, V26, P331; SOKOL RZ, 1988, FERTIL STERIL, V49, P865; TOROK L, 1985, ANDROLOGIA, V17, P497; ULSTEIN M, 1976, P355; VANDERLINDEN PJQ, 1992, OBSTET GYNECOL, V79, P126; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1061, DOI 10.1093/oxfordjournals.humrep.a138192; VERMEULEN A, 1978, FERTIL STERIL, V29, P320; VIGERSKY RA, 1981, J CLIN ENDOCR METAB, V52, P897, DOI 10.1210/jcem-52-5-897; WANG C, 1983, FERTIL STERIL, V40, P358; ZARATE A, 1973, FERTIL STERIL, V24, P485; 1991, FERTIL STERIL, V59, P956	58	71	74	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 2	1995	332	5					312	317		10.1056/NEJM199502023320507	http://dx.doi.org/10.1056/NEJM199502023320507			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD396	7816068				2022-12-28	WOS:A1995QD39600030
J	MERCADOASIS, LB; OLDFIELD, EH; CUTLER, GB				MERCADOASIS, LB; OLDFIELD, EH; CUTLER, GB			PITUITARY-TUMOR HEMORRHAGE IN CUSHING DISEASE	ANNALS OF INTERNAL MEDICINE			English	Note							APOPLEXY		NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA								AHMED M, 1989, HORM RES, V31, P125, DOI 10.1159/000181101; ARAFAH BM, 1990, J CLIN ENDOCR METAB, V71, P323, DOI 10.1210/jcem-71-2-323; CARDOSO ER, 1984, NEUROSURGERY, V14, P363, DOI 10.1227/00006123-198403000-00021; MOHR G, 1982, SURG NEUROL, V18, P181, DOI 10.1016/0090-3019(82)90388-3; ONESTI ST, 1990, NEUROSURGERY, V26, P980, DOI 10.1227/00006123-199006000-00010; PELKONEN R, 1978, AM J MED, V65, P773, DOI 10.1016/0002-9343(78)90795-7; REID RL, 1985, ARCH NEUROL-CHICAGO, V42, P712, DOI 10.1001/archneur.1985.04060070106028; ROVIT RL, 1965, J NEUROSURG, V23, P270, DOI 10.3171/jns.1965.23.3.0270; ROVIT RL, 1972, J NEUROSURG, V37, P280, DOI 10.3171/jns.1972.37.3.0280; SCHULTE HM, 1985, HORM RES, V21, P69, DOI 10.1159/000180028; Veldhuis J D, 1980, Endocr Rev, V1, P100; WAKAI S, 1981, J NEUROSURG, V55, P187, DOI 10.3171/jns.1981.55.2.0187	12	9	9	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	FEB 1	1995	122	3					189	190		10.7326/0003-4819-122-3-199502010-00006	http://dx.doi.org/10.7326/0003-4819-122-3-199502010-00006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD733	7810937				2022-12-28	WOS:A1995QD73300006
J	SHEARER, MJ				SHEARER, MJ			VITAMIN-K	LANCET			English	Article							BONE GLA PROTEIN; ELDERLY WOMEN; CIRCULATING LEVELS; HIP FRACTURE; PHYLLOQUINONE; OSTEOCALCIN; DEFICIENCY; MENAQUINONE-9; MAINTENANCE; PROPHYLAXIS				SHEARER, MJ (corresponding author), ST THOMAS HOSP, CTR HAEMOPHILIA, LONDON SE1 7EH, ENGLAND.		Shearer, Martin/GWZ-2085-2022					Booth Sarah L., 1993, Journal of Food Composition and Analysis, V6, P109, DOI 10.1006/jfca.1993.1014; CONLY JM, 1992, AM J GASTROENTEROL, V87, P311; CORNELISSEN EAM, 1992, ARCH DIS CHILD, V67, P1250, DOI 10.1136/adc.67.10.1250; CROUCHER C, 1994, BRIT MED J, V308, P894, DOI 10.1136/bmj.308.6933.894; DRAPER G, 1994, BRIT MED J, V308, P867, DOI 10.1136/bmj.308.6933.867; FERLAND G, 1993, J CLIN INVEST, V91, P1761, DOI 10.1172/JCI116386; FERLAND G, 1992, J AM DIET ASSOC, V92, P593; FIORE CE, 1990, SOUTH MED J, V83, P538, DOI 10.1097/00007611-199005000-00013; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; HANAWA Y, 1988, EUR J PEDIATR, V147, P472, DOI 10.1007/BF00441969; HART JP, 1985, J CLIN ENDOCR METAB, V60, P1268, DOI 10.1210/jcem-60-6-1268; Hathaway W E, 1987, Hematol Oncol Clin North Am, V1, P367; HODGES SJ, 1993, J BONE MINER RES, V8, P1005; HODGES SJ, 1993, J BONE MINER RES, V8, P1241; ICHIHASHI T, 1992, J NUTR, V122, P506, DOI 10.1093/jn/122.3.506; KNAPEN MHJ, 1989, ANN INTERN MED, V111, P1001, DOI 10.7326/0003-4819-111-12-1001; KNAPEN MHJ, 1993, CALCIFIED TISSUE INT, V53, P81, DOI 10.1007/BF01321883; LOUGHNAN PM, 1993, J PAEDIATR CHILD H, V29, P177, DOI 10.1111/j.1440-1754.1993.tb00480.x; MAILLARD C, 1992, ENDOCRINOLOGY, V130, P1599, DOI 10.1210/en.130.3.1599; PAULI RM, 1987, AM J HUM GENET, V41, P566; PLANTALECH L, 1991, J BONE MINER RES, V6, P1211; ROSEN HN, 1993, AM J MED, V94, P62, DOI 10.1016/0002-9343(93)90121-5; SADOWSKI JA, 1989, AM J CLIN NUTR, V50, P100, DOI 10.1093/ajcn/50.1.100; SAUPE J, 1993, AM J CLIN NUTR, V58, P204, DOI 10.1093/ajcn/58.2.204; SCHUBIGER G, 1993, J PEDIATR GASTR NUTR, V16, P435, DOI 10.1097/00005176-199305000-00016; SHEARER MJ, 1992, BLOOD REV, V6, P92, DOI 10.1016/0268-960X(92)90011-E; SZULC P, 1994, J BONE MINER RES, V9, P1591; SZULC P, 1993, J CLIN INVEST, V91, P1769, DOI 10.1172/JCI116387; THIJSSEN HHW, 1994, BRIT J NUTR, V72, P415, DOI 10.1079/BJN19940043; TRIFFITT JT, 1987, CLIN SCI, V72, P399, DOI 10.1042/cs0720399; USUI Y, 1990, AM J CLIN NUTR, V51, P846, DOI 10.1093/ajcn/51.5.846; VONKRIES R, 1993, THROMB HAEMOSTASIS, V69, P293; WILL BH, 1992, J NUTR, V122, P953, DOI 10.1093/jn/122.4.953; 1991, 41 DEP HLTH REP	34	357	376	0	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 28	1995	345	8944					229	234		10.1016/S0140-6736(95)90227-9	http://dx.doi.org/10.1016/S0140-6736(95)90227-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7823718				2022-12-28	WOS:A1995QD53200013
J	CHANG, MW; BARR, E; SELTZER, J; JIANG, YQ; NABEL, GJ; NABEL, EG; PARMACEK, MS; LEIDEN, JM				CHANG, MW; BARR, E; SELTZER, J; JIANG, YQ; NABEL, GJ; NABEL, EG; PARMACEK, MS; LEIDEN, JM			CYTOSTATIC GENE-THERAPY FOR VASCULAR PROLIFERATIVE DISORDERS WITH A CONSTITUTIVELY ACTIVE FORM OF THE RETINOBLASTOMA GENE-PRODUCT	SCIENCE			English	Article							MUSCLE CELL-PROLIFERATION; TRANSCRIPTION FACTOR; CYCLE; ATHEROSCLEROSIS; RESTENOSIS; PROTEIN; P53; OLIGONUCLEOTIDES; BINDING; INJURY	Vascular smooth muscle cell (SMC) proliferation in response to injury is an important etiologic factor in vascular proliferative disorders such as atherosclerosis and restenosis after balloon angioplasty. The retinoblastoma gene product (Rb) is present in the unphosphorylated and active form in quiescent primary arterial SMCs, but is rapidly inactivated by phosphorylation in response to growth factor stimulation in vitro, A replication-defective adenovirus encoding a nonphosphorylatable, constitutively active form of Rb was constructed. Infection of cultured primary rat aortic SMCs with this virus inhibited growth factor-stimulated cell proliferation in vitro. Localized arterial infection with the virus at the time of balloon angioplasty significantly reduced SMC proliferation and neointima formation in both the rat carotid and porcine femoral artery models of restenosis, These results demonstrate the role of Rb in regulating vascular SMC proliferation and suggest a gene therapy approach for vascular proliferative disorders associated with arterial injury.	UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PATHOL, CHICAGO, IL 60637 USA; UNIV MICHIGAN, MED CTR, DEPT MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA	University of Chicago; University of Chicago; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan				Parmacek, Michael/0000-0003-1449-4665				BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARR E, 1994, GENE THER, V1, P51; BARR E, 1994, TRENDS CARDIOVAS MED, V4, P57, DOI 10.1016/1050-1738(94)90010-8; BLANK RS, 1988, J CELL BIOL, V107, P299, DOI 10.1083/jcb.107.1.299; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; Chang M.-W., UNPUB; CHANG MW, IN PRESS MOL MED; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CLOWES AW, 1983, LAB INVEST, V49, P327; COHEN AJ, 1990, AIDS, V4, P807, DOI 10.1097/00002030-199008000-00014; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EPSTEIN SE, 1993, CIRCULATION, V88, P1351, DOI 10.1161/01.CIR.88.3.1351; FAULDS D, 1990, DRUGS, V39, P597, DOI 10.2165/00003495-199039040-00008; FINGERLE J, 1989, P NATL ACAD SCI USA, V86, P8412, DOI 10.1073/pnas.86.21.8412; FORRESTER JS, 1991, J AM COLL CARDIOL, V17, P758, DOI 10.1016/S0735-1097(10)80196-2; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GUZMAN LA, 1994, CIRCULATION, V90, P147; GUZMAN PJ, 1993, CIRCULATION, V88, P2838, DOI 10.1161/01.CIR.88.6.2838; GUZMAN RJ, 1994, P NATL ACAD SCI USA, V91, P10732, DOI 10.1073/pnas.91.22.10732; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; IP JH, 1990, J AM COLL CARDIOL, V15, P1667, DOI 10.1016/0735-1097(90)92845-S; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KARPINSKI BA, 1989, MOL CELL BIOL, V9, P2588, DOI 10.1128/MCB.9.6.2588; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KIM DW, 1993, GENE, V134, P307; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KOZARSKY K, 1993, SOMAT CELL MOLEC GEN, V19, P449, DOI 10.1007/BF01233250; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LIBBY P, 1992, CIRCULATION, V86, P47; LINDNER V, 1992, J CLIN INVEST, V90, P2044, DOI 10.1172/JCI116085; LIU MW, 1989, CIRCULATION, V79, P1374, DOI 10.1161/01.CIR.79.6.1374; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; OHNO T, 1994, SCIENCE, V265, P781, DOI 10.1126/science.8047883; OWENS GK, 1986, J CELL BIOL, V102, P343, DOI 10.1083/jcb.102.2.343; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; PRESCOTT MF, 1991, AM J PATHOL, V139, P139; REITMAN JS, 1982, ATHEROSCLEROSIS, V43, P119, DOI 10.1016/0021-9150(82)90104-6; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHWARTZ RS, 1992, J AM COLL CARDIOL, V20, P1284, DOI 10.1016/0735-1097(92)90389-5; SIMON RH, 1993, HUM GENE THER, V4, P771, DOI 10.1089/hum.1993.4.6-771; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; TRIPATHY SK, 1994, P NATL ACAD SCI USA, V91, P11557, DOI 10.1073/pnas.91.24.11557; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINER BH, 1985, CIRCULATION, V72, P1081, DOI 10.1161/01.CIR.72.5.1081; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480	57	417	455	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	1995	267	5197					518	522		10.1126/science.7824950	http://dx.doi.org/10.1126/science.7824950			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD403	7824950				2022-12-28	WOS:A1995QD40300040
J	BARNETT, HJM; ELIASZIW, M; MELDRUM, HE				BARNETT, HJM; ELIASZIW, M; MELDRUM, HE			DRUG-THERAPY - DRUGS AND SURGERY IN THE PREVENTION OF ISCHEMIC STROKE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							NONRHEUMATIC ATRIAL-FIBRILLATION; ASYMPTOMATIC CAROTID STENOSIS; CORONARY-ARTERY BYPASS; RANDOMIZED TRIAL; CEREBRAL-ISCHEMIA; SECONDARY PREVENTION; CEREBROVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; THROMBOEMBOLIC STROKE; ACETYLSALICYLIC-ACID		UNIV WESTERN ONTARIO, DEPT CLIN NEUROL SCI, LONDON, ON, CANADA; UNIV WESTERN ONTARIO, DEPT EPIDEMIOL & BIOSTAT, LONDON, ON, CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario)	BARNETT, HJM (corresponding author), JOHN P ROBARTS RES INST, 100 PERTH DR, POB 5015, LONDON, ON N6A 5K8, CANADA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024456] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS-24456] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACHESON J, 1969, BMJ-BRIT MED J, V1, P614, DOI 10.1136/bmj.1.5644.614; ACKERMAN RH, 1990, ANN NEUROL, V28, P224; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ANDERSON DC, 1992, ANN INTERN MED, V116, P1, DOI 10.7326/0003-4819-116-1-1; [Anonymous], 1989, Stroke, V20, P844; [Anonymous], 1990, Stroke, V21, P1122; [Anonymous], 1985, Stroke, V16, P406; [Anonymous], 1988, BRIT MED J, V296, P320; [Anonymous], 1994, Lancet, V343, P499; [Anonymous], 1991, Lancet, V338, P1345; ANTONOV AS, 1992, THROMB RES, V67, P135, DOI 10.1016/0049-3848(92)90133-U; ARRAIZ G, 1989, CHRONIC DIS CAN, V10, P25; ASHBY M, 1963, BRIT MED J, P894; BARNETT HJM, 1993, STROKE, V24, P1281, DOI 10.1161/01.STR.24.9.1281; BARNETT HJM, 1985, NEW ENGL J MED, V313, P1191, DOI 10.1056/nejm198511073131904; BARNETT HJM, 1990, STROKE, V21, P40; BONITA R, 1993, STROKE POPULATIONS C, P59; BORNSTEIN NM, 1994, STROKE, V25, P275, DOI 10.1161/01.STR.25.2.275; BORNSTEIN NM, 1992, NEUROL CLIN, V10, P269, DOI 10.1016/S0733-8619(18)30246-9; BOUSSER MG, 1983, STROKE, V14, P5, DOI 10.1161/01.STR.14.1.5; BOYSEN G, 1988, STROKE, V19, P1211, DOI 10.1161/01.STR.19.10.1211; BOYSEN G, 1993, STROKE POPULATIONS C, P187; BROWN MM, 1992, NEUROL RES, V14, P159, DOI 10.1080/01616412.1992.11740040; BURCH JW, 1978, P NATL ACAD SCI USA, V75, P5181, DOI 10.1073/pnas.75.10.5181; CAIRNS JA, 1994, LANCET, V343, P497, DOI 10.1016/S0140-6736(94)91457-5; Canadian Cooperative Study Group, 1978, N Engl J Med, V299, P53; CHESEBRO JH, 1986, J AM COLL CARDIOL, V8, pB41, DOI 10.1016/S0735-1097(86)80006-7; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; DAVIES KN, 1993, J NEUROL NEUROSUR PS, V56, P967, DOI 10.1136/jnnp.56.9.967; DIDISHEIM P, 1968, THROMB DIATH HAEMOST, V20, P257, DOI 10.1055/s-0038-1651265; DIENER HC, 1991, STROKE, V22, P1229; DIMINNO G, 1985, J CLIN INVEST, V75, P328, DOI 10.1172/JCI111705; DYKEN ML, 1993, STROKE, V24, P1251, DOI 10.1161/01.STR.24.8.1251; DYKEN ML, 1981, PROPHYLAXIS VENOUS P, P141; EASTCOTT HHG, 1954, LANCET, V2, P994; EDMUNDS LH, 1987, ANN THORAC SURG, V44, P430, DOI 10.1016/S0003-4975(10)63816-7; ELIASZIW M, 1994, STROKE, V25, P304, DOI 10.1161/01.STR.25.2.304; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; EZEKOWITZ MD, 1993, NEW ENGL J MED, V328, P148; FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/jnnp.54.12.1044; FIELDS WS, 1970, J AMER MED ASSOC, V211, P1993, DOI 10.1001/jama.211.12.1993; FIELDS WS, 1977, STROKE, V8, P301, DOI 10.1161/01.STR.8.3.301; FIHN SD, 1993, ANN INTERN MED, V118, P511, DOI 10.7326/0003-4819-118-7-199304010-00005; GENT M, 1985, STROKE, V16, P416, DOI 10.1161/01.STR.16.3.416; GENT M, 1989, LANCET, V1, P1215, DOI 10.1016/S0140-6736(89)92327-1; GENTON E, 1977, STROKE, V8, P147, DOI 10.1161/01.STR.8.1.150; GRAOR RA, 1988, STROKE, V19, P1441, DOI 10.1161/01.STR.19.11.1441; GROTTA JC, 1992, NEUROLOGY, V42, P111, DOI 10.1212/WNL.42.1.111; GUIRAUDCHAUMEIL B, 1982, REV NEUROL, V138, P367; GUSTAFSSON C, 1987, STROKE, V18, P299; HARBISON JW, 1992, STROKE, V23, P1723, DOI 10.1161/01.STR.23.12.1723; HARRISON MJ, 1971, LANCET, V2, P743; HART RG, 1986, ARCH NEUROL-CHICAGO, V43, P71; HASS WK, 1989, NEW ENGL J MED, V321, P501, DOI 10.1056/NEJM198908243210804; HELGASON CM, 1993, STROKE, V24, P345, DOI 10.1161/01.STR.24.3.345; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HENNERICI M, 1987, BRAIN, V110, P777, DOI 10.1093/brain/110.3.777; HERSHEY LA, 1991, AM J MED, V91, P288, DOI 10.1016/0002-9343(91)90130-P; HIGASHIDA RT, 1993, J NEUROSURG, V78, P192, DOI 10.3171/jns.1993.78.2.0192; HIRSH J, 1992, CHEST, V102, pS327, DOI 10.1378/chest.102.4_Supplement.327S; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; Howard G, 1991, J Stroke Cerebrovasc Dis, V1, P166, DOI 10.1016/S1052-3057(10)80013-8; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KRETSCHMER G, 1990, ANN SURG, V211, P317, DOI 10.1097/00000658-199003000-00002; LEVINE HJ, 1989, CHEST, V95, pS98, DOI 10.1378/chest.95.2.98S; LEVY M, 1974, NEW ENGL J MED, V290, P1158, DOI 10.1056/NEJM197405232902102; LINDBLAD B, 1993, STROKE, V24, P1125, DOI 10.1161/01.STR.24.8.1125; LOELIGER EA, 1982, LANCET, V1, P64; MANSON JE, 1991, JAMA-J AM MED ASSOC, V266, P521, DOI 10.1001/jama.266.4.521; MATCHAR DB, 1994, ANN INTERN MED, V121, P41, DOI 10.7326/0003-4819-121-1-199407010-00008; MATCHAR DB, 1994, ANN INTERN MED, V121, P470, DOI 10.7326/0003-4819-121-6-199409150-00019; MAYBERG MR, 1991, JAMA-J AM MED ASSOC, V266, P3289, DOI 10.1001/jama.266.23.3289; MCBRIDE R, 1994, LANCET, V343, P687; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MCCRORY DC, 1993, STROKE, V24, P1285, DOI 10.1161/01.STR.24.9.1285; MONCADA S, 1981, PHILOS T R SOC B, V294, P305, DOI 10.1098/rstb.1981.0108; MONETA GL, 1993, J VASC SURG, V17, P152, DOI 10.1016/0741-5214(93)90019-I; MOULTON AW, 1991, AM J MED, V91, P156, DOI 10.1016/0002-9343(91)90008-L; MUNDALL J, 1972, NEUROLOGY, V22, P280, DOI 10.1212/WNL.22.3.280; MUSTARD JF, 1967, BLOOD-J HEMATOL, V29, P859, DOI 10.1182/blood.V29.6.859.859; NEWMAN DC, 1988, ANN THORAC SURG, V45, P574, DOI 10.1016/S0003-4975(10)64544-4; NORRIS JW, 1991, STROKE, V22, P1485, DOI 10.1161/01.STR.22.12.1485; OBRIEN JR, 1990, THROMB HAEMOSTASIS, V64, P486; PAGE C, 1992, AM J PATHOL, V141, P673; PELZ DM, 1993, CAN ASSOC RADIOL J, V44, P247; PETERSEN P, 1989, LANCET, V1, P175; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; REED GL, 1988, NEW ENGL J MED, V319, P1246, DOI 10.1056/NEJM198811103191903; RILES TS, 1992, STROKE, V23, P341, DOI 10.1161/01.STR.23.3.341; ROPPER AH, 1982, NEW ENGL J MED, V307, P1388, DOI 10.1056/NEJM198211253072207; ROTHWELL PM, 1993, SURGERY STROKE, P369; RUSSELL RW, 1961, LANCET, V2, P1422; SALTIEL E, 1987, DRUGS, V34, P222, DOI 10.2165/00003495-198734020-00003; SHAW DA, 1984, J NEUROL SCI, V64, P45, DOI 10.1016/0022-510X(84)90054-6; SHAW PJ, 1987, STROKE, V18, P700, DOI 10.1161/01.STR.18.4.700; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; SORENSEN PS, 1983, STROKE, V14, P15, DOI 10.1161/01.STR.14.1.15; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; TURNER RR, 1987, AM J CLIN PATHOL, V87, P569, DOI 10.1093/ajcp/87.5.569; TURNIPSEED WD, 1980, ANN SURG, V192, P365, DOI 10.1097/00000658-198009000-00012; TURPIE AGG, 1993, NEW ENGL J MED, V329, P524, DOI 10.1056/NEJM199308193290802; VAITKUS PT, 1992, ARCH INTERN MED, V152, P2020, DOI 10.1001/archinte.152.10.2020; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WEISS H J, 1970, Federation Proceedings, V29, P381; WIEBERS DO, 1992, MAYO CLIN PROC, V67, P513; WINSLOW CM, 1988, NEW ENGL J MED, V318, P721, DOI 10.1056/NEJM198803243181201; WINSLOW CM, 1988, NEW ENGL J MED, V319, P724; 1993, LANCET, V342, P1255; 1994, CLIN ADVISORY CAROTI; 1983, STROKE, V14, P668	112	179	180	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 26	1995	332	4					238	248		10.1056/NEJM199501263320408	http://dx.doi.org/10.1056/NEJM199501263320408			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC270	7808491				2022-12-28	WOS:A1995QC27000008
J	LEFKOWITZ, RJ				LEFKOWITZ, RJ			CLINICAL IMPLICATIONS OF BASIC RESEARCH - G-PROTEINS IN MEDICINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SIGNAL-TRANSDUCTION				LEFKOWITZ, RJ (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710, USA.		Lefkowitz, Robert/AAW-2649-2021					IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LINDER ME, 1992, SCI AM, V267, P56; LINDER ME, 1992, SCI AM, V267, P64; RODBELL M, 1992, CURR TOP CELL REGUL, V32, P1; SPIEGEL AM, 1993, J CLIN INVEST, V92, P1119, DOI 10.1172/JCI116680	6	23	24	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 19	1995	332	3					186	187		10.1056/NEJM199501193320312	http://dx.doi.org/10.1056/NEJM199501193320312			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB160	7800014				2022-12-28	WOS:A1995QB16000012
J	MACKALL, CL; FLEISHER, TA; BROWN, MR; ANDRICH, MP; CHEN, CC; FEUERSTEIN, IM; HOROWITZ, ME; MAGRATH, IT; SHAD, AT; STEINBERG, SM; WEXLER, LH; GRESS, RE				MACKALL, CL; FLEISHER, TA; BROWN, MR; ANDRICH, MP; CHEN, CC; FEUERSTEIN, IM; HOROWITZ, ME; MAGRATH, IT; SHAD, AT; STEINBERG, SM; WEXLER, LH; GRESS, RE			AGE, THYMOPOIESIS, AND CD4+ T-LYMPHOCYTE REGENERATION AFTER INTENSIVE CHEMOTHERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; IMMUNODEFICIENCY-VIRUS INFECTION; ISOFORM EXPRESSION; CELL REGENERATION; SUBSETS; THYMECTOMY; DEPLETION; PROGENY; THERAPY; THYMUS	Background. Inadequate reconstitution of CD4+ T lymphocytes is an important clinical problem complicating chemotherapy, human immunodeficiency virus infection, and bone marrow transplantation, but relatively little is known about how CD4+ T lymphocytes regenerate. There are two main possibilities: bone marrow-derived progenitors could reconstitute the lymphocyte population using a thymus-dependent pathway, or thymus-independent pathways could predominate. Previous studies have suggested that the CD45RA glycoprotein on CD4+ T lymphocytes is a marker for progeny generated by a thymus-dependent pathway. Methods. We studied 15 patients 1 to 24 years of age who had undergone intensive chemotherapy for cancer. The absolute numbers of CD4+ T lymphocytes in peripheral blood and the expression of CD45 isoforms (CD45RA and CD45RO) on these lymphocytes were studied serially during lymphocyte regeneration after the completion of therapy. Radiographic imaging of the thymus was performed concomitantly. Results. There was an inverse relation between the patients' ages and the CD4+ T-lymphocyte counts six months after therapy was completed (r=-0.92). The CD4+ recovery correlated quantitatively with the appearance of CD45RA+CD4+ T lymphocytes in the blood (r=0.64). There was a higher proportion of CD45RA+CD4+ T lymphocytes in patients with thymic enlargement after chemotherapy than in patients without such enlargement (two-sided P=0.015). Conclusions. Thymus-dependent regeneration of CD4+ T lymphocytes occurs primarily in children, whereas even young adults have deficiencies in this pathway. Our results suggest that rapid T-cell regeneration requires residual thymic function in patients receiving high-dose chemotherapy.	NCI, DIV CANC BIOL DIAG & CTR, EXPTL IMMUNOL BRANCH, BETHESDA, MD USA; NCI, DIV CANC TREATMENT, MED BRANCH, BETHESDA, MD USA; NCI, DIV CANC TREATMENT, PEDIAT BRANCH, BETHESDA, MD USA; NCI, BIOSTAT & DATA MANAGEMENT SECT, BETHESDA, MD USA; NIH, CTR CLIN, DEPT NUCL MED, BETHESDA, MD 20892 USA; NIH, CTR CLIN, DEPT CLIN PATHOL, BETHESDA, MD 20892 USA; UNIFORMED SERV UNIV HLTH SCI, HENRY M JACKSON FDN ADV MIL MED, BETHESDA, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; Uniformed Services University of the Health Sciences - USA	MACKALL, CL (corresponding author), NIH, CTR CLIN, DEPT RADIOL, BLDG 10, RM 4B14, BETHESDA, MD 20892 USA.							ALTMAN S, 1993, P NATL ACAD SCI USA, V90, P10898, DOI 10.1073/pnas.90.23.10898; ATKINSON K, 1982, BLOOD, V59, P1292; BREARLEY S, 1987, CLIN EXP IMMUNOL, V70, P322; BUCHSCHACHER GL, 1993, JAMA-J AM MED ASSOC, V269, P2880, DOI 10.1001/jama.269.22.2880; CHOYKE PL, 1987, AM J ROENTGENOL, V149, P269, DOI 10.2214/ajr.149.2.269; Civin C I, 1992, Prog Clin Biol Res, V377, P461; DEGAST GC, 1985, BLOOD, V66, P428; ERKELLERYUKSEL FM, 1992, J PEDIATR-US, V120, P216, DOI 10.1016/S0022-3476(05)80430-5; FANCI AS, 1988, SCIENCE, V239, P617; FAVROT M, 1983, CLIN EXP IMMUNOL, V54, P59; FORMAN SJ, 1982, TRANSPLANTATION, V34, P96; FUJII Y, 1992, EUR J IMMUNOL, V22, P1843, DOI 10.1002/eji.1830220725; ISRAEL O, 1993, J NUCL MED, V34, P1330; JOHNSTON MI, 1993, SCIENCE, V260, P1286, DOI 10.1126/science.7684163; MACKALL CL, 1994, BLOOD, V84, P2221; MACKALL CL, 1993, BLOOD, V82, P2585; MELMS A, 1993, J NEUROL NEUROSUR PS, V56, P46, DOI 10.1136/jnnp.56.1.46; MILLER JF, 1961, LANCET, V2, P748; MOSES RD, 1989, TRANSPLANTATION, V47, P435, DOI 10.1097/00007890-198903000-00007; MUELLER BU, 1994, PEDIATRICS, V94, P724; PAPIERNIK M, 1992, PEDIATRICS, V89, P297; PEYLANRAMU N, 1989, J CLIN ONCOL, V7, P1800, DOI 10.1200/JCO.1989.7.12.1800; PILARSKI LM, 1989, EUR J IMMUNOL, V19, P589, DOI 10.1002/eji.1830190403; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P7727, DOI 10.1073/pnas.87.19.7727; SPRENT J, 1989, FUNDAMENTAL IMMUNOLO, P84; STANLEY SK, 1993, J EXP MED, V178, P1151, DOI 10.1084/jem.178.4.1151; STUTMAN O, 1986, IMMUNOL REV, V91, P159, DOI 10.1111/j.1600-065X.1986.tb01488.x; ZINKERNAGEL RM, 1980, J IMMUNOL, V124, P2356	28	902	920	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 19	1995	332	3					143	149		10.1056/NEJM199501193320303	http://dx.doi.org/10.1056/NEJM199501193320303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB160	7800006				2022-12-28	WOS:A1995QB16000003
J	BLENDON, RJ; BRODIE, M; BENSON, J				BLENDON, RJ; BRODIE, M; BENSON, J			WHAT SHOULD BE DONE NOW THAT NATIONAL-HEALTH SYSTEM REFORM IS DEAD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									HARVARD UNIV,SCH PUBL HLTH,HARVARD PROGRAM PUBL OPIN & HLTH CARE,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health	BLENDON, RJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.							ANDERSEN A, 1994, MED BENEFITS, V11, P2; BLENDON RJ, 1994, JAMA-J AM MED ASSOC, V271, P1539, DOI 10.1001/jama.271.19.1539; KAISER HJ, 1994, MED BENEFITS, V11, P9; 1993, IN PRESS INCOME POVE; 1994, TIME            0804	5	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					243	244		10.1001/jama.273.3.243	http://dx.doi.org/10.1001/jama.273.3.243			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QB234	7807668				2022-12-28	WOS:A1995QB23400033
J	PERSUTTE, WH; LENKE, RR				PERSUTTE, WH; LENKE, RR			FAILURE OF AMNIOTIC-FLUID CELL-GROWTH - IS IT RELATED TO FETAL ANEUPLOIDY	LANCET			English	Note							AMNIOCENTESIS; DIAGNOSIS	We investigated outcome in patients whose amniotic-fluid-cell samples showed unexplained growth failure in culture, 32 of 7872 amniocentesis samples were classified as unexplained growth failures. 10 women did not have repeat cytogenetic testing, but among their pregnancies there were 4 abnormal outcomes (1 fetal bladder-outlet obstruction, 2 stillbirths, and 1 acardiac twin). Of the 2 2 patients who had repeat karyotypic analysis, 18 had normal fetal karyotypes, However, 4 fetuses were aneuploid (2 trisomy 21, 1 trisomy 13, and 1 Pallister-Killian syndrome).			PERSUTTE, WH (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT OBSTET & GYNAECOL,CAMPUS BOX E-197,4200 E 9TH AVE,DENVER,CO 80262, USA.							ASSEL BG, 1992, OBSTET GYNECOL, V79, P940; BELL JA, 1987, MED J AUSTRALIA, V146, P12, DOI 10.5694/j.1326-5377.1987.tb120118.x; BENACERRAF BR, 1988, RADIOLOGY, V169, P709, DOI 10.1148/radiology.169.3.3055033; BENIRSCHKE K, 1977, TERATOLOGY, V15, P311, DOI 10.1002/tera.1420150313; DEACON JS, 1980, AM J MED GENET, V5, P85, DOI 10.1002/ajmg.1320050112; DONNELFELD AE, 1993, BRIT J OBSTET GYNAEC, V100, pS26; NICOLAIDES KH, 1986, LANCET, V1, P283; REBELLO MT, 1991, PRENATAL DIAG, V11, P35, DOI 10.1002/pd.1970110107	8	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					96	97		10.1016/S0140-6736(95)90064-0	http://dx.doi.org/10.1016/S0140-6736(95)90064-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815890				2022-12-28	WOS:A1995QB80400011
J	LEFEBVRE, S; BURGLEN, L; REBOULLET, S; CLERMONT, O; BURLET, P; VIOLLET, L; BENICHOU, B; CRUAUD, C; MILLASSEAU, P; ZEVIANI, M; LEPASLIER, D; FREZAL, J; COHEN, D; WEISSENBACH, J; MUNNICH, A; MELKI, J				LEFEBVRE, S; BURGLEN, L; REBOULLET, S; CLERMONT, O; BURLET, P; VIOLLET, L; BENICHOU, B; CRUAUD, C; MILLASSEAU, P; ZEVIANI, M; LEPASLIER, D; FREZAL, J; COHEN, D; WEISSENBACH, J; MUNNICH, A; MELKI, J			IDENTIFICATION AND CHARACTERIZATION OF A SPINAL MUSCULAR ATROPHY-DETERMINING GENE	CELL			English	Article							WERDNIG-HOFFMANN DISEASE; LINKAGE MAP; CHROMOSOME-5; LOCUS; FREQUENCY; MARKERS; CONTIG; REGION; 5Q13	Spinal muscular atrophy (SMA) is a common fatal autosomal recessive disorder characterized by degeneration of lower motor neurons, leading to progressive paralysis with muscular atrophy. The gene for SMA has been mapped to chromosome 5q13, where large-scale deletions have been reported. We describe here the inverted duplication of a 500 kb element in normal chromosomes and narrow the critical region to 140 kb within the telomeric region. This interval contains a 20 kb gene encoding a novel protein of 294 amino acids. An highly homologous gene is present in the centromeric element of 95% of controls. The telomeric gene is either lacking or interrupted in 226 of 229 patients, and patients retaining this gene (3 of 229) carry either a point mutation (Y272C) or short deletions in the consensus splice sites of introns 6 and 7. These data suggest that this gene, termed the survival motor neuron (SMN) gene, is an SMA-determining gene.	CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE; GENETHON,F-91002 EVRY,FRANCE		LEFEBVRE, S (corresponding author), HOP NECKER ENFANTS MALAD,INST NECKER,INSERM,U393,UNITE RECH HANDICAPS GENET ENFANT,F-75743 PARIS 15,FRANCE.		Lefebvre, Suzie/D-5092-2017; Zeviani, Massimo/AAU-2632-2021; Zeviani, Massimo/K-2891-2014	Zeviani, Massimo/0000-0002-9067-5508; Le Paslier, Denis/0000-0003-4335-9956; BERNARD, BENICHOU/0000-0002-9331-0926; Cruaud, Corinne/0000-0002-4752-7278				BOTTEMA CDK, 1990, AM J HUM GENET, V47, P835; BRZUSTOWICZ LM, 1990, NATURE, V344, P540, DOI 10.1038/344540a0; BURGHES AHM, 1994, GENOMICS, V21, P394, DOI 10.1006/geno.1994.1282; CARLOCK LR, 1985, AM J HUM GENET, V37, P839; CLERMONT O, 1994, AM J HUM GENET, V54, P687; CZEIZEL A, 1989, J MED GENET, V26, P761, DOI 10.1136/jmg.26.12.761; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DIDONATO CJ, 1994, AM J HUM GENET, V55, P1218; FOURNIER B, 1994, J CLIN INVEST, V94, P526, DOI 10.1172/JCI117365; FRANCIS MJ, 1993, HUM MOL GENET, V2, P1161, DOI 10.1093/hmg/2.8.1161; GILLIAM TC, 1990, NATURE, V345, P823, DOI 10.1038/345823a0; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; HAZAN J, 1992, GENOMICS, V12, P183, DOI 10.1016/0888-7543(92)90364-X; HERRMANN BG, 1987, CELL, V48, P813, DOI 10.1016/0092-8674(87)90078-X; HIGASHI Y, 1988, AM J HUM GENET, V42, P17; Hoffmann J., 1900, MUENCHEN MED WSCHR, V47, P1649; KLEYN PW, 1993, P NATL ACAD SCI USA, V90, P6801, DOI 10.1073/pnas.90.14.6801; KUGELBERG E, 1956, ARCH NEURO PSYCHIATR, V75, P500, DOI 10.1001/archneurpsyc.1956.02330230050005; LIEN LL, 1991, P NATL ACAD SCI USA, V88, P7873, DOI 10.1073/pnas.88.17.7873; MCLEAN MD, 1994, HUM MOL GENET, V3, P1951; MELKI J, 1990, LANCET, V336, P271, DOI 10.1016/0140-6736(90)91803-I; MELKI J, 1990, NATURE, V344, P767, DOI 10.1038/344767a0; MELKI J, 1994, SCIENCE, V264, P1474, DOI 10.1126/science.7910982; MELKI J, 1993, GENOMICS, V15, P521, DOI 10.1006/geno.1993.1103; MORRISON KE, 1992, AM J HUM GENET, V50, P520; Munsat TL., 1991, NEUROMUSCUL DISORD, V1, P81, DOI [10.1016/0960-8966(91)90052-t, DOI 10.1016/0960-8966(91)90052-T]; MURRU S, 1991, BLOOD, V77, P1342; Orkin S., 1987, MOL BASIS BLOOD DISE, P106; PEARN J, 1978, J MED GENET, V15, P409, DOI 10.1136/jmg.15.6.409; PEARN JH, 1973, J MED GENET, V10, P260, DOI 10.1136/jmg.10.3.260; ROBERTS DF, 1970, ARCH DIS CHILD, V45, P33, DOI 10.1136/adc.45.239.33; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Sambrook J, 1989, MOL CLONING LABORATO; SHETH P, 1991, AM J HUM GENET, V48, P764; SOARES VM, 1993, GENOMICS, V15, P365, DOI 10.1006/geno.1993.1069; Werdnig G., 1894, ARCH PSYCHIAT, V26, P706	36	2787	2914	11	135	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					155	165		10.1016/0092-8674(95)90460-3	http://dx.doi.org/10.1016/0092-8674(95)90460-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813012	Bronze			2022-12-28	WOS:A1995QB91000019
J	LEWIN, B				LEWIN, B			GENES FOR SMA - MULTUM IN PARVO	CELL			English	Review							CHROMOSOME-5Q21; IDENTIFICATION; MUTATIONS; CONTIG											Bruno S., 1994, American Journal of Human Genetics, V55, pA130; CARPTEN J, 1994, IN PRESS GENOMICS; FRANCIS MJ, 1993, HUM MOL GENET, V2, P1161, DOI 10.1093/hmg/2.8.1161; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KLEYN PW, 1993, P NATL ACAD SCI USA, V90, P6801, DOI 10.1073/pnas.90.14.6801; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; MELKI J, 1990, NATURE, V344, P767, DOI 10.1038/344767a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; THOMPSON TG, 1995, IN PRESS NATURE GENE	13	55	56	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					1	5		10.1016/0092-8674(95)90442-5	http://dx.doi.org/10.1016/0092-8674(95)90442-5			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813005	Bronze			2022-12-28	WOS:A1995QB91000001
J	GODLEE, F				GODLEE, F			THE WORLD-HEALTH-ORGANIZATION .2. WHO IN RETREAT - IS IT LOSING ITS INFLUENCE	BRITISH MEDICAL JOURNAL			English	Article								WHO says it has three,main functions: to set normative standards; to provide technical advice and assistance on medical matters; and to advocate changes in health policy. During its 46 year history the first two functions have been a constant and uncontroversial backbone through which WHO has earned its reputation for scientific excellence. The third function, advocacy, came to the fore with the launch of Health for All in 1977, after which WHO took a key role in influencing international health policy. WHO's friends and critics alike now say that the organisation is losing its influence and retreating into its technical and biomedical shell. This article maps the changes in WHO's approach over the past 46 years and considers whether fears about its loss:of influence are justified.										JACOBSON H, 1973, ANATOMY INFLUENCE DE; Kanji N., 1989, Health Policy and Planning, V4, P110, DOI 10.1093/heapol/4.2.110; WALT G, 1993, HEALTH POLICY, V24, P125, DOI 10.1016/0168-8510(93)90030-S; WALT G, 1992, DRUGS POLICY DEV COU; 1988, LANCET, V1, P291; 1990, 1989 REP INT STUD C; 1985, 34TH SESSION WORLD H; 1993, 1993 WORLD BANK DEV, P4; 1981, GLOBAL STRATEGY HLTH; 1978, ALMA ATA DECLARATION	10	50	54	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 3	1994	309	6967					1491	1495		10.1136/bmj.309.6967.1491	http://dx.doi.org/10.1136/bmj.309.6967.1491			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW053	7804058	Green Published			2022-12-28	WOS:A1994PW05300030
J	GOODMAN, NW				GOODMAN, NW			SURVEY OF FULFILLMENT OF CRITERIA FOR AUTHORSHIP IN PUBLISHED MEDICAL-RESEARCH	BRITISH MEDICAL JOURNAL			English	Article											GOODMAN, NW (corresponding author), UNIV BRISTOL,SOUTHMEAD HOSP,DEPT ANAESTHESIA,MED SCH UNIT,BRISTOL BS10 5NB,AVON,ENGLAND.							FOTION N, 1984, ANN INTERN MED, V100, P592, DOI 10.7326/0003-4819-100-4-592; MOULD SM, 1986, BRIT MED J, V292, P1017, DOI 10.1136/bmj.292.6526.1017-d; SHAPIRO DW, 1994, JAMA-J AM MED ASSOC, V271, P438, DOI 10.1001/jama.271.6.438; 1994, BRIT MED J, V308, P39; 1993, LANCET, V342, P315	5	85	89	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 3	1994	309	6967					1482	1482		10.1136/bmj.309.6967.1482	http://dx.doi.org/10.1136/bmj.309.6967.1482			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW053	7804054	Green Published			2022-12-28	WOS:A1994PW05300026
J	LEONARD, RCF; RODGER, A; DIXON, JM				LEONARD, RCF; RODGER, A; DIXON, JM			ABC OF BREAST DISEASES - METASTATIC BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article									ALFRED HOSP,WILLIAM BUCKLAND RADIOTHERAPY CTR,MELBOURNE,VIC,AUSTRALIA; MONASH UNIV,MELBOURNE,VIC 3004,AUSTRALIA; ROYAL INFIRM,EDINBURGH,MIDLOTHIAN,SCOTLAND	Florey Institute of Neuroscience & Mental Health; Monash University; Royal Infirmary of Edinburgh	LEONARD, RCF (corresponding author), WESTERN GEN HOSP,DEPT CLIN ONCOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.								0	44	44	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 3	1994	309	6967					1501	1504		10.1136/bmj.309.6967.1501	http://dx.doi.org/10.1136/bmj.309.6967.1501			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW053	7804062	Green Published			2022-12-28	WOS:A1994PW05300038
J	ROSOLEN, A; DRIGO, P; ZANESCO, L				ROSOLEN, A; DRIGO, P; ZANESCO, L			ACUTE HEMIPARESIS ASSOCIATED WITH CIPROFLOXACIN	BRITISH MEDICAL JOURNAL			English	Letter							SEIZURES; SAFETY				ROSOLEN, A (corresponding author), UNIV PADUA,DEPT PAEDIAT,I-35128 PADUA,ITALY.							ARCIERI GM, 1989, AM J MED, V87, pS92, DOI 10.1016/0002-9343(89)90032-6; BADER MB, 1992, CHEST, V101, P883, DOI 10.1378/chest.101.3.883-b; CHYSKY V, 1991, INFECTION, V19, P289, DOI 10.1007/BF01644970; MCCUE JD, 1991, AM J MED, V90, P528, DOI 10.1016/0002-9343(91)80097-6; OMAHONY MS, 1991, LANCET, V338, P259, DOI 10.1016/0140-6736(91)90403-C	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1994	309	6966					1411	1411		10.1136/bmj.309.6966.1411b	http://dx.doi.org/10.1136/bmj.309.6966.1411b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7819850	Green Published			2022-12-28	WOS:A1994PU76400026
J	SUTTON, R; FINNIE, I; RHODES, JM; LOMBARD, MJ; GILMORE, I				SUTTON, R; FINNIE, I; RHODES, JM; LOMBARD, MJ; GILMORE, I			PREVENTING BILIARY STENT OCCLUSION	LANCET			English	Letter							RANDOMIZED TRIAL; OBSTRUCTION				SUTTON, R (corresponding author), ROYAL LIVERPOOL UNIV HOSP,DEPT GASTROENTEROL,LIVERPOOL L7 8XP,MERSEYSIDE,ENGLAND.							ANDERSON JR, 1989, GUT, V30, pI132; DAVIDS PHP, 1992, LANCET, V340, P1488, DOI 10.1016/0140-6736(92)92752-2; FINNIE IA, 1994, GUT, V35, pS50; SHEPHERD HA, 1988, BRIT J SURG, V75, P1166, DOI 10.1002/bjs.1800751207	4	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1088	1088						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7818665				2022-12-28	WOS:A1994PL85200047
J	LI, C; ULLRICH, B; ZHANG, JZ; ANDERSON, RGW; BROSE, N; SUDHOF, TC				LI, C; ULLRICH, B; ZHANG, JZ; ANDERSON, RGW; BROSE, N; SUDHOF, TC			CA2+-DEPENDENT AND CA2+-INDEPENDENT ACTIVITIES OF NEURAL AND NONNEURAL SYNAPTOTAGMINS	NATURE			English	Article							NEUROTRANSMITTER RELEASE; PROTEIN; FUSION; SYNTAXIN; BINDING; DOCKING	SYNAPTOTAGMINS (Syts) are brain-specific Ca2+/phospholipid-binding proteins(1-5). In hippocampal synapses, Syt I is essential for fast Ca2+-dependent synaptic vesicle exocytosis but not for Ca2+-independent exocytosis(3). In vertebrates and invertebrates(6-9), Syt may therefore participate in Ca2+-dependent synaptic membrane fusion, either by serving as the Ca2+ sensor in the last step of fast Ca2+-triggered neurotransmitter release, or by collaborating with an additional Ca2+ sensor. While Syt I binds Ca2+ (refs 10, 11), its phospholipid binding is triggered at lower calcium concentrations (EC(50)=3-6 mu M) than those required for exocytosis(12). Furthermore, Syts bind clathrin-AP2 with high affinity, indicating that they may play a general role in endocytosis(4,5) rather than being confined to a specialized function in regulated exocytosis(3). Here me resolve this apparent contradiction by describing four Syts, three of which (Syt VI, VII and VIII) are widely expressed in non-neural tissues. All Syts tested share a common domain structure, with a cytoplasmic region composed of two C-2 domains that interacts with clathrin-AP2 (K-d=0.1-1.0 nM) and with neural and non-neural syntaxins. The first C-2 domains of Syt I, II, III, V and VII, but not of IV, VI or VIII, bind phospholipids with a similar Ca2+-concentration dependence (EC(50)=3-6 mu M). The same C-2 domains also bind syntaxin as a function of Ca2+ but the Ca2+-concentration dependence of Syt I, II, and V (>200 mu M) differs from that of Syt III and VII (<10 mu M), Syts therefore appear to be ubiquitous proteins with a role in exocytosis mediated by syntaxin binding. The Ca2+ levels needed to trigger syntaxin binding by the different Syts suggest that they play distinct roles in membrane fusion; the level required by Syt I approximates those required for synaptic exocytosis.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; DAVLETOV BA, 1994, J BIOL CHEM, V269, P28547; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DIANTONIO A, 1994, NEURON, V12, P909, DOI 10.1016/0896-6273(94)90342-5; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GODA Y, 1994, P NATL ACAD SCI USA, V91, P12942, DOI 10.1073/pnas.91.26.12942; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HEIDELBERGER R, 1994, NATURE, V371, P51; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PERIN MS, 1994, J BIOL CHEM, V266, P623; Sambrook J, 1989, MOL CLONING LABORATO; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; ULLRICH U, 1994, NEURON, V13, P1281; YOSHIDA A, 1992, J BIOL CHEM, V267, P25925; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	30	548	563	1	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					594	599		10.1038/375594a0	http://dx.doi.org/10.1038/375594a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791877				2022-12-28	WOS:A1995RD28700053
J	MATHUR, R; DOUGLAS, NJ				MATHUR, R; DOUGLAS, NJ			FAMILY STUDIES IN PATIENTS WITH THE SLEEP-APNEA HYPOPNEA SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						SLEEP APNEA SYNDROMES; HYPOPNEA; HEREDITARY DISEASES; FACIAL BONES; AIRWAY OBSTRUCTION	POPULATION; MORPHOLOGY; GENETICS; OBESITY	Objective: To determine whether familial factors affect development of the sleep apnea-hypopnea syndrome and upper airway caliber. Design: A case-control study. Setting Tertiary, referral clinical sleep laboratory. Participants: 51 first-degree relatives of patients with the sleep apnea- hypopnea syndrome and 51 controls matched for age, sex, height, and weight who were drawn at random from a family practice register. To avoid studying the familial nature of obesity, only relatives of index patients with body mass indices less than 30.0 kg/m(2) were recruited. Measurements: Assessment of sleep-related symptoms; breathing, sleep, and oxygenation patterns on overnight polysomnograms; upper airway dimensions by acoustic reflection; and facial structure by lateral cephalometry. Results: More relatives of patients with the sleep apnea-hypopnea syndrome reported snoring (24 relatives compared with 7 controls; P < 0.001) and daytime sleepiness (28 relatives compared with 16 controls; P = 0.01). Relatives had more apneas and hypopneas per hour (median of 13/h [95% CI, 3 to 82/h] for relatives compared with median of 4/h [CI, 0 to 53/h] for controls; P < 0.001), more arousals from sleep (30/h [CI, 11 to 87/h] for relatives compared with 17/h [CI, 4 to 59/h] for controls; P < 0.001), poorer sleep quality, and more oxygen desaturations. Relatives also had narrower upper airways with retroposed maxillae and mandibles and longer soft palates with wider uvulae. Conclusion: The sleep apnea-hypopnea syndrome has a strong familial component. The familial tendency may be caused by differences in facial structure.	UNIV EDINBURGH, EDINBURGH, MIDLOTHIAN, SCOTLAND	University of Edinburgh			Douglas, Neil/B-1491-2013					[Anonymous], 1992, SLEEP, V15, P174; BLOOM JW, 1988, CHEST, V93, P678, DOI 10.1378/chest.93.4.678; Cochran W.G, 1957, STAT METHODS, V6th ed; DOUGLAS NJ, 1993, THORAX, V48, P719, DOI 10.1136/thx.48.7.719; DOUGLAS NJ, 1992, LANCET, V339, P347, DOI 10.1016/0140-6736(92)91660-Z; Elliot J, 1978, JAMA, V240, P2611; FINDLEY LJ, 1986, CHEST, V90, P686, DOI 10.1378/chest.90.5.686; GREENBERG GD, 1987, SLEEP, V10, P254, DOI 10.1093/sleep/10.3.254; HAPONIK EF, 1983, AM REV RESPIR DIS, V127, P221; HARVOLD EP, 1981, AM J ORTHOD DENTOFAC, V79, P359, DOI 10.1016/0002-9416(81)90379-1; JAMIESON A, 1986, SLEEP, V9, P469, DOI 10.1093/sleep/9.4.469; JENNUM P, 1992, J SLEEP RES, V1, P240; LOWE AA, 1986, AM J ORTHOD DENTOFAC, V90, P484, DOI 10.1016/0889-5406(86)90108-3; MARIJA JN, 1990, SPSS INTRO STATISTIC; MARSHALL I, 1993, PHYSIOL MEAS, V14, P157, DOI 10.1088/0967-3334/14/2/007; PARTINEN M, 1990, CHEST, V97, P27, DOI 10.1378/chest.97.1.27; Rechtschaffen A, 1968, NIH PUBLICATION, V204; REDLINE S, 1992, AM REV RESPIR DIS, V145, P440, DOI 10.1164/ajrccm/145.2_Pt_1.440; REDLINE S, 1992, American Review of Respiratory Disease, V145, pA866; STAUFFER JL, 1989, AM REV RESPIR DIS, V140, P724, DOI 10.1164/ajrccm/140.3.724; STROHL KP, 1978, NEW ENGL J MED, V299, P969, DOI 10.1056/NEJM197811022991801; STUNKARD AJ, 1986, NEW ENGL J MED, V314, P193, DOI 10.1056/NEJM198601233140401; TAASAN VC, 1981, AM J MED, V71, P240; WHYTE KF, 1989, Q J MED, V72, P659; YILDIRIM N, 1991, AM REV RESPIR DIS, V144, P845, DOI 10.1164/ajrccm/144.4.845; YOSHIZAWA T, 1993, INTERNAL MED, V32, P94, DOI 10.2169/internalmedicine.32.94; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	27	134	141	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1995	122	3					174	178		10.7326/0003-4819-122-3-199502010-00003	http://dx.doi.org/10.7326/0003-4819-122-3-199502010-00003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD733	7810934				2022-12-28	WOS:A1995QD73300003
J	CATANZARO, A				CATANZARO, A			PREVENTING NOSOCOMIAL TRANSMISSION OF TUBERCULOSIS	LANCET			English	Editorial Material									UNIV CALIF SAN DIEGO,MED CTR,DEPT FAMILY & PREVENT MED,SAN DIEGO,CA 92103	University of California System; University of California San Diego	CATANZARO, A (corresponding author), UNIV CALIF SAN DIEGO,MED CTR,DEPT MED,SAN DIEGO,CA 92103, USA.							ADAL KA, 1994, NEW ENGL J MED, V331, P169, DOI 10.1056/NEJM199407213310306; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; NETTLEMAN MD, 1994, ANN INTERN MED, V121, P37, DOI 10.7326/0003-4819-121-1-199407010-00007; 1995, LANCET, V345, P235; 1993, FED REGISTER, V58, P52810	5	10	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 28	1995	345	8944					204	205		10.1016/S0140-6736(95)90216-3	http://dx.doi.org/10.1016/S0140-6736(95)90216-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7823708	Bronze			2022-12-28	WOS:A1995QD53200002
J	HORROBIN, DF; MORSE, PF				HORROBIN, DF; MORSE, PF			EVENING PRIMROSE OIL AND ATOPIC ECZEMA	LANCET			English	Letter							ESSENTIAL FATTY-ACIDS				HORROBIN, DF (corresponding author), SCOTIA PHARMACEUT LTD,GUILDFORD GU1 1BA,SURREY,ENGLAND.							GALLI E, 1994, BRIT J DERMATOL, V130, P752, DOI 10.1111/j.1365-2133.1994.tb03413.x; MANKU MS, 1984, BRIT J DERMATOL, V110, P643, DOI 10.1111/j.1365-2133.1984.tb04698.x; MORSE PF, 1989, BRIT J DERMATOL, V121, P75, DOI 10.1111/j.1365-2133.1989.tb01403.x; STRANNEGARD IL, 1987, INT ARCH ALLER A IMM, V82, P422, DOI 10.1159/000234245; 1994, BRIT J DERMATOL, V131, P383; 1993, LANCET          0619	6	12	12	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 28	1995	345	8944					260	261		10.1016/S0140-6736(95)90258-9	http://dx.doi.org/10.1016/S0140-6736(95)90258-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7823743				2022-12-28	WOS:A1995QD53200056
J	ZITTOUN, RA; MANDELLI, F; WILLEMZE, R; DEWITTE, T; LABAR, B; RESEGOTTI, L; LEONI, F; DAMASIO, E; VISANI, G; PAPA, G; CARONIA, F; HAYAT, M; STRYCKMANS, P; ROTOLI, B; LEONI, P; PEETERMANS, ME; DARDENNE, M; VEGNA, ML; PETTI, MC; SOLBU, G; SUCIU, S				ZITTOUN, RA; MANDELLI, F; WILLEMZE, R; DEWITTE, T; LABAR, B; RESEGOTTI, L; LEONI, F; DAMASIO, E; VISANI, G; PAPA, G; CARONIA, F; HAYAT, M; STRYCKMANS, P; ROTOLI, B; LEONI, P; PEETERMANS, ME; DARDENNE, M; VEGNA, ML; PETTI, MC; SOLBU, G; SUCIU, S			AUTOLOGOUS OR ALLOGENEIC BONE-MARROW TRANSPLANTATION COMPARED WITH INTENSIVE CHEMOTHERAPY IN ACUTE MYELOGENOUS LEUKEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYELOID-LEUKEMIA; ACUTE NONLYMPHOCYTIC LEUKEMIA; 1ST COMPLETE REMISSION; PROSPECTIVE CONTROLLED TRIAL; NON-LYMPHOBLASTIC LEUKEMIA; HIGH-DOSE CHEMOTHERAPY; CONSOLIDATION CHEMOTHERAPY; COOPERATIVE GROUP; POSTREMISSION TREATMENT; PHASE-III	Background. Allogeneic or autologous bone marrow transplantation and intensive consolidation chemotherapy are used to treat acute myelogenous leukemia in a first complete remission. Methods. After induction treatment with daunorubicin and cytarabine, patients who had a complete remission received a first course of intensive consolidation chemotherapy, combining intermediate-dose cytarabine and amsacrine. Patients with an HLA-identical sibling were assigned to undergo allogeneic bone marrow transplantation; the others were randomly assigned to undergo autologous bone marrow transplantation (with unpurged bone marrow) or a second course of intensive chemotherapy, combining high-dose cytarabine and daunorubicin. Comparisons were made on the basis of the intention to treat. Results. A total of 623 patients had a complete remission; 168 were assigned to undergo allogeneic bone marrow transplantation, and 254 were randomly assigned to one of the other two groups. Of these patients, 343 completed the treatment assignment: 144 in the allogeneic-transplantation group, 95 in the autologous-transplantation group, and 104 in the intensive-chemotherapy group. The relapse rate was highest in the intensive-chemotherapy group and lowest in the allogeneic-transplantation group, whereas the mortality rate was highest after allogeneic transplantation and lowest after intensive chemotherapy. The projected rate of disease-free survival at four years was 55 percent for allogeneic transplantation, 48 percent for autologous transplantation, and 30 percent for intensive chemotherapy. However, the overall survival after complete remission was similar in the three groups, since more patients who relapsed after a second course of intensive chemotherapy had a response to subsequent autologous bone marrow transplantation. Other differences were also observed, especially with regard to hematopoietic recovery (it occurred later after autologous transplantation) and the duration of hospitalization (it was longer with bone marrow transplantation). Conclusions. During first complete remission in acute myelogenous leukemia, autologous as well as allogeneic bone marrow transplantation results in better disease free survival than intensive consolidation chemotherapy with high-dose cytarabine and daunorubicin. Transplantation soon after a relapse or during a second complete remission might also be appropriate.	UNIV ROMA LA SAPIENZA,DEPT HEMATOL,ROME,ITALY; LEIDEN UNIV,DEPT HEMATOL,LEIDEN,NETHERLANDS; ST RADBOUD HOSP,DEPT HEMATOL,NIJMEGEN,NETHERLANDS; HOSP REBRO,DEPT HEMATOL,ZAGREB,CROATIA; OSPED MAGGIORE SG BATTISTA,DEPT HEMATOL,TURIN,ITALY; UNIV FLORENCE,DEPT HEMATOL,FLORENCE,ITALY; OSPED SAN MARTINO GENOVA,DEPT HEMATOL,GENOA,ITALY; UNIV BOLOGNA,IST LA SERAGNOLI,DEPT HEMATOL,BOLOGNA,ITALY; UNIV ROMA TOR VERGATA,DEPT HEMATOL,ROME,ITALY; OSPED CERVELLO,DEPT HEMATOL,PALERMO,ITALY; INST GUSTAVE ROUSSY,DEPT HEMATOL,VILLEJUIF,FRANCE; INST JULES BORDET,DEPT HEMATOL,B-1000 BRUSSELS,BELGIUM; UNIV NAPLES 2,DEPT HEMATOL,NAPLES,ITALY; UNIV ANCONA,DEPT HEMATOL,ANCONA,ITALY; UNIV ANTWERP,DEPT HEMATOL,B-2020 ANTWERP,BELGIUM; EORTC DATA CTR,DEPT HEMATOL,BRUSSELS,BELGIUM	Sapienza University Rome; Leiden University; Leiden University - Excl LUMC; Radboud University Nijmegen; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; University of Florence; University of Genoa; IRCCS AOU San Martino IST; University of Bologna; University of Rome Tor Vergata; UNICANCER; Gustave Roussy; Institut Jules Bordet; Universita della Campania Vanvitelli; Marche Polytechnic University; University of Antwerp; European Organisation for Research & Treatment of Cancer	ZITTOUN, RA (corresponding author), HOP HOTEL DIEU,DEPT HEMATOL,1 PL PARVIS NOTRE DAME,F-75181 PARIS 04,FRANCE.		de Witte, T.J.M./L-4762-2015					APPELBAUM FR, 1988, BLOOD, V72, P179; BEGG CB, 1984, J CLIN ONCOL, V2, P369, DOI 10.1200/JCO.1984.2.5.369; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; BUCHNER T, 1985, J CLIN ONCOL, V3, P1583; BURNETT AK, 1984, LANCET, V2, P1068; BUYSE ME, 1984, CANCER CLIN TRIALS, P337; CARELLA AM, 1988, BONE MARROW TRANSPL, V3, P537; CASSILETH PA, 1984, BLOOD, V63, P843; CASSILETH PA, 1992, BLOOD, V79, P1924; CASSILETH PA, 1987, CANCER TREAT REP, V71, P137; CHAMPLIN RE, 1985, ANN INTERN MED, V102, P285, DOI 10.7326/0003-4819-102-3-285; CLIFT RA, 1987, BONE MARROW TRANSPL, V2, P243; CLIFT RA, 1992, J CLIN ONCOL, V10, P1723, DOI 10.1200/JCO.1992.10.11.1723; FENAUX P, 1993, BLOOD, V82, P3241; GOLDSTONE AH, 1986, BRIT J HAEMATOL, V64, P529, DOI 10.1111/j.1365-2141.1986.tb02209.x; GORIN NC, 1991, LEUKEMIA, V5, P896; GORIN NC, 1990, BLOOD, V75, P1606; HAROUSSEAU JL, 1991, J CLIN ONCOL, V9, P1432, DOI 10.1200/JCO.1991.9.8.1432; HAROUSSEAU JL, 1992, LEUKEMIA, V6, P120; HERMANS J, 1989, EUR J CANCER CLIN ON, V25, P545, DOI 10.1016/0277-5379(89)90268-X; HERZIG RH, 1987, J CLIN ONCOL, V5, P927, DOI 10.1200/JCO.1987.5.6.927; HOROWITZ MM, 1990, BLOOD, V75, P555; KEATING MJ, 1988, LEUKEMIA, V2, P403; KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441; LOWENBERG B, 1990, J CLIN ONCOL, V8, P287; MACHIN D, 1989, STATISTICS CONFIDENC, P64; MAYER RJ, 1994, NEW ENGL J MED, V331, P896, DOI 10.1056/NEJM199410063311402; MAYER RJ, 1988, J CLIN ONCOL, V6, P1532, DOI 10.1200/JCO.1988.6.10.1532; MCMILLAN AK, 1990, BLOOD, V76, P480; PETERSEN FB, 1993, J CLIN ONCOL, V11, P1353, DOI 10.1200/JCO.1993.11.7.1353; PREISLER HD, 1987, J CLIN ONCOL, V5, P722, DOI 10.1200/JCO.1987.5.5.722; REIFFERS J, 1989, BRIT J HAEMATOL, V72, P57, DOI 10.1111/j.1365-2141.1989.tb07652.x; ROHATINER AZS, 1988, J CLIN ONCOL, V6, P218, DOI 10.1200/JCO.1988.6.2.218; SANTOS GW, 1983, NEW ENGL J MED, V309, P1347, DOI 10.1056/NEJM198312013092202; SANTOS GW, 1989, BLOOD, V74, P901; SCHILLER GJ, 1992, J CLIN ONCOL, V10, P41, DOI 10.1200/JCO.1992.10.1.41; STONE RM, 1993, HEMATOL ONCOL CLIN N, V7, P47, DOI 10.1016/S0889-8588(18)30257-0; SUCIU S, 1991, ANN HEMATOL, V62, P41, DOI 10.1007/BF01714898; WILLEMZE R, 1991, ANN HEMATOL, V62, P59, DOI 10.1007/BF01714901; WOLFF SN, 1989, J CLIN ONCOL, V7, P1260, DOI 10.1200/JCO.1989.7.9.1260; ZANDER AR, 1988, J CLIN ONCOL, V6, P1548, DOI 10.1200/JCO.1988.6.10.1548; ZITTOUN R, 1992, LEUKEMIA, V6, P76; ZITTOUN R, 1989, BLOOD, V73, P896; 1989, LANCET, V1, P1119	44	720	742	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	1995	332	4					217	223		10.1056/NEJM199501263320403	http://dx.doi.org/10.1056/NEJM199501263320403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC270	7808487	Green Submitted			2022-12-28	WOS:A1995QC27000003
J	KHAN, MA; HAMEED, A; TAHIR, M; GANDAPUR, AJ; REHMAN, H; DURRANI, FM; AHMAD, A				KHAN, MA; HAMEED, A; TAHIR, M; GANDAPUR, AJ; REHMAN, H; DURRANI, FM; AHMAD, A			HEMATOPOIETIC GROWTH-FACTOR GM-CSF FOR APLASTIC-ANEMIA IN CHILDREN	LANCET			English	Letter							COLONY-STIMULATING FACTOR; ANEMIA		KHYBER MED COLL,HAYAT SHAHEED TEACHING HOSP,DEPT HAEMATOL,PESHAWAR,PAKISTAN		KHAN, MA (corresponding author), KHYBER MED COLL,HAYAT SHAHEED TEACHING HOSP,DEPT PAEDIAT,PESHAWAR,PAKISTAN.							CAMITTA BM, 1976, BLOOD, V48, P63; CHAMPLIN RE, 1989, BLOOD, V73, P694; DONEY K, 1993, BRIT J HAEMATOL, V85, P182, DOI 10.1111/j.1365-2141.1993.tb08665.x; IMASHUKU, 1994, LANCET          1029, P1236; KEMAHLI S, 1994, BRIT J HAEMATOL, V87, P871; KUZROCK R, 1992, AM J MED, V93, P41; MARSH, 1994, LANCET          0916, P172	7	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					199	199		10.1016/S0140-6736(95)90208-2	http://dx.doi.org/10.1016/S0140-6736(95)90208-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7823700				2022-12-28	WOS:A1995QC55000055
J	SHUSTER, S				SHUSTER, S			CAPSAICIN AND THE CAUSE OF CAUSALGIA	LANCET			English	Note							PAIN	From self-experimentation, I propose that the pain which occurs after application of capsaicin is causalgia and that this ''capsaicin causalgia'' is due to actual or functional depletion of neuropeptides such as substance P. This idea could provide an objective definition of the causalgic syndromes and improve the means of diagnosis. The analogy with capsaicin causalgia could also be extended to the pain of epidermal necrolysis, solar and thermal burns, and leprosy. the concept could lead to a better treatment of these causalgic syndromes by modulation of neuropeptide concentration of responsivity, or by mitigation of the consequences of its depletion.			SHUSTER, S (corresponding author), UNIV NEWCASTLE UPON TYNE,DEPT DERMATOL,NEWCASTLE TYNE NE2 4BW,TYNE & WEAR,ENGLAND.							BARBUT D, 1981, BRAIN RES, V205, P289, DOI 10.1016/0006-8993(81)90340-1; BRENEMAN DL, 1992, J AM ACAD DERMATOL, V26, P91, DOI 10.1016/0190-9622(92)70013-6; DOTSON RM, 1993, MUSCLE NERVE, V16, P1049, DOI 10.1002/mus.880161008; LEWIS T, 1927, BLOOD VESSELS HUMAN, P69; LYNN B, 1990, PAIN, V51, P61; PORTER R, 1982, CIBA F S, V91; SCHOTT GD, 1986, BRAIN, V109, P717, DOI 10.1093/brain/109.4.717; SIMONE DA, 1989, PAIN, V38, P99, DOI 10.1016/0304-3959(89)90079-1; WALTON J, 1993, BRAINS DISEASES NERV, P563; 1986, CLASSIFICATION CH S3, V26, pS29	10	8	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					160	161		10.1016/S0140-6736(95)90169-8	http://dx.doi.org/10.1016/S0140-6736(95)90169-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7823672				2022-12-28	WOS:A1995QC55000012
J	LIMOUSIN, P; POLLAK, P; BENAZZOUZ, A; HOFFMANN, D; LEBAS, JF; BROUSSOLLE, E; PERRET, JE; BENABID, AL				LIMOUSIN, P; POLLAK, P; BENAZZOUZ, A; HOFFMANN, D; LEBAS, JF; BROUSSOLLE, E; PERRET, JE; BENABID, AL			EFFECT ON PARKINSONIAN SIGNS AND SYMPTOMS OF BILATERAL SUBTHALAMIC NUCLEUS STIMULATION	LANCET			English	Article							INTERMEDIATE THALAMIC NUCLEUS; MOVEMENT-DISORDERS; DISEASE; PRIMATE; TREMOR; DYSKINESIAS; REVERSAL; LESIONS	In monkeys rendered parkinsonian, lesions and electrical stimulation of the subthalamic nucleus reduce all major motor disturbances, The effect of electrical stimulation of the subthalamic nucleus was assessed in three patients with disabling akinetic-rigid Parkinson's disease and severe motor fluctuations. Quadripolar electrodes connected to a pulse generator were implanted in the subthalamic nuclei on both sides, Patients were evaluated with the unified Parkinson's disease rating scale and timed motor tests. 3 months after surgery, activities of daily living scores had improved by 58-88% and motor scores by 42-84%. This improvement was maintained for up to 8 months in the first patient operated upon. One patient was confused for 2 weeks after surgery, and another developed neuropsychological impairment related to a thalamic infarction which improved over 3 months, In one patient, stimulation could induce ballism that was stopped by reduction of stimulation. This is the first demonstration in human beings of the part played by the subthalamic nuclei in the pathophysiology of Parkinson's disease.	UNIV GRENOBLE 1,DEPT CLIN & BIOL NEUROSCI,F-38041 GRENOBLE,FRANCE; HOP NEUROL,LYON,FRANCE	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CHU Lyon			Broussolle, Emmanuel/H-1592-2017; Benazzouz, Abdelhamid/E-5050-2016	Broussolle, Emmanuel/0000-0002-0410-9519; 				ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; AZIZ TZ, 1992, BRIT J NEUROSURG, V6, P575, DOI 10.3109/02688699209002375; AZIZ TZ, 1991, MOVEMENT DISORD, V6, P288, DOI 10.1002/mds.870060404; BENABID AL, 1991, LANCET, V337, P403, DOI 10.1016/0140-6736(91)91175-T; BENAZZOUZ A, 1993, EUR J NEUROSCI, V5, P382, DOI 10.1111/j.1460-9568.1993.tb00505.x; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; BLOND S, 1992, J NEUROSURG, V77, P62, DOI 10.3171/jns.1992.77.1.0062; CAPARROSLEFEBVRE D, 1993, J NEUROL NEUROSUR PS, V56, P268, DOI 10.1136/jnnp.56.3.268; DeLong M. R., 1987, BASAL GANGLIA, P415, DOI 10.1007/978-1-4684-5347-8_29; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; DELONG MR, 1985, J NEUROPHYSIOL, V53, P530, DOI 10.1152/jn.1985.53.2.530; FAHN S, 1992, NEW ENGL J MED, V327, P1589, DOI 10.1056/NEJM199211263272209; Fahn S., 1987, RECENT DEV PARKINSON, VVol. 2, P153; HAMADA I, 1992, J NEUROPHYSIOL, V68, P1850, DOI 10.1152/jn.1992.68.5.1850; HITCHCOCK ER, 1988, LANCET, V1, P1274; LAITINEN LV, 1992, J NEUROSURG, V76, P53, DOI 10.3171/jns.1992.76.1.0053; LINDVALL O, 1992, ANN NEUROL, V31, P155, DOI 10.1002/ana.410310206; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; NGUYEN JP, 1993, ARCH NEUROL-CHICAGO, V50, P498, DOI 10.1001/archneur.1993.00540050050014; PILLON B, 1986, NEUROLOGY, V36, P1179, DOI 10.1212/WNL.36.9.1179; POLLAK P, 1993, ADV NEUROL, V60, P408; Schaltenbrand G., 1977, ATLAS STEREOTAXY HUM; SHANNON KM, 1990, CLIN NEUROPHARMACOL, V13, P413, DOI 10.1097/00002826-199010000-00003; Talairach J., 1957, ATLAS ANATOMIE STERE; 1992, MOV DISORD, V7, P2	25	1059	1102	3	66	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					91	95		10.1016/S0140-6736(95)90062-4	http://dx.doi.org/10.1016/S0140-6736(95)90062-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815888				2022-12-28	WOS:A1995QB80400009
J	WALT, RP				WALT, RP			PREVENTING ADMISSIONS FOR GASTROINTESTINAL-BLEEDING	LANCET			English	Editorial Material											WALT, RP (corresponding author), BIRMINGHAM HEARTLANDS HOSP,DEPT MED,BIRMINGHAM B9 5ST,W MIDLANDS,ENGLAND.							JENSEN DM, 1994, NEW ENGL J MED, V330, P382, DOI 10.1056/NEJM199402103300602; KOCKALL TA, 1994, GUT S5, V35, pS47; LABENZ J, 1994, DIGESTION, V55, P19, DOI 10.1159/000201117; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; MARCH L, 1994, BRIT MED J, V309, P1041, DOI 10.1136/bmj.309.6961.1041; PENSTON JG, 1992, ALIMENT PHARM THERAP, V6, P629; POWELL KU, 1994, Q J MED, V87, P283; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0	8	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					77	78		10.1016/S0140-6736(95)90057-8	http://dx.doi.org/10.1016/S0140-6736(95)90057-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815883				2022-12-28	WOS:A1995QB80400004
J	CALVERT, R; RANDERSON, J; EVANS, P; CAWKWELL, L; LEWIS, F; DIXON, MF; JACK, A; OWEN, R; SHIACH, C; MORGAN, GJ				CALVERT, R; RANDERSON, J; EVANS, P; CAWKWELL, L; LEWIS, F; DIXON, MF; JACK, A; OWEN, R; SHIACH, C; MORGAN, GJ			GENETIC ABNORMALITIES DURING TRANSITION FROM HELICOBACTER-PYLORI-ASSOCIATED GASTRITIS TO LOW-GRADE MALTOMA	LANCET			English	Note							POLYMERASE CHAIN-REACTION	The helicobacter-associated transition from chronic gastritis to MALToma (lymphoma of mucosa-associated lymphoid tissue) may require genetic change in the host. We have studied gastrectomy specimens from twelve cases of primary B-cell gastric lymphoma showing evidence of chronic gastritis and low-grade or high-grade MALToma to look for allele imbalance at microsatellites for six tumour-suppressor genes. We detected allelic imbalance at two of these loci (DCC in three, APC in two). In two DCC cases allele imbalance was seen in the transition from chronic gastritis to low-grade MALToma and in the third between low-grade and high-grade. Allele imbalance between chronic gastritis and low-grade MALToma is not necessarily causal in the transition. Rather, genetic change has occurred in the process of transformation.	LEEDS GEN INFIRM,DEPT MOLEC HAEMATOL,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	Leeds General Infirmary; University of Leeds			Maestro, Roberta/P-9748-2019; Maestro, Roberta/M-1846-2015	Maestro, Roberta/0000-0002-6642-5592; Maestro, Roberta/0000-0002-6642-5592; Randerson-Moor, Juliette/0000-0003-0303-0072; morgan, gareth/0000-0002-4271-6360				CAWKWELL L, 1993, BRIT J CANCER, V67, P1262, DOI 10.1038/bjc.1993.236; CAWKWELL L, 1994, BRIT J CANCER, V70, P813, DOI 10.1038/bjc.1994.404; DEANE M, 1991, LEUKEMIA, V5, P726; ENNO A, 1994, J CLIN PATHOL, V173, pA166; GRIBBEN JG, 1991, BLOOD, V78, P3275; MCCARTHY KP, 1990, J CLIN PATHOL, V43, P429, DOI 10.1136/jcp.43.5.429; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F	7	75	75	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					26	27		10.1016/S0140-6736(95)91154-5	http://dx.doi.org/10.1016/S0140-6736(95)91154-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799702				2022-12-28	WOS:A1995QA29000012
J	JAMES, A				JAMES, A			FAT-SOLUBLE VITAMINS	LANCET			English	Editorial Material																			0	1	1	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					7	7		10.1016/S0140-6736(95)91148-0	http://dx.doi.org/10.1016/S0140-6736(95)91148-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799735				2022-12-28	WOS:A1995QA29000007
J	HAWKEY, CJ				HAWKEY, CJ			CONTROVERSIES IN MANAGEMENT - ERADICATION OF HELICOBACTER-PYLORI SHOULD BE PIVOTAL IN MANAGING PEPTIC-ULCERATION - ERADICATION LARGELY PREVENTS RELAPSE .13.	BRITISH MEDICAL JOURNAL			English	Article							GASTRITIS; DISEASE				HAWKEY, CJ (corresponding author), UNIV NOTTINGHAM HOSP,DIV GASTROENTEROL,NOTTINGHAM NG7 2UH,ENGLAND.							[Anonymous], 1882, BERLINER KLIN WOCHEN, V19, P221; GRAHAM DY, 1993, SCAND J GASTROENTERO, V28, P939, DOI 10.3109/00365529309098288; HENTSCHEL E, 1993, NEW ENGL J MED, V328, P308, DOI 10.1056/NEJM199302043280503; HOSKING SW, 1994, LANCET, V343, P508, DOI 10.1016/S0140-6736(94)91460-5; LAMBERTS R, 1993, GASTROENTEROLOGY, V104, P1356, DOI 10.1016/0016-5085(93)90344-C; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; NEAL KR, 1994, BRIT MED J, V308, P176; SIPPONEN P, 1990, SCAND J GASTROENTERO, V25, P966, DOI 10.3109/00365529008997621; TAYLOR F, 1918, PRACTICE MED, P693; TYTGAT GNJ, 1994, ALIMENT PHARM THERAP, V8, P359; VAIRA D, 1994, GUT, V35, P309, DOI 10.1136/gut.35.3.309; VALLE J, 1991, SCAND J GASTROENTERO, V26, P1057, DOI 10.3109/00365529109003956; WISEMAN R, 1696, 8 CHIRURGICAL TREATI, P239; 1976, BRIT MED J, V2, P1275; 1977, LANCET, V1, P129	15	12	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 10	1994	309	6968					1570	1571		10.1136/bmj.309.6968.1570	http://dx.doi.org/10.1136/bmj.309.6968.1570			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX564	7819903	Green Published			2022-12-28	WOS:A1994PX56400029
J	MARSHALL, E				MARSHALL, E			AUTHORSHIP - DISPUTE SLOWS PAPER ON REMARKABLE VACCINE	SCIENCE			English	Article																			0	6	6	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1712	1715		10.1126/science.7792593	http://dx.doi.org/10.1126/science.7792593			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792593				2022-12-28	WOS:A1995RE66800027
J	KNAUS, WA; HARRELL, FE; LYNN, J; GOLDMAN, L; PHILLIPS, RS; CONNERS, AF; DAWSON, NV; FULKERSON, WJ; CALIFF, RM; DESBIENS, N; LAYDE, P; OYE, RK; BELLAMY, PE; HAKIM, RB; WAGNER, DP				KNAUS, WA; HARRELL, FE; LYNN, J; GOLDMAN, L; PHILLIPS, RS; CONNERS, AF; DAWSON, NV; FULKERSON, WJ; CALIFF, RM; DESBIENS, N; LAYDE, P; OYE, RK; BELLAMY, PE; HAKIM, RB; WAGNER, DP			THE SUPPORT PROGNOSTIC MODEL - OBJECTIVE ESTIMATES OF SURVIVAL FOR SERIOUSLY ILL HOSPITALIZED ADULTS	ANNALS OF INTERNAL MEDICINE			English	Article							INTENSIVE-CARE UNIT; REGRESSION-MODELS; PREDICTIVE INSTRUMENT; MYOCARDIAL-INFARCTION; ACUTE PHYSIOLOGY; APACHE-II; MORTALITY; MULTICENTER; SCIENCE; RISK	Objective: To develop and validate a prognostic model that estimates survival over a 180-day period for seriously ill hospitalized adults (phase I of SUPPORT [Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments]) and to compare this model's predictions with those of an existing prognostic system and with physicians' independent estimates (SUPPORT phase II). Design: Prospective cohort study. Setting: 5 tertiary care academic centers in the United States. Participants: 4301 hospitalized adults were selected for phase I according to diagnosis and severity of illness; 4028 patients were evaluated from phase II. Measurements: A survival model was developed using the following predictor variables: diagnosis, age, number of days in the hospital before study entry, presence of cancer, neurologic function, and 11 physiologic measures recorded on day 3 after study entry. Physicians were interviewed on day 3. Patients were followed for survival for 180 days after study entry. Results: The area under the receiver-operating characteristics (ROC) curve for prediction of surviving 180 days was 0.79 in phase 1, 0.78 in the phase II independent validation, and 0.78 when the acute physiology score from the APACHE (Acute Physiology, Age, Chronic Health Evaluation) III prognostic scoring system was substituted for the SUPPORT physiology score. For phase II patients, the SUPPORT model had equal discrimination and slightly improved calibration compared with physicians' estimates. Combining the SUPPORT model with physicians' estimates improved both predictive accuracy (ROC curve area = 0.82) and the ability to identify patients with high probabilities of survival or death. Conclusions: A limited amount of readily available clinical information can provide a foundation for longterm survival estimates that are as accurate as physicians' estimates. The best survival estimates combine an objective prognosis with a physician's clinical estimate.	GEORGE WASHINGTON UNIV, MED CTR, WASHINGTON, DC 20037 USA; DUKE UNIV, MED CTR, DIV BIOMETRY, CTR HEART, DURHAM, NC 27705 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, SCH MED, CTR EVALUAT CLIN SCI, HANOVER, NH 03755 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; CLEVELAND METROHLTH MED CTR, CLEVELAND, OH 44109 USA; MARSHFIELD MED RES FDN, MARSHFIELD, WI 54449 USA; MARSHFIELD CLIN FDN MED RES & EDUC, MARSHFIELD, WI 54449 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90024 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02215 USA; DUKE UNIV, DUKE S HOSP, MED CTR, DURHAM, NC 27710 USA; MED COLL WISCONSIN, DEPT FAMILY & COMMUN MED, MILWAUKEE, WI 53226 USA	George Washington University; Duke University; Dartmouth College; Harvard University; Beth Israel Deaconess Medical Center; MetroHealth System; Marshfield Clinic; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Harvard University; Brigham & Women's Hospital; Duke University; Medical College of Wisconsin	KNAUS, WA (corresponding author), ROBERT WOOD JOHNSON FDN CRITICALLY ILL HOSP ADULT, NATL COORDINATING CTR, ICU RES UNIT, WASHINGTON, DC 20037 USA.		Knaus, William/AAX-2138-2020	Connors, Alfred F./0000-0001-7123-3360				ANNAS GJ, 1994, NEW ENGL J MED, V330, P223, DOI 10.1056/NEJM199401203300324; [Anonymous], 1988, RATIONAL CHOICE UNCE; AUSTRIAN R, 1964, ANN INTERN MED, V60, P759, DOI 10.7326/0003-4819-60-5-759; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; BRANNEN AL, 1989, ARCH INTERN MED, V149, P1083, DOI 10.1001/archinte.149.5.1083; CALIFF RM, 1982, CONGESTIVE HEART FAI, P31; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; CONNORS AF, 1990, J CLIN EPIDEMIOL, V43, pS47, DOI 10.1016/0895-4356(90)90218-E; COWEN JS, 1994, CRIT CARE CLIN, V10, P53, DOI 10.1016/S0749-0704(18)30144-1; COX DR, 1972, J R STAT SOC B, V34, P187; DAMIANO AM, 1992, J CLIN EPIDEMIOL, V45, P93, DOI 10.1016/0895-4356(92)90001-4; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; ESCARCE JJ, 1990, JAMA-J AM MED ASSOC, V264, P2389, DOI 10.1001/jama.264.18.2389; FEINSTEIN AR, 1983, ANN INTERN MED, V99, P393, DOI 10.7326/0003-4819-99-3-393; FLECK A, 1985, LANCET, V1, P781; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; HARRELL FE, 1985, BIOSTATISTICS STAT B, P333; HARRELL FE, 1986, 11TH P ANN SAS US GR, P823; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; Katz J., 1984, SILENT WORLD DOCTOR; KNAUS WA, 1991, SCIENCE, V254, P389, DOI 10.1126/science.1925596; KNAUS WA, 1993, JAMA-J AM MED ASSOC, V270, P1233, DOI 10.1001/jama.270.10.1233; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KNAUS WA, 1992, CHEST, V101, P1656, DOI 10.1378/chest.101.6.1656; KRUSE JA, 1988, JAMA-J AM MED ASSOC, V260, P1739, DOI 10.1001/jama.260.12.1739; LANKEN PN, 1991, ANN INTERN MED, V115, P478; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; LYNN J, 1990, J CLIN EPIDEMIOL, V43, pS1, DOI 10.1016/0895-4356(90)90211-7; MCCLISH DK, 1989, MED DECIS MAKING, V9, P125, DOI 10.1177/0272989X8900900207; MOSKOWITZ AJ, 1988, ANN INTERN MED, V108, P435, DOI 10.7326/0003-4819-108-3-435; MURPHY DJ, 1990, J CLIN EPIDEMIOL, V43, pS11, DOI 10.1016/0895-4356(90)90213-9; MURPHY DJ, 1990, J CLIN EPIDEMIOL S, V43; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; SELKER HP, 1991, MED CARE, V29, P1196, DOI 10.1097/00005650-199112000-00003; Stone CJ, 1985, P STAT COMP SECT AM, P45; VANHOUWELINGEN JC, 1990, STAT MED, V9, P1303, DOI 10.1002/sim.4780091109; WAGNER DP, 1994, CRIT CARE MED, V22, P1359, DOI 10.1097/00003246-199409000-00004; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; 1982, MAKING HLTH CARE DEC, P245	47	408	413	1	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1995	122	3					191	203		10.7326/0003-4819-122-3-199502010-00007	http://dx.doi.org/10.7326/0003-4819-122-3-199502010-00007			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD733	7810938				2022-12-28	WOS:A1995QD73300007
J	BOWYER, P; CLARKE, BR; LUNNESS, P; DANIELS, MJ; OSBOURN, AE				BOWYER, P; CLARKE, BR; LUNNESS, P; DANIELS, MJ; OSBOURN, AE			HOST-RANGE OF A PLANT-PATHOGENIC FUNGUS DETERMINED BY A SAPONIN DETOXIFYING ENZYME	SCIENCE			English	Article							GAEUMANNOMYCES-GRAMINIS; NEUROSPORA-CRASSA; ESCHERICHIA-COLI; TRANSFORMATION; RESISTANCE; CLONING; ACID; GENE	Antifungal saponins occur in many plant species and may provide a preformed chemical barrier to attack by phytopathogenic fungi. Some fungal pathogens can enzymatically detoxify host plant saponins, which suggests that saponin detoxification may determine the host range of these fungi. A gene encoding a saponin detoxifying enzyme was cloned from the cereal-infecting fungus Gaeumannomyces graminis. Fungal mutants generated by targeted gene disruption were no longer able to infect the saponin-containing host oats but retained full pathogenicity to wheat (which does not contain saponins). Thus, the ability of a phytopathogenic fungus to detoxify a plant saponin can determine its host range.	JOHN INNES INST,JOHN INNES CTR PLANT SCI RES,SAINSBURY LAB,NORWICH NR4 7UH,NORFOLK,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center				bowyer, paul/0000-0002-1083-9286				ARNESON PA, 1968, PHYTOPATHOLOGY, V58, P536; AUSTIN B, 1990, EXP MYCOL, V14, P9, DOI 10.1016/0147-5975(90)90082-5; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BALLANCE DJ, 1986, MOL GEN GENET, V202, P271, DOI 10.1007/BF00331649; BANGHAM AD, 1962, NATURE, V196, P952, DOI 10.1038/196952a0; BOWYER PK, UNPUB; BUXTON FP, 1983, MOL GEN GENET, V190, P403, DOI 10.1007/BF00331067; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CROMBIE WML, 1986, PHYTOCHEMISTRY, V25, P2075, DOI 10.1016/0031-9422(86)80069-3; DOURMASHKIN RR, 1962, NATURE, V194, P1116, DOI 10.1038/1941116a0; DURBIN RD, 1969, BIOCHIM BIOPHYS ACTA, V191, P176, DOI 10.1016/0005-2744(69)90331-3; FORD JE, 1977, PHYTOCHEMISTRY, V16, P545, DOI 10.1016/0031-9422(77)80011-3; FRITIG B, 1993, MECHANISMS PLANT DEF, V2; HENSON JM, 1988, CURR GENET, V14, P113, DOI 10.1007/BF00569334; MAHATO SB, 1991, PHYTOCHEMISTRY, V30, P1357, DOI 10.1016/0031-9422(91)84170-W; MAHATO SB, 1988, PHYTOCHEMISTRY, V28, P3037; OSBOURN AE, 1991, PHYSIOL MOL PLANT P, V38, P301, DOI 10.1016/S0885-5765(05)80121-3; OSBOURN AE, 1994, PHYSIOL MOL PLANT P, V45, P457, DOI 10.1016/S0885-5765(05)80042-6; PEGG GF, 1986, PHYSIOL MOL PLANT P, V28, P187, DOI 10.1016/S0048-4059(86)80063-7; PRICE KR, 1991, CRC CRIT REV FOOD SC, V26, P27; PUNT PJ, 1987, GENE, V56, P117, DOI 10.1016/0378-1119(87)90164-8; RAEDER U, 1985, LETT APPL MICROBIOL, V1, P17, DOI 10.1111/j.1472-765X.1985.tb01479.x; SCHONBECK F, 1976, PHYSL PLANT PATHOLOG, P653; TURNER EM, 1961, J EXP BOT, V12, P169, DOI 10.1093/jxb/12.1.169; VERHOEFF K, 1975, PHYTOPATHOL Z, V82, P333; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	26	191	201	0	42	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 20	1995	267	5196					371	374		10.1126/science.7824933	http://dx.doi.org/10.1126/science.7824933			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC273	7824933				2022-12-28	WOS:A1995QC27300033
J	HANNAN, EL; SIU, AL; KUMAR, D; KILBURN, H; CHASSIN, MR				HANNAN, EL; SIU, AL; KUMAR, D; KILBURN, H; CHASSIN, MR			THE DECLINE IN CORONARY-ARTERY BYPASS GRAFT-SURGERY MORTALITY IN NEW-YORK-STATE - THE ROLE OF SURGEON VOLUME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SURGICAL VOLUME; OPERATIONS; HOSPITALS	Objective.-To examine the longitudinal relationship between surgeon volume and in-hospital mortality for coronary artery bypass graft (CABG) surgery in New York State and to explain changes in mortality that occurred over time. Design.-Observation of clinically risk-adjusted operative mortality over time. Setting.-All 30 New York State hospitals in which CABG surgery was performed for 1989 through 1992. Patients.-All 57187 patients undergoing isolated CABG surgery in New York State in 1989 through 1992 in the 30 hospitals. Main Outcome Measures.-Actual, expected, and risk-adjusted mortality. Results-Risk-adjusted in-hospital mortality decreased for all categories of surgeons. Low-volume surgeons (less than or equal to 50 operations per year) experienced a 60% reduction in risk-adjusted mortality in the 4-year period, whereas the highest-volume surgeons (>150 operations per year) experienced a 34% reduction. The percentage of patients undergoing CABG surgery by low-volume surgeons decreased from 7.6% in 1989 to 5.7% in 1992, a 25% decrease. Conclusions.-The overall decline in risk-adjusted mortality could not be explained by shifts in patients away from low-volume surgeons to high-volume surgeons. The proportionately larger decrease in risk-adjusted mortality for low-volume surgeons could not be explained by changes in patient case mix or by improvements in the performance of surgeons with persistently low volumes. Part of the decrease was a result of the exodus of low-volume surgeons with high risk-adjusted mortality (in all years studied), the markedly better performance of surgeons who were new to the system (especially in 1991 and 1992), and the performance of surgeons who were not consistently low-volume surgeons (especially in 1992).	NEW YORK STATE DEPT HLTH,ALBANY,NY 12201	State University of New York (SUNY) System	HANNAN, EL (corresponding author), SUNY ALBANY,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,135 WESTERN AVE,203 HUSTED HALL,ALBANY,NY 12203, USA.		Kalra, D/H-6661-2019	Kalra, D/0000-0001-5254-4067	AHRQ HHS [HS 06503] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; HANNAN EL, 1991, MED CARE, V29, P1094, DOI 10.1097/00005650-199111000-00003; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; HUGHES RG, 1987, MED CARE, V25, P489, DOI 10.1097/00005650-198706000-00004; KELLY JV, 1987, HEALTH SERV RES, V22, P369; LUFT HS, 1980, MED CARE, V18, P940, DOI 10.1097/00005650-198009000-00006; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; LUFT HS, 1987, HEALTH SERV RES, V22, P157; LUFT HS, 1990, HOSPITAL VOLUME PHYS; MAERKI SC, 1986, MED CARE, V24, P148, DOI 10.1097/00005650-198602000-00006; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P785, DOI 10.1001/jama.257.6.785; SLOAN FA, 1986, SURGERY, V99, P446	14	301	304	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					209	213		10.1001/jama.273.3.209	http://dx.doi.org/10.1001/jama.273.3.209			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB234	7807659				2022-12-28	WOS:A1995QB23400024
J	FELDMAN, B; POUEYMIROU, W; PAPAIOANNOU, VE; DECHIARA, TM; GOLDFARB, M				FELDMAN, B; POUEYMIROU, W; PAPAIOANNOU, VE; DECHIARA, TM; GOLDFARB, M			REQUIREMENT OF FGF-4 FOR POSTIMPLANTATION MOUSE DEVELOPMENT	SCIENCE			English	Article							GROWTH-FACTOR FAMILY; EMBRYONAL CARCINOMA-CELLS; EXPRESSION; PROTOONCOGENE; LIMB; GENE; GASTRULATION; ONCOGENE; INT-2; DIFFERENTIATION	Fibroblast growth factors (FGFs) are thought to influence many processes in vertebrate development because of their diverse sites of expression and wide range of biological activities in in vitro culture systems. As a means of elucidating embryonic functions of FGF-4, gene targeting was used to generate mice harboring a disrupted Fgf4 gene. Embryos homozygous for the null allele underwent uterine implantation and induced uterine decidualization but did not develop substantially thereafter. As was consistent with their behavior in vivo, Fgf4 null embryos cultured in vitro displayed severely impaired proliferation of the inner cell mass, whereas growth and differentiation of the inner cell mass were rescued when null embryos were cultured in the presence of FGF-4 protein.	REGENERON PHARMACEUT INC, TARRYTOWN, NY 10591 USA; COLUMBIA UNIV, COLL PHYS & SURG, INTEGRATED PROGRAM CELLULAR MOLEC & BIOPHYS STUDI, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT GENET & DEV, NEW YORK, NY 10032 USA	Regeneron; Columbia University; Columbia University				Feldman, Benjamin/0000-0003-4838-8641; Papaioannou, Virginia/0000-0001-7558-8601	NICHD NIH HHS [HD21988, HD27198] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027198, U01HD021988] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BROOKES S, 1989, NUCLEIC ACIDS RES, V17, P4037, DOI 10.1093/nar/17.11.4037; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; DELLIBOVI P, 1988, MOL CELL BIOL, V8, P2933, DOI 10.1128/MCB.8.7.2933; DRUCKER BJ, 1993, MECH DEVELOP, V40, P155, DOI 10.1016/0925-4773(93)90073-7; FELDMAN B, UNPUB; GAO G, UNPUB; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; HALABAN R, 1988, ONCOGENE RES, V3, P177; HAUB O, 1991, DEVELOPMENT, V112, P397; HEATH JK, 1989, DEVELOPMENT, V107, P113; Heath JK, 1991, CURR OPIN CELL BIOL, V3, P935, DOI 10.1016/0955-0674(91)90110-K; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; HEBERT JM, 1991, DEVELOPMENT, V112, P407; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MIYAGAWA K, 1988, ONCOGENE, V3, P383; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; NISWANDER L, 1993, DEVELOPMENT, V119, P287; PATERNO GD, 1989, DEVELOPMENT, V106, P79; RAPPOLEE DA, 1994, DEVELOPMENT, V120, P2259; Robertson E. J., 1987, TERATOCARCINOMAS EMB; Schultz G A, 1993, Oxf Rev Reprod Biol, V15, P43; SCHWARTZBERG PL, 1989, SCIENCE, V246, P799, DOI 10.1126/science.2554496; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TIESMAN J, 1989, IN VITRO CELL DEV B, V25, P1193; VELCICH A, 1989, ONCOGENE RES, V5, P31; VOGEL A, 1993, DEVELOPMENT, V119, P199; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x	36	608	626	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 13	1995	267	5195					246	249		10.1126/science.7809630	http://dx.doi.org/10.1126/science.7809630			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7809630				2022-12-28	WOS:A1995QB15300038
J	CURTIS, JR; PARK, DR; KRONE, MR; PEARLMAN, RA				CURTIS, JR; PARK, DR; KRONE, MR; PEARLMAN, RA			USE OF THE MEDICAL FUTILITY RATIONALE IN DO-NOT-ATTEMPT-RESUSCITATION ORDERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOPULMONARY-RESUSCITATION; TEACHING HOSPITALS; DECISIONS; QUALITY; LIFE	Objective.-To describe the use of the medical futility rationale in do-not-attempt-resuscitation (DNAR) orders written for medical inpatients. Design.-Structured interviews with medical residents. Methods.-Second- and third-year internal medicine residents (n=44) were telephoned weekly and briefly interviewed about each patient who received a DNAR order in the preceding week, Setting.-Two university-affiliate hospitals: a veterans affairs medical center and a municipal hospital. Patients.-One hundred forty-five medical inpatients for whom DNAR orders were written during their hospitalization. Results.-Residents stated that the medical futility rationale applied for 91 patients (63%), but this rationale was invoked independent of patient or surrogate choice for only 17 patients (12%). Of the 91 patients for whom futility applied, both quantitative futility (low probability of success) and qualitative futility (poor quality of life if cardiopulmonary resuscitation [CPR] were performed) applied to 45 (49%), quantitative futility alone to 30 (33%), and qualitative futility atone to 16 (18%). Residents report that they discussed resuscitation issues with all communicative patients for whom the medical futility rationale was invoked, Among patients for whom quantitative futility applied, residents' predictions of the probability that patients would survive to hospital discharge after CPR varied from 0% (for 60% of patients) to 75%, For 32% of these patients, residents predicted survival at 5% or more, Logistic regression modeling showed that the presence of organ failure (odds ratio [OR], 8.9; 95% confidence interval [CI], 3.3 to 23.9), the residents' estimates of the probability of surviving CPR (OR, 0.94; 95% CI, 0.88 to 0.99), and nonwhite race (OR, 2.7; 95% CI, 1.1 to 6.3) were associated with the determination of quantitative futility, In one third of the cases where qualitative futility applied, residents made the judgment of qualitative futility without discussing quality of life with communicative patients. Logistic regression modeling showed immobility (OR, 3.2; 95% CI, 1.1 to 9.0) and age greater than or equal to 75 years (OR, 0.3; 95% CI, 0.1 to 0.8) to be associated with the determination of qualitative futility. Conclusions.-While residents did not appear to use the medical futility rationale to avoid discussing DNAR issues with patients, we found evidence of important misunderstandings of the concepts of both quantitative and qualitative futility, tf the futility rationale is to be applied to withholding or withdrawing medical interventions, practice guidelines for its use should be developed, and education about medical futility must be incorporated into medical school, residency training, and continuing medical education programs.	UNIV WASHINGTON,DEPT MED,DIV GERONTOL & GERIATR MED,SEATTLE,WA; VET AFFAIRS MED CTR,SEATTLE,WA 98108; UNIV WASHINGTON,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	CURTIS, JR (corresponding author), UNIV WASHINGTON,MED CTR,DIV PULM & CRIT CARE,RM-12,SEATTLE,WA 98195, USA.							[Anonymous], 1991, ANN INTERN MED, V115, P478; BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; EVANS AL, 1985, JAMA-J AM MED ASSOC, V253, P2236, DOI 10.1001/jama.253.15.2236; FARBER SJ, 1988, NEW ENGL J MED, V318, P1757; HACKLER JC, 1990, JAMA-J AM MED ASSOC, V264, P1281, DOI 10.1001/jama.264.10.1281; JECKER NS, 1992, ARCH INTERN MED, V152, P1140, DOI 10.1001/archinte.152.6.1140; JONSSON PV, 1988, ARCH INTERN MED, V148, P2373, DOI 10.1001/archinte.148.11.2373; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; LANTOS JD, 1989, AM J MED, V87, P81; LIANG KY, 1993, ANNU REV PUBL HEALTH, V14, P43, DOI 10.1146/annurev.pu.14.050193.000355; LO B, 1985, ARCH INTERN MED, V145, P1115, DOI 10.1001/archinte.145.6.1115; LO B, 1991, JAMA-J AM MED ASSOC, V265, P1874, DOI 10.1001/jama.265.14.1874; MURPHY DJ, 1988, JAMA-J AM MED ASSOC, V260, P2098, DOI 10.1001/jama.260.14.2098; ROSENBERG M, 1993, ARCH INTERN MED, V153, P1370, DOI 10.1001/archinte.153.11.1370; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SCHNEIDERMAN LJ, 1993, ARCH INTERN MED, V153, P437, DOI 10.1001/archinte.153.4.437; STARR TJ, 1986, J GEN INTERN MED, V1, P373, DOI 10.1007/BF02596420; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; TOMLINSON T, 1990, JAMA-J AM MED ASSOC, V264, P1276, DOI 10.1001/jama.264.10.1276; TRUOG RD, 1992, NEW ENGL J MED, V326, P1560, DOI 10.1056/NEJM199206043262310; UHLMANN RF, 1991, ARCH INTERN MED, V151, P495, DOI 10.1001/archinte.151.3.495; UHLMANN RF, 1984, WESTERN J MED, V140, P114; YOUNGER SJ, 1988, JAMA-J AM MED ASSOC, V260, P2094, DOI 10.1001/jama.260.14.2094; YOUNGNER SJ, 1990, JAMA-J AM MED ASSOC, V264, P1295, DOI 10.1001/jama.264.10.1295; YOUNGNER SJ, 1985, JAMA-J AM MED ASSOC, V253, P54; ZIMMERMAN JE, 1986, JAMA-J AM MED ASSOC, V255, P351, DOI 10.1001/jama.255.3.351; 1983, DECIDING FARGO LIFE; 1986, JAMA-J AM MED ASSOC, V255, P2905; 1989, CRIT CARE MED, V18, P1435; 1991, JAMA-J AM MED ASSOC, V265, P1868	31	122	122	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 11	1995	273	2					124	128		10.1001/jama.273.2.124	http://dx.doi.org/10.1001/jama.273.2.124			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ687	7799492				2022-12-28	WOS:A1995PZ68700025
J	KATTLOVE, H; LIBERATI, A; KEELER, E; BROOK, RH				KATTLOVE, H; LIBERATI, A; KEELER, E; BROOK, RH			BENEFITS AND COSTS OF SCREENING AND TREATMENT FOR EARLY BREAST-CANCER - DEVELOPMENT OF A BASIC BENEFIT PACKAGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHEST-X-RAY; RANDOMIZED CLINICAL-TRIAL; ROUTINE FOLLOW-UP; RADICAL-MASTECTOMY; PSYCHOLOGICAL ADJUSTMENT; CONSERVING TREATMENT; ELDERLY PATIENTS; DEATH RATES; BODY-IMAGE; STAGE-I	Objective.-To develop a basic benefit package for detection and treatment of early breast cancer by evaluating the effectiveness and costs for screening mammography, primary surgery, adjuvant therapy, and follow-up care. Data Sources.-Published articles were retrieved through MEDLINE; additional articles were obtained through searches of their bibliographies. Cancer statistics were taken from Surveillance, Epidemiology, and End Results (SEER) Program data, population statistics were taken from US Census data, and charges from 1993 Southern California Medicare fees were used to represent costs. Study Selection.-Studies were selected on the basis of their design. Preference, in decreasing order, was given to meta-analyses of randomized trials, individual randomized clinical trials, prospective cohort studies, retrospective cohort studies, and case series. Data Extraction.-Studies were examined for the effect of the intervention on overall survival, disease-free survival, and health-related quality of life. We evaluated effects on survival in terms of number of lives saved at 10 years and average years of life saved. Costs were related to the benefits observed and modeled onto a hypothetical health care organization of 500 000 lives. Results.-Based on this analysis, we recommend a basic benefit plan for the detection and treatment of early breast cancer that would include the following: (1) screening mammography only for women aged 50 to 69 years; (2) choice of mastectomy or breast-conserving surgery with radiation therapy for all women with early breast cancer; (3) adjuvant therapy for all women at risk of recurrence; and (4) only clinical follow-up without routine testing for metastatic disease. Conclusions.-By choosing which services they provide to specific groups of patients, providers can substantially reduce their expenses and still provide quality health benefits.	RAND CORP, SANTA MONICA, CA 90407 USA; UNIV CALIF LOS ANGELES, DEPT MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, CTR HLTH SCI, LOS ANGELES, CA 90024 USA; IST RIC FARMACOL MARIO NEGRI, CLIN EPIDEMIOL LAB, MILAN, ITALY	RAND Corporation; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Istituto di Ricerche Farmacologiche Mario Negri IRCCS								ABE O, 1992, LANCET, V339, P71; ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; ANDREOLI C, 1987, TUMORI, V73, P463, DOI 10.1177/030089168707300506; [Anonymous], 1992, Lancet, V339, P1; ARNSTEIN NB, 1984, CANCER, V54, P2243, DOI 10.1002/1097-0142(19841115)54:10<2243::AID-CNCR2820541030>3.0.CO;2-V; ASHCROFT JJ, 1985, J ROY SOC MED, V78, P43; BAIDER L, 1986, GEN HOSP PSYCHIAT, V8, P251, DOI 10.1016/0163-8343(86)90006-X; BAINES CJ, 1994, ANN INTERN MED, V120, P326, DOI 10.7326/0003-4819-120-4-199402150-00011; BARTELINK H, 1985, INT J RADIAT ONCOL, V11, P381, DOI 10.1016/0360-3016(85)90161-0; BATES T, 1991, BRIT J SURG, V78, P591, DOI 10.1002/bjs.1800780523; BECK JR, 1982, AM J MED, V73, P883, DOI 10.1016/0002-9343(82)90786-0; BECKMANN J, 1983, DAN MED BULL, V30, P10; BLACK PB, 1981, BRIT MED J, V282, P2095; BLICHERTTOFT M, 1988, ACTA ONCOL, V27, P671, DOI 10.3109/02841868809091767; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BROYN T, 1982, ACTA CHIR SCAND, V148, P401; CHAMBERLAIN J, 1992, BRIT MED J, V304, P346; CHAMBERLAIN J, 1988, LANCET, V2, P411; CIATTO S, 1989, BRIT J CANCER, V60, P102, DOI 10.1038/bjc.1989.229; CIATTO S, 1985, TUMORI, V71, P325, DOI 10.1177/030089168507100402; CIATTO S, 1983, TUMORI, V69, P151, DOI 10.1177/030089168306900211; CLARK RM, 1992, JNCI-J NATL CANCER I, V84, P683, DOI 10.1093/jnci/84.9.683; CUZICK J, 1987, CANCER TREAT REP, V71, P15; CUZICK J, 1987, CANCER TREAT REP, V71, P7; DEHAES JCJM, 1986, EUR J SURG ONCOL, V12, P337; DELTURCO MR, 1994, JAMA-J AM MED ASSOC, V271, P1593, DOI 10.1001/jama.1994.03510440053032; DEWAR JA, 1985, BRIT MED J, V291, P1464, DOI 10.1136/bmj.291.6507.1464; DIXON JM, 1992, BRIT MED J, V304, P996, DOI 10.1136/bmj.304.6833.996; ELWOOD JM, 1993, ONLINE J CURR CL FEB; FALLOWFIELD LJ, 1986, BMJ-BRIT MED J, V293, P1331, DOI 10.1136/bmj.293.6558.1331; FALLOWFIELD LJ, 1990, BRIT MED J, V301, P575, DOI 10.1136/bmj.301.6752.575; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; FRISELL J, 1991, BREAST CANCER RES TR, V18, P49, DOI 10.1007/BF01975443; GANZ PA, 1992, CANCER-AM CANCER SOC, V69, P1729, DOI 10.1002/1097-0142(19920401)69:7<1729::AID-CNCR2820690714>3.0.CO;2-D; GASPARINI G, 1993, J NATL CANCER I, V85, P1206, DOI 10.1093/jnci/85.15.1206; GAZET JC, 1988, LANCET, V1, P679; HANNISDAL E, 1993, EUR J CANCER, V29A, P992, DOI 10.1016/S0959-8049(05)80208-4; HOLLI K, 1989, EUR J CANCER CLIN ON, V25, P251, DOI 10.1016/0277-5379(89)90016-3; HOLMBERG L, 1989, CANCER-AM CANCER SOC, V64, P969, DOI 10.1002/1097-0142(19890815)64:4<969::AID-CNCR2820640433>3.0.CO;2-O; HOLMBERG L, 1990, J NATL CANCER I, V82, P277; JENKS S, 1993, J NATL CANCER I, V85, P348, DOI 10.1093/jnci/85.5.348; KEMENY MM, 1988, CANCER, V62, P1231, DOI 10.1002/1097-0142(19880915)62:6<1231::AID-CNCR2820620631>3.0.CO;2-8; KINDLER M, 1989, ONCOLOGY, V46, P360; LASRY JCM, 1987, J CHRON DIS, V40, P529, DOI 10.1016/0021-9681(87)90010-5; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LEVY SM, 1989, J CLIN ONCOL, V7, P367, DOI 10.1200/JCO.1989.7.3.367; LICHTER AS, 1992, J CLIN ONCOL, V10, P976, DOI 10.1200/JCO.1992.10.6.976; LOGAGER VB, 1990, EUR J CANCER, V26, P553, DOI 10.1016/0277-5379(90)90073-3; MAUNSELL E, 1989, J CLIN EPIDEMIOL, V42, P765, DOI 10.1016/0895-4356(89)90074-7; MCARDLE JM, 1990, BRIT J SURG, V77, P1221, DOI 10.1002/bjs.1800771110; MEYER L, 1989, ACTA ONCOL, V28, P13, DOI 10.3109/02841868909111174; MILLER AB, 1992, CAN MED ASSOC J, V147, P1477; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; MILLER BA, 1993, CA-CANCER J CLIN, V43, P27, DOI 10.3322/canjclin.43.1.27; Miller R. G., 1981, SURVIVAL ANAL; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; ORMISTON MC, 1985, J ROY SOC MED, V78, P920, DOI 10.1177/014107688507801108; PANDYA KJ, 1983, CANCER TREAT S, V2, P117; PEER PGM, 1994, J NATL CANCER I, V86, P436, DOI 10.1093/jnci/86.6.436; ROBERTS MM, 1990, LANCET, V335, P241; ROBERTSON JFR, 1992, EUR J CANCER, V28A, P908, DOI 10.1016/0959-8049(92)90148-U; RUBENS RD, 1993, J CLIN ONCOL, V11, P3, DOI 10.1200/JCO.1993.11.1.3; RUTGERS EJT, 1989, BRIT J SURG, V76, P187, DOI 10.1002/bjs.1800760227; SANGER CK, 1981, CANCER, V48, P2341, DOI 10.1002/1097-0142(19811115)48:10<2341::AID-CNCR2820481034>3.0.CO;2-3; SARRAZIN D, 1989, RADIOTHER ONCOL, V14, P177, DOI 10.1016/0167-8140(89)90165-5; SAUER R, 1992, Strahlentherapie und Onkologie, V168, P191; SCANLON EF, 1980, CANCER, V46, P977, DOI 10.1002/1097-0142(19800815)46:4+<977::AID-CNCR2820461320>3.0.CO;2-0; SCHAIN W, 1983, BREAST CANCER RES TR, V3, P377, DOI 10.1007/BF01807591; SHAPIRO S, 1989, CANCER, V63, P1873, DOI 10.1002/1097-0142(19890515)63:10<1873::AID-CNCR2820631002>3.0.CO;2-6; SICKLES EA, 1993, J NATL CANCER I, V85, P1621, DOI 10.1093/jnci/85.20.1621; SMIGEL K, 1993, J NATL CANCER I, V85, P1626, DOI 10.1093/jnci/85.20.1626; STEINBERG MD, 1985, AM J PSYCHIAT, V142, P34; STIERER M, 1989, CANCER, V64, P1128, DOI 10.1002/1097-0142(19890901)64:5<1128::AID-CNCR2820640527>3.0.CO;2-H; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; TAYLOR SE, 1985, CANCER, V55, P2506, DOI 10.1002/1097-0142(19850515)55:10<2506::AID-CNCR2820551033>3.0.CO;2-0; TOMIN R, 1987, J CLIN ONCOL, V5, P62, DOI 10.1200/JCO.1987.5.1.62; VALLAGUSSA P, 1981, BREAST CANCER RES TR, V1, P349; VANDONGEN JA, 1992, EUR J CANCER, V28A, P801, DOI 10.1016/0959-8049(92)90118-L; VERONESI U, 1993, NEW ENGL J MED, V328, P1587, DOI 10.1056/NEJM199306033282202; VERONESI U, 1990, EUR J CANCER, V26, P668, DOI 10.1016/0277-5379(90)90113-8; VESTERGAARD A, 1989, EUR J CANCER CLIN ON, V25, P687, DOI 10.1016/0277-5379(89)90205-8; WAGMAN LD, 1991, SURG GYNECOL OBSTET, V172, P191; WELLISCH DK, 1989, PSYCHOSOMATICS, V30, P365, DOI 10.1016/S0033-3182(89)72241-6; WICKERHAM L, 1984, BREAST CANCER RES TR, V4, P303, DOI 10.1007/BF01806043; WINCHESTER DP, 1979, CANCER, V43, P956, DOI 10.1002/1097-0142(197903)43:3<956::AID-CNCR2820430326>3.0.CO;2-L; WOLBERG WH, 1989, CANCER-AM CANCER SOC, V63, P1645, DOI 10.1002/1097-0142(19890415)63:8<1645::AID-CNCR2820630835>3.0.CO;2-8; WOOLF SH, 1990, J CLIN EPIDEMIOL, V43, P891, DOI 10.1016/0895-4356(90)90073-X; ZIEGLER J, 1993, J NATL CANCER I, V85, P351, DOI 10.1093/jnci/85.5.351; ZWAVELING A, 1987, J SURG ONCOL, V34, P194, DOI 10.1002/jso.2930340314; 1994, CANCER NET NEWS 0509; 1994, JAMA-J AM MED ASSOC, V271, P1587	92	120	121	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 11	1995	273	2					142	148		10.1001/jama.273.2.142	http://dx.doi.org/10.1001/jama.273.2.142			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PZ687	7799495				2022-12-28	WOS:A1995PZ68700028
J	KERLIKOWSKE, K; GRADY, D; RUBIN, SM; SANDROCK, C; ERNSTER, VL				KERLIKOWSKE, K; GRADY, D; RUBIN, SM; SANDROCK, C; ERNSTER, VL			EFFICACY OF SCREENING MAMMOGRAPHY - A METAANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							BREAST-CANCER DETECTION; DETECTION DEMONSTRATION PROJECT; NATURAL MENOPAUSE; RANDOMIZED TRIAL; DEATH RATES; 2 VIEWS; MORTALITY; AGE; PROGRAM; WOMEN	Objective.-To determine the efficacy of screening mammography by age, number of mammographic views per screen, screening interval, and duration of follow-up. Design.-Literature review and meta-analysis. Data Identification and Analysis.-Literature search of English-language studies reported from January 1966 to October 31, 1993, using MEDLINE, manual literature review, and consultation with experts. A total of 13 studies were selected, and their results were combined using meta-analytic techniques based on the assumption of fixed effects. Main Results.-The overall summary relative risk (RR) estimate for breast cancer mortality for women aged 50 to 74 years undergoing screening mammography compared with those who did not was 0.74 (95% confidence interval [CI], 0.66 to 0.83). The magnitude of the benefit in this age group was similar regardless of number of mammographic views per screen, screening interval, or duration of follow-up. In contrast, none of the summary RR estimates for women aged 40 to 49 years was significantly less than 1.0, irrespective of screening intervention or duration of follow-up. The overall summary RR estimate in women aged 40 to 49 years was 0.93 (95% CI, 0.76 to 1.13); the summary RR estimate for those studies that used two-view mammography was 0.87 (95% CI, 0.68 to 1.12) compared with 1.02 (95% CI, 0.73 to 1.44) for those studies that used one-view mammography, and for those studies with 7 to 9 years of follow-up, the summary RR estimate was 1.02 (95% CI, 0.82 to 1.27) compared with 0.83 (95% CI, 0.65 to 1.06) for those studies with 10 to 12 years of follow-up. Conclusion.-Screening mammography significantly reduces breast cancer mortality in women aged 50 to 74 years after 7 to 9 years of follow-up, regardless of screening interval or number of mammographic views per screen. There is no reduction in breast cancer mortality in women aged 40 to 49 years after 7 to 9 years of follow-up. Screening mammography may be effective in reducing breast cancer mortality in women aged 40 to 49 years after 10 to 12 years of follow-up, but the same benefit could probably be achieved by beginning screening at menopause or 50 years of age.	UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,DIV GEN INTERNAL MED,SAN FRANCISCO,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	KERLIKOWSKE, K (corresponding author), VET AFFAIRS MED CTR,GEN INTERNAL MED SECT,111A1,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.				NCI NIH HHS [P50 CA58207] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058207] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; ANDERSSON I, 1978, AM J ROENTGENOL, V130, P349, DOI 10.2214/ajr.130.2.349; ANDERSSON I, 1985, MATURITAS, V7, P21, DOI 10.1016/0378-5122(85)90031-3; BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; BASSETT LW, 1987, RADIOLOGY, V165, P95, DOI 10.1148/radiology.165.1.3628795; BULPITT CJ, 1988, LANCET, V2, P93; CHU KC, 1988, JNCI-J NATL CANCER I, V80, P1125, DOI 10.1093/jnci/80.14.1125; COLLETTE HJA, 1992, J EPIDEMIOL COMMUN H, V46, P382, DOI 10.1136/jech.46.4.382; ELWOOD JM, 1993, ONLINE J CURR CLIN T, V2; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; FRISELL J, 1991, BREAST CANCER RES TR, V18, P49, DOI 10.1007/BF01975443; FRISELL J, 1986, BREAST CANCER RES TR, V8, P45, DOI 10.1007/BF01805924; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; LETTON AH, 1981, CANCER, V48, P404, DOI 10.1002/1097-0142(19810715)48:2<404::AID-CNCR2820480230>3.0.CO;2-X; LETTON AH, 1977, CANCER, V40, P1, DOI 10.1002/1097-0142(197707)40:1<1::AID-CNCR2820400102>3.0.CO;2-#; MILLER AB, 1992, CAN MED ASSOC J, V147, P1477; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; MILLER AB, 1991, CANCER SCREENING, P3; MOSKOWITZ M, 1986, RADIOLOGY, V161, P37, DOI 10.1148/radiology.161.1.3532183; MOSS SM, 1992, J EPIDEMIOL COMMUN H, V46, P362, DOI 10.1136/jech.46.4.362; MUIR BB, 1984, RADIOLOGY, V151, P39, DOI 10.1148/radiology.151.1.6701330; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; OMALEY M, 1990, DOES SCREENING BREAS; PALLI D, 1989, J EPIDEMIOL COMMUN H, V43, P241, DOI 10.1136/jech.43.3.241; PEER PGM, 1994, J NATL CANCER I, V89, P436; PEETERS PHM, 1989, INT J CANCER, V43, P226, DOI 10.1002/ijc.2910430209; ROBERTS MM, 1990, LANCET, V335, P241; SEIDMAN H, 1987, CA-CANCER J CLIN, V37, P258, DOI 10.3322/canjclin.37.5.258; SHAPIRO S, 1977, CANCER, V39, P2772, DOI 10.1002/1097-0142(197706)39:6<2772::AID-CNCR2820390665>3.0.CO;2-K; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; Shapiro S, 1988, PERIODIC SCREENING B; SICKLES EA, 1986, AM J ROENTGENOL, V147, P1149, DOI 10.2214/ajr.147.6.1149; SICKLES EA, 1993, J NATL CANCER I, V85, P1621, DOI 10.1093/jnci/85.20.1621; SMART CR, 1993, CANCER, V72, P1449, DOI 10.1002/1097-0142(19930815)72:4+<1449::AID-CNCR2820721406>3.0.CO;2-C; STANFORD JL, 1987, J CHRON DIS, V40, P995, DOI 10.1016/0021-9681(87)90113-5; TABAR L, 1987, BRIT J CANCER, V55, P547, DOI 10.1038/bjc.1987.112; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; TABAR L, 1989, J EPIDEMIOL COMMUN H, V43, P107, DOI 10.1136/jech.43.2.107; VANDIJCK JAAM, 1992, BRIT J RADIOL, V65, P971, DOI 10.1259/0007-1285-65-779-971; VERBEEK ALM, 1985, LANCET, V1, P865, DOI 10.1016/S0140-6736(85)92223-8; WALD N, 1993, J EUR SOC MASTOLOGY, V13, P1; WHELAN EA, 1990, AM J EPIDEMIOL, V131, P625, DOI 10.1093/oxfordjournals.aje.a115546	42	835	851	2	62	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 11	1995	273	2					149	154		10.1001/jama.273.2.149	http://dx.doi.org/10.1001/jama.273.2.149			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ687	7799496				2022-12-28	WOS:A1995PZ68700029
J	KOSS, R; NADZAM, D; LOEB, JM				KOSS, R; NADZAM, D; LOEB, JM			INDICATOR MEASUREMENT SYSTEM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											KOSS, R (corresponding author), JOINT COMMISS ACCREDITAT HEALTHCARE ORG,OAKBROOK TERRACE,IL 60181, USA.								0	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 11	1995	273	2					99	99						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ687	7799504				2022-12-28	WOS:A1995PZ68700006
J	BATES, CJ				BATES, CJ			VITAMIN-A	LANCET			English	Article							A SUPPLEMENTATION; BETA-CAROTENE; CHILDHOOD MORTALITY; CHILDREN; TRIAL; METAANALYSIS; POPULATION; DIARRHEA; TOXICITY; MEASLES				BATES, CJ (corresponding author), MRC, DUNN NUTR CTR, CAMBRIDGE CB4 1XJ, ENGLAND.							Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; [Anonymous], 1993, Lancet, V342, P7; BARCLAY AJG, 1987, BMJ-BRIT MED J, V294, P294, DOI 10.1136/bmj.294.6567.294; Beaton G, 1993, ACC SCN STATE ART SE; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; CHENG L, 1993, EUR J CLIN NUTR, V47, P88; DAULAIRE NMP, 1992, BMJ-BRIT MED J, V304, P207, DOI 10.1136/bmj.304.6821.207; DEFRANCISCO A, 1993, LANCET, V342, P526, DOI 10.1016/0140-6736(93)91648-6; FAWZI WW, 1994, AM J CLIN NUTR, V59, P401, DOI 10.1093/ajcn/59.2.401; FAWZI WW, 1993, JAMA-J AM MED ASSOC, V269, P898, DOI 10.1001/jama.269.7.898; GAREWAL HS, 1993, J CELL BIOCHEM, P262; GLASZIOU PP, 1993, BMJ-BRIT MED J, V306, P366, DOI 10.1136/bmj.306.6874.366; HATHCOCK JN, 1990, AM J CLIN NUTR, V52, P183, DOI 10.1093/ajcn/52.2.183; HERRERA MG, 1992, LANCET, V340, P267, DOI 10.1016/0140-6736(92)92357-L; Hong Waun Ki, 1994, P597; HUSSEY GD, 1990, NEW ENGL J MED, V323, P160, DOI 10.1056/NEJM199007193230304; MUHILAL, 1988, AM J CLIN NUTR, V48, P1271, DOI 10.1093/ajcn/48.5.1271; NAGAO A, 1994, FASEB J, V8, P968, DOI 10.1096/fasebj.8.12.8088462; RAHMATHULLAH L, 1990, NEW ENGL J MED, V323, P929, DOI 10.1056/NEJM199010043231401; Ross A. Catharine, 1994, P521; ROUSSEAU EJ, 1992, FREE RADICAL BIO MED, V13, P407, DOI 10.1016/0891-5849(92)90183-H; SARMA U, 1994, EUR J CLIN NUTR, V48, P1; SEMBA RD, 1993, LANCET, V341, P5, DOI 10.1016/0140-6736(93)92478-C; SOMMER A, 1986, LANCET, V1, P1169; STANSFIELD SK, 1993, LANCET, V342, P578, DOI 10.1016/0140-6736(93)91410-N; VANPOPPEL G, 1993, AM J CLIN NUTR, V57, P402, DOI 10.1093/ajcn/57.3.402; VERMA AK, 1991, CONT ISS CL, V14, P25; VIJAYARAGHAVAN K, 1990, LANCET, V336, P1342, DOI 10.1016/0140-6736(90)92895-O; WALD NJ, 1988, BRIT J CANCER, V57, P428, DOI 10.1038/bjc.1988.97; WEST KP, 1991, LANCET, V338, P67, DOI 10.1016/0140-6736(91)90070-6; WOLF G, 1993, NUTR REV, V51, P205, DOI 10.1111/j.1753-4887.1993.tb03104.x; 1991, REPORT HLTH SOCIAL S, V41; 1988, FAO FOOD NUTR SER, V23	33	103	108	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 7	1995	345	8941					31	35		10.1016/S0140-6736(95)91157-X	http://dx.doi.org/10.1016/S0140-6736(95)91157-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799706				2022-12-28	WOS:A1995QA29000015
J	SHEAR, JB; FISHMAN, HA; ALLBRITTON, NL; GARIGAN, D; ZARE, RN; SCHELLER, RH				SHEAR, JB; FISHMAN, HA; ALLBRITTON, NL; GARIGAN, D; ZARE, RN; SCHELLER, RH			SINGLE CELLS AS BIOSENSORS FOR CHEMICAL SEPARATIONS	SCIENCE			English	Article							PC12 CELLS; CALCIUM INFLUX; ACETYLCHOLINE; RECEPTORS; SENSOR; ACTIVATION; GLUCOSE; RELEASE	A biosensor system based on the response of living cells was demonstrated that can detect specific components of a complex mixture fractionated by a microcolumn separation technique. This system uses ligand-receptor binding and signal-transduction pathways to biochemically amplify the presence of an analyte after electrophoretic separation. The transduced signal was measured by means of two approaches: (i) fluorescence determination of intracellular calcium concentrations in one or more rat PC-12 cells and (ii) measurement of transmembrane current in a Xenopus laevis oocyte microinjected with messenger RNA that encodes a specific receptor. This analysis system has the potential to identify biologically active ligands present in a complex mixture with exceptional sensitivity and selectivity.	STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305; STANFORD UNIV,DEPT NEUROBIOL,STANFORD,CA 94305; STANFORD UNIV,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305	Stanford University; Stanford University; Stanford University			Zare, Richard N./A-8410-2009	Zare, Richard/0000-0001-5266-4253	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH112188, R01MH045423, R01MH045324] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH112188, MH45324-05, MH45423-03] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABDELLATIF MS, 1988, ANAL LETT, V21, P943; BRIGGS CA, 1991, BRIT J PHARMACOL, V104, P1038, DOI 10.1111/j.1476-5381.1991.tb12546.x; BUSH AB, 1991, J NEUROCHEM, V57, P562, DOI 10.1111/j.1471-4159.1991.tb03787.x; COOPER JR, 1986, BIOCH BASIS NEUROPHA, P173; DELORME EM, 1988, J NEUROCHEM, V50, P1248, DOI 10.1111/j.1471-4159.1988.tb10601.x; FASOLATO C, 1990, J BIOL CHEM, V265, P20351; FISHMAN HA, 1994, ANAL CHEM, V66, P2318, DOI 10.1021/ac00086a018; GANDHI CR, 1992, BIOCHEM J, V287, P897, DOI 10.1042/bj2870897; GIAEVER I, 1973, J IMMUNOL, V110, P1424; GREANEY MD, 1993, J CHROMATOGR-BIOMED, V622, P125, DOI 10.1016/0378-4347(93)80258-6; GREENE LA, 1977, NATURE, V268, P349, DOI 10.1038/268349a0; GREENE LA, 1991, CULTURING NERVE CELL, P207; JACKSON T, 1991, PHARMACOL THERAPEUT, V50, P425, DOI 10.1016/0163-7258(91)90052-N; KIST TBL, 1994, BRAZ J MED BIOL RES, V27, P11; MONNIG CA, 1994, ANAL CHEM, V66, pR280, DOI 10.1021/ac00084a013; MORI M, 1988, J BIOL CHEM, V263, P14574; NIE S, UNPUB; OATES MD, 1990, ANAL CHEM, V62, P1573, DOI 10.1021/ac00214a006; OLEFIROWICZ TM, 1990, ANAL CHEM, V62, P1872, DOI 10.1021/ac00216a026; PARCE JW, 1989, SCIENCE, V246, P243, DOI 10.1126/science.2799384; POZZAN T, 1986, BIOCHEM J, V234, P547, DOI 10.1042/bj2340547; ROGERS KR, 1989, ANAL BIOCHEM, V182, P353, DOI 10.1016/0003-2697(89)90607-6; ROUNDS MA, 1993, J CHROMATOGR A, V653, P148, DOI 10.1016/0021-9673(93)80404-V; SANDS SB, 1991, BRAIN RES, V560, P38, DOI 10.1016/0006-8993(91)91211-I; SMITH RD, 1993, ANAL CHEM, V65, pA574, DOI 10.1021/ac00061a001; SUGAO N, 1993, ANAL CHEM, V65, P363, DOI 10.1021/ac00052a009; SUZUKI H, 1987, ANAL CHIM ACTA, V199, P85, DOI 10.1016/S0003-2670(00)82799-3; TURNER APF, 1991, ADV BIOSENSORS; UPDIKE SJ, 1967, NATURE, V214, P986, DOI 10.1038/214986a0; YAMAMOTO K, 1991, J CHROMATOGR, V588, P327	30	60	64	4	22	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 6	1995	267	5194					74	77		10.1126/science.7809609	http://dx.doi.org/10.1126/science.7809609			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA235	7809609				2022-12-28	WOS:A1995QA23500030
J	MACINTYRE, I				MACINTYRE, I			ANOTHER KIND OF FLYING DOCTOR	BRITISH MEDICAL JOURNAL			English	Article											MACINTYRE, I (corresponding author), WESTERN GEN HOSP,DEPT GEN SURG,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.			Macintyre, Iain/0000-0003-2716-8500					0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1745	1746		10.1136/bmj.309.6970.1745	http://dx.doi.org/10.1136/bmj.309.6970.1745			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7820011	Green Published			2022-12-28	WOS:A1994PY71700043
J	PEARN, J				PEARN, J			THE EARLIEST DAYS OF FIRST-AID	BRITISH MEDICAL JOURNAL			English	Article								First aid, as a profession in its own right, has a history of only 120 years. It evolved from the teachings of the Royal Humane Society and military surgeons, who saw the wisdom of training in splinting and bandaging for battlefield wounds. In 1878 two Aberdeenshire military officers, Surgeon-Major Peter Shepherd of the Royal Herbert Military Hospital, Woolwich, London, and Colonel Francis Duncan established the concept of teaching first aid skills to civilians. This radical new enterprise, conducted under the auspices of the newly formed St John Ambulance Association, was a natural evolution from the body's philanthropic and ambuance transport work. Shepherd conducted the first class in the hall of the Presbyterian school in Woolwich using a comprehensive first aid curriculum that he had developed. Within months of that first class, local Woolwich civilians used their skills when the pleasure boat Princess Alice sank in the Thames at Woolwich, killing 600 people. Within a decade, the new discipline of first aid spread rapidly throughout the world, and by the end of the 19th century, hundreds of thousands of St John first aid certificates had been awarded in four continents. Shepherd's pioneering classes changed the world's concept of the need for the provision of skilled prehospital care.			PEARN, J (corresponding author), ROYAL CHILDRENS HOSP,DEPT CHILD HLTH,BRISBANE,QLD 4029,AUSTRALIA.			Pearn, John/0000-0002-8815-2994				CANTLIE N, 1939, J CANTLIE ROMANCE ME, P19; CLIFFORD Joan, 1971, SERVICE MANKIND FURL; FLETCHER NC, 1929, J AMBULANCE ASS ITS, P12; FURNEAUX R, 1963, ZULU WAR ISANDHLWANA, P89; LEAVENSWHITE W, 1878, SOUTHPORT VISIT 0713; PEARN JH, 1993, MED HERBS WOUNDWORTS, P1; VINCENT WT, 1890, RECORDS WOOLWICH DIS, V1, P434; 1885, CITY PRESS      0218, P1; 1878, BERROWS WORCEST 0504; 1879, KENTISH INDEPEN 0215, P1; 1878, KENTISH INDEPEN 0119, P1; 1885, MED PRESS CIRCU 0311, P1; 1878, WOOLWICH GAZETT 1130; 1878, KENTISH INDEPEN 0302; 1878, DAILY TELEGRAPH 0314, P2; 1878, STANDARD        0122, P1; 1878, DAILY CHRONICLE 0625; 1878, KENTISH MERCURY 1130; 1878, DERBYSKIRE TIME 0720; 1879, STANDARD        0212	20	22	22	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1718	1720		10.1136/bmj.309.6970.1718	http://dx.doi.org/10.1136/bmj.309.6970.1718			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7820000	Green Published			2022-12-28	WOS:A1994PY71700030
J	CRAGG, D; HALLAM, L				CRAGG, D; HALLAM, L			QUALITY STANDARDS FOR DEPUTIZING SERVICES	BRITISH MEDICAL JOURNAL			English	Note									UNIV MANCHESTER,RUSHOLME HLTH CTR,CTR PRIMARY CARE RES,MANCHESTER M14 5NP,LANCS,ENGLAND	University of Manchester	CRAGG, D (corresponding author), UNIV MANCHESTER,RUSHOLME HLTH CTR,DEPT GEN PRACTICE,MANCHESTER M14 5NP,LANCS,ENGLAND.								0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1630	1630						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819947				2022-12-28	WOS:A1994PY22000031
J	GODLEE, F				GODLEE, F			WHO AT COUNTRY LEVEL - A LITTLE IMPACT, NO STRATEGY	BRITISH MEDICAL JOURNAL			English	Article								The acid test of WHO's effect on the world's health is its impact at country level. Unless it has an impact there, all of its declarations, its debates at the World Health Assembly, its conferences, its pamphlets, its political maneuvering in Geneva and the regions, all of these come to nothing. Working as it does through national governments, WHO insists that it has no role in directly managing or delivering health care. Judging WHO's impact in individual countries is therefore difficult-its approaches are largely indirect, and initiatives may take years to bear fruit. But from the meagre resources that WHO makes available at country level it is clear why its country operations are criticised as the weakest link in an already weak chain of influence from its headquarters in Geneva to the people in its member states. Poorly funded, undertrained, and with no clear strategy to follow, its staff at country level stand little chance of making an impact.										DAES EIA, 1994, A4834 S, V34; LAWSON JS, 1994, STRENGTHENING HLTH S; LEE K, 1992, HEALTH POLICY PLANN, V7, P387, DOI 10.1093/heapol/7.4.387; TOLLISON RD, 1993, PUBLICATION SOCIAL A, V53; 1991, EFFECTIVENESS MULTIL	5	10	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1636	1639		10.1136/bmj.309.6969.1636	http://dx.doi.org/10.1136/bmj.309.6969.1636			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819949	Green Published			2022-12-28	WOS:A1994PY22000033
J	SPILLER, RC				SPILLER, RC			IRRITABLE BOWEL OR IRRITABLE MIND - MEDICAL-TREATMENT WORKS FOR THOSE WITH CLEAR DIAGNOSIS	BRITISH MEDICAL JOURNAL			English	Article							PSYCHOSOCIAL FACTORS; FOOD INTOLERANCE; MOTILITY; PREDOMINANT; SYMPTOMS; DIARRHEA				SPILLER, RC (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,NOTTINGHAM NG7 2UH,ENGLAND.		spiller, robin/ABE-6690-2021	spiller, robin/0000-0001-6371-4500				Drossman D., 1990, GASTR INT, V3, P159; DROSSMAN DA, 1988, GASTROENTEROLOGY, V95, P701, DOI 10.1016/S0016-5085(88)80017-9; GORARD DA, 1994, GUT, V35, P203, DOI 10.1136/gut.35.2.203; HARVEY RF, 1987, LANCET, V1, P963; JONES VA, 1982, LANCET, V2, P1115; KELLOW JE, 1987, GASTROENTEROLOGY, V92, P1885, DOI 10.1016/0016-5085(87)90620-2; KELLOW JE, 1990, GASTROENTEROLOGY, V98, P1208, DOI 10.1016/0016-5085(90)90335-X; KELLOW JE, 1991, GASTROENTEROLOGY, V101, P1621, DOI 10.1016/0016-5085(91)90400-F; NANDA R, 1989, GUT, V30, P1099, DOI 10.1136/gut.30.8.1099; PRIOR A, 1990, GUT, V31, P458, DOI 10.1136/gut.31.4.458; SANDLER RS, 1984, GASTROENTEROLOGY, V87, P314; SANDRAGESARAN K, 1991, GUT S, V32, pS14; SMITH RC, 1990, GASTROENTEROLOGY, V98, P293, DOI 10.1016/0016-5085(90)90817-K; THOMPSON DG, 1979, LANCET, V2, P1321; WHITEHEAD WE, 1988, GASTROENTEROLOGY, V95, P709, DOI 10.1016/S0016-5085(88)80018-0; WHITEHEAD WE, 1980, DIGEST DIS SCI, V25, P404, DOI 10.1007/BF01395503	16	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1646	1647		10.1136/bmj.309.6969.1646	http://dx.doi.org/10.1136/bmj.309.6969.1646			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819952	Green Published			2022-12-28	WOS:A1994PY22000039
J	DOUGLAS, KA; REDMAN, CWG				DOUGLAS, KA; REDMAN, CWG			ECLAMPSIA IN THE UNITED-KINGDOM	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREECLAMPSIA; HYPERTENSION; MANAGEMENT; PREGNANCY	Objectives--To measure the incidence eclampsia, establish how often it is preceded by signs of pre-eclampsia, document the morbidity associated with eclampsia, and determine the maternal case fatality rates. Design-A prospective, descriptive study of every case of eclampsia in the United Kingdom in 1992. Information was collected from reviews of hospital case notes and questionnaires to general practitioners. Setting-All 279 hospitals in the United Kingdom with a consultant obstetric unit. Results-Obstetricians and midwives notified 582 possible cases, and 383 were confirmed as eclampsia. The national incidence of eclampsia was 4.9/10 000 maternities (95% confidence interval 4.5 to 5.4). Most convulsions occurred despite antenatal care (70%) and within one week of the woman's last visit to a doctor or midwife (85%). Three quarters of first seizures occurred in hospital, of which 38% developed before both proteinuria and hypertension had been documented. Forty four per cent of cases occurred postpartum, more than a third (38%) antepartum, and the remainder (18%) intrapartum. Nearly one in 50 women (1.8%) died, and 35% of all women had at least one major complication. The rate of stillbirths and neonatal deaths was 22.2/1000 and 34.1/1000, respectively. Preterm eclampsia occurred more commonly antepartum and was associated with more maternal complications and fetuses that were small for gestational age, as well as with higher rates of stillbirth and neonatal mortality. Antepartum eclampsia, which was more likely to occur preterm, was associated with a higher rate of maternal complications and a higher neonatal mortality. Both factors (gestational prematurity and antepartum occurrence) contributed independently to the severity of the outcome. Conclusion-Eclampsia occurs in nearly one in 2000 maternities in the United Kingdom and is associated with high maternal morbidity and fatality in cases. It may present unheralded by warning signs. Preterm and antenatal eclampsia seem to be particularly severe.	UNIV OXFORD, JOHN RADCLIFFE HOSP, NUFFIELD DEPT OBSTET & GYNAECOL, OXFORD OX3 9DU, ENGLAND	University of Oxford			Douglas, Kirsty/E-3083-2017	Douglas, Kirsty/0000-0003-0174-782X				CAMPBELL DM, 1980, PREGNANCY HYPERTENS, P483; CORKILL TF, 1961, PATHOL MICROBIOL, V24, P428, DOI 10.1159/000161149; DOUGLAS KA, 1992, BRIT J OBSTET GYNAEC, V99, P355, DOI 10.1111/j.1471-0528.1992.tb13745.x; DULEY I, 1992, OXFORD DATABASE PERI; EDEN TW, 1922, J OBSTET GYN BR COMM, V29, P386; Hall M, 1992, Int J Technol Assess Health Care, V8 Suppl 1, P75; LLERA ML, 1992, AM J OBSTET GYNECOL, V166, P4; MOLLER B, 1986, ACTA OBSTET GYN SCAN, V65, P307; MOODLEY J, 1983, S AFR MED J, V63, P530; MOORE PJ, 1985, S AFR MED J, V67, P597; PORAPAKKHAM S, 1979, OBSTET GYNECOL, V54, P26, DOI 10.1097/00006250-197907000-00007; REDMAN CWG, 1993, LANCET, V341, P1451, DOI 10.1016/0140-6736(93)90890-S; REDMAN CWG, 1988, LANCET, V1, P809; ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O; SAFTLAS AF, 1990, AM J OBSTET GYNECOL, V163, P460, DOI 10.1016/0002-9378(90)91176-D; SIBAI BM, 1986, AM J OBSTET GYNECOL, V154, P581, DOI 10.1016/0002-9378(86)90605-8; WEINSTEIN L, 1982, AM J OBSTET GYNECOL, V142, P159, DOI 10.1016/S0002-9378(16)32330-4; WIGHTMAN H, 1978, BRIT MED J, V2, P235, DOI 10.1136/bmj.2.6132.235; YUDKIN PL, 1987, EARLY HUM DEV, V15, P45, DOI 10.1016/0378-3782(87)90099-5; 1991, REPORT CONFIDENTIAL; 1994, REPORT CONFIDENTIAL	21	526	548	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 26	1994	309	6966					1395	1400		10.1136/bmj.309.6966.1395	http://dx.doi.org/10.1136/bmj.309.6966.1395			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7819845	Green Submitted, Green Published			2022-12-28	WOS:A1994PU76400017
J	RIDKER, PM; VAUGHAN, DE; STAMPFER, MJ; GLYNN, RJ; HENNEKENS, CH				RIDKER, PM; VAUGHAN, DE; STAMPFER, MJ; GLYNN, RJ; HENNEKENS, CH			ASSOCIATION OF MODERATE ALCOHOL-CONSUMPTION AND PLASMA-CONCENTRATION OF ENDOGENOUS TISSUE-TYPE PLASMINOGEN-ACTIVATOR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH-DENSITY-LIPOPROTEIN; CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; CARDIOVASCULAR MORTALITY; FIBRINOLYTIC-ACTIVITY; PLATELET-AGGREGATION; CIRCADIAN VARIATION; HDL CHOLESTEROL; ARTERY DISEASE; BLOOD-LIPIDS	Objective.-To assess whether an association exists between moderate alcohol consumption and plasma concentration of endogenous tissue-type plasminogen activator (t-PA), a serine protease that plays a central role in the regulation of intravascular fibrinolysis. Design.-Survey of self-reported alcohol consumption and plasma fibrinolytic capacity, controlled for lipid and nonlipid cardiac risk factors. Setting.-Participants in the Physicians' Health Study. Participants.-A total of 631 apparently healthy male physicians aged 40 to 84 years with no history of myocardial infarction, stroke, or transient cerebral ischemia. Main Outcome Measure.-Plasma concentration of t-PA antigen. Results.-A direct association was found between alcohol consumption and plasma level of t-PA antigen, such that mean plasma levels of t-PA antigen for daily, weekly, monthly, and rare or never drinkers were 10.9, 9.7, 9.1, and 8.1 ng/mL, respectively (P trend=.0002). The relation between alcohol consumption and t-PA antigen level was not materially changed in analyses that adjusted for total cholesterol and high-density lipoprotein cholesterol or nonlipid cardiovascular risk factors including age, body mass index, parental history of coronary heart disease, exercise frequency, and systolic and diastolic blood pressure. Conclusions.-These data indicate a positive association between moderate alcohol intake and plasma level of endogenous t-PA antigen that is independent of high-density lipoprotein cholesterol. This finding supports the hypothesis that changes in fibrinolytic potential may be an important mechanism whereby moderate alcohol consumption decreases risk of heart disease.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV CARDIOL,BOSTON,MA 02215; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,CHANNING LAB,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	RIDKER, PM (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV PREVENT MED,900 COMMONWEALTH AVE E,BOSTON,MA 02215, USA.				NCI NIH HHS [CA-34944] Funding Source: Medline; NHLBI NIH HHS [HL-34595, HL-26490] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALKANO T, 1984, RES ADV ALCOHOL DRUG, V8, P209; ANDREOTTI F, 1991, CHRONOBIOL INT, V8, P336, DOI 10.3109/07420529109059170; ANGLETON P, 1989, CIRCULATION, V79, P101, DOI 10.1161/01.CIR.79.1.101; [Anonymous], 1989, NEW ENGL J MED, V321, P129; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; BRIDGES AB, 1993, BRIT HEART J, V69, P121; BURING JE, 1992, CIRCULATION, V85, P22, DOI 10.1161/01.CIR.85.1.22; BURR ML, 1986, BRIT J NUTR, V56, P81, DOI 10.1079/BJN19860087; CASTELLI WP, 1977, LANCET, V2, P153; COLDITZ GA, 1985, AM HEART J, V109, P886, DOI 10.1016/0002-8703(85)90654-4; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; DEYKIN D, 1982, NEW ENGL J MED, V306, P852, DOI 10.1056/NEJM198204083061406; DIEHL AK, 1988, ATHEROSCLEROSIS, V69, P145, DOI 10.1016/0021-9150(88)90008-1; ELIASSON M, 1993, FIBRINOLYSIS, V7, P316, DOI 10.1016/0268-9499(93)90147-N; ELMER O, 1984, HAEMOSTASIS, V14, P223; ERNST N, 1980, CIRCULATION, V62, P41; FRIEDMAN GD, 1993, NEW ENGL J MED, V329, P1882, DOI 10.1056/NEJM199312163292510; GAZIANO JM, 1993, NEW ENGL J MED, V329, P1829, DOI 10.1056/NEJM199312163292501; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; HARTUNG GH, 1983, JAMA-J AM MED ASSOC, V249, P747, DOI 10.1001/jama.249.6.747; HASKELL WL, 1984, NEW ENGL J MED, V310, P805, DOI 10.1056/NEJM198403293101301; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; HENNEKENS CH, 1978, AM J EPIDEMIOL, V107, P196, DOI 10.1093/oxfordjournals.aje.a112525; ISO H, 1993, THROMB HAEMOSTASIS, V70, P475; JACKSON R, 1992, AM J EPIDEMIOL, V136, P819, DOI 10.1093/aje/136.7.819; KLATSKY AL, 1974, ANN INTERN MED, V81, P294, DOI 10.7326/0003-4819-81-3-294; KLATSKY AL, 1986, AM J CARDIOL, V58, P710, DOI 10.1016/0002-9149(86)90342-5; KLATSKY AL, 1990, AM J CARDIOL, V66, P1237, DOI 10.1016/0002-9149(90)91107-H; KLATSKY AL, 1990, ALCOHOL HEALTH RES W, V14, P289; LANGER RD, 1992, CIRCULATION, V85, P910, DOI 10.1161/01.CIR.85.3.910; LAUG WE, 1983, JAMA-J AM MED ASSOC, V250, P772, DOI 10.1001/jama.250.6.772; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; MIKHAILIDIS DP, 1983, BRIT MED J, V287, P1495, DOI 10.1136/bmj.287.6404.1495; MOORE RD, 1986, MEDICINE, V65, P242, DOI 10.1097/00005792-198607000-00004; PIKAAR NA, 1987, METABOLISM, V36, P538, DOI 10.1016/0026-0495(87)90163-6; RANBY M, 1986, CLIN CHEM, V32, P2160; RIDKER PM, 1992, CIRCULATION, V85, P1822, DOI 10.1161/01.CIR.85.5.1822; RIDKER PM, 1993, LANCET, V341, P1165, DOI 10.1016/0140-6736(93)90998-V; RIDKER PM, 1993, ARTERIOSCLER THROMB, V13, P1587, DOI 10.1161/01.ATV.13.11.1587; RIDKER PM, 1994, LANCET, V343, P940, DOI 10.1016/S0140-6736(94)90064-7; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; SMOKOVITIS A, 1988, HAEMOSTASIS, V18, P146; SMOKOVITIS A, 1991, ALCOHOL, V8, P17, DOI 10.1016/0741-8329(91)91152-R; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881; SUMI H, 1988, ALCOHOL ALCOHOLISM, V23, P33; THORNTON J, 1983, LANCET, V2, P819; UNDERWOOD MJ, 1993, CARDIOVASC RES, V27, P882, DOI 10.1093/cvr/27.5.882; VEENSTRA J, 1990, THROMB HAEMOSTASIS, V63, P345; VEENSTRA J, 1990, FIBRINOLYSIS, V2, P64; YANO K, 1977, NEW ENGL J MED, V297, P405, DOI 10.1056/NEJM197708252970801; [No title captured]	53	262	265	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	1994	272	12					929	933		10.1001/jama.272.12.929	http://dx.doi.org/10.1001/jama.272.12.929			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG737	7794308				2022-12-28	WOS:A1994PG73700019
J	MARMOT, MG; ELLIOTT, P; SHIPLEY, MJ; DYER, AR; UESHIMA, H; BEEVERS, DG; STAMLER, R; KESTELOOT, H; ROSE, G; STAMLER, J				MARMOT, MG; ELLIOTT, P; SHIPLEY, MJ; DYER, AR; UESHIMA, H; BEEVERS, DG; STAMLER, R; KESTELOOT, H; ROSE, G; STAMLER, J			ALCOHOL AND BLOOD-PRESSURE - THE INTERSALT STUDY	BRITISH MEDICAL JOURNAL			English	Article							ALCOHOL-CONSUMPTION; HYPERTENSION; HEALTH	Objectives-To assess the relation between alcohol intake and blood pressure in men and women and in men at younger and older ages; to examine the influence of amount and pattern of alcohol consumption, as well as of acute effects, taking into account body mass index, smoking, and urinary sodium and potassium excretion. Design-Subjects reported alcohol consumption for each of seven days before standardised blood pressure measurement, and whether they had consumed any alcohol in the 24 hours before measurement. Setting-50 centres worldwide. Subjects-4844 men and 4837 women aged 20-59. Main outcome measures-Effect of alcohol on blood pressure estimated by taking a weighted average of regression coefficients from centres. Acute effect assessed by examining mean differences in blood pressure of non-drinkers and of heavy drinkers who had and had not consumed alcohol in the 24 hours before measurement. Effect of pattern of consumption assessed by examining mean in blood pressure of non-drinkers with drinkers (i) whose intake was concentrated in fewer days or who were drinking more frequently, and (ii) whose alcohol intake varied little over the seven days or varied more substantially, as indicated by the standard deviation of daily consumption Results-Of the 48 centres in which some people reported consuming at least 300 ml/week of alcohol, 35 had positive regression coefficients linking heavy alcohol consumption to blood pressure. Overall, alcohol consumption was associated with blood pressure, significantly-at the highest intake. After: account was taken of key confounders, men who drank 300-499 ml alcohol/week had systolic/diastolic blood pressure on average 2.7/1.6 mm Hg higher than non-drinkers, and men who drank greater than or equal to 500 ml alcohol/week had pressures of 4.6/3.0 mm Hg higher. For women, heavy drinkers (greater than or equal to 300 ml/week) had blood pressures higher by 3.9/3.1 mm Hg than non-drinkers. Heavy drinking and blood pressure were strongly associated in both sexes, and in men at both younger (20-39 years) and older (40-59 years) ages. In men who were heavy drinkers, episodic drinkers (those with great variation in daily alcohol consumption) had greater differences in blood pressure compared with non-drinkers than did regular drinkers of relatively constant amounts. Conclusion-The significant relation of heavy drinking (3-4 or more drinks/day) to blood pressure, observed in both men and women, and in younger and older men, was independent of and added to the effect on blood pressure of body mass index and urinary excretion of sodium and potassium. The findings indicate the usefulness of targeting those at high risk as well as the general population to reduce the adverse effects of alcohol on blood pressure.	UNIV LONDON LONDON SCH HYG & TROP MED, DEPT PUBL HLTH & POLICY, ENVIRONM EPIDEMIOL UNIT, LONDON WC1E 7HT, ENGLAND; NORTHWESTERN UNIV, SCH MED, DEPT PREVENT MED, CHICAGO, IL 60611 USA; SHIGA UNIV MED SCI, DEPT HLTH SCI, OTSU, SHIGA 52021, JAPAN; DUDLEY RD GEN HOSP, DEPT MED, BIRMINGHAM B18 7QH, W MIDLANDS, ENGLAND; UNIV HOSP ST RAPHAEL, DEPT EPIDEMIOL, B-3000 LOUVAIN, BELGIUM; UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, LONDON WC1E 7HT, ENGLAND	University of London; London School of Hygiene & Tropical Medicine; Northwestern University; Shiga University of Medical Science; University of London; London School of Hygiene & Tropical Medicine	MARMOT, MG (corresponding author), UCL, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, MORTIMER ST, LONDON WC1E 6EA, ENGLAND.		Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		BEEVERS DG, 1989, J HUM HYPERTENS, V3, P279; CRIQUI MH, 1981, HYPERTENSION, V3, P557, DOI 10.1161/01.HYP.3.5.557; DYER AR, 1977, CIRCULATION, V56, P1067, DOI 10.1161/01.CIR.56.6.1067; ELLIOTT P, 1988, BRIT MED J, V297, P319; ELLIOTT P, 1988, CONTROL CLIN TRIALS, V9, pS1, DOI 10.1016/0197-2456(88)90028-1; ELLIOTT P, 1987, J EPIDEMIOL COMMUN H, V41, P37, DOI 10.1136/jech.41.1.37; Elliott P, 1992, CORONARY HEART DISEA, P166; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; KLATSKY AL, 1986, CIRCULATION, V73, P628, DOI 10.1161/01.CIR.73.4.628; KLATSKY AL, 1977, NEW ENGL J MED, V296, P1194, DOI 10.1056/NEJM197705262962103; KLATSKY AL, 1985, HDB HYPERTENSION, V6, P159; MAHESWARAN R, 1991, HYPERTENSION, V17, P787, DOI 10.1161/01.HYP.17.6.787; POTTER JF, 1984, LANCET, V1, P119; ROSE G, 1990, BRIT MED J, V301, P1031, DOI 10.1136/bmj.301.6759.1031; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; ROSE G, 1986, J HYPERTENS, V4, P781; SAUNDERS JB, 1981, LANCET, V2, P653; STAMLER J, 1989, HYPERTENSION, V14, P570, DOI 10.1161/01.HYP.14.5.570; STAMLER R, 1991, HYPERTENSION S1, V17, P16; WANNAMETHEE G, 1991, J HUM HYPERTENS, V5, P59	20	240	246	0	22	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 14	1994	308	6939					1263	1267		10.1136/bmj.308.6939.1263	http://dx.doi.org/10.1136/bmj.308.6939.1263			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM147	7802765	Green Published			2022-12-28	WOS:A1994NM14700016
J	LANGEN, R; CHANG, IJ; GERMANAS, JP; RICHARDS, JH; WINKLER, JR; GRAY, HB				LANGEN, R; CHANG, IJ; GERMANAS, JP; RICHARDS, JH; WINKLER, JR; GRAY, HB			ELECTRON-TUNNELING IN PROTEINS - COUPLING THROUGH A BETA-STRAND	SCIENCE			English	Article							BLUE COPPER PROTEINS; BIOLOGICAL MOLECULES; CRYSTAL-STRUCTURE; MATRIX-ELEMENTS; CYTOCHROME-C; AZURIN; PATHWAYS; RESOLUTION; SYSTEMS; MODEL	Electron coupling through a beta strand has been investigated by measurement of the intramolecular electron-transfer (ET) rates in ruthenium-modified derivatives of the beta barrel blue copper protein Pseudomonas aeruginosa azurin. Surface histidines, introduced on the methionine-121 beta strand by mutagenesis, were modified with a Ru(2,2'-bipyridine)(2)(imidazole)(2+) complex. The Cu+ to Ru3+ rate constants yielded a distance-decay constant of 1.1 per angstrom, a value close to the distance-decay constant of 1.0 per angstrom predicted for electron tunneling through an idealized beta strand. Activationless ET rate constants in combination with a tunneling-pathway analysis of the structures of azurin and cytochrome c confirm that there is a generally efficient network for coupling the internal (native) redox center to the surface of both proteins.	CALTECH,BECKMAN INST,PASADENA,CA 91125	California Institute of Technology			Winkler, Jay R/B-7372-2009	Germanas, Juris/0000-0002-1207-802X				Bertini I., 1994, BIOINORGANIC CHEM; BROO A, 1991, J PHYS CHEM-US, V95, P4925, DOI 10.1021/j100166a002; CASIMIRO DR, 1993, J PHYS CHEM-US, V97, P13073, DOI 10.1021/j100152a007; CASIMIRO DR, 1993, J AM CHEM SOC, V115, P1485, DOI 10.1021/ja00057a037; CHANG IJ, 1991, J AM CHEM SOC, V113, P7056, DOI 10.1021/ja00018a064; CHANG TK, 1991, P NATL ACAD SCI USA, V88, P1325, DOI 10.1073/pnas.88.4.1325; CHRISTENSEN HEM, 1992, J PHYS CHEM-US, V96, P4451, DOI 10.1021/j100190a060; EVENSON JW, 1993, SCIENCE, V262, P1247, DOI 10.1126/science.8235654; FARID RS, 1993, CURR OPIN STRUC BIOL, V3, P225, DOI 10.1016/S0959-440X(05)80157-5; FARVER O, 1992, J AM CHEM SOC, V114, P5764, DOI 10.1021/ja00040a043; FRIESNER RA, 1994, STRUCTURE, V2, P339, DOI 10.1016/S0969-2126(00)00035-6; GRUSCHUS JM, 1993, J PHYS CHEM-US, V97, P5581, DOI 10.1021/j100123a021; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P3640, DOI 10.1073/pnas.71.9.3640; JORTNER J, 1976, J CHEM PHYS, V64, P4860, DOI 10.1063/1.432142; KARPISHIN TB, 1994, STRUCTURE, V2, P415, DOI 10.1016/S0969-2126(00)00043-5; LEE FS, 1993, J COMPUT CHEM, V14, P161, DOI 10.1002/jcc.540140205; LOWERY MD, 1992, INORG CHIM ACTA, V200, P233; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NAR H, 1992, FEBS LETT, V306, P119, DOI 10.1016/0014-5793(92)80981-L; NAR H, 1991, J MOL BIOL, V221, P765, DOI 10.1016/0022-2836(91)80173-R; ONUCHIC JN, 1991, J CHEM PHYS, V95, P1131, DOI 10.1063/1.461142; ONUCHIC JN, 1990, J CHEM PHYS, V92, P722, DOI 10.1063/1.458426; ONUCHIC JN, 1992, ANNU REV BIOPH BIOM, V21, P349, DOI 10.1146/annurev.biophys.21.1.349; SIDDARTH P, 1993, J PHYS CHEM-US, V97, P13078, DOI 10.1021/j100152a008; SIDDARTH P, 1993, J PHYS CHEM-US, V97, P2400, DOI 10.1021/j100112a047; SIDDARTH P, 1990, J PHYS CHEM-US, V94, P8430, DOI 10.1021/j100385a015; SIDDARTH P, 1992, J PHYS CHEM-US, V96, P3213, DOI 10.1021/j100187a008; SIDDARTH PB, 1990, J PHYS CHEM-US, V94, P3213; Sigel H., 1991, METAL IONS BIOL SYST, V27; SKOURTIS SS, 1994, J PHYS CHEM-US, V98, P3379, DOI 10.1021/j100064a019; STUCHEBRUKHOV AA, 1995, J PHYS CHEM-US, V99, P7581, DOI 10.1021/j100019a044; STUDIER FW, 1990, METHODS ENZYMOLOGY; WUTTKE DS, 1992, SCIENCE, V256, P1007, DOI 10.1126/science.256.5059.1007; [No title captured]	37	324	333	0	88	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1733	1735		10.1126/science.7792598	http://dx.doi.org/10.1126/science.7792598			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792598				2022-12-28	WOS:A1995RE66800036
J	GERBERDING, JL				GERBERDING, JL			DRUG-THERAPY - MANAGEMENT OF OCCUPATIONAL EXPOSURES TO BLOOD-BORNE VIRUSES	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; HEALTH-CARE WORKERS; B-SURFACE-ANTIGEN; RECOMBINANT INTERFERON-ALFA; POST-TRANSFUSION HEPATITIS; NEW-YORK-CITY; SCID-HU MICE; NON-A; CONTROLLED TRIAL		UNIV CALIF SAN FRANCISCO,DEPT MED INFECT DIS,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	GERBERDING, JL (corresponding author), SAN FRANCISCO GEN HOSP,CTR EPIDEMIOL & PREVENT,MED SERV 5H22,SAN FRANCISCO,CA 94110, USA.							ALKHAJA N, 1991, SCAND J THORAC CARD, V25, P7, DOI 10.3109/14017439109098076; ALTER HJ, 1976, NEW ENGL J MED, V295, P909, DOI 10.1056/NEJM197610212951701; ALTER HJ, 1972, ANN INTERN MED, V77, P691, DOI 10.7326/0003-4819-77-5-691; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; ANTONE J, 1980, LANCET, V1, P1142; BECKER Y, 1990, J CHEMOTHERAPY, V2, P152, DOI 10.1080/1120009X.1990.11739008; CANCIOBELLO TP, 1982, J INFECT DIS, V146, P652, DOI 10.1093/infdis/146.5.652; CARDO D, 1994, 34TH INT C ANT AG CH, P237; CAVALCANTE N J F, 1991, AIDS Care, V3, P311, DOI 10.1080/09540129108253078; CHAN CY, 1992, J GASTROEN HEPATOL, V7, P266, DOI 10.1111/j.1440-1746.1992.tb00977.x; CHAUDHARY RK, 1991, J CLIN MICROBIOL, V29, P2329, DOI 10.1128/JCM.29.10.2329-2330.1991; CLERICI M, 1994, JAMA-J AM MED ASSOC, V271, P42, DOI 10.1001/jama.271.1.42; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DAVIDSON M, 1986, J INFECTION, V13, P31, DOI 10.1016/S0163-4453(86)92653-8; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; DIENSTAG JL, 1986, SEMIN LIVER DIS, V6, P67, DOI 10.1055/s-2008-1040795; Dilley JW, 1990, FOCUS, V5, P3; DUSHEIKO GM, 1990, LANCET, V336, P503, DOI 10.1016/0140-6736(90)92049-N; EVERHART JE, 1990, ANN INTERN MED, V112, P544, DOI 10.7326/0003-4819-112-7-544; FAHRNER R, 1994, 34 INT C ANT AG CHEM, P133; FARCI P, 1992, SCIENCE, V258, P135, DOI 10.1126/science.1279801; FAZELY F, 1991, J ACQ IMMUN DEF SYND, V4, P1093; FORSETER G, 1993, AM J INFECT CONTROL, V21, P5, DOI 10.1016/0196-6553(93)90200-N; GERBERDING J, 1993, ANN INTERN MED, V118, P979, DOI 10.7326/0003-4819-118-12-199306150-00012; GERBERDING JL, 1992, CLIN INFECT DIS, V14, P1179, DOI 10.1093/clinids/14.6.1179; GERBERDING JL, 1994, J INFECT DIS, V170, P1410, DOI 10.1093/infdis/170.6.1410; GERBERDING JL, 1991, 31ST INT C ANT AG CH, P261; GRADY GF, 1978, J INFECT DIS, V138, P625, DOI 10.1093/infdis/138.5.625; HADLER SC, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P766; HAMMOND GW, 1991, VACCINE, V9, P97, DOI 10.1016/0264-410X(91)90263-6; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HOFMANN H, 1990, INFECTION, V18, P286, DOI 10.1007/BF01647006; HSU HH, 1991, HEPATOLOGY, V14, P763, DOI 10.1002/hep.1840140504; INGERSLEV J, 1988, SCAND J CLIN LAB INV, V48, P333, DOI 10.3109/00365518809167504; IPPOLITO G, 1993, ARCH INTERN MED, V153, P1451, DOI 10.1001/archinte.153.12.1451; JENISON SA, 1987, J INFECT DIS, V156, P299, DOI 10.1093/infdis/156.2.299; JILG W, 1988, J MED VIROL, V24, P377, DOI 10.1002/jmv.1890240404; JILG W, 1984, J MED VIROL, V13, P171, DOI 10.1002/jmv.1890130207; KALTER DC, 1991, DERMATOL CLIN, V9, P415; KIYOSAWA K, 1991, ANN INTERN MED, V115, P367, DOI 10.7326/0003-4819-115-5-367; KLEIN RS, 1991, LANCET, V338, P1539, DOI 10.1016/0140-6736(91)92369-D; KNODELL RG, 1976, LANCET, V1, P557; KRAWCZYNSKI K, 1993, HEPATOLOGY, V18, pA110, DOI 10.1016/0270-9139(93)91968-X; LAFON SW, 1990, 30TH INT C ANT AG CH, P167; LUNDGREN B, 1991, J ACQ IMMUN DEF SYND, V4, P489; MARRANCONI F, 1992, INFECTION, V20, P111, DOI 10.1007/BF01711079; MAST ST, 1993, J INFECT DIS, V168, P1589, DOI 10.1093/infdis/168.6.1589; MATHES LE, 1992, ANTIMICROB AGENTS CH, V36, P2715, DOI 10.1128/AAC.36.12.2715; MCCLURE HM, 1990, ANN NY ACAD SCI, V616, P287; MCCUNE JM, 1990, SCIENCE, V247, P564, DOI 10.1126/science.2300816; MITSUI T, 1992, HEPATOLOGY, V16, P1109, DOI 10.1002/hep.1840160502; NOMMENSEN FE, 1989, LANCET, V2, P847; PALMOVIC D, 1987, J INFECTION, V15, P221, DOI 10.1016/S0163-4453(87)92603-X; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PETERSEN NJ, 1976, HEALTH LAB SCI, V13, P233; PETERSEN NJ, 1980, NY ACAD SCI, V353, P157; PURO V, 1992, AIDS, V6, P963, DOI 10.1097/00002030-199209000-00009; RICHMAN KM, 1993, J ACQ IMMUN DEF SYND, V6, P402; ROBINSON EN, 1993, CLIN INFECT DIS, V17, P357; ROBINSON WS, 1990, PRINCIPLES PRACTICE, P1204; ROBSON SC, 1992, S AFR MED J, V82, P317; RUPRECHT RM, 1986, NATURE, V323, P467, DOI 10.1038/323467a0; SCHEIERMANN N, 1983, DEV BIOLOGICALS, V54, P347; SCHIFF E, 1987, AM J GASTROENTEROL, V82, P287; SEEFF LB, 1977, GASTROENTEROLOGY, V72, P111; SEEFF LB, 1978, ANN INTERN MED, V88, P285, DOI 10.7326/0003-4819-88-3-285; SHAW FE, 1989, VACCINE, V7, P425, DOI 10.1016/0264-410X(89)90157-6; SHEV S, 1991, SCAND J INFECT DIS, V23, P407, DOI 10.3109/00365549109075087; SHIELS MT, 1987, GASTROENTEROLOGY, V93, P675, DOI 10.1016/0016-5085(87)90427-6; SHIH CC, 1991, J INFECT DIS, V163, P625, DOI 10.1093/infdis/163.3.625; SODEYAMA T, 1993, ARCH INTERN MED, V153, P1565, DOI 10.1001/archinte.153.13.1565; SPERLING RS, 1992, NEW ENGL J MED, V326, P857, DOI 10.1056/NEJM199203263261303; SPRECHER E, 1987, J VIROL, V61, P2515, DOI 10.1128/JVI.61.8.2515-2522.1987; TAKAHASHI M, 1991, GASTROENTEROL JPN, V26, P483; TAVARES L, 1987, CANCER RES, V47, P3190; TINDALL B, 1995, MED MANAGEMENT AIDS, P105; TOKARS JI, 1993, ANN INTERN MED, V118, P913, DOI 10.7326/0003-4819-118-12-199306150-00001; VALLARI DS, 1992, J CLIN MICROBIOL, V30, P552, DOI 10.1128/JCM.30.3.552-556.1992; VANDOORNUM GJJ, 1991, J MED VIROL, V35, P22, DOI 10.1002/jmv.1890350106; VANROMPAY KKA, 1992, ANTIMICROB AGENTS CH, V36, P2381, DOI 10.1128/AAC.36.11.2381; VILLAREJOS VM, 1974, NEW ENGL J MED, V291, P1375, DOI 10.1056/NEJM197412262912602; WAHL M, 1983, DEV BIOL STAND, V54, P341; WAHN V, 1986, LANCET, V2, P694; WAINWRIGHT RB, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P762; WERNER BG, 1982, ANN INTERN MED, V97, P367, DOI 10.7326/0003-4819-97-3-367; WESTMORELAND D, 1990, EPIDEMIOL INFECT, V104, P499, DOI 10.1017/S0950268800047506; WOOD RC, 1993, JAMA-J AM MED ASSOC, V270, P2935, DOI 10.1001/jama.270.24.2935; WORMSER GP, 1991, AM J INFECT CONTROL, V19, P237, DOI 10.1016/S0196-6553(05)80255-X; 1990, MMWR-MORBID MORTAL W, V39, P1; 1992, MMWR-MORBID MORTAL W, V41, P823; 1986, MMWR-MORBID MORTAL W, V35, P231; 1990, MMWR-MORBID MORTAL W, V39, P17; 1991, FED REGISTER, V56, P64004; 1976, LANCET, V2, P492; 1993, MMWR-MORBID MORTAL W, V42, P707; 1987, MMWR-MORBID MORTAL W, V36, P353; 1978, MMWR-MORBID MORTAL W, V27, P247; 1991, MMWR-MORBID MORTAL W, V40, P1; 1994, MMWR-MORBID MORTAL W, V43, P285	102	273	282	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 16	1995	332	7					444	451		10.1056/NEJM199502163320707	http://dx.doi.org/10.1056/NEJM199502163320707			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF770	7824017				2022-12-28	WOS:A1995QF77000007
J	LICHTER, AS; LAWRENCE, TS				LICHTER, AS; LAWRENCE, TS			MEDICAL PROGRESS - RECENT ADVANCES IN RADIATION ONCOLOGY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SMALL-CELL-CARCINOMA; INVASIVE BLADDER-CANCER; SOFT-TISSUE SARCOMAS; BREAST-CANCER; POSTOPERATIVE RADIOTHERAPY; ADJUVANT CHEMOTHERAPY; IONIZING-RADIATION; RANDOMIZED TRIAL; RECTAL-CARCINOMA; DOSE-RESPONSE				LICHTER, AS (corresponding author), UNIV MICHIGAN, MED CTR, DEPT RADIAT ONCOL, 1500 E MED CTR DR, RM AGH B2C490, ANN ARBOR, MI 48109 USA.							ALLAN DJ, 1992, INT J RADIAT BIOL, V62, P145, DOI 10.1080/09553009214551951; ANG KK, 1987, INT J RADIAT ONCOL, V13, P557, DOI 10.1016/0360-3016(87)90071-X; BALSLEV IB, 1986, CANCER-AM CANCER SOC, V58, P22, DOI 10.1002/1097-0142(19860701)58:1<22::AID-CNCR2820580106>3.0.CO;2-Q; BLEEHEN NM, 1991, BRIT J CANCER, V64, P769, DOI 10.1038/bjc.1991.396; BOOTHMAN DA, 1991, CANCER RES, V51, P5587; BUNN PA, 1987, ANN INTERN MED, V106, P655, DOI 10.7326/0003-4819-106-5-655; BYFIELD J, 1990, ANTITUMOR DRUG RAD I, P87; CHAE HP, 1993, CANCER RES, V53, P447; COLEMAN CN, 1993, RADIOTHER ONCOL, V28, P1; COLOMBO F, 1989, NEUROSURGERY, V24, P833, DOI 10.1227/00006123-198906000-00008; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; COX JD, 1991, INT J RADIAT ONCOL, V20, P1191, DOI 10.1016/0360-3016(91)90227-U; COX JD, 1990, J CLIN ONCOL, V8, P1543, DOI 10.1200/JCO.1990.8.9.1543; CUMMINGS BJ, 1991, INT J RADIAT ONCOL, V21, P1115, DOI 10.1016/0360-3016(91)90265-6; CUZICK J, 1994, J CLIN ONCOL, V12, P447, DOI 10.1200/JCO.1994.12.3.447; CUZICK J, 1987, CANCER TREAT REP, V71, P7; DENHAM JW, 1986, RADIOTHER ONCOL, V7, P107, DOI 10.1016/S0167-8140(86)80090-1; DOGGETT SW, 1988, INT J RADIAT ONCOL, V15, P1069, DOI 10.1016/0360-3016(88)90186-1; ELKIND MM, 1959, NATURE, V184, P1293, DOI 10.1038/1841293a0; ELKIND MM, 1985, CANCER, V56, P2351, DOI 10.1002/1097-0142(19851115)56:10<2351::AID-CNCR2820561002>3.0.CO;2-H; ENNEKING WF, 1981, CANCER, V47, P1005, DOI 10.1002/1097-0142(19810301)47:5<1005::AID-CNCR2820470532>3.0.CO;2-9; FISHER B, 1988, JNCI-J NATL CANCER I, V80, P21, DOI 10.1093/jnci/80.1.21; FISHER B, 1994, NEW ENGL J MED, V330, P1458; FITZPATRICK PJ, 1976, INT J RADIAT ONCOL, V1, P197, DOI 10.1016/0360-3016(76)90041-9; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FOWBLE B, 1988, J CLIN ONCOL, V6, P1107, DOI 10.1200/JCO.1988.6.7.1107; FUKS Z, 1991, INT J RADIAT ONCOL, V21, P537, DOI 10.1016/0360-3016(91)90668-T; FULLER BG, 1992, INT J RADIAT ONCOL, V23, P413, DOI 10.1016/0360-3016(92)90762-7; GOFFMAN T, 1991, CANCER, V67, P572, DOI 10.1002/1097-0142(19910201)67:3<572::AID-CNCR2820670308>3.0.CO;2-D; HAIMOVITZFRIEDMAN A, 1991, CANCER RES, V51, P2552; HAZUKA MB, 1993, INT J RADIAT ONCOL, V27, P273, DOI 10.1016/0360-3016(93)90238-Q; HERSKOVIC A, 1992, NEW ENGL J MED, V326, P1593, DOI 10.1056/NEJM199206113262403; HORIOT JC, 1992, RADIOTHER ONCOL, V25, P231, DOI 10.1016/0167-8140(92)90242-M; HUGHES LL, 1989, INT J RADIAT ONCOL, V17, P1153, DOI 10.1016/0360-3016(89)90520-8; ILIAKIS G, 1992, INT J RADIAT BIOL, V61, P315, DOI 10.1080/09553009214550991; ILIAKIS G, 1988, INT J RADIAT BIOL, V53, P541, DOI 10.1080/09553008814550901; JEGGO PA, 1990, MUTAT RES, V239, P1, DOI 10.1016/0165-1110(90)90028-A; JOHNSON DH, 1986, CRC CR REV ONCOL-HEM, V4, P303, DOI 10.1016/S1040-8428(86)80026-9; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KAUFMAN DS, 1993, NEW ENGL J MED, V329, P1377, DOI 10.1056/NEJM199311043291903; KONDZIOLKA D, 1993, STEREOTACTIC RADIOSU, P136; KROOK JE, 1991, NEW ENGL J MED, V324, P709, DOI 10.1056/NEJM199103143241101; Lawrence, 1993, Semin Radiat Oncol, V3, P20, DOI 10.1016/S1053-4296(05)80074-8; LAWRENCE TS, 1990, RADIAT RES, V123, P192, DOI 10.2307/3577544; LAWRENCE TS, 1992, INT J RADIAT ONCOL, V23, P781, DOI 10.1016/0360-3016(92)90651-W; LEEPER DB, 1973, RADIAT RES, V53, P326, DOI 10.2307/3573538; LEIBEL SA, 1991, INT J RADIAT ONCOL, V21, P549, DOI 10.1016/0360-3016(91)90669-U; LEIBEL SA, 1991, INT J RADIAT ONCOL, V21, P805, DOI 10.1016/0360-3016(91)90701-5; LEKSELL L, 1951, ACTA CHIR SCAND, V102, P316; Lichter, 1992, Semin Radiat Oncol, V2, P257, DOI 10.1016/1053-4296(92)90023-E; LICHTER AS, 1992, J CLIN ONCOL, V10, P976, DOI 10.1200/JCO.1992.10.6.976; LICHTER AS, 1987, CANCER INVEST, V5, P243, DOI 10.3109/07357908709011742; LICHTER AS, 1991, INT J RADIAT ONCOL, V21, P853, DOI 10.1016/0360-3016(91)90708-C; LICHTER AS, 1983, COMPUT TOMOGR, P1; LINDBERG RD, 1981, CANCER, V47, P2391, DOI 10.1002/1097-0142(19810515)47:10<2391::AID-CNCR2820471012>3.0.CO;2-B; LOEFFLER JS, 1993, FRONT RADIAT THER ON, V27, P227; LOSASSO T, 1993, INT J RADIAT ONCOL, V25, P161, DOI 10.1016/0360-3016(93)90337-U; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUNSFORD LD, 1991, J NEUROSURG, V75, P512, DOI 10.3171/jns.1991.75.4.0512; MAGERAS GS, 1992, MED PHYS, V19, P945, DOI 10.1118/1.596782; MARKS G, 1991, ARCH SURG-CHICAGO, V126, P1534; MARKS LB, 1992, INT J RADIAT ONCOL, V23, P1021, DOI 10.1016/0360-3016(92)90908-Z; MOHAN R, 1988, INT J RADIAT ONCOL, V15, P481, DOI 10.1016/S0360-3016(98)90033-5; Munro T R, 1970, Radiat Res, V44, P747; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; NELSON DF, 1993, INT J RADIAT ONCOL, V25, P193, DOI 10.1016/0360-3016(93)90340-2; NETA R, 1991, CANCER CELL-MON REV, V3, P391; NIGRO ND, 1974, DIS COLON RECTUM, V17, P354, DOI 10.1007/BF02586980; OCONNOR PM, 1993, CANCER RES, V53, P4776; OKAYASU R, 1988, INT J RADIAT BIOL, V53, P729, DOI 10.1080/09553008814551101; OVERGAARD M, 1990, INT J RADIAT ONCOL, V19, P1121, DOI 10.1016/0360-3016(90)90214-5; OWEN JB, 1992, INT J RADIAT ONCOL, V24, P983, DOI 10.1016/0360-3016(92)90483-X; PAPILLON J, 1989, INT J RADIAT ONCOL, V17, P1161, DOI 10.1016/0360-3016(89)90521-X; PERRY MC, 1987, NEW ENGL J MED, V316, P912, DOI 10.1056/NEJM198704093161504; PETERS LJ, 1988, ACTA ONCOL, V27, P185, DOI 10.3109/02841868809090339; PHILLIPS TL, 1991, INT J RADIAT ONCOL, V21, P709, DOI 10.1016/0360-3016(91)90690-6; PIGNON JP, 1992, NEW ENGL J MED, V327, P1618, DOI 10.1056/NEJM199212033272302; PORTER AT, 1993, INT J RADIAT ONCOL, V25, P805, DOI 10.1016/0360-3016(93)90309-J; POWLIS WD, 1993, INT J RADIAT ONCOL, V25, P171, DOI 10.1016/0360-3016(93)90338-V; PROSNITZ LR, 1983, NEW ENGL J MED, V309, P834, DOI 10.1056/NEJM198310063091406; PROSNITZ LR, 1983, NEW ENGL J MED, V309, P771, DOI 10.1056/NEJM198309293091306; RAGAZ J, 1993, P AN M AM SOC CLIN, V12, P60; ROBERTSON JM, 1993, J CLIN ONCOL, V11, P1286, DOI 10.1200/JCO.1993.11.7.1286; ROSENBERG SA, 1982, ANN SURG, V196, P305, DOI 10.1097/00000658-198209000-00009; ROSENMAN J, 1991, CANCER INVEST, V9, P465; ROTH JA, 1988, J THORAC CARDIOV SUR, V96, P242; ROTH JA, 1993, CANCER PRINCIPLES PR, V1, P776; SANDLER HM, 1992, RADIOTHER ONCOL, V23, P53, DOI 10.1016/0167-8140(92)90305-E; SCHER HI, 1990, SEMIN ONCOL, V17, P555; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHILSKY RL, 1992, SEMIN ONCOL, V19, P2; SINCLAIR W K, 1972, Current Topics in Radiation Research Quarterly, V7, P323; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SONDIK EJ, 1994, J NATL CANCER I, V86, P655, DOI 10.1093/jnci/86.9.655; SUIT HD, 1988, J CLIN ONCOL, V6, P854, DOI 10.1200/JCO.1988.6.5.854; SUIT HD, 1992, INT J RADIAT ONCOL, V23, P653, DOI 10.1016/0360-3016(92)90025-D; TANUM G, 1991, CANCER, V67, P2462, DOI 10.1002/1097-0142(19910515)67:10<2462::AID-CNCR2820671012>3.0.CO;2-1; TEPPER JE, 1987, INT J RADIAT ONCOL, V13, P5, DOI 10.1016/0360-3016(87)90252-5; THAMES HD, 1980, BRIT J CANCER, V41, P35; THAMES HD, 1992, INT J RADIAT ONCOL, V22, P241, DOI 10.1016/0360-3016(92)90039-K; THOMAS PRM, 1988, RADIOTHER ONCOL, V13, P245, DOI 10.1016/0167-8140(88)90219-8; TISHLER RB, 1992, CANCER RES, V52, P3495; UCKUN FM, 1989, INT J RADIAT ONCOL, V16, P415, DOI 10.1016/0360-3016(89)90338-6; UCKUN FM, 1990, BLOOD, V75, P638; VOKES, 1990, J CLIN ONCOL, V8, P1447, DOI 10.1200/JCO.1990.8.8.1447; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; VOKES EE, 1990, J CLIN ONCOL, V8, P911, DOI 10.1200/JCO.1990.8.5.911; Wang CC, 1990, RAD THERAPY HEAD NEC; WARDE P, 1992, J CLIN ONCOL, V10, P890, DOI 10.1200/JCO.1992.10.6.890; WEICHSELBAUM RR, 1991, J NATL CANCER I, V83, P480, DOI 10.1093/jnci/83.7.480; WEICHSELBAUM RR, 1992, INT J RADIAT ONCOL, V24, P565, DOI 10.1016/0360-3016(92)91075-X; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WINSTON KR, 1988, NEUROSURGERY, V22, P454, DOI 10.1227/00006123-198803000-00002; WITHERS HR, 1988, ACTA ONCOL, V27, P131, DOI 10.3109/02841868809090333; WOLF GT, 1991, NEW ENGL J MED, V324, P1685, DOI 10.1056/nejm199106133242402; WONG CS, 1993, INT J RADIAT ONCOL, V25, P669; 1992, J NATL CANCER I, V11, P1	117	100	108	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 9	1995	332	6					371	379		10.1056/NEJM199502093320607	http://dx.doi.org/10.1056/NEJM199502093320607			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF300	7824000				2022-12-28	WOS:A1995QF30000007
J	SCHULZ, KF; CHALMERS, I; HAYES, RJ; ALTMAN, DG				SCHULZ, KF; CHALMERS, I; HAYES, RJ; ALTMAN, DG			EMPIRICAL-EVIDENCE OF BIAS - DIMENSIONS OF METHODOLOGICAL QUALITY ASSOCIATED WITH ESTIMATES OF TREATMENT EFFECTS IN CONTROLLED TRIALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DESIGN AFFECTS OUTCOMES; CLINICAL-TRIALS; RANDOMIZED TRIALS; THERAPY	Objective.-To determine if inadequate approaches to randomized controlled trial design and execution are associated with evidence of bias in estimating treatment effects. Design.-An observational study in which we assessed the methodological quality of 250 controlled trials from 33 meta-analyses and then analyzed, using multiple logistic regression models, the associations between those assessments and estimated treatment effects. Data Sources.-Meta-analyses from the Cochrane Pregnancy and Childbirth Database. Main Outcome Measures.-The associations between estimates of treatment effects and inadequate allocation concealment, exclusions after randomization, and lack of double-blinding. Results.-Compared with trials in which authors reported adequately concealed treatment allocation, trials in which concealment was either inadequate or unclear (did not report or incompletely reported a concealment approach) yielded larger estimates of treatment effects (P<.001). Odds ratios were exaggerated by 41% for inadequately concealed trials and by 30% for unclearly concealed trials (adjusted for other aspects of quality). Trials in which participants had been excluded after randomization did not yield larger estimates of effects, but that lack of association may be due to incomplete reporting. Trials that were not double-blind also yielded larger estimates of effects (P=.01), with odds ratios being exaggerated by 17%. Conclusions.-This study provides empirical evidence that inadequate methodological approaches in controlled trials, particularly those representing poor allocation concealment, are associated with bias. Readers of trial reports should be wary of these pitfalls, and investigators must improve their design, execution, and reporting of trials.	UK COCHRANE CTR,OXFORD,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND; IMPERIAL CANC RES FUND,MED STAT LAB,LONDON WC2A 3PX,ENGLAND	Cochrane Centre; University of London; London School of Hygiene & Tropical Medicine; Cancer Research UK	SCHULZ, KF (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR PREVENT SERV,DIV STD HIV PREVENT,MAILSTOP E-02,ATLANTA,GA 30333, USA.			Hayes, Richard/0000-0002-1729-9892				AITKIN M, 1989, STATISTICAL MODELING; ALTMAN DG, 1991, BRIT MED J, V302, P1481, DOI 10.1136/bmj.302.6791.1481; ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; CHALMERS I, 1986, CONTROL CLIN TRIALS, V7, P306, DOI 10.1016/0197-2456(86)90038-3; Chalmers I, 1989, EFFECTIVE CARE PREGN; CHALMERS I, 1989, EFFECTIVE CARE PREGN, V1, P39; CHALMERS I, 1992, OXFORD DATABASE PERI; CHALMERS TC, 1983, NEW ENGL J MED, V309, P1358, DOI 10.1056/NEJM198312013092204; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; CHALMERS TC, 1977, NEW ENGL J MED, V297, P1091, DOI 10.1056/NEJM197711172972004; COLDITZ GA, 1989, STAT MED, V8, P441, DOI 10.1002/sim.4780080408; Dean A. G., 1990, EPI INFO VERSION 5 W; DERSIMONIAN R, 1982, NEW ENGL J MED, V306, P1332, DOI 10.1056/NEJM198206033062204; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; DEVINE EC, 1983, NURS RES, V32, P267; EMERSON JD, 1990, CONTROL CLIN TRIALS, V11, P339, DOI 10.1016/0197-2456(90)90175-2; ENKIN MW, 1993, COCHRANE DATABASE SY; FRANCIS B, 1993, GLIM 4 STATISTICAL S; GILLMAN MW, 1984, NEW ENGL J MED, V310, P1610; GOTZSCHE PC, 1989, EUR J CLIN PHARMACOL, V36, P429, DOI 10.1007/BF00558064; GREENLAND S, 1994, AM J EPIDEMIOL, V140, P290, DOI 10.1093/oxfordjournals.aje.a117248; LIBERATI A, 1986, J CLIN ONCOL, V4, P942, DOI 10.1200/JCO.1986.4.6.942; MILLER JN, 1989, STAT MED, V8, P455, DOI 10.1002/sim.4780080409; MOSTELLER F, 1980, CONTROL CLIN TRIALS, V1, P37, DOI 10.1016/S0197-2456(80)80006-7; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; POCOCK SJ, 1979, BIOMETRICS, V35, P183, DOI 10.2307/2529944; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; SCHULZ KF, 1994, JAMA-J AM MED ASSOC, V272, P125, DOI 10.1001/jama.272.2.125; SCHULZ KF, 1994, METHODOLOGICAL QUALI; WORTMAN PM, 1983, EVALUATION STUDIES R, V8, P536; 1994, JAMA-J AM MED ASSOC, V272, P1926	31	4632	4793	1	166	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	1995	273	5					408	412		10.1001/jama.273.5.408	http://dx.doi.org/10.1001/jama.273.5.408			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD203	7823387				2022-12-28	WOS:A1995QD20300026
J	VALLES, J; ARTIGAS, A; RELLO, J; BONSOMS, N; FONTANALS, D; BLANCH, L; FERNANDEZ, R; BAIGORRI, F; MESTRE, J				VALLES, J; ARTIGAS, A; RELLO, J; BONSOMS, N; FONTANALS, D; BLANCH, L; FERNANDEZ, R; BAIGORRI, F; MESTRE, J			CONTINUOUS ASPIRATION OF SUBGLOTTIC SECRETIONS IN PREVENTING VENTILATOR-ASSOCIATED PNEUMONIA	ANNALS OF INTERNAL MEDICINE			English	Article						VENTILATORS, MECHANICAL; PNEUMONIA; SUCTION; GROSS INFECTION	CONTINUOUS MECHANICAL VENTILATION; MULTIPLE TRAUMA PATIENTS; GRAM-NEGATIVE BACILLI; INTENSIVE-CARE UNITS; NOSOCOMIAL PNEUMONIA; SELECTIVE DECONTAMINATION; INTUBATED PATIENTS; DIGESTIVE-TRACT; RESPIRATORY-TRACT; LOWER AIRWAY	Objective: To determine whether continuous subglottic aspiration prevents nosocomial pneumonia in mechanically ventilated patients. Design: A randomized, controlled, blinded study. Setting: Medical-surgical intensive care unit. Patients: 190 patients who were admitted to the intensive care unit during a 33-month period and whose condition suggested the need for prolonged intubation (>3 days). Intervention: 76 patients were randomly allocated to receive continuous aspiration of subglottic secretions, and 77 control patients were allocated to receive usual care. Measurements: The numbers of cases of ventilator-associated pneumonia, ventilated days, days in intensive care unit, and deaths were recorded. The amount of subglottic secretions aspirated daily and surveillance cultures in the subglottic secretions were also obtained periodically. Etiologic diagnosis was based on the quantitative culture of secretions obtained by protected specimen brush or bronchoalveolar lavage. Results: The incidence rate of ventilator-associated pneumonia was 19.9 episodes/1000 ventilator days in the patients receiving continuous aspiration of subglottic secretions and 39.6 episodes/1000 ventilator days in the control patients (relative risk, 1.98; 95% CI, 1.03 to 3.82). This difference was due to a significant (P < 0.03) reduction in the number of gram-positive cocci and Haemophilus influenzae organisms in the patients receiving continuous aspiration. However, no differences were observed in the number of Pseudomonas aeruginosa or Enterobacteriaceae organisms. Episodes of ventilator-associated pneumonia occurred later in patients receiving continuous aspiration (12.0 +/- 7.1 days) than in the control patients (5.9 +/- 2.1 days) (P = 0.003). The same microorganisms isolated from protected specimen brush or bronchoalveolar lavage cultures in patients with ventilator-associated pneumonia were previously isolated from cultures of subglottic secretions in 85% of cases. No significant differences in outcome were found. Conclusions: The incidence of nosocomial pneumonia in mechanically ventilated patients can be significantly reduced by using a simple method that decreases the chronic microaspirations through the cuff of endotracheal tubes.	UNIV AUTONOMA BARCELONA, E-08193 BARCELONA, SPAIN	Autonomous University of Barcelona	VALLES, J (corresponding author), HOSP SABADELL, DEPT INTENS CARE, PARC TAULI S-N, E-08208 SABADELL, SPAIN.		Rello, Jordi/P-2402-2019; Fernandez, Rafael/A-9586-2010	Rello, Jordi/0000-0003-0676-6210; Fernandez, Rafael/0000-0001-5711-5317; antonio, artigas/0000-0002-8029-1017				ALBERT RK, 1981, NEW ENGL J MED, V304, P1465, DOI 10.1056/NEJM198106113042404; ANDREWS CP, 1981, CHEST, V80, P254, DOI 10.1378/chest.80.3.254; CAMERON JL, 1973, SURG GYNECOL OBSTET, V136, P68; CELIS R, 1988, CHEST, V93, P318, DOI 10.1378/chest.93.2.318; Craven D E, 1987, Semin Respir Infect, V2, P20; CRAVEN DE, 1991, AM J MED, V91, pS44, DOI 10.1016/0002-9343(91)90343-V; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; CROSS AS, 1981, AM J MED, V70, P681, DOI 10.1016/0002-9343(81)90596-9; DRIKS MR, 1987, NEW ENGL J MED, V317, P1376, DOI 10.1056/NEJM198711263172204; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; GASTINNE H, 1992, NEW ENGL J MED, V326, P594, DOI 10.1056/NEJM199202273260903; GROSS PA, 1980, AM J MED, V68, P219, DOI 10.1016/0002-9343(80)90357-5; HIGUCHI JH, 1980, J LAB CLIN MED, V95, P698; JIMENEZ P, 1989, CRIT CARE MED, V17, P882, DOI 10.1097/00003246-198909000-00007; JOHANSON WG, 1969, NEW ENGL J MED, V281, P1137, DOI 10.1056/NEJM196911202812101; JOHANSON WG, 1972, ANN INTERN MED, V77, P701, DOI 10.7326/0003-4819-77-5-701; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEDINGHAM IM, 1988, LANCET, V1, P785; Lee E.T., 1992, STAT METHODS SURVIVA, P66; Lennette E.H, 1985, MANUAL CLIN MICROBIO, V4th ed.; LEVINE SA, 1991, CLIN CHEST MED, V12, P523; LOURIA DB, 1962, AM REV RESPIR DIS, V85, P649; MAHUL P, 1992, INTENS CARE MED, V18, P20, DOI 10.1007/BF01706421; MEDURI GU, 1990, CHEST, V97, P1208, DOI 10.1378/chest.97.5.1208; NIEDERMAN MS, 1989, CHEST, V95, P155, DOI 10.1378/chest.95.1.155; ONOFRIO JM, 1983, AM REV RESPIR DIS, V127, P335; PRESTON GA, 1981, AM J MED, V70, P641, DOI 10.1016/0002-9343(81)90588-X; RELLO J, 1994, INTENS CARE MED, V20, P193, DOI 10.1007/BF01704699; RELLO J, 1993, CHEST, V104, P1230, DOI 10.1378/chest.104.4.1230; RELLO J, 1992, CHEST, V102, P525, DOI 10.1378/chest.102.2.525; RELLO J, 1991, CHEST, V100, P439, DOI 10.1378/chest.100.2.439; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P153; SCHWARTZ SN, 1978, J INFECT DIS, V138, P227, DOI 10.1093/infdis/138.2.227; STOUTENBEEK C P, 1992, Intensive Care Medicine, V18, pS18, DOI 10.1007/BF01752972; STOUTENBEEK CP, 1984, INTENS CARE MED, V10, P185, DOI 10.1007/BF00259435; TEASDALE G, 1974, LANCET, V2, P81; TOBIN MJ, 1984, CRIT CARE MED, V12, P191, DOI 10.1097/00003246-198403000-00008; TOEWS GB, 1979, AM REV RESPIR DIS, V120, P559; TORRES A, 1992, ANN INTERN MED, V116, P540, DOI 10.7326/0003-4819-116-7-540; TRYBA M, 1987, AM J MED, V83, P117, DOI 10.1016/0002-9343(87)90840-0; WENZEL RP, 1989, EUR J CLIN MICROBIOL, V8, P56, DOI 10.1007/BF01964121; WIMBERLEY N, 1979, AM REV RESPIR DIS, V119, P337	42	366	391	1	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1995	122	3					179	186		10.7326/0003-4819-122-3-199502010-00004	http://dx.doi.org/10.7326/0003-4819-122-3-199502010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD733	7810935				2022-12-28	WOS:A1995QD73300004
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA ELECTRONIC BULLETIN BOARD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FESHERS LN,ROCKVILLE,MD 20857, USA.							FDA ENFORCEMENT REPO; FDA MED B	2	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	1995	273	4					279	279						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC057	7815644				2022-12-28	WOS:A1995QC05700006
J	OVERDUIN, M; HARVEY, TS; BAGBY, S; TONG, KI; YAU, P; TAKEICHI, M; IKURA, M				OVERDUIN, M; HARVEY, TS; BAGBY, S; TONG, KI; YAU, P; TAKEICHI, M; IKURA, M			SOLUTION STRUCTURE OF THE EPITHELIAL CADHERIN DOMAIN RESPONSIBLE FOR SELECTIVE CELL-ADHESION	SCIENCE			English	Article							BINDING-SITE; MOLECULE UVOMORULIN; CYTOPLASMIC DOMAIN; HUMAN CD2; PROTEINS; FACE	Cadherins are calcium-dependent cell adhesion molecules containing extracellular repeats of approximately 110 amino acids. The three-dimensional structure of the amino-terminal repeat of mouse epithelial cadherin was determined by multidimensional heteronuclear magnetic resonance spectroscopy. The calcium ion was bound by a short alpha helix and by loops at one end of the seven-stranded beta-barrel structure. An exposed concave face is in a position to provide homophilic binding specificity and was also sensitive to calcium ligation. Unexpected structural similarities with the immunoglobulin fold suggest an evolutionary relation between calcium-dependent and calcium-independent cell adhesion molecules.	UNIV TORONTO,ONTARIO CANC INST,DIV MOLEC & STRUCT BIOL,TORONTO,ON M4X 1K9,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M4X 1K9,CANADA; KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Kyoto University			Harvey, Timothy S/F-9863-2013; Overduin, Michael/AAG-3632-2020	Harvey, Timothy S/0000-0001-6270-1943; Overduin, Michael/0000-0002-3114-6585; Bagby, Stefan/0000-0003-2302-9511; Ikura, Mitsuhiko/0000-0002-9524-1303				AMES JB, 1994, BIOCHEMISTRY-US, V33, P10743, DOI 10.1021/bi00201a023; ARULANANDAM ARN, 1993, P NATL ACAD SCI USA, V90, P11613, DOI 10.1073/pnas.90.24.11613; BAGBY S, 1994, STRUCTURE, V2, P107, DOI 10.1016/S0969-2126(00)00013-7; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; Brunger A.T., 1993, X PLOR VERSION 3 1 S; EDELMAN M, 1991, ANNU REV BIOCHEM, V60, P155; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; HUBER AH, 1994, NEURON, V12, P717, DOI 10.1016/0896-6273(94)90326-3; JONES EY, 1993, CURR OPIN STRUC BIOL, V3, P846, DOI 10.1016/0959-440X(93)90147-D; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; MOINGEON P, 1989, IMMUNOL REV, V111, P111, DOI 10.1111/j.1600-065X.1989.tb00544.x; MUHANDIRAM DR, 1993, J MAGN RESON SER B, V102, P317, DOI 10.1006/jmrb.1993.1102; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; OVERDUIN M, UNPUB; OZAWA M, 1990, MECH DEVELOP, V33, P49, DOI 10.1016/0925-4773(90)90134-8; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; OZAWA M, 1990, J CELL BIOL, V111, P1645, DOI 10.1083/jcb.111.4.1645; PASCAL S, 1994, J MAGN RESON, V101, P197; POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x; POLJAK RJ, 1974, P NATL ACAD SCI USA, V71, P3440, DOI 10.1073/pnas.71.9.3440; SOMOZA C, 1993, J EXP MED, V178, P549, DOI 10.1084/jem.178.2.549; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; TONG KI, 1994, FEBS LETT, V352, P318; WISHART DS, 1993, J BIOMOL NMR, V4, P171; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	30	364	381	1	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 20	1995	267	5196					386	389		10.1126/science.7824937	http://dx.doi.org/10.1126/science.7824937			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC273	7824937				2022-12-28	WOS:A1995QC27300038
J	VANSELOW, NA; DONALDSON, MS; YORDY, KD				VANSELOW, NA; DONALDSON, MS; YORDY, KD			A NEW DEFINITION OF PRIMARY-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									NATL ACAD SCI,INST MED,WASHINGTON,DC 20418; NATL ACAD SCI,COMM FUTURE PRIMARY CARE,WASHINGTON,DC	National Academies of Sciences, Engineering & Medicine; National Academies of Sciences, Engineering & Medicine									0	43	43	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					192	192		10.1001/jama.273.3.192	http://dx.doi.org/10.1001/jama.273.3.192			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB234	7807653				2022-12-28	WOS:A1995QB23400018
J	SERRANO, M; GOMEZLAHOZ, E; DEPINHO, RA; BEACH, D; BARSAGI, D				SERRANO, M; GOMEZLAHOZ, E; DEPINHO, RA; BEACH, D; BARSAGI, D			INHIBITION OF RAS-INDUCED PROLIFERATION AND CELLULAR-TRANSFORMATION BY P16(INK4)	SCIENCE			English	Article							RETINOBLASTOMA GENE-PRODUCT; CYCLIN-DEPENDENT KINASES; C-MYC; ADENOVIRUS E1A; PROTEIN; BINDING; G(1); P21; PHOSPHORYLATION; FIBROBLASTS	The cyclin-dependent kinase 4 (CDK4) regulates progression through the G(1) phase of the cell cycle. The activity of CDK4 is controlled by the opposing effects of the D-type cyclin, an activating subunit, and p16(INK4), inhibitory subunit. Ectopic expression of p16(INK4) blocked entry into S phase of the cell cycle induced by oncogenic Ha-Ras, and this block was relieved by coexpression of a catalytically inactive CDK4 mutant. Expression of p16(INK4) suppressed cellular transformation of primary rat embryo fibroblasts by oncogenic Ha-Ras and Myc, but not by Ha-Ras and E1a. Together, these observations provide direct evidence that p16(INK4) inhibit cell growth.	COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724; ALBERT EINSTEIN COLL MED,DEPT IMMUNOL & MICROBIOL,NEW YORK,NY 10461; ALBERT EINSTEIN COLL MED,DEPT MED,NEW YORK,NY 10461	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; Yeshiva University; Yeshiva University			Serrano, Manuel/H-2634-2015	Serrano, Manuel/0000-0001-7177-9312; DePinho, Ronald/0000-0002-5625-577X; Bar-Sagi, Dafna/0000-0003-2597-8948	NCI NIH HHS [CA55360] Funding Source: Medline; NEI NIH HHS [EY09300-01] Funding Source: Medline; NICHD NIH HHS [HD28317-02] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028317] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R37CA055360, R01CA055360] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009300] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BATES S, 1994, ONCOGENE, V9, P1633; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FASANO O, 1983, Journal of Molecular and Applied Genetics, V2, P173; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZLAHOZ E, UNPUB; GOMEZLAHOZ E, 1994, P NATL ACAD SCI USA, V91, P5503; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HARLOW E, 1992, NATURE, V359, P270, DOI 10.1038/359270a0; HARPER JW, 1993, CELL, V75, P805; Hollingsworth RE, 1993, CURR OPIN CELL BIOL, V5, P194, DOI 10.1016/0955-0674(93)90102-V; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LUKAS J, 1994, ONCOGENE, V9, P707; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORI T, 1994, CANCER RES, V54, P3396; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2456, DOI 10.1128/MCB.13.4.2456; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TAM SW, 1994, CANCER RES, V54, P5816; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	44	418	440	0	6	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 13	1995	267	5195					249	252		10.1126/science.7809631	http://dx.doi.org/10.1126/science.7809631			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7809631				2022-12-28	WOS:A1995QB15300039
J	MANGINO, JE; MOSER, SA; WAITES, KB				MANGINO, JE; MOSER, SA; WAITES, KB			WHEN TO USE FLUCONAZOLE	LANCET			English	Editorial Material							CRYPTOCOCCAL MENINGITIS; CONTROLLED TRIAL; AMPHOTERICIN-B; PREVENT		UNIV ALABAMA,DEPT PATHOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham	MANGINO, JE (corresponding author), UNIV ALABAMA,DIV INFECT DIS,BIRMINGHAM,AL, USA.		Moser, Stephen A/A-1168-2008					BODEY GP, 1992, CLIN INFECT DIS, V14, pS161, DOI 10.1093/clinids/14.Supplement_1.S161; COMO JA, 1994, NEW ENGL J MED, V330, P263, DOI 10.1056/NEJM199401273300407; DENNING DW, 1994, AM J MED, V97, P135, DOI 10.1016/0002-9343(94)90023-X; GOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301; GRASELA TH, 1994, ANN PHARMACOTHER, V28, P261, DOI 10.1177/106002809402800220; GRASELA TH, 1994, ANN PHARMACOTHER, V28, P252, DOI 10.1177/106002809402800219; HEALD A, 1994, 34TH INT C ANT AG CH; LAINE L, 1992, ANN INTERN MED, V177, P655; PERFECT JR, 1993, AM J MED, V94, P233, DOI 10.1016/0002-9343(93)90053-R; POWDERLY WG, 1992, NEW ENGL J MED, V326, P793, DOI 10.1056/NEJM199203193261203; REX JH, 1994, NEW ENGL J MED, V331, P1325, DOI 10.1056/NEJM199411173312001; SAAG MS, 1992, NEW ENGL J MED, V326, P83, DOI 10.1056/NEJM199201093260202; WINSTON DJ, 1993, ANN INTERN MED, V181, P495	13	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					6	7		10.1016/S0140-6736(95)91147-2	http://dx.doi.org/10.1016/S0140-6736(95)91147-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799720				2022-12-28	WOS:A1995QA29000006
J	VANDAMME, P; CRAMM, M; VANDERAUWERA, JC; VRANCKX, R; MEHEUS, A				VANDAMME, P; CRAMM, M; VANDERAUWERA, JC; VRANCKX, R; MEHEUS, A			HORIZONTAL TRANSMISSION OF HEPATITIS-B VIRUS	LANCET			English	Note							TRANSMISSION; CHILDREN; INFECTION; FAMILIES	In 1991-92, a cross-sectional survey in Flanders (Belgium) for hepatitis B virus (HBV) markers among 277 relatives of institutionalised mentally handicapped persons to evaluate the prevalence of hepatitis B and the risk of infection showed that relatives of an HBV positive resident were 7.6 times more likely to be infected than relatives of an HBV seronegative mentally handicapped person. HBV infection among the family members could be attributed in 83% to exposure to an HBV positive resident. This study demonstrated the importance of horizontal transmission among relatives of institutionalised mentally handicapped people, even if family contact is reduced to weekend and holiday activities. We recommend that HBV vaccination policy should be expanded to include relatives of institutionalised mentally retarded people.	INST HYG & EPIDEMIOL,B-1050 BRUSSELS,BELGIUM		VANDAMME, P (corresponding author), UNIV ANTWERP,DEPT EPIDEMIOL & COMMUNITY MED,B-2610 ANTWERP,BELGIUM.		van damme, pierre/I-4846-2013					BERNIER RH, 1982, AM J EPIDEMIOL, V116, P199, DOI 10.1093/oxfordjournals.aje.a113406; CANCIOBELLO TP, 1982, J INFECT DIS, V146, P652, DOI 10.1093/infdis/146.5.652; DAVIS LG, 1989, LANCET, V1, P889; FRANKS AL, 1989, NEW ENGL J MED, V321, P1301, DOI 10.1056/NEJM198911093211905; FRIEDE A, 1988, AM J PUBLIC HEALTH, V78, P26, DOI 10.2105/AJPH.78.1.26; HAYASHI J, 1987, AM J EPIDEMIOL, V125, P492, DOI 10.1093/oxfordjournals.aje.a114555; JENISON SA, 1987, J INFECT DIS, V156, P299, DOI 10.1093/infdis/156.2.299; MCPHILLIPS JC, 1984, J PEDIATR GASTR NUTR, V3, P69, DOI 10.1097/00005176-198401000-00015; VANDAMME P, 1989, LANCET, V1, P840; VANDITZHUIJSEN TJM, 1988, AM J EPIDEMIOL, V128, P629, DOI 10.1093/oxfordjournals.aje.a115010	10	28	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					27	29		10.1016/S0140-6736(95)91155-3	http://dx.doi.org/10.1016/S0140-6736(95)91155-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799703				2022-12-28	WOS:A1995QA29000013
J	HEILBRON, JL; BYNUM, WF				HEILBRON, JL; BYNUM, WF			1895 AND ALL THAT	NATURE			English	Editorial Material									WELLCOME INST HIST MED,LONDON NW1 2BE,ENGLAND	University of London; University College London	HEILBRON, JL (corresponding author), UNIV CALIF BERKELEY,OFF HIST SCI & TECHNOL,BERKELEY,CA 94720, USA.							CANTOR G, BEITRAGE BEGRUNDUNG; Cardano G, 1545, ARTIS MAGNAE SIVE RE; CAYLEY A, THEORY LINEAR TRANSF; FRACASTORO G, SYPHILIS SIVE MORBUS; HOWARD HE, TERRITORY BIRD LIFE; HUTTON J, THEORY EARTH PROOFS; Lyell C., 1833, PRINCIPLES GEOLOGY; MERCATOR G, ATLAS SIVE COSMOGRAP; PARE A, METHODE TRAICTER PLA	9	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 5	1995	373	6509					11	14		10.1038/373011a0	http://dx.doi.org/10.1038/373011a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800027				2022-12-28	WOS:A1995QA23900021
J	SHOCK, M				SHOCK, M			MEDICINE AT THE CENTER OF THE NATIONS AFFAIRS	BRITISH MEDICAL JOURNAL			English	Article								The medical profession was shaped a century or so ago by the interaction of three forces. These were a class structure in which doctors were largely held to be gentlemen to whom deference was due, a society dominated by the activity of production (hence the label of the working class for the majority), and the doctrines of liberalism as the guiding star in politics. Prime Minister Gladstone defined his task as ''opening doors and windows.'' The outcome was a minimum of government interference and control with the belief that professional self regulation was the way to ensure that practice matched principle. The state (the word was hardly ever used) was self effacing almost to the point of non-existence. These are ghosts of the past, but it is a comparatively recent past. Within memory, the major domestic preoccupation of politicians of all parties was how, and to what ends, the working class could be absorbed into the political system. Health had a crucial part to ploy in this task, as Lloyd George and others saw early on. The ''panel'' was very much a forerunner of the NHS. Indeed, Bevan based part of his case in 1946 on the claim that 21 million people were already on the ''panel,'' clear evidence of the degree to which society was still dominated by production. While speaking of Nye Bevan, we might examine his claim that the NHS was ''pure socialism.'' In fact, it was rather closer to being ''impure liberalism'' in the consideration with which general practitioners and consultants were treated, the considerable freedom enjoyed by local administrations, and the low profile of government itself. That is why many remember the period as something of a golden age. It suited almost everyone very well.			SHOCK, M (corresponding author), UNIV OXFORD LINCOLN COLL,OXFORD OX1 3DR,ENGLAND.								0	19	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1730	1733		10.1136/bmj.309.6970.1730	http://dx.doi.org/10.1136/bmj.309.6970.1730			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7820005	Green Published			2022-12-28	WOS:A1994PY71700035
J	SANCAR, A				SANCAR, A			MECHANISMS OF DNA EXCISION-REPAIR	SCIENCE			English	Editorial Material							RNA POLYMERASE-II; XERODERMA-PIGMENTOSUM; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; DAMAGED DNA; GENE ERCC-1; PROTEINS; COMPLEMENTATION; ENDONUCLEASE; PURIFICATION				SANCAR, A (corresponding author), UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599, USA.							AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; BOYCE RP, 1964, P NATL ACAD SCI USA, V51, P293, DOI 10.1073/pnas.51.2.293; BUZDER SN, 1994, NATURE, V369, P578; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DEMPLE B, 1991, ANNU REV GENET, V25, P315, DOI 10.1146/annurev.ge.25.120191.001531; Doll R, 1981, J NATL CANCER I, V66, P1192; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FLORES O, 1992, J BIOL CHEM, V267, P2786; FRIEDBERG EC, 1988, MICROBIOL REV, V52, P70, DOI 10.1128/MMBR.52.1.70-102.1988; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; HABRAKEN Y, 1994, NUCLEIC ACIDS RES, V22, P3312, DOI 10.1093/nar/22.16.3312; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; HUGHES EN, 1992, J BIOL CHEM, V267, P13520; KASTAN MB, 1993, CELL, V71, P587; KATO T, 1994, NUCLEIC ACIDS RES, V22, P4119, DOI 10.1093/nar/22.20.4119; KELNER A, 1949, P NATL ACAD SCI USA, V35, P73, DOI 10.1073/pnas.35.2.73; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI YF, 1993, P NATL ACAD SCI USA, V90, P4389, DOI 10.1073/pnas.90.10.4389; LIN JJ, 1992, J BIOL CHEM, V267, P17692; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; LOWE SW, 1994, CELL, V74, P957; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACINNES MA, 1993, MOL CELL BIOL, V13, P6393, DOI 10.1128/MCB.13.10.6393; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; MU D, UNPUB; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; ODONOVAN A, 1994, J BIOL CHEM, V269, P16963; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; Park CHK, UNPUB; PETERSON SN, 1991, NUCLEIC ACIDS RES, V19, P6027, DOI 10.1093/nar/19.21.6027; PETTIJOHN D, 1964, J MOL BIOL, V7, P395; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; REARDON JT, 1993, COLD SPRING HARB SYM, V58, P605, DOI 10.1101/SQB.1993.058.01.067; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; RUPERT CS, 1958, J GEN PHYSIOL, V41, P451, DOI 10.1085/jgp.41.3.451; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; SANCAR GB, 1990, MUTAT RES, V236, P147, DOI 10.1016/0921-8777(90)90002-M; SCHAEFFER L, 1993, SCIENCE, V268, P58; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SETLOW RB, 1964, P NATL ACAD SCI USA, V51, P226, DOI 10.1073/pnas.51.2.226; SHIOMI T, 1994, MUTAT RES, V314, P167, DOI 10.1016/0921-8777(94)90080-9; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEFANINI M, 1993, AM J HUM GENET, V53, P817; SUNG P, 1993, J BIOL CHEM, V268, P26391; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; THOMPSON LH, 1981, P NATL ACAD SCI-BIOL, V78, P3734, DOI 10.1073/pnas.78.6.3734; THOMPSON LH, 1994, P NATL ACAD SCI USA, V91, P6855, DOI 10.1073/pnas.91.15.6855; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; TREIBER DK, 1994, P NATL ACAD SCI USA, V91, P5672, DOI 10.1073/pnas.91.12.5672; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; WALKER G, 1984, ANN REV BIOCH, V54, P425; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WEBER CA, 1990, EMBO J, V8, P1437; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157	78	511	529	2	38	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					1954	1956		10.1126/science.7801120	http://dx.doi.org/10.1126/science.7801120			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801120				2022-12-28	WOS:A1994PZ26700019
J	CHAWLA, JC				CHAWLA, JC			ABC OF SPORTS MEDICINE - SPORT FOR PEOPLE WITH DISABILITY	BRITISH MEDICAL JOURNAL			English	Article											CHAWLA, JC (corresponding author), UNIV WALES COLL MED,CARDIFF,S GLAM,WALES.								0	13	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 4	1994	308	6942					1500	1504		10.1136/bmj.308.6942.1500	http://dx.doi.org/10.1136/bmj.308.6942.1500			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ229	7802770	Green Published			2022-12-28	WOS:A1994NQ22900027
J	FRIEDMAN, AM; FISCHMANN, TO; STEITZ, TA				FRIEDMAN, AM; FISCHMANN, TO; STEITZ, TA			CRYSTAL-STRUCTURE OF LAC REPRESSOR CORE TETRAMER AND ITS IMPLICATIONS FOR DNA LOOPING	SCIENCE			English	Article							LACTOSE REPRESSOR; BINDING-PROTEIN; 3-DIMENSIONAL STRUCTURE; ESCHERICHIA-COLI; OPERATOR; SEQUENCE; OPERON; GENE; ASSOCIATION; PROMOTER	The crystal structure of the tryptic core fragment of the lac repressor of Escherichia coli (LacR) complexed with the inducer isopropyl-beta-D-thiogalactoside was determined at 2.6 Angstrom resolution. The quaternary structure consists of two dyad-symmetric dimers that are nearly parallel to each other. This structure places all four DNA binding domains of intact LacR on the same side of the tetramer, and results in a deep, V-shaped cleft between the two dimers. Each monomer contributes a carboxyl-terminal helix to an antiparallel four-helix bundle that functions as a tetramerization domain. Some of the side chains whose mutation reduce DNA binding form clusters on a surface near the amino terminus. Placing the structure of the DNA binding domain complexed with operator previously determined by nuclear magnetic resonance onto this surface results in two operators being adjacent and nearly parallel to each other. Structural considerations suggest that the two dimers of LacR may flexibly alter their relative orientation in order to bind to the known varied spacings between two operators.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06520; YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06520	Yale University; Howard Hughes Medical Institute; Yale University; Yale University			Friedman, Alan M/J-2696-2012; Steitz, Thomas A./C-6559-2009		NIGMS NIH HHS [GM22778] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTI S, 1991, NEW BIOL, V3, P57; BARKLEY MD, 1975, BIOCHEMISTRY-US, V14, P1700, DOI 10.1021/bi00679a024; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CARRA JH, EMBO J, V12, P35; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P1371; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P22206; CHANG WI, 1993, J BIOL CHEM, V268, P17613; CHARLIER M, 1980, NATURE, V286, P423, DOI 10.1038/286423a0; CHEN B, 1971, NATURE-NEW BIOL, V233, P67, DOI 10.1038/newbio233067a0; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHUPRINA VP, 1993, J MOL BIOL, V234, P446, DOI 10.1006/jmbi.1993.1598; CROMER DT, 1970, J CHEM PHYS, V53, P1891, DOI 10.1063/1.1674266; DANDANELL G, 1987, NATURE, V325, P823, DOI 10.1038/325823a0; DUNN TM, 1984, P NATL ACAD SCI-BIOL, V81, P5017, DOI 10.1073/pnas.81.16.5017; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Friedman A. J., UNPUB; GEISLER N, 1977, BIOCHEMISTRY-US, V16, P938, DOI 10.1021/bi00624a020; GILBERT W, 1973, P NATL ACAD SCI USA, V70, P3581, DOI 10.1073/pnas.70.12.3581; GILBERT W, 1966, P NATL ACAD SCI USA, V56, P1891, DOI 10.1073/pnas.56.6.1891; GORDON AJE, 1988, J MOL BIOL, V200, P239, DOI 10.1016/0022-2836(88)90237-9; GRIFFITH J, 1986, NATURE, V322, P750, DOI 10.1038/322750a0; HARRIS LJ, 1992, NATURE, V360, P369, DOI 10.1038/360369a0; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOPE H, 1989, ACTA CRYSTALLOGR B, V45, P190, DOI 10.1107/S0108768188013710; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; KANIA J, 1976, P NATL ACAD SCI USA, V73, P3529, DOI 10.1073/pnas.73.10.3529; KAPTEIN R, 1985, J MOL BIOL, V182, P179, DOI 10.1016/0022-2836(85)90036-1; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; KRAMER H, 1987, EMBO J, V6, P1481, DOI 10.1002/j.1460-2075.1987.tb02390.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE W, 1994, NAT STRUCT BIOL, V265, P386; MAJORS J, 1975, P NATL ACAD SCI USA, V72, P4394, DOI 10.1073/pnas.72.11.4394; MAJUMDAR A, 1984, P NATL ACAD SCI-BIOL, V81, P6100, DOI 10.1073/pnas.81.19.6100; MANDAL N, 1990, GENE DEV, V4, P410, DOI 10.1101/gad.4.3.410; MCKAY DB, 1982, J MOL BIOL, V156, P175, DOI 10.1016/0022-2836(82)90465-X; MONOD J, 1985, J MOL BIOL, V12, P88; MOWBRAY SL, 1993, J MOL BIOL, V225, P155; MULLERHILL B, 1983, NATURE, V302, P163, DOI 10.1038/302163a0; NICHOLS JC, 1993, J BIOL CHEM, V268, P17602; NICK H, 1985, NATURE, V313, P795, DOI 10.1038/313795a0; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; OGATA RT, 1979, J MOL BIOL, V132, P709, DOI 10.1016/0022-2836(79)90384-X; OH BH, 1993, J BIOL CHEM, V268, P11348; OHSHIMA Y, 1975, J MOL BIOL, V91, P515, DOI 10.1016/0022-2836(75)90277-6; PARDEE AB, 1959, J MOL BIOL, V1, P165, DOI 10.1016/S0022-2836(59)80045-0; PLATT T, 1973, J BIOL CHEM, V248, P110; PORSCHKE D, 1987, BIOPHYS CHEM, V28, P137, DOI 10.1016/0301-4622(87)80083-2; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; Quiocho FA, 1991, CURR OPIN STRUC BIOL, V1, P922, DOI 10.1016/0959-440X(91)90087-A; ROSENBERG JM, 1977, NUCLEIC ACIDS RES, V4, P567, DOI 10.1093/nar/4.3.567; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; SCHMITZ A, 1976, J BIOL CHEM, V251, P3359; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; STRANEY SB, 1987, CELL, V51, P699, DOI 10.1016/0092-8674(87)90093-6; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; THEVENY B, 1987, NATURE, V329, P79, DOI 10.1038/329079a0; VYAS NK, 1991, J BIOL CHEM, V266, P5226; WHITSON PA, 1987, J BIOL CHEM, V262, P14592; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	71	269	271	0	23	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1721	1727		10.1126/science.7792597	http://dx.doi.org/10.1126/science.7792597			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792597				2022-12-28	WOS:A1995RE66800033
J	ISHAI, A; SAGI, D				ISHAI, A; SAGI, D			COMMON MECHANISMS OF VISUAL-IMAGERY AND PERCEPTION	SCIENCE			English	Article							MENTAL-IMAGERY; AGNOSIA; CORTEX; BRAIN	Detection of a visual target can be facilitated by flanking visual masks. A similar enhancement in detection thresholds was obtained when observers imagined the previously perceived masks. Imagery-induced facilitation was detected for as long as 5 minutes after observation of the masks by the targeted eye. These results indicated the existence of a low-level (monocular) memory that stores the sensory trace for several minutes and enables reactivation of early representations by higher processes. This memory, with its iconic nature, may subserve the interface between mental images and percepts.			ISHAI, A (corresponding author), WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL.		Sagi, Dov/A-5454-2008	Sagi, Dov/0000-0002-8446-9230				BEHRMANN M, 1992, NATURE, V359, P636, DOI 10.1038/359636a0; BIHAN DL, 1993, P NATL ACAD SCI USA, V90, P1182; CRAVERLEMLEY C, 1987, PERCEPTION, V16, P599, DOI 10.1068/p160599; CRAVERLEMLEY C, 1992, PSYCHOL REV, V99, P6633; FARAH MJ, 1988, J EXP PSYCHOL GEN, V117, P248, DOI 10.1037/0096-3445.117.3.248; FARAH MJ, 1989, TRENDS NEUROSCI, V12, P395, DOI 10.1016/0166-2236(89)90079-9; FARAH MJ, 1985, J EXP PSYCHOL GEN, V114, P91, DOI 10.1037/0096-3445.114.1.91; GOLDENBERG G, 1989, NEUROPSYCHOLOGIA, V27, P641, DOI 10.1016/0028-3932(89)90110-3; ISHAI A, 1995, GCDS951 WEIZM I SCI; JANKOWIAK J, 1992, J COGNITIVE NEUROSCI, V4, P119, DOI 10.1162/jocn.1992.4.2.119; KARNI A, 1991, P NATL ACAD SCI USA, V88, P4966, DOI 10.1073/pnas.88.11.4966; KOSSLYN SM, 1993, J COGNITIVE NEUROSCI, V5, P263, DOI 10.1162/jocn.1993.5.3.263; KOSSLYN SM, 1994, TRENDS NEUROSCI, V17, P290, DOI 10.1016/0166-2236(94)90059-0; MEHTA Z, 1992, NEUROPSYCHOLOGIA, V30, P645, DOI 10.1016/0028-3932(92)90069-X; POLAT U, 1994, P NATL ACAD SCI USA, V91, P1206, DOI 10.1073/pnas.91.4.1206; POLAT U, 1993, VISION RES, V33, P993, DOI 10.1016/0042-6989(93)90081-7; ROLAND PE, 1994, TRENDS NEUROSCI, V17, P281, DOI 10.1016/0166-2236(94)90057-4; ROLAND PE, 1987, J NEUROSCI, V7, P2373; SAKAI K, 1994, TRENDS NEUROSCI, V17, P287, DOI 10.1016/0166-2236(94)90058-2; SEGAL SJ, 1970, J EXP PSYCHOL, V83, P458, DOI 10.1037/h0028840	20	146	149	0	15	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1772	1774		10.1126/science.7792605	http://dx.doi.org/10.1126/science.7792605			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RE668	7792605				2022-12-28	WOS:A1995RE66800048
J	LAWRENCE, CM; RODWELL, VW; STAUFFACHER, CV				LAWRENCE, CM; RODWELL, VW; STAUFFACHER, CV			CRYSTAL-STRUCTURE OF PSEUDOMONAS-MEVALONII HMG-COA REDUCTASE AT 3.0 ANGSTROM RESOLUTION	SCIENCE			English	Article							COENZYME-A REDUCTASE; ACTIVATED PROTEIN-KINASE; AREA DETECTOR DIFFRACTOMETER; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; RAT-LIVER; CHEMICAL MODIFICATION; MEMBRANE DOMAIN; CATALYTIC SITE; CRYSTALLOGRAPHY; IDENTIFICATION	The rate-limiting step in cholesterol biosynthesis in mammals is catalyzed by 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a four-electron oxidoreductase that converts HMG-CoA to mevalonate. The crystal structure of HMG-CoA reductase from Pseudomonas mevalonii was determined at 3.0 angstrom resolution by multiple isomorphous replacement. The structure reveals a tightly bound dimer that brings together at the subunit interface the conserved residues implicated in substrate binding and catalysis. These dimers are packed about a threefold crystallographic axis, forming a hexamer with 23 point group symmetry. Difference Fourier studies reveal the binding sites for the substrates HMG-CoA and reduced or oxidized nicotinamide adenine dinucleotide [NAD(H)] and demonstrate that the active sites are at the dimer interfaces. The HMG-CoA is bound by a domain with an unusual fold, consisting of a central alpha helix surrounded by a triangular set of walls of beta sheets and alpha helices. The NAD(H) is bound by a domain characterized by an antiparallel beta structure that defines a class of dinucleotide-binding domains.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907; PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus			Lawrence, C. Martin/AAH-3420-2020	Lawrence, C. Martin/0000-0002-5398-466X	NHLBI NIH HHS [HL 47113] Funding Source: Medline; NIAID NIH HHS [AI 127713] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047113] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEACH MJ, 1989, J BACTERIOL, V171, P2994, DOI 10.1128/jb.171.6.2994-3001.1989; BOLLN JT, 1993, 1993 AM CRYST ASS 2; BROWN MS, 1986, SCIENCE, V232, P32; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CHUN KT, 1992, J BIOL CHEM, V267, P4236; CLARKE CF, 1985, J BIOL CHEM, V260, P4363; CLARKE PR, 1990, FEBS LETT, V269, P213, DOI 10.1016/0014-5793(90)81157-J; CLARKE PR, 1990, EMBO J, V9, P2439, DOI 10.1002/j.1460-2075.1990.tb07420.x; DARNAY BG, 1993, J BIOL CHEM, V268, P8429; DARNAY BG, 1992, J BIOL CHEM, V267, P15064; DUGAN RE, 1986, BIOCHEM BIOPH RES CO, V141, P278, DOI 10.1016/S0006-291X(86)80365-5; EDWARDS PA, 1985, J BIOL CHEM, V260, P278; ENDO A, 1992, J LIPID RES, V33, P1569; GILL JF, 1985, J BIOL CHEM, V260, P9393; GILL JF, 1984, J BACTERIOL, V160, P294, DOI 10.1128/JB.160.1.294-298.1984; GILLESPIE JG, 1992, FEBS LETT, V306, P59, DOI 10.1016/0014-5793(92)80837-7; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORDANSTARCK TC, 1989, J BIOL CHEM, V264, P17919; JORDANSTARCK TC, 1989, J BIOL CHEM, V264, P17913; KIRTLEY ME, 1967, BIOCHEMISTRY-US, V6, P230, DOI 10.1021/bi00853a036; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE CM, 1995, ACTA CRYSTALLOGR D, V51, P386, DOI 10.1107/S0907444994009819; LESLIE GW, 1987, ASPECTS PROTEIN CRYS, P35; LOUISFLAMBERG P, 1990, BIOCHEMISTRY-US, V29, P4115, DOI 10.1021/bi00469a014; MAYER RJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P110, DOI 10.1016/0003-9861(88)90014-8; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; OMKUMAR RV, 1994, J BIOL CHEM, V269, P16862; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1985, CELL, V42, P203, DOI 10.1016/S0092-8674(85)80116-1; Pflugrath J. W., 1984, Methods and Applications in Crystallographic Computing. International Summer School on Crystallographic Computing, P404; ROITELMAN J, 1989, J LIPID RES, V30, P97; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; SCALNICK DG, 1988, J BIOL CHEM, V263, P6836; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG Y, 1989, J BACTERIOL, V171, P5567, DOI 10.1128/jb.171.10.5567-5571.1989; WANG YL, 1990, J BIOL CHEM, V265, P21634; XUONG NH, 1985, ACTA CRYSTALLOGR B, V41, P267, DOI 10.1107/S0108768185002105; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433	46	73	78	1	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1758	1762		10.1126/science.7792601	http://dx.doi.org/10.1126/science.7792601			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792601				2022-12-28	WOS:A1995RE66800044
J	SELHUB, J; JACQUES, PF; BOSTOM, AG; DAGOSTINO, RB; WILSON, PWF; BELANGER, AJ; OLEARY, DH; WOLF, PA; SCHAEFER, EJ; ROSENBERG, IH				SELHUB, J; JACQUES, PF; BOSTOM, AG; DAGOSTINO, RB; WILSON, PWF; BELANGER, AJ; OLEARY, DH; WOLF, PA; SCHAEFER, EJ; ROSENBERG, IH			ASSOCIATION BETWEEN PLASMA HOMOCYSTEINE CONCENTRATIONS AND EXTRACRANIAL CAROTID-ARTERY STENOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; ATHEROTHROMBOTIC BRAIN INFARCTION; RISK-FACTORS; CARDIOVASCULAR HEALTH; ATHEROSCLEROSIS RISK; VASCULAR-DISEASE; ELDERLY PATIENTS; FOLLOW-UP; ULTRASOUND; FOLATE	Background. Epidemiologic studies have identified hyperhomocysteinemia as a possible risk factor for atherosclerosis. We determined the risk of carotid-artery atherosclerosis in relation to both plasma homocysteine concentrations and nutritional determinants of hyperhomocysteinemia. Methods. We performed a cross-sectional study of 1041 elderly subjects (418 men and 623 women; age range, 67 to 96 years) from the Framingham Heart Study. We examined the relation between the maximal degree of stenosis of the extracranial carotid arteries (as assessed by ultrasonography) and plasma homocysteine concentrations, as well as plasma concentrations and intakes of vitamins involved in homocysteine metabolism, including folate, vitamin B-12, and vitamin B-6. The subjects were classified into two categories according to the findings in the more diseased of the two carotid vessels: stenosis of 0 to 24 percent and stenosis of 25 to 100 percent. Results. The prevalence of carotid stenosis of less than or equal to 25 percent was 43 percent in the men and 34 percent in the women. The odds ratio for stenosis of greater than or equal to 25 percent was 2.0 (95 percent confidence interval, 1.4 to 2.9) for subjects with the highest plasma homocysteine concentrations (greater than or equal to 14.4 mu mol per liter) as compared with those with the lowest concentrations (less than or equal to 9.1 mu mol per liter), after adjustment for sex, age, plasma high-density lipoprotein cholesterol concentration, systolic blood pressure, and smoking status (P<0.001 for trend). Plasma concentrations of folate and pyridoxal-5'-phosphate (the coenzyme form of vitamin B-6) and the level of folate intake were inversely associated with carotid-artery stenosis after adjustment for age, sex, and other risk factors. Conclusions. High plasma homocysteine concentrations and low concentrations of folate and vitamin B,, through their role in homocysteine metabolism, are associated with an increased risk of extracranial carotid-artery stenosis in the elderly.	FRAMINGHAM HEART DIS EPIDEMIOL STUDY, FRAMINGHAM, MA USA; BOSTON UNIV, DEPT MATH, STAT & CONSULTING UNIT, BOSTON, MA 02215 USA; GEISINGER MED CTR, DEPT RADIOL, DANVILLE, PA 17822 USA; BOSTON UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02118 USA; UNIV BOSTON HOSP, EVANS MEM DEPT CLIN RES, PREVENT MED & EPIDEMIOL SECT, BOSTON, MA 02118 USA; UNIV BOSTON HOSP, DEPT MED, BOSTON, MA 02118 USA	Framingham Heart Study; Boston University; Geisinger Medical Center; Boston University	SELHUB, J (corresponding author), TUFTS UNIV, USDA, HUMAN NUTR RES CTR AGING, 711 WASHINGTON ST, BOSTON, MA 02111 USA.		Wilson, Peter W.F./J-2455-2016	Wolf, Philip/0000-0002-3628-301X	NHLBI NIH HHS [R01-HL-40423-05, N01-HC-38038] Funding Source: Medline; NINDS NIH HHS [2-R01-NS-17950-12] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040423] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; ARONOW WS, 1992, NEW YORK STATE J MED, V92, P424; ARONOW WS, 1993, AM J CARDIOL, V71, P999, DOI 10.1016/0002-9149(93)90923-Z; ARONOW WS, 1993, AM J CARDIOL, V71, P1479, DOI 10.1016/0002-9149(93)90622-J; ARONOW WS, 1992, CORONARY ARTERY DIS, V3, P249, DOI 10.1097/00019501-199203000-00012; BLANKENHORN DH, 1993, CIRCULATION, V88, P20, DOI 10.1161/01.CIR.88.1.20; BOND MG, 1989, AM J MED, V86, P33; BOTS ML, 1992, HYPERTENSION, V19, P717, DOI 10.1161/01.HYP.19.6.717; BRATTSTROM L, 1990, ATHEROSCLEROSIS, V81, P51, DOI 10.1016/0021-9150(90)90058-Q; CAMP VM, 1983, CLIN CHEM, V29, P642; CHAMBLESS LE, 1993, AM J EPIDEMIOL, V138, P660; CLARKE R, 1992, IRISH J MED SCI, V161, P61, DOI 10.1007/BF02983714; CROUSE JR, 1987, STROKE, V18, P990, DOI 10.1161/01.STR.18.6.990; DAWBER T. R., 1957, AMER JOUR PUBL HEALTH, V47, P4, DOI 10.2105/AJPH.47.4_Pt_2.4; FALKE P, 1989, INT ANGIOL, V8, P175; FINEEDELSTEIN JS, 1994, NEUROLOGY, V44, P1046, DOI 10.1212/WNL.44.6.1046; FURBERG CD, 1993, CIRCULATION S1, V88, P1; HEISS G, 1991, AM J EPIDEMIOL, V134, P250, DOI 10.1093/oxfordjournals.aje.a116078; JACQUES PF, 1993, AM J CLIN NUTR, V57, P182, DOI 10.1093/ajcn/57.2.182; JOOSTEN E, 1993, AM J CLIN NUTR, V58, P468, DOI 10.1093/ajcn/58.4.468; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; MALINOW MR, 1993, CIRCULATION, V87, P1107, DOI 10.1161/01.CIR.87.4.1107; MCCULLY KS, 1969, AM J PATHOL, V56, P111; MCNAMARA JR, 1987, CLIN CHIM ACTA, V166, P1, DOI 10.1016/0009-8981(87)90188-4; NEWMAN AB, 1993, CIRCULATION, V88, P837, DOI 10.1161/01.CIR.88.3.837; O'Leary D H, 1992, Ann Epidemiol, V2, P147, DOI 10.1016/1047-2797(92)90049-V; OLEARY DH, 1992, STROKE, V23, P1752, DOI 10.1161/01.STR.23.12.1752; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RUBBA P, 1990, METABOLISM, V39, P1191, DOI 10.1016/0026-0495(90)90093-R; RUSSELL RM, 1992, AM J CLIN NUTR, V55, P1203; SALONEN JT, 1991, ARTERIOSCLER THROMB, V11, P1245, DOI 10.1161/01.ATV.11.5.1245; SALONEN R, 1988, ARTERIOSCLEROSIS, V8, P788, DOI 10.1161/01.ATV.8.6.788; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; TAMURA T, 1990, CLIN CHEM, V36, P1993; UBBINK JB, 1993, AM J CLIN NUTR, V57, P47, DOI 10.1093/ajcn/57.1.47; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; WARNICK GR, 1982, CLIN CHEM, V28, P1379; 1990, SAS PROCEDURES GUIDE; 1990, MONOGRAPHS EPIDEMIOL, V15, P92	40	1006	1052	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 2	1995	332	5					286	291		10.1056/NEJM199502023320502	http://dx.doi.org/10.1056/NEJM199502023320502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD396	7816063	Bronze			2022-12-28	WOS:A1995QD39600002
J	PAWLOTSKY, JM; ROUDOTTHORAVAL, F; SIMMONDS, P; MELLOR, J; BENYAHIA, M; ANDRE, C; VOISIN, MC; INTRATOR, L; ZAFRANI, ES; DUVAL, J; DHUMEAUX, D				PAWLOTSKY, JM; ROUDOTTHORAVAL, F; SIMMONDS, P; MELLOR, J; BENYAHIA, M; ANDRE, C; VOISIN, MC; INTRATOR, L; ZAFRANI, ES; DUVAL, J; DHUMEAUX, D			EXTRAHEPATIC IMMUNOLOGICAL MANIFESTATIONS IN CHRONIC HEPATITIS-C AND HEPATITIS-C VIRUS SEROTYPES	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS C; HEPATITIS C VIRUSES; HEPATITIS, CHRONIC ACTIVE; SEROTYPING; CRYOGLOBULINEMIA	ESSENTIAL MIXED CRYOGLOBULINEMIA; POLYMERASE CHAIN-REACTION; INTERFERON-ALPHA THERAPY; INFECTION; GENOTYPES; SEQUENCE; HCV; AUTOANTIBODIES; REGION; TYPE-1	Objective: To determine, using a serotyping assay, whether the occurrence of extrahepatic immunologic disorders in patients with chronic hepatitis C is dependent on hepatitis C virus serotype. II Design: Prospective study. Setting: Liver unit and virology laboratory of a university hospital. Patients: 59 consecutive patients with chronic hepatitis C. Measurements: Hepatitis C virus serotype was determined using a recently developed immunoenzymatic assay that detects antibodies directed to serotype-specific immunodominant epitopes. Cryoglobulin, rheumatoid factor, and numerous antitissue antibodies were sought. Biopsies of labial salivary glands were done in 49 of the 59 patients. Results: Prevalence was 59% for serotype 1, 10% for serotype 2, 12% for serotype 3, and 3% for mixed infection. Fifteen percent of patients could not be serotyped. Cryoglobulinemia was found in 36% of patients and rheumatoid factor was found in the serum of 71%. At least one antitissue antibody was found in the serum of 41% of patients; salivary gland biopsy showed lymphocytic capillaritis in 49% of patients. These immunologic abnormalities were seen in patients infected with any of the three serotypes, and prevalences of the abnormalities did not differ significantly among patients infected with different serotypes. Conclusions: We confirm that the prevalence of extrahepatic immunologic abnormalities is high in patients with chronic hepatitis C. These abnormalities may occur in patients infected with any of the three major hepatitis C virus serotypes now present in developed countries.	UNIV PARIS 12, CRETEIL, FRANCE; UNIV EDINBURGH, DEPT MED MICROBIOL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND	Universite Paris-Est-Creteil-Val-de-Marne (UPEC); University of Edinburgh			Pawlotsky, Jean-Michel/R-8159-2018	Simmonds, Peter/0000-0002-7964-4700; Pawlotsky, Jean-Michel/0000-0003-0745-7559				ABUAF N, 1993, J HEPATOL, V18, P359, DOI 10.1016/S0168-8278(05)80281-8; AGNELLO V, 1992, NEW ENGL J MED, V327, P1490, DOI 10.1056/NEJM199211193272104; ALONSO C, 1994, J CLIN MICROBIOL, V32, P211, DOI 10.1128/JCM.32.1.211-212.1994; AUTHIER FJ, 1993, ANN NEUROL, V34, P749, DOI 10.1002/ana.410340524; BRECHOT C, 1993, J HEPATOL, V17, P265, DOI 10.1016/S0168-8278(05)80203-X; BUKH J, 1993, P NATL ACAD SCI USA, V90, P8234, DOI 10.1073/pnas.90.17.8234; CHA TA, 1992, P NATL ACAD SCI USA, V89, P7144, DOI 10.1073/pnas.89.15.7144; CHAN SW, 1992, J GEN VIROL, V73, P1131, DOI 10.1099/0022-1317-73-5-1131; CHEMELLO L, 1994, NEW ENGL J MED, V330, P143, DOI 10.1056/NEJM199401133300215; CHISHOLM DM, 1968, J CLIN PATHOL, V21, P656, DOI 10.1136/jcp.21.5.656; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; CZAJA AJ, 1992, GASTROENTEROLOGY, V103, P1290, DOI 10.1016/0016-5085(92)91518-9; DAMMACCO F, 1992, CLIN EXP IMMUNOL, V87, P352, DOI 10.1111/j.1365-2249.1992.tb03001.x; ENOMOTO N, 1990, BIOCHEM BIOPH RES CO, V170, P1021, DOI 10.1016/0006-291X(90)90494-8; FERAY C, 1993, HEPATOLOGY, V18, pA59, DOI 10.1016/0270-9139(93)91763-I; FERRI C, 1991, CLIN EXP RHEUMATOL, V9, P621; GEROLAMI V, 1993, J INFECT DIS, V168, P1328, DOI 10.1093/infdis/168.5.1328; HIJIKATA M, 1993, J VIROL, V67, P1953, DOI 10.1128/JVI.67.4.1953-1958.1993; JOHNSON RJ, 1993, NEW ENGL J MED, V328, P465, DOI 10.1056/NEJM199302183280703; JUBERT C, 1994, ARCH DERMATOL, V130, P73, DOI 10.1001/archderm.130.1.73; LENZI M, 1990, LANCET, V335, P258, DOI 10.1016/0140-6736(90)90070-L; LI JS, 1991, GENE, V105, P167; LUNEL F, 1994, GASTROENTEROLOGY, V106, P1291, DOI 10.1016/0016-5085(94)90022-1; LUNEL F, 1992, HEPATOLOGY, V16, P630, DOI 10.1002/hep.1840160304; MAGRIN S, 1991, J HEPATOL, V13, P364, DOI 10.1016/0168-8278(91)90082-M; MANNS MP, 1991, J CLIN INVEST, V88, P1370, DOI 10.1172/JCI115443; MARCELLIN P, 1993, GASTROENTEROLOGY, V104, P272, DOI 10.1016/0016-5085(93)90862-7; MCOMISH F, 1993, TRANSFUSION, V33, P7, DOI 10.1046/j.1537-2995.1993.33193142314.x; MCOMISH F, 1994, J CLIN MICROBIOL, V32, P884, DOI 10.1128/JCM.32.4.884-892.1994; MICHEL G, 1992, LANCET, V339, P267, DOI 10.1016/0140-6736(92)91332-3; MISIANI R, 1992, ANN INTERN MED, V117, P573, DOI 10.7326/0003-4819-117-7-573; NOUSBAUM JB, 1993, HEPATOLOGY, V18, pA88; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; OKAMOTO H, 1993, J GEN VIROL, V74, P2385, DOI 10.1099/0022-1317-74-11-2385; PAWLOTSKY JM, 1994, HEPATOLOGY, V19, P841, DOI 10.1016/0270-9139(94)90281-X; PAWLOTSKY JM, 1993, GUT, V34, pS66, DOI 10.1136/gut.34.2_Suppl.S66; PISTELLO M, 1994, J CLIN MICROBIOL, V32, P232, DOI 10.1128/JCM.32.1.232-234.1994; ROITT IM, 1972, WHO BOOKLET IMMUNOLO, P1; SIMMONDS P, 1993, J GEN VIROL, V74, P661, DOI 10.1099/0022-1317-74-4-661; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; SIMMONDS P, 1993, J CLIN MICROBIOL, V31, P1493, DOI 10.1128/JCM.31.6.1493-1503.1993; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1016/0270-9139(94)90887-7; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; TAKADA N, 1993, J HEPATOL, V17, P277, DOI 10.1016/S0168-8278(05)80205-3; TRAN A, 1993, HEPATOLOGY, V18, P253, DOI 10.1002/hep.1840180205; YAMAMOTO AM, 1993, GASTROENTEROLOGY, V104, P1762, DOI 10.1016/0016-5085(93)90657-X; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203	48	317	324	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1995	122	3					169	173		10.7326/0003-4819-122-3-199502010-00002	http://dx.doi.org/10.7326/0003-4819-122-3-199502010-00002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD733	7810933				2022-12-28	WOS:A1995QD73300002
J	SOYSETH, V; KONGERUD, J; HAARR, D; STRAND, O; BOLLE, R; BOE, J				SOYSETH, V; KONGERUD, J; HAARR, D; STRAND, O; BOLLE, R; BOE, J			RELATION OF EXPOSURE TO AIRWAY IRRITANTS IN INFANCY TO PREVALENCE OF BRONCHIAL HYPERRESPONSIVENESS IN SCHOOLCHILDREN	LANCET			English	Article							INHALED HISTAMINE; ASTHMA; CHILDREN; SYMPTOMS	To find out whether exposure to sulphur dioxide during infancy is related to the prevalence of bronchial hyperresponsiveness (BHR), we studied schoolchildren (aged 7-13 years) from two areas of Norway-a Valley containing a sulphur-dioxide-emitting aluminium smelter and a similar but non-industrialised valley. Bronchial responsiveness was assessed in 529 of the 620 participants. The median exposures to sulphur dioxide and fluoride were 37.1 mu g/m(3) and 4.4 mu g/m(3) at ages 0-12 months and 37.9 mu g/m(3) and 4.4 mu g/m(3) at 13-36 months. The risk of BHR increased with exposure to sulphur dioxide and fluoride at these ages; the odds ratio for a 10 mu g/m(3) increase in sulphur dioxide exposure at 0-12 months was 1.62 (95% CI 1.11-2.35) and that for a 1 mu g/m(3) increase in fluoride exposure was 1.35 (1.07-1.70) at 0-12 months and 1.38 (1.05-1.82) at 13-36 months. Exposure to these low concentrations of airway irritants during early childhood is associated with an increased prevalence of BHR in schoolchildren.	UNIV OSLO, RIKSHOSP, DEPT THORAC MED, N-0027 OSLO, NORWAY; ARDAL MUNICIPAL, PRIMARY HLTH CARE UNIT, ARDALSTANGEN, NORWAY; REG HOSP, DEPT PAEDIAT, TROMSO, NORWAY	University of Oslo; National Hospital Norway	SOYSETH, V (corresponding author), HYDRO ALUMINIUM ARDAL, N-5870 OVRE ARDAL, NORWAY.							ANDERSON HR, 1989, ARCH DIS CHILD, V64, P172, DOI 10.1136/adc.64.1.172; ANDRAE S, 1988, ARCH DIS CHILD, V63, P473, DOI 10.1136/adc.63.5.473; [Anonymous], 1985, THEORETICAL EPIDEMIO; BELIN L, 1985, ALLERGY S4, V40, P60; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COTES JE, 1979, LUNG FUNCTION, P340; DAVIES RJ, 1993, AGENT ACTION SUPPL, V43, P87; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; DODGE R, 1985, AM J EPIDEMIOL, V121, P720, DOI 10.1093/aje/121.5.720; ERNST P, 1986, AM REV RESPIR DIS, V133, P307; FERRIS BG, 1988, EPIDEMIOLOGY HLTH RI, P120; Hosmer D., 1989, APPL LOGISTIC REGRES, P82; KONGERUD J, 1991, EUR RESPIR J, V4, P159; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; LESOUEF PN, 1989, AM REV RESPIR DIS, V139, P62, DOI 10.1164/ajrccm/139.1.62; MANTEL N, 1959, J NATL CANCER I, V22, P719; PEAT JK, 1987, CLIN ALLERGY, V17, P283, DOI 10.1111/j.1365-2222.1987.tb02016.x; ROBINS JM, 1986, BIOMETRICS, V68, P525; RONNEBERG A, 1994, INT J EPIDEMIOL, V23, P267, DOI 10.1093/ije/23.2.267; Rothman KJ, 1986, MODERN EPIDEMIOLOGY, P84; SHEPPARD D, 1988, J ALLERGY CLIN IMMUN, V82, P961, DOI 10.1016/0091-6749(88)90131-5; SOYSETH V, IN PRESS CHEST; STEENJOHNSEN J, 1993, NOR J EPIDEMIOL, V3, P44; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; WEINBERG CR, 1993, AM J EPIDEMIOL, V137, P1	25	40	40	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 28	1995	345	8944					217	220		10.1016/S0140-6736(95)90222-8	http://dx.doi.org/10.1016/S0140-6736(95)90222-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7823714				2022-12-28	WOS:A1995QD53200008
J	CHEN, JH; RAUCH, CA; WHITE, JH; ENGLUND, PT; COZZARELLI, NR				CHEN, JH; RAUCH, CA; WHITE, JH; ENGLUND, PT; COZZARELLI, NR			THE TOPOLOGY OF THE KINETOPLAST DNA NETWORK	CELL			English	Article							LEISHMANIA-TARENTOLAE; TRYPANOSOMA-BRUCEI; REPLICATION; MINICIRCLES; HYBRIDIZATION; CATENANES; PROTEIN; GYRASE	Kinetoplast DNA (kDNA) of trypanosomatid parasites is a network of similar to 5000 catenated DNA minicircles and similar to 25 maxicircles. We developed the following strategy to deduce the topological linkage of the minicircles of the Crithidia fasciculata network. First, we used graph theory to provide precise models of possible network structures. Second, on the basis of these models, we predicted the frequencies of minicircle oligomers expected from random network breakage. Third, we determined the fragmentation pattern of kDNA networks as a function of the extent of digestion. Fourth, by comparison of the results with the predictions, we identified the model that best represents the network. We conclude that each minicircle is linked on average to three other minicircles. A honeycomb arrangement probably results, with each minicircle typically at the vertex of a hexagonal cell. This topology has implications for the assembly, structure, and function of kDNA networks.	JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA; UNIV CALIF LOS ANGELES, DEPT MATH, LOS ANGELES, CA 90024 USA	Johns Hopkins University; University of California System; University of California Los Angeles	CHEN, JH (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, 229 STANLEY HALL, BERKELEY, CA 94720 USA.		Chen, Junghuei/B-5217-2011		NIEHS NIH HHS [ES01896-15] Funding Source: Medline; NIGMS NIH HHS [GM31657, GM27608] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027608, R01GM027608, R37GM031657, R01GM031657] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORST P, 1980, BIOCHIM BIOPHYS ACTA, V610, P197, DOI 10.1016/0005-2787(80)90001-5; BORST P, 1979, PLASMID, V2, P20, DOI 10.1016/0147-619X(79)90003-9; FERGUSON M, 1992, CELL, V70, P621, DOI 10.1016/0092-8674(92)90431-B; FERGUSON ML, 1994, J CELL BIOL, V126, P631, DOI 10.1083/jcb.126.3.631; GIBSON W, 1990, MOL BIOCHEM PARASIT, V42, P45, DOI 10.1016/0166-6851(90)90111-X; HAJDUK SL, 1984, CELL, V36, P483, DOI 10.1016/0092-8674(84)90241-1; HAJDUK SL, 1986, MOL CELL BIOL, V6, P4372, DOI 10.1128/MCB.6.12.4372; HOEIJMAKERS JHJ, 1980, PLASMID, V4, P97, DOI 10.1016/0147-619X(80)90086-4; KRASNOW MA, 1983, NATURE, V304, P559, DOI 10.1038/304559a0; KREUZER KN, 1980, CELL, V20, P245, DOI 10.1016/0092-8674(80)90252-4; MARINI JC, 1980, J BIOL CHEM, V255, P4976; MIZUUCHI K, 1984, J BIOL CHEM, V259, P9199; MOREL C, 1980, P NATL ACAD SCI-BIOL, V77, P6810, DOI 10.1073/pnas.77.11.6810; PEREZMORGA D, 1993, J CELL BIOL, V123, P1069, DOI 10.1083/jcb.123.5.1069; RAUCH CA, 1991, THESIS JOHNS HOPKINS; RAUCH GA, 1991, EMBO J, V12, P403; RAY DS, 1987, PLASMID, V17, P177, DOI 10.1016/0147-619X(87)90026-6; RENGER HC, 1972, J CELL BIOL, V54, P346, DOI 10.1083/jcb.54.2.346; RYAN KA, 1988, ANNU REV MICROBIOL, V42, P339, DOI 10.1146/annurev.mi.42.100188.002011; SIMPSON L, 1974, J PROTOZOOL, V21, P382, DOI 10.1111/j.1550-7408.1974.tb03675.x; SIMPSON L, 1971, J MOL BIOL, V56, P443, DOI 10.1016/0022-2836(71)90394-9; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; SIMPSON L, 1987, ANNU REV MICROBIOL, V41, P363, DOI 10.1146/annurev.mi.41.100187.002051; STUART K, 1992, INT REV CYTOL, V141, P65, DOI 10.1016/S0074-7696(08)62063-X; SUGISAKI H, 1987, MOL BIOCHEM PARASIT, V23, P253, DOI 10.1016/0166-6851(87)90032-6; SUNDIN O, 1980, CELL, V21, P103, DOI 10.1016/0092-8674(80)90118-X; THRESHER RJ, 1990, P NATL ACAD SCI USA, V87, P5056, DOI 10.1073/pnas.87.13.5056; WILLIAMS RC, 1977, P NATL ACAD SCI USA, V74, P2311, DOI 10.1073/pnas.74.6.2311; WIRTH DF, 1982, P NATL ACAD SCI-BIOL, V79, P6999, DOI 10.1073/pnas.79.22.6999	29	119	119	1	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 13	1995	80	1					61	69		10.1016/0092-8674(95)90451-4	http://dx.doi.org/10.1016/0092-8674(95)90451-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813018	hybrid			2022-12-28	WOS:A1995QB91000010
J	GRIMES, J; BASAK, AK; ROY, P; STUART, D				GRIMES, J; BASAK, AK; ROY, P; STUART, D			THE CRYSTAL-STRUCTURE OF BLUETONGUE VIRUS VP7	NATURE			English	Article							CORE-LIKE PARTICLES; RESOLUTION; PROTEIN; SURFACE	BLUETONGUE virus (BTV), a representative of the orbivirus genus of the Reoviridae, is considerably larger (at 80 nm across), and structurally more complex, than any virus for which we have comprehensive structural information. Orbiviruses infect mammalian hosts through insect vectors and cause economically important diseases of domesticated animals(1). They possess a segmented double-stranded RNA genome within a capsid composed of four major types of polypeptide chains(1). An outer layer of VP2 and VP5 is removed as the virus enters the target cell, to leave an intact core within the cell. This fore is 70 nm across and composed of 78O copies of VP7 (M(r) 38K) that, as trimers, form 260 'bristly' capsomeres clothing an inner scaffold constructed from VP3 (M(r)103K)(2). We report here the crystal structure of VP7 from BTV serotype 10, which reveals a molecular architecture not seen previously in viral structural proteins. Each subunit consists of two domains, one a beta-sandwich, the other a bundle of alpha-helices, and a short carboxy-terminal arm which might tie trimers together during capsid formation. A concentration of methionine residues at the core of the molecule could provide plasticity, relieving structural mismatches during assembly.	OXFORD CTR MOLEC SCI,OXFORD OX1 3QT,ENGLAND; NERC,INST VIROL & ENVIRONM MICROBIOL,OXFORD OX1 3SR,ENGLAND; UNIV ALABAMA,SCH PUBL HLTH,BIRMINGHAM,AL 35294	University of Oxford; UK Centre for Ecology & Hydrology (UKCEH); UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); University of Alabama System; University of Alabama Birmingham	GRIMES, J (corresponding author), UNIV OXFORD,MOLEC BIOPHYS LAB,REX RICHARDS BLDG,S PARKS RD,OXFORD OX1 3QU,ENGLAND.			Grimes, Jonathan Mark/0000-0001-9698-0389; Roy, Polly/0000-0001-6535-6911; Stuart, David/0000-0002-3426-4210				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BRUNGER AT, 1992, XPLOR VERSION 3 0; Creighton T.E., 1993, PROTEINS; EATON BT, 1991, VIROLOGY, V180, P687, DOI 10.1016/0042-6822(91)90082-M; FISHER AJ, 1993, NATURE, V361, P176, DOI 10.1038/361176a0; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HEWAT EA, 1992, VIROLOGY, V189, P10, DOI 10.1016/0042-6822(92)90676-G; HOUGH E, 1989, NATURE, V338, P357, DOI 10.1038/338357a0; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES EY, 1991, ISOMORPHOUS REPLACEM, P39; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KNUDSON EL, 1990, VIROLOGY, P1405; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEBLOIS H, 1993, J VIROL, V67, P353, DOI 10.1128/JVI.67.1.353-359.1993; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; LOGAN D, 1993, NATURE, V362, P566, DOI 10.1038/362566a0; McPherson A, 1982, PREPARATION ANAL PRO; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MERTENS PPC, 1993, INFECTION CULICOIDES; OLIVEIRA MA, 1993, STRUCTURE, V1, P51, DOI 10.1016/0969-2126(93)90008-5; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PRASAD BVV, 1992, J VIROL, V66, P2135, DOI 10.1128/JVI.66.4.2135-2142.1992; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROSSMANN MG, 1983, J MOL BIOL, V165, P711, DOI 10.1016/S0022-2836(83)80276-9; ROY R, 1990, BLUETONGUE VIRUS, P43; STUART D, 1993, CURR OPIN STRUC BIOL, V3, P167, DOI 10.1016/S0959-440X(05)80148-4; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WISTOW G, 1983, J MOL BIOL, V170, P175, DOI 10.1016/S0022-2836(83)80232-0	30	137	147	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					167	170		10.1038/373167a0	http://dx.doi.org/10.1038/373167a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7816101				2022-12-28	WOS:A1995QB06300064
J	WILLIAMS, R				WILLIAMS, R			DE INERTIA URBANORUM	BRITISH MEDICAL JOURNAL			English	Article																		ANDERSON D, 1991, ENERGY ENV; ANGRIST SW, 1967, ORDER CHAOS LAWS ENE; ARCHER MD, 1974, FUTURES          JUN, P261; ARCHER MD, 1991, PHOTOCHEMSITRY PHOTO; Bryant C., 1993, Biologist (London), V40, P58; CAIRNCROSS F, 1991, COSTING EARTH, P133; Cooper KH, 1970, NEW AEROBICS; FOWLER D, 1990, GREENHOUSE EFFECT TE, P10; HARRISS RC, 1989, OZONE DEPLETION GREE, P79; HOLMAN C, 1991, ROAD TRANSPORT AIR P, P11; JOUZEL J, 1993, NATURE, V364, P407, DOI 10.1038/364407a0; KASTING JF, 1993, SCIENCE, V259, P920, DOI 10.1126/science.11536547; LAMB HH, 1972, CLIMATE PRESENT PAST, V1, P45; NEFTEL A, 1985, NATURE, V315, P45, DOI 10.1038/315045a0; Orwell G., 1946, COLLECTED ESSAYS JOU, V4, P127; RICE RA, 1972, TECHNOL REV, V74, P31; RILEY F, 1923, SETTLE DISTRICT N W, P29; SHINE KP, 1989, OZONE DEPLETION HLTH, P72; SMITH R, 1993, BRIT MED J, V306, P1285, DOI 10.1136/bmj.306.6888.1285; WALKER JCG, 1992, GLOBAL PLANET CHANGE, V97, P151, DOI 10.1016/0921-8181(92)90009-Y; Wilkie, 1968, MUSCLE; WILLIAMS RE, 1975, BRIT MED J, V4, P25, DOI 10.1136/bmj.4.5987.25; 1974, NEW ENCY BRITANNICA, V17, P1018; 1993, DESIGN MANUAL ROADS, V11; 1992, CLIMATE CHANGE DISCU; 1993, TRANSPORT STATISTICS, P10	26	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1741	1745		10.1136/bmj.309.6970.1741	http://dx.doi.org/10.1136/bmj.309.6970.1741			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7820010	Green Published			2022-12-28	WOS:A1994PY71700042
J	BARTLEY, M; POWER, C; BLANE, D; SMITH, GD; SHIPLEY, M				BARTLEY, M; POWER, C; BLANE, D; SMITH, GD; SHIPLEY, M			BIRTH-WEIGHT AND LATER SOCIOECONOMIC DISADVANTAGE - EVIDENCE FROM THE 1958 BRITISH COHORT STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ADULT LIFE; MORTALITY RISK; DISEASE; HEALTH; MIGRATION; INFANCY; SMOKING; GROWTH; DEATH; FETAL	Objective-To investigate the relation between birth weight and socioeconomic disadvantage during childhood and adolescence in a birth cohort study. Design-Longitudinal analysis of birth weight in relation to social class, household amenities and overcrowding, and financial difficulties as reported by parents at interview when participants were aged 7, 11, and 16 years; and receipt of unemployment or supplementary benefits as reported by participants at age 23. Subjects-Male participants in the 1958 birth cohort (national child development study) born to parents resident in Great Britain during the week of 3-9 March 1958. Data on birth weight and financial difficulties between birth and 23 years were available for 4321; data on housing conditions and social class at ages 7, 11 and 16 years were available for 3370. Main outcome measures-Socioeconomic disadvantage at later ages in men weighing 6 lb (2721g) or under at birth compared with those weighing over 6 lb and between fifths of the distribution of birth weight. Results-Cohort members who weighed 6 lb or under at birth were more likely to experience socioeconomic disadvantage subsequently. Those in lower fifths of the distribution were more likely to experience socioeconomic disadvantage. Conclusion-Low birth weight is associated with socioeconomic disadvantage in childhood and adolescence. Studies of the association of indicators of early development and adult disease need to take into account experiences right through from birth to adulthood if they are to elucidate the combination of risks attributable to developmental problems and socioeconomic disadvantage.	INST CHILD HLTH, DIV PUBL HLTH, LONDON WC1N 1EH, ENGLAND; CHARING CROSS & WESTMINSTER MED SCH, ACAD DEPT PSYCHIAT, LONDON W6 8RP, ENGLAND; UNIV GLASGOW, DEPT PUBL HLTH, GLASGOW G12 8RZ, LANARK, SCOTLAND; UCL, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6EA, ENGLAND	University of London; University College London; Imperial College London; University of Glasgow; University of London; University College London; UCL Medical School	BARTLEY, M (corresponding author), CITY UNIV LONDON, SOCIAL STAT RES UNIT, LONDON EC1R 0BN, ENGLAND.		Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314				BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1991, BRIT MED J, V303, P671, DOI 10.1136/bmj.303.6804.671; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Barker DJP, 1992, FETAL INFANT ORIGINS; BARTLEY M, 1992, SOCIOL HEALTH ILL, V14, P313; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; BENTHAM G, 1988, SOC SCI MED, V26, P49, DOI 10.1016/0277-9536(88)90044-5; Brown M., 1982, DESPITE WELFARE STAT; Butler N.R., 1963, PERINATAL MORTALITY; COLLEY JRT, 1973, BRIT MED J, V3, P195, DOI 10.1136/bmj.3.5873.195; ESSEN J, 1978, CHILD CARE HLTH DEV, V4, P357, DOI 10.1111/j.1365-2214.1978.tb00095.x; ESSEN J, 1982, CONTINUITIES CHILDHO; ESSEX J, 1978, CHILD CARE HLTH DEV, V3, P41; FOGELMAN KR, 1988, BRIT MED J, V297, P1233, DOI 10.1136/bmj.297.6658.1233; FORSDAHL A, 1978, J EPIDEMIOL COMMUN H, V32, P34, DOI 10.1136/jech.32.1.34; GOLDBLATT P, 1990, LONGITUDINAL STUDY M, P163; GOLDSTEIN H, 1983, GROWING UP GB; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; KUH D, 1989, INT J EPIDEMIOL, V18, P663, DOI 10.1093/ije/18.3.663; KUH D, 1993, SOC HIST MED, V6, P101; KUH DJL, 1993, SOC SCI MED, V37, P905, DOI 10.1016/0277-9536(93)90145-T; MANN SL, 1992, J EPIDEMIOL COMMUN H, V46, P286, DOI 10.1136/jech.46.3.286; MARTYN CN, 1993, J EPIDEMIOL COMMUN H, V47, P76, DOI 10.1136/jech.47.1.76; NIE NH, 1983, STATISTICAL PACKAGE; PARKER DJP, 1992, J EPIDEMIOL COMMUN H, V46, P8, DOI 10.1136/jech.46.1.8; PILLING D, 1990, ESCAPE DISADVANTAGE; Power C., 1991, HLTH CLASS EARLY YEA; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; SMITH GD, 1992, BRIT MED J, V304, P638, DOI 10.1136/bmj.304.6827.638-b; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; SMITH GD, 1990, BMJ-BRIT MED J, V301, P373, DOI 10.1136/bmj.301.6748.373; SMITH GD, 1992, LANCET, V340, P709; VERNON HM, 1939, HLTH RELATION OCCUPA; Wadsworth M. E. J., 1991, IMPRINT TIME CHILDHO; Wilkinson RG, 1986, CLASS HLTH RES LONGI; WILLIAMS DRR, 1979, J EPIDEMIOL COMMUN H, V33, P199, DOI 10.1136/jech.33.3.199	36	98	99	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 3	1994	309	6967					1475	1478		10.1136/bmj.309.6967.1475	http://dx.doi.org/10.1136/bmj.309.6967.1475			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW053	7804048	Green Published			2022-12-28	WOS:A1994PW05300020
J	MICHAELS, JA; RUTTER, P; COLLIN, J; LEGG, FM; GALLAND, RB				MICHAELS, JA; RUTTER, P; COLLIN, J; LEGG, FM; GALLAND, RB			RELATION BETWEEN RATES OF LEG AMPUTATION AND DISTAL ARTERIAL RECONSTRUCTIVE SURGERY	BRITISH MEDICAL JOURNAL			English	Article									UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT SURG,OXFORD OX3 9DU,ENGLAND	University of Oxford								CHESHIRE NJW, 1992, J VASC SURG, V15, P167, DOI 10.1016/0741-5214(92)70025-G; LINDHOLT JS, 1994, EUR J VASCULAR SURG, V8, P31, DOI 10.1016/S0950-821X(05)80116-1; MICHAELS JA, 1994, BRIT MED J, V309, P387, DOI 10.1136/bmj.309.6951.387; MICHAELS JA, 1994, BRIT J SURG, V81, P377, DOI 10.1002/bjs.1800810318	4	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 3	1994	309	6967					1479	1480		10.1136/bmj.309.6967.1479a	http://dx.doi.org/10.1136/bmj.309.6967.1479a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW053	7804051	Green Published			2022-12-28	WOS:A1994PW05300022
J	GONZALEZREYES, A; ELLIOTT, H; STJOHNSTON, D				GONZALEZREYES, A; ELLIOTT, H; STJOHNSTON, D			POLARIZATION OF BOTH MAJOR BODY AXES IN DROSOPHILA BY GURKEN-TORPEDO SIGNALING	NATURE			English	Article							EGF RECEPTOR HOMOLOG; FAINT-LITTLE-BALL; BICOID RNA; OOGENESIS; GENE; MELANOGASTER; OOCYTE; AXIS; LOCALIZATION; ENCODES	Anterior-posterior polarity in Drosophila arises from the movement of the oocyte to the posterior of the egg chamber, and the subsequent acquisition of posterior fate by the adjacent somatic follicle cells. We demonstrate that gurken is necessary in the oocyte and torpedo/DER in the follicle cells for the induction of posterior fate. As the gurken-torpedo/DER pathway also establishes dorsoventral polarity later in oogenesis, Drosophila uses the same germline to soma signalling pathway to determine both embryonic axes.	UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 1QR,ENGLAND	University of Cambridge	GONZALEZREYES, A (corresponding author), UNIV CAMBRIDGE,CRC INST,CAMBRIDGE CB2 1QR,ENGLAND.		St Johnston, Daniel/C-9568-2009; Gonzalez-Reyes, Acaimo/L-1993-2014	Gonzalez-Reyes, Acaimo/0000-0003-3048-0968; St Johnston, Daniel/0000-0001-5582-3301	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASHBURNER M, 1990, GENETICS, V126, P679; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Chasan Rebecca, 1993, P387; CHEUNG HK, 1992, DEVELOPMENT, V114, P653; CHRISTERSON LB, 1994, GENE DEV, V8, P614, DOI 10.1101/gad.8.5.614; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; Driever Wolfgang, 1993, P301; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; FASANO L, 1988, DEVELOPMENT, V104, P245; FROHNHOFER H, 1982, THESIS U TUBINGEN; FUJISUE M, 1993, DEVELOPMENT, V118, P163; GINIGER E, 1993, ROUX ARCH DEV BIOL, V202, P112, DOI 10.1007/BF00636536; GONZALEZREYES A, 1994, SCIENCE, V266, P639, DOI 10.1126/science.7939717; GROSSNIKLAUS U, 1989, DEVELOPMENT, V107, P189; HOU XS, 1995, CELL, V81, P63, DOI 10.1016/0092-8674(95)90371-2; KAMMERMEYER KL, 1987, DEVELOPMENT, V100, P201; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KLYMKOWSKY MW, 1994, DEV BIOL, V165, P372, DOI 10.1006/dbio.1994.1260; KOCH EA, 1983, CELL TISSUE RES, V228, P21; LANE ME, 1994, GENE DEV, V8, P2986, DOI 10.1101/gad.8.24.2986; LANTZ V, 1994, GENE DEV, V8, P598, DOI 10.1101/gad.8.5.598; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; NEUMANSILBERBER.FS, 1993, CELL, V75, P165; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; ROTH S, 1994, DEVELOPMENT, V120, P2245; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHUPACH T, 1991, CELL-CELL INTERACTIONS IN EARLY DEVELOPMENT, P163; SCHUPBACH T, 1991, GENETICS, V129, P1119; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SHILO BZ, 1991, TRENDS GENET, V7, P388, DOI 10.1016/0168-9525(91)90261-N; Spradling Allan C., 1993, P1; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; TOLIAS PP, 1990, EMBO J, V9, P1457, DOI 10.1002/j.1460-2075.1990.tb08262.x; WIESCHAUS E, 1978, ROUX ARCH DEV BIOL, V184, P75, DOI 10.1007/BF00848670; YUGE M, 1990, DEVELOPMENT, V110, P1051	43	417	423	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 22	1995	375	6533					654	658		10.1038/375654a0	http://dx.doi.org/10.1038/375654a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791898				2022-12-28	WOS:A1995RE57600051
J	MANOLAGAS, SC; JILKA, RL				MANOLAGAS, SC; JILKA, RL			MECHANISMS OF DISEASE - BONE-MARROW, CYTOKINES, AND BONE REMODELING - EMERGING INSIGHTS INTO THE PATHOPHYSIOLOGY OF OSTEOPOROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LEUKEMIA INHIBITORY FACTOR; INTERLEUKIN-6 PRODUCTION; STROMAL CELLS; NORMAL WOMEN; RESORPTION; HISTOMORPHOMETRY; PRECURSORS; INVITRO; AGE; 17-BETA-ESTRADIOL		MCCLELLAN VET AFFAIRS MED CTR,LITTLE ROCK,AR		MANOLAGAS, SC (corresponding author), UNIV ARKANSAS MED SCI HOSP,CTR OSTEOPOROSIS & METAB BONE DIS,DEPT INTERNAL MED,LITTLE ROCK,AR 72205, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043003, R01AR041313] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 43003, AR 41313] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALHUMIDAN A, 1991, J BONE MINER RES, V6, P3; ARLOT M, 1984, BRIT MED J, V289, P517, DOI 10.1136/bmj.289.6444.517; ASHTON BA, 1980, CLIN ORTHOP RELAT R, V151, P294; BALENA R, 1993, J CLIN INVEST, V92, P2577, DOI 10.1172/JCI116872; Bellido T., 1994, Bone and Mineral, V25, pS39; BELLIDO T, 1993, J BONE MINER RES, V8, pS131; BENAYAHU D, 1989, J CELL PHYSIOL, V140, P1, DOI 10.1002/jcp.1041400102; BENAYAHU D, 1991, CALCIFIED TISSUE INT, V49, P202, DOI 10.1007/BF02556119; BISMAR H, 1994, J BONE MINER RES  S1, V9, pS158; BLACK K, 1991, ENDOCRINOLOGY, V128, P2657, DOI 10.1210/endo-128-5-2657; CHAUDHARY LR, 1992, ENDOCRINOLOGY, V130, P2528, DOI 10.1210/en.130.5.2528; DEMPSTER DW, 1986, J BONE MINER RES, V1, P15; DEMULDER A, 1992, J BONE MINER RES, V7, P1337; DEVLIN RD, 1994, J BONE MINER RES, V9, pS140; EASTELL R, 1988, J CLIN ENDOCR METAB, V67, P741, DOI 10.1210/jcem-67-4-741; ERIKSEN EF, 1990, J BONE MINER RES, V5, P311, DOI 10.1002/jbmr.5650050402; EVANS DB, 1994, BIOCHEM BIOPH RES CO, V199, P220, DOI 10.1006/bbrc.1994.1217; GALLAGHER JC, 1987, J BONE MINER RES, V2, P491; GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130; GIRASOLE G, 1992, J BONE MINER RES, V7, pS96; GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668; HATTERSLEY G, 1991, ENDOCRINOLOGY, V128, P259, DOI 10.1210/endo-128-1-259; HEANEY RP, 1990, BONE MINER, V11, P67, DOI 10.1016/0169-6009(90)90016-9; HOROWITZ MC, 1992, CYTOKINES BONE METAB, P185; ISHIMI Y, 1990, J IMMUNOL, V145, P3297; Jilka R. L., 1994, Bone and Mineral, V25, pS15; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; JILKA RL, 1994, J BONE MINER RES, V9, pS143; KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169-6009(91)90124-I; KIMBLE RB, 1994, J CLIN INVEST, V93, P1959, DOI 10.1172/JCI117187; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KLEIN B, 1991, BLOOD, V78, P1198; KOTAKE S, 1994, J BONE MINER RES, V9, pS140; KURIHARA N, 1991, J BONE MINER RES, V6, P257; KURIHARA N, 1990, ENDOCRINOLOGY, V126, P2733, DOI 10.1210/endo-126-5-2733; LOWIK CWGM, 1989, BIOCHEM BIOPH RES CO, V162, P1546, DOI 10.1016/0006-291X(89)90851-6; MALAVAL L, 1994, J CELL PHYSIOL, V158, P555, DOI 10.1002/jcp.1041580322; MANOLAGAS SC, 1993, J BONE MINER RES, V8, pS141; MANOLAGAS SC, 1994, CURRENT OPINION ENDO, P275; MARKS SC, 1976, BIOCHEMISTRY PHYSIOL, V4, P227; MATSUSHITA M, 1986, AM J PATHOL, V125, P276; METCALF D, 1989, P NATL ACAD SCI USA, V86, P5948, DOI 10.1073/pnas.86.15.5948; MUNDY G, 1992, BIOL PHYSL OSTEOCLAS, P171; NORDIN BEC, 1992, J CLIN ENDOCR METAB, V74, P20, DOI 10.1210/jc.74.1.20; OHSAKI Y, 1992, ENDOCRINOLOGY, V131, P2229, DOI 10.1210/en.131.5.2229; Owen M., 1985, BONE MINERAL RES ANN, V1, P1; PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303; Parfitt AM., 1990, BONE TREATISE, VI, P351; Parfitt AM., 1992, TRIANGLE, V31, P99; PASSERI G, 1993, ENDOCRINOLOGY, V133, P822, DOI 10.1210/en.133.2.822; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; POTTRATZ ST, 1994, J CLIN INVEST, V93, P944, DOI 10.1172/JCI117100; RAY A, 1994, J BIOL CHEM, V269, P12940; RODAN SB, 1990, ENDOCRINOLOGY, V127, P1602, DOI 10.1210/endo-127-4-1602; ROODMAN GD, 1992, J CLIN INVEST, V89, P46, DOI 10.1172/JCI115584; SATO T, 1992, J BONE MINER RES, V7, pS272; SERKE S, 1991, ANN HEMATOL, V62, P45, DOI 10.1007/BF01714899; SHEVDE N, 1994, P SOC EXP BIOL MED, V205, P306; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; TAICHMAN RS, 1994, J EXP MED, V179, P1677, DOI 10.1084/jem.179.5.1677; TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924; TURNER RT, 1988, ENDOCRINOLOGY, V122, P1146, DOI 10.1210/endo-122-3-1146	63	1386	1447	2	163	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 2	1995	332	5					305	311		10.1056/NEJM199502023320506	http://dx.doi.org/10.1056/NEJM199502023320506			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD396	7816067				2022-12-28	WOS:A1995QD39600006
J	PERSING, DH; HERWALDT, BL; GLASER, C; LANE, RS; THOMFORD, JW; MATHIESEN, D; KRAUSE, PJ; PHILLIP, DF; CONRAD, PA				PERSING, DH; HERWALDT, BL; GLASER, C; LANE, RS; THOMFORD, JW; MATHIESEN, D; KRAUSE, PJ; PHILLIP, DF; CONRAD, PA			INFECTION WITH A BABESIA-LIKE ORGANISM IN NORTHERN CALIFORNIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; THEILERIA-PARVA; BORRELIA-BURGDORFERI; PROTOZOAN PARASITE; LYME-DISEASE; ANTIBODY; PIROPLASMS; MICROTI; STATE; TICKS	Background. Human babesiosis is a tick-transmitted zoonosis associated with two protozoa of the family Piroplasmorida: Babesia microti (in the United States) and B. divergens (in Europe). Recently, infection with an unusual babesia-like piroplasm (designated WA1) was described in a patient from Washington State. We studied four patients in California who were identified as being infected with a similar protozoal parasite. All four patients had undergone splenectomy, two because of trauma and two for other medical reasons. Two of the patients had complicated courses, and one died. Methods. Piroplasm-specific nuclear small-subunit ribosomal DNA was recovered from the blood of the four patients by amplification with the polymerase chain reaction. The genetic sequences were compared with those of other known piroplasm species. Indirect immunofluorescent-antibody testing of serum from the four patients and from other potentially exposed persons was performed with WA1 and babesia antigens. Results. Genetic sequence analysis showed that the organisms from all four patients were nearly identical. Phylogenic analysis showed that this strain is more closely related to a known canine pathogen (B. gibsoni) and to theileria species than to some members of the genus babesia. Serum from three of the patients was reactive to WA1 but not to B. microti antigen. Serologic testing showed WA1-antibody seroprevalence rates of 16 percent (8 of 51 persons at risk) and 3.5 percent (4 of 115) in two geographically distinct areas of northern California. Conclusions. A newly identified babesia-like organism causes infections in humans in the western United States. The clinical spectrum associated with infection with this protozoan ranges from asymptomatic infection or influenza-like illness to fulminant, fatal disease.	MAYO CLIN & MAYO FDN, DIV EXPTL PATHOL, ROCHESTER, MN 55905 USA; CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV PARASIT DIS, ATLANTA, GA 30341 USA; UNIV CALIF SAN FRANCISCO, DIV PEDIAT INFECT DIS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CTR AIDS PREVENT STUDIES, SAN FRANCISCO, CA 94143 USA; UNIV CALIF BERKELEY, DEPT ENVIRONM SCI POLICY & MANAGEMENT, ENTOMOL GRP, BERKELEY, CA 94720 USA; UNIV CALIF DAVIS, SCH VET MED, DEPT VET PATHOL MICROBIOL & IMMUNOL, DAVIS, CA 95616 USA; UNIV CONNECTICUT, DIV PEDIAT INFECT DIS, FARMINGTON, CT USA; CALIF MED DETACHMENT, PREVENT MED SERV, FT ORD, CA USA	Mayo Clinic; Centers for Disease Control & Prevention - USA; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Berkeley; University of California System; University of California Davis; University of Connecticut	PERSING, DH (corresponding author), MAYO CLIN & MAYO FDN, DEPT LAB MED & PATHOL, DIV CLIN MICROBIOL, MOLEC MICROBIOL LAB, ROCHESTER, MN 55905 USA.				NIAID NIH HHS [AI32403, AI30548] Funding Source: Medline; NIAMS NIH HHS [AR41497] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032403, P01AI030548] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041497] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLSOPP MTEP, 1994, PARASITOLOGY, V108, P147, DOI 10.1017/S0031182000068232; ANDERSON JF, 1979, SCIENCE, V204, P1431, DOI 10.1126/science.451574; BALDWIN CL, 1988, INFECT IMMUN, V56, P462, DOI 10.1128/IAI.56.2.462-467.1988; BISHOP R, 1992, PARASITOLOGY, V104, P215, DOI 10.1017/S0031182000061655; BREDT AB, 1981, JAMA-J AM MED ASSOC, V245, P1938, DOI 10.1001/jama.245.19.1938; BURGDORFER W, 1985, AM J TROP MED HYG, V34, P925, DOI 10.4269/ajtmh.1985.34.925; CONRAD P, 1991, J AM VET MED ASSOC, V199, P601; FIGUEROA JV, 1992, J CLIN MICROBIOL, V30, P2576, DOI 10.1128/JCM.30.10.2576-2582.1992; FUCCILLO DA, 1992, MANUAL CLIN LABORATO, P545; JERANT AF, 1993, WESTERN J MED, V158, P622; KRAUSE P, 1994, 34TH INT C ANT AG CH, P2001; KRAUSE PJ, 1994, J INFECT DIS, V169, P923, DOI 10.1093/infdis/169.4.923; KRAUSE PJ, 1991, J CLIN MICROBIOL, V29, P1; LANE RS, 1986, ZBL BAKT-INT J MED M, V263, P55; LANE RS, 1992, AM J EPIDEMIOL, V136, P1358, DOI 10.1093/oxfordjournals.aje.a116448; LEVINE ND, 1971, T AM MICROSC SOC, V90, P2, DOI 10.2307/3224894; MEHLHORN H, 1984, ADV PARASIT, V23, P37, DOI 10.1016/S0065-308X(08)60285-7; MERTZ LE, 1988, ANN NY ACAD SCI, V539, P474, DOI 10.1111/j.1749-6632.1988.tb31911.x; OLEMOIYOI OK, 1989, EXP PARASITOL, V69, P204, DOI 10.1016/0014-4894(89)90067-2; OLIVEIRA MR, 1979, J PARASITOL, V65, P816, DOI 10.2307/3280370; Persing David H., 1993, P475; PERSING DH, 1992, J CLIN MICROBIOL, V30, P2097, DOI 10.1128/JCM.30.8.2097-2103.1992; POPOVSKY MA, 1988, TRANSFUSION, V28, P59, DOI 10.1046/j.1537-2995.1988.28188127955.x; QUICK RE, 1993, ANN INTERN MED, V119, P284, DOI 10.7326/0003-4819-119-4-199308150-00006; RUEBUSH TK, 1977, NEW ENGL J MED, V297, P825, DOI 10.1056/NEJM197710132971511; SCHOLTENS RG, 1968, AM J TROP MED HYG, V17, P810, DOI 10.4269/ajtmh.1968.17.810; Telford S. R. III, 1993, PARASIT PROTOZOA, V5, P1; Theiler A., 1904, TRANSVAAL AGR J, V2, P421; THOMFORD JW, 1994, J INFECT DIS, V169, P1050, DOI 10.1093/infdis/169.5.1050; YAMANE I, 1993, AM J VET RES, V54, P1579; 1994, CALIF MORB, V7, P1; 1992, CALIF MORB, V3, P1; 1994, CALIF MORB, V9, P1	33	182	188	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 2	1995	332	5					298	303		10.1056/NEJM199502023320504	http://dx.doi.org/10.1056/NEJM199502023320504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD396	7816065				2022-12-28	WOS:A1995QD39600004
J	MCFARLAND, KF				MCFARLAND, KF			WHY MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	1995	273	5					362	362						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD203	7823368				2022-12-28	WOS:A1995QD20300002
J	BLENDON, RJ; SCHECK, AC; DONELAN, K; HILL, CA; SMITH, M; BEATRICE, D; ALTMAN, D				BLENDON, RJ; SCHECK, AC; DONELAN, K; HILL, CA; SMITH, M; BEATRICE, D; ALTMAN, D			HOW WHITE AND AFRICAN-AMERICANS VIEW THEIR HEALTH AND SOCIAL-PROBLEMS - DIFFERENT EXPERIENCES, DIFFERENT EXPECTATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-CARE; SERVICES; BLACK		HENRY J KAISER FAMILY FDN,MENLO PK,CA; UNIV CHICAGO,NATL OPIN RES CTR,CHICAGO,IL 60637	University of Chicago	BLENDON, RJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Donelan, Karen/R-6162-2019; Scheck, Adrienne/AAH-5040-2020					BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; BLENDON RJ, 1994, JAMA-J AM MED ASSOC, V271, P949, DOI 10.1001/jama.271.12.949; BURSTIN HR, 1992, JAMA-J AM MED ASSOC, V268, P2383, DOI 10.1001/jama.268.17.2383; DAWSON M, 1994, NBPS1 U CHIC REP; Fowler F. J., 1988, SURVEY RES METHODS; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; HART P, 1991, WALL STREET J    MAY; KAHN KL, 1994, JAMA-J AM MED ASSOC, V271, P1169, DOI 10.1001/jama.271.15.1169; LAVEIST TA, 1993, MILBANK Q, V71, P41, DOI 10.2307/3350274; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; SORLIE P, 1992, LANCET, V340, P346, DOI 10.1016/0140-6736(92)91413-3; WARE JE, 1975, MED CARE, V13, P669, DOI 10.1097/00005650-197508000-00006; Weissman JS., 1994, FALLING SAFETY NET I; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; YERGAN J, 1987, MED CARE, V25, P592, DOI 10.1097/00005650-198707000-00003; 1993, GENERAL SOCIAL SURVE; 1990, SAS SYSTEM RELEASE 6; 1993, WALL STREET J    JUN	18	94	95	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	1995	273	4					341	346		10.1001/jama.273.4.341	http://dx.doi.org/10.1001/jama.273.4.341			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QC057	7815666				2022-12-28	WOS:A1995QC05700038
J	ALTMAN, D				ALTMAN, D			THE 1995 HEALTH-POLICY DEBATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											ALTMAN, D (corresponding author), KAISER FAMILY FDN,2400 SAND HILL RD,MENLO PK,CA 94025, USA.							KAISER HJ, 1993, HLTH INSURANCE SURVE, V2; LIPSON DJ, 1994, KEEPING PROMISE ACHI; 1994, 9428 US BUR CENS STA; 1994, ELECTION NIGHT SURVE; 1992, EC IMPLICATIONS RISI; 1994, G WASHINGTON U PUBLI, V656; 1994, SURVEY EMPLOYER SPON; 1994, KPMG PEAT MARWICK EM	8	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					247	248						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB234	7807672				2022-12-28	WOS:A1995QB23400037
J	WACHTER, RM; LUCE, JM; SAFRIN, S; BERRIOS, DC; CHARLEBOIS, E; SCITOVSKY, AA				WACHTER, RM; LUCE, JM; SAFRIN, S; BERRIOS, DC; CHARLEBOIS, E; SCITOVSKY, AA			COST AND OUTCOME OF INTENSIVE-CARE FOR PATIENTS WITH AIDS, PNEUMOCYSTIS-CARINII PNEUMONIA, AND SEVERE RESPIRATORY-FAILURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; MECHANICAL VENTILATION; VIRUS INFECTION; CONTROLLED TRIAL; TERM SURVIVAL; MEDICAL-CARE; HIV; CORTICOSTEROIDS; PATTERNS; THERAPY	Objective.-To determine the costs and outcomes associated with intensive care unit (ICU) admission for patients with acquired immunodeficiency syndrome (AIDS)-related Pneumocystis carinii pneumonia (PCP), and severe respiratory failure. Design.-Survival and cost-effectiveness analysis. Setting.-A large municipal teaching hospital serving an indigent population. Patients.-Consecutive patients intubated and mechanically ventilated for AIDS, PCP, and respiratory failure from 1981 through 1991 (n=113). The cohort was separated into three groups for analysis: patients admitted to the ICU in 1981 through 1985 (era I, n=43), those admitted in 1986 through 1988 (era II, n=33), and those admitted in 1989 through 1991 (era III, n=37). Main Outcome Measures.-Hospital charges and survival time; cost per year of life saved, using a zero-cost, zero-life assumption. Results.-Twenty-eight (25%) of the 113 patients mechanically ventilated for PCP and respiratory failure survived to hospital discharge: six (14%) of 43 in era I, 13 (39%) of 33 in era II, and nine (24%) of 37 in era III (P=.04). Post-ICU admission charges averaged $57 874 for the entire cohort, remaining relatively stable across the three eras. Cost of care for survivors was significantly more expensive than for those dying before discharge. The cost of ICU admission and subsequent hospitalization averaged $174 781 per year of life saved; $305 795 in era 1, $94 528 in era II, and $215 233 in era III. Improved survival rates and shorter lengths of ICU stay led to the improved cost-effectiveness in era II, while the opposite trends resulted in worsening cost-effectiveness in recent years. The strongest predictors of hospital mortality in era III were low CD4 cell counts on hospital admission and the development of pneumothorax during mechanical ventilation. Conclusions.-The cost-effectiveness of intensive care for patients with PCP and severe respiratory failure improved during the first 8 years of the AIDS epidemic but fell in recent years such that it is now below that of many accepted medical interventions.	UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOSTAT & EPIDEMIOL,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,MED CTR,MED SERV,SAN FRANCISCO,CA 94110; PALO ALTO MED FDN,DIV HLTH ECON,PALO ALTO,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; Palo Alto Medical Foundation Research Institute	WACHTER, RM (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,BOX 0862,SAN FRANCISCO,CA 94143, USA.							ANGELL M, 1985, JAMA-J AM MED ASSOC, V254, P1203, DOI 10.1001/jama.254.9.1203; BAGGOTT LA, 1987, CHEST S, V92; BENNETT CL, 1991, J ACQ IMMUN DEF SYND, V4, P197; BENNETT CL, 1990, ARCH INTERN MED, V150, P1447, DOI 10.1001/archinte.150.7.1447; BENNETT RL, 1993, J ACQ IMMUN DEF SYND, V6, P1319; BONE RC, 1991, ARCH INTERN MED, V151, P1061, DOI 10.1001/archinte.151.6.1061; BOZZETTE SA, 1990, NEW ENGL J MED, V323, P1451, DOI 10.1056/NEJM199011223232104; BOZZETTE SA, 1992, CHEST, V101, P1404, DOI 10.1378/chest.101.5.1404; CALLAHAN D, 1991, J AM GERIATR SOC, V39, P622, DOI 10.1111/j.1532-5415.1991.tb03605.x; CLEMENT M, 1989, American Review of Respiratory Disease, V139, pA250; CURTIS JR, 1994, AM J RESP CRIT CARE, V150, P1305, DOI 10.1164/ajrccm.150.5.7952557; DANIELS N, 1991, JAMA-J AM MED ASSOC, V265, P2232, DOI 10.1001/jama.265.17.2232; DOHN MN, 1992, ARCH INTERN MED, V152, P2465, DOI 10.1001/archinte.152.12.2465; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2493, DOI 10.1001/jama.263.18.2493; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; EFFEREN LS, 1989, AM J MED, V87, P401, DOI 10.1016/S0002-9343(89)80821-6; ELSADR W, 1988, AM REV RESPIR DIS, V137, P1264, DOI 10.1164/ajrccm/137.6.1264; ENGELHARDT HT, 1986, JAMA-J AM MED ASSOC, V255, P1159, DOI 10.1001/jama.255.9.1159; FREEDBERG KA, 1991, J ACQ IMMUN DEF SYND, V4, P521; FRIEDMAN Y, 1989, CHEST, V96, P862, DOI 10.1378/chest.96.4.862; FRIEDMAN Y, 1991, JAMA-J AM MED ASSOC, V266, P89, DOI 10.1001/jama.266.1.89; GACHOT B, 1992, INTENS CARE MED, V18, P155, DOI 10.1007/BF01709239; GAGNON S, 1990, NEW ENGL J MED, V323, P1444, DOI 10.1056/NEJM199011223232103; GARAY S, 1986, AM REV RESPIR DIS, V133, pA344; GOLDMAN L, 1992, CIRCULATION, V85, P1960, DOI 10.1161/01.CIR.85.5.1960; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; HARDY AM, 1986, JAMA-J AM MED ASSOC, V255, P209, DOI 10.1001/jama.255.2.209; HARRIS JE, 1990, JAMA-J AM MED ASSOC, V263, P397, DOI 10.1001/jama.263.3.397; HAWLEY PH, 1994, CHEST, V106, P1456, DOI 10.1378/chest.106.5.1456; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; HOPEWELL PC, 1988, J INFECT DIS, V157, P1115, DOI 10.1093/infdis/157.6.1115; JACOBSON LP, 1993, AM J EPIDEMIOL, V138, P952, DOI 10.1093/oxfordjournals.aje.a116815; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Levine M E, 1989, Crit Care Nurs Q, V12, P82; LEVINSKY NG, 1984, NEW ENGL J MED, V311, P1573, DOI 10.1056/NEJM198412133112412; LEVINSKY NG, 1993, NEW ENGL J MED, V329, P1395, DOI 10.1056/NEJM199311043291907; MANDELBLATT JS, 1988, JAMA-J AM MED ASSOC, V259, P2409, DOI 10.1001/jama.259.16.2409; MONTANER JSG, 1990, ANN INTERN MED, V113, P14, DOI 10.7326/0003-4819-113-1-14; MONTANER JSG, 1989, CHEST, V95, P881, DOI 10.1378/chest.95.4.881; MONTANER JSG, 1992, CHEST, V102, P1823, DOI 10.1378/chest.102.6.1823; MURRAY JF, 1984, NEW ENGL J MED, V310, P1682, DOI 10.1056/NEJM198406213102529; OSMOND D, 1994, JAMA-J AM MED ASSOC, V271, P1083, DOI 10.1001/jama.271.14.1083; OYE RK, 1991, CHEST, V99, P685, DOI 10.1378/chest.99.3.685; PEAR R, 1993, NY TIMES        0320, P11; PERUZZI WT, 1991, CRIT CARE MED, V19, P892, DOI 10.1097/00003246-199107000-00012; PETERS BS, 1991, BRIT MED J, V302, P203, DOI 10.1136/bmj.302.6770.203; RELMAN AS, 1990, NEW ENGL J MED, V323, P911, DOI 10.1056/NEJM199009273231310; ROGERS PL, 1989, CRIT CARE MED, V17, P113, DOI 10.1097/00003246-198902000-00001; ROSEN MJ, 1986, J INTENSIVE CARE MED, V1, P55; SCHAPIRA DV, 1993, JAMA-J AM MED ASSOC, V269, P783, DOI 10.1001/jama.269.6.783; SCHEIN RMH, 1986, CRIT CARE MED, V14, P1026, DOI 10.1097/00003246-198612000-00006; SCHULMAN KA, 1991, ANN INTERN MED, V114, P798, DOI 10.7326/0003-4819-114-9-798; SCITOVSKY AA, 1986, JAMA-J AM MED ASSOC, V256, P3103, DOI 10.1001/jama.256.22.3103; SCITOVSKY AA, 1989, MILBANK Q, V67, P318, DOI 10.2307/3350143; SMITH RL, 1989, CHEST, V96, P857, DOI 10.1378/chest.96.4.857; Sonnefeld S T, 1991, Health Care Financ Rev, V13, P1; STAIKOWSKY F, 1993, CHEST, V104, P756, DOI 10.1378/chest.104.3.756; STEIN M, 1992, AM J MED, V93, P387, DOI 10.1016/0002-9343(92)90167-A; STEINBROOK R, 1986, NEW ENGL J MED, V314, P457, DOI 10.1056/NEJM198602133140730; STOVER DE, 1985, AM J MED, V78, P429, DOI 10.1016/0002-9343(85)90334-1; STRAUSS MJ, 1986, JAMA-J AM MED ASSOC, V255, P1143, DOI 10.1001/jama.255.9.1143; TOBIN MJ, 1994, NEW ENGL J MED, V330, P1056, DOI 10.1056/NEJM199404143301507; TUCKER KJ, 1992, WESTERN J MED, V157, P637; UDVARHELYI IS, 1992, ANN INTERN MED, V116, P238, DOI 10.7326/0003-4819-116-3-238; WACHTER RM, 1988, ARCH INTERN MED, V148, P149, DOI 10.1001/archinte.148.1.149; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; WACHTER RM, 1991, AM REV RESPIR DIS, V143, P251, DOI 10.1164/ajrccm/143.2.251; WACHTER RM, 1986, AM REV RESPIR DIS, V134, P891, DOI 10.1164/arrd.1986.134.5.891; WACHTER RM, 1992, JAMA-J AM MED ASSOC, V267, P541, DOI 10.1001/jama.267.4.541; WELCH HG, 1989, NEW ENGL J MED, V321, P807, DOI 10.1056/NEJM198909213211207; YARCHOAN R, 1991, ANN INTERN MED, V115, P184, DOI 10.7326/0003-4819-115-3-184; 1991, PRIORITIZATION HLTH	73	81	82	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					230	235		10.1001/jama.273.3.230	http://dx.doi.org/10.1001/jama.273.3.230			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB234	7807663				2022-12-28	WOS:A1995QB23400028
J	GOSDEN, CM				GOSDEN, CM			WHEN AMNIOTIC-FLUID CELLS DO NOT GROW	LANCET			English	Editorial Material							FETAL				GOSDEN, CM (corresponding author), UNIV LIVERPOOL,DEPT OBSTET & GYNAECOL,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							GOSDEN C, 1978, J MED GENET, V15, P262, DOI 10.1136/jmg.15.4.262; MARTEAU TM, 1992, PRENATAL DIAG, V12, P205, DOI 10.1002/pd.1970120309; NICOLAIDES KH, 1992, LANCET, V340, P704, DOI 10.1016/0140-6736(92)92240-G	3	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					78	78		10.1016/S0140-6736(95)90058-6	http://dx.doi.org/10.1016/S0140-6736(95)90058-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815884				2022-12-28	WOS:A1995QB80400005
J	DAI, XC; DEMESMAEKER, A; JOYCE, GF				DAI, XC; DEMESMAEKER, A; JOYCE, GF			CLEAVAGE OF AN AMIDE BOND BY A RIBOZYME	SCIENCE			English	Article							TETRAHYMENA RIBOZYME; RNA WORLD; CATALYSIS; BINDING; EVOLUTION; SUBSTRATE; SEQUENCE; ANTIBODY; ENZYME; ORIGIN	A variant form of a group I ribozyme, optimized by in vitro evolution for its ability to catalyze magnesium-dependent phosphoester transfer reactions involving DNA substrates, also catalyzes the cleavage of an unactivated alkyl amide when that linkage is presented in the context of an oligodeoxynucleotide analog. Substrates containing an amide bond that joins either two DNA oligos, or a DNA oligo and a short peptide, are cleaved in a magnesium-dependent fashion to generate the expected products. The first-order rate constant, k(cat), is 0.1 x 10(-5) min(-1) to 1 x 10(-5) min(-1) for the DNA-flanked substrates, which corresponds to a rate acceleration of more than 10(3) as compared with the uncatalyzed reaction.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT BIOL MOLEC, LA JOLLA, CA 92037 USA; CIBA GEIGY LTD, CENT RES LABS, BASEL, SWITZERLAND	Scripps Research Institute; Scripps Research Institute; Novartis								BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; BENKOVIC SJ, 1990, SCIENCE, V250, P1135, DOI 10.1126/science.2251500; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; BEVILACQUA PC, 1991, BIOCHEMISTRY-US, V30, P10632, DOI 10.1021/bi00108a005; BREAKER RR, 1994, TRENDS BIOTECHNOL, V12, P268, DOI 10.1016/0167-7799(94)90138-4; CECH TR, 1992, J BIOL CHEM, V267, P17479; CHAPMAN KB, 1994, CURR OPIN STRUC BIOL, V4, P618, DOI 10.1016/S0959-440X(94)90227-5; EHLER KW, 1976, BIOCHIM BIOPHYS ACTA, V434, P233, DOI 10.1016/0005-2795(76)90055-6; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8299, DOI 10.1021/bi00083a034; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; IVERSON BL, 1989, SCIENCE, V243, P1184, DOI 10.1126/science.2922606; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; JOYCE GF, 1994, CURR OPIN STRUC BIOL, V4, P331, DOI 10.1016/S0959-440X(94)90100-7; KAHNE D, 1988, J AM CHEM SOC, V110, P7529, DOI 10.1021/ja00230a041; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; LEBRETON J, 1993, TETRAHEDRON LETT, V34, P6383, DOI 10.1016/0040-4039(93)85051-W; MARTIN MT, 1994, J AM CHEM SOC, V116, P6508, DOI 10.1021/ja00094a003; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1991, NATURE, V353, P302, DOI 10.1038/353302a0; PICCIRILLI JA, 1992, SCIENCE, V256, P1420, DOI 10.1126/science.1604316; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; PRUDENT JR, 1994, SCIENCE, V264, P1924; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; RAILLARD SA, UNPUB; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; TSANG J, 1994, BIOCHEMISTRY-US, V33, P5966, DOI 10.1021/bi00185a038; TSANG JC, UNPUB; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383; YAMANA T, 1972, CHEM PHARM BULL, V20, P881; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZIEBOLL G, 1994, J MOL EVOL, V38, P561	35	91	108	0	15	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 13	1995	267	5195					237	240		10.1126/science.7809628	http://dx.doi.org/10.1126/science.7809628			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7809628				2022-12-28	WOS:A1995QB15300035
J	MATSUFUJI, S; MATSUFUJI, T; MIYAZAKI, Y; MURAKAMI, Y; ATKINS, JF; GESTELAND, RF; HAYASHI, S				MATSUFUJI, S; MATSUFUJI, T; MIYAZAKI, Y; MURAKAMI, Y; ATKINS, JF; GESTELAND, RF; HAYASHI, S			AUTOREGULATORY FRAMESHIFTING IN DECODING MAMMALIAN ORNITHINE DECARBOXYLASE ANTIZYME	CELL			English	Article							RELEASE FACTOR-II; MESSENGER-RNA; INHIBITORY PROTEIN; GENE-EXPRESSION; RAT-LIVER; POLYAMINES; DEGRADATION; CELLS; PSEUDOKNOT; SEQUENCE	Rat antizyme gene expression requires programmed, ribosomal frameshifting. A novel autoregulatory mechanism enables modulation of frameshifting according to the cellular concentration of polyamines. Antizyme binds to, and destabilizes, ornithine decarboxylase, a key enzyme in polyamine synthesis, Rapid degradation ensues, thus completing a regulatory circuit. In vitro experiments with a fusion construct using reticulocyte lysates demonstrate polyamine-dependent expression with a frameshift efficiency of 19% at the optimal concentration of spermidine. The frameshift is +1 and occurs at the codon just preceding the terminator of the initiating frame. Both the termination codon of the initiating frame and a pseudoknot downstream in the mRNA have a stimulatory effect. The shift site sequence, UCC-UGA-U, is not similar to other known frameshift sites. The mechanism does not seem to involve re-pairing of peptidyl-tRNA in the new frame but rather reading or occlusion of a fourth base.	UNIV UTAH, DEPT HUMAN GENET, SALT LAKE CITY, UT 84112 USA; JIKEI UNIV, SCH MED, DEPT NUTR, MINATO KU, TOKYO 105, JAPAN	Utah System of Higher Education; University of Utah; Jikei University	MATSUFUJI, S (corresponding author), UNIV UTAH, HOWARD HUGHES MED INST, SALT LAKE CITY, UT 84112 USA.			Atkins, John/0000-0001-7933-0165	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048152] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM48152] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLQUIST P, 1981, J MOL BIOL, V153, P23, DOI 10.1016/0022-2836(81)90524-6; Atkins J. F., 1995, P471; ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2; ATKINS JF, 1975, J BIOL CHEM, V250, P5688; BALASUNDARAM D, 1994, P NATL ACAD SCI USA, V91, P172, DOI 10.1073/pnas.91.1.172; BRAULT V, 1992, P NATL ACAD SCI USA, V89, P2262, DOI 10.1073/pnas.89.6.2262; BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4; CHAMORRO M, 1992, P NATL ACAD SCI USA, V89, P713, DOI 10.1073/pnas.89.2.713; CRAIGEN WJ, 1986, NATURE, V322, P273, DOI 10.1038/322273a0; CURRAN JF, 1988, J MOL BIOL, V203, P75, DOI 10.1016/0022-2836(88)90092-7; FARABAUGH PJ, 1993, CELL, V74, P93, DOI 10.1016/0092-8674(93)90297-4; FONG WF, 1976, BIOCHIM BIOPHYS ACTA, V428, P456, DOI 10.1016/0304-4165(76)90054-4; GESTELAND RF, 1992, ANNU REV BIOCHEM, V45, P747; GORLACH M, 1989, EUR J BIOCHEM, V184, P589, DOI 10.1111/j.1432-1033.1989.tb15054.x; Hayashi S., 1989, ORNITHINE DECARBOXYL, P35; HAYASHI S, 1989, ORNITHINE DECARBOXYL, P47; HEIDER J, 1992, EMBO J, V11, P3759, DOI 10.1002/j.1460-2075.1992.tb05461.x; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; ICHIBA T, 1994, BIOCHEM BIOPH RES CO, V200, P1721, DOI 10.1006/bbrc.1994.1651; JANDA M, 1987, VIROLOGY, V158, P259, DOI 10.1016/0042-6822(87)90265-0; KAMEJI T, 1987, J BIOL CHEM, V262, P2427; KITANI T, 1984, J BIOL CHEM, V259, P36; LI XQ, 1993, MOL CELL BIOL, V13, P2377, DOI 10.1128/MCB.13.4.2377; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; MATSUFUJI S, 1990, J BIOCHEM, V107, P87, DOI 10.1093/oxfordjournals.jbchem.a123018; MATSUFUJI S, 1990, J BIOCHEM-TOKYO, V108, P365, DOI 10.1093/oxfordjournals.jbchem.a123207; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; MIYAZAKI Y, 1992, GENE, V113, P191, DOI 10.1016/0378-1119(92)90395-6; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1985, BIOCHEM J, V225, P689, DOI 10.1042/bj2250689; MURAKAMI Y, 1985, BIOCHEM J, V226, P893, DOI 10.1042/bj2260893; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; MURAKAMI Y, 1992, BIOCHEM J, V283, P661, DOI 10.1042/bj2830661; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PLEIJ CWA, 1985, NUCLEIC ACIDS RES, V13, P1717, DOI 10.1093/nar/13.5.1717; ROM E, 1994, P NATL ACAD SCI USA, V91, P3959, DOI 10.1073/pnas.91.9.3959; ROM E, 1994, P NATL ACAD SCI USA, V91, P9195; RUSSELL DH, 1969, MOL PHARMACOL, V5, P253; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; ten Dam E B, 1990, Virus Genes, V4, P121, DOI 10.1007/BF00678404; TOKUNAGA F, 1994, J BIOL CHEM, V269, P17382; Weiss R B, 1990, Prog Nucleic Acid Res Mol Biol, V39, P159, DOI 10.1016/S0079-6603(08)60626-1; WEISS RB, 1987, COLD SPRING HARB SYM, V52, P687, DOI 10.1101/SQB.1987.052.01.078	46	421	435	2	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 13	1995	80	1					51	60		10.1016/0092-8674(95)90450-6	http://dx.doi.org/10.1016/0092-8674(95)90450-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813017	Green Published, Bronze			2022-12-28	WOS:A1995QB91000009
J	HARGREAVES, MR; BENSON, MK				HARGREAVES, MR; BENSON, MK			INHALED SODIUM CROMOGLYCATE IN ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR COUGH	LANCET			English	Article							IRRITANT RECEPTORS; C-FIBERS; BRADYKININ; REFLEX; BRONCHOCONSTRICTION; SULINDAC; AIRWAYS; CAPSAICIN; RESPONSES; ENALAPRIL	Cough is a frequent side-effect of angiotensin-converting enzyme (ACE) inhibitors. We examined the effects of inhaled sodium cromoglycate in 10 patients with ACE-inhibitor cough in a double-blind crossover study. After a 2-week run-in, patients were randomised to either 2 weeks' inhaled sodium cromoglycate or placebo followed by a further 2 weeks on the other treatment. Patients kept a cough diary during each study period. Cough severity was recorded on a scale from 0 to 12. At the end of each study period the cough threshold to inhaled capsaicin was measured. 9 patients reported a reduction in cough after sodium cromoglycate. Median (range) daily cough scores during run-in and placebo periods were 3.6 (1.9-6.4) and 4.1 (0.6-8.1), respectively (p<0.05). Median daily cough score after sodium cromoglycate was 1.8 (0.4-3; p<0.01). There was a significant relation between initial cough severity and benefit from sodium cromoglycate; and cough-reflex sensitivity to inhaled capsaicin was significantly reduced. Inhaled sodium cromoglycate is an effective treatment for ACE-inhibitor cough. Its effect may be due to suppression of afferent vagal activity.	CHURCHILL HOSP,OSLER CHEST UNIT,OXFORD OX3 9DU,ENGLAND	University of Oxford	HARGREAVES, MR (corresponding author), JOHN RADCLIFFE HOSP,DEPT CARDIOVASC MED,OXFORD OX3 9DU,ENGLAND.							ALDIS WL, 1991, CHEST, V100, P1741; ALLISTONE A, 1985, CLIN SCI, V68, P227, DOI 10.1042/cs0680227; BARNES PJ, 1986, LANCET, V1, P242; BENJAMIN N, 1989, J PHYSIOL-LONDON, V412, P543, DOI 10.1113/jphysiol.1989.sp017630; BUCKNALL CE, 1988, BRIT MED J, V296, P86, DOI 10.1136/bmj.296.6615.86; CASCIERI MA, 1983, MOL PHARMACOL, V25, P287; COLERIDGE HM, 1976, NATURE, V264, P451, DOI 10.1038/264451a0; CROSSMAN DC, 1993, J APPL PHYSIOL, V75, P167, DOI 10.1152/jappl.1993.75.1.167; DIXON M, 1980, BRIT J PHARMACOL, V70, P11, DOI 10.1111/j.1476-5381.1980.tb10898.x; DIXON M, 1979, BRIT J PHARMACOL, V67, P569, DOI 10.1111/j.1476-5381.1979.tb08703.x; FULLER RW, 1985, J APPL PHYSIOL, V58, P1080, DOI 10.1152/jappl.1985.58.4.1080; FULLER RW, 1987, AM REV RESPIR DIS, V135, P176; FULLER RW, 1987, BMJ-BRIT MED J, V295, P1025, DOI 10.1136/bmj.295.6605.1025-a; GALLER M, 1982, J PHARMACOL EXP THER, V220, P23; GILCHRIST NL, 1989, J HUM HYPERTENS, V3, P451; HANSSON L, 1992, AM REV RESPIR DIS, V145, P1191, DOI 10.1164/ajrccm/145.5.1191; HARGREAVES M, 1992, CLIN SCI, V83, P399, DOI 10.1042/cs0830399; HARGREAVES M, 1993, BRIT J CLIN PRACT, V47, P319; HARRIES MG, 1981, LANCET, V1, P5; JOOS G, 1987, THORAX, V42, P779, DOI 10.1136/thx.42.10.779; KARLSSON JA, 1988, J APPL PHYSIOL, V65, P1007, DOI 10.1152/jappl.1988.65.3.1007; KATSUMATA U, 1991, TOHOKU J EXP MED, V164, P103, DOI 10.1620/tjem.164.103; KAUFMAN MP, 1980, J APPL PHYSIOL, V48, P511, DOI 10.1152/jappl.1980.48.3.511; LINDGREN BR, 1987, EUR J PHARMACOL, V135, P383, DOI 10.1016/0014-2999(87)90688-1; MCEWAN JR, 1990, J PHARMACOL EXP THER, V255, P161; NICHOLLS MG, 1987, LANCET, V1, P872; OLDHAM PD, 1968, INTERPRETATION NUMER, P148; POCOCK SJ, 1983, CLIN TRIALS PRACTICA, P110; RYAN JW, 1982, ANNU REV PHYSIOL, V44, P241, DOI 10.1146/annurev.ph.44.030182.001325; YEO WW, 1991, Q J MED, V293, P763	30	52	63	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					13	16		10.1016/S0140-6736(95)91151-0	http://dx.doi.org/10.1016/S0140-6736(95)91151-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799699				2022-12-28	WOS:A1995QA29000009
J	AGGLETON, JP; BLAND, JM; KENTRIDGE, RW; NEAVE, NJ				AGGLETON, JP; BLAND, JM; KENTRIDGE, RW; NEAVE, NJ			HANDEDNESS AND LONGEVITY - ARCHIVAL STUDY OF CRICKETERS	BRITISH MEDICAL JOURNAL			English	Article							LEFT-HANDERS; AGE; PREFERENCE	Objective-To test whether handedness is associated with a change in longevity. Design-Archival survey. Setting-British Isles. Subjects-All first class cricketers born before 1961 whose bowling hand was specified (right, n = 5041; left, n = 1132) in a comprehensive encyclopaedia. Main outcome measures-Bowling hand and life span. Results-Regression analysis of the 5960 players born between 1840 and 1960 (3387 dead, 2573 alive) showed no significant relation between mortality and handedness (P = 0.3). Left handedness was, however, associated with an increased likelihood of death from unnatural causes (P = 0.03, log hazard 0.37, 95% confidence interval 0.04 to 0.70). This effect was especially related to deaths during warfare (P = 0.009, log hazard 0.53, 0.13 to 0.92). Conclusion-Left handedness is not, in general, associated with an increase in mortality.	UNIV DURHAM,DEPT PSYCHOL,DURHAM DH1 3LE,ENGLAND; ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND	Durham University; St Georges University London			Kentridge, Robert W/A-5430-2008	Kentridge, Robert W/0000-0003-3688-3899; Neave, Nick/0000-0002-5380-4614; Aggleton, John/0000-0002-5573-1308				AGGLETON JP, 1993, J EPIDEMIOL COMMUN H, V47, P206, DOI 10.1136/jech.47.3.206; ANDERSON MG, 1989, NATURE, V341, P112, DOI 10.1038/341112a0; ANNETT M, 1993, PERCEPT MOTOR SKILL, V76, P295, DOI 10.2466/pms.1993.76.1.295; Bailey Philip, 1993, WHOS WHO CRICKETERS; BRYDEN MP, 1977, NEUROPSYCHOLOGIA, V15, P617, DOI 10.1016/0028-3932(77)90067-7; COREN S, 1991, PSYCHOL BULL, V109, P90, DOI 10.1037/0033-2909.109.1.90; COREN S, 1989, AM J PUBLIC HEALTH, V79, P1; COX DR, 1972, J R STAT SOC B, V34, P187; GILBERT AN, 1992, NEUROPSYCHOLOGIA, V30, P601, DOI 10.1016/0028-3932(92)90065-T; HALPERN DF, 1988, NATURE, V333, P213, DOI 10.1038/333213b0; HARRIS LJ, 1993, PSYCHOL BULL, V114, P203, DOI 10.1037/0033-2909.114.2.203; HUGDAHL K, 1993, NEUROPSYCHOLOGIA, V31, P325, DOI 10.1016/0028-3932(93)90156-T; KUHLEMEIER KV, 1991, AM J PUBLIC HEALTH, V81, P513, DOI 10.2105/AJPH.81.4.513; MARKS JS, 1991, NEW ENGL J MED, V325, P1042; PETERS M, 1991, NEUROPSYCHOLOGIA, V29, P1257, DOI 10.1016/0028-3932(91)90039-B; PETO R, 1994, BRIT MED J, V308, P408, DOI 10.1136/bmj.308.6925.408; ROTHMAN KJ, 1991, NEW ENGL J MED, V325, P1041; THORN P, 1982, CRICKET STATISTICIAN, V37, P30; THORN P, 1984, CRICKET STATISTICIAN, V45, P27; TURNER BS, 1993, BRIT MED J, V307, P1577, DOI 10.1136/bmj.307.6919.1577; WOLF PA, 1991, NEW ENGL J MED, V325, P1042; WOOD CJ, 1989, BRIT J PSYCHOL, V80, P227, DOI 10.1111/j.2044-8295.1989.tb02316.x; WOOD EK, 1988, NATURE, V335, P212, DOI 10.1038/335212a0	23	28	28	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1681	1684		10.1136/bmj.309.6970.1681	http://dx.doi.org/10.1136/bmj.309.6970.1681			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PY717	7819983	Green Published			2022-12-28	WOS:A1994PY71700007
J	HALPERN, SM; MUNRO, DD				HALPERN, SM; MUNRO, DD			TICKBORNE MELANOMA	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFECTION; BORRELIA				HALPERN, SM (corresponding author), ST BARTHOLOMEWS HOSP, DEPT DERMATOL, LONDON EC1A 7BE, ENGLAND.							ANDERSON JF, 1991, SCAND J INFECT DIS, P23; KAHL O, 1992, MED VET ENTOMOL, V6, P363, DOI 10.1111/j.1365-2915.1992.tb00634.x; MAUTNER VF, 1990, NERVENARZT, V61, P94; Reiner K L, 1991, J Okla State Med Assoc, V84, P503	4	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 24	1994	309	6970					1693	1693		10.1136/bmj.309.6970.1693	http://dx.doi.org/10.1136/bmj.309.6970.1693			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819991	Green Published			2022-12-28	WOS:A1994PY71700017
J	MARSHALL, J; SHARP, E; BARRISON, IG				MARSHALL, J; SHARP, E; BARRISON, IG			ONCE BITTEN, TWICE SHY	BRITISH MEDICAL JOURNAL			English	Article									HEMEL HEMPSTEAD GEN HOSP,DEPT MED,HEMEL HEMPSTEAD HP2 4AD,HERTS,ENGLAND; HEMEL HEMPSTEAD GEN HOSP,DEPT SURG,HEMEL HEMPSTEAD HP2 4AD,HERTS,ENGLAND									AZIMI P, 1990, PEDIATR INFECT DIS J, V9, P670; MOLINA JM, 1991, SCAND J INFECT DIS, V23, P659, DOI 10.3109/00365549109024289; RUMLEY RL, 1987, ANN RHEUM DIS, V46, P793, DOI 10.1136/ard.46.10.793	3	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1694	1695		10.1136/bmj.309.6970.1694a	http://dx.doi.org/10.1136/bmj.309.6970.1694a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819993	Green Published			2022-12-28	WOS:A1994PY71700019
J	STRACHAN, DR				STRACHAN, DR			THE CHRISTMAS CLACKER	BRITISH MEDICAL JOURNAL			English	Note											STRACHAN, DR (corresponding author), HULL ROYAL INFIRM,KINGSTON HULL HU3 2JZ,N HUMBERSIDE,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1747	1747						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7820014				2022-12-28	WOS:A1994PY71700044
J	HALLAM, L; CRAGG, D				HALLAM, L; CRAGG, D			ORGANIZATION OF PRIMARY-CARE SERVICES OUTSIDE NORMAL WORKING HOURS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine the use and organisation of out of hours services in primary care. Design-Telephone survey. Setting-Family health services authorities in England and Wales. Main outcome measures-Rate of use of out of hours care, methods of provision, and role of authorities. Results-12-25% of authorities were unable to answer one or more key questions in the survey because of insufficient :information. The mean number of night visits made per unrestricted principal per 1000 patients per year was 35.3. 13 of the 19 authorities with averages above 40 covered large towns or cities. 81 authorities had at least one commercial deputising service. In 46 metropolitan districts and one other district over 75% of general practitioners had consent to use a deputising service, although not all did so. Information on cooperation between practices was limited. 22 cooperatives were recognised by the authorities, nine were not officially recognised, and a further 13 were nearing institution. Only two cooperatives were in areas with extensive use of deputising services. Conclusion-Methods of providing out of hours care are changing, and without good information systems family health services authorities will not be able to monitor the effect on quality and cost effectiveness of care.			HALLAM, L (corresponding author), UNIV MANCHESTER,RUSHOLME HLTH CTR,CTR PRIMARY CARE RES,DEPT GEN PRACTICE,MANCHESTER M14 5NP,LANCS,ENGLAND.							FOSTER A, 1991, FHSAS TODAYS TOMORRO; HALLAM L, 1994, BRIT MED J, V308, P249, DOI 10.1136/bmj.308.6923.249; JONES H, 1992, PULSE           0704, P7; MAWHINNEY B, 1993, PULSE           1127, P18; MAWHINNEY B, 1993, PULSE           1127, P15; MILNER PC, 1988, J EPIDEMIOL COMMUN H, V42, P274, DOI 10.1136/jech.42.3.274; NEWTON P, 1994, PULSE           0108, P1; WARRY R, 1993, GENERAL PRACTIT 1008, P1; 1989, GENERAL PRACTICE NAT; 1993, NHS10 AUD COMM REP; 1993, GENERAL PRACTIT 0703, P32	11	40	40	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1621	1623		10.1136/bmj.309.6969.1621	http://dx.doi.org/10.1136/bmj.309.6969.1621			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819944	Green Published			2022-12-28	WOS:A1994PY22000026
J	GUERINA, NG; HSU, HW; MEISSNER, HC; MAGUIRE, JH; LYNFIELD, R; STECHENBERG, B; ABROMS, I; PASTERNACK, MS; HOFF, R; EATON, RB; GRADY, GF; CHEESEMAN, SH; MCINTOSH, K; MEDEARIS, DN; ROBB, R; WEIBLEN, BJ				GUERINA, NG; HSU, HW; MEISSNER, HC; MAGUIRE, JH; LYNFIELD, R; STECHENBERG, B; ABROMS, I; PASTERNACK, MS; HOFF, R; EATON, RB; GRADY, GF; CHEESEMAN, SH; MCINTOSH, K; MEDEARIS, DN; ROBB, R; WEIBLEN, BJ			NEONATAL SEROLOGIC SCREENING AND EARLY TREATMENT FOR CONGENITAL TOXOPLASMA-GONDII INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TISSUE-CULTURE; PREGNANCIES; MANAGEMENT	Background. Most infants with congenital Toxoplasma gondii infection have no symptoms at birth, but many will have retinal disease or neurologic abnormalities later in life. Early detection and treatment of congenital toxoplasmosis may reduce these sequelae. Methods. In Massachusetts since January 1986, and in New Hampshire since July 1988, newborns have been screened for intrauterine infection with T. gondii by means of an IgM capture immunoassay of blood specimens routinely collected for screening for metabolic disorders. Congenital infection is confirmed by assays for specific IgG and IgM antibodies in serum from infants and their mothers. For this study, infants with serologic evidence of infection underwent extensive clinical evaluation and received one year of treatment. Results. Through June 1992, 100 of 635,000 infants tested had positive screening tests. Congenital infection was confirmed in 52 infants, 50 of whom were identified only through neonatal screening and not through initial clinical examination. However, after the serologic results became available, more detailed examinations revealed abnormalities of either the central nervous system or the retina in 19 of 48 infants evaluated (40 percent). After treatment, only 1 of 46 children had a neurologic deficit (hemiplegia attributable to a cerebral lesion present at birth). Thirty-nine treated children had follow-up ophthalmologic examinations when one to six years old; four (10 percent) had eye lesions that may have developed postnatally (a macular lesion in one child and minor retinal scars in three). Conclusions. Routine neonatal screening for toxoplasmosis identifies congenital infections that are subclinical, and early treatment may reduce the severe long-term sequelae.	CHILDRENS HOSP, DIV INFECT DIS, BOSTON, MA 02115 USA; CHILDRENS HOSP, DIV NEWBORN MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; NEWTON WELLESLEY HOSP, DIV NEONATOL, NEWTON, MA USA; MASSACHUSETTS STATE LAB INST, NEW ENGLAND REG NEWBORN SCREENING PROGRAM, BOSTON, MA USA; TUFTS UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02111 USA; BRIGHAM & WOMENS HOSP, DEPT INFECT DIS, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA USA; MASSACHUSETTS GEN HOSP, PEDIAT INFECT DIS UNIT, BOSTON, MA 02114 USA; BAYSTATE MED CTR, DIV PEDIAT INFECT DIS, SPRINGFIELD, MA 01107 USA; UNIV MASSACHUSETTS, MED CTR, DEPT NEUROL, WORCESTER, MA 01655 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Newton Wellesley Hospital; Tufts University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Baystate Medical Center; University of Massachusetts System; University of Massachusetts Worcester	GUERINA, NG (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, DEPT PEDIAT INFECT DIS, DIV NEWBORN MED, NEMC 44, 750 WASHINGTON ST, BOSTON, MA 02111 USA.							BONADIO WA, 1992, PEDIATR INFECT DIS J, V11, P589, DOI 10.1097/00006454-199207000-00015; CHANG CH, 1972, J PEDIATR-US, V81, P790, DOI 10.1016/S0022-3476(72)80106-9; COUVREUR J, 1984, ANN PEDIATR-PARIS, V31, P855; COUVREUR J, 1984, ANN PEDIATR-PARIS, V31, P815; DAFFOS F, 1988, NEW ENGL J MED, V318, P271, DOI 10.1056/NEJM198802043180502; DEROUIN F, 1987, J CLIN MICROBIOL, V25, P1597, DOI 10.1128/JCM.25.9.1597-1600.1987; DEVROEDE M, 1979, ACTA PAEDIATR SCAND, V68, P761, DOI 10.1111/j.1651-2227.1979.tb18453.x; HOFF R, 1990, ALB BIR DEF, P169; HSU HW, 1992, SCAND J INFECT DIS, P59; KOPPE JG, 1974, EUR J OBSTET GYN R B, V4, P101, DOI 10.1016/0028-2243(74)90029-X; KOPPE JG, 1986, LANCET, V1, P254; MCCABE R, 1988, NEW ENGL J MED, V318, P313, DOI 10.1056/NEJM198802043180509; NAOT Y, 1981, J PEDIATR-US, V98, P32, DOI 10.1016/S0022-3476(81)80528-8; Remington JS., 1990, INFECT DIS FETUS NEW, V3, P89; ROBERTS T, 1990, J AM VET MED ASSOC, V196, P249; SEVER JL, 1988, PEDIATRICS, V82, P181; THORP JM, 1988, NEW ENGL J MED, V319, P372, DOI 10.1056/NEJM198808113190615; WEIBLEN BJ, 1993, LABORATORY METHODS N, P191; WILSON CB, 1980, PEDIATRICS, V66, P767	19	290	312	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 30	1994	330	26					1858	1863		10.1056/NEJM199406303302604	http://dx.doi.org/10.1056/NEJM199406303302604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT530	7818637				2022-12-28	WOS:A1994NT53000004
J	ABRUTYN, E; MOSSEY, J; BERLIN, JA; BOSCIA, J; LEVISON, M; PITSAKIS, P; KAYE, D				ABRUTYN, E; MOSSEY, J; BERLIN, JA; BOSCIA, J; LEVISON, M; PITSAKIS, P; KAYE, D			DOES ASYMPTOMATIC BACTERIURIA PREDICT MORTALITY AND DOES ANTIMICROBIAL TREATMENT REDUCE MORTALITY IN ELDERLY AMBULATORY WOMEN	ANNALS OF INTERNAL MEDICINE			English	Article						BACTERIURIA; URINARY TRACT INFECTIONS; RISK FACTORS; HEALTH STATUS INDICATORS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE)	URINARY-TRACT INFECTIONS; NO THERAPY; SURVIVAL; EPIDEMIOLOGY; POPULATION; HEALTH	Objective: To determine whether asymptomatic bacteriuria in elderly ambulatory women is a marker of increased mortality and, if so, whether it is because of an association with other determinants of mortality or because asymptomatic bacteriuria is itself an independent cause, the removal of which might improve longevity. Design: A cohort study and a controlled clinical trial of the effect of antimicrobial treatment. Setting: A geriatric center and 21 continuing care retirement communities. Participants: Women without urinary tract catheters. Measurements: Urine cultures every 6 months (the same organism at 10(5) colony-forming units or more per mL on two midstream urine specimens defined asymptomatic bacteriuria), comorbidity, and mortality. Results: In the observational study, infected residents (n = 318) were older, and sicker, and had higher mortality (18.7 per 100 000 resident-days) than uninfected residents (n = 1173; 10.1 per 100 000 resident-days). However, in a multivariate Cox analysis, infection was not related to mortality (relative risk, 1.1; P > 0.2), whereas age at entry and self-rated health (score 1 [excellent] to 4 [bad or poor]) were strong predictors. In the clinical trial, mortality in 166 treated residents (13.8 per 100 000 resident-days) was comparable to that of 192 untreated residents (15.1 per 100 000 resident-days); the relative rate was 0.92 (95% CI, 0.57 to 1.47). The cure rates among treated and untreated residents were 82.9% and 15.6%, respectively. Conclusion: Urinary tract infection was not an independent risk factor for mortality, and its treatment did not lower the mortality rate. Screening and treatment of asymptomatic bacteriuria in ambulatory elderly women to decrease mortality do not appear warranted.	MED COLL PENN, EASTERN PENN PSYCHIAT INST, PHILADELPHIA, PA 19129 USA; UNIV PENN, SCH MED, CTR CLIN EPIDEMIOL & BIOSTAT, PHILADELPHIA, PA 19104 USA; MED COLL PENN, DEPT MED, PHILADELPHIA, PA 19129 USA	Drexel University; University of Pennsylvania; Pennsylvania Medicine; Drexel University	ABRUTYN, E (corresponding author), DEPT VET AFFAIRS MED CTR, 38TH & WOODLAND AVE, PHILADELPHIA, PA 19104 USA.				NATIONAL INSTITUTE ON AGING [P01AG003934] Funding Source: NIH RePORTER; NIA NIH HHS [AG03934] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRUTYN E, 1991, J AM GERIATR SOC, V39, P388, DOI 10.1111/j.1532-5415.1991.tb02905.x; ABRUTYN E, 1988, J AM GERIATR SOC, V36, P473, DOI 10.1111/j.1532-5415.1988.tb02389.x; ABRUTYN E, 1992, GERIATR NEPHROL UROL, V2, P99; BOSCIA JA, 1987, JAMA-J AM MED ASSOC, V257, P1067, DOI 10.1001/jama.257.8.1067; BOSCIA JA, 1986, AM J MED, V80, P208, DOI 10.1016/0002-9343(86)90011-2; DONTAS AS, 1981, NEW ENGL J MED, V304, P939, DOI 10.1056/NEJM198104163041604; DONTAS AS, 1991, J AM GERIATR SOC, V39, P641, DOI 10.1111/j.1532-5415.1991.tb03616.x; EVANS DA, 1982, LANCET, V1, P156; GLECKMAN RA, 1987, ANTIMICROB AGENTS CH, V31, P1; HEINAMAKI P, 1986, GERONTOLOGY, V32, P167, DOI 10.1159/000212784; IDLER EL, 1990, AM J EPIDEMIOL, V131, P91, DOI 10.1093/oxfordjournals.aje.a115489; IDLER EL, 1990, ADV MED SOCIOLOGY, V1, P131; KAHN RL, 1960, AM J PSYCHIAT, V117, P326, DOI 10.1176/ajp.117.4.326; KAPLAN GA, 1983, AM J EPIDEMIOL, V117, P292, DOI 10.1093/oxfordjournals.aje.a113541; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; KUNIN CM, 1992, AM J EPIDEMIOL, V135, P291; LAWTON MP, 1982, J GERONTOL, V37, P91, DOI 10.1093/geronj/37.1.91; LEE ET, 1992, STAT METHODS SURVIVA, P109; MOSSEY JM, 1982, AM J PUBLIC HEALTH, V72, P800, DOI 10.2105/AJPH.72.8.800; NICOLLE LE, 1993, INFECT CONT HOSP EP, V14, P220; NICOLLE LE, 1987, ANN INTERN MED, V106, P682, DOI 10.7326/0003-4819-106-5-682; NICOLLE LE, 1987, AM J MED, V83, P27, DOI 10.1016/0002-9343(87)90493-1; NORDENSTAM GR, 1986, NEW ENGL J MED, V314, P1152, DOI 10.1056/NEJM198605013141804; PLATT R, 1982, NEW ENGL J MED, V307, P637, DOI 10.1056/NEJM198209093071101; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P171; SCHAEFFER AJ, 1991, EUR UROL, V19, P2; SOURANDER LB, 1972, GERONTOL CLIN, V14, P274, DOI 10.1159/000245403; STAMM WE, 1993, NEW ENGL J MED, V329, P1328, DOI 10.1056/NEJM199310283291808; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4; ZHANEL GG, 1990, ARCH INTERN MED, V150, P1389, DOI 10.1001/archinte.150.7.1389; 1986, INT CLASSIFICATION D, P1	31	155	157	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1994	120	10					827	833		10.7326/0003-4819-120-10-199405150-00003	http://dx.doi.org/10.7326/0003-4819-120-10-199405150-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK458	7818631				2022-12-28	WOS:A1994NK45800003
J	VERGHESE, A				VERGHESE, A			QUITTERS NAIL	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											VERGHESE, A (corresponding author), TEXAS TECH UNIV,EL PASO,TX 79905, USA.								0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 7	1994	330	14					974	974						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND793	7818625				2022-12-28	WOS:A1994ND79300005
J	SAVITSKY, K; BARSHIRA, A; GILAD, S; ROTMAN, G; ZIV, Y; VANAGAITE, L; TAGLE, DA; SMITH, S; UZIEL, T; SFEZ, S; ASHKENAZI, M; PECKER, I; FRYDMAN, M; HARNIK, R; PATANJALI, SR; SIMMONS, A; CLINES, GA; SARTIEL, A; GATTI, RA; CHESSA, L; SANAL, O; LAVIN, MF; JASPERS, NGJ; MALCOLM, A; TAYLOR, R; ARLETT, CF; MIKI, T; WEISSMAN, SM; LOVETT, M; COLLINS, FS; SHILOH, Y				SAVITSKY, K; BARSHIRA, A; GILAD, S; ROTMAN, G; ZIV, Y; VANAGAITE, L; TAGLE, DA; SMITH, S; UZIEL, T; SFEZ, S; ASHKENAZI, M; PECKER, I; FRYDMAN, M; HARNIK, R; PATANJALI, SR; SIMMONS, A; CLINES, GA; SARTIEL, A; GATTI, RA; CHESSA, L; SANAL, O; LAVIN, MF; JASPERS, NGJ; MALCOLM, A; TAYLOR, R; ARLETT, CF; MIKI, T; WEISSMAN, SM; LOVETT, M; COLLINS, FS; SHILOH, Y			A SINGLE ATAXIA-TELANGIECTASIA GENE WITH A PRODUCT SIMILAR TO PI-3 KINASE	SCIENCE			English	Article							SCHIZOSACCHAROMYCES-POMBE; IONIZING-RADIATION; DNA-SYNTHESIS; COMPLEMENTATION ANALYSIS; CDNA SELECTION; FAMILIES; PROTEIN; CELLS; PATHWAYS; CANCERS	A gene, ATM, that is mutated in the autosomal recessive disorder ataxia telangiectasia (AT) was identified by positional cloning on chromosome 11q22-23. AT is characterized by cerebellar degeneration, immunodeficiency, chromosomal instability, cancer predisposition, radiation sensitivity, and cell cycle abnormalities. The disease is genetically heterogeneous, with four complementation groups that have been suspected to represent different genes. ATM, which has a transcript of 12 kilobases, was found to be mutated in AT patients from all complementation groups, indicating that it is probably the sole gene responsible for this disorder. A partial ATM complementary DNA clone of 5.9 kilobases encoded a putative protein that is similar to several yeast and mammalian phosphatidylinositol-3' kinases that are involved in mitogenic signal transduction, meiotic recombination, and cell cycle control. The discovery of ATM should enhance understanding of AT and related syndromes and may allow the identification of AT heterozygotes, who are at increased risk of cancer.	TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN GENET,IL-69978 TEL AVIV,ISRAEL; NIH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892; CHAIM SHEBA MED CTR,INST HUMAN GENET,IL-52621 TEL HASHOMER,ISRAEL; YALE UNIV,SCH MED,BOYER CTR MOLEC MED,NEW HAVEN,CT 06536; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,MCDERMOTT CTR,DALLAS,TX 75235; UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90095; UNIV ROMA LA SAPIENZA,DIPARTIMENTO MED SPERIMENTALE,I-00161 ROME,ITALY; HACETTEPE UNIV,FAC MED,DEPT PEDIAT,ANKARA 06100,TURKEY; QUEENSLAND INST MED RES,HERSTON,QLD 4006,AUSTRALIA; ERASMUS UNIV ROTTERDAM,DEPT CELL BIOL & GENET,3000 DR ROTTERDAM,NETHERLANDS; UNIV BIRMINGHAM,CRC,INST CANC STUDIES,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Chaim Sheba Medical Center; Yale University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Sapienza University Rome; Hacettepe University; QIMR Berghofer Medical Research Institute; Erasmus University Rotterdam; University of Birmingham; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769	NHGRI NIH HHS [HG00882] Funding Source: Medline; NINDS NIH HHS [NS31763] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031763] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ARLETT CF, 1985, ATAXIA TELANGIECTASI, P101; BEAMISH H, 1994, RADIAT RES, V138, pS130, DOI 10.2307/3578780; BORRESEN AL, 1990, GENE CHROMOSOME CANC, V2, P339, DOI 10.1002/gcc.2870020412; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CARR AG, UNPUB; CHEN P, 1984, MUTAT RES, V129, P165, DOI 10.1016/0027-5107(84)90149-0; Chen P., UNPUB; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; DIECHA N, 1995, CELL, V80, P269; FORD MD, 1984, MUTAT RES, V125, P115, DOI 10.1016/0027-5107(84)90038-1; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; GREEN MHL, 1987, J CELL SCI S, V6, P127; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; JASPERS NGJ, 1988, CYTOGENET CELL GENET, V49, P259, DOI 10.1159/000132673; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUNZ J, 1993, CELL, V73, P586; LANGE E, IN PRESS AM J HUM GE; LAVIN M, UNPUB; LAVIN MF, 1993, NATO ASI SERIES H, V77, P235; LEHMANN AR, 1982, ATAXIA TELANGIECTASI, P83; LIU Q, 1995, BIOTECHNIQUES, V18, P470; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MCCONVILLE CM, 1994, INT J RADIAT BIOL, V66, pS45, DOI 10.1080/09553009414551851; Meyn M. S., 1994, American Journal of Human Genetics, V55, pA3; MEYN MS, 1993, AM J HUM GENET, V53, P1206; MONFAR M, 1995, MOL CELL BIOL, V15, P325; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; MURNANE JP, 1982, P NATL ACAD SCI-BIOL, V79, P1960, DOI 10.1073/pnas.79.6.1960; OSKATO R, 1993, AM J HUM GENET, V53, P1055; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; PARIMOO S, 1993, NUCLEIC ACIDS RES, V21, P4422, DOI 10.1093/nar/21.18.4422; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RICHARD CW, 1993, GENOMICS, V17, P1, DOI 10.1006/geno.1993.1275; ROTMAN G, 1994, INT J RADIAT BIOL, V66, pS63, DOI 10.1080/09553009414551871; ROTMAN G, 1994, GENOMICS, V24, P234, DOI 10.1006/geno.1994.1611; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SEATON BL, 1992, GENE, V119, P83, DOI 10.1016/0378-1119(92)90069-2; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; Shiloh Y., 1994, American Journal of Human Genetics, V55, pA49; SHILOH Y, IN PRESS EUR J HUM G; SHILOH Y, 1985, ATAXIA TELANGIECTASI, P111; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TAGLE DA, 1993, NATURE, V361, P751, DOI 10.1038/361751a0; UHRHAMMER N, IN PRESS AM J HUM GE; VANAGAITE L, 1995, HUM GENET, V95, P451; VANAGAITE L, UNPUB; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WEINERT TA, UNPUB; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZAMPETTIBOSSELE.F, 1981, INT J RADIAT BIOL, V39, P547; ZIV Y, 1991, GENOMICS, V9, P373, DOI 10.1016/0888-7543(91)90268-J; ZIV Y, UNPUB; ZIV Y, 1992, HUM GENET, V88, P6219; ZIV Y, IN PRESS SOMATIC CEL	68	2232	2307	0	75	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1749	1753		10.1126/science.7792600	http://dx.doi.org/10.1126/science.7792600			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792600				2022-12-28	WOS:A1995RE66800042
J	NOWAK, MA; MAY, RM; PHILLIPS, RE; ROWLANDJONES, S; LALLOO, DG; MCADAM, S; KLENERMAN, P; KOPPE, B; SIGMUND, K; BANGHAM, CRM; MCMICHAEL, AJ				NOWAK, MA; MAY, RM; PHILLIPS, RE; ROWLANDJONES, S; LALLOO, DG; MCADAM, S; KLENERMAN, P; KOPPE, B; SIGMUND, K; BANGHAM, CRM; MCMICHAEL, AJ			ANTIGENIC OSCILLATIONS AND SHIFTING IMMUNODOMINANCE IN HIV-1 INFECTIONS	NATURE			English	Article							T-CELL DETERMINANTS; LYMPHOCYTES-T; SELECTION; VIRUS; RECOGNITION; RESPONSES; DOMINANCE; PEPTIDES; GENES	A TYPICAL protein antigen contains several epitopes that can be recognized by cytotoxic T lymphocytes (CTL), but in a characteristic antiviral immune response in vivo, CTL recognize only a small number of these potential epitopes, sometimes only one(1,2), this phenomenon is known as immunodominance(1-10). Antigenic variation within CTL epitopes has been demonstrated for the human immunodeficiency virus HIV-1 (ref. 11) and other viruses(12-17) and such 'antigenic escape' may be responsible for viral persistence. Here we develop a new mathematical model that deals with the interaction between CTL and multiple epitopes of a genetically variable pathogen, acid show that the nonlinear competition among CTL responses against different epitopes can explain immunodominance. This model suggests that an antigenically homogeneous pathogen population tends to induce a dominant response against a single epitope, whereas a heterogeneous pathogen population can stimulate complicated fluctuating responses against multiple epitopes. Antigenic variation in the immunodominant epitope can shift responses to weaker epitopes and thereby reduce immunological control of the pathogen population. These ideas are consistent with detailed longitudinal studies of CTL responses in HIV-1 infected patients. For vaccine design, the model suggests that the major response should be directed against conserved epitopes even if they are subdominant.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC IMMUNOL GRP,OXFORD OX3 9DU,ENGLAND; UNIV VIENNA,INST MATH,A-1090 VIENNA,AUSTRIA	University of Oxford; University of Vienna	NOWAK, MA (corresponding author), UNIV OXFORD,DEPT ZOOL,S PARKS RD,OXFORD OX1 3PS,ENGLAND.		Nowak, Martin A/A-6977-2008	Lalloo, David/0000-0001-7680-2200; klenerman, paul/0000-0003-4307-9161; Bangham, Charles/0000-0003-2624-3599	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADORINI L, 1988, J EXP MED, V168, P2091, DOI 10.1084/jem.168.6.2091; AEBISCHER T, 1991, P NATL ACAD SCI USA, V88, P11047, DOI 10.1073/pnas.88.24.11047; BANGHAM CRM, 1989, T CELLS, P281; BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; CAMPOSLIMA P, 1993, SCIENCE, V260, P98; Carpenter S., 1990, Applied Virology Research, V2, P99; Gegin Cem, 1992, Journal of Immunology, V149, P3331; HILL AB, 1993, IMMUNOL REV, V133, P75, DOI 10.1111/j.1600-065X.1993.tb01510.x; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LIU ZR, 1993, J IMMUNOL, V151, P1852; MCMICHAEL AJ, 1994, AIDS S1, V8, pS155; MOSKOPHIDIS D, 1995, J VIROL, V69, P2187, DOI 10.1128/JVI.69.4.2187-2193.1995; NIEWIESK S, 1995, J VIROL, V69, P2649, DOI 10.1128/JVI.69.4.2649-2653.1995; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; NOWAK M, 1993, AIDS, V7, pS3, DOI 10.1097/00002030-199301001-00002; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; NOWAK MA, IN PRESS J THEOR BIO; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; SAFRIT JT, 1994, J EXP MED, V179, P463, DOI 10.1084/jem.179.2.463; SCHAEFFER EB, 1989, P NATL ACAD SCI USA, V86, P4649, DOI 10.1073/pnas.86.12.4649; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729; TAKAHASHI H, 1989, SCIENCE, V246, P118, DOI 10.1126/science.2789433; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; WALKER BD, 1988, SCIENCE, V240, P64, DOI 10.1126/science.2451288; ZINKERNAGEL RM, 1978, J EXP MED, V148, P592, DOI 10.1084/jem.148.2.592	28	306	311	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					606	611		10.1038/375606a0	http://dx.doi.org/10.1038/375606a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791879				2022-12-28	WOS:A1995RD28700056
J	POWERS, NL; SALVI, RJ; WANG, J; SPONGR, V; QIU, CX				POWERS, NL; SALVI, RJ; WANG, J; SPONGR, V; QIU, CX			ELEVATION OF AUDITORY-THRESHOLDS BY SPONTANEOUS COCHLEAR OSCILLATIONS	NATURE			English	Article							SPONTANEOUS OTOACOUSTIC EMISSIONS; OUTER HAIR-CELLS; ACOUSTIC EMISSIONS; EAR CANALS; NERVE; RESPONSES; FREQUENCY; PATTERNS	THE inner ear sometimes acts as a robust sound generator, continuously broadcasting sounds (spontaneous otoacoustic emissions) which can be intense enough to be heard by other individuals standing nearby(1-4). Paradoxically, most individuals are unaware of the sounds generated within their ears, Two hypotheses could explain this paradox: (1) the spontaneous emissions may not be transmitted to the central nervous system; or (2) the spontaneous emission produces a continuous, high rate of neural activity, which, like the natural pattern of spontaneous activity, is ignored by the central nervous system. Here we demonstrate that high-intensity spontaneous otoacoustic emissions can vigorously activate auditory nerve fibres in mammals (Chinchilla laniger). This 'internal biological noise' creates a 'line busy' signal that significantly degrades a neuron's ability to respond to sound and results in a hearing loss completely different from that caused by damage to sensory cells(1,4).	SUNY BUFFALO,DEPT COMMUNICAT DISORDERS & SCI,HEARING RES LAB,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo				Wang, Jian/0000-0003-3633-6799				ASHMORE JF, 1987, J PHYSIOL-LONDON, V388, P323, DOI 10.1113/jphysiol.1987.sp016617; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; CLARK WW, 1984, HEARING RES, V16, P299, DOI 10.1016/0378-5955(84)90119-9; DALLOS P, 1976, J ACOUST SOC AM, V60, P510, DOI 10.1121/1.381086; DIELER R, 1991, J NEUROCYTOL, V20, P637, DOI 10.1007/BF01187066; ELDREDGE DH, 1981, J ACOUST SOC AM, V69, P1091, DOI 10.1121/1.385688; EVANS EF, 1981, TINNITUS, P108; FROYMOVICH O, 1995, J ACOUST SOC AM, V97, P3021, DOI 10.1121/1.411867; KEMP DT, 1978, J ACOUST SOC AM, V64, P1386, DOI 10.1121/1.382104; Kiang NY, 1970, SENSORINEURAL HEARIN, P241, DOI DOI 10.1002/9780470719756.CH15; Kiang NYS, 1965, DISCHARGE PATTERNS S; Liberman M. C., 1986, BASIC APPL ASPECTS N, P163; LIBERMAN MC, 1982, SCIENCE, V217, P1239; LONSBURYMARTIN BL, 1990, ANN OTO RHINOL LARYN, V99, P15, DOI 10.1177/00034894900990S502; MCFADDEN D, 1984, J ACOUST SOC AM, V76, P443, DOI 10.1121/1.391585; NEDZELNITSKY V, 1980, J ACOUST SOC AM, V68, P1676, DOI 10.1121/1.385200; POWERS NL, 1991, THESIS SUNY BUFFALO; RUGGERO MA, 1984, HEARING RES, V13, P293, DOI 10.1016/0378-5955(84)90083-2; SACHS MB, 1968, J ACOUST SOC AM, V43, P1120, DOI 10.1121/1.1910947; SALVI R, 1982, NEW PERSPECTIVES NOI, P165; SCHMIEDT RA, 1980, J NEUROPHYSIOL, V43, P1367, DOI 10.1152/jn.1980.43.5.1367; SINEX DG, 1984, HEARING RES, V13, P285, DOI 10.1016/0378-5955(84)90082-0; SINEX DG, 1986, J NEUROPHYSIOL, V56, P1763, DOI 10.1152/jn.1986.56.6.1763; SPOENDLIN H, 1972, ACTA OTO-LARYNGOL, V73, P235, DOI 10.3109/00016487209138937; SUBRAMANIAM M, 1994, HEARING RES, V74, P204, DOI 10.1016/0378-5955(94)90188-0; WILSON JP, 1980, HEARING RES, V2, P233, DOI 10.1016/0378-5955(80)90060-X; WILSON JP, 1981, TINNITUS, P82; ZUREK PM, 1982, J ACOUST SOC AM, V72, P774, DOI 10.1121/1.388258; ZUREK PM, 1981, J ACOUST SOC AM, V70, P446, DOI 10.1121/1.386787; ZUREK PM, 1981, J ACOUST SOC AM, V69, P514, DOI 10.1121/1.385481	30	33	33	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					585	587		10.1038/375585a0	http://dx.doi.org/10.1038/375585a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791874				2022-12-28	WOS:A1995RD28700050
J	STEHBENS, WE				STEHBENS, WE			VALIDITY OF THE 4S SIMVASTATIN TRIAL	LANCET			English	Letter											STEHBENS, WE (corresponding author), WELLINGTON SCH MED, DEPT PATHOL, WELLINGTON 2, NEW ZEALAND.							BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; PEDERSEN TR, 1994, LANCET, V344, P1383; STEHBENS WE, 1966, AM J PATHOL, V48, P483; STEHBENS WE, 1993, LIPID HYPOTHESIS ATH; 1994, LANCET, V344, P1765	5	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 28	1995	345	8944					264	264		10.1016/S0140-6736(95)90261-9	http://dx.doi.org/10.1016/S0140-6736(95)90261-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7823749				2022-12-28	WOS:A1995QD53200064
J	GUR, RC; MOZLEY, LH; MOZLEY, PD; RESNICK, SM; KARP, JS; ALAVI, A; ARNOLD, SE; GUR, RE				GUR, RC; MOZLEY, LH; MOZLEY, PD; RESNICK, SM; KARP, JS; ALAVI, A; ARNOLD, SE; GUR, RE			SEX-DIFFERENCES IN REGIONAL CEREBRAL GLUCOSE-METABOLISM DURING A RESTING STATE	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; BLOOD-FLOW; CORPUS-CALLOSUM; BRAIN-FUNCTION; ASYMMETRIES; VOLUME; PET; HANDEDNESS; SCHIZOPHRENIA; DEOXYGLUCOSE	Positron emission tomography was used to evaluate the regional distribution of cerebral glucose metabolism in 61 healthy adults at rest. Although the profile of metabolic activity was similar for men and women, some sex differences and hemispheric asymmetries were detectable. Men had relatively higher metabolism than women in temporal-limbic regions and cerebellum and relatively lower metabolism in cingulate regions. In both sexes, metabolism was relatively higher in left association cortices and the cingulate region and in right ventro-temporal limbic regions and their projections. These results are consistent with the hypothesis that differences in cognitive and emotional processing have biological substrates.	UNIV PENN, SCH MED, CTR FUNCT & METAB IMAGING, DEPT RADIOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania	GUR, RC (corresponding author), UNIV PENN, SCH MED, DEPT PSYCHIAT, BRAIN BEHAV LAB, NEUROPSYCHIAT SECT, PHILADELPHIA, PA 19104 USA.		Arnold, Steven E/J-7546-2012; Gur, Ruben/K-1999-2019	Gur, Ruben/0000-0002-9657-1996	NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH042191, R01MH042191, P30MH043880, P30MH048539, P50MH043880] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLEN LS, 1990, J COMP NEUROL, V302, P697, DOI 10.1002/cne.903020402; ALLEN LS, 1989, J NEUROSCI, V9, P497; BARTLETT EJ, 1991, PSYCHIAT RES-NEUROIM, V40, P11, DOI 10.1016/0925-4927(91)90025-L; BERREBI AS, 1988, BRAIN RES, V438, P216, DOI 10.1016/0006-8993(88)91340-6; Bryden MP, 1983, NEUROPSYCHOLOGY HUMA, P6; Campbell Anne., 1993, MEN WOMEN AGGRESSION; Damasio A. R., 1983, NEUROPSYCHOLOGY HUMA, P85; DENNO DW, 1994, J CRIM LAW CRIM, V85, P80, DOI 10.2307/1144115; Downer CLJ., 1962, INTERHEMISPHERIC REL, P87; GAZZANIG.MS, 1965, BRAIN, V88, P221, DOI 10.1093/brain/88.2.221; GESCHWIN.N, 1965, BRAIN, V88, P237, DOI 10.1093/brain/88.2.237; GESCHWIND N, 1968, SCIENCE, V161, P186, DOI 10.1126/science.161.3837.186; GOUCHIE C, 1991, PSYCHONEUROENDOCRINO, V16, P323, DOI 10.1016/0306-4530(91)90018-O; GUR RC, 1982, SCIENCE, V217, P659, DOI 10.1126/science.217.4560.657; GUR RE, 1987, ARCH GEN PSYCHIAT, V44, P126; KARP JS, 1990, J NUCL MED, V31, P617; KARP JS, 1991, J CEREBR BLOOD F MET, V11, pA38, DOI 10.1038/jcbfm.1991.35; KENNEDY C, 1982, ANN NEUROL, V12, P333, DOI 10.1002/ana.410120404; KERTESZ A, 1990, BRAIN RES, V530, P40, DOI 10.1016/0006-8993(90)90655-U; KUHL DE, 1982, J CEREBR BLOOD F MET, V2, P163, DOI 10.1038/jcbfm.1982.15; LEVY J, 1972, BRAIN, V95, P61, DOI 10.1093/brain/95.1.61; Maccoby E.E., 1974, PSYCHOL SEX DIFFEREN; MESULAM MM, 1985, PRINCIPLES BEHAVIORA; MIURA SA, 1990, J NEUROSCI RES, V27, P500, DOI 10.1002/jnr.490270410; NATALE M, 1983, NEUROPSYCHOLOGIA, V21, P555, DOI 10.1016/0028-3932(83)90011-8; Papez JW, 1937, ARCH NEURO PSYCHIATR, V38, P725, DOI 10.1001/archneurpsyc.1937.02260220069003; PERLMUTTER JS, 1987, J CEREBR BLOOD F MET, V7, P64, DOI 10.1038/jcbfm.1987.9; PETERSON BS, 1993, MAGN RESON IMAGING, V11, P493, DOI 10.1016/0730-725X(93)90468-S; PHELPS ME, 1982, J CEREBR BLOOD F MET, V2, P113, DOI 10.1038/jcbfm.1982.14; REIVICH M, 1985, J CEREBR BLOOD F MET, V5, P179, DOI 10.1038/jcbfm.1985.24; RESNICK SM, 1993, J NUCL MED, V34, P2201; RISBERG J, 1986, NEUROPSYCHOLOGIA, V24, P135, DOI 10.1016/0028-3932(86)90047-3; SACKEIM HA, 1978, SCIENCE, V202, P434, DOI 10.1126/science.705335; SHTASEL DL, 1991, ARCH GEN PSYCHIAT, V48, P1022; Spielberger CD, 1970, MANUAL STATE TRAIT A; TUCKER DM, 1981, PSYCHOL BULL, V89, P19, DOI 10.1037/0033-2909.89.1.19; WITELSON SF, 1973, BRAIN, V96, P641, DOI 10.1093/brain/96.3.641; WITELSON SF, 1992, J COMP NEUROL, V323, P326, DOI 10.1002/cne.903230303; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; [No title captured]; [No title captured]; [No title captured]	42	301	306	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	1995	267	5197					528	531		10.1126/science.7824953	http://dx.doi.org/10.1126/science.7824953			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QD403	7824953				2022-12-28	WOS:A1995QD40300043
J	PHILLIPS, DM				PHILLIPS, DM			HUMAN-IMMUNODEFICIENCY-VIRUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											PHILLIPS, DM (corresponding author), POPULAT COUNCIL,1230 YORK AVE,NEW YORK,NY 10021, USA.								0	2	2	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	1995	332	4					233	233		10.1056/NEJM199501263320406	http://dx.doi.org/10.1056/NEJM199501263320406			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC270	7808490				2022-12-28	WOS:A1995QC27000006
J	MEYDANI, M				MEYDANI, M			VITAMIN-E	LANCET			English	Article							LOW-DENSITY-LIPOPROTEIN; CORONARY HEART-DISEASE; LIPID-PEROXIDATION; E SUPPLEMENTATION; DIETARY SUPPLEMENTATION; CARDIOVASCULAR-DISEASE; OXIDATIVE MODIFICATION; PLATELET-FUNCTION; ALPHA-TOCOPHEROL; E CONSUMPTION				MEYDANI, M (corresponding author), TUFTS UNIV,USDA,HUMAN NUTR RES CTR AGING,ANTIOXIDANT RES LAB,BOSTON,MA 02111, USA.							AXFORDGATELY RA, 1993, CAN J CARDIOL, V9, P94; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BARSACCHI R, 1992, INT J CARDIOL, V37, P339, DOI 10.1016/0167-5273(92)90264-4; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; BOXER LA, 1979, NEW ENGL J MED, V301, P901, DOI 10.1056/NEJM197910253011702; CHAVANCE M, 1993, FASEB J, V7, pA415; COGHLAN JG, 1993, J THORAC CARDIOV SUR, V106, P268; COLETTE C, 1988, AM J CLIN NUTR, V47, P256, DOI 10.1093/ajcn/47.2.256; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; GEY KF, 1993, BRIT MED BULL, V49, P679, DOI 10.1093/oxfordjournals.bmb.a072640; GREENBERG ER, 1994, NEW ENGL J MED, V331, P141, DOI 10.1056/NEJM199407213310301; HENSE HW, 1993, ATHEROSCLEROSIS, V103, P21, DOI 10.1016/0021-9150(93)90036-T; HORWITT MK, 1986, AM J CLIN NUTR, V44, P973, DOI 10.1093/ajcn/44.6.973; JIALAL I, 1992, J LIPID RES, V33, P899; KLEIJNEN J, 1989, EUR J CLIN PHARMACOL, V37, P541, DOI 10.1007/BF00562540; KLEINVELD HA, 1993, FREE RADIC BIOL MED, V15, P278; KNEKT P, 1994, AM J EPIDEMIOL, V139, P1180, DOI 10.1093/oxfordjournals.aje.a116964; KOK FJ, 1987, AM J CLIN NUTR, V45, P462, DOI 10.1093/ajcn/45.2.462; KOWDLEY KV, 1992, GASTROENTEROLOGY, V102, P1; MAGGI E, 1993, J HYPERTENS, V11, P1103, DOI 10.1097/00004872-199310000-00015; MAYNE ST, 1994, J NATL CANCER I, V86, P33, DOI 10.1093/jnci/86.1.33; MEYDANI M, 1993, FASEB J, V7, pA415; MEYDANI M, 1991, J NUTR, V121, P484, DOI 10.1093/jn/121.4.484; MEYDANI M, 1993, FREE RADICALS AGING, P184; MEYDANI M, 1992, NUTRITION ELDERLY BO, P103; MEYDANI SN, 1990, AM J CLIN NUTR, V52, P557, DOI 10.1093/ajcn/52.3.557; MEYDANI SN, 1993, J CLIN INVEST, V92, P105, DOI 10.1172/JCI116537; MEYDANI SN, 1994, FASEB J, V8, pA274; MEYDANI SN, 1992, P INT C NUTR IMM, P105; REAVEN PD, 1993, ARTERIOSCLER THROMB, V13, P590, DOI 10.1161/01.ATV.13.4.590; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; RIEMERSMA RA, 1990, EUR J CLIN NUTR, V44, P143; RIFICI VA, 1993, J AM COLL NUTR, V12, P631; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SALONEN JT, 1985, AM J CARDIOL, V56, P226, DOI 10.1016/0002-9149(85)90839-2; SHUTE WE, 1947, MED RES, V160, P191; SILBERT PL, 1990, CLIN EXP PHARMACOL P, V17, P645, DOI 10.1111/j.1440-1681.1990.tb01365.x; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEINER M, IN PRESS AM J CLIN N; TAYLOR PR, 1994, CANCER RES, V54, pS2029; TRABER MG, 1994, FREE RADICAL BIO MED, V16, P229, DOI 10.1016/0891-5849(94)90148-1; TRABER MG, 1993, VITAMIN E ITS USEFUL; VERLANGIERI AJ, 1992, J AM COLL NUTR, V11, P131; 1994, NEW ENGL J MED, V330, P1029	44	332	340	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					170	175		10.1016/S0140-6736(95)90172-8	http://dx.doi.org/10.1016/S0140-6736(95)90172-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7823675				2022-12-28	WOS:A1995QC55000015
J	LONGSTRETH, GF; FEITELBERG, SP				LONGSTRETH, GF; FEITELBERG, SP			OUTPATIENT CARE OF SELECTED PATIENTS WITH ACUTE NONVARICEAL UPPER GASTROINTESTINAL HEMORRHAGE	LANCET			English	Article								Patients with upper gastrointestinal haemorrhage (UGIH) are usually cared for in hospital. To evaluate the efficacy and safety of outpatient care of selected patients with acute non-variceal UGIH who had endoscopy, we retrospectively analysed 4.5 years' experience of patients treated without hospital admission. We developed practice guidelines for outpatient care, and prospectively studied patients treated during the first 6 months of their use. 78 (8.4%) of 933 patients in the retrospective series and 34 (24.1%) of 141 in the prospective series received outpatient care. The guidelines comprised early notification of a gastroenterologist, urgent endoscopy, clinical, laboratory, and endoscopic criteria for outpatient care, and details of care. In the prospective study patients treated as outpatients were younger than those admitted (52.8 [SE 3.6] vs 63.0 [1.5] years) and had a slightly longer time from onset of bleeding to endoscopy (2.4 [0.2] vs 2.1 [0.2] days). Outpatients were less likely to have alcoholism, other major concomitant disease, syncope or presyncope, or supine tachycardia. Outpatients had higher haemoglobin concentrations than inpatients (125 [4] vs 106 [3] g/L). Most patients in both groups had peptic ulcers. There were no complications in the retrospective series; 1 of the 34 prospective outpatients was admitted with rebleeding. All outpatients survived. The estimated hospital cost saved per outpatient was about $990. A substantial proportion of carefully selected patients with acute non-variceal UGIH can be effectively cared for without admission to hospital.			LONGSTRETH, GF (corresponding author), KAISER PERMANENTE MED CTR,DEPT MED,SAN DIEGO,CA 92120, USA.							CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; CUTLER JA, 1981, DIG DIS SCI S, V26, P90; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; FREEMAN ML, 1993, GASTROINTEST ENDOSC, V39, P359, DOI 10.1016/S0016-5107(93)70106-6; GILBERT DA, 1990, DIG DIS SCI S, V36, P8; GOSTOUT CJ, 1992, SEMIN GASTROINTEST D, V33, P53; GUPTA PK, 1993, MED CLIN N AM, V77, P973, DOI 10.1016/S0025-7125(16)30206-1; HARLAND R, 1992, J ROY SOC MED, V85, P26; JOHNSTON JH, 1990, GASTROINTEST ENDOS S, V36, P16; KURATA JH, 1988, J CLIN GASTROENTEROL, V10, P259, DOI 10.1097/00004836-198806000-00007; LAINE L, 1992, GASTROENTEROLOGY, V102, P314, DOI 10.1016/0016-5085(92)91816-M; LAINE L, 1989, ANN INTERN MED, V110, P510, DOI 10.7326/0003-4819-110-7-510; LICHTENSTEIN DR, 1992, GASTROINTESTINAL EME, P92; LONGSTRETH GF, 1994, J CLIN GASTROENTEROL, V19, P189, DOI 10.1097/00004836-199410000-00003; LONGSTRETH GF, 1986, J CLIN GASTROENTEROL, V8, P23, DOI 10.1097/00004836-198602000-00006; LONGSTRETH GF, IN PRESS AM J GASTRO; TERBLANCHE J, 1992, ANNU REV MED, V43, P69, DOI 10.1146/annurev.med.43.1.69; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706; 1989, JAMA-J AM MED ASSOC, V262, P1369	19	109	111	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					108	111		10.1016/S0140-6736(95)90068-3	http://dx.doi.org/10.1016/S0140-6736(95)90068-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815854				2022-12-28	WOS:A1995QB80400015
J	ORSCHESCHEK, K; MERZ, H; HELL, J; BINDER, T; BARTELS, H; FELLER, AC				ORSCHESCHEK, K; MERZ, H; HELL, J; BINDER, T; BARTELS, H; FELLER, AC			LARGE-CELL ANAPLASTIC LYMPHOMA-SPECIFIC TRANSLOCATION (T[2-5] [P23-Q35]) IN HODGKINS-DISEASE - INDICATION OF A COMMON PATHOGENESIS	LANCET			English	Article							KI-1 LYMPHOMA; RECEPTOR; EXPRESSION; 5Q35	Chromosomal aberrations are characteristic and specific events; the detection of chromosomal abnormalities often provides information on diagnosis and prognosis of disease. Some patients with large-cell anaplastic lymphoma (Ki 1 lymphoma) have the translocation t(2;5) (p23; q35), involving a possible growth-regulating tyrosine kinase. We found this translocation in 11 patients with Hodgkin's disease of nodular sclerosis and mixed-cellularity types. This finding has implications for the understanding of the relation between large-cell anaplastic lymphoma and Hodgkin's disease, diseases with morphological and immunophenotypical similarities. Study of this translocation may help understanding of the origins of cancer and cancer growth. It also allows a more precise definition of Hodgkin's disease and may be used as an indicator for clonality-which has long been sought.	UNIV LUBECK,DEPT PATHOL,D-23538 LUBECK,GERMANY; UNIV ULM,DEPT INTERNAL MED 3,W-7900 ULM,GERMANY; STADT KRANKENHAUS SUD,DEPT HEMATOL ONCOL,LUBECK,GERMANY	University of Lubeck; Ulm University			Feller, Alfred/E-3853-2010					ANAGNOSTOPOULOS I, 1989, BLOOD, V74, P810; BOEHM T, 1989, EUR J BIOCHEM, V185, P1, DOI 10.1111/j.1432-1033.1989.tb15074.x; FISCHER P, 1988, BLOOD, V72, P234; FONATSCH C, 1986, CANCER GENET CYTOGEN, V20, P39, DOI 10.1016/0165-4608(86)90106-8; JUCKER M, 1991, BLOOD, V77, P2413; KADIN ME, 1985, LANCET, V123, P864; LADANYI M, 1991, GENE CHROMOSOME CANC, V3, P294, DOI 10.1002/gcc.2870030408; Lennert K, 1992, HISTOPATHOLOGY NONHO; MACLENNAN KA, 1992, INT REV EXP PATHOL, V33, P27; MASON DY, 1990, BRIT J HAEMATOL, V74, P161; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MERZ H, 1991, BLOOD, V78, P1311; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; ORSCHESCHEK K, 1994, EUR J IMMUNOL, V24, P2682, DOI 10.1002/eji.1830241117; PEBUSQUE MJ, 1993, GENE CHROMOSOME CANC, V8, P119, DOI 10.1002/gcc.2870080209; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	17	100	100	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					87	90		10.1016/S0140-6736(95)90061-6	http://dx.doi.org/10.1016/S0140-6736(95)90061-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815887				2022-12-28	WOS:A1995QB80400008
J	FLIER, JS				FLIER, JS			THE ADIPOCYTE - STORAGE DEPOT OR NODE ON THE ENERGY INFORMATION SUPERHIGHWAY	CELL			English	Review							BROWN ADIPOSE-TISSUE; OBESITY; ADIPSIN; INVOLVEMENT; EXPRESSION; PROTEIN; MICE; FAT				FLIER, JS (corresponding author), BETH ISRAEL HOSP,DIV ENDOCRINOL,330 BROOKLINE AVE,BOSTON,MA 02215, USA.		Flier, jeffrey/AAG-6223-2019					BALDO A, 1993, J CLIN INVEST, V92, P1543, DOI 10.1172/JCI116733; BRAY GA, 1979, PHYSIOL REV, V51, P598; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; COOK KS, 1985, P NATL ACAD SCI USA, V82, P6480, DOI 10.1073/pnas.82.19.6480; FLIER JS, 1987, SCIENCE, V237, P405, DOI 10.1126/science.3299706; FREDERICH RC, 1992, HYPERTENSION, V19, P339, DOI 10.1161/01.HYP.19.4.339; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; HIMMSHAGEN J, 1989, PROG LIPID RES, V28, P67, DOI 10.1016/0163-7827(89)90009-X; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; KENNEDY GC, 1953, PROC R SOC SER B-BIO, V140, P578, DOI 10.1098/rspb.1953.0009; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MROSOVSKY N, 1986, PHYSIOL BEHAV, V38, P407, DOI 10.1016/0031-9384(86)90113-7; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; ROSEN BS, 1989, SCIENCE, V244, P1483, DOI 10.1126/science.2734615; SAMUELSSON L, 1991, EMBO J, V10, P3787, DOI 10.1002/j.1460-2075.1991.tb04948.x; TANAKA J, 1993, EXP NEUROL, V119, P235, DOI 10.1006/exnr.1993.1025; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; UMEK RM, 1991, SCIENCE, V151, P288; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	22	243	253	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					15	18		10.1016/0092-8674(95)90445-X	http://dx.doi.org/10.1016/0092-8674(95)90445-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813011	Bronze			2022-12-28	WOS:A1995QB91000004
J	KOVACSOVICSBANKOWSKI, M; ROCK, KL				KOVACSOVICSBANKOWSKI, M; ROCK, KL			A PHAGOSOME-TO-CYTOSOL PATHWAY FOR EXOGENOUS ANTIGENS PRESENTED ON MHC CLASS-I MOLECULES	SCIENCE			English	Article							TOXIC LYMPHOCYTES-T; CELLS; PROTEIN; EXPRESSION; GELONIN	Peptides from endogenous proteins are presented by major histocompatibility complex class I molecules, but antigens (Ags) in the extracellular fluids are generally not. However, pathogens or particulate Ags that are internalized into phagosomes of macrophages (MOs) stimulate CD8 T cells. The presentation of these Ags is resistant to chloroquine but is blocked by inhibitors of the proteasome, a mutation in the TAP1-TAP2 transporter, and brefeldin A. Moreover, phagocytosis of a ribosomal-inactivating protein inhibited MM protein synthesis. These results demonstrate that MOs transfer Ags from phagosomes into the cytosol and that endogenous and exogenous Ags use a final common pathway for class I presentation.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV LYMPHOCYTE BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NIAID NIH HHS [AI31337, AI20248] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020248, R01AI020248, R01AI031337] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACIK I, 1994, J IMMUNOL, V152, P381; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; CARTER VC, 1981, J IMMUNOL, V126, P1655; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; FURUNO K, 1986, BIOCHEM J, V237, P859, DOI 10.1042/bj2370859; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; KAUFMANN SHE, 1988, IMMUNOL TODAY, V9, P168, DOI 10.1016/0167-5699(88)91292-3; KNOP K, 1993, CURR OPIN CELL BIOL, V5, P990; KOVACSOVICSBANK.M, 1994, EUR J IMMUNOL, V24, P2421; KOVACSOVICSBANK.M, UNPUB; KOVACSOVICSBANKOWS, 1993, P NATL ACAD SCI USA, V90, P4942; LAMBERT JM, 1985, J BIOL CHEM, V260, P2035; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; ROCK KL, 1990, J IMMUNOL, V145, P804; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; STAERZ UD, 1987, NATURE, V329, P449, DOI 10.1038/329449a0; STIRPE F, 1980, J BIOL CHEM, V255, P6947; SZALAY G, 1994, EUR J IMMUNOL, V24, P1471, DOI 10.1002/eji.1830240703; Townsend A, 1993, Semin Cell Biol, V4, P53, DOI 10.1006/scel.1993.1007; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; WATSON J, 1979, J EXP MED, V150, P1510, DOI 10.1084/jem.150.6.1510; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5; ZIEGLER HK, 1982, P NATL ACAD SCI-BIOL, V79, P175, DOI 10.1073/pnas.79.1.175	27	714	728	0	25	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 13	1995	267	5195					243	246		10.1126/science.7809629	http://dx.doi.org/10.1126/science.7809629			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7809629				2022-12-28	WOS:A1995QB15300037
J	CAMPBELL, EJM; CAMPBELL, DME; ROBERTS, RS				CAMPBELL, EJM; CAMPBELL, DME; ROBERTS, RS			ABILITY TO DISTINGUISH WHISKEY (UISGE BEATHA) FROM BRANDY (COGNAC)	BRITISH MEDICAL JOURNAL			English	Article								Objective-To assess ability to distinguish between first rate malt whisky and brandy and between different brands of each. Design-Crossover with two sessions of 12 blind-fold tastings of two whiskies and two brandies before and after supper, repeated not more than seven days later. Setting-Dundas, Ontario. Participants-4 volunteers aged 50-68 years, all moderate drinkers of alcohol and members of a wine club. Main outcome measures-Proportion of samples correctly identified (whisky v brandy) and, of those, the proportion of brands correctly identified. Results-Only one participant produced irrefutable statistical evidence (P < 0.0001) of being able to distinguish between whisky and brandy, correctly identifying 50/51 (98%) samples. Two participants achieved some success in identification (72%, P = 0.0031 and 65% P = 0.031). The fourth participant's responses reflected pure guesswork. Brandy was no easier to identify than whisky (P = 0.84). The participant who was best able to distinguish between whisky and brandy was also best able to identify correctly the brand of whisky (100%, P < 0.0001). Conclusion-Despite the fact that not all participants completed the full number of tastings the results show that some participants could distinguish neither between malt whisky and brandy nor between different brands of whisky and brandy. However, the success of one participant shows that ''it can be done'' and that his whisky specific ability is acquired not innate.	MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON,ON,CANADA	McMaster University								CHADWICK SJD, 1993, BRIT MED J, V287, P1912; DAICHES D, 1969, SCOTCH WHISKY ITS PA	2	5	5	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1686	1688		10.1136/bmj.309.6970.1686	http://dx.doi.org/10.1136/bmj.309.6970.1686			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819986	Green Published			2022-12-28	WOS:A1994PY71700010
J	PORTER, R				PORTER, R			DR DOUBLEDOSE - A TASTE OF ONES OWN MEDICINE	BRITISH MEDICAL JOURNAL			English	Article											PORTER, R (corresponding author), WELLCOME INST HIST MED,LONDON NW1 2BE,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)			0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1714	1718		10.1136/bmj.309.6970.1714	http://dx.doi.org/10.1136/bmj.309.6970.1714			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819999	Green Published			2022-12-28	WOS:A1994PY71700029
J	ISACSSON, G; REDFORS, I; WASSERMAN, D; BERGMAN, U				ISACSSON, G; REDFORS, I; WASSERMAN, D; BERGMAN, U			CHOICE OF ANTIDEPRESSANTS - QUESTIONNAIRE SURVEY OF PSYCHIATRISTS AND GENERAL-PRACTITIONERS IN 2 AREAS OF SWEDEN	BRITISH MEDICAL JOURNAL			English	Article							SUICIDE	Objective-To identify factors that affect physicians' choice of specific antidepressant drugs in order to evaluate the validity of epidemiological studies of the risks (particularly suicide) and benefits of different compounds. Design-Questionnaire survey of 264 psychiatrists and general practitioners in an urban area and a rural area of Sweden with validation of data by independent prescription surveys. Setting-Urban area of greater Stockholm and rural county of Jamtland, Sweden. Subjects-228 physicians (86%) who answered the questionnaire. Main outcome measures-The drugs used as first line drugs of choice, as drugs of choice in particularly severe depression, and as drugs of choice for disorders other than depression. Results-Amitriptyline was the most common first line drug of choice among both psychiatrists and general practitioners. The patterns of choice of antidepressants in the two areas accorded with prescribing patterns in two independent prescription surveys. Amitriptyline was chosen even more frequently for severe depression and depression with severe insomnia. Clomipramine was chosen comparatively more often for depression with severe anxiety. Low toxicity compounds (mainly lofepramine, mianserin, and moclobemide) were more often the drug of choice in depression associated with overt risk of suicide. Amitriptyline and clomipramine were used extensively for disorders other than depression (40% and 54% of prescriptions, compared with 13-19% for some other major antidepressants). Conclusion-Patient groups treated with different antidepressant compounds may not be comparable with respect to diagnoses and severity of disease. In particular, lofepramine, mianserin, and moclobemide, and possibly amitriptyline, seem to be chosen more often for patients prone to suicide.	ORSA PRIMARY HLTH CARE CTR,ORSA,SWEDEN; KAROLINSKA HOSP,CTR SUICIDE RES & PREVENT,STOCKHOLM,SWEDEN; HUDDINGE UNIV HOSP,KAROLINSKA INST,DEPT MED LAB SCI & TECHNOL,DIV CLIN PHARMACOL,HUDDINGE,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	ISACSSON, G (corresponding author), HUDDINGE UNIV HOSP,KAROLINSKA INST,DEPT CLIN NEUROSCI & FAMILY MED,PSYCHIAT SECT,S-14186 HUDDINGE,SWEDEN.							AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; BARRACLOUGH BM, 1975, PSYCHOL MED, V5, P55, DOI 10.1017/S0033291700007212; GOODE H, 1994, BRIT MED J, V308, P915; Henry J A, 1992, Eur J Med, V1, P343; ISACSSON G, 1994, BRIT MED J, V308, P506, DOI 10.1136/bmj.308.6927.506; ISACSSON G, 1992, ACTA PSYCHIAT SCAND, V85, P444, DOI 10.1111/j.1600-0447.1992.tb03209.x; ISACSSON G, 1994, BRIT MED J, V308, P916; ISOMETSA E, 1994, BRIT MED J, V308, P915, DOI 10.1136/bmj.308.6933.915; ISOMETSA ET, 1994, AM J PSYCHIAT, V151, P530; KAPUR S, 1992, JAMA-J AM MED ASSOC, V268, P3441, DOI 10.1001/jama.268.24.3441; OHARE T, 1994, BRIT MED J, V308, P915; OWEN A, 1994, BRIT MED J, V308, P915; Siegel S., 1988, NONPARAMETRIC STAT B; Tomson G, 1990, Lakartidningen, V87, P1483; WESSLING A, 1991, EUR J CLIN PHARMACOL, V40, P495, DOI 10.1007/BF00315229	15	37	37	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 10	1994	309	6968					1546	1549		10.1136/bmj.309.6968.1546	http://dx.doi.org/10.1136/bmj.309.6968.1546			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PX564	7819894	Green Published			2022-12-28	WOS:A1994PX56400020
J	RECORD, CO				RECORD, CO			CONTROVERSIES IN MANAGEMENT - ERADICATION OF HELICOBACTER-PYLORI SHOULD BE PIVOTAL IN MANAGING PEPTIC-ULCERATION - HELICOBACTER-PYLORI IS NOT THE CAUSATIVE AGENT	BRITISH MEDICAL JOURNAL			English	Article							CAMPYLOBACTER				RECORD, CO (corresponding author), ROYAL VICTORIA INFIRM,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							CHIBA N, 1992, AM J GASTROENTEROL, V87, P1716; GOODWIN CS, 1992, HELICOBACTER PYLORI, P224; HOSKING S W, 1992, Gastroenterology, V102, pA85; HUNT RH, 1992, HELICOBACTER PYLORI, P187; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MEGRAUD F, 1992, HELICOBACTER PYLORI, P107; MORRIS A, 1987, AM J GASTROENTEROL, V82, P192; PORRO GB, 1988, LANCET, V1, P593; RAUWS EAJ, 1992, HELICOBACTER PYLORI, P232; REINBACH DH, 1993, GUT, V34, P1344, DOI 10.1136/gut.34.10.1344; SOBALA GM, 1992, HELICOBACTER PYLORI, P150; TYTGAT G, 1993, HELICOBACTER PYLORI, V8, P75; WYATT JI, 1992, HELICOBACTER PYLORI, P140	13	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 10	1994	309	6968					1571	1572		10.1136/bmj.309.6968.1571	http://dx.doi.org/10.1136/bmj.309.6968.1571			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX564	7819904	Green Published			2022-12-28	WOS:A1994PX56400030
J	KEENEY, RL				KEENEY, RL			DECISIONS ABOUT LIFE-THREATENING RISKS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MORTALITY				KEENEY, RL (corresponding author), UNIV SO CALIF,LOS ANGELES,CA 90089, USA.							BEAUCHAMP TS, 1982, PHILOS ETHICS; GRAHAM JD, 1992, RISK ANAL, V12, P333, DOI 10.1111/j.1539-6924.1992.tb00684.x; GRAHAM JD, 1986, RISK EVALUATION MANA, P503; KEENEY RL, 1984, RISK ANAL, V4, P117, DOI 10.1111/j.1539-6924.1984.tb00941.x; KEENEY RL, 1990, RISK ANAL, V10, P147, DOI 10.1111/j.1539-6924.1990.tb01029.x; Kitagawa EM, 1973, DIFFERENTIAL MORTALI; MACRAE J, 1992, COMMUNICATION   0310; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; PAUKER SG, 1987, NEW ENGL J MED, V316, P250, DOI 10.1056/NEJM198701293160505; WILDAVSKY A, 1980, PUBLIC INTEREST, V60, P23; Wildavsky AaronB., 1988, SEARCHING SAFETY	11	30	30	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 21	1994	331	3					193	196		10.1056/NEJM199407213310311	http://dx.doi.org/10.1056/NEJM199407213310311			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NW797	7794298				2022-12-28	WOS:A1994NW79700011
J	ASHWAL, S; CRANFORD, R; BERNAT, JL; CELESIA, G; COULTER, D; EISENBERG, H; MYER, E; PLUM, F; WALKER, M; WATTS, C; ROGSTAD, T				ASHWAL, S; CRANFORD, R; BERNAT, JL; CELESIA, G; COULTER, D; EISENBERG, H; MYER, E; PLUM, F; WALKER, M; WATTS, C; ROGSTAD, T			MEDICAL ASPECTS OF THE PERSISTENT VEGETATIVE STATE .1.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CEREBRAL BLOOD-FLOW; SOMATOSENSORY EVOKED-POTENTIALS; PROLONGED POSTTRAUMATIC UNAWARENESS; NON-TRAUMATIC COMA; HEAD-INJURY; CARDIAC-ARREST; BRAIN-DEATH; PROGNOSIS; PREDICTION; CHILDREN	This consensus statement of the Multi-Society Task Force summarizes current knowledge of the medical aspects of the persistent vegetative state in adults and children. The vegetative state is a clinical condition of complete unawareness of the self and the environment, accompanied by sleep-wake cycles, with either complete or partial preservation of hypothalamic and brain-stem autonomic functions. In addition, patients in a vegetative state show no evidence of sustained, reproducible, purposeful, or voluntary behavioral responses to visual, auditory, tactile, or noxious stimuli; show no evidence of language comprehension or expression; have bowel and bladder incontinence; and have variably preserved cranial-nerve and spinal reflexes. We define persistent vegetative state as a vegetative state present one month after acute traumatic or nontraumatic brain injury or lasting for at least one month in patients with degenerative or metabolic disorders or developmental malformations. The clinical course and outcome of a persistent vegetative state depend on its cause. Three categories of disorder can cause such a state: acute traumatic and non-traumatic brain injuries, degenerative and metabolic brain disorders, and severe congenital malformations of the nervous system. Recovery of consciousness from a posttraumatic persistent vegetative state is unlikely after 12 months in adults and children. Recovery from a nontraumatic persistent vegetative state after three months is exceedingly rare in both adults and children. Patients with degenerative or metabolic disorders or congenital malformations who remain in a persistent vegetative state for several months are unlikely to recover consciousness. The life span of adults and children in such a state is substantially reduced. For most such patients, life expectancy ranges from 2 to 5 years; survival beyond 10 years is unusual.	LOMA LINDA UNIV, SCH MED, LOMA LINDA, CA USA; AMER ACAD NEUROL, MINNEAPOLIS, MN USA; HENNEPIN CTY MED CTR, MINNEAPOLIS, MN USA; DARTMOUTH COLL SCH MED, HANOVER, NH USA; LOYOLA UNIV, STRITCH SCH MED, MAYWOOD, IL 60153 USA; BOSTON UNIV, SCH MED, BOSTON, MA 02118 USA; MARYLAND INST EMERGENCY MED SERV SYST, BALTIMORE, MD 21201 USA; VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA, RICHMOND, VA USA; AMER ACAD PEDIAT, EVANSTON, IL USA; CORNELL UNIV, NEW YORK HOSP, COLL MED, NEW YORK, NY USA; PRIMARY CHILDRENS HOSP & MED CTR, SALT LAKE CITY, UT USA; UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX USA	Loma Linda University; Hennepin County Medical Center; Dartmouth College; Loyola University Chicago; Boston University; Virginia Commonwealth University; American Academy of Pediatrics; Cornell University; NewYork-Presbyterian Hospital; University of Texas System; University of Texas Health San Antonio	ASHWAL, S (corresponding author), AMER ACAD NEUROL, MULTI SOC TASK FORCE PVS, 221 UNIV AVE SE, MINNEAPOLIS, MN 55414 USA.							ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; AGARDH CD, 1983, ANN NEUROL, V14, P482, DOI 10.1002/ana.410140414; AHMED I, 1988, CLIN ELECTROENCEPHAL, V19, P78, DOI 10.1177/155005948801900209; [Anonymous], 1989, NEUROLOGY, V39, P125; [Anonymous], 1987, PEDIATRICS, V80, P298; [Anonymous], 1993, ANN NEUROL, V33, P386; ASHWAL S, 1994, PEDIATR NEUROL, V10, P27, DOI 10.1016/0887-8994(94)90063-9; ASHWAL S, 1989, PEDIATRICS, V84, P429; ASHWAL S, 1989, ANN NEUROL, V25, P539, DOI 10.1002/ana.410250603; ASHWAL S, 1992, FETAL AND PERINATAL NEUROLOGY, P357; ASHWAL S, 1990, NEUROLOGY, V40, P820, DOI 10.1212/WNL.40.5.820; ASHWAL S, 1992, ANN NEUROL, V32, P570, DOI 10.1002/ana.410320414; AYLWARD GP, 1978, DEV MED CHILD NEUROL, V20, P211; BANJA JD, 1990, PHYS MED REHABIL, V4, P579; BATES D, 1991, J NEUROL NEUROSUR PS, V54, P569, DOI 10.1136/jnnp.54.7.569; Bernat J L, 1992, J Clin Ethics, V3, P176; BERNAT JL, 1991, CLIN NEUROLOGY, V1, P2; BOYD K, 1991, LANCET, V337, P96; BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; Brazelton T. B., 1973, CLIN DEV MED, V50; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; BRIERLEY JB, 1971, LANCET, V2, P560; BRUNKO E, 1987, ELECTROEN CLIN NEURO, V66, P15, DOI 10.1016/0013-4694(87)90133-7; CAMPBELL AGM, 1984, BMJ-BRIT MED J, V289, P1022, DOI 10.1136/bmj.289.6451.1022; CANTOR NL, 1989, AM J LAW MED, V15, P381; CELESIA GG, 1993, NEUROLOGY, V43, P1457, DOI 10.1212/WNL.43.8.1457; CHATRIAN E, 1990, CURRENT PRACTICE CLI, P463; Childs A, 1991, Brain Inj, V5, P73, DOI 10.3109/02699059108998515; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; COULTER DL, 1987, NEW ENGL J MED, V316, P840, DOI 10.1056/NEJM198704023161404; COULTER DL, 1991, ANN NEUROL, V30, P473; COULTER DL, 1990, MED ETHICS, V5, P13; Cranford R E, 1991, Law Med Health Care, V19, P13; CRANFORD RE, 1988, HASTINGS CENT REP, V18, P27, DOI 10.2307/3562014; CRANFORD RE, 1993, NEUROLOGY, V43, P222; DALLE OG, 1977, APALLIC SYNDROME; DANZE F, 1989, Neurosurgical Review, V12, P477, DOI 10.1007/BF01790694; DAROFF RB, 1990, 115TH ANN M AM NEUR; DEBEYL DZ, 1986, NEUROLOGY, V36, P134, DOI 10.1212/WNL.36.1.134-b; DEVOLDER AG, 1990, ARCH NEUROL-CHICAGO, V47, P197, DOI 10.1001/archneur.1990.00530020103022; DOUGHERTY JH, 1981, NEUROLOGY, V31, P991, DOI 10.1212/WNL.31.8.991; DYER C, 1992, BRIT MED J, V305, P853; FEINBERG WM, 1984, AM J DIS CHILD, V138, P128, DOI 10.1001/archpedi.1984.02140400014003; FENICHEL GM, 1990, NEONATAL NEUROLOGY, P225; FRANK LM, 1985, NEUROLOGY, V35, P931, DOI 10.1212/WNL.35.6.931; GILLIES JD, 1980, DEV MED CHILD NEUROL, V22, P642; Graham D I, 1983, Acta Neurochir Suppl (Wien), V32, P65; HANSOTIA PL, 1985, ARCH NEUROL-CHICAGO, V42, P1048, DOI 10.1001/archneur.1985.04060100030015; HELLEMA H, 1991, BRIT MED J, V302, P984; HIGASHI K, 1977, J NEUROL NEUROSUR PS, V40, P876, DOI 10.1136/jnnp.40.9.876; HIGASHI K, 1981, J NEUROL NEUROSUR PS, V44, P552, DOI 10.1136/jnnp.44.6.552; HOULDEN DA, 1990, NEUROSURGERY, V27, P701, DOI 10.1227/00006123-199011000-00006; HUME AL, 1979, ANN NEUROL, V5, P379, DOI 10.1002/ana.410050412; Ingvar D H, 1978, Ann N Y Acad Sci, V315, P184; INGVAR DH, 1973, ACTA NEUROL SCAND, V49, P233; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1991, BMJ-BRIT MED J, V302, P1256, DOI 10.1136/bmj.302.6787.1256; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1991, CURR ANAESTH CRIT CA, V2, P57; JONES DG, 1989, J MED ETHICS, V15, P173, DOI 10.1136/jme.15.4.173; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; KINNEY HC, 1994, NEW ENGL J MED, V330, P1469, DOI 10.1056/NEJM199405263302101; KNOBLOCH H, 1980, GESELL AMATRUDAS MAN; KOREIN J, 1990, TRANSPLANT P, V22, P982; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; Levy D E, 1978, Ann N Y Acad Sci, V315, P293, DOI 10.1111/j.1749-6632.1978.tb50347.x; LEVY DE, 1981, ANN INTERN MED, V94, P293, DOI 10.7326/0003-4819-94-3-293; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; LEVY DE, 1987, ANN NEUROL, V22, P673, DOI 10.1002/ana.410220602; LINDSAY K, 1990, NEUROSURGERY, V26, P278, DOI 10.1227/00006123-199002000-00015; LYNN J, 1981, JAMA-J AM MED ASSOC, V246, P2184; MCCLELLAN DR, 1986, COMA TRAMATIQUE, P165; Minderhoud J M, 1985, Ned Tijdschr Geneeskd, V129, P2385; Mizrahi E M, 1985, Pediatr Neurol, V1, P302, DOI 10.1016/0887-8994(85)90033-5; Momose T, 1989, Radiat Med, V7, P243; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUTOH K, 1987, BRAIN DEV-JPN, V9, P605, DOI 10.1016/S0387-7604(87)80094-3; ODER W, 1991, INTENS CARE MED, V17, P149, DOI 10.1007/BF01704718; OKSENBERG A, 1989, SLEEP 88, P286; Plum F, 1980, DIAGNOSIS STUPOR COM, Vthird; Rappaport M, 1991, J Neuropsychiatry Clin Neurosci, V3, P180; RELKIN NR, 1990, ANN NEUROL, V28, P221; Sato S, 1979, Neurol Med Chir (Tokyo), V19, P327, DOI 10.2176/nmc.19.327; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; SAZBON L, 1991, J NEUROL NEUROSUR PS, V54, P149, DOI 10.1136/jnnp.54.2.149; SAZBON L, 1992, Brain Injury, V6, P359, DOI 10.3109/02699059209034950; SAZBON L, 1993, J NEUROL NEUROSUR PS, V56, P407, DOI 10.1136/jnnp.56.4.407; SHALIT MN, 1972, NEUROLOGY, V22, P155, DOI 10.1212/WNL.22.2.155; SHEWMON DA, 1989, NEUROL CLIN, V7, P823, DOI 10.1016/S0733-8619(18)30392-X; Shewmon DA., 1990, BRAIN DEV-JPN, V12, P664; SHUTTLEWORTH E, 1983, NEUROLOGY, V33, P372, DOI 10.1212/WNL.33.3.372; SMITH SA, 1989, PEDIATR NEUROL, V1, P149; SONNET ML, 1990, PRESSE MED, V19, P166; SPUDIS EV, 1991, J NEUROL SCI, V102, P128, DOI 10.1016/0022-510X(91)90060-K; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; STUMPF DA, 1990, NEW ENGL J MED, V322, P669; Tasseau F, 1991, ETATS VEGETATIFS CHR; TRESCH DD, 1991, ARCH INTERN MED, V151, P930, DOI 10.1001/archinte.151.5.930; TSAO CY, 1991, CLIN ELECTROENCEPHAL, V22, P141, DOI 10.1177/155005949102200304; TSUBOKAWA T, 1990, Brain Injury, V4, P329, DOI 10.3109/02699059009026186; WALSHE TM, 1985, ARCH NEUROL-CHICAGO, V42, P1045, DOI 10.1001/archneur.1985.04060100027014; WHITE L E, 1985, Neurology, V35, P199; [No title captured]; [No title captured]; 1983, DECIDING FOREGO LIFE, P171; 1990, JAMA-J AM MED ASSOC, V263, P426	108	967	989	3	59	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 26	1994	330	21					1499	1508						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM068	7818633				2022-12-28	WOS:A1994NM06800007
J	COHEN, J				COHEN, J			RESEARCH MATERIALS - SHARE AND SHARE ALIKE ISNT ALWAYS THE RULE IN SCIENCE	SCIENCE			English	Article																			0	29	29	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1715	1718		10.1126/science.7792594	http://dx.doi.org/10.1126/science.7792594			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792594				2022-12-28	WOS:A1995RE66800030
J	KEYNES, M				KEYNES, M			CREATIVITY AND PSYCHOPATHOLOGY	LANCET			English	Editorial Material																		ANDREASON EW, 1987, AM J PSYCHIAT, V224, P67; Becker Georg, 1978, MAD GENIUS CONTROVER; BRAIN WR, 1964, DOCTORS PAST PRESENT; EYSNECK HJ, 1983, ROEPER REV       MAY, P10; Galton F., 1983, INQUIRY HUMAN FACULT; GALTON F, 1892, HEREDITARY GENIUS, P23; HARE E, 1987, BMJ-BRIT MED J, V295, P1587, DOI 10.1136/bmj.295.6613.1587; Jamison K. R., 1993, TOUCHED FIRE MANIC D, DOI [10.4135/9781483349985.n388, DOI 10.4135/9781483349985.N388]; JAMISON KR, 1989, PSYCHIATRY, V32, P125; JUDA A, 1949, AM J PSYCHIAT, V106, P296, DOI 10.1176/ajp.106.4.296; JUDA A, 1953, ERBVERHAELTNISSE SOW; KESSEL N, 1989, GENIUS HIST IDEA; MAUDSLEY H, 1867, PATHOLOGY MIND, P297; POST F, 1994, BRIT J PSYCHIAT, V165, P22, DOI 10.1192/bjp.165.1.22; SLATER E, 1959, CONFIN PSYCHIAT, V2, P65; SLATER E, 1970, ACTA PSYCHIATRICA S, V219, P209	16	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					138	139		10.1016/S0140-6736(95)90159-0	http://dx.doi.org/10.1016/S0140-6736(95)90159-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QC550	7823663				2022-12-28	WOS:A1995QC55000002
J	BULLITT, E; MAKOWSKI, L				BULLITT, E; MAKOWSKI, L			STRUCTURAL POLYMORPHISM OF BACTERIAL ADHESION PILI	NATURE			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; SUBUNIT; IMAGES; PROTEINS; FLAGELLA; TIP	BACTERIAL adhesion pill are designed to bind specifically and maintain attachment of bacteria to target cells. Uropathogenic P-pili are sufficiently mechanically resilient to resist the cleansing action of urine flow that removes most other bacteria(1). P-pili are 68 Angstrom in diameter and similar to 1 mu m long(2), and are composed of similar to 1,000 copies of the principal structural protein, PapA(3). They are attached to the outer membrane by a minor structural protein, PapH(4) and are terminated by an similar to 20 Angstrom diameter fibrillus composed of PapK, PapE and PapF, which presents the host-binding adhesin PapG(5-7). The amino-acid sequences of PapA(3,8), PapE(9), and PapF(9) are similar, with highly conserved C-termini being responsible for binding to PapD(10-12), the periplasmic chaperone. Our three-dimensional reconstruction indicates that pill are formed by the tight winding of a much thinner structure. A structural transition allows the pilus to unravel without depolymerizing, producing a thin, extended structure five times the length of the original pilus.	FLORIDA STATE UNIV, INST MOLEC BIOPHYS, TALLAHASSEE, FL 32306 USA	State University System of Florida; Florida State University	BULLITT, E (corresponding author), BOSTON UNIV, SCH MED, DEPT BIOPHYS, BOSTON, MA 02118 USA.							AMOS LA, 1975, J MOL BIOL, V99, P51, DOI 10.1016/S0022-2836(75)80158-6; BAGA M, 1987, CELL, V49, P241, DOI 10.1016/0092-8674(87)90565-4; BAGA M, 1984, J BACTERIOL, V157, P330; BRINTON CC, 1965, T NEW YORK ACAD SCI, V27, P1003, DOI 10.1111/j.2164-0947.1965.tb02342.x; CALLADINE CR, 1978, J MOL BIOL, V118, P457, DOI 10.1016/0022-2836(78)90285-1; DENICH K, 1991, INFECT IMMUN, V59, P3849, DOI 10.1128/IAI.59.11.3849-3858.1991; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; EGELMAN EH, 1986, ULTRAMICROSCOPY, V19, P367, DOI 10.1016/0304-3991(86)90096-3; GONG MF, 1992, J MOL BIOL, V228, P735, DOI 10.1016/0022-2836(92)90860-M; HULTGREN SJ, 1991, ANNU REV MICROBIOL, V45, P383, DOI 10.1146/annurev.micro.45.1.383; HULTGREN SJ, 1993, ADV PROTEIN CHEM, V44, P99, DOI 10.1016/S0065-3233(08)60565-3; JACOBDUBUISSON F, 1993, EMBO J, V12, P837, DOI 10.1002/j.1460-2075.1993.tb05724.x; KAMIYA R, 1976, J MOL BIOL, V106, P167, DOI 10.1016/0022-2836(76)90306-5; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; KUEHN MJ, 1991, P NATL ACAD SCI USA, V88, P10586, DOI 10.1073/pnas.88.23.10586; LINDBERG F, 1987, NATURE, V328, P84, DOI 10.1038/328084a0; LINDBERG F, 1986, P NATL ACAD SCI USA, V83, P1891, DOI 10.1073/pnas.83.6.1891; MACNAB RM, 1977, J MOL BIOL, V112, P1, DOI 10.1016/S0022-2836(77)80153-8; MAKOWSKI L, 1992, J MOL BIOL, V228, P885, DOI 10.1016/0022-2836(92)90872-H; MARKLUND BI, 1992, J BACTERIOL, V157, P330; MORGAN DG, 1992, ULTRAMICROSCOPY, V46, P263, DOI 10.1016/0304-3991(92)90019-G; ORSKOV I, 1980, INFECT IMMUN, V27, P657, DOI 10.1128/IAI.27.2.657-666.1980; OWEN C, 1993, J CELL BIOL, V123, P337, DOI 10.1083/jcb.123.2.337; SLONIM LN, 1992, EMBO J, V11, P4747, DOI 10.1002/j.1460-2075.1992.tb05580.x	24	180	195	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 12	1995	373	6510					164	167		10.1038/373164a0	http://dx.doi.org/10.1038/373164a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7816100				2022-12-28	WOS:A1995QB06300063
J	BAERHEIM, A; SANDVIK, H				BAERHEIM, A; SANDVIK, H			EFFECT OF ALE, GARLIC, AND SOURED CREAM ON THE APPETITE OF LEECHES	BRITISH MEDICAL JOURNAL			English	Article											BAERHEIM, A (corresponding author), UNIV BERGEN,DIV GEN PRACTICE,ULRIKSDAL 8C,N-5009 BERGEN,NORWAY.							JOSEPH PK, 1989, INDIAN J EXP BIOL, V27, P997; Laerum O D, 1991, Tidsskr Nor Laegeforen, V111, P924; LENT CM, 1988, SCI AM, V258, P98, DOI 10.1038/scientificamerican0688-98; SANDVIK H, IN PRESS TIDSSKR NOR; 1828, EYR, V3, P57	5	8	8	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1689	1689		10.1136/bmj.309.6970.1689	http://dx.doi.org/10.1136/bmj.309.6970.1689			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819987	Green Published			2022-12-28	WOS:A1994PY71700012
J	CURRIE, PF; JACOB, AJ; FOREMAN, AR; ELTON, RA; BRETTLE, RP; BOON, NA				CURRIE, PF; JACOB, AJ; FOREMAN, AR; ELTON, RA; BRETTLE, RP; BOON, NA			HEART-MUSCLE DISEASE-RELATED TO HIV-INFECTION - PROGNOSTIC IMPLICATIONS	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HOMOSEXUAL MEN; AIDS; RISK; DYSFUNCTION	Objectives-To determine the natural course of heart muscle disease in patients infected with HIV. Design-Prospective echocardiographic survey and observational study over four years. Setting-Edinburgh. Subjects-296 adults infected with HIV (mean age 32.7 years (range 21.5 to 67.6) drawn from all the major groups at risk of HIV infection in Britain. Main outcome measures-Detection of myocardial dysfunction and time to death from index echocardiogram in serial echocardiography. Results-Cardiac dysfunction was identified in 44 subjects (dilated cardiomyopathy, 13; isolated right ventricular dysfunction, 12; borderline left ventricular dysfunction, 19). Dilated cardiomyopathy was strongly associated with a CD4 cell count of < 100x10(6)/1, in contrast with the other forms of cardiac dysfunction. During the study 12/13 (92%) subjects with dilated cardiomyopathy, 5/12 (42%) with right ventricular dysfunction, and 8/19 (42%) with borderline left ventricular function died of conditions related to AIDS. Survival was significantly reduced in the subjects with dilated cardiomyopathy compared with those with normal hearts (P < 0.001). The median survival from the index echocardiogram was 101 days (95% confidence interval 42 to 146) for the subjects with cardiomyopathy compared with 472 days (383 to 560) for those with normal hearts and a CD4 cell count of < 20x10(6)/1. No significant difference existed in survival for subjects with borderline left or isolated right ventricular dysfunction. Conclusion-Even after adjustment for the significantly reduced CD4 cell count with which dilated cardiomyopathy is associated, the outlook for patients with HIV infection and dilated cardiomyopathy is poor. Isolated right and borderline left ventricular dysfunction are not associated with reduced CD4 cells counts and do not carry adverse prognostic implications.	CITY HOSP EDINBURGH,REG INFECT DIS UNIT,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,MED STAT UNIT,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	University of Edinburgh	CURRIE, PF (corresponding author), ROYAL INFIRM,DEPT CARDIOL,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND.							ACIERNO LJ, 1989, J AM COLL CARDIOL, V13, P1144, DOI 10.1016/0735-1097(89)90277-5; ANDERSON DW, 1992, PATHOLOGY AIDS OTHER; CURRIE PF, 1993, Q J MED, V86, P751; DEWOLF F, 1988, J INFECT DIS, V158, P615, DOI 10.1093/infdis/158.3.615; GOEDERT JJ, 1987, JAMA-J AM MED ASSOC, V257, P331, DOI 10.1001/jama.257.3.331; GREENSPAN D, 1987, J INFECT DIS, V155, P475, DOI 10.1093/infdis/155.3.475; HERSKOWITZ A, 1994, J AM COLL CARDIOL, V24, P1025, DOI 10.1016/0735-1097(94)90865-6; HIMELMAN RB, 1989, J AM COLL CARDIOL, V13, P1030, DOI 10.1016/0735-1097(89)90256-8; HIMELMAN RB, 1989, AM J CARDIOL, V64, P1396, DOI 10.1016/0002-9149(89)90594-8; JACOB AJ, 1992, BRIT HEART J, V68, P549, DOI 10.1136/hrt.68.12.549; KINNEY EL, 1989, ANGIOLOGY, V40, P970, DOI 10.1177/000331978904001106; KLEIN RS, 1984, NEW ENGL J MED, V311, P354, DOI 10.1056/NEJM198408093110602; MELBYE M, 1987, LANCET, V1, P728; MONSUEZ JJ, 1988, AM J CARDIOL, V62, P1311, DOI 10.1016/0002-9149(88)90286-X; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; PETERS BS, 1991, BRIT MED J, V302, P203, DOI 10.1136/bmj.302.6770.203; PHILLIPS AN, 1991, LANCET, V337, P389; WILLOUGHBY SB, 1993, AM J CARDIOL, V71, P446, DOI 10.1016/0002-9149(93)90451-H; 1994, LANCET, V343, P871; 1986, MMWR-MORBID MORTAL W, V35, P334	20	100	102	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1605	1607		10.1136/bmj.309.6969.1605	http://dx.doi.org/10.1136/bmj.309.6969.1605			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819934	Green Published			2022-12-28	WOS:A1994PY22000014
J	MASON, PD; PUSEY, CD				MASON, PD; PUSEY, CD			GLOMERULONEPHRITIS - DIAGNOSIS AND TREATMENT	BRITISH MEDICAL JOURNAL			English	Review							IDIOPATHIC MEMBRANOUS NEPHROPATHY; DEPENDENT NEPHROTIC SYNDROME; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; UNTREATED PATIENTS; CONTROLLED TRIAL; METHYLPREDNISOLONE; CYCLOPHOSPHAMIDE; CHLORAMBUCIL; PREDNISONE; CHILDREN				MASON, PD (corresponding author), HAMMERSMITH HOSP,DEPT MED,RENAL UNIT,LONDON W12 0NN,ENGLAND.							AUSTIN HA, 1986, NEW ENGL J MED, V314, P614, DOI 10.1056/NEJM198603063141004; BERNARD DB, 1988, KIDNEY INT, V33, P1184, DOI 10.1038/ki.1988.129; DAMICO G, 1992, AM J KIDNEY DIS, V20, P315, DOI 10.1016/S0272-6386(12)70293-7; DONADIO JV, 1989, AM J KIDNEY DIS, V14, P445, DOI 10.1016/S0272-6386(89)80143-X; DONADIO JV, 1988, KIDNEY INT, V33, P708, DOI 10.1038/ki.1988.56; FOUQUE D, 1992, BMJ-BRIT MED J, V304, P216, DOI 10.1136/bmj.304.6821.216; GASKIN G, 1992, OXFORD TXB CLIN NEPH, V1, P612; GLASSOCK RJ, 1991, KIDNEY, P1280; KLAHR S, 1991, LANCET, V338, P423, DOI 10.1016/0140-6736(91)91043-T; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; MADIO MP, 1990, KIDNEY INT, V38, P529; MELOCOTON TL, 1991, AM J KIDNEY DIS, V18, P583, DOI 10.1016/S0272-6386(12)80654-8; MUSTONEN J, 1983, CLIN NEPHROL, V20, P172; NIAUDET D, 1991, CLIN NEPHROL, V35, P831; NOLASCO F, 1986, KIDNEY INT, V29, P1215, DOI 10.1038/ki.1986.130; PEI Y, 1987, AM J MED, V82, P938, DOI 10.1016/0002-9343(87)90155-0; PONTICELLI C, 1989, NEW ENGL J MED, V320, P8, DOI 10.1056/NEJM198901053200102; PONTICELLI C, 1984, NEW ENGL J MED, V310, P946, DOI 10.1056/NEJM198404123101503; REES AJ, 1992, OXFORD TXB CLIN NEPH, V1, P318; SCHENA FP, 1988, AM J MED, V85, P315, DOI 10.1016/0002-9343(88)90580-3; SCHENA FP, 1990, NEPHROL DIAL TRANS S, V1, P47; SCHIEPPATI A, 1993, NEW ENGL J MED, V329, P85, DOI 10.1056/NEJM199307083290203; SIEGEL NJ, 1981, KIDNEY INT, V19, P454, DOI 10.1038/ki.1981.39; TARSHISH P, 1992, PEDIATR NEPHROL, V6, P123, DOI 10.1007/BF00866289; TEJANI A, 1990, NEPHRON, V55, P1, DOI 10.1159/000185909; TROMPETER RS, 1986, ARCH DIS CHILD, V61, P727, DOI 10.1136/adc.61.8.727; TURNER AN, 1992, OXFORD TXB CLIN NEPH, V1, P438; WILLIAMS DG, 1987, OXFORD TXB MED, V18, P36; 1988, LANCET, V1, P380; 1987, ARCH DIS CHILD, V62, P1102	30	26	27	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 10	1994	309	6968					1557	1563		10.1136/bmj.309.6968.1557	http://dx.doi.org/10.1136/bmj.309.6968.1557			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX564	7819900	Green Published			2022-12-28	WOS:A1994PX56400026
J	ALLISON, SP				ALLISON, SP			CONTROVERSIES IN MANAGEMENT - IS ROUTINE COMPUTED-TOMOGRAPHY IN STROKES UNNECESSARY - COSTS OUTWEIGH BENEFITS	BRITISH MEDICAL JOURNAL			English	Article											ALLISON, SP (corresponding author), UNIV NOTTINGHAM HOSP,NOTTINGHAM NG7 2UH,ENGLAND.							BROWN M, 1992, MED INT, V99, P4158; Ebrahim S., 1990, CLIN EPIDEMIOLOGY ST; LANGHORNE P, 1993, LANCET, V342, P395, DOI 10.1016/0140-6736(93)92813-9; PESSIN MS, 1993, NEUROLOGY, V43, P1298, DOI 10.1212/WNL.43.7.1298; SOTANIEMI KA, 1990, STROKE, V21, P1562, DOI 10.1161/01.STR.21.11.1562; 1991, CIRCULATION, V84, P527; 1988, TREATMENT STROKE KIN; 1990, STROKE BETTER MANAGE	8	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 3	1994	309	6967					1499	1500		10.1136/bmj.309.6967.1499	http://dx.doi.org/10.1136/bmj.309.6967.1499			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW053	7804061	Green Published			2022-12-28	WOS:A1994PW05300035
J	MACKENBACH, JP				MACKENBACH, JP			SOCIOECONOMIC INEQUALITIES HEALTH IN THE NETHERLANDS - IMPACT OF A 5-YEAR RESEARCH-PROGRAM	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY	The attention paid to the socioeconomic inequalities in health in the Netherlands has increased greatly in recent years. A national research programme was started in 1989, and among other things, this has increased the yearly number of publications on socioeconomic inequalities in health by about 25%. The programme has increased-awareness of inequalities among researchers and policy makers: as well as improved the information available on health inequalities and the reasons,for them. Cross party-agreement on the need to reduce these inequalities has led to a consensus based approach which contrasts with the heavily politicised debate in countries such as the United Kingdom.			MACKENBACH, JP (corresponding author), ERASMUS UNIV ROTTERDAM,DEPT PUBL HLTH,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.							APPELS A, 1990, TIJDSCHR SOC GEZONDH, V68, P298; BLOEMHOFF A, 1990, INVLOED SOCIAAL EC S; BOSHUIZEN HC, 1994, TIJDSCHR SOC GEZONDH, V72, P122; DEJONG GA, 1980, TIJDSCH SOC GEZOND S, V58; DOORNBOS G, 1990, INT J EPIDEMIOL, V19, P374, DOI 10.1093/ije/19.2.374; DUIJKERS TJ, 1989, INT J EPIDEMIOL, V18, P658, DOI 10.1093/ije/18.3.658; GUNNINGSCHEPERS LJ, 1989, HLTH PROMOTION, V4, P149; HODIAMONT P, 1986, ZOEKEN NAAR ZIEKE ZI; HOEYMANS N, 1993, SOCIAAL EC STATUS LE; JOOSTEN J, 1992, SOCIAAL EC GEZONDHEI; KUNST AE, 1994, INT J EPIDEMIOL, V23, P742, DOI 10.1093/ije/23.4.742; KUNST AE, 1994, AM J PUBLIC HEALTH, V84, P932, DOI 10.2105/AJPH.84.6.932; KUNST AE, 1990, SOC SCI MED, V31, P141, DOI 10.1016/0277-9536(90)90055-W; KUNST AE, 1990, SOCIALE ONGELIJKHEID; KUNST AE, 1992, INT VARIATION SOCIOE; LAUIJZERMAN A, 1980, VERGELIJKEND BUURTON; MACKENBACH JP, 1994, SOC SCI MED, V38, P299, DOI 10.1016/0277-9536(94)90399-9; MACKENBACH JP, 1992, SOC SCI MED, V34, P213, DOI 10.1016/0277-9536(92)90264-Q; MACKENBACH JP, 1987, WRR VOORSTUDIES, V58, P59; MACKENBACH JP, 1994, ONGEZONDE VERSCHILLE; Mares N E, 1988, Ned Tijdschr Geneeskd, V132, P1109; OOYENDIJK WTM, 1991, SOCIAAL EC STATUS GE; POPPING R, 1993, REGISTRATIE BEROEP O; RANCHOR AV, 1993, SOCIAAL EC STATUS MY; RANCHOR AV, 1990, REEKS SOCIAAL EC GEZ, V7; ROSE G, 1981, BRIT HEART J, V18, P663; SCHALKVANDERWEI.Y, 1993, SOCIAAL EC STATUS MO; Schrijvers Carola T. M., 1994, American Journal of Epidemiology, V139, P408; SCHRIJVERS CTM, 1994, REEKS SOCIAAL EC GEZ, V14; SCHROER CAP, 1990, GEZONDHEIDSVERSCHILL; Townsend P., 1988, INEQUALITIES HLTH; VANBERKELVANSCH.AB, 1990, 6 REEKS SOC EC GEZ; VANDERLUCHT F, 1993, SOCIAAL EC STATUS GE; VANDERMEER JWB, 1993, SOCIAAL EC VERSCHILL; VANLOON AJM, 1993, SOCIAAL EC STATUS KA; WADSWORTH MEJ, 1986, CLASS HLTH RES LONGI; [No title captured]; 1994, 16 REEKS SOC EC GEZ; 1985, TARGETS HLTH ALL; 1994, BELEIDSPLAN MEERJARE; 1985, NOTA 2000 ONTWIKKELI; 1991, VOORSTUDIES ACHTERGR, V72; 1992, NETHERLANDS HLTH INT	43	62	62	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 3	1994	309	6967					1487	1491		10.1136/bmj.309.6967.1487	http://dx.doi.org/10.1136/bmj.309.6967.1487			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PW053	7804057	Green Published			2022-12-28	WOS:A1994PW05300029
J	MARTEAU, T				MARTEAU, T			SCREENING FOR CARRIERS OF CYSTIC-FIBROSIS - PSYCHOLOGICAL CONSEQUENCES ARE UNCLEAR	BRITISH MEDICAL JOURNAL			English	Article							EARLY-PREGNANCY				MARTEAU, T (corresponding author), UNITED MED & DENT SCH,PSYCHOL & GENET RES GRP,LONDON SE1 9RT,ENGLAND.			Marteau, Theresa/0000-0003-3025-1129	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEKKER H, 1993, BRIT MED J, V306, P1584, DOI 10.1136/bmj.306.6892.1584; BRITTON J, 1991, LANCET, V338, P1524, DOI 10.1016/0140-6736(91)92341-X; ELBORN JS, 1991, THORAX, V46, P881, DOI 10.1136/thx.46.12.881; HARRIS H, 1993, BRIT MED J, V306, P1580, DOI 10.1136/bmj.306.6892.1580; Holland WW, 1990, SCREENING HLTH CARE; ILES S, 1989, BAILLIERE CLIN OB GY, V3, P769, DOI 10.1016/S0950-3552(89)80064-1; SUTCLIFFE M, 1993, LANCET, V342, P1174, DOI 10.1016/0140-6736(93)92158-P; WALTERS S, 1993, BRIT MED J, V306, P549, DOI 10.1136/bmj.306.6877.549; WEST R, 1993, SMOKING PREGNANCY GU, P9; 1991, LANCET, V338, P131; 1992, SMOKING YOUNG REPORT	11	6	6	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1994	309	6966					1429	1430		10.1136/bmj.309.6966.1429	http://dx.doi.org/10.1136/bmj.309.6966.1429			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PU764	7819858	Green Published			2022-12-28	WOS:A1994PU76400033
J	MURPHY, CJ; ARKIN, MR; JENKINS, Y; GHATLIA, ND; BOSSMANN, SH; TURRO, NJ; BARTON, JK				MURPHY, CJ; ARKIN, MR; JENKINS, Y; GHATLIA, ND; BOSSMANN, SH; TURRO, NJ; BARTON, JK			LONG-RANGE PHOTOINDUCED ELECTRON-TRANSFER THROUGH A DNA HELIX	SCIENCE			English	Article							MARCUS INVERTED REGION; MOLECULAR LIGHT SWITCH; METAL-COMPLEXES; EXCITED-STATE; DIIMINE COMPLEXES; RUTHENIUM(II); DISTANCE; RHODIUM(III); RECOGNITION; SEQUENCE	Rapid photoinduced electron transfer is demonstrated over a distance of greater than 40 angstroms between metallointercalators that are tethered to the 5' termini of a 15-base pair DNA duplex. An oligomeric assembly was synthesized in which the donor is Ru(phen)2dppz2+ (phen, phenanthroline, and dppz, dipyridophenazine) and the acceptor is Rh(phi)2phen3+ (phi, phenanthrenequinone diimine). These metal complexes are intercalated either one or two base steps in from the helix termini. Although the ruthenium-modified oligonucleotide hybridized to an unmodified complement luminesces intensely, the ruthenium-modified oligomer hybridized to the rhodium-modified oligomer shows no detectable luminescence. Time-resolved studies point to a lower limit of 10(9) per second for the quenching rate. No quenching was observed upon metallation of two complementary octamers by Ru(phen)3(2+) and Rh(phen)3(3+) under conditions where the phen complexes do not intercalate. The stacked aromatic heterocycles of the DNA duplex therefore serve as an efficient medium for coupling electron donors and acceptors over very long distances.	CALTECH, BECKMAN INST, PASADENA, CA 91125 USA; COLUMBIA UNIV, DEPT CHEM, NEW YORK, NY 10027 USA	California Institute of Technology; Columbia University			Bossmann, Stefan/AAG-9881-2020	Murphy, Catherine/0000-0001-7066-5575	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049216] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49216] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOUYAL E, 1990, J CHEM SOC DALTON, P1841, DOI 10.1039/dt9900001841; BANNWARTH W, 1988, HELV CHIM ACTA, V71, P2085, DOI 10.1002/hlca.19880710826; BARTON JK, 1986, J AM CHEM SOC, V108, P6391, DOI 10.1021/ja00280a047; BARTON JK, 1986, J AM CHEM SOC, V108, P2081, DOI 10.1021/ja00268a057; BERATAN DN, 1991, ADV CHEM SER, P71; BOWLER BE, 1990, PROG INORG CHEM, V38, P259; BRUN AM, 1992, J AM CHEM SOC, V114, P3656, DOI 10.1021/ja00036a013; CHAMBRON JC, 1985, NOUV J CHIM, V9, P527; CHEN CHB, 1986, P NATL ACAD SCI USA, V83, P7147, DOI 10.1073/pnas.83.19.7147; CHOW CS, 1990, J AM CHEM SOC, V112, P2839, DOI 10.1021/ja00163a076; CHOW CS, 1992, BIOCHEMISTRY-US, V31, P972, DOI 10.1021/bi00119a005; CLEMENTI E, 1982, INT J QUANTUM CHEM, P213; CLOSS GL, 1988, SCIENCE, V240, P440, DOI 10.1126/science.240.4851.440; CLOSS GL, 1986, J PHYS CHEM-US, V90, P3673, DOI 10.1021/j100407a039; DAVID SS, 1993, J AM CHEM SOC, V115, P2984, DOI 10.1021/ja00060a060; FRIEDMAN AE, 1990, J AM CHEM SOC, V112, P4960, DOI 10.1021/ja00168a052; FROMHERZ P, 1986, J AM CHEM SOC, V108, P5361, DOI 10.1021/ja00277a060; FURUE M, 1990, CHEM LETT, P2065, DOI 10.1246/cl.1990.2065; GUPTA N, 1992, ANGEW CHEM INT EDIT, V31, P1048, DOI 10.1002/anie.199210481; HARTSHORN RM, 1992, J AM CHEM SOC, V114, P5919, DOI 10.1021/ja00041a002; HOFFMAN BM, 1991, STRUCT BOND, V75, P85; HOFFMANN TA, 1964, ADV CHEM PHYS, V7, P84; JENKINS Y, 1992, BIOCHEMISTRY-US, V31, P10809, DOI 10.1021/bi00159a023; JENKINS Y, 1992, J AM CHEM SOC, V114, P8736, DOI 10.1021/ja00048a077; JORAN AD, 1987, NATURE, V327, P508, DOI 10.1038/327508a0; JORAN AD, 1984, J AM CHEM SOC, V106, P6090, DOI 10.1021/ja00332a062; KALYANASUNDARAM K, 1992, J PHYS CHEM-US, V96, P5865, DOI 10.1021/j100193a041; KROTZ AH, 1993, J AM CHEM SOC, V115, P3877, DOI 10.1021/ja00063a004; KROTZ AH, 1990, IN PRESS INORG CHEM, V29; KUMAR CV, 1985, J AM CHEM SOC, V107, P5518, DOI 10.1021/ja00305a032; LARSSON S, 1982, CHEM PHYS LETT, V90, P136, DOI 10.1016/0009-2614(82)83627-0; LINDBERG O, 1954, METHODS BIOCH ANAL, V3; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MARCUS RA, 1964, ANNU REV PHYS CHEM, V15, P155, DOI 10.1146/annurev.pc.15.100164.001103; MARKS TJ, 1985, SCIENCE, V227, P881, DOI 10.1126/science.227.4689.881; MCLENDON G, 1988, ACCOUNTS CHEM RES, V21, P160, DOI 10.1021/ar00148a005; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; MURPHY CF, UNPUB; NALEWAY CA, 1991, J PHYS CHEM-US, V95, P8434, DOI 10.1021/j100175a005; NOZAKI K, 1992, J PHYS CHEM-US, V96, P10880, DOI 10.1021/j100205a051; PURUGGANAN MD, 1988, SCIENCE, V241, P1645, DOI 10.1126/science.3420416; PYLE AM, 1990, J AM CHEM SOC, V112, P9432, DOI 10.1021/ja00181a077; PYLE AM, 1990, INORG CHEM, V29, P4487, DOI 10.1021/ic00347a031; PYLE AM, 1989, J AM CHEM SOC, V111, P4520, DOI 10.1021/ja00194a070; RATNER MA, 1990, J PHYS CHEM-US, V94, P4877, DOI 10.1021/j100375a024; SCHOUTEN PG, 1991, NATURE, V353, P736, DOI 10.1038/353736a0; SITLANI A, 1992, J AM CHEM SOC, V114, P2303, DOI 10.1021/ja00033a003; TANAKA M, 1991, J PHYS CHEM-US, V95, P955, DOI 10.1021/j100155a084; TELSER J, 1989, J AM CHEM SOC, V111, P7221, DOI 10.1021/ja00200a049; Turro N.J, 1991, MODERN MOL PHOTOCHEM; UCHIDA K, 1989, NUCLEIC ACIDS RES, V17, P10259, DOI 10.1093/nar/17.24.10259; WASIELEWSKI MR, 1992, CHEM REV, V92, P435, DOI 10.1021/cr00011a005; WOITELLIER S, 1989, INORG CHEM, V28, P758, DOI 10.1021/ic00303a029	53	894	936	3	172	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	1993	262	5136					1025	1029		10.1126/science.7802858	http://dx.doi.org/10.1126/science.7802858			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	7802858				2022-12-28	WOS:A1993MG18700026
J	LAPUMA, J; STOCKING, CB; RHOADES, WD; DARLING, CM				LAPUMA, J; STOCKING, CB; RHOADES, WD; DARLING, CM			FINANCIAL TIES AS PART OF INFORMED CONSENT TO POSTMARKETING RESEARCH - ATTITUDES OF AMERICAN DOCTORS AND PATIENTS	BRITISH MEDICAL JOURNAL			English	Article								Postmarketing research, often called phase IV trials, is intended to familiarise doctors and patients with newly approved drugs. La Puma and colleagues, in Chicago, studied doctors' and patients' attitudes to whether doctors should receive payment for taking part in such research. We asked for commentaries on their findings from four ethical experts, who put the study in a British context, present the views of patients, and examine some methodological assumptions.	UNIV CHICAGO,CTR CLIN MED ETH,CHICAGO,IL 60637; LUTHERAN GEN HOSP,PARK RIDGE,IL 60068	University of Chicago			La Puma, John/M-5558-2019	La Puma, John/0000-0002-0514-720X; Ferner, Robin/0000-0003-3769-1346				LAPUMA J, 1995, PHARMACOECONOMICS, V7, P187, DOI 10.2165/00019053-199507030-00001; LAPUMA J, 1994, HOSP HLTH SERV ADM, V39, P93; RAY WA, 1993, NEW ENGL J MED, V329, P2029, DOI 10.1056/NEJM199312303292710; STEPHENS MDB, 1993, DRUG SAFETY, V8, P1, DOI 10.2165/00002018-199308010-00001; 1994, NATIONAL I HLTH GUID, V23, P1; 1988, BRIT MED J, V296, P399	6	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 24	1995	310	6995					1660	1661		10.1136/bmj.310.6995.1660	http://dx.doi.org/10.1136/bmj.310.6995.1660			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RF698	7795459	Green Published			2022-12-28	WOS:A1995RF69800031
J	TAGGART, SCO; CUSTOVIC, A; RICHARDS, DH; WOODCOCK, A				TAGGART, SCO; CUSTOVIC, A; RICHARDS, DH; WOODCOCK, A			GR106642X - A NEW, NON-OZONE DEPLETING PROPELLANT FOR INHALERS	BRITISH MEDICAL JOURNAL			English	Article									WYTHENSHAWE HOSP,NW LUNG CTR,MANCHESTER M23 9LT,LANCS,ENGLAND; GLAXO RES & DEV,UXBRIDGE UB11 1BT,MIDDX,ENGLAND	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; GlaxoSmithKline			Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Woodcock, Ashley/0000-0002-5428-8578				BARNES PJ, 1983, BRIT J CLIN PHARMACO, V15, P677, DOI 10.1111/j.1365-2125.1983.tb01549.x; Jones B., 2015, DESIGN ANAL CROSS OV, V3rd; KNOX AJ, 1991, EUR RESPIR J, V4, P497; MOLINA MJ, 1974, NATURE, V249, P810, DOI 10.1038/249810a0; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	5	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 24	1995	310	6995					1639	1640		10.1136/bmj.310.6995.1639a	http://dx.doi.org/10.1136/bmj.310.6995.1639a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF698	7795451	Green Published			2022-12-28	WOS:A1995RF69800022
J	KIRCHHOFF, F; GREENOUGH, TC; BRETTLER, DB; SULLIVAN, JL; DESROSIERS, RC				KIRCHHOFF, F; GREENOUGH, TC; BRETTLER, DB; SULLIVAN, JL; DESROSIERS, RC			BRIEF REPORT - ABSENCE OF INTACT NEF SEQUENCES IN A LONG-TERM SURVIVOR WITH NONPROGRESSIVE HIV-1 INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							IMMUNODEFICIENCY-VIRUS TYPE-1; GENE; CHIMPANZEES; VACCINE; AIDS		HARVARD UNIV,SCH MED,NEW ENGLAND REG PRIMATE RES CTR,SOUTHBOROUGH,MA 01772; UNIV MASSACHUSETTS,SCH MED,DEPT PEDIAT & MED,PROGRAM MOLEC MED,WORCESTER,MA	Harvard University; University of Massachusetts System; University of Massachusetts Worcester			Kirchhoff, Frank/O-8367-2018	Kirchhoff, Frank/0000-0002-7052-2360	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042257] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025328, R37AI025328] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42257] Funding Source: Medline; NIAID NIH HHS [AI25328, AI26507] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLUMBERG BM, 1992, J VIROL, V66, P5256, DOI 10.1128/JVI.66.9.5256-5264.1992; BRETTLER DB, 1992, BLOOD, V80, P2396; BUCHBINDER SP, 1994, AIDS, V8, P1123, DOI 10.1097/00002030-199408000-00014; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DESROSIERS RC, 1992, AIDS RES HUM RETROV, V8, P411, DOI 10.1089/aid.1992.8.411; EICHBERG JW, 1987, J VIROL, V61, P3804, DOI 10.1128/JVI.61.12.3804-3808.1987; GREENOUGH TC, 1994, AIDS RES HUM RETROV, V10, P395, DOI 10.1089/aid.1994.10.395; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HUANG YX, 1995, J VIROL, V69, P93, DOI 10.1128/JVI.69.1.93-100.1995; JAMIESON BD, 1994, J VIROL, V68, P3478, DOI 10.1128/JVI.68.6.3478-3485.1994; JOHNSON BK, 1993, AIDS RES HUM RETROV, V9, P375, DOI 10.1089/aid.1993.9.375; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIRCHHOFF F, 1994, J VIROL, V68, P2031, DOI 10.1128/JVI.68.3.2031-2037.1994; MYERS G, 1993, HUMAN RETROVIRUSES A, V1; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SHUGARS DC, 1993, J VIROL, V67, P4639, DOI 10.1128/JVI.67.8.4639-4650.1993; SULLIVAN JL, 1986, J PEDIATR-US, V108, P504, DOI 10.1016/S0022-3476(86)80823-X; SULLIVAN JL, 1986, J PEDIATR, V109, P1075; WILLIAMS LM, 1991, VIROLOGY, V184, P723, DOI 10.1016/0042-6822(91)90442-E; ZHANG LQ, 1993, J VIROL, V67, P3345, DOI 10.1128/JVI.67.6.3345-3356.1993; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; 1994, AIDS RES HUM RETROV, V10, P221	22	892	908	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	1995	332	4					228	232		10.1056/NEJM199501263320405	http://dx.doi.org/10.1056/NEJM199501263320405			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC270	7808489				2022-12-28	WOS:A1995QC27000005
J	GREENBLATT, DJ; VONMOLTKE, LL; HARMATZ, JS; HARREL, LM; TOBIAS, S; SHADER, RI; WRIGHT, CE				GREENBLATT, DJ; VONMOLTKE, LL; HARMATZ, JS; HARREL, LM; TOBIAS, S; SHADER, RI; WRIGHT, CE			INTERACTION OF TRIAZOLAM AND KETOCONAZOLE	LANCET			English	Letter									UPJOHN CO,KALAMAZOO,MI	Pfizer	GREENBLATT, DJ (corresponding author), TUFTS UNIV,SCH MED,BOSTON,MA 02111, USA.							ALBENGRES E, 1992, INT J CLIN PHARM TH, V30, P555; HONIG PK, 1993, JAMA-J AM MED ASSOC, V269, P1513, DOI 10.1001/jama.269.12.1513; OLKKOLA KT, 1994, CLIN PHARMACOL THER, V55, P481, DOI 10.1038/clpt.1994.60; VONMOLTKE LL, 1994, BRIT J CLIN PHARMACO, V38, P23; VONMOLTKE LL, 1994, CLIN PHARMACOL THER, V55, P179	5	20	20	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					191	191		10.1016/S0140-6736(95)90193-0	http://dx.doi.org/10.1016/S0140-6736(95)90193-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7823684				2022-12-28	WOS:A1995QC55000037
J	CLUTTONBROCK, TH; PARKER, GA				CLUTTONBROCK, TH; PARKER, GA			PUNISHMENT IN ANIMAL SOCIETIES	NATURE			English	Review							NORTHERN ELEPHANT SEALS; RECIPROCAL ALTRUISM; STUMPTAIL MACAQUES; PRISONERS-DILEMMA; POLISTES-FUSCATUS; RHESUS MACAQUES; MACACA-MULATTA; VERVET MONKEYS; MATE CHOICE; EVOLUTION	Although positive reciprocity (reciprocal altruism) has been a focus of interest in evolutionary biology, negative reciprocity (retaliatory infliction of fitness reduction) has been largely ignored. In social animals, retaliatory aggression is common, individuals often punish other group members that infringe their interests, and punishment can cause subordinates to desist from behaviour likely to reduce the fitness of dominant animals. Punishing strategies are used to establish and maintain dominance relationships, to discourage parasites and cheats, to discipline offspring or prospective sexual partners and to maintain cooperative behaviour.	UNIV LIVERPOOL, DEPT ENVIRONM & EVOLUTIONARY BIOL, POPULAT BIOL RES GRP, LIVERPOOL L69 3BX, MERSEYSIDE, ENGLAND	University of Liverpool	CLUTTONBROCK, TH (corresponding author), UNIV CAMBRIDGE, DEPT ZOOL, LARGE ANIM RES GRP, DOWNING ST, CAMBRIDGE CB2 3EJ, ENGLAND.		Parker, Geoff/C-4337-2008	Parker, Geoff/0000-0003-4795-6352				Andersson M., 1984, ANIM BEHAV, V33, P1394; APPLEBY MC, 1980, BEHAVIOUR, V74, P294, DOI 10.1163/156853980X00519; AURELI F, 1992, ANIM BEHAV, V44, P283, DOI 10.1016/0003-3472(92)90034-7; AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; AXELROD R, 1986, AM POLIT SCI REV, V80, P1095, DOI 10.2307/1960858; Axelrod R., 1984, EVOLUTION COOPERATIO, DOI DOI 10.2307/3323905; BEAN P, 1981, PUNISHMENT PHILOS CR; BOYD R, 1992, ETHOL SOCIOBIOL, V13, P171, DOI 10.1016/0162-3095(92)90032-Y; Brown J.L., 1987, HELPING COMMUNAL BRE; Cheney D. L., 1990, MONKEYS SEE WORLD IN; CHENEY DL, 1989, BEHAVIOUR, V110, P258, DOI 10.1163/156853989X00501; CHENEY DL, 1986, ANIM BEHAV, V34, P1722, DOI 10.1016/S0003-3472(86)80259-7; CLUTTONBROCK TH, 1988, BEHAV ECOL SOCIOBIOL, V23, P281, DOI 10.1007/BF00300575; CLUTTONBROCK TH, 1979, ANIM BEHAV, V27, P211, DOI 10.1016/0003-3472(79)90141-6; CLUTTONBROCK TH, IN PRESS ANIM BEHAV; CLUTTONBROCK TH, 1982, RED DEER BEHAVIOR EC; CORDS M, 1990, 13TH C INT PRIM SOC; De Waal, 1989, PEACEMAKING PRIMATES; De Waal Frans B. M., 1992, P233; DEWAAL F, 1982, CHIMPANZEE POLITICS; DEWAAL FBM, 1988, ETHOL SOCIOBIOL, V9, P101, DOI 10.1016/0162-3095(88)90016-7; DEWAAL FBM, 1993, ANIMAL SOCIAL CONFLI, P114; DRUKKER B, 1991, ANIM BEHAV, V42, P171, DOI 10.1016/S0003-3472(05)80548-2; DRUMMOND H, 1992, ANIM BEHAV, V44, P881, DOI 10.1016/S0003-3472(05)80584-6; DUGATKIN LA, 1992, TRENDS ECOL EVOL, V7, P202, DOI 10.1016/0169-5347(92)90074-L; EHARDT CL, 1992, COALITIONS ALLIANCES, P82; ENOMOTO T, 1981, Primates, V22, P15, DOI 10.1007/BF02382553; FISHER J, 1964, NATURAL HIST AGGRESS, P7; Goodall J, 1986, CHIMPANZEES GOMBE, DOI DOI 10.1002/AJPA.1330730313; HAMILTON WD, 1970, NATURE, V228, P1218, DOI 10.1038/2281218a0; HAMMERSTEIN P, 1981, ANIM BEHAV, V29, P193, DOI 10.1016/S0003-3472(81)80166-2; HARRELL WA, 1980, INT J SPORT PSYCHOL, V11, P290; HAUSER MD, 1993, BEHAV ECOL, V4, P206, DOI 10.1093/beheco/4.3.206; HAUSER MD, 1992, P NATL ACAD SCI USA, V89, P12137, DOI 10.1073/pnas.89.24.12137; Hinde RA., 1974, BIOL BASES HUMAN SOC; HIRSHLEIFER D, 1989, J ECON BEHAV ORGAN, V12, P87, DOI 10.1016/0167-2681(89)90078-4; HIRSHLEIFER J, 1988, J CONFLICT RESOLUT, V32, P367, DOI 10.1177/0022002788032002006; HOEBEL EA, 1954, LAWS PRIMITIVE MAN S; HORROCKS JA, 1983, AM NAT, V122, P417, DOI 10.1086/284144; HORSFALL JA, 1984, ANIM BEHAV, V32, P216, DOI 10.1016/S0003-3472(84)80340-1; HUNTE W, 1987, BEHAV ECOL SOCIOBIOL, V20, P257, DOI 10.1007/BF00292178; Huntingford F.A., 1987, ANIMAL CONFLICT; JUDGE PG, 1991, AM J PRIMATOL, V23, P225, DOI 10.1002/ajp.1350230403; Kummer H., 1968, SOCIAL ORG HAMADRYAS; LEBOEUF BJ, 1991, BEHAVIOUR, V116, P143, DOI 10.1163/156853990X00400; LEONARD ML, 1988, BEHAV ECOL SOCIOBIOL, V23, P265, DOI 10.1007/BF00302949; LINDBURG DG, 1983, PERSPECTIVES PRIMATE; MANSON JH, 1994, ANIM BEHAV, V48, P473, DOI 10.1006/anbe.1994.1262; MANSON JH, 1992, ANIM BEHAV, V44, P405, DOI 10.1016/0003-3472(92)90051-A; Maynard Smith J., 1982, pi; Mendoza S., 1993, PRIMATE SOCIAL CONFL, P85; MILLS G, 1991, KALAHARI HYENAS; MULDER RA, 1993, ANIM BEHAV, V45, P830, DOI 10.1006/anbe.1993.1100; NADLER RD, 1982, FOLIA PRIMATOL, V38, P233, DOI 10.1159/000156059; NADLER RD, 1982, ORANG UTAN ITS BIOL, P231; NADLER RD, 1988, HUMAN SEXUAL AGGRESS, P154; NIEUWENHUIJSEN K, 1988, PSYCHOBIOLOGY, V16, P357; NOWAK MA, 1992, NATURE, V355, P250, DOI 10.1038/355250a0; OLIVER P, 1980, AM J SOCIOL, V85, P1356, DOI 10.1086/227168; PACKER C, 1977, NATURE, V265, P441, DOI 10.1038/265441a0; PARKER GA, 1981, ANIM BEHAV, V29, P221, DOI 10.1016/S0003-3472(81)80170-4; PARKER GA, 1974, J THEOR BIOL, V47, P223, DOI 10.1016/0022-5193(74)90111-8; PARKER GA, 1978, ANIM BEHAV, V26, P97, DOI 10.1016/0003-3472(78)90009-X; PHILLIPS A, 1970, ANCIET ISRAELS CRIMI; RAJPUROHIT LS, 1991, FOLIA PRIMATOL, V56, P17, DOI 10.1159/000156523; RATNIEKS FLW, 1988, AM NAT, V132, P217, DOI 10.1086/284846; REEVE HK, 1987, BEHAVIOUR, V102, P147, DOI 10.1163/156853986X00090; REEVE HK, 1983, BEHAV ECOL SOCIOBIOL, V13, P63, DOI 10.1007/BF00295077; REEVE HK, 1992, NATURE, V358, P147, DOI 10.1038/358147a0; REEVE HK, 1992, NATURE, V359, P823, DOI 10.1038/359823a0; REITER J, 1981, ANIM BEHAV, V29, P670, DOI 10.1016/S0003-3472(81)80002-4; REITER J, 1978, BEHAV ECOL SOCIOBIOL, V3, P337, DOI 10.1007/BF00303199; ROBERTS S, 1979, ORDER DISPUTE; ROWELL T, 1972, SOCIAL BEHAVIOR MONK; Schelling Thomas C., 1960, STRATEGY CONFLICT; Silk J. B., 1993, PRIMATE SOCIAL CONFL, P49; SMITH JM, 1973, NATURE, V246, P15, DOI 10.1038/246015a0; SMITH JM, 1974, J THEOR BIOL, V47, P209, DOI 10.1016/0022-5193(74)90110-6; SMITH JM, 1976, ANIM BEHAV, V24, P159, DOI 10.1016/S0003-3472(76)80110-8; SMUTS B, 1987, NAT HIST, V96, P36; Smuts B.B., 1985, SEX FRIENDSHIP BABOO; SMUTS BB, 1993, ADV STUD BEHAV, V22, P1, DOI 10.1016/S0065-3454(08)60404-0; STRASSMANN JE, 1983, ANIM BEHAV, V31, P431, DOI 10.1016/S0003-3472(83)80063-3; Teas J., 1984, Monographs in Primatology, V4, P237; THOMPSON EA, 1981, AM ECON REV, V71, P366; Trivers R. L., 1985, SOCIAL EVOLUTION; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755; TRIVERS RL, 1974, AM ZOOL, V14, P249; VEHRENCAMP SL, 1983, ANIM BEHAV, V31, P667, DOI 10.1016/S0003-3472(83)80222-X; Walters J.R., 1987, P306; Wood-Gush D. G. M., 1971, BEHAVIOUR DOMESTIC F; YAMAGISHI T, 1986, J PERS SOC PSYCHOL, V51, P110, DOI 10.1037/0022-3514.51.1.110; [No title captured]; 1738, GROTIUS JURE BELLICT	94	664	673	3	245	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 19	1995	373	6511					209	216		10.1038/373209a0	http://dx.doi.org/10.1038/373209a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QC278	7816134				2022-12-28	WOS:A1995QC27800053
J	COWEY, A; STOERIG, P				COWEY, A; STOERIG, P			BLINDSIGHT IN MONKEYS	NATURE			English	Article							RESIDUAL VISION	BLINDSIGHT, the visually evoked voluntary responses of patients with striate cortical destruction that are demonstrated despite a phenomenal blindness, has attracted attention from neuroscientists and philosophers interested in problems of perceptual consciousness and its neuronal basis(1-3). It is assumed to be mediated by the numerous extra-geniculostriate cortical retinofugal pathways whose properties are studied primarily in monkeys(4). Like patients with blindsight(4-7), monkeys with lesions of the primary visual cortex can learn to detect, localize and distinguish between visual stimuli presented within their visual field defects(4,8-11). Although the patients deny seeing the stimuli they can nevertheless respond to (by forced-choice guessing) in their phenomenally blind fields, it is not known whether the monkeys experience the same absence of phenomenal vision. To determine whether they too have blindsight, or whether they actuary see the stimuli in their held defects, monkeys who showed excellent detection in tasks where a visual stimulus was presented on every trial, albeit at different positions, were tested in a signal-detection task(12) in which half the trials were blank trials, with no visual stimulus. They classified the visual stimuli presented in the field defect as blank trials, demonstrating, like patients, blindsight rather than degraded real vision.	UNIV MUNICH,INST MED PSYCHOL,D-80336 MUNICH,GERMANY	University of Munich	COWEY, A (corresponding author), UNIV OXFORD,DEPT EXPTL PSYCHOL,S PARKS RD,OXFORD OX1 3UD,ENGLAND.							BARBUR JL, 1980, BRAIN, V103, P905, DOI 10.1093/brain/103.4.905; BARBUR JL, 1993, BRAIN, V116, P1293, DOI 10.1093/brain/116.6.1293; BLYTHE IM, 1987, BRAIN, V110, P887, DOI 10.1093/brain/110.4.887; COWEY A, 1963, Q J EXP PSYCHOL, V15, P91, DOI 10.1080/17470216308416561; COWEY A, 1991, TRENDS NEUROSCI, V14, P140, DOI 10.1016/0166-2236(91)90085-9; Crick F., 1990, Seminars in the Neurosciences, V2, P263; FENDRICH R, 1992, SCIENCE, V258, P1489, DOI 10.1126/science.1439839; Kluver H, 1941, J PSYCHOL, V11, P23; MOHLER CW, 1977, J NEUROPHYSIOL, V40, P74, DOI 10.1152/jn.1977.40.1.74; NELKIN N, 1993, PHILOS SCI, V60, P419, DOI 10.1086/289744; PASIK P, 1982, CONTRIBUTIONS SENSOR, V7, P147; STOERIG P, 1993, THEOR MED, V14, P117, DOI 10.1007/BF00997271; STOERIG P, 1991, BRAIN, V114, P1489; Swets J., 1982, EVALUATION DIAGNOSTI; WEISKRANTZ L, 1990, PROC R SOC SER B-BIO, V239, P247, DOI 10.1098/rspb.1990.0016; Weiskrantz L., 1986, BLINDSIGHT CASE STUD	16	213	215	0	46	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					247	249		10.1038/373247a0	http://dx.doi.org/10.1038/373247a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QC278	7816139				2022-12-28	WOS:A1995QC27800064
J	ALLEGRA, CJ				ALLEGRA, CJ			NEW THERAPEUTIC STRATEGIES FOR PATIENTS WITH GASTROINTESTINAL MALIGNANCIES USING BIOCHEMICAL MODULATION OF FLUOROURACIL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							HUMAN THYMIDYLATE SYNTHASE; ADVANCED COLORECTAL-CARCINOMA; HIGH-DOSE LEUCOVORIN; COLON-CARCINOMA; INTERFERON ALFA-2A; ADJUVANT THERAPY; FOLINIC ACID; PHASE-II; 5-FLUOROURACIL; CANCER				ALLEGRA, CJ (corresponding author), NATL NAVAL MED CTR, NCI,NAVY MED ONCOL BRANCH,8901 WISCONSIN AVE, BLDG 8, ROOM 5101, BETHESDA, MD 20889 USA.							BOBBIOPALLAVICINI E, 1993, J CHEMOTHERAPY, V5, P52; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; CALVERT AH, 1986, J CLIN ONCOL, V4, P1245, DOI 10.1200/JCO.1986.4.8.1245; CHU E, 1990, CANCER RES, V50, P5834; CHU E, 1993, P NATL ACAD SCI USA, V90, P517, DOI 10.1073/pnas.90.2.517; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; CLARKE SJ, 1994, ANN ONCOL, V5, P5; DANENBERG PV, 1978, BIOCHEMISTRY-US, V17, P4018, DOI 10.1021/bi00612a022; EVANS RM, 1981, CANCER RES, V41, P3288; GREM JL, 1993, J CLIN ONCOL, V11, P1737, DOI 10.1200/JCO.1993.11.9.1737; GREM JL, 1991, J CLIN ONCOL, V9, P1811, DOI 10.1200/JCO.1991.9.10.1811; HOUGHTON JA, 1993, CANCER RES, V53, P4243; JACKMAN AL, 1990, CANCER RES, V50, P5212; JOHNSTON PG, 1991, CANCER RES, V51, P6668; JOHNSTON PG, 1992, CANCER RES, V52, P4306; JOHNSTON PG, 1993, BIOCHEM PHARMACOL, V45, P2483, DOI 10.1016/0006-2952(93)90230-T; JOHNSTON PG, 1993, P AN M AM SOC CLIN, V12, P202; KEMENY N, 1990, CANCER, V66, P2470, DOI 10.1002/1097-0142(19901215)66:12<2470::AID-CNCR2820661205>3.0.CO;2-Y; KEYOMARSI K, 1988, J BIOL CHEM, V263, P14402; LENZ HJ, 1993, P AN M AM SOC CLIN, V12, P199; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; PAZDUR R, 1990, J CLIN ONCOL, V8, P2027, DOI 10.1200/JCO.1990.8.12.2027; PETRELLI N, 1990, J CLIN ONCOL, V8, P491; PIEDBOIS P, 1992, J CLIN ONCOL, V10, P896; POON MA, 1991, J CLIN ONCOL, V9, P1967, DOI 10.1200/JCO.1991.9.11.1967; SCHWARTZ EL, 1992, BIOCHEM BIOPH RES CO, V182, P1232, DOI 10.1016/0006-291X(92)91863-L; SMITH IE, 1994, ANN ONCOL, V5, P5; SORENSEN JM, 1993, P AN M AM SOC CLIN, V12, P158; SOTOS GA, 1994, CANCER TREAT REV, V20, P11, DOI 10.1016/0305-7372(94)90009-4; SWAIN SM, 1989, J CLIN ONCOL, V7, P890, DOI 10.1200/JCO.1989.7.7.890; ULLMAN B, 1978, P NATL ACAD SCI USA, V75, P980, DOI 10.1073/pnas.75.2.980; WADLER S, 1990, SEMIN ONCOL, V17, P16; WOLMARK N, 1993, J CLIN ONCOL, V11, P1879, DOI 10.1200/JCO.1993.11.10.1879; ZALCBERG J, 1994, ANN ONCOL, V5, P5	34	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					236	239		10.1001/jama.273.3.236	http://dx.doi.org/10.1001/jama.273.3.236			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB234	7807664				2022-12-28	WOS:A1995QB23400029
J	LEVIN, M; NEWPORT, MJ; DSOUZA, S; KALABALIKIS, P; BROWN, IN; LENICKER, HM; AGIUS, PV; DAVIES, EG; THRASHER, A; KLEIN, N; BLACKWELL, JM				LEVIN, M; NEWPORT, MJ; DSOUZA, S; KALABALIKIS, P; BROWN, IN; LENICKER, HM; AGIUS, PV; DAVIES, EG; THRASHER, A; KLEIN, N; BLACKWELL, JM			FAMILIAL DISSEMINATED ATYPICAL MYCOBACTERIAL INFECTION IN CHILDHOOD - A HUMAN MYCOBACTERIAL SUSCEPTIBILITY GENE	LANCET			English	Article							LEISHMANIA-DONOVANI; NATURAL-RESISTANCE; MOUSE; LSH; BCG; CHROMOSOME-1; MACROPHAGES; ACTIVATION; DISEASE; LOCUS	Inherited defects in specific components of the immune system have provided many clues to the immunological mechanisms underlying resistance to microbial infection. We report a familial immune defect predisposing to disseminated atypical mycobacterial infection in childhood. 6 children with disseminated atypical mycobacterial infection and no recognised form of immunodeficency were identified. Four, including two brothers, come from a village in Malta, and two are brothers of Creek Cypriot origin. They presented with fever, weight loss, lymphadenopathy, and hepatosplenomegaly. They had anaemia and an acute phase response. A range of different mycobacteria (Mycobacterium fortuitum, M chelonei, and four strains of M avium intracellulare complex) were isolated. Treatment with multiple antibiotics failed to eradicate the infection, although treatment with gamma interferon was associated with improvement. Three have died and the surviving children have chronic infection. Tumour necrosis factor-cr production in response to endotoxin and gamma-interferon was found to be defective in affected patients and their parents. T-cell proliferative responses to mycobacterial and recall antigens were reduced in parents of affected children and gamma-interferon production was diminished in the affected patients and their parents. Clinical and immunological features suggest that these patients are phenotypically similar to Lsh/Ity/Bcg susceptible mice. Understanding of this defect may provide insights into the mechanisms responsible for susceptibility to mycobacteria.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, ST MARYS HOSP, SCH MED, DEPT IMMUNOL, LONDON W2 1PG, ENGLAND; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, ST MARYS HOSP, SCH MED, DEPT MED MICROBIOL, LONDON W2 1PG, ENGLAND; ST LUKES HOSP, DEPT PAEDIAT, GUARDAMANGIA, MALTA; ST GEORGE HOSP, DEPT CHILD HLTH, LONDON, ENGLAND; UCL HOSP, DEPT MED, LONDON, ENGLAND; UNIV CAMBRIDGE, ADDENBROOKES HOSP, SCH CLIN, DEPT MED, CAMBRIDGE, ENGLAND	Imperial College London; Imperial College London; St Georges University London; University College London Hospitals NHS Foundation Trust; University of London; University College London; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	LEVIN, M (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, ST MARYS HOSP, SCH MED, DEPT PAEDIAT, LONDON W2 1PG, ENGLAND.		Blackwell, Jenefer M/H-3015-2015	Newport, Melanie/0000-0002-8946-7525; Klein, Nigel/0000-0003-3925-9258; Levin, Michael/0000-0003-2767-6919	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APPELBERG R, 1990, CLIN EXP IMMUNOL, V80, P324, DOI 10.1111/j.1365-2249.1990.tb03288.x; BLACKWELL JM, 1989, RES IMMUNOL, V140, P767, DOI 10.1016/0923-2494(89)90029-1; BLACKWELL JM, 1989, RES IMMUNOL, V140, P798, DOI 10.1016/0923-2494(89)90036-9; BRADLEY DJ, 1979, CLIN EXP IMMUNOL, V37, P7; BRADLEY DJ, 1974, NATURE, V250, P353, DOI 10.1038/250353a0; BROWN IN, 1982, IMMUNOLOGY, V47, P149; BUSCHMAN E, 1989, RES IMMUNOL, V140, P793, DOI 10.1016/0923-2494(89)90035-7; DANNENBERG AM, 1989, REV INFECT DIS, V11, pS369; EDWARDS LB, 1969, AM REV RESPIR DIS, V99, P1; ENGBAEK HC, 1964, ACTA TUBERC PNEUM SC, V45, P105; GOTO Y, 1984, INFECT IMMUN, V46, P135, DOI 10.1128/IAI.46.1.135-140.1984; HAULIK JA, 1992, J INFECT DIS, V165, P577; HOLLAND SM, 1994, NEW ENGL J MED, V330, P1348, DOI 10.1056/NEJM199405123301904; KAYE PM, 1989, RES IMMUNOL, V140, P810, DOI 10.1016/0923-2494(89)90038-2; Klein N. J., 1994, Immunology and Infectious Diseases (Oxford), V4, P33; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PILKINGTON C, 1993, ARCH DIS CHILD, V69, P644, DOI 10.1136/adc.69.6.644; PLANT J, 1979, CLIN EXP IMMUNOL, V37, P1; PLANT J, 1976, J INFECT DIS, V133, P72, DOI 10.1093/infdis/133.1.72; PLANT JE, 1982, NATURE, V297, P510, DOI 10.1038/297510a0; ROACH TIA, 1991, INFECT IMMUN, V59, P3935, DOI 10.1128/IAI.59.11.3935-3944.1991; SCHURR E, 1990, GENOMICS, V8, P477, DOI 10.1016/0888-7543(90)90034-R; SCHURR E, 1991, IMMUNOPARASITOL TOD, pA42, DOI 10.1016/S0167-5699(05)80012-X; SEGAL AW, 1992, J INHERIT METAB DIS, V15, P683, DOI 10.1007/BF01799624; SKAMENE E, 1984, IMMUNOGENETICS, V19, P117, DOI 10.1007/BF00387854; SKAMENE E, 1982, NATURE, V297, P506, DOI 10.1038/297506a0; SNIDER DE, 1987, AM REV RESPIR DIS, V136, P492; Starke J R, 1992, Adv Pediatr Infect Dis, V7, P123; UCHIYAMA N, 1981, J PEDIATR-US, V98, P785, DOI 10.1016/S0022-3476(81)80848-7; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D	30	176	183	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 14	1995	345	8942					79	83		10.1016/S0140-6736(95)90059-4	http://dx.doi.org/10.1016/S0140-6736(95)90059-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815885				2022-12-28	WOS:A1995QB80400006
J	AYLIN, P; MAJEED, FA				AYLIN, P; MAJEED, FA			THE KILLING SEASON - FACT OR FICTION	BRITISH MEDICAL JOURNAL			English	Article									ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND	St Georges University London	AYLIN, P (corresponding author), OFF POPULAT CENSUSES & SURVEYS,DEPT HLTH STAT,LONDON WC2B 6JB,ENGLAND.		Aylin, Paul/A-1073-2014	Aylin, Paul/0000-0003-4589-1743				BUCHWALD D, 1989, ARCH INTERN MED, V149, P765, DOI 10.1001/archinte.149.4.765; DILLNER L, 1994, BRIT MED J, V308, P1108; Hennekens CR, 1987, EPIDEMIOLOGY MED, P85; 1991, PATIENTS CHARTER RAI	4	31	31	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1690	1690		10.1136/bmj.309.6970.1690	http://dx.doi.org/10.1136/bmj.309.6970.1690			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819988	Green Published			2022-12-28	WOS:A1994PY71700013
J	GODDARD, N; COULL, D				GODDARD, N; COULL, D			COLOR-BLIND CRICKETERS AND SNOWBALLS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine whether colour blindness affects batting in professional cricketers. Design-Comparison of batting averages of colour blind cricketers and those with normal vision. Setting-Players on 18 first class county cricket teams. Subjects-280 of 306 players were tested. Main outcome measures-Results of Isihara colour blindness tests. Results-Batting average for the colour blind group (12 players) was slightly lower than for players with normal vision (20.88 v 26.31). There was no difference in the number of batsmen and bowlers affected. Batting averages before and after the introduction of the white ball into Sunday League cricket did not differ significantly. Conclusions-That batting performance is not significantly impaired by colour blindness suggests that to some extent these players are self selected. Routine testing of cricketers for colour blindness is not recommended.			GODDARD, N (corresponding author), ROYAL FREE HOSP,SCH MED,LONDON NW3 2QG,ENGLAND.							FRINDALL B, 1994, PLAYFAIR CRICKET ANN; TREVORROPER PD, 1976, LECTURE NOTES OPHTHA	2	5	5	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1684	1685		10.1136/bmj.309.6970.1684	http://dx.doi.org/10.1136/bmj.309.6970.1684			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819984	Green Published			2022-12-28	WOS:A1994PY71700008
J	MAGUIRE, P				MAGUIRE, P			ABC OF BREAST DISEASES - PSYCHOLOGICAL-ASPECTS	BRITISH MEDICAL JOURNAL			English	Article											MAGUIRE, P (corresponding author), CANC RES CAMPAIGN,PSYCHOL MED GRP,MANCHESTER,LANCS,ENGLAND.								0	21	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1649	1652		10.1136/bmj.309.6969.1649	http://dx.doi.org/10.1136/bmj.309.6969.1649			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PY220	7819954	Green Published			2022-12-28	WOS:A1994PY22000042
J	SAGGARMALIK, AK; MISSOURIS, CG; GILL, JS; SINGER, DRJ; MARKANDU, ND; MACGREGOR, GA				SAGGARMALIK, AK; MISSOURIS, CG; GILL, JS; SINGER, DRJ; MARKANDU, ND; MACGREGOR, GA			LEFT-VENTRICULAR MASS IN NORMOTENSIVE SUBJECTS WITH AUTOSOMAL-DOMINANT POLYCYSTIC KIDNEY-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE		ST GEORGE HOSP,SCH MED,DEPT CARDIOL SCI,LONDON SW17 0RE,ENGLAND	St Georges University London	SAGGARMALIK, AK (corresponding author), ST GEORGE HOSP,SCH MED,BLOOD PRESSURE UNIT,LONDON SW17 0RE,ENGLAND.							ABISAMRA F, 1983, AM J MED, V75, P26, DOI 10.1016/0002-9343(83)90114-6; IGLESIAS CG, 1983, AM J KIDNEY DIS, V2, P630; JOHNSTON DW, 1993, BMJ-BRIT MED J, V306, P963, DOI 10.1136/bmj.306.6883.963; TIMIO M, 1992, CLIN NEPHROL, V37, P245; ZEIER M, 1993, J AM SOC NEPHROL, V3, P1451	5	44	44	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1617	1618		10.1136/bmj.309.6969.1617	http://dx.doi.org/10.1136/bmj.309.6969.1617			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819937	Green Published			2022-12-28	WOS:A1994PY22000018
J	PANDEY, M; GAUTAM, A; SHUKLA, VK				PANDEY, M; GAUTAM, A; SHUKLA, VK			ABO AND RH BLOOD-GROUPS IN PATIENTS WITH CHOLELITHIASIS AND CARCINOMA OF THE GALLBLADDER	BRITISH MEDICAL JOURNAL			English	Article							CANCER		BANARAS HINDU UNIV,INST MED SCI,DEPT SURG,VARANASI 221005,UTTAR PRADESH,INDIA	Banaras Hindu University (BHU)			Pandey, Manoj/AAS-2315-2020; Gautam, Amitabh/A-5636-2013	Pandey, Manoj/0000-0002-1496-9846; Gautam, Amitabh/0000-0002-0969-7866				AIRD I, 1953, BRIT MED J, V1, P799, DOI 10.1136/bmj.1.4814.799; HENDERSON J, 1993, J EPIDEMIOL COMMUN H, V47, P287, DOI 10.1136/jech.47.4.287; JUVONEN T, 1992, BRIT MED J, V305, P26, DOI 10.1136/bmj.305.6844.26; SHUKLA VK, 1985, J SURG ONCOL, V28, P32, DOI 10.1002/jso.2930280109; SLATER G, 1993, DIS COLON RECTUM, V36, P5, DOI 10.1007/BF02050293	5	27	28	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 24	1995	310	6995					1639	1639		10.1136/bmj.310.6995.1639	http://dx.doi.org/10.1136/bmj.310.6995.1639			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF698	7795450	Green Published			2022-12-28	WOS:A1995RF69800021
J	SANES, JN; DONOGHUE, JP; THANGARAJ, V; EDELMAN, RR; WARACH, S				SANES, JN; DONOGHUE, JP; THANGARAJ, V; EDELMAN, RR; WARACH, S			SHARED NEURAL SUBSTRATES CONTROLLING HAND MOVEMENTS IN HUMAN MOTOR CORTEX	SCIENCE			English	Article							CEREBRAL BLOOD-FLOW; POSITRON EMISSION TOMOGRAPHY; SUPPLEMENTARY MOTOR; VOLUNTARY MOVEMENTS; CORTICAL AREAS; ORGANIZATION; CONNECTIONS; STIMULATION; MONKEYS; ARM	Voluntary hand movements in humans involve the primary motor cortex (M1). A functional magnetic resonance imaging method that measures relative cerebral blood flow was used to identify a distributed, overlapping pattern of hand movement representation within the posterior precentral gyrus, which contains M1. The observed pattern resembles those reported in nonhuman primates and differs from a somatotopically organized plan typically used to portray human motor cortex organization. Finger and wrist movements activated a wide expanse of the posterior precentral gyrus, and representations for different finger movements overlapped each other and the wrist representation. Multiple sites of activation occurred in the precentral gyrus for all movements. The overlapping representations may mediate motor and cognitive functions requiring coordinated neural processing for finger and wrist actions rather than discrete control implied by somatotopic maps.	HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT RADIOL, BOSTON, MA 02115 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	SANES, JN (corresponding author), BROWN UNIV, DIV BIOL & MED, DEPT NEUROSCI, PROVIDENCE, RI 02912 USA.		Warach, Steven/R-5074-2019		NIA NIH HHS [AG 10634] Funding Source: Medline; NINDS NIH HHS [NS 25074, NS 01634] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS025074, K08NS001634, R01NS025074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG010634] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BENNETT KMB, 1994, J PHYSIOL-LONDON, V477, P291, DOI 10.1113/jphysiol.1994.sp020191; BOECKER H, 1994, BRAIN, V117, P1231, DOI 10.1093/brain/117.6.1231; COLEBATCH JG, 1991, J NEUROPHYSIOL, V65, P1392, DOI 10.1152/jn.1991.65.6.1392; CONSTABLE RT, 1993, MAGN RESON IMAGING, V11, P451, DOI 10.1016/0730-725X(93)90463-N; DELBER MP, 1991, EXP BRAIN RES, V84, P393; DONOGHUE JP, 1992, EXP BRAIN RES, V89, P1; EDELMAN RR, 1994, RADIOLOGY, V192, P513, DOI 10.1148/radiology.192.2.8029425; GOULD HJ, 1986, J COMP NEUROL, V247, P297, DOI 10.1002/cne.902470303; GRAFTON ST, 1991, J NEUROPHYSIOL, V66, P735, DOI 10.1152/jn.1991.66.3.735; GRAFTON ST, 1993, EXP BRAIN RES, V95, P172; HESS G, 1994, J NEUROPHYSIOL, V71, P2543, DOI 10.1152/jn.1994.71.6.2543; HUNTLEY GW, 1991, J NEUROPHYSIOL, V66, P390, DOI 10.1152/jn.1991.66.2.390; JACOBS KM, 1991, SCIENCE, V251, P944, DOI 10.1126/science.2000496; KIM SG, 1993, J NEUROPHYSIOL, V69, P297, DOI 10.1152/jn.1993.69.1.297; KIM SG, 1993, SCIENCE, V261, P615, DOI 10.1126/science.8342027; KWAN HC, 1978, J NEUROPHYSIOL, V41, P1120, DOI 10.1152/jn.1978.41.5.1120; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LUKASHIN AV, 1994, P NATL ACAD SCI USA, V91, P8651, DOI 10.1073/pnas.91.18.8651; MCKIERNAN BJ, 1994, ROC NEUR ABS, V20, P983; NUDO RJ, 1992, J NEUROSCI, V12, P2918, DOI 10.1523/JNEUROSCI.12-08-02918.1992; Penfield W, 1937, BRAIN, V60, P389, DOI 10.1093/brain/60.4.389; RAO SM, 1995, NEUROLOGY, V45, P919, DOI 10.1212/WNL.45.5.919; RAO SM, 1993, NEUROLOGY, V43, P2311, DOI 10.1212/WNL.43.11.2311; ROLAND PE, 1980, J NEUROPHYSIOL, V43, P137, DOI 10.1152/jn.1980.43.1.137; ROLAND PE, 1980, J NEUROPHYSIOL, V43, P118, DOI 10.1152/jn.1980.43.1.118; SANES JN, 1994, BEHAV BRAIN SCI, V17, P221, DOI 10.1017/S0140525X00034270; SCHAD LR, 1993, MAGN RESON IMAGING, V11, P461, DOI 10.1016/0730-725X(93)90464-O; SCHIEBER MH, 1993, SCIENCE, V261, P489, DOI 10.1126/science.8332915; WOOLSEY CN, 1950, RES PUBL ASSOC RES N, V30, P238	29	367	376	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 23	1995	268	5218					1775	1777		10.1126/science.7792606	http://dx.doi.org/10.1126/science.7792606			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792606				2022-12-28	WOS:A1995RE66800049
J	FREIS, ED				FREIS, ED			THE EFFICACY AND SAFETY OF DIURETICS IN TREATING HYPERTENSION	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							SYSTEMIC HYPERTENSION; INDUCED HYPOKALEMIA; BLOOD-PRESSURE; THERAPY; TRIAL; POTASSIUM; PLASMA; MORTALITY; ELECTROLYTES; ARRHYTHMIAS	The efficacy of thiazides and related diuretics in preventing most of the complications of hypertension has been conclusively documented in long-term controlled trials. Among their adverse effects, thiazides may induce a short-term increase in serum cholesterol levels. However, the elevation returns to pretreatment levels during long-term therapy. In addition, long-term treatment with thiazides is not associated with an elevation of blood glucose levels or an increased incidence of diabetes. Because the long-term controlled trials have shown that thiazides provide more protection against stroke than against coronary heart disease events, it is possible that the difference may be caused by adverse effects of the diuretics. In three of four recent trials that used low doses of thiazides plus potassium-sparing diuretics, the number of sudden deaths was reduced more than in other trials that used high doses of diuretics alone. A recent case-control study also found that small doses of diuretics combined with potassium-sparing drugs were associated with a reduced number of sudden deaths compared with high doses used alone. Although these results suggest that small doses reduce the risk for sudden death more than do large doses, they cannot be regarded as conclusive. A randomized double-blind trial comparing low and high doses of thiazide diuretics and potassium-sparing drugs must be done. For now, however, small doses seem prudent for treating hypertension.			FREIS, ED (corresponding author), VET ADM MED CTR, HYPERTENS RES CLIN, 50 IRVING ST NW, WASHINGTON, DC 20422 USA.							AMERY A, 1982, ACTA CARDIOL, V37, P235; AMERY A, 1985, LANCET, V1, P1349; AMES RP, 1976, AM J MED, V61, P748, DOI 10.1016/0002-9343(76)90156-X; [Anonymous], 1985, J Hypertens, V3, P379; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1970, JAMA, V213, P1143; ARAOYE MA, 1978, AM HEART J, V96, P731, DOI 10.1016/0002-8703(78)90005-4; BERGLUND G, 1986, J HYPERTENS, V4, pS525; BERGSTROM J, 1973, ACTA MED SCAND, V194, P427; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CORT JH, 1954, LANCET, V1, P1202; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DYCKNER T, 1979, AM HEART J, V97, P12, DOI 10.1016/0002-8703(79)90108-X; ELIN RJ, 1988, YEARBOOK CHICAGO, V34, P161; FLETCHER GF, 1968, AM HEART J, V75, P319, DOI 10.1016/0002-8703(68)90088-4; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; Guyton AC, 1991, TXB MED PHYSL; HELGELAND A, 1980, AM J MED, V69, P725, DOI 10.1016/0002-9343(80)90438-6; HOLLAND OB, 1981, AM J MED, V70, P762, DOI 10.1016/0002-9343(81)90530-1; HOLLIFIELD JW, 1981, ACTA MED SCAND, P67; Hypertension Detection Follow-up Program Cooperative Group, 1979, JAMA-J AM MED ASSOC, V242, P2562, DOI DOI 10.1001/JAMA.1979.03300230018021; ISERI IT, 1952, AM HEART J, V43, P315; KANNEL WB, 1977, LANCET, V1, P1362; KASSIRER JP, 1977, KIDNEY INT, V11, P505, DOI 10.1038/ki.1977.67; KJELSBERG MO, 1985, AM J CARDIOL, V55, P1; KOSTIS JB, 1992, J AM COLL CARDIOL, V19, P1910; LASSER NL, 1984, AM J MED, V76, P52, DOI 10.1016/0002-9343(84)90957-4; LIEF PD, 1984, KIDNEY INT, V25, P203; LIM P, 1972, BMJ-BRIT MED J, V3, P620, DOI 10.1136/bmj.3.5827.620; MADIAS JE, 1984, ARCH INTERN MED, V144, P2171, DOI 10.1001/archinte.144.11.2171; MATERSON BJ, 1982, JAMA-J AM MED ASSOC, V248, P1996; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MIETTINEN TA, 1985, JAMA-J AM MED ASSOC, V254, P2097, DOI 10.1001/jama.254.15.2097; PAPADEMETRIOU V, 1988, ARCH INTERN MED, V148, P1272, DOI 10.1001/archinte.148.6.1272; PAPADEMETRIOU V, 1985, AM HEART J, V110, P595, DOI 10.1016/0002-8703(85)90080-8; PAPADEMETRIOU V, 1984, AM J CARDIOL, V54, P1015, DOI 10.1016/S0002-9149(84)80136-8; PAPADEMETRIOU V, 1989, AM J CARDIOL, V64, P1152, DOI 10.1016/0002-9149(89)90869-2; PAPADEMETRIOU V, 1983, AM J CARDIOL, V52, P1017, DOI 10.1016/0002-9149(83)90523-4; PRISANT LM, 1992, AM J HYPERTENS, V5, P775, DOI 10.1093/ajh/5.10.775; ROGERS WJ, 1979, AM J CARDIOL, V43, P801, DOI 10.1016/0002-9149(79)90081-X; RUDE RK, 1989, AM J CARDIOL, V63, pG31, DOI 10.1016/0002-9149(89)90216-6; SCHOENFELD MR, 1964, CURR THER RES CLIN E, V6, P180; SHEEHAN J, 1982, BMJ-BRIT MED J, V285, P1157, DOI 10.1136/bmj.285.6349.1157; SIEGEL D, 1992, JAMA-J AM MED ASSOC, V267, P1083, DOI 10.1001/jama.267.8.1083; SISCOVICK DS, 1994, NEW ENGL J MED, V330, P1852, DOI 10.1056/NEJM199406303302603; SMITH WM, 1977, CIRC RES, V40, P98; STRUTHERS AD, 1983, LANCET, V1, P1358; WILHELMSEN L, 1987, J HYPERTENS, V5, P561, DOI 10.1097/00004872-198710000-00009; WILKSTRAND J, 1992, JAMA-J AM MED ASSOC, V304, P405; 1977, BRIT MED J, V1, P1437; 1982, JAMA-J AM MED ASSOC, V248, P2004; 1908, LANCET, V1, P1261; 1994, WHOLESALE PRICES PHA	54	50	51	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1995	122	3					223	226		10.7326/0003-4819-122-3-199502010-00011	http://dx.doi.org/10.7326/0003-4819-122-3-199502010-00011			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD733	7810942				2022-12-28	WOS:A1995QD73300011
J	SHERLOCK, S				SHERLOCK, S			ALCOHOLIC LIVER-DISEASE	LANCET			English	Review											SHERLOCK, S (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT SURG,POND ST,LONDON NW3 2QG,ENGLAND.		Morgan, Marsha Y/C-5909-2009					BADDOUR N, 1992, Gastroenterology, V102, pA777; BELL H, 1993, ALCOHOL CLIN EXP RES, V17, P246, DOI 10.1111/j.1530-0277.1993.tb00757.x; BLEN TH, 1993, ADDICTION, V88, P315; DAY CP, 1992, GUT, V33, P1444, DOI 10.1136/gut.33.11.1444; FONG TL, 1994, HEPATOLOGY, V19, P554, DOI 10.1002/hep.1840190303; KEARNS PJ, 1992, GASTROENTEROLOGY, V100, P200; LIEBER CS, 1993, SEMIN LIVER DIS, V13, P109; LUCEY MR, 1992, GASTROENTEROLOGY, V102, P1736, DOI 10.1016/0016-5085(92)91737-O; LUMENG L, 1994, GASTROENTEROLOGY, V107, P572, DOI 10.1016/0016-5085(94)90185-6; MENDENHALL CL, 1993, HEPATOLOGY, V17, P564, DOI 10.1002/hep.1840170407; MILLER C, 1994, ALCOHOL CLIN EXP RES, V18, P224, DOI 10.1111/j.1530-0277.1994.tb00004.x; NOMPLEGGI DJ, 1994, HEPATOLOGY, V19, P518; ORREGO H, 1994, J HEPATOL, V20, P343, DOI 10.1016/S0168-8278(94)80005-7; OSORIO RW, 1994, HEPATOLOGY, V20, P105, DOI 10.1016/0270-9139(94)90141-4; PRIJATMOKO D, 1993, GASTROENTEROLOGY, V105, P1839, DOI 10.1016/0016-5085(93)91083-T; RAMOND MJ, 1992, NEW ENGL J MED, V362, P507; SHERLOCK S, 1993, DISEASE LIVER BILIAR, P370; SHERLOCK S, 1994, DIS MON, V40, P121; SORRELL MF, 1994, ALCOHOL CLIN EXP RES, V18, P22; ZIGNEGO AL, 1994, HEPATOLOGY, V19, P577, DOI 10.1002/hep.1840190306	20	77	81	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 28	1995	345	8944					227	229						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7823717				2022-12-28	WOS:A1995QD53200012
J	MORAIYOUNG, C				MORAIYOUNG, C			A MUTUAL INVESTMENT COMPANY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	1995	273	4					340	340						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC057	7815665				2022-12-28	WOS:A1995QC05700037
J	GUPTA, S; CAMPBELL, D; DERIJARD, B; DAVIS, RJ				GUPTA, S; CAMPBELL, D; DERIJARD, B; DAVIS, RJ			TRANSCRIPTION FACTOR ATF2 REGULATION BY THE JNK SIGNAL-TRANSDUCTION PATHWAY	SCIENCE			English	Article							RETINOBLASTOMA GENE-PRODUCT; DNA-BINDING SPECIFICITY; LEUCINE ZIPPER PROTEINS; C-JUN; HETERODIMER FORMATION; TAX PROTEIN; CREB; FAMILY; E1A; PHOSPHORYLATION	Treatment of cells with pro-inflammatory cytokines or ultraviolet radiation causes activation of the c-Jun NH2-terminal protein kinase (JNK). Activating transcription factor-2 (ATF2) was found to be a target of the JNK signal transduction pathway. ATF2 was phosphorylated by JNK on two closely spaced threonine residues within the NH2-terminal activation domain. The replacement of these phosphorylation sites with alanine inhibited the transcriptional activity of ATF2. These mutations also inhibited ATF2-stimulated gene expression mediated by the retinoblastoma (Rb) tumor suppressor and the adenovirus early region 1A (E1A) oncoprotein. Furthermore, expression of dominant-negative JNK inhibited ATF2 transcriptional activity. Together, these data demonstrate a role for the JNK signal transduction pathway in transcriptional responses mediated by ATF2.	UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester								ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BENBROOK DM, 1990, ONCOGENE, V5, P295; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DELUCA LG, 1994, J BIOL CHEM, V269, P19193; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FLINT KJ, 1991, ONCOGENE, V6, P2019; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; Gupta SK, UNPUB; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOEFFLER JP, 1992, J INVEST DERMATOL, V98, pS21, DOI 10.1111/1523-1747.ep12462126; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KALLUNKI T, IN PRESS GENES DEV; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SETH A, 1992, J BIOL CHEM, V267, P24796; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DH, 1985, MOL CELL BIOL, V5, P2684, DOI 10.1128/MCB.5.10.2684; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	40	1342	1360	1	39	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 20	1995	267	5196					389	393		10.1126/science.7824938	http://dx.doi.org/10.1126/science.7824938			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC273	7824938				2022-12-28	WOS:A1995QC27300039
J	SANTORO, M; CARLOMAGNO, F; ROMANO, A; BOTTARO, DP; DATHAN, NA; GRIECO, M; FUSCO, A; VECCHIO, G; MATOSKOVA, B; KRAUS, MH; DIFIORE, PP				SANTORO, M; CARLOMAGNO, F; ROMANO, A; BOTTARO, DP; DATHAN, NA; GRIECO, M; FUSCO, A; VECCHIO, G; MATOSKOVA, B; KRAUS, MH; DIFIORE, PP			ACTIVATION OF RET AS A DOMINANT TRANSFORMING GENE BY GERMLINE MUTATIONS OF MEN2A AND MEN2B	SCIENCE			English	Article							CELLS; PROTOONCOGENE; RECEPTOR; ONCOGENE; KINASE	Multiple endocrine neoplasia types 2A and 2B (MEN2A and MEN2B) and familial medullary thyroid carcinoma are dominantly inherited cancer syndromes. All three syndromes are associated with mutations in RET, which encodes a receptor-like tyrosine kinase. The altered RET alleles were shown to be transforming genes in NIH 3T3 cells as a consequence of constitutive activation of the RET kinase. The MEN2A mutation resulted in RET dimerization at steady state, whereas the MEN2B mutation altered RET catalytic properties both quantitatively and qualitatively. Oncogenic conversion RET in these neoplastic syndromes establishes germline transmission of dominant transforming genes in human cancer.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; UNIV NAPLES,CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,NAPLES,ITALY; UNIV NAPLES,DEPT BIOL & PATOL CELLULARE & MOLEC L CALIFANO,NAPLES,ITALY; NCI,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20892; FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,CATANZARO,ITALY; NCI,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Naples Federico II; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Magna Graecia University of Catanzaro; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Di Fiore, Pier Paolo/K-2130-2012; Bottaro, Donald P/F-8550-2010; Bottaro, Donald P/AAF-3853-2020	Di Fiore, Pier Paolo/0000-0002-2252-0950; Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334; Grieco, Michele/0000-0002-4212-7814; Fusco, Alfredo/0000-0003-3332-5197				CARLOMAGNO F, UNPUB; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; COCHET C, 1988, J BIOL CHEM, V263, P3290; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; ROMANO A, 1994, ONCOGENE, V9, P2923; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, UNPUB; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TAKAHASHI M, 1988, ONCOGENE, V4, P805; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	20	716	729	0	12	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 20	1995	267	5196					381	383		10.1126/science.7824936	http://dx.doi.org/10.1126/science.7824936			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC273	7824936	Green Submitted			2022-12-28	WOS:A1995QC27300036
J	GANZ, LI; FRIEDMAN, PL				GANZ, LI; FRIEDMAN, PL			MEDICAL PROGRESS - SUPRAVENTRICULAR TACHYCARDIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							WOLFF-PARKINSON-WHITE; RADIOFREQUENCY CATHETER ABLATION; ACCESSORY ATRIOVENTRICULAR CONNECTIONS; MULTIFOCAL ATRIAL TACHYCARDIA; NODAL REENTRANT TACHYCARDIA; SHORT REFRACTORY PERIOD; WIDE QRS COMPLEX; SLOW-PATHWAY; RECIPROCATING TACHYCARDIA; ECTOPIC TACHYCARDIA		BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,CARDIAC ARRHYTHMIA SERV,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,CLIN ELECTROPHYSIOL LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School								AKHTAR M, 1993, CIRCULATION, V88, P282, DOI 10.1161/01.CIR.88.1.282; ANDERSON JL, 1992, AM J CARDIOL, V70, pA11, DOI 10.1016/0002-9149(92)91072-C; ARSURA E, 1988, AM J MED, V85, P519; Arsura E, 1989, AM J MED, V86, P142; ARSURA EL, 1987, CRIT CARE MED, V15, P591, DOI 10.1097/00003246-198706000-00010; ATIE J, 1990, AM J CARDIOL, V66, P1082, DOI 10.1016/0002-9149(90)90509-Y; AVITALL B, 1993, J AM COLL CARDIOL, V22, P921, DOI 10.1016/0735-1097(93)90212-J; BARDY GH, 1984, CIRCULATION, V70, P377, DOI 10.1161/01.CIR.70.3.377; BAUERNFEIND RA, 1980, CIRCULATION, V62, P1341, DOI 10.1161/01.CIR.62.6.1341; BERKMAN NL, 1968, NEW ENGL J MED, V278, P492, DOI 10.1056/NEJM196802292780906; BEST JF, 1986, CLIN CARDIOL, V9, P268, DOI 10.1002/clc.4960090607; BRUGADA P, 1991, CIRCULATION, V83, P1649, DOI 10.1161/01.CIR.83.5.1649; BRUGADA P, 1981, AM J CARDIOL, V48, P611, DOI 10.1016/0002-9149(81)90138-7; BRUGADA P, 1984, AM J CARDIOL, V53, P88, DOI 10.1016/0002-9149(84)90689-1; Cabrol C, 1967, ARCH MAL COEUR, V60, P1830; CALKINS H, 1991, CIRCULATION, V84, P2376, DOI 10.1161/01.CIR.84.6.2376; CALKINS H, 1992, CIRCULATION, V85, P1337, DOI 10.1161/01.CIR.85.4.1337; CALKINS H, 1991, NEW ENGL J MED, V324, P1612, DOI 10.1056/NEJM199106063242302; CAMM AJ, 1991, NEW ENGL J MED, V325, P1621, DOI 10.1056/NEJM199112053252306; CAMPBELL RWF, 1977, AM J CARDIOL, V40, P514, DOI 10.1016/0002-9149(77)90065-0; CHEN PS, 1992, J AM COLL CARDIOL, V19, P974, DOI 10.1016/0735-1097(92)90281-Q; CHEN SA, 1993, CIRCULATION, V88, P578, DOI 10.1161/01.CIR.88.2.578; CHEN SA, 1992, AM HEART J, V124, P356, DOI 10.1016/0002-8703(92)90598-P; COBB FR, 1968, CIRCULATION, V38, P1018, DOI 10.1161/01.CIR.38.6.1018; COLLORIDI V, 1992, AM HEART J, V123, P254, DOI 10.1016/0002-8703(92)90785-T; COX JL, 1990, J THORAC CARDIOV SUR, V99, P440; CRUZ FES, 1990, J AM COLL CARDIOL, V16, P739, DOI 10.1016/0735-1097(90)90368-Y; CUSHLEY MJ, 1983, BRIT J CLIN PHARMACO, V15, P161, DOI 10.1111/j.1365-2125.1983.tb01481.x; DIMARCO JP, 1990, ANN INTERN MED, V113, P996, DOI 10.7326/0003-4819-113-12-996_3; DIMARCO JP, 1985, J AM COLL CARDIOL, V6, P417, DOI 10.1016/S0735-1097(85)80181-9; DIMARCO JP, 1990, ANN INTERN MED, V113, P104, DOI 10.7326/0003-4819-113-2-104; DOUGHERTY AH, 1992, AM J CARDIOL, V70, P587, DOI 10.1016/0002-9149(92)90196-6; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; ELLENBOGEN KA, 1990, CIRCULATION, V81, P821, DOI 10.1161/01.CIR.81.3.821; EVANS VL, 1987, AM J CARDIOL, V60, pF83; FARRE J, 1979, AM J CARDIOL, V44, P1099, DOI 10.1016/0002-9149(79)90175-9; GALLAGHER JJ, 1978, EUR J CARDIOL, V8, P413; GALLAGHER JJ, 1984, TACHYCARDIAS MECHANI, P259; GARRATT C, 1989, LANCET, V1, P367; GARRATT CJ, 1991, CIRCULATION, V84, P1962, DOI 10.1161/01.CIR.84.5.1962; GIUDICI MC, 1993, PACE PACING CLIN ELE, V16, P12049; GOLDBERGER J, 1993, AM J CARDIOL, V72, P787, DOI 10.1016/0002-9149(93)91063-N; GOLDREYER BN, 1973, AM HEART J, V85, P205, DOI 10.1016/0002-8703(73)90462-6; GOY JJ, 1990, J AM COLL CARDIOL, V16, P418, DOI 10.1016/0735-1097(90)90595-G; GRIFFITH MJ, 1989, CLIN CARDIOL, V12, P409, DOI 10.1002/clc.4960120712; GRIFFITH MJ, 1988, LANCET, V1, P672; GUIRAUDON GM, 1989, AM J CARDIOL, V64, pJ92, DOI 10.1016/0002-9149(89)91209-5; GUIZE L, 1985, ANN MED INTERNE, V136, P474; GULAMHUSEIN S, 1982, CIRCULATION, V65, P348, DOI 10.1161/01.CIR.65.2.348; GURSOY S, 1992, NEW ENGL J MED, V327, P772, DOI 10.1056/NEJM199209103271105; HAINES DE, 1990, J AM COLL CARDIOL, V15, P1345, DOI 10.1016/S0735-1097(10)80025-7; HAISSAGUERRE M, 1992, CIRCULATION, V85, P2162, DOI 10.1161/01.CIR.85.6.2162; HELLESTRAND KJ, 1988, AM J CARDIOL, V62, pD16; HENTHORN RW, 1991, CIRCULATION, V83, P119, DOI 10.1161/01.CIR.83.1.119; HINDRICKS G, 1993, EUR HEART J, V14, P1644, DOI 10.1093/eurheartj/14.12.1644; ISERI LT, 1985, AM HEART J, V110, P789, DOI 10.1016/0002-8703(85)90458-2; IWA T, 1993, CIRCULATION, V88, P62; JACKMAN WM, 1991, NEW ENGL J MED, V324, P1605, DOI 10.1056/NEJM199106063242301; JACKMAN WM, 1992, NEW ENGL J MED, V327, P313, DOI 10.1056/NEJM199207303270504; JAZAYERI MR, 1992, CIRCULATION, V85, P1318, DOI 10.1161/01.CIR.85.4.1318; JOSEPHSON ME, 1993, CLIN CARDIAC ELECTRO; KALBFLEISCH SJ, 1993, J AM COLL CARDIOL, V21, P567, DOI 10.1016/0735-1097(93)90086-G; KALBFLEISCH SJ, 1993, J AM COLL CARDIOL, V21, P85, DOI 10.1016/0735-1097(93)90720-L; KALBFLEISCH SJ, 1992, J CARDIOVASC ELECTR, V3, P173, DOI 10.1111/j.1540-8167.1992.tb01106.x; KALBFLEISCH SJ, 1992, J AM COLL CARDIOL, V19, P1583, DOI 10.1016/0735-1097(92)90621-S; KASTOR JA, 1990, NEW ENGL J MED, V322, P1713; KAY GN, 1993, J CARDIOVASC ELECTR, V4, P371, DOI 10.1111/j.1540-8167.1993.tb01277.x; KAY GN, 1993, J AM COLL CARDIOL, V21, P901, DOI 10.1016/0735-1097(93)90345-2; KERR CR, 1985, AM HEART J, V110, P966, DOI 10.1016/0002-8703(85)90193-0; KLEIN G J, 1989, New England Journal of Medicine, V320, P1229, DOI 10.1056/NEJM198905113201901; KLEIN GJ, 1979, NEW ENGL J MED, V301, P1080, DOI 10.1056/NEJM197911153012003; KLEIN GJ, 1983, AM J CARDIOL, V52, P292, DOI 10.1016/0002-9149(83)90125-X; KLEIN GJ, 1989, CIRCULATION, V80, P1902, DOI 10.1161/01.CIR.80.6.1902; KOPELMAN HA, 1989, PROG CARDIOVASC DIS, V31, P355, DOI 10.1016/0033-0620(89)90030-3; KUCK KH, 1991, LANCET, V337, P1557, DOI 10.1016/0140-6736(91)93258-B; KUGLER JD, 1994, NEW ENGL J MED, V330, P1481, DOI 10.1056/NEJM199405263302103; KUNZE KP, 1986, J AM COLL CARDIOL, V7, P1121, DOI 10.1016/S0735-1097(86)80233-9; KUNZE KP, 1987, CIRCULATION, V75, P1050, DOI 10.1161/01.CIR.75.5.1050; LANGBERG JJ, 1992, J AM COLL CARDIOL, V19, P1588, DOI 10.1016/0735-1097(92)90622-T; LANGBERG JJ, 1993, CIRCULATION, V87, P1551, DOI 10.1161/01.CIR.87.5.1551; LARSSON K, 1988, CHEST, V93, P280, DOI 10.1378/chest.93.2.280; LEE MA, 1991, CIRCULATION, V83, P827, DOI 10.1161/01.CIR.83.3.827; LERMAN BB, 1991, CIRCULATION, V83, P1499, DOI 10.1161/01.CIR.83.5.1499; LERMAN BB, 1989, CIRCULATION, V80, P1536, DOI 10.1161/01.CIR.80.6.1536; LESH MD, 1994, CIRCULATION, V89, P1074, DOI 10.1161/01.CIR.89.3.1074; LESH MD, 1992, J AM COLL CARDIOL, V19, P1303, DOI 10.1016/0735-1097(92)90338-N; LEVINE JH, 1985, NEW ENGL J MED, V312, P21, DOI 10.1056/NEJM198501033120105; MAN KC, 1993, AM J CARDIOL, V72, P1323, DOI 10.1016/0002-9149(93)90308-Y; MARGOLIS B, 1980, AM J CARDIOL, V45, P621, DOI 10.1016/S0002-9149(80)80014-2; MEHTA D, 1988, LANCET, V1, P1181; MILSTEIN S, 1986, AM J CARDIOL, V57, P1097, DOI 10.1016/0002-9149(86)90681-8; MONTOYA PT, 1991, EUR HEART J, V12, P144; MORADY F, 1983, AM J CARDIOL, V51, P1623, DOI 10.1016/0002-9149(83)90198-4; MURDOCK CJ, 1991, AM J CARDIOL, V67, P506, DOI 10.1016/0002-9149(91)90012-A; NARULA OS, 1974, CIRCULATION, V50, P1114, DOI 10.1161/01.CIR.50.6.1114; Oren Jess W. Iv, 1993, Cardiology Clinics, V11, P121; PERELMAN MS, 1987, BRIT HEART J, V58, P528; PRAGER NA, 1993, J AM COLL CARDIOL, V22, P85, DOI 10.1016/0735-1097(93)90819-M; PRITCHETT ELC, 1991, AM J CARDIOL, V67, P976, DOI 10.1016/0002-9149(91)90170-P; PRITCHETT ELC, 1991, ANN INTERN MED, V114, P539, DOI 10.7326/0003-4819-114-7-539; PRITCHETT ELC, 1992, NEW ENGL J MED, V326, P1264; RABBANI LE, 1991, AM HEART J, V121, P816, DOI 10.1016/0002-8703(91)90193-L; RANKIN AC, 1989, BRIT HEART J, V62, P195; ROSEN KM, 1973, CIRCULATION, V47, P654, DOI 10.1161/01.CIR.47.3.654; ROSEN MR, 1980, AM J CARDIOL, V45, P1272, DOI 10.1016/0002-9149(80)90489-0; SAGER PT, 1990, AM HEART J, V119, P308, DOI 10.1016/S0002-8703(05)80021-3; SALERNO DM, 1987, ANN INTERN MED, V107, P623, DOI 10.7326/0003-4819-107-5-623; SANDERS WE, 1994, J AM COLL CARDIOL, V23, P926, DOI 10.1016/0735-1097(94)90639-4; SAPIRE DW, 1979, J PEDIATR-US, V94, P312, DOI 10.1016/S0022-3476(79)80855-0; SCHEINMA.MM, 1974, CIRCULATION, V50, P266, DOI 10.1161/01.CIR.50.2.266; SCHEINMAN MM, 1992, PACE, V15, P715, DOI 10.1111/j.1540-8159.1992.tb06835.x; SCHLUTER M, 1993, PACE, V16, P643, DOI 10.1111/j.1540-8159.1993.tb01637.x; SCHLUTER M, 1992, Z KARDIOL, V81, P249; SHARMA AD, 1990, AM J MED, V88, P337, DOI 10.1016/0002-9343(90)90486-W; SINGH BN, 1987, DRUGS, V34, P311, DOI 10.2165/00003495-198734030-00002; SMITH RF, 1964, CIRCULATION, V29, P672, DOI 10.1161/01.CIR.29.5.672; SMITH TW, 1984, PROG CARDIOVASC DIS, V27, P21, DOI 10.1016/0033-0620(84)90018-5; STEWART RB, 1986, ANN INTERN MED, V104, P766, DOI 10.7326/0003-4819-104-6-766; STRASBERG B, 1980, AM J CARDIOL, V45, P742, DOI 10.1016/0002-9149(80)90116-2; STRICKBERGER SA, 1993, AM J CARDIOL, V71, P473; SUNG RJ, 1980, ANN INTERN MED, V93, P682, DOI 10.7326/0003-4819-93-5-682; SUNG RJ, 1977, CIRCULATION, V56, P409, DOI 10.1161/01.CIR.56.3.409; TRACY CM, 1993, J AM COLL CARDIOL, V21, P910, DOI 10.1016/0735-1097(93)90346-3; WALDO AL, 1993, LANCET, V341, P1189, DOI 10.1016/0140-6736(93)91012-B; WALSH EP, 1992, CIRCULATION, V86, P1138, DOI 10.1161/01.CIR.86.4.1138; WATHEN M, 1992, AM J CARDIOL, V70, P886, DOI 10.1016/0002-9149(92)90732-E; WELLENS HJ, 1973, CIRCULATION, V47, P1229, DOI 10.1161/01.CIR.47.6.1229; WELLENS HJJ, 1978, AM J MED, V64, P27, DOI 10.1016/0002-9343(78)90176-6; WELLENS HJJ, 1975, CIRCULATION, V52, P779, DOI 10.1161/01.CIR.52.5.779; WELLENS HJJ, 1976, AM J CARDIOL, V38, P189, DOI 10.1016/0002-9149(76)90148-X; WELLENS HJJ, 1980, AM J CARDIOL, V45, P130, DOI 10.1016/0002-9149(80)90230-1; WELLENS HJJ, 1983, AM HEART J, V106, P876, DOI 10.1016/0002-8703(83)90010-8; WELLENS HJJ, 1982, AM J CARDIOL, V50, P1087, DOI 10.1016/0002-9149(82)90422-2; WELLENS HJJ, 1971, ELECTRICAL STIMULATI; WELLENS HJJ, 1986, MED MANAGEMENT CARDI, P121; WINNIFORD MD, 1984, AM J CARDIOL, V54, P1138, DOI 10.1016/S0002-9149(84)80162-9; Wolff L, 1930, AM HEART J, V5, P685, DOI 10.1016/S0002-8703(30)90086-5; WU D, 1981, CIRCULATION, V64, P823, DOI 10.1161/01.CIR.64.4.823; WU D, 1975, CIRCULATION, V51, P234, DOI 10.1161/01.CIR.51.2.234; WU DL, 1993, J AM COLL CARDIOL, V21, P1612, DOI 10.1016/0735-1097(93)90376-C	140	127	136	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 19	1995	332	3					162	173		10.1056/NEJM199501193320307	http://dx.doi.org/10.1056/NEJM199501193320307			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB160	7800009				2022-12-28	WOS:A1995QB16000007
J	THORN, SN; DANIELS, RG; AUDITOR, MTM; HILVERT, D				THORN, SN; DANIELS, RG; AUDITOR, MTM; HILVERT, D			LARGE RATE ACCELERATIONS IN ANTIBODY CATALYSIS BY STRATEGIC USE OF HAPTENIC CHARGE	NATURE			English	Article							PHYSICAL ORGANIC-CHEMISTRY; BENZISOXAZOLES; ENERGY	GENERAL acid-base catalysis contributes substantially to the efficacy of many enzymes, enabling an impressive array of eliminations, isomerizations, racemizations, hydrolyses and carbon-carbon bond-forming reactions to be carried out with high rates and selectivities(1). The fundamental challenge of exploiting similar effects in designed catalysts such as catalytic antibodies(2,3) is that of correctly positioning the catalytic groups in an appropriate active-site microenvironment, Charge complementarity between antibody and hapten (the template used to induce an antibody) has been used successfully in a number of instances to elicit acids and bases within immunoglobulin combining sites(4-9), but the activities of the catalysts obtained by this strategy are generally considerably lower than those of natural enzymes, Here we report that by optimizing hapten design and efficiently screening the immune response, antibodies can be obtained that act effectively as general base catalysts. Thus a cationic hapten correctly mimicking the transition-state geometry of all reacting bonds and bearing little resemblance to the reaction product has yielded carboxylate-containing antibodies that catalyse an E2 elimination with more than 10(3) turnovers per active site and rate accelerations of greater than 10(8). These results demonstrate that very large effects can be achieved by strategic use of haptenic charge.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT BIOL MOLEC, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute								AHRLOW E, 1988, ANTIBODIES LABORATOR; CASEY ML, 1973, J ORG CHEM, V38, P2295; CRAVATT BF, 1994, J AM CHEM SOC, V116, P6013, DOI 10.1021/ja00092a080; GERIT JA, 1991, J AM CHEM SOC, V113, P9667; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; HILVERT D, 1988, P NATL ACAD SCI USA, V85, P4953, DOI 10.1073/pnas.85.14.4953; HILVERT D, 1994, CURR OPIN STRUC BIOL, V4, P612, DOI 10.1016/S0959-440X(94)90226-7; JACKSON DY, 1991, J AM CHEM SOC, V113, P2319, DOI 10.1021/ja00006a070; JANDA KD, 1990, J AM CHEM SOC, V112, P1274, DOI 10.1021/ja00159a074; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; KEMP DS, 1975, J AM CHEM SOC, V97, P7312, DOI 10.1021/ja00858a018; KEMP DS, 1973, J AM CHEM SOC, V95, P6670, DOI 10.1021/ja00801a024; Kirby A.J., 1980, ADV PHYS ORG CHEM, V17, P183; KULIOPULOS A, 1990, BIOCHEMISTRY-US, V29, P10271, DOI 10.1021/bi00496a017; LAUER RC, 1974, EXPERIENTIA, V30, P560, DOI 10.1007/BF01926352; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LUNDBLAD RL, 1991, CHEM REAGENTS PROTEI, P267; PARKER AJ, 1969, CHEM REV, V69, P1, DOI 10.1021/cr60257a001; REYMOND JL, 1993, J AM CHEM SOC, V115, P3909, DOI 10.1021/ja00063a009; SHOKAT K, 1994, J AM CHEM SOC, V116, P2261, DOI 10.1021/ja00085a004; SHOKAT KM, 1989, NATURE, V338, P269, DOI 10.1038/338269a0; UNO T, 1992, J AM CHEM SOC, V114, P6573, DOI 10.1021/ja00042a055; WALSH CT, 1979, ENZYMATIC REACTION M; WARSHELL A, 1991, COMPUTER MODELING CH, P153	24	133	138	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					228	230		10.1038/373228a0	http://dx.doi.org/10.1038/373228a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	QC278	7816136				2022-12-28	WOS:A1995QC27800057
J	WU, L; NIEMEYER, B; COLLEY, N; SOCOLICH, M; ZUKER, CS				WU, L; NIEMEYER, B; COLLEY, N; SOCOLICH, M; ZUKER, CS			REGULATION OF PLC-MEDIATED SIGNALING IN-VIVO BY CDP-DIACYLGLYCEROL SYNTHASE	NATURE			English	Article							PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; PHOTORECEPTOR DEACTIVATION; DROSOPHILA PHOTORECEPTORS; DIGLYCERIDE SYNTHETASE; VISUAL TRANSDUCTION; MOLECULAR-CLONING; PHOSPHATIDIC-ACID; ESCHERICHIA-COLI; GENE	CDP-diacylglycerol synthase (CDS) is an enzyme required for the regeneration of the signalling molecule phosphatidylinositol-4,5-bisphosphate (PtdlnsP(2)) from phosphatidic acid. A photoreceptor cell-specific isoform of CDS from Drosophila is a key regulator of phototransduction, a G-protein-coupled signalling cascade mediated by phospholipase C, cds mutants cannot sustain a light-activated current as a result of depletion of PtdlnsP(2). Overexpression of CDS increases the amplitude of the light response, demonstrating that availability of PtdlnsP(2) is a determinant in the gain of this pathway. cds mutants undergo light-dependent retinal degeneration which can be suppressed by a mutation in phospholipase C. Thus, enzymes involved in PtdlnsP(2) metabolism regulate phosphoinositide-mediated signalling cascades in vivo.	UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT NEUROSCI, LA JOLLA, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego			Niemeyer, Barbara A./AAL-8972-2021	Wu, Louisa/0000-0001-8609-3081; Socolich, Michael/0000-0002-0702-1061	NEI NIH HHS [R01 EY008768] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008768] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ASHBRUNER M, 1989, DROSOPHILA LABORATOR; BAUMANN O, 1989, CELL TISSUE RES, V255, P511, DOI 10.1007/BF00218786; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1994, MOL CELL ENDOCRINOL, V98, P119, DOI 10.1016/0303-7207(94)90129-5; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; Breer H, 1992, Curr Opin Neurobiol, V2, P439, DOI 10.1016/0959-4388(92)90177-M; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; ELDRED WD, 1983, J HISTOCHEM CYTOCHEM, V31, P285, DOI 10.1177/31.2.6339606; EXTON JH, 1994, ANNU REV PHYSIOL, V56, P349; FEILER R, 1992, J NEUROSCI, V12, P3862; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; HARDIE RC, 1991, P ROY SOC B-BIOL SCI, V245, P203, DOI 10.1098/rspb.1991.0110; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HYDE DR, 1990, P NATL ACAD SCI USA, V87, P1008, DOI 10.1073/pnas.87.3.1008; ICHO T, 1985, J BIOL CHEM, V260, P2078; INOUE H, 1989, J BIOL CHEM, V264, P5996; JONES GA, 1993, J BIOL CHEM, V268, P20845; KENT C, 1991, FASEB J, V5, P2258, DOI 10.1096/fasebj.5.9.1860617; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; MARGOLSKEE RF, 1993, BIOESSAYS, V15, P645, DOI 10.1002/bies.950151003; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; MASAI I, 1992, P NATL ACAD SCI USA, V89, P6030, DOI 10.1073/pnas.89.13.6030; MASLANSKI JA, 1992, SCIENCE, V256, P243, DOI 10.1126/science.1314424; MCCABE MJ, 1992, ANN NY ACAD SCI, V663, P269, DOI 10.1111/j.1749-6632.1992.tb38670.x; MIYAZAKI S, 1993, DEV BIOL, V158, P62, DOI 10.1006/dbio.1993.1168; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MOOLENAAR WH, 1991, CELL GROWTH DIFFER, V2, P359; NIKOLOFF DM, 1991, ANNU REV GENET, V25, P559; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PAK WL, 1970, NATURE, V227, P518, DOI 10.1038/227518b0; PETERS KG, 1992, COLD SPRING HARB SYM, V57, P63, DOI 10.1101/SQB.1992.057.01.008; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; RANGANATHAN R, 1991, NATURE, V354, P230, DOI 10.1038/354230a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAEFFER E, 1989, CELL, V57, P403, DOI 10.1016/0092-8674(89)90915-X; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; SPARROW CP, 1985, J BIOL CHEM, V260, P2084; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VIHTELIC TS, 1993, J CELL BIOL, V122, P1013, DOI 10.1083/jcb.122.5.1013; YOSHIOKA T, 1985, J BIOCHEM-TOKYO, V97, P1251, DOI 10.1093/oxfordjournals.jbchem.a135171; Zuker Charles S., 1992, Current Opinion in Neurobiology, V2, P622, DOI 10.1016/0959-4388(92)90029-K	50	147	152	1	7	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 19	1995	373	6511					216	222		10.1038/373216a0	http://dx.doi.org/10.1038/373216a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816135				2022-12-28	WOS:A1995QC27800054
J	LEE, PR				LEE, PR			ADVANCING AMERICAS HEALTH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											LEE, PR (corresponding author), US PHS,OFF COMMUN,200 INDEPENDENCE AVE SW,ROOM 726-H,WASHINGTON,DC 20201, USA.							1994, HLTHY NATION RETURNS; 1994, HLTH CARE REFORM PUB	2	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					248	249						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB234	7807673				2022-12-28	WOS:A1995QB23400038
J	FERNER, RE; SCOTT, DK				FERNER, RE; SCOTT, DK			WHATALOTWEGOT - THE MESSAGES IN DRUG ADVERTISEMENTS	BRITISH MEDICAL JOURNAL			English	Article								Advertisers are increasingly using symbols to circumvent logical argument when trying to persuade people (the ''targets'' of the advertisement) to make choices that are not strictly rational. Symbols can convey covert meanings and awaken or exploit subconscious feelings, such as a desire for power or a fear of doing harm. Some of the ways in which pharmaceutical advertisements use these techniques are examined: advertising by contagion; adding to our worries; polarity of choices; teasers; idealisation. Rational prescribing should be based on logic, but advertisements do not depend on logical arguments for their most powerful effects: the advertisers may subvert us by appealing to our unconscious desires.	ANGLIA & OXFORD REG HLTH AUTHOR,OXFORD OX3 7LF,ENGLAND		FERNER, RE (corresponding author), CITY HOSP NHS TRUST,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND.			Ferner, Robin/0000-0003-3769-1346				AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; Barthes Roland, 1995, SEMIOTIC CHALLENGE; BELL E, 1993, OBSERVER        0530, P37; Dichter E., 1960, STRATEGY DESIRE; GOLDMAN R, 1986, SOC SCI MED, V22, P1047, DOI 10.1016/0277-9536(86)90205-4; KORNER RJ, 1994, BRIT MED J, V308, P191; LEXCHIN J, 1987, INT J HEALTH SERV, V17, P77, DOI 10.2190/4W1H-E70T-TL9X-VGGC; MCGAVOCK H, 1993, BRIT MED J, V307, P1118, DOI 10.1136/bmj.307.6912.1118; SCOTT DK, 1994, BRIT J CLIN PHARMACO, V37, P217, DOI 10.1111/j.1365-2125.1994.tb04265.x; Williamson Judith, 1978, DECODING ADVERTISEME; 1993, BRIT NATIONAL FORMUL, P31	11	13	15	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1734	1736		10.1136/bmj.309.6970.1734	http://dx.doi.org/10.1136/bmj.309.6970.1734			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PY717	7820006	Green Published			2022-12-28	WOS:A1994PY71700036
J	FOY, SJ				FOY, SJ			THE PATIENTS VIEW	BRITISH MEDICAL JOURNAL			English	Note																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1747	1747						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7820013				2022-12-28	WOS:A1994PY71700045
J	DAVIES, G; PYKE, S; KINMONTH, AL; WOOD, DA; COLES, C; CRAMB, R; DURRINGTON, P; KOK, Y; LEGUEN, C; MARTEAU, T; ODWYER, A; PYKE, SMD; STEELE, DW; THOMPSON, SG; YARWOOD, J				DAVIES, G; PYKE, S; KINMONTH, AL; WOOD, DA; COLES, C; CRAMB, R; DURRINGTON, P; KOK, Y; LEGUEN, C; MARTEAU, T; ODWYER, A; PYKE, SMD; STEELE, DW; THOMPSON, SG; YARWOOD, J			EFFECT OF NONATTENDERS ON THE POTENTIAL OF A PRIMARY-CARE PROGRAM TO REDUCE CARDIOVASCULAR RISK IN THE POPULATION	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; GENERAL-PRACTICE	Objectives-To determine the feasibility of enrolling non-attenders of a population based cardiovascular risk reduction programme (the British family heart study) into a further, similar programme and to assess the effect of non-attendance on the effectiveness of the programme. Design-Follow up of non-attenders by practice nurses, including home visits if necessary, to administer questionnaires and obtain physiological measurements. Setting-Eight general practices across England, Scotland, and Wales. Subjects-Non-attenders in a cardiovascular risk factor screening and intervention programme compared with attenders. Main outcome measures-Number of nonattenders enrolled; sociodemographic characteristics; personal and family history of coronary heart disease; cardiovascular risk factors; and total coronary risk score. Results-Data were collected from 106 (17%) of the 608 non-attending families (99 men and 42 women). Of the 543 non-attending families from five practices that attempted complete follow up, 256 had moved away or died. Only 76 were eventually enrolled into the study. The prevalence of coronary heart disease and a family history of coronary heart disease were similar among non-attenders and attenders as were the individual coronary risk factors studied except smoking. Women non-attenders were more likely to be current cigarette smokers than attenders (15/42 v 202/948, P = 0.02). Conclusions-The intensive follow up of nonattenders resulted in real intervention opportunities in only a small number. Since the effect of any intervention in a population is reduced by nonattendance audit of preventive medical programmes aimed at the population should allow for the effect of non-attenders on the overall results.	UNIV SOUTHAMPTON,FAC MED,SOUTHAMPTON,HANTS,ENGLAND; UNIV LONDON,LONDON SCH HYG & TROP MED,MED STAT UNIT,LONDON,ENGLAND	University of Southampton; University of London; London School of Hygiene & Tropical Medicine								CRIQUI MH, 1978, AM J EPIDEMIOL, V108, P367, DOI 10.1093/oxfordjournals.aje.a112633; DIFFORD F, 1987, BRIT MED J, V294, P1130, DOI 10.1136/bmj.294.6580.1130; KINMONTH AL, 1991, BRIT MED J, V303, P1060, DOI 10.1136/bmj.303.6809.1060-a; PILL R, 1988, J ROY COLL GEN PRACT, V38, P53; Rose G., 1992, STRATEGY PREVENTIVE; TUNSTALLPEDOE H, 1991, BRIT MED J, V303, P744, DOI 10.1136/bmj.303.6805.744; WRENCH JG, 1984, J ROY COLL GEN PRACT, V34, P477; 1992, HLTH NATION STRATEGY; 1994, BRIT MED J, V308, P313; 1991, BRIT MED J, V302, P1057	10	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 10	1994	309	6968					1553	1556		10.1136/bmj.309.6968.1553	http://dx.doi.org/10.1136/bmj.309.6968.1553			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX564	7819899	Green Published			2022-12-28	WOS:A1994PX56400025
J	TAUBES, G				TAUBES, G			PITTSBURGH - INTERWOVEN WITH THE FABRIC OF LEARNING	SCIENCE			English	Note																		1994, SCIENCE         1104, P872	1	3	3	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1709	1709		10.1126/science.7792591	http://dx.doi.org/10.1126/science.7792591			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792591				2022-12-28	WOS:A1995RE66800025
J	IRVING, M; ALLEN, TS; SABIDODAVID, C; CRAIK, JS; BRANDMEIER, B; KENDRICKJONES, J; CORRIE, JET; TRENTHAM, DR; GOLDMAN, YE				IRVING, M; ALLEN, TS; SABIDODAVID, C; CRAIK, JS; BRANDMEIER, B; KENDRICKJONES, J; CORRIE, JET; TRENTHAM, DR; GOLDMAN, YE			TILTING OF THE LIGHT-CHAIN REGION OF MYOSIN DURING STEP LENGTH CHANGES AND ACTIVE FORCE GENERATION IN SKELETAL-MUSCLE	NATURE			English	Article							CONTRACTING MUSCLE; MECHANICAL TRANSIENTS; FROG-MUSCLE; FIBERS; ORIENTATION; STIFFNESS; HEAD	FORCE generation and relative sliding between the myosin and actin filaments in muscle are thought to be caused by tilting of the head region of the myosin crossbridges between the filaments(1-3). Structural and spectroscopic experiments have demonstrated segmental flexibility of myosin in muscle(4-6), but have not shown a direct linkage between tilting of the myosin heads and either force generation or filament sliding. Here we use fluorescence polarization to detect changes in the orientation of the light-chain region of the head, the part most likely to tilt(5,7,8), and synchronized head movements by imposing rapid length steps(9-11). We found that the light-chain region of the myosin head tilts both during the imposed filament sliding and during the subsequent quick force recovery that is thought to signal the elementary force-generating event.	UNIV PENN,DEPT DEV & CELL BIOL,PHILADELPHIA,PA 19104; NATL INST MED RES,LONDON NW7 1AA,ENGLAND; MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; UNIV PENN,PENN MUSCLE INST,PHILADELPHIA,PA 19104	University of Pennsylvania; MRC National Institute for Medical Research; MRC Laboratory Molecular Biology; University of Pennsylvania	IRVING, M (corresponding author), UNIV LONDON KINGS COLL,RANDALL INST,26-29 DRURY LANE,LONDON WC2B 5RL,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERGER CL, 1994, BIOPHYS J, V66, pA189; CHASE PB, 1988, BIOPHYS J, V53, P935, DOI 10.1016/S0006-3495(88)83174-6; COOKE R, 1982, NATURE, V300, P776, DOI 10.1038/300776a0; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; CORRIE JET, 1994, J CHEM SOC PERK T 1, P2967, DOI 10.1039/p19940002967; DANTZIG JA, 1985, J GEN PHYSIOL, V86, P305, DOI 10.1085/jgp.86.3.305; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; GOLDMAN YE, 1984, J PHYSIOL-LONDON, V350, P497, DOI 10.1113/jphysiol.1984.sp015215; GOLDMAN YE, 1977, J PHYSIOL-LONDON, V269, pP55; GOLDMAN YE, 1987, BIOPHYS J, V52, P57, DOI 10.1016/S0006-3495(87)83188-0; HIGUCHI H, 1991, NATURE, V352, P352, DOI 10.1038/352352a0; HUXLEY AF, 1974, J PHYSIOL-LONDON, V243, P1; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1985, J MUSCLE RES CELL M, V6, P153, DOI 10.1007/BF00713057; HUXLEY HE, 1983, J MOL BIOL, V169, P469, DOI 10.1016/S0022-2836(83)80062-X; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IRVING M, 1992, NATURE, V357, P156, DOI 10.1038/357156a0; IRVING M, 1989, J PHYSIOL-LONDON, V418, pP57; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; LOMBARDI V, 1990, J PHYSIOL-LONDON, V431, P141, DOI 10.1113/jphysiol.1990.sp018324; LOMBARDI V, 1992, NATURE, V355, P638, DOI 10.1038/355638a0; LOMBARDI V, 1995, NATURE, V374, P553, DOI 10.1038/374553a0; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MARTYN DA, 1992, J GEN PHYSIOL, V99, P795, DOI 10.1085/jgp.99.5.795; MOSS RL, 1982, J BIOL CHEM, V257, P8588; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; REEDY MK, 1965, NATURE, V207, P1276, DOI 10.1038/2071276a0; ROWE T, 1992, EMBO J, V11, P4715, DOI 10.1002/j.1460-2075.1992.tb05576.x; SABIDODAVID C, 1994, BIOPHYS J, V66, P234; TANNER JW, 1992, J MOL BIOL, V223, P185, DOI 10.1016/0022-2836(92)90725-Y; THOMAS DD, 1987, ANNU REV PHYSIOL, V49, P691, DOI 10.1146/annurev.ph.49.030187.003355; TREGEAR RT, 1975, BIOPHYS J, V15, P455, DOI 10.1016/S0006-3495(75)85830-9; VIBERT P, 1988, J MUSCLE RES CELL M, V9, P296, DOI 10.1007/BF01773873; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	35	180	180	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 22	1995	375	6533					688	691		10.1038/375688a0	http://dx.doi.org/10.1038/375688a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791902				2022-12-28	WOS:A1995RE57600062
J	MACK, TM; COZEN, W; SHIBATA, DK; WEISS, LM; NATHWANI, BN; HERNANDEZ, AM; TAYLOR, CR; HAMILTON, AS; DEAPEN, DM; RAPPAPORT, EB				MACK, TM; COZEN, W; SHIBATA, DK; WEISS, LM; NATHWANI, BN; HERNANDEZ, AM; TAYLOR, CR; HAMILTON, AS; DEAPEN, DM; RAPPAPORT, EB			CONCORDANCE FOR HODGKINS-DISEASE IN IDENTICAL-TWINS SUGGESTING GENETIC SUSCEPTIBILITY TO THE YOUNG-ADULT FORM OF THE DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPSTEIN-BARR-VIRUS; REED-STERNBERG CELLS; UNLINKED DETERMINANTS; INSITU HYBRIDIZATION; DIAGNOSIS; SIBLINGS; IDENTIFICATION; INVOLVEMENT; CHILDREN; ZYGOSITY	Background. Relatives of young adults with Hodgkin's disease are at increased risk of Hodgkin's disease, and lines of evidence implicate both inheritance and environment. Methods. We have identified and followed 432 sets of twins affected by Hodgkin's disease. The number of cases of Hodgkin's disease observed before the age of 50 years in the healthy monozygotic and dizygotic twins of the patients with Hodgkin's disease was compared with the number expected from national age-specific incidence rates. Results. None of the 187 pairs of dizygotic twins became concordant for Hodgkin's disease, whereas 10 of the 179 pairs of monozygotic twins did; in 5 of these pairs, the second case appeared after the original ascertainment. During the observation period, 0.1 (monozygotic) and 0.1 (dizygotic) cases in the unaffected twins were expected. Monozygotic twins of patients with Hodgkin's disease thus had a greatly increased risk (standardized incidence ratio, 99; 95 percent confidence interval, 48 to 182), whereas no increase in the risk for dizygotic twins of patients with Hodgkin's disease was observed. Conclusions. Genetic susceptibility underlies Hodgkin's disease in young adulthood.	UNIV SO CALIF,SCH MED,DEPT PREVENT MED,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90033; CITY HOPE NATL MED CTR,DEPT PATHOL,DUARTE,CA 91010	University of Southern California; University of Southern California; City of Hope					NCI NIH HHS [CA 42581, CA 09492, CA 50341] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009492, R29CA050341, R35CA042581] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN G, 1979, ACTA GENET MED GEMEL, V28, P3, DOI 10.1017/S0001566000009284; ARMATA J, 1991, LANCET, V337, P502, DOI 10.1016/0140-6736(91)93448-I; CHAKRAVARTI A, 1986, GENET EPIDEMIOL, V3, P407, DOI 10.1002/gepi.1370030605; COZEN W, 1992, CANCER EPIDEM BIOMAR, V1, P261; CREAGAN ET, 1972, LANCET, V2, P547; CYBULSKY AV, 1988, DISEASE IMMUNOPATHOL, P57; DABBS DJ, 1986, AM J MED, V80, P63, DOI 10.1016/0002-9343(86)90049-5; DEAPEN D, 1992, ARTHRITIS RHEUM, V35, P311; DELSOL G, 1992, AM J PATHOL, V140, P247; DONHUIJSENANT R, 1988, ANN INTERN MED, V109, P946, DOI 10.7326/0003-4819-109-12-946; EVANS AS, 1984, INT J CANCER, V34, P149, DOI 10.1002/ijc.2910340203; GAUSE A, 1992, LYMPHOKINE CYTOK RES, V11, P109; GLEDHILL S, 1991, BRIT J CANCER, V64, P227, DOI 10.1038/bjc.1991.281; GRACZ K, 1979, J SURG ONCOL, V12, P221, DOI 10.1002/jso.2930120306; GRUFFERMAN S, 1977, NEW ENGL J MED, V296, P248, DOI 10.1056/NEJM197702032960504; GUTENSOHN N, 1977, INT J CANCER, V19, P595, DOI 10.1002/ijc.2910190502; GUTENSOHN N, 1981, NEW ENGL J MED, V304, P135, DOI 10.1056/NEJM198101153040302; HALAZUN JF, 1972, J PEDIATR-US, V80, P289, DOI 10.1016/S0022-3476(72)80594-8; JARRETT R, 1992, LEUKEMIA, V6, P14; KASRIEL J, 1976, J BIOSOC SCI, V8, P263, DOI 10.1017/S0021932000010737; KELLY CJ, 1988, DISEASE IMMUNOPATHOL, P35; KENDLER KS, 1989, ARCH GEN PSYCHIAT, V46, P477; KERZINSTORRAR L, 1983, BRIT J CANCER, V47, P707, DOI 10.1038/bjc.1983.109; KUMAR D, 1993, DIABETES, V42, P1351, DOI 10.2337/diabetes.42.9.1351; KVALE G, 1979, INT J CANCER, V23, P593, DOI 10.1002/ijc.2910230502; LIN A, 1994, PROG P AM SOC CLIN O, V13, P185; LIN A, 1993, P AM SOC CLIN ONCOL, V12, P184; LUKES RJ, 1966, CANCER RES, V26, P1063; LYNCH HT, 1976, CANCER, V38, P2033, DOI 10.1002/1097-0142(197611)38:5<2033::AID-CNCR2820380528>3.0.CO;2-P; MACK TM, 1980, VIRUSES CELL PROLIFE, V7, P1221; MACMAHON B, 1966, CANCER RES, V26, P1189; MALDONADO JE, 1972, LANCET, V2, P1259; MARTIN BJ, 1985, SCOT MED J, V30, P239, DOI 10.1177/003693308503000412; MCGUE M, 1992, SCHIZOPHRENIA BULL, V18, P171, DOI 10.1093/schbul/18.2.171; MERK K, 1990, CANCER, V66, P1938, DOI 10.1002/1097-0142(19901101)66:9<1938::AID-CNCR2820660915>3.0.CO;2-O; MILLER BA, 1993, NIHNCI032789 REP; MUELLER N, 1989, NEW ENGL J MED, V320, P689, DOI 10.1056/NEJM198903163201103; OLISA EG, 1974, JAMA-J AM MED ASSOC, V230, P536, DOI 10.1001/jama.1974.03240040014004; PECES R, 1991, NEPHROL DIAL TRANSPL, V6, P155, DOI 10.1093/ndt/6.3.155; Percy C., 1990, INT CLASSIFICATION D; PERLIN E, 1976, ONCOLOGY, V33, P116, DOI 10.1159/000225123; RISCH N, 1987, AM J HUM GENET, V40, P1; ROBERTSON SJ, 1987, CANCER, V59, P1314, DOI 10.1002/1097-0142(19870401)59:7<1314::AID-CNCR2820590714>3.0.CO;2-V; SCHNAPER HW, 1985, J CLIN INVEST, V76, P341, DOI 10.1172/JCI111967; SHALHOUB RJ, 1974, LANCET, V2, P556; SHERROD AE, 1986, CANCER, V57, P2135, DOI 10.1002/1097-0142(19860601)57:11<2135::AID-CNCR2820571109>3.0.CO;2-N; SHIBUYA H, 1984, ACTA RADIOL ONCOL, V23, P425, DOI 10.3109/02841868409136043; SMITHERS DW, 1970, LANCET, V2, P1285; THORLING K, 1973, DAN MED BULL, V20, P61; VIANNA NJ, 1974, LANCET, V2, P854; WEISS LM, 1989, NEW ENGL J MED, V320, P502, DOI 10.1056/NEJM198902233200806; WEISS LM, 1991, AM J PATHOL, V139, P1259; Zwolinska D, 1992, Pol Tyg Lek, V47, P671	54	215	217	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 16	1995	332	7					413	418		10.1056/NEJM199502163320701	http://dx.doi.org/10.1056/NEJM199502163320701			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF770	7824015	Bronze			2022-12-28	WOS:A1995QF77000001
J	BAZZOLI, GJ; MADURA, KJ; COOPER, GF; MACKENZIE, EJ; MAIER, RV				BAZZOLI, GJ; MADURA, KJ; COOPER, GF; MACKENZIE, EJ; MAIER, RV			PROGRESS IN THE DEVELOPMENT OF TRAUMA SYSTEMS IN THE UNITED-STATES - RESULTS OF A NATIONAL SURVEY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ORANGE COUNTY; CARE; IMPACT; REGIONALIZATION; MORTALITY; CENTERS	Objective.-To examine the status of trauma system development and key structural and operational characteristics of these systems. Design and Setting.-National survey of trauma systems with enabling state statute, regulation, or executive orders and for which designated trauma centers were present. Participants.-Trauma system administrators and directors of 37 state and regional organizations that had legal authority to administer trauma systems, which represented a response rate of 90.2%. Main Outcome Measures.-Trauma system components that had been implemented or were under development. Results.-From 1988 to 1993, the number of states meeting one set of criteria for a complete trauma system criteria increased from two to five. The most common deficiency in establishing trauma systems was failure to limit the number of designated trauma centers based on community need. Although most existing trauma systems have developed formal processes for designating trauma centers, prehospital triage protocols to allow hospital bypass, and centralized trauma registries, several systems lack standardized policies for interhospital transfer and systemwide evaluation. Conclusion.-State and regional organizations have accomplished a great deal but still have substantial work ahead in developing comprehensive trauma systems. Research is needed to better understand the relationship between trauma volume and outcomes of care as well as the impact of trauma system structure and operational characteristics on care delivery. Improved measures of patient outcome are also needed so that effective system evaluation can take place.	SAN DIEGO CTY DEPT EMERGENCY MED SERV,SAN DIEGO,CA; JOHNS HOPKINS UNIV,SCH PUBL HLTH,CTR INJURY RES & POLICY,BALTIMORE,MD; HARBORVIEW MED CTR,NW REG TRAUMA CTR,SEATTLE,WA	Johns Hopkins University; Harborview Medical Center	BAZZOLI, GJ (corresponding author), HOSP RES & EDUC TRUST,1 N FRANKLIN ST,CHICAGO,IL 60606, USA.							BAZZOLI GJ, 1993, 1993 INVENTORY TRAUM; BAZZOLI GJ, IN PRES J TRAUMA; CALES RH, 1984, ANN EMERG MED, V13, P1, DOI 10.1016/S0196-0644(84)80375-3; CALES RH, 1985, JAMA-J AM MED ASSOC, V254, P1059, DOI 10.1001/jama.254.8.1059; DAILEY JT, 1992, J TRAUMA, V33, P539, DOI 10.1097/00005373-199210000-00009; GUSS DA, 1989, ANN EMERG MED, V18, P1141, DOI 10.1016/S0196-0644(89)80048-4; KANE G, 1992, J TRAUMA, V32, P576, DOI 10.1097/00005373-199205000-00007; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; MACKENZIE EJ, 1990, J TRAUMA, V30, P681, DOI 10.1097/00005373-199006000-00005; MENDELOFF JM, 1991, ANNU REV PUBL HEALTH, V12, P401; MULLINS RJ, 1994, JAMA-J AM MED ASSOC, V271, P1919, DOI 10.1001/jama.271.24.1919; ORNATO JP, 1985, J TRAUMA, V25, P575, DOI 10.1097/00005373-198507000-00001; RHODES M, 1988, J TRAUMA, V28, P931, DOI 10.1097/00005373-198807000-00005; ROY PD, 1987, CAN J SURG, V30, P17; SCHWARTZ RJ, 1989, J TRAUMA, V29, P1611, DOI 10.1097/00005373-198912000-00002; SHACKFORD SR, 1986, J TRAUMA, V26, P812, DOI 10.1097/00005373-198609000-00006; SMITH JS, 1990, J TRAUMA, V30, P1533, DOI 10.1097/00005373-199012000-00017; SMITH RF, 1991, J TRAUMA, V30, P1066; WEST JG, 1988, JAMA-J AM MED ASSOC, V259, P3597, DOI 10.1001/jama.259.24.3597; WEST JG, 1983, ARCH SURG-CHICAGO, V118, P740; 1989, DEV TRAUMA SYSTEMS D; 1992, MODEL TRAUMA CARE SY; 1993, US DHHS FY1993 BUR H; 1992, GUIDELINES TRAUMA CA; 1989, IMPACT EMERGENCY MED; 1991, TRAUMA CTR DESIGNATI; 1990, RESOURCES OPTIMAL CA; 1992, 3RD P NAT INJ CONTR	28	104	104	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	1995	273	5					395	401						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD203	7823385				2022-12-28	WOS:A1995QD20300024
J	BENDITT, DG; PETERSEN, M; LURIE, KG; GRUBB, BP; SUTTON, R				BENDITT, DG; PETERSEN, M; LURIE, KG; GRUBB, BP; SUTTON, R			CARDIAC PACING FOR PREVENTION OF RECURRENT VASOVAGAL SYNCOPE	ANNALS OF INTERNAL MEDICINE			English	Review							NEURALLY MEDIATED SYNCOPE; TILT-TABLE TEST; UNEXPLAINED SYNCOPE; UPRIGHT TILT; YOUNG-PATIENTS; HEAD; REPRODUCIBILITY; ISOPROTERENOL; BRADYCARDIA; HYPERSENSITIVITY	Purpose: To review the status of cardiac pacing for the treatment of patients with recurrent vasovagal syncope. Data Sources: A MEDLINE search for English- and French-language articles published between 1980 and 1994 about cardiac pacing for prevention or treatment of vasovagal syncope. The term cardiac pacing was used in conjunction with the terms vasovagal, neurally mediated, or neurocardiogenic syncope, but not with the term carotid sinus hypersensitivity. Study Selection: Case reports and series from peer-reviewed journals were selected if they documented the presence of vasovagal syncope and assessed pacing effectiveness using tilt-table testing, clinical followup, or both. Four case reports and four series met these criteria. Data Extraction: Findings were summarized individually. Statistical analysis of combined data was inappropriate given differences among studies in patient selection, testing, and follow-up. Results: Pacing may be useful in selected patients with predominantly cardioinhibitory vasovagal responses. Pacing alone may eliminate symptoms in 25% of these patients and may prevent abrupt cardiovascular collapse in others (such as those in whom syncope occurs with minimal or no premonitory sensation). However, interpretation of most available reports has been limited both by the uncertainty associated with using the tilt-table technique to assess pacing effectiveness and by relatively short-term follow-up. Conclusions: The usefulness of cardiac pacing for patients with recurrent vasovagal syncope remains only partly understood. Randomized controlled trials are needed for this and other aspects of the treatment of this condition. Additionally, substantial room remains for innovation both in earlier recognition of imminent vasovagal syncope by implantable devices and in specifically designing cardiac pacing algorithms for treatment of this condition.	CHELSEA & WESTMINSTER HOSP, LONDON, ENGLAND; ROYAL BROMPTON & NATL HEART HOSP, LONDON SW3, ENGLAND; MED COLL OHIO, TOLEDO, OH 43699 USA	Imperial College London	BENDITT, DG (corresponding author), UNIV MINNESOTA, BOX 341 UMHC, MINNEAPOLIS, MN 55455 USA.							ALMQUIST A, 1985, CIRCULATION, V71, P927, DOI 10.1161/01.CIR.71.5.927; ALMQUIST A, 1989, NEW ENGL J MED, V320, P346, DOI 10.1056/NEJM198902093200603; BENDITT DG, 1991, PACE, V14, P1528, DOI 10.1111/j.1540-8159.1991.tb04074.x; BENDITT DG, 1993, CARDIOL REV, V1, P146; BLANC JJ, 1990, PRESSE MED, V19, P857; BRIGNOLE M, 1992, AM J CARDIOL, V70, P339, DOI 10.1016/0002-9149(92)90615-6; BROOKS R, 1993, AM J CARDIOL, V71, P1289, DOI 10.1016/0002-9149(93)90542-K; CALKINS H, 1993, AM J MED, V95, P473, DOI 10.1016/0002-9343(93)90329-N; CHEN MY, 1989, AM J CARDIOL, V63, P66, DOI 10.1016/0002-9149(89)91077-1; CHOSY JJ, 1965, J PSYCHOSOM RES, V9, P189, DOI 10.1016/0022-3999(65)90032-2; DAY SC, 1982, AM J MED, V73, P15, DOI 10.1016/0002-9343(82)90913-5; DEBUITLEIR M, 1993, AM J CARDIOL, V71, P304, DOI 10.1016/0002-9149(93)90795-E; DEMEY C, 1988, METHOD FIND EXP CLIN, V10, P57; DEMEY C, 1986, METHOD FIND EXP CLIN, V8, P449; DERMKSIAN G, 1958, JAMA-J AM MED ASSOC, V168, P1200, DOI 10.1001/jama.1958.03000090030007; FISH FA, 1992, AM J CARDIOL, V70, P605, DOI 10.1016/0002-9149(92)90199-9; Fitzpartick A., 1992, EUROPEAN J CARDIAC P, V2, P121; FITZPATRICK A, 1991, PACE, V14, P13, DOI 10.1111/j.1540-8159.1991.tb04042.x; FITZPATRICK A, 1991, EUR HEART J, V12, P389, DOI 10.1093/oxfordjournals.eurheartj.a059906; FITZPATRICK AP, 1991, J AM COLL CARDIOL, V17, P125, DOI 10.1016/0735-1097(91)90714-K; FITZPATRICK AP, 1990, PACE, V13, P619, DOI 10.1111/j.1540-8159.1990.tb02078.x; FORCINITO M, 1991, J AM COLL CARDIOL, V18, P1, DOI 10.1016/S0735-1097(10)80209-8; GRUBB BP, 1992, PACE, V15, P1477, DOI 10.1111/j.1540-8159.1992.tb02921.x; KAPOOR WN, 1990, MEDICINE, V69, P160, DOI 10.1097/00005792-199005000-00004; KAPOOR WN, 1992, ANN INTERN MED, V116, P358, DOI 10.7326/0003-4819-116-5-358; KOSINSKI D, 1994, J SEROTONIN RES, V1, P85; KUS T, 1989, CAN J CARDIOL, V5, P375; MACWILLIAM JA, 1987, J INT M C, V3, P253; MILSTEIN S, 1990, AM J CARDIOL, V65, P1339, DOI 10.1016/0002-9149(90)91324-Y; NEWMAN D, 1993, PACE, V16, P715, DOI 10.1111/j.1540-8159.1993.tb01650.x; PERRY JC, 1991, PACE, V14, P391, DOI 10.1111/j.1540-8159.1991.tb04084.x; PETERSEN M, 1994, BRIT HEART J, V71, P274; PONGIGLIONE G, 1990, J AM COLL CARDIOL, V16, P165, DOI 10.1016/0735-1097(90)90474-4; RAVIELE A, 1990, AM J CARDIOL, V65, P1322, DOI 10.1016/0002-9149(90)91321-V; ROSS RT, 1988, SYNCOPE; SAMOIL D, 1993, EUR J CARDIAC PACING, V1, P36; SAPIRE DW, 1983, AM HEART J, V106, P1406; SAVAGE DD, 1985, STROKE, V16, P626, DOI 10.1161/01.STR.16.4.626; SHELDON R, 1992, AM J CARDIOL, V69, P1300, DOI 10.1016/0002-9149(92)91225-S; SRA JS, 1992, J AM COLL CARDIOL, V19, P402, DOI 10.1016/0735-1097(92)90498-C; SRA JS, 1993, NEW ENGL J MED, V328, P1085, DOI 10.1056/NEJM199304153281504; Sutton R, 1992, EUR J CARDIAC PACING, V2, P180; VARDAS P, 1990, REV EUROPEENNE TECHN, V12, P910; VINGERHOETS AJJM, 1984, PSYCHOSOM MED, V46, P95; WAYNE HH, 1961, AM J MED, V30, P418, DOI 10.1016/0002-9343(61)90051-1; Weiss S, 1933, MEDICINE, V12, P297, DOI 10.1097/00005792-193309000-00003; XIAO CC, 1992, AM J CARDIOL, V69, P755	47	79	83	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1995	122	3					204	209		10.7326/0003-4819-122-3-199502010-00008	http://dx.doi.org/10.7326/0003-4819-122-3-199502010-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD733	7810939				2022-12-28	WOS:A1995QD73300008
J	JACKSON, LA; SCHUCHAT, A; REEVES, MW; WENGER, JD				JACKSON, LA; SCHUCHAT, A; REEVES, MW; WENGER, JD			SEROGROUP-C MENINGOCOCCAL OUTBREAKS IN THE UNITED-STATES - AN EMERGING THREAT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEISSERIA-MENINGITIDIS; POLYSACCHARIDE VACCINE; DISEASE; EPIDEMIC; INFLUENZA; AGE; MYCOPLASMA; INFECTIONS; CARRIAGE; CANADA	Objective.-Multiple outbreaks of serogroup C Neisseria meningitidis have recently been reported from diverse areas of the United States. To better define the characteristics of this increasingly important problem, we reviewed data on all known serogroup C outbreaks in the United States from January 1980 through June 1993. Data Sources.-MEDLINE searches, Centers for Disease Control and Prevention records, state health department officials, infectious disease experts, and the meningococcal vaccine manufacturer. Definition of an Outbreak.-Three or more cases of serogroup C meningococcal disease within a 3-month period, either among members of a community or persons attending a single school or other institution, for which those cases represented an attack rate of at least five per 100 000 population. Results.-Twenty-one outbreaks of serogroup C meningococcal disease were identified; eight occurred since 1991. In 1992 and the first half of 1993, approximately 180 000 doses of vaccine were administered for outbreak control, compared with approximately 34 000 doses from 1980 to 1991. Approximately 50% of community-outbreak cases were between the ages of 5 and 24 years, compared with only 19% of sporadic serogroup C cases (P<.001). Subtyping of patient isolates indicates that outbreaks are clonal; however, at least five distinct but closely related strains have caused recent outbreaks. Conclusions.-Serogroup C outbreaks are occurring more frequently in the United States. The effectiveness of preventive measures depends on early recognition; therefore, physicians should promptly report all cases of suspected meningococcal disease, and the causative serogroup should be established for every case.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA								ARTENSTEIN MS, 1970, NEW ENGL J MED, V282, P417, DOI 10.1056/NEJM197002192820803; ASHTON FE, 1991, J CLIN MICROBIOL, V29, P2489, DOI 10.1128/JCM.29.11.2489-2493.1991; BROOME CV, 1983, B WORLD HEALTH ORGAN, V61, P325; CARTWRIGHT KAV, 1991, LANCET, V338, P554, DOI 10.1016/0140-6736(91)91112-8; Dean A. G., 1990, EPI INFO VERSION 5 W; DEMORAIS JS, 1974, J INFECT DIS, V129, P568; EDMOND MB, 1993, 33RD INT C ANT AG CH; FEIGIN RD, 1982, NEW ENGL J MED, V307, P1255, DOI 10.1056/NEJM198211113072007; GILMORE A, 1992, CAN MED ASSOC J, V147, P729; GOLD R, 1992, CAN J PUBLIC HEALTH, V83, P5; GUILMETTE P, 1993, CAN DIS WKLY REP, V17, P295; HARRISON LH, 1991, ARCH INTERN MED, V151, P1005, DOI 10.1001/archinte.151.5.1005; HOUCK P, IN PRESS PUBLIC HLTH; HUDSON PJ, 1986, PEDIATR INFECT DIS J, V5, P213, DOI 10.1097/00006454-198603000-00011; IMREY PB, 1993, 3RD ANN M SOC HOSP E; JACOBS D, 1990, 15TH P ANN SAS US GR, P1413; JACOBSON JA, 1977, J INFECT DIS, V136, P104, DOI 10.1093/infdis/136.1.104; JAFARI H, 1993, 33RD INT C ANT AG CH; KRASINSKI K, 1987, AM J EPIDEMIOL, V125, P499, DOI 10.1093/oxfordjournals.aje.a114556; MASTERTON RG, 1988, J INFECTION, V17, P177, DOI 10.1016/S0163-4453(88)91907-X; MOORE PS, 1990, JAMA-J AM MED ASSOC, V264, P1271, DOI 10.1001/jama.264.10.1271; MOORE PS, 1989, LANCET, V2, P260; MORROW HW, 1991, MISS MORB REP, V9, P1; PELTOLA H, 1977, NEW ENGL J MED, V297, P686, DOI 10.1056/NEJM197709292971302; PELTOLA H, 1982, LANCET, V2, P595; PINNER RW, 1991, J INFECT DIS, V164, P368, DOI 10.1093/infdis/164.2.368; REINGOLD AL, 1985, LANCET, V2, P114; RONNE T, 1993, SCAND J INFECT DIS, V25, P331, DOI 10.3109/00365549309008507; SACCHI CT, 1992, J CLIN MICROBIOL, V30, P1734, DOI 10.1128/JCM.30.7.1734-1738.1992; SAEZNIETO JA, 1984, J INFECTION, V8, P49, DOI 10.1016/S0163-4453(84)93327-9; SCHOLTEN RJPM, 1994, J INFECT DIS, V169, P673, DOI 10.1093/infdis/169.3.673; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P873, DOI 10.1128/AEM.51.5.873-884.1986; TAPPERO JW, 1994, 34TH INT C ANT AG CH; THOMAS JC, 1991, AM J EPIDEMIOL, V133, P286, DOI 10.1093/oxfordjournals.aje.a115873; WAHDAN MH, 1977, B WORLD HEALTH ORGAN, V55, P645; WENGER JD, 1994, INFECT DIS CLIN PRAC, V3, P136, DOI 10.1097/00019048-199403000-00022; YOUNG LS, 1972, NEW ENGL J MED, V287, P5, DOI 10.1056/NEJM197207062870102; ZEIT, 1993, 33RD INT C ANT AG CH; 1993, MMWR-MORBID MORTAL W, V42, P21; 1985, MMWR-MORBID MORTAL W, V34, P255	40	201	206	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	1995	273	5					383	389		10.1001/jama.273.5.383	http://dx.doi.org/10.1001/jama.273.5.383			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD203	7823383				2022-12-28	WOS:A1995QD20300022
J	GALBUSERA, M; RUGGENENTI, P; NORIS, M; BURNOUFRADOSEVICH, M; BENIGNI, A; MANNUCCI, PM; REMUZZI, G				GALBUSERA, M; RUGGENENTI, P; NORIS, M; BURNOUFRADOSEVICH, M; BENIGNI, A; MANNUCCI, PM; REMUZZI, G			ALPHA(1)-ANTITRYPSIN THERAPY IN A CASE OF THROMBOTIC THROMBOCYTOPENIC PURPURA	LANCET			English	Note							PLASMA VONWILLEBRAND-FACTOR; HEMOLYTIC UREMIC SYNDROME; ENDOTHELIAL-CELLS; MULTIMERS	In thrombotic thrombocytopenic purpura (TTP), activated leucocytes release elastase which large von Willebrand factor (vWF) endothelium. We investigated the effect of an inhibitor of leucocyte elastase (alpha(1)-antitrypsin) on circulating vWF and platelet count in a patient with chronic relapsing TTP. alpha(1)-antitrypsin consistently normalised vWF multimeric composition but failed to Increase platelet count and induce remission. Plasma cryosupernatant, which never normalised VWF, always induced laboratory and clinical remission within 96 hours. In chronic relapsing TTP, unusually large VWF multimers are not the main cause of intravascular platelet aggregation.	MARIO NEGRI INST PHARMACOL RES,I-24125 BERGAMO,ITALY; OSPED RIUNITI BERGAMO,DIV NEPHROL & DIALYSIS,I-24100 BERGAMO,ITALY; LAB FRANCAIS FRACTIONNEMENT & BIOTECHNOL,LILLE,FRANCE; CTR ANGELO BIANCHI BONOMI,CTR HAEMOPHILIA & THOMBOSIS,MILAN,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Ospedali Riuniti di Bergamo			NORIS, MARINA/ABG-2219-2020; Ariela, Benigni/ABH-3492-2020; Galbusera, Miriam/AAA-7369-2020; Remuzzi, Giuseppe/V-9766-2017	NORIS, MARINA/0000-0001-7651-5033; Ariela, Benigni/0000-0002-4721-5485; Galbusera, Miriam/0000-0003-2434-7343; Remuzzi, Giuseppe/0000-0002-6194-3446				BYRNES JJ, 1977, NEW ENGL J MED, V297, P1386, DOI 10.1056/NEJM197712222972507; CHIGNARD M, 1993, EUR RESPIR J, V6, P791; FORSYTH KD, 1989, LANCET, V2, P411; KLUMPP T, 1979, CLIN CHEM, V25, P969; MANNUCCI PM, 1989, BLOOD, V74, P978; MOAKE JL, 1982, NEW ENGL J MED, V307, P1432, DOI 10.1056/NEJM198212023072306; MOAKE JL, 1986, J CLIN INVEST, V78, P1456, DOI 10.1172/JCI112736; RUGGENENTI P, 1993, AM J KIDNEY DIS, V21, P314, DOI 10.1016/S0272-6386(12)80752-9; WEWERS MD, 1987, NEW ENGL J MED, V316, P1055, DOI 10.1056/NEJM198704233161704	9	15	15	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 28	1995	345	8944					224	225		10.1016/S0140-6736(95)90224-4	http://dx.doi.org/10.1016/S0140-6736(95)90224-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7823715				2022-12-28	WOS:A1995QD53200010
J	SCOTT, G				SCOTT, G			NONINVASIVE TESTS FOR CHLAMYDIA-TRACHOMATIS	LANCET			English	Editorial Material							URINE SPECIMENS				SCOTT, G (corresponding author), ROYAL INFIRM,DEPT GENITOURINARY MED,EDINBURGH,MIDLOTHIAN,SCOTLAND.							CHERNESKY MA, 1994, J INFECT DIS, V170, P1308, DOI 10.1093/infdis/170.5.1308; JASCHEK G, 1993, J CLIN MICROBIOL, V31, P1209, DOI 10.1128/JCM.31.5.1209-1212.1993; JONES RB, 1986, J CLIN MICROBIOL, V24, P1029, DOI 10.1128/JCM.24.6.1029-1033.1986; LEONARDI GP, 1992, J CLIN MICROBIOL, V30, P2793, DOI 10.1128/JCM.30.11.2793-2796.1992; MOSS TR, 1993, SEX TRANSM DIS, V20, P61, DOI 10.1097/00007435-199303000-00001; SCHACHTER J, 1992, SEX TRANSM DIS, V19, P243, DOI 10.1097/00007435-199209000-00001; SVENSSON LO, 1991, GENITOURIN MED, V67, P117; 1995, LANCET, V345, P213	8	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 28	1995	345	8944					207	207		10.1016/S0140-6736(95)90218-X	http://dx.doi.org/10.1016/S0140-6736(95)90218-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7823710				2022-12-28	WOS:A1995QD53200004
J	EMANUEL, EJ; DUBLER, NN				EMANUEL, EJ; DUBLER, NN			PRESERVING THE PHYSICIAN-PATIENT RELATIONSHIP IN THE ERA OF MANAGED CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-MAINTENANCE-ORGANIZATIONS; MEDICAL-CARE; MALPRACTICE CLAIMS; QUALITY; COSTS; COMMUNICATION; CERTIFICATION; DISENROLLMENT; SATISFACTION; DETERMINANTS	Even without comprehensive health care reform legislation, the US health care system is undergoing significant changes. Probably the most important change is the expansion of managed care with significant price competition. One of the major concerns about this change is the effect of managed care on the physician-patient retationship. To provide a normative standard for evaluating the effect of changes, we need an ideal conception of the physician-patient relationship. This ideal can be summarized by six C's: choice, competence, communication, compassion, continuity, and (no) conflict of interest. For the 37 million uninsured Americans there is little chance of realizing the ideal physician-patient relationship, since they lack the choice of practice setting and physician, receive care in a rushed atmosphere that undermines communication and compassion, and have no continuity of care. While many insured Americans may believe they have an ideal physician-patient relationship, the relationship is threatened by lack of a regular assessment of competence, by financial incentives that undermine good communication, and by the persistence of conflict of interest. The shift to managed care may improve the choice of practice settings, especially in sections of the country that currently lack managed care; increase choice of preventive services; make quality assessments more routine; and improve communication by making greater use of primary care physicians and nonphysician providers. However, the expansion of managed care and the imposition of significant cost control have the potential to undermine all aspects of the ideal physician-patient relationship. Choice could be restricted by employers and by managed care selection of physicians; poor quality indicators could undermine assessments of competence; productivity requirements could eliminate time necessary for communication; changing from one to another managed care plan to secure the lowest costs could produce significant disruption in continuity of care; and use of salary schemes that reward physicians for not using medical services could increase conflict of interest.	HARVARD UNIV,SCH MED,DIV MED ETH,BOSTON,MA; MONTEFIORE MED CTR,ALBERT EINSTEIN COLL MED,DEPT EPIDEMIOL & SOCIAL MED,DIV BIOETH,BRONX,NY 10467	Harvard University; Harvard Medical School; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	EMANUEL, EJ (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC EPIDEMIOL & CONTROL,44 BINNEY ST,BOSTON,MA 02115, USA.							[Anonymous], 1990, NEW MED OLD ETHICS; APPELBAUM PS, 1967, INFORMED CONSENT LEG; APPLEGATE WB, 1986, ARCH INTERN MED, V146, P2249, DOI 10.1001/archinte.146.11.2249; BAKER LC, 1993, HEALTH AFFAIR, V12, P258, DOI 10.1377/hlthaff.12.suppl_1.258; BEAUCHAMPS T, 1989, PRINCIPLES BIOMEDICA, pCH3; BECKMAN H, 1990, J GEN INTERN MED, V5, P42, DOI 10.1007/BF02602308; BENSON JA, 1991, ANN INTERN MED, V114, P238, DOI 10.7326/0003-4819-114-3-238; BERNSTEIN AB, 1991, MED CARE, V29, P196; BLENDON RJ, 1994, J AM HEALTH POLICY, V4, P42; BRETT AS, 1992, NEW ENGL J MED, V326, P1253; BROCK DW, 1991, KENNEDY INST ETHIC J, V1, P28; BRODY H, 1992, HEALERS POWER, pCH4; BURKE M, 1992, HOSPITALS, P120; BURKE M, 1992, HOSPITALS, P122; BURKE M, 1992, HOSPITALS, P118; BURSTIN HR, 1992, JAMA-J AM MED ASSOC, V268, P2383, DOI 10.1001/jama.268.17.2383; CAMPBELL JD, 1990, SOC SCI MED, V30, P1359, DOI 10.1016/0277-9536(90)90316-K; CLEMENT DG, 1994, JAMA-J AM MED ASSOC, V271, P1487, DOI 10.1001/jama.271.19.1487; DWORKIN RONALD, 1977, TAKING RIGHTS SERIOU; ECKHOLM E, 1994, NY TIMES        0926, pA1; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; EMANUEL EJ, 1993, NEW ENGL J MED, V329, P879, DOI 10.1056/NEJM199309163291213; EMANUEL EJ, 1991, ENDS HUMAN LIFE MED, pCH1; FEILICH B, 1992, JAMA-J AM MED ASSOC, V268, P1413, DOI 10.1001/jama.1992.03490110051026; FOX PD, 1993, HEALTH AFFAIR, V12, P85, DOI 10.1377/hlthaff.12.1.85; FREIDSON E, 1973, MILBANK FUND Q, V51, P473, DOI 10.2307/3349630; FREUND C, 1993, NURSES NURSE PRACTIT; GRAY BH, 1991, PROFIT MOTIVE PATIEN, pCH5; GREEN J, 1991, JAMA-J AM MED ASSOC, V265, P1849; GREENFIELD S, 1988, JAMA-J AM MED ASSOC, V260, P2253, DOI 10.1001/jama.260.15.2253; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; HENNEBERGER M, 1994, NY TIMES        1009, pA50; HENNEBERGER M, 1994, NY TIMES        1009, pA1; HENNELLY VD, 1983, MED CARE, V21, P348, DOI 10.1097/00005650-198303000-00007; HICKSON GB, 1992, JAMA-J AM MED ASSOC, V267, P1359, DOI 10.1001/jama.267.10.1359; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; HOCH S, 1992, NY TIMES        0220, pA23; IGELHART JK, 1994, NEW ENGL J MED, V331, P63; IGLEHART JK, 1993, NEW ENGL J MED, V329, P1052, DOI 10.1056/NEJM199309303291428; INGELFINGER FJ, 1980, NEW ENGL J MED, V304, P1507; JELLINEK MS, 1993, JAMA-J AM MED ASSOC, V270, P1737, DOI 10.1001/jama.270.14.1737; KASS LR, 1988, MORE NATURAL SCI, pCH6; Katz J., 1984, SILENT WORLD DOCTOR; KAVESH W, 1993, NURSES NURSE PRACTIT; KRITCHEVSKY SB, 1991, JAMA-J AM MED ASSOC, V266, P1817, DOI 10.1001/jama.266.13.1817; LAFFEL G, 1992, JAMA-J AM MED ASSOC, V268, P407, DOI 10.1001/jama.268.3.407; LEVINSON W, 1993, J GEN INTERN MED, V8, P318, DOI 10.1007/BF02600146; LEWINEPSTEIN N, 1991, MED CARE, V29, P543, DOI 10.1097/00005650-199106000-00013; LOCALIO AR, 1993, JAMA-J AM MED ASSOC, V269, P366, DOI 10.1001/jama.269.3.366; MACKLIN R, 1993, ENEMIES PATIENTS, pCH1; MARZUK PM, 1985, NEW ENGL J MED, V313, P1474, DOI 10.1056/NEJM198512053132310; MCNEIL BJ, 1992, INQUIRY-J HEALTH CAR, V29, P298; MERKEL WT, 1990, J GEN INTERN MED, V5, P34, DOI 10.1007/BF02602307; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; MITCHELL JM, 1992, JAMA-J AM MED ASSOC, V268, P2055, DOI 10.1001/jama.268.15.2055; MORAN DW, 1991, HEALTH AFFAIR, V10, P120, DOI 10.1377/hlthaff.10.4.120; NELSON C, 1990, HLTH INSURANCE CONVE; Pear Robert, 1994, NY TIMES        0923, pA16; PERKINS HS, 1990, AM J MED, V89, P185, DOI 10.1016/0002-9343(90)90298-R; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1982, MAKING HLTH CARE DEC; RAMSEY PG, 1989, ANN INTERN MED, V110, P719, DOI 10.7326/0003-4819-110-9-719; RAWLS J, 1993, POLITICAL LIBERALI 1; RELMAN AS, 1985, NEW ENGL J MED, V313, P749, DOI 10.1056/NEJM198509193131209; RETCHIN SM, 1990, AM J PUBLIC HEALTH, V80, P411, DOI 10.2105/AJPH.80.4.411; ROBINSON ML, 1988, HOSPITALS, V62, P23; RODWIN M, 1993, MED MONEY MORALS; ROSENBACH ML, 1990, HEALTH AFFAIR, V9, P176, DOI 10.1377/hlthaff.9.4.176; SALEMSCHATZ S, 1994, JAMA-J AM MED ASSOC, V272, P871, DOI 10.1001/jama.272.11.871; SCHROEDER JL, 1985, JAMA-J AM MED ASSOC, V254, P3080, DOI 10.1001/jama.254.21.3080; SCHROEDER SA, 1993, NEW ENGL J MED, V328, P961, DOI 10.1056/NEJM199304013281312; SCHWARTZ WB, 1992, HEALTH AFFAIR, V11, P100, DOI 10.1377/hlthaff.11.2.100; SEITZ R, 1992, NY TIMES        1220, pD10; SIEGLER M, 1985, ARCH INTERN MED, V145, P713, DOI 10.1001/archinte.145.4.713; SOFAER S, 1993, HEALTH AFFAIR, V12, P76, DOI 10.1377/hlthaff.12.suppl_1.76; SORENSEN AA, 1981, MED CARE, V19, P766, DOI 10.1097/00005650-198107000-00007; SPIRO H, 1993, EMPATHY PRACTICE MED, pCH1; SZASZ TS, 1956, ARCH INTERN MED, V97, P585, DOI 10.1001/archinte.1956.00250230079008; THOMPSON DF, 1993, NEW ENGL J MED, V329, P573, DOI 10.1056/NEJM199308193290812; Travis M, 1989, J Health Care Mark, V9, P75; UDVARHELYI IS, 1991, ANN INTERN MED, V327, P424; VEATCH RM, 1980, THEORY MED ETHICS; WARE JE, 1975, MED CARE, V13, P669, DOI 10.1097/00005650-197508000-00006; Weber M., 1947, THEORY SOCIAL EC ORG, P87; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805; WOOLLEY FR, 1978, SOC SCI MED-MED SOC, V12, P123, DOI 10.1016/0160-7979(78)90034-6; 1986, NURSE PRACTITIONERS; 1993, KAISER COMMONWEALTH; 1994, EFFECTS MANAGED CARE; 1992, JAMA-J AM MED ASSOC, V267, P2366; 1993, MANAGED HLTH CARE EF	91	326	327	1	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	1995	273	4					323	329		10.1001/jama.273.4.323	http://dx.doi.org/10.1001/jama.273.4.323			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QC057	7815662				2022-12-28	WOS:A1995QC05700033
J	CALVIN, JE; KLEIN, LW; VANDENBERG, BJ; MEYER, P; CONDON, JV; SNELL, RJ; RAMIREZMORGEN, LM; PARRILLO, JE				CALVIN, JE; KLEIN, LW; VANDENBERG, BJ; MEYER, P; CONDON, JV; SNELL, RJ; RAMIREZMORGEN, LM; PARRILLO, JE			RISK STRATIFICATION IN UNSTABLE ANGINA - PROSPECTIVE VALIDATION OF THE BRAUNWALD CLASSIFICATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYOCARDIAL-INFARCTION; INTRAVENOUS NITROGLYCERIN; PECTORIS; PROPRANOLOL; THERAPY; MODELS	Objectives.-To validate the Braunwald classification of unstable angina as a predictor of in-hospital cardiac complications; to determine which factors of the Braunwald classification contributed significantly to this prediction; and to devise a method of combining these predictive factors into an overall odds ratio for complications. Design.-A validation cohort of consecutive patients followed prospectively for in-hospital cardiac complications including myocardial infarction and death. Setting.-A community-based academic medical center. Patients.-A total of 393 patients admitted consecutively to the coronary care and intermediate care units with unstable angina. Main Outcome Measures.-Major cardiac complications including death, myocardial infarction, congestive heart failure, cardiogenic shock, and severe ventricular dysrhythmias. Results.-Multiple logistic regression analysis identified four clinical factors used in the Braunwald classification that predicted the in-hospital occurrence of major cardiac complications: (1) myocardial infarction within less than 14 days (odds ratio [OR], 5.72; 95% confidence interval [CI], 1.92 to 16.97); (2) need for intravenous nitroglycerin (OR, 2.33; 95% CI, 1.31 to 4.17); (3) lack of beta-blocker or calcium channel blocker prior to admission (OR, 3.83; 95% CI, 1.55 to 9.42); and (4) baseline ST depression (OR, 2.81; 95% CI, 1.45 to 5.47). Two other clinical factors, diabetes and age, were also significant predictors. Validation of this model using parametric and nonparametric bootstrap techniques revealed excellent agreement between the CIs for adjusted ORs derived from the multiple logistic regression and those derived from the bootstrap. Conclusions.-The classification of unstable angina proposed by Braunwald includes four factors that predict risk of major in-hospital cardiac complications. Specific factors used in this classification can be combined with diabetes and age to better stratify risk of major cardiac complications in this disorder using a simpler model.			CALVIN, JE (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,CARDIOL SECT,1653 W CONGRESS PKWY,CHICAGO,IL 60612, USA.							BERTOLASI CA, 1976, CHEST, V70, P596, DOI 10.1378/chest.70.5.596; BERTOLET BD, 1993, CLIN CARDIOL, V16, P116, DOI 10.1002/clc.4960160207; BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; BRAUNWALD E, 1994, 940602 US DEP HLTH H; CALIFF RM, 1988, J AM COLL CARDIOL, V11, P20, DOI 10.1016/0735-1097(88)90160-X; CALVIN JE, 1994, CLIN RES, V42, pA248; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; COHEN M, 1991, AM J CARDIOL, V67, P1368, DOI 10.1016/0002-9149(91)90467-Y; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; CURFMAN GD, 1983, CIRCULATION, V67, P276, DOI 10.1161/01.CIR.67.2.276; Efron B., 1994, MONOGRAPHS STAT APPL; FINEBERG HV, 1984, NEW ENGL J MED, V310, P1301, DOI 10.1056/NEJM198405173102006; FREEMAN MR, 1989, AM HEART J, V117, P306, DOI 10.1016/0002-8703(89)90773-4; FUCHS J, 1990, EUR HEART J, V11, P1029, DOI 10.1093/oxfordjournals.eurheartj.a059630; GAZES PC, 1973, CIRCULATION, V48, P331, DOI 10.1161/01.CIR.48.2.331; GERWITZ H, 1979, CIRCULATION, V59, P707; GLANTZ SA, 1990, PRIMER APPLIED REGRE, P512; HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302; HARRELL FE, 1985, CANCER TREAT REP, V69, P1071; KAPLAN K, 1983, AM J CARDIOL, V51, P694, DOI 10.1016/S0002-9149(83)80117-9; MURPHY JJ, 1992, BRIT HEART J, V67, P395; NEUMANN FJ, 1989, BRIT HEART J, V62, P421; NORRIS RM, 1978, LANCET, V2, P907; THEROUX P, 1985, J AM COLL CARDIOL, V5, P717, DOI 10.1016/S0735-1097(85)80400-9; UDVARHELYI IS, 1992, J GEN INTERN MED, V7, P1, DOI 10.1007/BF02599092; WACKERS FJT, 1978, CIRCULATION, V57, P738, DOI 10.1161/01.CIR.57.4.738; 1986, BRIT HEART J, V56, P400	28	125	128	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 11	1995	273	2					136	141						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ687	7799494				2022-12-28	WOS:A1995PZ68700027
J	GRUMBACH, K; BODENHEIMER, T				GRUMBACH, K; BODENHEIMER, T			THE ORGANIZATION OF HEALTH-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; MEDICAL-CARE; CONTINUITY; SERVICES; REFORM; NEED		UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	GRUMBACH, K (corresponding author), UNIV CALIF SAN FRANCISCO,PRIMARY CARE RES CTR,DEPT FAMILY & COMMUNITY MED,BOX 1364,SAN FRANCISCO,CA 94143, USA.		Grumbach, Kevin/L-9222-2016					AIKEN LH, 1979, NEW ENGL J MED, V300, P1363, DOI 10.1056/NEJM197906143002404; BENSON P, 1984, AM J DIS CHILD, V138, P74, DOI 10.1001/archpedi.1984.02140390062019; BODENHEIMER TS, 1969, MED CARE REV, V26, P1125; BODENHEIMER TS, 1995, UNDERSTANDING HLTH P; CHAMEY E, 1967, PEDIATRICS, V40, P188; DAWSON W, 1975, REGIONALIZATION PERS; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; FIELDING JE, 1994, JAMA-J AM MED ASSOC, V271, P525, DOI 10.1001/jama.271.7.525; FRANKS P, 1993, JAMA-J AM MED ASSOC, V270, P1449, DOI 10.1001/jama.270.12.1449; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; FREYMANN JO, 1977, AM HLTH CARE SYSTEM; Friedson EL., 1970, PROFESSIONAL DOMINAN; Fry J., 1980, PRIMARY CARE; GONZALEZ M, 1993, PHYSICIAN MARKETPLAC; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GRUMBACH K, 1993, NEW ENGL J MED, V328, P940, DOI 10.1056/NEJM199304013281308; KROENKE K, 1989, AM J MED, V86, P262, DOI 10.1016/0002-9343(89)90293-3; LIGHT D, 1988, MILBANK Q, V66, P10, DOI 10.2307/3349912; LUCE JM, 1979, PERSPECT BIOL MED, V22, P377; LUFT HS, 1990, HOSPITAL VOLUME PHYS; MENKEN M, 1988, HEALTH AFFAIR, V7, P115, DOI 10.1377/hlthaff.7.5.115; Nutting P, 1990, COMMUNITY ORIENTED P; RIVO ML, 1994, JAMA-J AM MED ASSOC, V271, P1499, DOI 10.1001/jama.271.19.1499; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1074, DOI 10.1001/jama.270.9.1074; RODWIN V, 1984, HLTH PLANNING PREDIC; Roos N P, 1979, Inquiry, V16, P73; SHEA S, 1992, NEW ENGL J MED, V327, P776, DOI 10.1056/NEJM199209103271107; SHEAR CL, 1983, MED CARE, V21, P1204, DOI 10.1097/00005650-198312000-00007; SIDEL V, 1983, HLTH STATE; Somers A R, 1972, N Engl J Med, V287, P849, DOI 10.1056/NEJM197210262871704; STARFIELD B, 1992, PRIMARY CARE; Starr P, 1982, SOCIAL TRANSFORMATIO; WASSON JH, 1984, JAMA-J AM MED ASSOC, V252, P2413; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906; WHITE KL, 1961, NEW ENGL J MED, V265, P885, DOI 10.1056/NEJM196111022651805; 1991, FACTS FAMILY PRACTIC; 1990, MMWR-MORBID MORTAL W, V39, P448; 1993, GAOHRD9362 GEN ACC O	38	20	20	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 11	1995	273	2					160	167						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PZ687	7799498				2022-12-28	WOS:A1995PZ68700032
J	LITWIN, MS; HAYS, RD; FINK, A; GANZ, PA; LEAKE, B; LEACH, GE; BROOK, RH				LITWIN, MS; HAYS, RD; FINK, A; GANZ, PA; LEAKE, B; LEACH, GE; BROOK, RH			QUALITY-OF-LIFE OUTCOMES IN MEN FOR LOCALIZED PROSTATE-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RADICAL PROSTATECTOMY; RADIATION-THERAPY; CARCINOMA; STAGE; ADENOCARCINOMA; PAIN	Objective.-To assess health-related quality of life (HRQOL) in men treated for clinically localized prostate cancer. Design.-A cross-sectional analysis of HRQOL after treatment with radical prostatectomy, pelvic irradiation, or observation alone for clinically localized prostatic adenocarcinoma, and in age-matched comparison patients. Setting.-A large managed care population in California. Subjects.-A total of 528 men, including 214 treated for clinically localized prostate cancer (41 with evidence of metastatic disease were excluded from this analysis) and 273 age-matched, ZIP code-matched comparison patients without prostate cancer. Cancer patients were analyzed in three treatment groups: radical prostatectomy (n=98), primary pelvic irradiation (n=56), and observation alone (n=60). Main Outcome Measures.-General HRQOL was measured with the RAND 36-item Health Survey 1.0. Cancer-specific HRQOL was measured with the CAncer Rehabilitation Evaluation System-Short Form and the Functional Assessment of Cancer Therapy-General form, Disease-targeted quality of life was measured with a new instrument assessing function and bother in three organ systems: sexual, urinary, and bowel. Resuls.-No differences among treatment groups were seen in comparisons of general HRQOL. Significant differences among treatment groups were seen in both function and bother in the prostate-targeted measures of sexual, urinary, and bowel domains, When cancer patients were compared with men of similar age without prostate cancer, differences were seen in the sexual, urinary, and bowel function and bother but not in general HRQOL measures. Although cancer-free men were found not to have full potency or continence, prostate cancer patients treated with surgery or radiation reported significantly worse sexual, urinary, and bower function than men without cancer. Men who had undergone nerve-sparing prostatectomy did not differ from those who had undergone standard prostatectomy, but the power to detect a difference was low. Conclusions.-Although no differences were seen in general HRQOL, three disease-targeted domains were found to differ significantly among the treatment groups and comparison patients. Even after controlling for the sexual and urinary dysfunction experienced by older men without cancer, those receiving therapeutic interventions for their prostate cancer were found to have poorer disease-targeted HRQOL. We conclude that in addition to general HRQOL, disease-targeted measures must be used to assess outcomes of care in men treated for localized prostate cancer.	UNIV CALIF LOS ANGELES, SCH MED, DIV GEN INTERNAL MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DIV GERIATR, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT HLTH SERV, LOS ANGELES, CA 90024 USA; RAND CORP, HLTH SCI PROGRAM, SANTA MONICA, CA USA; SO CALIF PERMANENTE MED GRP, LOS ANGELES, CA 90027 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; RAND Corporation; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups	LITWIN, MS (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DIV UROL, 10833 LE CONTE AVE, LOS ANGELES, CA 90024 USA.		Hays, Ronald/D-5629-2013	Hays, Ronald/0000-0001-6697-907X; Litwin, Mark/0000-0002-2318-344X				BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; Cassileth B R, 1992, Qual Life Res, V1, P323, DOI 10.1007/BF00434946; CASSILETH BR, 1989, UROLOGY, V33, P57, DOI 10.1016/0090-4295(89)90108-8; CELLA D F, 1988, Comprehensive Therapy, V14, P69; Cella D F, 1990, Oncology (Williston Park), V4, P29; CELLA DF, 1987, CANCER-AM CANCER SOC, V60, P1661, DOI 10.1002/1097-0142(19871001)60:7<1661::AID-CNCR2820600740>3.0.CO;2-4; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; DASILVA FC, 1993, EUR UROL, V24, P113; DASILVA FC, 1993, CANCER, V71, P1138, DOI 10.1002/1097-0142(19930201)71:3+<1138::AID-CNCR2820711436>3.0.CO;2-7; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; FOSSA SD, 1992, PROSTATE, P145; FOWLER FJ, 1993, UROLOGY, V42, P622, DOI 10.1016/0090-4295(93)90524-E; FOWLER FJ, 1988, JAMA-J AM MED ASSOC, V259, P3018, DOI 10.1001/jama.259.20.3018; FOWLER FJ, 1991, EUR UROL, V20, P44; Ganz P A, 1992, Qual Life Res, V1, P19, DOI 10.1007/BF00435432; GBUREK B, 1992, Journal of Urology, V147, p466A; GIBBONS RP, 1989, J UROLOGY, V141, P564, DOI 10.1016/S0022-5347(17)40895-0; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; GREENFIELD S, 1993, MED CARE, V31, P141, DOI 10.1097/00005650-199302000-00005; Hays R D, 1993, Health Econ, V2, P217, DOI 10.1002/hec.4730020305; HERR HW, 1993, CANCER, V71, P1143, DOI 10.1002/1097-0142(19930201)71:3+<1143::AID-CNCR2820711437>3.0.CO;2-I; JACOBSEN SJ, 1993, UROLOGY, V42, P663, DOI 10.1016/0090-4295(93)90530-N; LEIBEL SA, 1980, UROL CLIN N AM, V7, P593; LIANG MH, 1985, ARTHRITIS RHEUM, V28, P542, DOI 10.1002/art.1780280513; LITWIN MS, 1993, J UROLOGY, V149, P84, DOI 10.1016/S0022-5347(17)36005-6; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; MAUSNER JS, 1974, EPIDEMIOLOGY INTRO T, P146; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; PATRICK DL, 1989, MED CARE, V27, pS217, DOI 10.1097/00005650-198903001-00018; PAULSON DF, 1990, J UROLOGY, V144, P1180, DOI 10.1016/S0022-5347(17)39686-6; PAULSON DF, 1988, J UROLOGY, V140, P535, DOI 10.1016/S0022-5347(17)41712-5; PEDERSEN KV, 1993, EUR UROL, V24, P7; RAY GR, 1973, RADIOLOGY, V106, P407, DOI 10.1148/106.2.407; RIEKER P, 1993, P AN M AM SOC CLIN, V12, P452; Schag C A, 1990, Oncology (Williston Park), V4, P135; SCHAG CAC, 1991, CANCER, V68, P1406, DOI 10.1002/1097-0142(19910915)68:6<1406::AID-CNCR2820680638>3.0.CO;2-2; SCHAG CAC, 1988, CANCER REHABILITATIO; SHARP JW, 1993, CANCER, V71, P1078, DOI 10.1002/1097-0142(19930201)71:3+<1078::AID-CNCR2820711429>3.0.CO;2-Z; Steward A., 1992, MEASURING FUNCTIONIN, P345; TANNOCK I, 1989, J CLIN ONCOL, V7, P590, DOI 10.1200/JCO.1989.7.5.590; Tannock I F, 1990, Oncology (Williston Park), V4, P149; TCHEKMEDYIAN NS, 1991, QUALITY LIFE CURRENT; TULSKY DS, 1990, P SOC BEHAV MED, V11, P45; VILLAVICENCIO H, 1993, EUR UROL, V24, P118; WALSH PC, 1982, J UROLOGY, V128, P492, DOI 10.1016/S0022-5347(17)53012-8; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	46	822	832	0	37	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 11	1995	273	2					129	135		10.1001/jama.273.2.129	http://dx.doi.org/10.1001/jama.273.2.129			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PZ687	7799493				2022-12-28	WOS:A1995PZ68700026
J	BLAUW, GJ; WESTENDORP, RGJ				BLAUW, GJ; WESTENDORP, RGJ			ASTHMA DEATHS IN NEW-ZEALAND - WHODUNNIT	LANCET			English	Editorial Material							DRUGS		LEIDEN UNIV HOSP,DEPT GEN INTERNAL MED,LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	BLAUW, GJ (corresponding author), LEIDEN UNIV HOSP,DEPT CLIN EPIDEMIOL,LEIDEN,NETHERLANDS.		Blauw, Gerard/GWD-1079-2022; Blauw, Gerard/AAW-7904-2021					BEASLEY R, 1991, AUST NZ J MED, V21, P753, DOI 10.1111/j.1445-5994.1991.tb01385.x; BENSON RL, 1948, J ALLERGY, V19, P129, DOI 10.1016/0021-8707(48)90101-4; COLLINS JM, 1969, BRIT J PHARMACOL, V36, P35, DOI 10.1111/j.1476-5381.1969.tb08301.x; CRANE J, 1989, LANCET, V1, P917; GANDEVIA B, 1968, MED J AUSTRALIA, V2, P279; GRANT IWB, 1983, BRIT MED J, V286, P374, DOI 10.1136/bmj.286.6362.374; INMAN WHW, 1969, LANCET, V2, P279; KEATING G, 1984, BRIT MED J, V289, P348, DOI 10.1136/bmj.289.6441.348; MOLFINO NA, 1994, EUR RESPIR J, V7, P981; SEARS MR, 1986, AM J EPIDEMIOL, V124, P1004, DOI 10.1093/oxfordjournals.aje.a114470; SLY RM, 1985, J ALLERGY CLIN IMMUN, V75, P443; SPEIZER FE, 1968, BRIT MED J, V1, P339, DOI 10.1136/bmj.1.5588.339; SPEIZER FE, 1968, BRIT MED J, V1, P335, DOI 10.1136/bmj.1.5588.335; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; WEBER RW, 1979, J ALLERGY CLIN IMMUN, V63, P116, DOI 10.1016/0091-6749(79)90201-X; WILSON JD, 1991, POST MARKETING SURVE, V5, P105	16	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					2	3		10.1016/S0140-6736(95)91143-X	http://dx.doi.org/10.1016/S0140-6736(95)91143-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799701				2022-12-28	WOS:A1995QA29000002
J	JAKEMAN, P				JAKEMAN, P			RISK OF RELAPSE IN MULTIBACILLARY LEPROSY	LANCET			English	Editorial Material											JAKEMAN, P (corresponding author), LEPROSY MISSION EVALUAT UNIT,SINGAPORE,SINGAPORE.							CARTEL JL, 1991, LEPROSY REV, V62, P186; 1994, WHO TECH REP SER, V847, P6; WHOCTDLEP941; 1993, LEPROSY REV, V64, P377; 1994, WHO WEEKLY EPIDEMIOL, V69, P301	5	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					4	5		10.1016/S0140-6736(95)91145-6	http://dx.doi.org/10.1016/S0140-6736(95)91145-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799708				2022-12-28	WOS:A1995QA29000004
J	TRAVISANO, M; MONGOLD, JA; BENNETT, AF; LENSKI, RE				TRAVISANO, M; MONGOLD, JA; BENNETT, AF; LENSKI, RE			EXPERIMENTAL TESTS OF THE ROLES OF ADAPTATION, CHANCE, AND HISTORY IN EVOLUTION	SCIENCE			English	Article							ESCHERICHIA-COLI; PROGRAM	The contributions of adaptation, chance, and history to the evolution of fitness and cell size were measured in two separate experiments using bacteria. In both experiments, populations propagated in identical environments achieved similar fitnesses, regardless of prior history or subsequent chance events. In contrast, the evolution of cell size, a trait weakly correlated with fitness, was more strongly influenced by history and chance.	MICHIGAN STATE UNIV, CTR MICROBIAL ECOL, E LANSING, MI 48824 USA; UNIV CALIF IRVINE, DEPT ECOL & EVOLUTIONARY BIOL, IRVINE, CA 92717 USA	Michigan State University; University of California System; University of California Irvine			Travisano, Michael/AAI-4809-2020	Lenski, Richard/0000-0002-1064-8375				BENNETT AF, 1992, EVOLUTION, V46, P16, DOI 10.1111/j.1558-5646.1992.tb01981.x; Calder WA., 1984, SIZE FUNCTION LIFE H; CROW J F, 1970, P591, DOI 10.1093/bioinformatics/btr330; DYKHUIZEN DE, 1983, MICROBIOL REV, V47, P150, DOI 10.1128/MMBR.47.2.150-168.1983; Fisher R.A., 1930, GENETICAL THEORY NAT; Gould S. J., 1989, WONDERFUL LIFE BURGE; GOULD SJ, 1979, PROC R SOC SER B-BIO, V205, P581, DOI 10.1098/rspb.1979.0086; KIMURA M, 1968, NATURE, V217, P624, DOI 10.1038/217624a0; Kimura M., 1983, NEUTRAL THEORY MOL E; KING JL, 1969, SCIENCE, V164, P788, DOI 10.1126/science.164.3881.788; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; LENSKI RE, ENCY MICROBIOL, V2, P125; MAYR E, 1983, AM NAT, V121, P324, DOI 10.1086/284064; OSTER G, 1982, EVOLUTION, V36, P444, DOI 10.1111/j.1558-5646.1982.tb05066.x; PARKER GA, 1990, NATURE, V348, P27, DOI 10.1038/348027a0; Portner HO, 2008, SCIENCE, V322, P690, DOI 10.1126/science.1163156; SMITH JM, 1985, Q REV BIOL, V60, P265, DOI 10.1086/414425; SOKAL RR, 1981, BIOMETRY, P217; Stephens D.W., 1986, pi; TRAVISANO M, IN PRESS EVOLUTION; VASI F, 1994, AM NAT, V144, P432, DOI 10.1086/285685; Williams G. C, 1992, NATURAL SELECTION DO; Wright S., 1969, THEORY GENE FREQUENC, V2, P520	23	359	361	3	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 6	1995	267	5194					87	90		10.1126/science.7809610	http://dx.doi.org/10.1126/science.7809610			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA235	7809610				2022-12-28	WOS:A1995QA23500035
J	COUNSELL, CE; CLARKE, MJ; SLATTERY, J; SANDERCOCK, PAG				COUNSELL, CE; CLARKE, MJ; SLATTERY, J; SANDERCOCK, PAG			THE MIRACLE OF DICE THERAPY FOR ACUTE STROKE - FACT OR FICTIONAL PRODUCT OF SUBGROUP ANALYSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PUBLICATION BIAS; MYOCARDIAL-INFARCTION; RANDOMIZED TRIALS; CLINICAL-TRIALS; NEED	Objective-To determine whether inappropriate subgroup analysis together with chance could change the conclusion of a systematic review of several randomised trials of an ineffective treatment. Design-44 randomised controlled trials of DICE therapy for stroke were performed (simulated by rolling different coloured dice; two trials per investigator). Each roll of the dice yielded the outcome (death or survival) for that ''patient.'' Publication bias was also simulated. The results were combined in a systematic review. Setting-Edinburgh. Main outcome measure-Mortality. Results-The ''hypothesis generating'' trial suggested that DICE therapy provided complete protection against death from acute stroke. However, analysis of all the trials suggested a reduction of only 11% (SD 11) in the odds of death. A predefined subgroup analysis by colour of dice suggested that red dice therapy increased the odds by 9% (22). If the analysis excluded red dice trials and those of poor methodological quality the odds decreased by 22% (13, 2P = 0.09). Analysis of ''published'' trials showed a decrease of 23% (13, 2P = 0.07) while analysis of only those in which the trialist had become familiar with the intervention showed a decrease of 39% (17, 2P = 0 .02). Conclusion-The early benefits of DICE therapy were not confirmed by subsequent trials. A plausible (but inappropriate) subset analysis of the effects of treatment led to the qualitatively different conclusion that DICE therapy reduced mortality, whereas in truth it was ineffective. Chance influences the outcome of clinical trials and systematic reviews of trials much more than many investigators realise, and its effects may lead to incorrect conclusions about the benefits of treatment.	WESTERN GEN HOSP, DEPT CLIN NEUROSCI, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; RADCLIFFE INFIRM, CLIN TRIAL SERV UNIT, OXFORD OX2 6HE, ENGLAND; RADCLIFFE INFIRM, IMPERIAL CANC RES FUND, CANC STUDIES UNIT, OXFORD OX2 6HE, ENGLAND	University of Edinburgh; Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford			sandercock, peter/GQI-3167-2022	sandercock, peter/0000-0001-8484-0135	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1992, Lancet, V339, P1; [Anonymous], 1986, Lancet, V1, P397; BERLIN JA, 1989, J AM STAT ASSOC, V84, P381; BEROYZ G, 1994, LANCET, V343, P619; CHAN SS, 1982, CLIN RES, V30, pA234; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; HINE LK, 1989, JAMA-J AM MED ASSOC, V262, P3037, DOI 10.1001/jama.262.21.3037; IMPERIALE T F, 1991, Journal of the American Medical Association, V266, P260, DOI 10.1001/jama.266.2.260; KOUDSTAAL PJ, 1988, BRIT MED J, V297, P1571, DOI 10.1136/bmj.297.6663.1571; MOHR JP, 1994, CEREBROVASC DIS, V4, P197, DOI 10.1159/000108482; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; PETO R, 1993, ANN NY ACAD SCI, V703, P314, DOI 10.1111/j.1749-6632.1993.tb26369.x; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421; 1994, PREPARING MAINTAININ	20	84	88	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 24	1994	309	6970					1677	1681		10.1136/bmj.309.6970.1677	http://dx.doi.org/10.1136/bmj.309.6970.1677			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819982	Green Published			2022-12-28	WOS:A1994PY71700006
J	KALPANA, GV; MARMON, S; WANG, WD; CRABTREE, GR; GOFF, SP				KALPANA, GV; MARMON, S; WANG, WD; CRABTREE, GR; GOFF, SP			BINDING AND STIMULATION OF HIV-1 INTEGRASE BY A HUMAN HOMOLOG OF YEAST TRANSCRIPTION FACTOR SNF5	SCIENCE			English	Article							I-HYPERSENSITIVE SITES; SACCHAROMYCES-CEREVISIAE; RETROVIRUS INTEGRATION; PROTEIN INVITRO; CHROMATIN STRUCTURE; PREFERRED TARGETS; GENES; DNA; EXPRESSION; SNF2/SWI2	Upon entry into a host cell, retroviruses direct the reverse transcription of the viral RNA genome and the establishment of an integrated proviral DNA. The retroviral integrase protein (IN) is responsible for the insertion of the viral DNA into host chromosomal targets. The two-hybrid system was used to identify a human gene product that binds tightly to the human immunodeficiency virus-type 1 (HIV-1) integrase in vitro and stimulates its DNA-joining activity. The sequence of the gene suggests that the protein is a human homolog of yeast SNF5, a transcriptional activator required for high-level expression of many genes. The gene, termed INI1 (for integrase interactor 1), may encode a nuclear factor that promotes integration and targets incoming viral DNA to active genes.	COLUMBIA UNIV,COLL PHYS & SURG,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; STANFORD UNIV,HOWARD HUGHES MED INST,DEPT DEV BIOL,BECKMAN CTR B207,STANFORD,CA 94305	Columbia University; Howard Hughes Medical Institute; Howard Hughes Medical Institute; Stanford University			Wang, Weidong/AAV-2446-2021	Wang, Weidong/0000-0002-0658-7928; Kalpana, Ganjam/0000-0003-4111-0604	NIAID NIH HHS [U01 AI 24845] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI024845] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMS E, 1986, MOL CELL BIOL, V6, P3643, DOI 10.1128/MCB.6.11.3643; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; CRAIGIE R, 1992, TRENDS GENET, V8, P187, DOI 10.1016/0168-9525(92)90223-Q; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GOFF SP, 1992, ANNU REV GENET, V26, P527, DOI 10.1146/annurev.ge.26.120192.002523; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KALPANA GV, 1993, P NATL ACAD SCI USA, V90, P10593, DOI 10.1073/pnas.90.22.10593; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LEE MS, 1994, P NATL ACAD SCI USA, V91, P9823, DOI 10.1073/pnas.91.21.9823; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NEIGEBORN L, 1984, GENETICS, V108, P845; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; ROHDEWOHLD H, 1987, J VIROL, V61, P336, DOI 10.1128/JVI.61.2.336-343.1987; SANDMEYER SB, 1990, ANNU REV GENET, V24, P491; SCHERDIN U, 1990, J VIROL, V64, P907, DOI 10.1128/JVI.64.2.907-912.1990; SHIH CC, 1988, CELL, V53, P531, DOI 10.1016/0092-8674(88)90569-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VIJAYA S, 1986, J VIROL, V60, P683, DOI 10.1128/JVI.60.2.683-692.1986; WEISS R, 1984, RNA TUMOR VIRUSES; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WITHERSWARD ES, 1994, GENE DEV, V8, P1473, DOI 10.1101/gad.8.12.1473; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	40	433	459	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					2002	2006		10.1126/science.7801128	http://dx.doi.org/10.1126/science.7801128			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801128				2022-12-28	WOS:A1994PZ26700033
J	POWRIE, JK; WATTS, GF; INGHAM, JN; TAUB, NA; TALMUD, PJ; SHAW, KM				POWRIE, JK; WATTS, GF; INGHAM, JN; TAUB, NA; TALMUD, PJ; SHAW, KM			ROLE OF GLYCEMIC CONTROL IN DEVELOPMENT OF MICROALBUMINURIA IN PATIENTS WITH INSULIN-DEPENDENT DIABETES	BRITISH MEDICAL JOURNAL			English	Article							URINARY ALBUMIN EXCRETION; DELETION POLYMORPHISM; CONVERTING ENZYME; NEPHROPATHY; MELLITUS; PREVENTION; PRESSURE; GENE	Objective-To ascertain which factors determine the progression from very low rates of albumin excretion to persistent microalbuminuria in patients with insulin dependent diabetes mellitus. Design-A 10 year prospective study of a cohort of diabetic patients. Setting-Outpatient department of the Portsmouth District Hospitals. Subjects-97 patients with insulin dependent diabetes mellitus who were initially free of microalbuminuria and hypertension. Main outcome measure-Urinary albumin: creatinine ratio. Results-Eight of the 97 patients had developed microalbuminuria (urinary albumin:creatinine ratio >3 mg/mmol in three consecutive early morning samples) by the 10 year follow up. The group who developed microalbuminuria had higher baseline log(10) plasma glucose concentrations (mean (SD), 1.210 (0.122) v 0.984 (0.196) mmol/l, P < 0.001) and glycated haemoglobin concentrations (1.112% (0.069%) v 0.997% (0.076%), P < 0.001) and a younger age at onset of diabetes (10.0 (5.5) v 15.6 (7.8) years, P < 0.05). There was no difference in baseline duration of diabetes, smoking, sex, insulin dose, body mass index, serum creatinine concentration, or systolic, diastolic, or mean arterial blood pressure between the two groups. Multiple linear regression analysis showed that urinary albumin:creatinine ratio at 10 years was influenced by initial albumin: creatinine ratio (P = 0.006), initial glycated haemoglobin concentration (P = 0.002), and duration of diabetes (P = 0.045). Genotype for angiotensin converting enzyme was not related to the development of microalbuminuria nor, in a larger group of patients, the presence of any degree of diabetic nephropathy. Conclusion-In patients with insulin dependent diabetes mellitus the progression of minimal albuminuria and the development of microalbuminuria is determined primarily by poor long term glycaemic control. There is a weaker relation with longer duration of disease and younger age at onset of diabetes, but blood pressure does not seem to be implicated. Gene polymorphism for angiotensin converting enzyme is not linked to the development of microalbuminuria or established diabetic nephropathy.	UNIV WESTERN AUSTRALIA, ROYAL PERTH HOSP, PERTH, WA 6001, AUSTRALIA; QUEEN ALEXANDRA HOSP, DEPT ENDOCRINOL & DIABET, PORTSMOUTH PO6 3LY, HANTS, ENGLAND; UNITED MED & DENT SCH, ST THOMAS HOSP, DEPT PUBL HLTH MED, LONDON SE1 7EH, ENGLAND; UCL, SCH MED, DIV CARDIOVASC GENET, LONDON WC1E 6JJ, ENGLAND	Royal Perth Hospital; University of Western Australia; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; University College London; UCL Medical School	POWRIE, JK (corresponding author), UNITED MED & DENT SCH, ST THOMAS HOSP, DIV MED, LONDON SE1 7EH, ENGLAND.		Talmud, Philippa J/C-4402-2008	Watts, Gerald/0000-0003-2276-1524; Talmud, Philippa/0000-0002-5560-1933				CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; EARLE K, 1992, NEW ENGL J MED, V326, P673, DOI 10.1056/NEJM199203053261005; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; MARRE M, 1988, BMJ-BRIT MED J, V297, P1092, DOI 10.1136/bmj.297.6656.1092; MARRE M, 1994, DIABETES, V43, P384, DOI 10.2337/diabetes.43.3.384; MATHIESEN ER, 1990, DIABETES, V39, P245, DOI 10.2337/diabetes.39.2.245; MATHIESEN ER, 1984, DIABETOLOGIA, V26, P406; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; PARVING HH, 1982, ACTA ENDOCRINOL-COP, V100, P500; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; RUDBERG S, 1993, DIABETOLOGIA, V36, P1309, DOI 10.1007/BF00400811; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; VIBERTI G, 1984, DIABETES, V33, P686, DOI 10.2337/diab.33.7.686; VIBERTI GC, 1982, LANCET, V1, P1430; VIBERTI GC, 1987, BRIT MED J, V295, P515, DOI 10.1136/bmj.295.6597.515; WATTS GF, 1990, DIABETES RES CLIN PR, V9, P169, DOI 10.1016/0168-8227(90)90109-7; WATTS GF, 1986, CLIN CHEM, V32, P1544; WATTS GF, 1991, Q J MED, V79, P365; WATTS GF, 1988, CLIN CHIM ACTA, V172, P191, DOI 10.1016/0009-8981(88)90323-3; WATTS GF, 1989, DIABETIC MED, V6, P25, DOI 10.1111/j.1464-5491.1989.tb01134.x; WISEMAN MJ, 1984, DIABETOLOGIA, V26, P402; YIP J, 1993, BRIT MED J, V306, P1235	24	69	70	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1608	1612		10.1136/bmj.309.6969.1608	http://dx.doi.org/10.1136/bmj.309.6969.1608			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819935	Green Published			2022-12-28	WOS:A1994PY22000015
J	SMITH, R				SMITH, R			AN UNFREE NHS AND MEDICAL PRESS IN AN UNFREE SOCIETY	BRITISH MEDICAL JOURNAL			English	Article																		BRENDON P, 1991, COLUMBIA JOURNAL NOV, P68; CRAFT N, 1994, BRIT MED J, V309, P1640, DOI 10.1136/bmj.309.6969.1640a; DYER C, 1992, BRIT MED J, V305, P1177; DYER C, 1992, BRIT MED J, V304, P203; Handy C., 1976, UNDERSTANDING ORG; KINGMAN S, 1994, BRIT MED J, V308, P1001, DOI 10.1136/bmj.308.6935.1001a; PARSONS D, 1993, BRIT MED J, V306, P253, DOI 10.1136/bmj.306.6872.253; SHEARD S, 1994, BRIT MED J, V309, P1643, DOI 10.1136/bmj.309.6969.1643; SHILS E, 1991, COLUMBIA J REV   NOV, P68; SIMPSON J, 1992, BRIT MED J, V304, P1586, DOI 10.1136/bmj.304.6842.1586; SMITH R, 1992, BRIT MED J, V305, P1308, DOI 10.1136/bmj.305.6865.1308; SMITH R, 1991, BALANCING ACT; SMITH R, 1987, BRIT MED J, V295, P16334; WARDEN J, 1992, BRIT MED J, V305, P1180; 1992, HLTH SERVICE J  1203, P7	15	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1644	1645		10.1136/bmj.309.6969.1644	http://dx.doi.org/10.1136/bmj.309.6969.1644			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819951	Green Published			2022-12-28	WOS:A1994PY22000037
J	MCCARRON, PG; SMITH, GD; WOMERSLEY, JJ				MCCARRON, PG; SMITH, GD; WOMERSLEY, JJ			DEPRIVED AND MORTALITY IN GLASGOW - CHANGES FROM 1980 TO 1992	BRITISH MEDICAL JOURNAL			English	Article							HEALTH		UNIV GLASGOW,DEPT PUBL HLTH,GLASGOW G12 8RZ,LANARK,SCOTLAND; GREATER GLASGOW HLTH,DEPT PUBL HLTH,GLASGOW G1 1ET,LANARK,SCOTLAND	University of Glasgow			Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314				Carstairs V., 1991, DEPRIVATION HLTH SCO; FORWELL G, 1991, ANN REPORT DIRECTOR; PHILLIMORE P, 1994, BRIT MED J, V308, P1125, DOI 10.1136/bmj.308.6937.1125; SMITH GD, 1993, BRIT MED J, V307, P1085, DOI 10.1136/bmj.307.6912.1085; SMITH GD, 1990, BMJ-BRIT MED J, V301, P373, DOI 10.1136/bmj.301.6748.373	5	72	72	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 3	1994	309	6967					1481	1482		10.1136/bmj.309.6967.1481	http://dx.doi.org/10.1136/bmj.309.6967.1481			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW053	7804053	Green Published			2022-12-28	WOS:A1994PW05300025
J	TABRIZI, SJ; SCOTT, J; PUSEY, CD; LACEY, S; DAVIES, RAA; REES, AJ; BEYNON, H; OAKLEY, C; WHYTE, M				TABRIZI, SJ; SCOTT, J; PUSEY, CD; LACEY, S; DAVIES, RAA; REES, AJ; BEYNON, H; OAKLEY, C; WHYTE, M			GRAND ROUNDS - HAMMERSMITH-HOSPITAL - NOCARDIA-PERICARDITIS - A RARE OPPORTUNISTIC INFECTION	BRITISH MEDICAL JOURNAL			English	Discussion							CARDIAC-TAMPONADE; ASTEROIDES; TRIMETHOPRIM; DISEASE				TABRIZI, SJ (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,LONDON W12 0NN,ENGLAND.			Tabrizi, Sarah/0000-0003-2716-2045				BRICENO MT, 1961, MYCOPATHOLOGIA, V15, P358; CHAVEZ CM, 1972, CHEST, V61, P79, DOI 10.1378/chest.61.1.79; CLENNEY TL, 1993, CHEST, V103, P641, DOI 10.1378/chest.103.2.641; CURRY WA, 1980, ARCH INTERN MED, V140, P810; DEWSNUP DH, 1984, ANTIMICROB AGENTS CH, V25, P165, DOI 10.1128/AAC.25.2.165; Eppinger H, 1891, BEITR PATHOL ANAT AL, V9, P287; KESSLER R, 1991, ANN THORAC SURG, V52, P861, DOI 10.1016/0003-4975(91)91228-N; LEUNG WH, 1990, J RHEUMATOL, V17, P1237; Nocard E., 1888, ANN I PASTEUR, V2, P293; POLAND GA, 1990, MAYO CLIN PROC, V65, P819, DOI 10.1016/S0025-6196(12)62573-7; SMITH WG, 1963, MED J AUSTRALIA, V2, P534, DOI 10.5694/j.1326-5377.1963.tb25159.x; STAMM AM, 1983, ARCH INTERN MED, V143, P383, DOI 10.1001/archinte.143.2.383; SUSENS GP, 1967, ANN INTERN MED, V67, P1021, DOI 10.7326/0003-4819-67-5-1021; WALLACE RJ, 1982, REV INFECT DIS, V4, P315	14	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 3	1994	309	6967					1495	1497		10.1136/bmj.309.6967.1495	http://dx.doi.org/10.1136/bmj.309.6967.1495			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW053	7804059	Green Published			2022-12-28	WOS:A1994PW05300031
J	MACKENZIE, WR; HOXIE, NJ; PROCTOR, ME; GRADUS, MS; BLAIR, KA; PETERSON, DE; KAZMIERCZAK, JJ; ADDISS, DG; FOX, KR; ROSE, JB; DAVIS, JP				MACKENZIE, WR; HOXIE, NJ; PROCTOR, ME; GRADUS, MS; BLAIR, KA; PETERSON, DE; KAZMIERCZAK, JJ; ADDISS, DG; FOX, KR; ROSE, JB; DAVIS, JP			A MASSIVE OUTBREAK IN MILWAUKEE OF CRYPTOSPORIDIUM INFECTION TRANSMITTED THROUGH THE PUBLIC WATER-SUPPLY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DRINKING-WATER; SURFACE-WATER; GIARDIA; IMMUNOCOMPETENT; TRANSMISSION; DIARRHEA	Background. Early in the spring of 1993 there was a widespread outbreak of acute watery diarrhea among the residents of Milwaukee. Methods. We investigated the two Milwaukee water-treatment plants, gathered data from clinical laboratories on the results of tests for enteric pathogens, and examined ice made during the time of the outbreak for cryptosporidium oocysts. We surveyed residents with confirmed cryptosporidium infection and a sample of those with acute watery diarrhea consistent with cryptosporidium infection. To estimate the magnitude of the outbreak, we also conducted a survey using randomly selected telephone numbers in Milwaukee and four surrounding counties. Results. There were marked increases in the turbidity of treated water at the city's southern water-treatment plant from March 23 until April 9, when the plant was shut down. Cryptosporidium oocysts were identified in water from ice made in southern Milwaukee during these weeks. The rates of isolation of other enteric pathogens remained stable, but there was more than a 100-fold increase in the rate of isolation of cryptosporidium. The median duration of illness was 9 days (range, 1 to 55). The median maximal number of stools per day was 12 (range, 1 to 90). Among 285 people surveyed who had laboratory-confirmed cryptosporidiosis, the clinical manifestations included watery diarrhea (in 93 percent), abdominal cramps (in 84 percent), fever (in 57 percent), and vomiting (in 48 percent). We estimate that 403,000 people had watery diarrhea attributable to this outbreak. Conclusions. This massive outbreak of watery diarrhea was caused by cryptosporidium oocysts that passed through the filtration system of one of the city's water-treatment plants. Water-quality standards and the testing of patients for cryptosporidium were not adequate to detect this outbreak.	WISCONSIN DEPT HLTH & SOCIAL SERV, BUR PUBL HLTH, MADISON, WI 53703 USA; CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV PARASIT DIS, ATLANTA, GA 30341 USA; CTR DIS CONTROL & PREVENT, DIV FIELD EPIDEMIOL, EPIDEMIOL PROGRAM OFF, ATLANTA, GA 30341 USA; CTR DIS CONTROL & PREVENT, EPIDEM INTELLIGENCE SERV, ATLANTA, GA 30341 USA; MILWAUKEE DEPT HLTH, MILWAUKEE, WI USA; BUR LABS, MILWAUKEE, WI USA; UNIV S FLORIDA, TAMPA, FL USA; US EPA, CINCINNATI, OH 45268 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; State University System of Florida; University of South Florida; United States Environmental Protection Agency			Kenzie, William R Mac/F-1528-2013	Kenzie, William R Mac/0000-0001-7723-0339				ALPERT G, 1986, PEDIATRICS, V77, P152; ARROWOOD MJ, 1989, J CLIN MICROBIOL, V27, P1490, DOI 10.1128/JCM.27.7.1490-1495.1989; BADENOCH J, 1990, CRYPTOSPORIDIUM WATE; COLBOURNE JS, 1989, 1989 P AM WAT WORKS, P275; CURRENT WL, 1983, NEW ENGL J MED, V308, P1252, DOI 10.1056/NEJM198305263082102; CURRENT WL, 1991, CLIN MICROBIOL REV, V4, P325, DOI 10.1128/CMR.4.3.325-358.1991; DANTONIO RG, 1985, ANN INTERN MED, V103, P886, DOI 10.7326/0003-4819-103-6-886; FAYER R, 1986, MICROBIOL REV, V50, P458, DOI 10.1128/MMBR.50.4.458-483.1986; GALLAGHER MM, 1989, AM J PUBLIC HEALTH, V79, P39, DOI 10.2105/AJPH.79.1.39; HAYES EB, 1989, NEW ENGL J MED, V320, P1372, DOI 10.1056/NEJM198905253202103; JOKIPII L, 1985, GASTROENTEROLOGY, V89, P838, DOI 10.1016/0016-5085(85)90581-5; JOKIPII L, 1986, NEW ENGL J MED, V315, P1643, DOI 10.1056/NEJM198612253152604; JOSEPH C, 1991, EPIDEMIOL INFECT, V107, P509, DOI 10.1017/S0950268800049207; KOCH KL, 1985, ANN INTERN MED, V102, P593, DOI 10.7326/0003-4819-102-5-593; LECHEVALLIER MW, 1991, APPL ENVIRON MICROB, V57, P2617, DOI 10.1128/AEM.57.9.2617-2621.1991; LECHEVALLIER MW, 1992, APPL ENVIRON MICROB, V58, P780; LECHEVALLIER MW, 1991, APPL ENVIRON MICROB, V57, P2610, DOI 10.1128/AEM.57.9.2610-2616.1991; LELAND D, 1993, J AM WATER WORKS ASS, V85, P34; MA P, 1983, J INFECT DIS, V147, P824, DOI 10.1093/infdis/147.5.824; MEISEL JL, 1976, GASTROENTEROLOGY, V70, P1156; NAVIN TR, 1984, REV INFECT DIS, V6, P313; NIME FA, 1976, GASTROENTEROLOGY, V70, P592; PALIT C, 1983, SOCIOL METHOD RES, V12, P169, DOI 10.1177/0049124183012002005; PALIT D, 1988, CASS CATI VERSION 3; PALMER SR, 1990, BRIT MED J, V300, P774, DOI 10.1136/bmj.300.6727.774; RICHARDSON AJ, 1991, EPIDEMIOL INFECT, V107, P485, DOI 10.1017/S0950268800049189; ROSE JB, 1989, APPL ENVIRON MICROB, V55, P3189, DOI 10.1128/AEM.55.12.3189-3196.1989; ROSE JB, 1991, ENVIRON SCI TECHNOL, V25, P1393, DOI 10.1021/es00020a005; ROSE JB, 1990, METHODS INVESTIGATIO, P223; SKEELS MR, 1990, AM J PUBLIC HEALTH, V80, P305, DOI 10.2105/AJPH.80.3.305; WOLFSON JS, 1985, NEW ENGL J MED, V312, P1278, DOI 10.1056/NEJM198505163122002; XI JA, 1992, J VIROL, V66, P6527, DOI 10.1128/JVI.66.11.6527-6532.1992	32	1386	1439	5	175	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 21	1994	331	3					161	167		10.1056/NEJM199407213310304	http://dx.doi.org/10.1056/NEJM199407213310304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW797	7818640				2022-12-28	WOS:A1994NW79700004
J	HOUSMAN, D				HOUSMAN, D			HUMAN DNA POLYMORPHISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											HOUSMAN, D (corresponding author), MIT,CTR CANC RES,BLDG E17,RM 543,40 AMES ST,CAMBRIDGE,MA 02139, USA.							GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; WEBER JL, 1989, AM J HUM GENET, V44, P388	3	32	32	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 2	1995	332	5					318	320		10.1056/NEJM199502023320508	http://dx.doi.org/10.1056/NEJM199502023320508			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD396	7816069				2022-12-28	WOS:A1995QD39600007
J	THOMAS, BA				THOMAS, BA			POPULATION BREAST-CANCER SCREENING - THEORY, PRACTICE, AND SERVICE IMPLICATIONS	LANCET			English	Editorial Material											THOMAS, BA (corresponding author), JARVIS BREAST SCREENING TRAINING & DIAGNOST CTR, GUILDFORD, SURREY, ENGLAND.							HAKAMA M, 1995, LANCET, V345, P221; Moss S M, 1994, J Med Screen, V1, P193; SHAPIRO S, 1971, J AMER MED ASSOC, V215, P1777; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; TABAR L, 1992, LANCET, V339, P412, DOI 10.1016/0140-6736(92)90090-P; THOMAS BA, 1989, INT CONGR SER, V865, P11; Wald NJ, 1993, BREAST, V2, P209; YOUNG KC, 1994, CLIN RADIOL, V49, P461, DOI 10.1016/S0009-9260(05)81741-6; 1993, STANDARDS NHS BREAST; 1991, CMO91, P15	10	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 28	1995	345	8944					205	207		10.1016/S0140-6736(95)90217-1	http://dx.doi.org/10.1016/S0140-6736(95)90217-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7823709	Bronze			2022-12-28	WOS:A1995QD53200003
J	CAO, YZ; QIN, LM; ZHANG, LQ; SAFRIT, J; HO, DD				CAO, YZ; QIN, LM; ZHANG, LQ; SAFRIT, J; HO, DD			VIROLOGICAL AND IMMUNOLOGICAL CHARACTERIZATION OF LONG-TERM SURVIVORS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MONONUCLEAR-CELLS; HIV-1 INFECTION; HOMOSEXUAL MEN; MESSENGER-RNA; T-LYMPHOCYTES; BISEXUAL MEN; REPLICATION; AIDS; INDIVIDUALS; CORRELATE	Background. In most subjects infected with human immunodeficiency virus type 1 (HIV-1), clinical or laboratory evidence of immunodeficiency develops within 10 years of seroconversion, but a few infected people remain healthy and immunologically normal for more than a decade. Studies of these subjects, termed long-term survivors, may yield important clues for the development of prophylactic and therapeutic interventions against the acquired immunodeficiency syndrome. Methods and Results. We studied 10 seropositive subjects who remained asymptomatic with normal and stable CD4+ lymphocyte counts despite 12 to 15 years of HIV-1 infection. Plasma cultures were uniformly negative for infectious virus. However, particle-associated HIV-1 RNA was detected in four subjects with a sensitive branched-DNA signal-amplification assay, whereas in five others the levels of HIV-1 RNA were too low to detect. Infectious HIV-1 was detected in peripheral-blood mononuclear cells (PBMC) of three subjects by standard limiting-dilution cultures, and infectious virus was recovered from another subject with use of a CD8-depleted culture. The other six subjects had no detectable infectious virus in their PBMC. A quantitative polymerase-chain-reaction assay revealed that all subjects had detectable but low titers of viral DNA in PBMC. Overall, the viral burden in the plasma and PBMC of long-term survivors was orders of magnitude lower than that typically found in subjects with progressive disease. There was no in vitro evidence of resistance by host CD4+ lymphocytes to HIV-1 infection. However, longterm survivors had a vigorous, virus-inhibitory CD8+ lymphocyte response and a strong neutralizing-antibody response. In two subjects the kinetics of viral replication was consistent with the presence of a substantially attenuated strain of HIV-1. Conclusions. Subjects who remain asymptomatic for many years despite HIV-1 infection have low levels of HIV-1 and a combination of strong virus-specific immune responses with some degree of attenuation of the virus.	NYU,SCH MED,AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016	New York University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032427, R01AI024030, R01AI025541] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32427, AI25541, AI24030] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAGASRA O, 1992, NEW ENGL J MED, V326, P1385, DOI 10.1056/NEJM199205213262103; BUCHBINDER SP, 1994, AIDS, V8, P1123, DOI 10.1097/00002030-199408000-00014; CAO Y, IN PRESS AIDS RES HU; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FULTZ T, 1995, 2ND NAT C HUM RETR R; GREENOUGH TC, 1994, AIDS RES HUM RETROV, V10, P395, DOI 10.1089/aid.1994.10.395; HO DD, 1991, J VIROL, V65, P489, DOI 10.1128/JVI.65.1.489-493.1991; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HUANG YX, 1995, J VIROL, V69, P93, DOI 10.1128/JVI.69.1.93-100.1995; JASON J, 1989, JAMA-J AM MED ASSOC, V261, P725, DOI 10.1001/jama.261.5.725; JASSOY C, 1993, J VIROL, V67, P2844, DOI 10.1128/JVI.67.5.2844-2852.1993; KANNAGI M, 1988, J IMMUNOL, V140, P2237; KEET IPM, 1994, J INFECT DIS, V169, P1236, DOI 10.1093/infdis/169.6.1236; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; LEARMONT J, 1992, LANCET, V340, P863, DOI 10.1016/0140-6736(92)93281-Q; LIFSON AR, 1991, J INFECT DIS, V163, P959, DOI 10.1093/infdis/163.5.959; LIFSON AR, 1988, J INFECT DIS, V158, P1360, DOI 10.1093/infdis/158.6.1360; MICHAEL NL, 1992, J VIROL, V66, P310, DOI 10.1128/JVI.66.1.310-316.1992; MOORE J, IN PRESS J VIROL; MUNOZ A, 1989, AM J EPIDEMIOL, V130, P530, DOI 10.1093/oxfordjournals.aje.a115367; PACHL C, IN PRESS J ACQUIR IM; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PATTERSON BK, 1993, SCIENCE, V260, P976, DOI 10.1126/science.8493534; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SCHRAGER LK, 1994, AIDS S, V1, pS95; SHEPPARD HW, 1993, AIDS, V7, P1159, DOI 10.1097/00002030-199309000-00002; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; SPIRA AI, 1995, J VIROL, V69, P422, DOI 10.1128/JVI.69.1.422-429.1995; WALKER CM, 1991, CELL IMMUNOL, V137, P420, DOI 10.1016/0008-8749(91)90090-X; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WALKER CM, 1991, J VIROL, V65, P5921, DOI 10.1128/JVI.65.11.5921-5927.1991; WILLIAMS LM, 1991, VIROLOGY, V184, P723, DOI 10.1016/0042-6822(91)90442-E	39	922	950	1	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	1995	332	4					201	208		10.1056/NEJM199501263320401	http://dx.doi.org/10.1056/NEJM199501263320401			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC270	7808485				2022-12-28	WOS:A1995QC27000001
J	MILBERG, JA; DAVIS, DR; STEINBERG, KP; HUDSON, LD				MILBERG, JA; DAVIS, DR; STEINBERG, KP; HUDSON, LD			IMPROVED SURVIVAL OF PATIENTS WITH ACUTE RESPIRATORY-DISTRESS-SYNDROME (ARDS) - 1983-1993	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VENTILATION; SEVERITY	Objective.-To analyze temporal trends in acute respiratory distress syndrome (ARDS) fatality rates since 1983 at one institution. Design.-Cohort. Setting.-Intensive care units of a large county hospital. Patients.-Consecutive adult patients (greater than or equal to 18 years of age) meeting ARDS criteria were identified through daily surveillance of intensive care units (N=918 from 1983 through 1993). The major causes were sepsis syndrome in 37% and major trauma in 25%; 37% had other risks. Sixty-five percent were male. The median age was 45 years (range, 18 to 92 years); 70% were younger than 60 years. Main Outcome Measure.-Hospital mortality. Results.-Overall fatality rates showed no trend from 1983 to 1987, declined slightly in 1988 and 1989, and decreased to a low of 36% in 1993 (95% confidence interval, 25% to 46%). The crude rates were largely unchanged after adjustment for age, ARDS risk, and gender distribution. While patients both younger than 60 years and 60 years or older experienced declines in fatality rate, the larger decrease occurred in the younger cohort. In sepsis patients, ARDS fatality rates declined steadily, from 67% in 1990 to 40% in 1993 (95% confidence interval, 23% to 57%). The decline in sepsis-related ARDS fatality was confined largely to patients less than 60 years of age. Trauma patients and all other patients also experienced declines in fatality rates after 1987, although these trends were not as strong and consistent as in the sepsis population. Conclusions.-In this large series, we observed a significant decrease in fatality rates occurring largely in patients younger than 60 years and in those with sepsis syndrome as their risk for ARDS. We are unable to determine the extent to which experimental therapies or other changes in treatment have contributed to the observed decline in the ARDS fatality rate, institution-specific rates and temporal trends in ARDS fatality rates should be considered in clinical trials designed to prevent ARDS and the high mortality associated with this syndrome.			MILBERG, JA (corresponding author), UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT MED,DIV PULM & CRIT CARE MED,ZA-62,325 9TH AVE,SEATTLE,WA 98104, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL030542] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30542] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMATO MBP, 1993, AM REV RESPIR DIS, V147, pA890; ARMITAGE P, 1987, STATISTICAL METHODS; ARTIGAS A, 1990, ACUTE RESPIRATORY FA, P37; ASHBAUGH DG, 1967, LANCET, V2, P319; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BIDANI A, 1994, JAMA-J AM MED ASSOC, V272, P957, DOI 10.1001/jama.272.12.957; GATTINONI L, 1986, JAMA-J AM MED ASSOC, V256, P881, DOI 10.1001/jama.256.7.881; Hosmer DW, 1989, APPL LOGISTIC REGRES, P140; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEE PC, 1990, CHEST, V97, P430, DOI 10.1378/chest.97.2.430; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P295, DOI 10.1164/ajrccm.149.2.8306022; SELVIN S, 1991, STATISTICAL ANAL EPI; SUCHYTA MR, 1991, CHEST, V99, P951, DOI 10.1378/chest.99.4.951; SUCHYTA MR, 1992, CHEST, V101, P1074, DOI 10.1378/chest.101.4.1074; TUXEN DV, 1994, AM J RESP CRIT CARE, V150, P870, DOI 10.1164/ajrccm.150.3.8087364; ZAPOL WM, 1990, ACUTE RESPIRATORY FA, P367	17	502	532	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	1995	273	4					306	309		10.1001/jama.273.4.306	http://dx.doi.org/10.1001/jama.273.4.306			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC057	7815658				2022-12-28	WOS:A1995QC05700029
J	GRIFFITHS, E; CORTES, A; GILBERT, N; STEVENSON, P; MACDONALD, S; PEPPER, D				GRIFFITHS, E; CORTES, A; GILBERT, N; STEVENSON, P; MACDONALD, S; PEPPER, D			HEMOGLOBIN-BASED BLOOD SUBSTITUTES AND SEPSIS	LANCET			English	Note							HEMOGLOBIN	An important concern that has received little attention is the possible increased susceptibility to bacterial infections of patients infused with cell-free haemoglobin-based blood substitutes. We show that pyridoxalated polymerised human haemoglobin promotes fulminating Escherichia coli septicaemia in mice, which draws attention to the potential danger of such products in the clinic.	NATL INST BIOL STAND & CONTROLS,S MIMMS,HERTS,ENGLAND; SCOTTISH NATL BLOOD TRANSFUS SERV,NATL SCI LAB,EDINBURGH,MIDLOTHIAN,SCOTLAND	National Institute for Biological Standards & Control				Gilbert, Nick/0000-0003-0505-6081				Bullen J.J., 1987, IRON INFECTION MOL P; CROWLEY JP, 1993, CIRC SHOCK, V41, P144; HOYT DB, 1981, J TRAUMA, V21, P938, DOI 10.1097/00005373-198111000-00005; KIM YM, 1994, ARCH BIOCHEM BIOPHYS, V309, P308, DOI 10.1006/abbi.1994.1118; LEE JT, 1979, SURGERY, V86, P41; LOOKER D, 1992, NATURE, V356, P258, DOI 10.1038/356258a0; MACDONALD SL, 1994, METHOD ENZYMOL, V231, P287; OTTO BR, 1992, NATURE, V358, P23, DOI 10.1038/358023b0; ROBSON MC, 1973, J SURG RES, V14, P426, DOI 10.1016/0022-4804(73)90049-8; Vandegriff K D, 1992, Biotechnol Genet Eng Rev, V10, P403	10	50	50	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					158	160		10.1016/S0140-6736(95)90168-X	http://dx.doi.org/10.1016/S0140-6736(95)90168-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7823671				2022-12-28	WOS:A1995QC55000011
J	MCCAIG, LF; HUGHES, JM				MCCAIG, LF; HUGHES, JM			TRENDS IN ANTIMICROBIAL DRUG PRESCRIBING AMONG OFFICE-BASED PHYSICIANS IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIBIOTIC USE; RESISTANCE; EPIDEMIOLOGY; GUIDELINES; AGENTS	Objective.-To assess changes in oral antimicrobial drug prescribing by office-based physicians from 1980 through 1992, with emphasis on the treatment of otitis media and sinusitis and on the possible impact of demographic variables on such use. Design.-The National Ambulatory Medical Care Survey is a sample survey of office-based physicians in the United States conducted by the National Center for Health Statistics, Centers for Disease Control and Prevention. Setting.-Physicians' offices. Patients or Other Participants.-Physicians sampled for the 1980, 1985, 1989, and 1992 National Ambulatory Medical Care Surveys, which included groups of 2959, 5032, 2540, and 3000 physicians, respectively. Sample physicians responding in 1980, 1985, 1989, and 1999 reported data for 46 081, 71 594, 38 384, and 34 606 sample office visits, respectively, including information on antimicrobial drug prescribing. Main Outcome Measure.-Trends in the antimicrobial drug prescription rates. Results.-From 1980 through 1992, increasing prescribing measured by the annual drug prescription rate per 1000 population, was found for the more expensive, broad-spectrum antimicrobial drugs, such as the cephalosporins; decreasing rates were observed for less expensive antimicrobial drugs with a narrower spectrum, such as the penicillins. No trend was found for trimethoprim-sulfamethoxazole, the erythromycins, or the tetracyclines. During the decade, an increasing trend in the visit rate to office-based physicians for otitis media was observed, while the visit rate for sinusitis among adults was found to be higher in 1992 than in each of the other study years. Conclusions.-The increased use of broader-spectrum and more expensive antimicrobial drugs have implications for all patients because of the impact on health care costs and the potential for the emergence of antimicrobial resistance. The data suggest that the incidence of otitis media and sinusitis is increasing.	CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, ATLANTA, GA 30333 USA; CTR DIS CONTROL & PREVENT, NATL CTR HLTH STAT, DIV HLTH CARE STAT, AMBULATORY CARE STAT BRANCH, HYATTSVILLE, MD 20782 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)								ADAMS PF, 1992, VITAL HLTH STAT 184, V10; BENSON V, 1994, VITAL HLTH STAT 189, V10; BERKELMAN RL, 1994, SCIENCE, V264, P368, DOI 10.1126/science.8153621; BILLUPS NF, 1989, AM DRUG INDEX; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; BRYANT E, 1988, VITAL HLTH STAT 108, V2; CHRETIEN JH, 1975, ARCH INTERN MED, V135, P1063, DOI 10.1001/archinte.135.8.1063; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; ENA J, 1993, JAMA-J AM MED ASSOC, V269, P598, DOI 10.1001/jama.269.5.598; FARYNA A, 1987, J GEN INTERN MED, V2, P102, DOI 10.1007/BF02596306; HAHN B, 1992, PHS AHCPR930007 PUBL; HOLMBERG SD, 1987, REV INFECT DIS, V9, P1065; INFANTERIVARD C, 1983, EPIDEMIOL REV, V15, P44; KUNIN CM, 1973, ANN INTERN MED, V79, P555, DOI 10.7326/0003-4819-79-4-555; KUNIN CM, 1993, ANN INTERN MED, V118, P557, DOI 10.7326/0003-4819-118-7-199304010-00011; KUNIN CM, 1985, J INFECT DIS, V151, P388, DOI 10.1093/infdis/151.3.388; KUNIN CM, 1990, PRINCIPLES PRACTICE; LEE LA, 1994, J INFECT DIS, V170, P128, DOI 10.1093/infdis/170.1.128; MARR JJ, 1988, J INFECT DIS, V157, P869, DOI 10.1093/infdis/157.5.869; MCAIG LF, 1994, ADV DATA VITAL HLTH, V245; MCEVOY GK, 1988, AM HOSPITAL FORMULAR; MELNICK SL, 1992, ANN PHARMACOTHER, V26, P1292, DOI 10.1177/106002809202601020; MURRAY BE, 1994, NEW ENGL J MED, V330, P1229, DOI 10.1056/NEJM199404283301710; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; PHELPS CE, 1989, MED CARE, V27, P194, DOI 10.1097/00005650-198902000-00009; RICHTSMEIER WJ, 1992, ANN OTO RHINOL LARYN, V101, P46, DOI 10.1177/00034894921010S110; SCHABERG DR, 1991, AM J MED, V91, pS72, DOI 10.1016/0002-9343(91)90346-Y; SCHAPPERT S, 1992, ADV DATA VITAL HLTH, V214; SIMBERKOFF MS, 1994, JAMA-J AM MED ASSOC, V271, P1875, DOI 10.1001/jama.271.23.1875; SIRKEN MG, 1990, MANUAL STANDARDS PRO; SOYKA LF, 1975, PEDIATRICS, V55, P552; TOMASZ A, 1994, NEW ENGL J MED, V330, P1247, DOI 10.1056/NEJM199404283301725; WILLETT LR, 1994, J GEN INTERN MED, V9, P38, DOI 10.1007/BF02599141; WYATT TD, 1990, BRIT MED J, V300, P441, DOI 10.1136/bmj.300.6722.441; 1990, DRUG EVALUATIONS SUB; 1992, PHYSICIANS DESK REFE; 1992, EMERGING INFECTIONS; 1988, DRUG FACTS COMP; 1994, ADRESSING EMERGING I; 1994, MED LETT, V36, P19; 1985, VITAL HLTH STAT 50, V10; 1988, PHYSICIANS DESK REFE; 1992, NATIONAL AMBULATORY	44	607	618	0	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					214	219		10.1001/jama.273.3.214	http://dx.doi.org/10.1001/jama.273.3.214			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB234	7807660				2022-12-28	WOS:A1995QB23400025
J	RAVIGLIONE, MC; SNIDER, DE; KOCHI, A				RAVIGLIONE, MC; SNIDER, DE; KOCHI, A			GLOBAL EPIDEMIOLOGY OF TUBERCULOSIS - MORBIDITY AND MORTALITY OF A WORLDWIDE EPIDEMIC	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED PATIENTS; IMMUNE-DEFICIENCY-SYNDROME; PULMONARY TUBERCULOSIS; RESISTANT TUBERCULOSIS; ACTIVE TUBERCULOSIS; DRUG-USERS; RISK; EMERGENCE; DEATHS	This article describes the global epidemiology of tuberculosis and reviews recent estimates of tuberculosis incidence and mortality in the world. The highest prevalence of tuberculosis infection and estimated annual risk of tuberculosis infection are in sub-Saharan Africa and Southeast Asia. Overall, almost 3.8 million cases of tuberculosis were reported in the world in 1990, of which 49% were in Southeast Asia. From the period 1984 through 1986 to the period 1989 through 1991, notification rates increased in ail World Health Organization regions, except the American and the European regions. In 1990, there were an estimated 7.5 million cases of tuberculosis and 2.5 million deaths worldwide. The human immunodeficiency virus epidemic is causing increases in the number of tuberculosis cases, particularly in Africa, although increases are also expected in Southeast Asia. In many industrialized countries, tuberculosis has recently failed to decline, and in eastern Europe and the former Soviet Union, cases and deaths are increasing. Drug resistance is a serious problem, especially in the United States. If worldwide control of tuberculosis does not improve, 90 million new cases and 30 million deaths are expected in the decade 1990 through 1999.	CTR DIS CONTROL & PREVENT, ATLANTA, GA 30341 USA	Centers for Disease Control & Prevention - USA	RAVIGLIONE, MC (corresponding author), WHO, TB PROGRAMME, CH-1211 GENEVA 27, SWITZERLAND.			RAVIGLIONE, Mario/0000-0002-9331-2067				AISU T, 1992, 1992 WORLD C TUB BET; ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; ALLEN S, 1992, AM REV RESPIR DIS, V146, P1439, DOI 10.1164/ajrccm/146.6.1439; [Anonymous], 1994, MMWR MORB MORTAL WKL; BAMRUNGTRAKUL T, 1993, 17TH E REG C TUB RES; BOUVET E, 1991, B EPIDEMIOLOGIQUE HE, V45, P196; CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535; CAUTHEN GM, 1988, WHO TB88154 PUBL; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P961; CHUM HL, 1992, NOV WORLD C TUB BETH; CLERMONT HC, 1990, 6TH INT C AIDS SAN F; CULLINAN P, 1991, THORAX, V46, P347, DOI 10.1136/thx.46.5.347; Dalcomo Margareth Pretti, 1993, Revista Argentina del Torax, V54, P29; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DECOCK KM, 1991, BMJ-BRIT MED J, V302, P496, DOI 10.1136/bmj.302.6775.496; DIDILESCU C, 1993, TUBERCULOZA ROMANIA; DIPERRI G, 1989, LANCET, V2, P1502; DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213; DOLIN PJ, 1993, WHOTB93173 PUBL; DROLET GJ, 1938, AM REV TUBERC, V87, P125; Dubos Rene, 1987, WHITE PLAGUE TUBERCU; ELLIOTT AM, 1990, BRIT MED J, V301, P412, DOI 10.1136/bmj.301.6749.412; Enarson D A, 1991, Bull Int Union Tuberc Lung Dis, V66, P195; ERIKI PP, 1991, AM REV RESPIR DIS, V143, P185, DOI 10.1164/ajrccm/143.1.185; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GIRARDI E, 1993, 9TH INT C AIDS HIV S; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; GUELAR A, 1993, AIDS, V7, P1345, DOI 10.1097/00002030-199310000-00007; HAMBURG MA, 1994, NEW ENGL J MED, V330, P1750, DOI 10.1056/NEJM199406163302410; Hargreaves J., 1994, Communicable Diseases Intelligence, V18, P330; HONG YP, 1993, TUBERCLE LUNG DIS, V74, P323, DOI 10.1016/0962-8479(93)90107-9; HUMPHRIES MJ, 1984, BRIT J DIS CHEST, V78, P149, DOI 10.1016/0007-0971(84)90115-3; HURET B, 1993, B EPIDEMIOL HEBDOMAD, V52, P243; Jain NK, 1992, IND J TUBERC, V92, P145; JESSURUN J, 1990, J ACQ IMMUN DEF SYND, V3, P579; KAUR A, 1992, J ACQ IMMUN DEF SYND, V5, P883; KOCHI A, 1993, RES MICROBIOL, V144, P104, DOI 10.1016/0923-2508(93)90023-U; KRITSKI AL, 1993, J ACQ IMMUN DEF SYND, V6, P1008; LINDHART M, 1939, STATISTICS PULMONARY; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; MBAGA JM, 1990, E AFR MED J, V67, P95; MCLEOD DT, 1989, T ROY SOC TROP MED H, V83, P694, DOI 10.1016/0035-9203(89)90400-8; MOHANTY KC, 1993, 17TH E REG C TUB RES; MONNO L, 1991, LANCET, V337, P852, DOI 10.1016/0140-6736(91)92559-K; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; NARAIN JP, 1992, TUBERCLE LUNG DIS, V73, P311, DOI 10.1016/0962-8479(92)90033-G; ONORATO I, 1993, 33RD INT C ANT AG CH; PAPE JW, 1985, ANN INTERN MED, V103, P674, DOI 10.7326/0003-4819-103-5-674; PAYANANDANA V, 1993, 1993 MIN PUBL HLTH D; Raviglione M. C., 1993, Morbidity and Mortality Weekly Report, V42, P628; RAVIGLIONE MC, 1994, TUBERCLE LUNG DIS, V75, P400, DOI 10.1016/0962-8479(94)90113-9; RAVIGLIONE MC, 1993, B WORLD HEALTH ORGAN, V71, P297; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; SCHWOEBEL V, 1993, BEH, V50, P235; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SINGH II, 1993, 17TH E REG C TUB RES; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; SNIDER DE, 1993, HEART LUNG, V22, P365; SPRINGETT V H, 1971, Tubercle, V52, P73, DOI 10.1016/0041-3879(71)90015-8; STYBLO K, 1969, Bulletin of the International Union Against Tuberculosis, V42, P5; STYBLO K, 1981, Bulletin of the International Union Against Tuberculosis, V56, P118; Styblo K., 1985, B INT UNION TUBERC, V60, P117; SUDRE P, 1992, B WORLD HEALTH ORGAN, V70, P149; Sutherland I, 1976, Adv Tuberc Res, V19, P1; TANSUPHASWASDIK.S, 1993, 17TH P E REG C TUB R; WURBURTON ARE, 1993, COMMUNICAB DIS REP, V3, pR175; 1992, MMWR-MORBID MORTAL W, V41, P13; 1991, MMWR-MORBID MORTAL W, V40, P485; 1974, B WORLD HEALTH ORGAN, V51, P473; 1991, 44TH WORLD HLTH ASS; 1989, CHILDHOOD TUBERCULOS; 1990, MMWR-MORBID MORTAL W, V39, P7; 1989, MMWR-MORBID MORTAL W, V38, P313; 1994, WHOTB94175 PUBL; 1994, WHOTB94179 PUBL; 1993, 1993 WORLD BANK WORL, P1; 1993, B OFFICE FEDERAL SAN, V41, P739; 1993, TUBERCULOSIS STATIST; 1994, WKLY EPIDEMIOL REC, V69, P189	80	1251	1301	1	58	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					220	226		10.1001/jama.273.3.220	http://dx.doi.org/10.1001/jama.273.3.220			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB234	7807661				2022-12-28	WOS:A1995QB23400026
J	ROCKEFELLER, JD				ROCKEFELLER, JD			MOVING AHEAD WITH HEALTH-CARE SYSTEM REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											ROCKEFELLER, JD (corresponding author), US SENATE,WASHINGTON,DC 20510, USA.							LADENHEIM KE, 1994, SPECIAL REPORT COMMU; 1994, 1994 FED HOSP INS TR; 1994, COVERAGE PREMIUM HOU; 1992, HLTH STATE MEASURING; 1994, HLTH CARE HAWAII IMP	5	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					250	251						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QB234	7807674				2022-12-28	WOS:A1995QB23400039
J	OBAYASHI, T; YOSHIDA, M; MORI, T; GOTO, H; YASUOKA, A; IWASAKI, H; TESHIMA, H; KOHNO, S; HORIUCHI, A; ITO, A; YAMAGUCHI, H; SHIMADA, K; KAWAI, T				OBAYASHI, T; YOSHIDA, M; MORI, T; GOTO, H; YASUOKA, A; IWASAKI, H; TESHIMA, H; KOHNO, S; HORIUCHI, A; ITO, A; YAMAGUCHI, H; SHIMADA, K; KAWAI, T			PLASMA (1-]3)-BETA-D-GLUCAN MEASUREMENT IN DIAGNOSIS OF INVASIVE DEEP MYCOSIS AND FUNGAL FEBRILE EPISODES	LANCET			English	Article							PNEUMOCYSTIS-CARINII; HUMAN-BLOOD; LIMULUS; CANDIDIASIS; IMMUNOASSAY; ENDOTOXIN	(1-->3)-beta-D-glucan is a characteristic fungal cell-wall constituent. To assess the clinical usefulness of this glucan in screening for invasive fungal infection or fungal febrile episodes, we measured the plasma concentration at the time of routine blood culture in 202 febrile episodes by means of factor G, a horseshoe-crab coagulation enzyme that is extremely sensitive to this polysaccharide. With a plasma cut-off value of 20 pg/mL, 37 of 41 of definite fungal infections (confirmed at or by microbiology) had positive results of 59 episodes of non-fungal fever, or collagen diseases had concentrations below the cut-off value (specificity 100%). Of 102 episodes of fever of unknown origin, 26 had plasma glucan concentrations of more than 20 pg/mL. With those 102 cases taken as non-fungal infections, the positive predictive Value of the test was estimated as 59% (37/63), the negative predictive value as 97% (135/139), and the efficiency as 85% (172/202). The positive predictive Value should improve if there were a sensitive gold standard that could discriminate fungal from non-fungal infections. Causative fungi included candida, aspergillus, cryptococcus, and trichosporon. Determination of plasma (1-->3)-beta-D-glucan with factor G is a highly sensitive and specific test for invasive deep mycosis and fungal febrile episodes, and will substantially benefit immunocompromised patients.	JICHI MED SCH,DEPT INTERNAL MED,DIV HEMATOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; JUNTENDO UNIV,SCH MED,DEPT INTERNAL MED,TOKYO,JAPAN; TOKYO METROPOLITAN KOMAGOME GEN HOSP,DEPT PULM DIS,TOKYO,JAPAN; UNIV TOKYO,INST MED SCI,DEPT INFECT DIS,TOKYO,JAPAN; FUKUI MED SCH,DEPT INTERNAL MED 1,FUKUI,JAPAN; CTR ADULT DIS,DEPT INTERNAL MED 5,OSAKA 537,JAPAN; NAGASAKI UNIV,SCH MED,DEPT INTERNAL MED 2,NAGASAKI 852,JAPAN; KINKI UNIV,SCH MED,DEPT INTERNAL MED 3,OSAKA,OSAKA 577,JAPAN; YOKOHAMA CITY UNIV,SCH HOSP,DIV CLIN LAB,YOKOHAMA,KANAGAWA,JAPAN; TEIKYO UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,TOKYO,JAPAN	Jichi Medical University; Juntendo University; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; University of Tokyo; University of Fukui; Nagasaki University; Kindai University (Kinki University); Yokohama City University; Teikyo University	OBAYASHI, T (corresponding author), JICHI MED SCH,DEPT CLIN PATHOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN.							EDMAN JC, 1988, NATURE, V334, P519, DOI 10.1038/334519a0; HOPWOOD V, 1991, FUNGAL INFECTION COM, P311; IWAMA A, 1993, EUR J HAEMATOL, V51, P156, DOI 10.1111/j.1600-0609.1993.tb00617.x; KAKINUMA A, 1981, BIOCHEM BIOPH RES CO, V101, P434, DOI 10.1016/0006-291X(81)91278-X; KAMMER RB, 1974, AM J MED, V56, P506, DOI 10.1016/0002-9343(74)90483-5; LEVIN J, 1968, THROMB DIATH HAEMOST, V19, P186; LEVIN J, 1970, J LAB CLIN MED, V75, P903; MORITA T, 1981, FEBS LETT, V129, P318, DOI 10.1016/0014-5793(81)80192-5; NAKAMURA A, 1991, J CLIN MICROBIOL, V29, P2363, DOI 10.1128/JCM.29.11.2363-2367.1991; NAKAMURA T, 1986, EUR J BIOCHEM, V154, P511, DOI 10.1111/j.1432-1033.1986.tb09427.x; OBAYASHI T, 1992, J MED VET MYCOL, V30, P275; OBAYASHI T, 1986, INFECT IMMUN, V53, P294, DOI 10.1128/IAI.53.2.294-297.1986; OBAYASHI T, 1987, DETECTION BACTERIAL, P357; REISS E, 1986, MOL IMMUNOLOGY MYCOT, P11; Soyama K., 1986, Japanese Journal of Medical Mycology, V27, P165; TAMURA T, 1994, CLIN CHIM ACTA, V226, P109; TANAKA S, 1991, CARBOHYD RES, V218, P167, DOI 10.1016/0008-6215(91)84095-V; VANDEVENTER SJH, 1988, LANCET, V1, P605; WALSH TJ, 1991, NEW ENGL J MED, V324, P1026, DOI 10.1056/NEJM199104113241504; YPMAWONG MF, 1992, INFECT IMMUN, V60, P4140, DOI 10.1128/IAI.60.10.4140-4145.1992	20	398	428	0	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					17	20		10.1016/S0140-6736(95)91152-9	http://dx.doi.org/10.1016/S0140-6736(95)91152-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799700				2022-12-28	WOS:A1995QA29000010
J	BARON, JH				BARON, JH			ROBINSON,FREDERICK,CAYLEY ACTS-OF-MERCY MURALS AT THE MIDDLESEX-HOSPITAL, LONDON	BRITISH MEDICAL JOURNAL			English	Article											BARON, JH (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT SURG,LONDON W12 0NN,ENGLAND.							BROWN D, 1977, FC ROBINSON ARA; CORK R, 1984, ARTLINE, V2, P6; STEVENS M, 1977, CONNOISSEUR, V196, P23	3	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1723	1724		10.1136/bmj.309.6970.1723	http://dx.doi.org/10.1136/bmj.309.6970.1723			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7820002	Green Published			2022-12-28	WOS:A1994PY71700032
J	PHEILS, MT				PHEILS, MT			THANK-YOU, MR SHAW	BRITISH MEDICAL JOURNAL			English	Editorial Material																		HOLROYD M, 1991, B SHAW, V3, P168; SHAW GB, 1925, TIMES           1023; SHAW GB, 1931, DOCTORS DELUSIONS, P112	3	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1724	1726		10.1136/bmj.309.6970.1724	http://dx.doi.org/10.1136/bmj.309.6970.1724			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7820003	Green Published			2022-12-28	WOS:A1994PY71700033
J	WRIGHT, V				WRIGHT, V			AN AUDIT OF EXCUSES	BRITISH MEDICAL JOURNAL			English	Editorial Material											WRIGHT, V (corresponding author), RES SCH MED,RHEUMATOL & REHABIL RES UNIT,LEEDS LS2 9NZ,W YORKSHIRE,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1739	1740		10.1136/bmj.309.6970.1739	http://dx.doi.org/10.1136/bmj.309.6970.1739			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7820009	Green Published			2022-12-28	WOS:A1994PY71700040
J	BEUTLER, M; HARTMANN, K; KUHN, M; GARTMANN, J				BEUTLER, M; HARTMANN, K; KUHN, M; GARTMANN, J			ARTHRALGIAS AND OMEPRAZOLE	BRITISH MEDICAL JOURNAL			English	Letter											BEUTLER, M (corresponding author), SWISS DRUG MONITORING CTR,CH-7000 CHUR,SWITZERLAND.							1991, B SADRAC, V59, P1	1	13	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1620	1620		10.1136/bmj.309.6969.1620	http://dx.doi.org/10.1136/bmj.309.6969.1620			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819941	Green Published			2022-12-28	WOS:A1994PY22000022
J	MALIN, A; TERNOUTH, I; SARBAH, S				MALIN, A; TERNOUTH, I; SARBAH, S			EPITROCHLEAR LYMPH-NODES AS MARKER OF HIV DISEASE IN SUB-SAHARAN AFRICA	BRITISH MEDICAL JOURNAL			English	Article									UNIV ZIMBABWE,DEPT CLIN PHARMACOL,HARARE,ZIMBABWE; PARIRENYATWA HOSP,HARARE,ZIMBABWE	University of Zimbabwe								ABRAMS DI, 1984, ANN INTERN MED, V100, P801, DOI 10.7326/0003-4819-100-6-801; CURRARINO G, 1977, PEDIATR RADIOL, V6, P160, DOI 10.1007/BF00972108; MCCRAE T, 1930, OSLERS PRINCIPLES PR, P273; SELBY CD, 1992, R COLL PHYSICIANS LO, V2, P159; YU A, 1984, MED PEDIATR ONCOL, V12, P244, DOI 10.1002/mpo.2950120405	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 10	1994	309	6968					1550	1551		10.1136/bmj.309.6968.1550	http://dx.doi.org/10.1136/bmj.309.6968.1550			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX564	7819896	Green Published			2022-12-28	WOS:A1994PX56400022
J	EVANS, SA; STONER, J; HARDY, C				EVANS, SA; STONER, J; HARDY, C			ARE GENERAL-PRACTITIONERS EQUIPPED TO MANAGE ACUTE SEVERE ASTHMA	BRITISH MEDICAL JOURNAL			English	Article									MANCHESTER ROYAL INFIRM,DEPT RESP MED,MANCHESTER M13 9WL,LANCS,ENGLAND; PETERLOO MED CTR,MANCHESTER,LANCS,ENGLAND	University of Manchester								KENDRICK AH, 1993, BRIT MED J, V307, P422, DOI 10.1136/bmj.307.6901.422; MORGAN MDL, 1982, BRIT MED J, V285, P849, DOI 10.1136/bmj.285.6345.849; NEVILLE RG, 1993, BRIT MED J, V306, P559, DOI 10.1136/bmj.306.6877.559; 1990, BRIT MED J, V30, P797; 1993, BRIT MED J, V306, P776	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 3	1994	309	6967					1486	1486		10.1136/bmj.309.6967.1486	http://dx.doi.org/10.1136/bmj.309.6967.1486			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW053	7804056	Green Published			2022-12-28	WOS:A1994PW05300028
J	STOKOE, D; MACDONALD, SG; CADWALLADER, K; SYMONS, M; HANCOCK, JF				STOKOE, D; MACDONALD, SG; CADWALLADER, K; SYMONS, M; HANCOCK, JF			ACTIVATION OF RAF AS A RESULT OF RECRUITMENT TO THE PLASMA-MEMBRANE	SCIENCE			English	Article							PROTEIN-KINASE KINASE; SIGNAL-TRANSDUCTION; IN-VITRO; ASSOCIATION; P21(RAS); CELLS; TRANSFORMATION; SUFFICIENT; COMPLEXES; PATHWAY	The small guanine nucleotide binding protein Ras participates in a growth promoting signal transduction pathway. The mechanism by which interaction of Ras with the protein kinase Raf leads to activation of Raf was studied. Raf was targeted to the plasma membrane by addition of the COOH-terminal localization signals of K-ras. This modified form of Raf (RafCAAX) was activated to the same extent as Raf coexpressed with oncogenic mutant Ras. Plasma membrane localization rather than farnesylation or the presence of the additional COOH-terminal sequence accounted for the activation of RafCAAX. The acti vation of RafCAAX was completely independent of Ras; it was neither potentiated by oncogenic mutant Ras nor abrogated by dominant negative Ras. Raf, once recruited to the plasma membrane, was not anchored there by Ras; most activated Raf in cells was associated with plasma membrane cytoskeletal elements, not the lipid bilayer. Thus, Ras functions in the activation of Raf by recruiting Raf to the plasma membrane where a separate, Ras-independent, activation of Raf occurs.	ONXY PHARMACEUT,RICHMOND,CA 94806					Hancock, John/0000-0003-0542-4710				BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CADWALLADER K, IN PRESS MOL CELL BI; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MACDONALD SG, UNPUB; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; SAITO Y, 1994, FEBS LETT, V341, P119, DOI 10.1016/0014-5793(94)80252-1; TRAVERSE S, 1993, ONCOGENE, V8, P3175; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	29	902	918	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 3	1994	264	5164					1463	1467		10.1126/science.7811320	http://dx.doi.org/10.1126/science.7811320			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP221	7811320				2022-12-28	WOS:A1994NP22100044
J	LEE, N; MILLMAN, A				LEE, N; MILLMAN, A			AN INTRODUCTION TO COMPUTING IN MEDICAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article									GLOUCESTERSHIRE ROYAL HOSP,GLOUCESTER,ENGLAND	Gloucestershire Royal Hospital	LEE, N (corresponding author), WESTERN EYE & HILLINGDON HOSP,HILLINGDON,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 24	1995	310	6995					1650	1652		10.1136/bmj.310.6995.1650	http://dx.doi.org/10.1136/bmj.310.6995.1650			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF698	7795456	Green Published			2022-12-28	WOS:A1995RF69800028
J	SORDINO, P; VANDERHOEVEN, F; DUBOULE, D				SORDINO, P; VANDERHOEVEN, F; DUBOULE, D			HOX GENE-EXPRESSION IN TELEOST FINS AND THE ORIGIN OF VERTEBRATE DIGITS	NATURE			English	Article							PATTERN-FORMATION; LIMB; MICE	Hox genes are essential for growth and patterning of the tetrapod limb skeleton(1-5). Mice mutant for the Hoxd-13 gene have an important delay in morphogenesis owing to reduced proliferation(2). Based on the appearance of atavisms in such mice, we suggested that modifications of Hox gene regulation may have been a source of morphological variation during the evolution of tetrapod limbs(2,6). Pectoral and pelvic fins are homologous to fore- and hindlimbs, respectively. To compare the relative importance of Hox genes during fin versus limb morphogenesis, we cloned zebrafish (Danio rerio) HoxD and HoxA complex genes and analysed their expression during fin development. The results suggest a scheme for the fin-limb transition in which the distal autopods (digits) are neomorphic structures produced by unequal proliferation of the posterior part of an ancestral appendix.	UNIV GENEVA, DEPT ZOOL & ANIM BIOL, CH-1211 GENEVA 4, SWITZERLAND	University of Geneva				duboule, denis/0000-0001-9961-2960				AHLBERG PE, 1994, NATURE, V368, P507, DOI 10.1038/368507a0; COATES M, 1991, DEV PATTERNING VERTE, P328; COATES MI, 1994, DEVELOPMENT, P169; DANE PJ, 1985, J EMBRYOL EXP MORPH, V87, P145; DAVIS AP, 1994, DEVELOPMENT, V120, P2187; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DUBOULE D, 1994, SCIENCE, V266, P575, DOI 10.1126/science.7939709; DUBOULE D, 1994, DEVELOPMENT, P135; FAVIER B, 1995, P NATL ACAD SCI USA, V92, P310, DOI 10.1073/pnas.92.1.310; GERAUDIE J, ACTA ZOOL-STOCKHOLM, V59, P85; HAACK H, 1993, DEV BIOL, V157, P410, DOI 10.1006/dbio.1993.1145; Hinchliffe J. R., 1980, DEV VERTEBRATE LIMB; HOLMGREN NILS, 1952, ACTA ZOOL [STOCKHOLM], V33, P1; IZPISUABELMONTE JC, 1992, DEV BIOL, V152, P26, DOI 10.1016/0012-1606(92)90153-8; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; POTTHOFF T, 1993, B MAR SCI, V52, P669; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; SHUBIN N, 1995, EVOL BIOL, V28, P39; SHUBIN NH, 1986, EVOL BIOL, V20, P319; SMALL KM, 1993, GENE DEV, V7, P2318, DOI 10.1101/gad.7.12a.2318; STRAHLE U, 1993, ZEBRAFISH SCI MONITO, V2, P5; STREISINGER G, 1986, GENETICS, V112, P311; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; THOROGOOD P, 1991, NATO ADV SCI I A-LIF, V205, P347; TICKLE C, 1991, DEVELOPMENT, P113; YOKOUCHI Y, 1991, NATURE, V353, P443, DOI 10.1038/353443a0	30	277	281	2	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 22	1995	375	6533					678	681		10.1038/375678a0	http://dx.doi.org/10.1038/375678a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791900				2022-12-28	WOS:A1995RE57600059
J	HUBER, M; RETTLER, I; BERNASCONI, K; FRENK, E; LAVRIJSEN, SPM; PONEC, M; BON, A; LAUTENSCHLAGER, S; SCHORDERET, DF; HOHL, D				HUBER, M; RETTLER, I; BERNASCONI, K; FRENK, E; LAVRIJSEN, SPM; PONEC, M; BON, A; LAUTENSCHLAGER, S; SCHORDERET, DF; HOHL, D			MUTATIONS OF KERATINOCYTE TRANSGLUTAMINASE IN LAMELLAR ICHTHYOSIS	SCIENCE			English	Article							AMINO-ACID-SEQUENCE; MEMBRANE ANCHORAGE; EPIDERMAL-CELLS; DIFFERENTIATION; ENVELOPE; CLONING; EXPRESSION; GENE	Lamellar ichthyosis Is a severe congenital skin disorder characterized by generalized large scales and variable redness. Affected individuals in three families exhibited drastically reduced keratinocyte transglutaminase (TGK) activity. In two of these families, expression of TGK transcripts was diminished or abnormal and no TGK protein was detected. Homozygous or compound heterozygous mutations of the TGK gene were identified in all families. These data suggest that defects in TGK cause lamellar ichthyosis and that intact cross-linkage of cornified cell envelopes is required for epidermal tissue homeostasis.	CHU VAUDOIS, HOP BEAUMONT, DEPT DERMATOL, CUTANEOUS BIOL LAB, CH-1011 LAUSANNE, SWITZERLAND; LEIDEN UNIV HOSP, DEPT DERMATOL, 2333 AA LEIDEN, NETHERLANDS; MUNICIPAL DERMATOL CLIN, CH-8000 ZURICH, SWITZERLAND; CHU VAUDOIS, DEPT MED GENET, CH-1011 LAUSANNE, SWITZERLAND; CHU VAUDOIS, MOLEC GENET UNIT, CH-1011 LAUSANNE, SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Leiden University; Leiden University Medical Center (LUMC); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)			Huber, Marcel/M-8822-2016; Hohl, Daniel M/N-7554-2016	Huber, Marcel/0000-0003-3821-2378; 				CHAKRAVARTY R, 1990, BIOCHEM J, V271, P25, DOI 10.1042/bj2710025; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; CLADARAS C, 1987, J BIOL CHEM, V262, P2310; COOPER DN, 1993, ANN MED, V25, P11, DOI 10.3109/07853899309147851; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; FROST P, 1966, ARCH DERMATOL, V94, P113, DOI 10.1001/archderm.94.2.113; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HO KC, 1992, J BIOL CHEM, V267, P12660; HOHL D, 1993, ARCH DERMATOL, V129, P618, DOI 10.1001/archderm.129.5.618; HOHL D, 1991, J BIOL CHEM, V266, P6626; HOHL D, 1993, MOL BIOL SKIN, pCH5; HUBER ME, UNPUB; KIM HC, 1991, J BIOL CHEM, V266, P536; KIM IG, 1992, J BIOL CHEM, V267, P7710; LAVRIJSEN APM, 1993, IN PRESS ARCH DERMAT; LICHTI U, 1985, J BIOL CHEM, V260, P1422; MA ASP, 1986, J CELL BIOL, V103, P41, DOI 10.1083/jcb.103.1.41; MIKKOLA H, 1994, BLOOD, V84, P517; PHILLIPS MA, 1993, BIOCHEMISTRY-US, V32, P11057, DOI 10.1021/bi00092a015; PHILLIPS MA, 1992, J BIOL CHEM, V267, P2282; PHILLIPS SB, 1993, DERMATOLOGY GENERAL, pCH42; REICHERT U, 1993, MOL BIOL SKIN, pCH4; Sambrook J, 1989, MOL CLONING LABORATO; THACHER SM, 1989, J INVEST DERMATOL, V92, P578; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; TOKUNAGA F, 1993, J BIOL CHEM, V268, P262; TRAUPE H, 1989, ICHTHYOSES, P111; WERAARCHAKULBOONMARK N, 1992, P NATL ACAD SCI USA, V89, P9804, DOI 10.1073/pnas.89.20.9804	28	377	394	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	1995	267	5197					525	528		10.1126/science.7824952	http://dx.doi.org/10.1126/science.7824952			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD403	7824952				2022-12-28	WOS:A1995QD40300042
J	VILLE, Y; HYETT, J; HECHER, K; NICOLAIDES, K				VILLE, Y; HYETT, J; HECHER, K; NICOLAIDES, K			PRELIMINARY EXPERIENCE WITH ENDOSCOPIC LASER-SURGERY FOR SEVERE TWIN-TWIN TRANSFUSION SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THERAPEUTIC AMNIOCENTESIS; NEUROLOGIC DAMAGE; ANTENATAL ORIGIN; NEWBORN-INFANTS; STUCK TWIN; PREGNANCY; VOLUME	Background. In monozygotic twin pregnancies, there are placental vascular communications between the two fetuses. In 15 percent of such pregnancies there is an imbalance in net blood flow between the twins, resulting in the twin-twin transfusion syndrome. The recipient twin may have severe hydramnios during the second trimester of pregnancy, and there is a high risk of perinatal death and cerebral palsy in survivors. This condition can now be treated by endoscopic coagulation of the vascular anastomoses responsible for fetofetal transfusion with a neodymium:yttrium-aluminum-garnet (Nd:YAG) laser. Methods. We performed intrauterine surgery in 45 pregnant women carrying twins at 15 to 28 weeks of gestation (median, 21); in each case there was severe hydramnios in one fetus due to the twin-twin transfusion syndrome. With the use of local anesthesia and continuous ultrasound visualization, a rigid fetoscope 2 mm in diameter, housed in a 2.7-mm cannula, was introduced transabdominally into the amniotic cavity of the recipient twin. A systematic search was made for all vessels approaching or crossing the membrane between the twins, and these were coagulated with an Nd:YAG laser by means of a fiber in the side arm of the cannula. Results. Coagulation of the communicating vessels was successful in all cases. The total number of fetuses who survived to delivery was 48 (53 percent), and the number of pregnancies with at least 1 survivor was 32 (71 percent). Among the live-born infants, the median gestational age at delivery was 35 weeks (range, 25 to 40), and the median birth weight was 2098 g (range, 550 to 4252). The median interval between the endoscopic laser procedure and delivery was 14 weeks (range, 0 to 21). All the survivors were developing normally at a median age of 12 months (range, 2 to 24). Conclusions. Our preliminary experience suggests that the twin-twin transfusion syndrome can be treated effectively by endoscopic laser coagulation of the communicating placental vessels.	UNIV LONDON KINGS COLL,SCH MED,HARRIS BIRTHRIGHT RES CTR FETAL MED,LONDON SE5 8RX,ENGLAND	University of London; King's College London				Nicolaides, Kypros/0000-0003-1266-0711				BEJAR R, 1988, AM J OBSTET GYNECOL, V159, P357, DOI 10.1016/S0002-9378(88)80084-X; BEJAR R, 1990, AM J OBSTET GYNECOL, V162, P1230, DOI 10.1016/0002-9378(90)90024-2; BENDON R W, 1989, Pediatric Pathology, V9, P591; BENIRSCHKE K, 1973, NEW ENGL J MED, V288, P1276, DOI 10.1056/NEJM197306142882406; DELIA JE, 1990, OBSTET GYNECOL, V75, P1046; ELLIOTT JP, 1991, OBSTET GYNECOL, V77, P537; FUSI L, 1991, OBSTET GYNECOL, V78, P517; GOLDBERG RN, 1980, J PEDIATR-US, V96, P1060, DOI 10.1016/S0022-3476(80)80642-1; HADLOCK FP, 1985, AM J OBSTET GYNECOL, V151, P333, DOI 10.1016/0002-9378(85)90298-4; HRUBEC Z, 1984, NEW ENGL J MED, V310, P435, DOI 10.1056/NEJM198402163100706; LARROCHE JC, 1990, BIOL NEONATE, V57, P261; PATTEN RM, 1989, RADIOLOGY, V172, P153, DOI 10.1148/radiology.172.1.2662249; PINETTE MG, 1993, OBSTET GYNECOL, V82, P841; REISNER DP, 1993, AM J OBSTET GYNECOL, V169, P991, DOI 10.1016/0002-9378(93)90041-G; SAUDNERS NJ, 1991, FETAL DIAGN THER, V6, P34; SAUNDERS NJ, 1992, AM J OBSTET GYNECOL, V166, P820, DOI 10.1016/0002-9378(92)91340-G; VILLE Y, 1992, ULTRASOUND OBST GYN, V2, P429, DOI 10.1046/j.1469-0705.1992.02060429.x; WEIR PE, 1979, BRIT J OBSTET GYNAEC, V86, P849, DOI 10.1111/j.1471-0528.1979.tb10710.x	18	263	267	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	1995	332	4					224	227		10.1056/NEJM199501263320404	http://dx.doi.org/10.1056/NEJM199501263320404			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC270	7808488	Bronze			2022-12-28	WOS:A1995QC27000004
J	NIGHTINGALE, SL				NIGHTINGALE, SL			MORE PEDIATRIC USE INFORMATION WITH PRESCRIPTION DRUGS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	1995	273	4					279	279						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC057	7815644				2022-12-28	WOS:A1995QC05700005
J	DUGGLEBY, HJ; TOLLEY, SP; HILL, CP; DODSON, EJ; DODSON, G; MOODY, PCE				DUGGLEBY, HJ; TOLLEY, SP; HILL, CP; DODSON, EJ; DODSON, G; MOODY, PCE			PENICILLIN ACYLASE HAS A SINGLE-AMINO-ACID CATALYTIC CENTER	NATURE			English	Article							ESCHERICHIA-COLI ATCC-11105; HYDROLYSIS; MECHANISM; SUBUNITS; SERINE	PENICILLIN acylase (penicillin amidohydrolase, EC3.5.1.11) is widely distributed among microorganisms, including bacteria, yeast and filamentous fungi. It is used on an industrial scale for the production of 6-aminopenicillanic acid, the starting material for the synthesis of semi-synthetic penicillins. Its in vivo role remains unclear, however, and the observation that expression of the Escherichia coli enzyme in vivo is regulated by both temperature and phenylacetic acid has prompted speculation that the enzyme could be involved in the assimilation of aromatic compounds as carbon sources in the organism's free-living mode(1). The mature E. coli enzyme is a periplasmic 80K heterodimer of A and B chains (209 and 566 amino acids, respectively(2,3)) synthesized as a single cytoplasmic precursor containing a 26-amino-acid signal sequence to direct export to the cytoplasm and a 54-amino-acid spacer between the A and B chains which may influence the final folding of the chains(5). The N-terminal serine of the B chain reacts with phenylmethylsulphonyl fluoride, which is consistent with a catalytic role for the serine hydrouyl group. Modifying this serine to a cysteine(6,7) inactivates the enzyme, whereas threonine, arginine or glycine substitution prevents in vivo processing of the enzyme indicating that this must be an important recognition site for cleavage. Here we report the crystal structure of penicillin acylase at 1.9 Angstrom resolution. Our analysis shows that the environment of the catalytically active N-terminal serine of the B chain contains no adjacent histidine equivalent to that found in the serine proteases. The nearest base to the hydroxyl of this serine is its own alpha-amino group, which may act by a new mechanism to endow the enzyme with its catalytic properties.	UNIV YORK,DEPT CHEM,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK			Moody, Peter/A-6832-2008	Moody, Peter/0000-0003-1762-9238				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BLOW DM, 1969, NATURE, V221, P337, DOI 10.1038/221337a0; BOCK A, 1983, FEMS MICROBIOL LETT, V20, P135, DOI 10.1016/0378-1097(83)90182-9; BOCK A, 1983, FEMS MICROBIOL LETT, V20, P140; BRUNGER AT, 1987, SCIENCE, V23, P458; BURLINGAME R, 1983, J BACTERIOL, V155, P113, DOI 10.1128/JB.155.1.113-121.1983; CHOI KS, 1992, J BACTERIOL, V174, P6270, DOI 10.1128/JB.174.19.6270-6276.1992; COLE M, 1969, BIOCHEM J, V155, P733; DAUMY GO, 1985, J BACTERIOL, V163, P1279, DOI 10.1128/JB.163.3.1279-1281.1985; HUANG HT, 1963, APPL MICROBIOL, V11, P1; HUNT PD, 1990, PROTEIN ENG, V3, P635, DOI 10.1093/protein/3.7.635; KONECNY J, 1981, BIOTECHNOL LETT, V3, P112; KRAULIS PJ, 1990, J APPL CRYSTALLOGR, V24, P946; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; KUTZBACH C, 1974, HOPPESEYLERS Z PHYSL, V354, P45; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; MARTIN J, 1990, BIOCHIM BIOPHYS ACTA, V1037, P133, DOI 10.1016/0167-4838(90)90158-C; MILLER M, 1993, FEBS LETT, V328, P275, DOI 10.1016/0014-5793(93)80943-O; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; Savidge T A, 1975, Methods Enzymol, V43, P705; SCHUMACHER G, 1986, NUCLEIC ACIDS RES, V14, P5713, DOI 10.1093/nar/14.14.5713; SLADE A, 1991, EUR J BIOCHEM, V197, P75, DOI 10.1111/j.1432-1033.1991.tb15884.x; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; TANFORD C, 1962, ADV PROTEIN CHEM, V17, P69; Virden R, 1990, BIOTECHNOL GENET, V8, P189, DOI [10.1080/02648725.1990.10647869, DOI 10.1080/02648725.1990.10647869]	25	419	434	3	69	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					264	268		10.1038/373264a0	http://dx.doi.org/10.1038/373264a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816145				2022-12-28	WOS:A1995QC27800070
J	SHINE, KI				SHINE, KI			QUALITY OF HEALTH AND HEALTH-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											SHINE, KI (corresponding author), NATL ACAD SCI,INST MED,2101 CONSTITUT AVE,WASHINGTON,DC 20418, USA.								0	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					244	245						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QB234	7807669				2022-12-28	WOS:A1995QB23400034
J	NAVAS, TA; ZHOU, Z; ELLEDGE, SJ				NAVAS, TA; ZHOU, Z; ELLEDGE, SJ			DNA-POLYMERASE-EPSILON LINKS THE DNA-REPLICATION MACHINERY TO THE S-PHASE CHECKPOINT	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; RIBONUCLEOTIDE REDUCTASE; ATAXIA-TELANGIECTASIA; REPAIR SYNTHESIS; YEAST; GENE; DAMAGE; MITOSIS; P53	Inhibition of DNA synthesis induces transcription of DNA damage-inducible genes and prevents mitotic entry through the action of the S phase checkpoint. We have isolated a mutant, dun2, defective for both of these responses. DUN2 is identical to POL2, encoding DNA polymerase epsilon (pol epsilon). Unlike sad1 mutants defective for multiple cell cycle checkpoints, pol2 mutants are defective only for the S phase checkpoint and the activation of DUN1 kinase necessary for the transcriptional response to damage. Interallelic complementation and mutation analysis indicate that pol epsilon contains two separable essential domains, an N-terminal polymerase domain and a C-terminal checkpoint domain unique to epsilon polymerases. We propose that DNA pol epsilon acts as a sensor of DNA replication that coordinates the transcriptional and cell cycle responses to replication blocks.	BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine					NIGMS NIH HHS [GM44664] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044664, R37GM044664] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; ALLEN JB, 1994, YEAST, V10, P1267, DOI 10.1002/yea.320101003; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ARAKI H, 1991, P NATL ACAD SCI USA, V88, P4601, DOI 10.1073/pnas.88.11.4601; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; BURGERS PMJ, 1990, EUR J BIOCHEM, V191, P617, DOI 10.1111/j.1432-1033.1990.tb19165.x; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDIERY WS, 1993, CELL, V75, P817; ELLEDGE SJ, 1989, MOL CELL BIOL, V9, P4932, DOI 10.1128/MCB.9.11.4932; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; HARPER JW, 1993, CELL, V75, P805; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KESTI T, 1993, J BIOL CHEM, V268, P10238; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE SH, 1991, J BIOL CHEM, V266, P22707; LI JJ, 1993, CELL, V74, P223, DOI 10.1016/0092-8674(93)90413-K; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MORRISON AL, 1990, CELL, V62, P1142; NAGASAWA H, 1985, MUTAT RES, V148, P71, DOI 10.1016/0027-5107(85)90209-X; NISHIDA C, 1988, J BIOL CHEM, V263, P501; PEARSON RB, 1993, PROTEIN PHOSPHORYLAT, P265; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; ROBERGE M, 1992, Trends in Cell Biology, V2, P277, DOI 10.1016/0962-8924(92)90201-W; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; SASSANFAR M, 1990, J MOL BIOL, V212, P79, DOI 10.1016/0022-2836(90)90306-7; SIEDE W, 1993, P NATL ACAD SCI USA, V90, P7985, DOI 10.1073/pnas.90.17.7985; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1993, GENETICS, V134, P63; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHENG P, 1993, MOL CELL BIOL, V13, P5829, DOI 10.1128/MCB.13.9.5829; ZHOU Z, 1992, GENETICS, V131, P851; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	43	371	375	1	11	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					29	39		10.1016/0092-8674(95)90448-4	http://dx.doi.org/10.1016/0092-8674(95)90448-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813016	Bronze			2022-12-28	WOS:A1995QB91000007
J	REYNAUD, CA; GARCIA, C; HEIN, WR; WEILL, JC				REYNAUD, CA; GARCIA, C; HEIN, WR; WEILL, JC			HYPERMUTATION GENERATING THE SHEEP IMMUNOGLOBULIN REPERTOIRE IS AN ANTIGEN-INDEPENDENT PROCESS	CELL			English	Article							PEYERS-PATCHES; LYMPHOCYTE-B; GENES; EXPRESSION; MICE; CELLS; ILEAL; SEQUENCES; TOLERANCE; DIVERSITY	Somatic hypermutation of light chain V genes during development of B cells in sheep ileal Peyer's patches was studied in three experimental conditions: in sterile fragments of the ileum surgically isolated from the gut during fetal life, in germ-free sheep, and in animals thymectomized during early fetal life. The somatic mutation pattern was found identical to control tissues in all three experiments. The same age-dependent amount of mutations, a higher than theoretical R/S ratio in complementarity-determining regions (CDRs), and a similar clustering of mutations in CDRs were observed. The mechanism, as estimated from the silent mutation pattern, appears to target mutations to CDRs; moreover, the major V lambda genes have a specific codon usage with a high purine content at the first two bases of the codons and a low content at the third position, which, together with a specific targeting of mutations to purines, favors replacement mutations in CDRs.	BASEL INST IMMUNOL,CH-4002 BASEL,SWITZERLAND		REYNAUD, CA (corresponding author), UNIV PARIS 05,FAC MED NECKER ENFANTS MALAD,INST NECKER,INSERM,U373,F-75730 PARIS 15,FRANCE.		Cordier, Corinne/F-9966-2018; Hein, Wayne/E-9090-2013	Cordier, Corinne/0000-0003-4799-6143; Hein, Wayne/0000-0003-0769-6525				BECKER RS, 1990, CELL, V63, P987, DOI 10.1016/0092-8674(90)90502-6; BETZ AG, 1993, IMMUNOL TODAY, V14, P405, DOI 10.1016/0167-5699(93)90144-A; BETZ AG, 1993, P NATL ACAD SCI USA, V90, P2385, DOI 10.1073/pnas.90.6.2385; BOS NA, 1989, EUR J IMMUNOL, V19, P1811, DOI 10.1002/eji.1830191008; BRENNER S, 1966, NATURE, V211, P242, DOI 10.1038/211242a0; DEENEN GJ, 1993, INT IMMUNOL, V5, P735, DOI 10.1093/intimm/5.7.735; EKINO S, 1993, EUR J IMMUNOL, V23, P772, DOI 10.1002/eji.1830230331; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; HEIN WR, 1989, IMMUNOLOGY, V68, P365; HEIN WR, 1990, EUR J IMMUNOL, V20, P1805, DOI 10.1002/eji.1830200827; HUETZ F, 1993, EMBO J, V12, P1819, DOI 10.1002/j.1460-2075.1993.tb05830.x; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LANDSVERK T, 1987, IMMUNOL CELL BIOL, V65, P251, DOI 10.1038/icb.1987.28; Lawton A R 3rd, 1974, Contemp Top Immunobiol, V3, P193; LEDERBERG J, 1959, SCIENCE, V129, P1649, DOI 10.1126/science.129.3364.1649; MA A, 1992, EMBO J, V11, P2727, DOI 10.1002/j.1460-2075.1992.tb05338.x; METCALF ES, 1976, J EXP MED, V143, P1327, DOI 10.1084/jem.143.6.1327; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NOSSAL GJV, 1975, J EXP MED, V141, P904; REYNAUD CA, 1991, CELL, V64, P995, DOI 10.1016/0092-8674(91)90323-Q; REYNOLDS JD, 1983, EUR J IMMUNOL, V13, P627, DOI 10.1002/eji.1830130805; REYNOLDS JD, 1983, IMMUNOLOGY, V49, P501; REYNOLDS JD, 1986, J IMMUNOL, V136, P2005; REYNOLDS JD, 1976, THESIS AUSTR NATIONA; ROGOZIN IB, 1992, BIOCHIM BIOPHYS ACTA, V1171, P11, DOI 10.1016/0167-4781(92)90134-L; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; VIALE AC, 1992, J EXP MED, V175, P1449, DOI 10.1084/jem.175.6.1449	28	265	270	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					115	125		10.1016/0092-8674(95)90456-5	http://dx.doi.org/10.1016/0092-8674(95)90456-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813007	Bronze			2022-12-28	WOS:A1995QB91000015
J	PEARCE, N; BEASLEY, R; CRANE, J; BURGESS, C; JACKSON, R				PEARCE, N; BEASLEY, R; CRANE, J; BURGESS, C; JACKSON, R			END OF THE NEW-ZEALAND ASTHMA MORTALITY EPIDEMIC	LANCET			English	Article							BETA-AGONISTS; PRESCRIBED FENOTEROL; DEATHS	In 1989, a case-control study reported that inhaled fenoterol was associated with the epidemic of asthma deaths that had affected New Zealand since 1976. The New Zealand Department of Health issued warnings about the safety of fenoterol and restricted its availability. The associated time trends are consistent with the hypothesis that fenoterol was the main factor in the New Zealand asthma mortality epidemic. The epidemic commenced when fenoterol was introduced in 1976, and the New Zealand death rate remained the highest in the world for more than a decade. After publication of the case-control study, the death rate fell by half and has now remained low for a further 3 years (1990-92). Time-trend data do not suggest a class effect of inhaled beta-agonists in the epidemic: there was no association between beta-agonist sales and the start of the epidemic, and total sales of inhaled beta-agonists actually increased slightly during 1989-90 when the epidemic came to an end. Time-trend data are also inconsistent with the hypothesis that the epidemic may have occurred because of underprescribing of inhaled corticosteroids. Similarly, time-trend data is inconsistent with hypotheses postulating a major role of social factors such as unemployment. Data on time trends should be assessed with caution, because time trends in asthma deaths can be affected by many factors. Nevertheless, the New Zealand time trends are consistent with fenoterol being the main cause of the New Zealand asthma mortality epidemic and are inconsistent with a significant role for other suggested causes.			PEARCE, N (corresponding author), WELLINGTON SCH MED,DEPT MED,WELLINGTON ASTHMA RES GRP,POB 7343,WELLINGTON,NEW ZEALAND.			Jackson, Rod/0000-0001-5914-6934; Pearce, Neil/0000-0002-9938-7852; Beasley, Richard/0000-0003-0337-406X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEASLEY R, 1989, NEW ZEAL MED J, V102, P294; BEASLEY R, 1991, AUST NZ J MED, V21, P753, DOI 10.1111/j.1445-5994.1991.tb01385.x; BERNSTEIN DS, 1990, OPTIM CONTR APPL MET, V11, P1, DOI 10.1002/oca.4660110102; CRANE J, 1989, LANCET, V1, P917; CRANE J, 1992, BRIT MED J, V304, P1307, DOI 10.1136/bmj.304.6837.1307; Cried CP, 1993, EUR RESPIR J, V6, p426S; DAVIS P, 1994, HEALTH POLICY, V29, P113, DOI 10.1016/0168-8510(94)90010-8; GARRETT J, 1992, POSITIVE DIRECTIONS; GRAINGER J, 1991, THORAX, V46, P105, DOI 10.1136/thx.46.2.105; HAAS JF, 1992, BRIT MED J, V304, P1634, DOI 10.1136/bmj.304.6842.1634; HENSLEY MJ, 1992, MED J AUSTRALIA, V157, P568; HENSLEY MJ, 1992, MED J AUSTRALIA, V156, P882, DOI 10.5694/j.1326-5377.1992.tb137010.x; HORWITZ RI, 1991, CHEST, V100, P1586, DOI 10.1378/chest.100.6.1586; JACKSON RT, 1982, BRIT MED J, V285, P771, DOI 10.1136/bmj.285.6344.771; JACKSON RT, 1983, NZ MED J, V96, P727; KEATING G, 1984, BRIT MED J, V289, P348, DOI 10.1136/bmj.289.6441.348; MULLEN M, 1993, JAMA-J AM MED ASSOC, V270, P1842, DOI 10.1001/jama.270.15.1842; PEARCE N, 1990, THORAX, V45, P170, DOI 10.1136/thx.45.3.170; PEARCE N, 1991, CLIN EXP ALLERGY, V21, P401, DOI 10.1111/j.1365-2222.1991.tb01679.x; PEARCE N, 1992, NEW ENGL J MED, V327, P355; PEARCE N, 1994, JAMA-J AM MED ASSOC, V271, P822, DOI 10.1001/jama.271.11.822; Prime Ministerial Task Force on Employment, 1994, EMPLOYMENT ISSUES; SEARS MR, 1986, AM J EPIDEMIOL, V124, P1004, DOI 10.1093/oxfordjournals.aje.a114470; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STOLLEY PD, 1972, AM REV RESPIR DIS, V105, P883; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604, DOI 10.1164/ajrccm.149.3.8118625; SUISSA S, 1992, BRIT MED J, V305, P889, DOI 10.1136/bmj.305.6858.889; WILSON JD, 1981, LANCET, V1, P1235; WOODMAN K, 1992, CLIN PHARMACOL THER, V51, P566, DOI 10.1038/clpt.1992.64	30	137	141	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					41	44		10.1016/S0140-6736(95)91159-6	http://dx.doi.org/10.1016/S0140-6736(95)91159-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799709				2022-12-28	WOS:A1995QA29000017
J	WIESENFELD, K; MOSS, F				WIESENFELD, K; MOSS, F			STOCHASTIC RESONANCE AND THE BENEFITS OF NOISE - FROM ICE AGES TO CRAYFISH AND SQUIDS	NATURE			English	Article							CLIMATIC TRANSITIONS; BISTABLE SYSTEMS; DEVILS-HOLE; FIELDS; INFORMATION; ESCAPE	Noise in dynamical systems is usually considered a nuisance. But in certain nonlinear systems, including electronic circuits and biological sensory apparatus, the presence of noise can in fact enhance the detection of weak signals. This phenomenon, called stochastic resonance, may find useful application in physical, technological and biomedical contexts.	UNIV MISSOURI, DEPT PHYS & ASTRON, ST LOUIS, MO 63121 USA	University of Missouri System; University of Missouri Saint Louis	WIESENFELD, K (corresponding author), GEORGIA INST TECHNOL, SCH PHYS, ATLANTA, GA 30332 USA.							ADAIR RK, 1991, PHYS REV A, V43, P1039, DOI 10.1103/PhysRevA.43.1039; Anishchenko V. S., 1992, International Journal of Bifurcation and Chaos in Applied Sciences and Engineering, V2, P397, DOI 10.1142/S0218127492000379; ANISHCHENKO VS, 1994, INT J BIFURCAT CHAOS, V4, P441, DOI 10.1142/S0218127494000290; BENNETT WR, 1994, PHYS TODAY, V47, P23, DOI 10.1063/1.881417; BENZI R, 1982, TELLUS, V34, P10, DOI 10.1111/j.2153-3490.1982.tb01787.x; BENZI R, 1981, J PHYS A-MATH GEN, V14, pL453, DOI 10.1088/0305-4470/14/11/006; BRAUN HA, 1994, NATURE, V367, P270, DOI 10.1038/367270a0; BULSARA A, 1993, J STAT PHYS, V70, P1, DOI 10.1007/BF01053949; BULSARA AR, 1994, PHYS REV E, V49, P4989, DOI 10.1103/PhysRevE.49.4989; CARROLL TL, 1993, PHYS REV LETT, V70, P576, DOI 10.1103/PhysRevLett.70.576; DOUGLASS JK, 1993, NATURE, V365, P337, DOI 10.1038/365337a0; DYKAMAN MI, 1990, PHYS REV LETT, V65, P2606; FAUVE S, 1983, PHYS LETT A, V97, P5, DOI 10.1016/0375-9601(83)90086-5; GAMMAITONI L, 1989, PHYS REV LETT, V62, P349, DOI 10.1103/PhysRevLett.62.349; GAMMAITONI L, 1993, PHYS REV LETT, V71, P3625, DOI 10.1103/PhysRevLett.71.3625; GHIL M, 1987, TOPICS GEOPHYSICAL 4; GINGL Z, IN PRESS EUROPHYS LE; HIBBS A, IN PRESS J APPL PHYS; HIBBS A, 1993, AIP C P, V295, P720; IMBRIE J, 1993, NATURE, V363, P531, DOI 10.1038/363531a0; JUNG P, 1989, EUROPHYS LETT, V8, P505, DOI 10.1209/0295-5075/8/6/003; JUNG P, 1993, PHYS REP, V234, P175, DOI 10.1016/0370-1573(93)90022-6; JUNG P, 1991, PHYS REV A, V44, P8032, DOI 10.1103/PhysRevA.44.8032; KELSO JAS, IN PRESS MULTISTABIL; KRUGLIKOV IL, IN PRESS BIOELECTROM; LOFSTEDT R, 1994, PHYS REV LETT, V72, P1947, DOI 10.1103/PhysRevLett.72.1947; LONGTIN A, 1991, PHYS REV LETT, V67, P656, DOI 10.1103/PhysRevLett.67.656; LONGTIN A, 1993, J STAT PHYS, V70, P309, DOI 10.1007/BF01053970; Makeyev V. M., 1993, Biophysics (English Translation of Biofizika), V38, P189; MATTEUCCI G, 1991, CLIM DYNAM, V6, P67; MCNAMARA B, 1988, PHYS REV LETT, V60, P2626, DOI 10.1103/PhysRevLett.60.2626; MCNAMARA B, 1989, PHYS REV A, V39, P4854, DOI 10.1103/PhysRevA.39.4854; MOSS F, 1993, ANN NY ACAD SCI, V706, P26, DOI 10.1111/j.1749-6632.1993.tb24679.x; Necker LA., 1832, LONDON EDINBURGH, V1, P329, DOI [10.1080/14786443208647909, DOI 10.1080/14786443208647909]; NEIMAN A, 1994, PHYS REV LETT, V72, P2988, DOI 10.1103/PhysRevLett.72.2988; NICOLIS C, 1993, J STAT PHYS, V70, P3, DOI 10.1007/BF01053950; PANTAZELOU E, IN PRESS INT J BIFUR; POLK C, IN PRESS 13TH P A M; RIANI M, 1994, PHYS REV LETT, V72, P3120, DOI 10.1103/PhysRevLett.72.3120; SIMON A, 1992, PHYS REV LETT, V68, P3375, DOI 10.1103/PhysRevLett.68.3375; STOCKS NG, 1993, J PHYS A-MATH GEN, V26, pL385, DOI 10.1088/0305-4470/26/7/007; TENFORDE TS, 1992, ANNU REV PUBL HEALTH, V13, P173, DOI 10.1146/annurev.publhealth.13.1.173; WEAVER JC, 1990, SCIENCE, V247, P459, DOI 10.1126/science.2300806; WIESENFELD K, 1994, PHYS REV LETT, V72, P2125, DOI 10.1103/PhysRevLett.72.2125; WIESENFELD K, IN PRESS NUOVO CIM S; WINOGRAD IJ, 1992, SCIENCE, V258, P255, DOI 10.1126/science.258.5080.255; ZHOU T, 1990, PHYS REV A, V42, P3161, DOI 10.1103/PhysRevA.42.3161	48	1522	1541	7	138	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 5	1995	373	6509					33	36		10.1038/373033a0	http://dx.doi.org/10.1038/373033a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800036				2022-12-28	WOS:A1995QA23900046
J	MILLER, WR; ELLIS, IO; SAINSBURY, JRC; DIXON, JM				MILLER, WR; ELLIS, IO; SAINSBURY, JRC; DIXON, JM			ABC OF BREAST DISEASES - PROGNOSTIC FACTORS	BRITISH MEDICAL JOURNAL			English	Article							AMP BINDING-PROTEINS; CANCER; RECURRENCE; SURVIVAL		CITY HOSP NOTTINGHAM,NOTTINGHAM,ENGLAND; HUDDERSFIELD ROYAL INFIRM,HUDDERSFIELD,W YORKSHIRE,ENGLAND; EDINBURGH ROYAL INFIRM,EDINBURGH,MIDLOTHIAN,SCOTLAND	Nottingham University Hospital NHS Trust; Nottingham City Hospital; Royal Infirmary of Edinburgh	MILLER, WR (corresponding author), WESTERN GEN HOSP,IMPERIAL CANC RES FUND,MED ONCOL UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		Miller, William/AAY-5398-2020	Ellis, Ian/0000-0001-5292-8474				Brown JM, 1993, BREAST, V2, P144; CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H; HAWKINS RA, 1987, BRIT J SURG, V74, P1009, DOI 10.1002/bjs.1800741118; KALLIONIEMI OP, 1987, BRIT J CANCER, V56, P637, DOI 10.1038/bjc.1987.258; MILLER WR, 1993, BREAST CANCER RES TR, V26, P89, DOI 10.1007/BF00682703; MILLER WR, 1990, BRIT J CANCER, V61, P263, DOI 10.1038/bjc.1990.48; NIXON AJ, 1994, J CLIN ONCOL, V12, P888, DOI 10.1200/JCO.1994.12.5.888; SAINSBURY JRC, 1987, LANCET, V1, P1398; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120	9	40	40	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 10	1994	309	6968					1573	1576		10.1136/bmj.309.6968.1573	http://dx.doi.org/10.1136/bmj.309.6968.1573			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX564	7819905	Green Published			2022-12-28	WOS:A1994PX56400033
J	URWIN, G; YUAN, MF; FELDMAN, RA				URWIN, G; YUAN, MF; FELDMAN, RA			PROSPECTIVE-STUDY OF BACTERIAL-MENINGITIS IN NORTH-EAST THAMES REGION, 1991-3, DURING INTRODUCTION OF HAEMOPHILUS-INFLUENZAE VACCINE	BRITISH MEDICAL JOURNAL			English	Article							B INVASIVE DISEASE; UNITED-STATES; SURVEILLANCE; EPIDEMIOLOGY	Objective-To describe the epidemiology of primary bacterial meningitis in the North East Thames region over a three year period before and during the introduction of the vaccine for Haemophilus influenzae type b. Design-Analysis of information on cases of primary bacterial meningitis identified by microbiology laboratories in the region, with collection of case data by questionnaire. Main outcome measures-Annual incidence rates for types of meningitis according to age and ethnic group. Results-The annual incidence rates for the three major causes of bacterial meningitis in the general population were 1.9/100 000 for Neisseria meningitidis, 1.6/100 000 for Haemophilus influenzae before vaccination, and 1.0/100 000 for Streptococcus pneumoniae. Higher rates of H influenzae meningitis were found in Asians compared with white people (3.6/100 000 v 1.5/100 000, P=0.01). As a result of the vaccine programme introduced in October 1992 the number of cases of H influenzae meningitis in children under 5 years has fallen by 87%. Conclusions-Bacterial meningitis is a serious problem especially in preschool children. There are differences in the incidence of some causes of bacterial meningitis in different ethnic groups; with H influenzae type b being significantly more common among black and Asian people than among white people. The immunisation programme for H influenzae type b in the North East Thames region has been successful in reducing the incidence of this type of meningitis in Asian and white populations. The numbers were too small to evaluate in the black population.	UNIV LONDON QUEEN MARY & WESTFIELD COLL,LONDON HOSP,COLL MED,DEPT EPIDEMIOL & MED STAT,LONDON E1 4NS,ENGLAND; UNIV LONDON LONDON HOSP,COLL MED,DEPT MED MICROBIOL,LONDON E1 2AD,ENGLAND	University of London; Queen Mary University London; University of London; University College London								ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221; BREWSTER D, 1993, HLTH B EDINB, V56, P385; CARTWRIGHT KAV, 1986, LANCET, V2, P558; FALLON RJ, 1991, BRIT MED J, V303, P1203, DOI 10.1136/bmj.303.6811.1203-b; GILLAM S, 1990, POSTGRAD MED J, V66, P989, DOI 10.1136/pgmj.66.782.989; HOWARD AJ, 1991, BRIT MED J, V303, P441, DOI 10.1136/bmj.303.6800.441; Jackson Lisa A., 1993, Morbidity and Mortality Weekly Report, V42, P21; Jones D M, 1991, CDR (Lond Engl Rev), V1, pR76; MACLEOD C, 1994, CDR REV, V2, pR13; NAZARETH B, 1992, COMM DIS REP REV, V2, P13; OBRIEN H, 1994, COM DIS REP CDR REV, V2, pR17; PELTOLA H, 1992, LANCET, V340, P592, DOI 10.1016/0140-6736(92)92117-X; RALEIGH VS, 1994, BRIT MED J, V309, P287, DOI 10.1136/bmj.309.6950.287; SCHLECH WF, 1985, JAMA-J AM MED ASSOC, V253, P1749, DOI 10.1001/jama.253.12.1749; TUDORWILLIAMS G, 1989, ARCH DIS CHILD, V64, P517, DOI 10.1136/adc.64.4.517; WARD JI, 1986, J INFECT DIS, V153, P17, DOI 10.1093/infdis/153.1.17; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316	17	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1994	309	6966					1412	1414		10.1136/bmj.309.6966.1412	http://dx.doi.org/10.1136/bmj.309.6966.1412			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7819853	Green Published			2022-12-28	WOS:A1994PU76400027
J	FAIRMAN, WA; VANDENBERG, RJ; ARRIZA, JL; KAVANAUGH, MP; AMARA, SG				FAIRMAN, WA; VANDENBERG, RJ; ARRIZA, JL; KAVANAUGH, MP; AMARA, SG			AN EXCITATORY AMINO-ACID TRANSPORTER WITH PROPERTIES OF A LIGAND-GATED CHLORIDE CHANNEL	NATURE			English	Article							XENOPUS-LAEVIS OOCYTES; GLUTAMATE TRANSPORTER; RAT-BRAIN; ASPARTATE TRANSPORTER; EXPRESSION; CALCIUM; SALAMANDER; BLOCKERS; RECEPTOR; CLONING	EXCITATORY amino-acid transporters (EAATs) in the central nervous system maintain extracellular glutamate concentrations below excitotoxic levels and may limit the activation of glutamate receptors. Here we report the cloning of a novel human aspartate/glutamate transporter, EAAT4, which is expressed predominantly in the cerebellum. The transport activity encoded by EAAT4 has high apparent affinity for L-aspartate and L-glutamate, and has a pharmacological profile consistent with previously described cerebellar transport activities. In Xenopus oocytes expressing EAAT4, L-aspartate and L-glutamate elicited a current predominantly carried by chloride ions. This chloride conductance was not blocked by components that block endogenous oocyte chloride channels. Thus EAAT4 combines the re-uptake of neurotransmitter with a mechanism for increasing chloride permeability, both of which could regulate excitatory neurotransmission.	OREGON HLTH SCI UNIV,HOWARD HUGHES MED INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201	Howard Hughes Medical Institute; Oregon Health & Science University; Oregon Health & Science University			Vandenberg, Robert John/E-6018-2016	Vandenberg, Robert John/0000-0003-1523-4814; Amara, Susan/0000-0001-8914-1106				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; BARBOUR B, 1991, J PHYSIOL-LONDON, V436, P169, DOI 10.1113/jphysiol.1991.sp018545; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; COYLE JT, 1985, J NEUROSCI RES, V16, P491; CUNNINGHAM SA, 1992, AM J PHYSIOL, V262, P783; ELIASOF S, 1993, J NEUROSCI, V13, P402; FLETCHER EJ, 1991, J NEUROCHEM, V57, P911, DOI 10.1111/j.1471-4159.1991.tb08237.x; GREGER R, 1990, METHOD ENZYMOL, V191, P793; KANAI Y, 1994, J BIOL CHEM, V269, P20599; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KLOCKNER U, 1993, J BIOL CHEM, V268, P14594; KUHAR MJ, 1978, J NEUROCHEM, V31, P251, DOI 10.1111/j.1471-4159.1978.tb12456.x; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; MILEDI R, 1982, PROC R SOC SER B-BIO, V215, P491, DOI 10.1098/rspb.1982.0056; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; PIN JP, 1984, FEBS LETT, V175, P31, DOI 10.1016/0014-5793(84)80563-3; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; ROBINSON MB, 1993, J NEUROCHEM, V60, P167, DOI 10.1111/j.1471-4159.1993.tb05835.x; SARANTIS M, 1988, NATURE, V332, P451, DOI 10.1038/332451a0; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; WADICHE JI, IN PRESS NEURON; WHITE MM, 1990, MOL PHARMACOL, V37, P720; WI G, 1992, PFLUGERS ARCH, V420, P227; ZACZEK R, 1987, NEUROPHARMACOLOGY, V26, P281, DOI 10.1016/0028-3908(87)90179-1	30	979	997	0	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					599	603		10.1038/375599a0	http://dx.doi.org/10.1038/375599a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791878				2022-12-28	WOS:A1995RD28700054
J	ESTEBAN, A; FRUTOS, F; TOBIN, MJ; ALIA, I; SOLSONA, JF; VALVERDU, I; FERNANDEZ, R; DELACAL, MA; BENITO, S; TOMAS, R; CARRIEDO, D; MACIAS, S; BLANCO, J				ESTEBAN, A; FRUTOS, F; TOBIN, MJ; ALIA, I; SOLSONA, JF; VALVERDU, I; FERNANDEZ, R; DELACAL, MA; BENITO, S; TOMAS, R; CARRIEDO, D; MACIAS, S; BLANCO, J			A COMPARISON OF 4 METHODS OF WEANING PATIENTS FROM MECHANICAL VENTILATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRESSURE SUPPORT; WORK	Background. Weaning patients from mechanical ventilation is an important problem in intensive care units. Weaning is usually conducted in an empirical manner, and a standardized approach has not been developed. Methods. We carried out a prospective, randomized, multicenter study involving 546 patients who had received mechanical ventilation for a mean (+/-SD) of 7.5+/-6.1 days and who were considered by their physicians to be ready for weaning. One hundred thirty patients had respiratory distress during a two-hour trial of spontaneous breathing. These patients were randomly assigned to undergo one of four weaning techniques: intermittent mandatory ventilation, in which the ventilator rate was initially set at a mean (+/-SD) of 10.0+/-2.2 breaths per minute and then decreased, if possible, at least twice a day, usually by 2 to 4 breaths per minute (29 patients); pressure-support ventilation, in which pressure support was initially set at 18.0+/-6.1 cm of water and then reduced, it possible, by 2 to 4 cm of water at least twice a day (37 patients); intermittent trials of spontaneous breathing, conducted two or more times a day if possible (33 patients); or a once-daily trial of spontaneous breathing (31 patients). Standardized protocols were followed for each technique. Results. The median duration of weaning was 5 days for intermittent mandatory ventilation (first quartile, 3 days; third quartile, 11 days), 4 days for pressure-support ventilation (2 and 12 days, respectively), 3 days for intermittent (multiple) trials of spontaneous breathing (2 and 6 days, respectively), and 3 days for a once-daily trial of spontaneous breathing (1 and 6 days, respectively). After adjustment for other covariates, the rate of successful weaning was higher with a once-daily trial of spontaneous breathing than with intermittent mandatory ventilation (rate ratio, 2.83; 95 percent confidence interval, 1.36 to 5.89; P<0.006) or pressure-support ventilation (rate ratio, 2.05; 95 percent confidence interval, 1.04 to 4.04; P<0.04), There was no significant difference in the rate of success between once-daily trials and multiple trials of spontaneous breathing. Conclusions. A once-daily trial of spontaneous breathing led to extubation about three times more quickly than intermittent mandatory ventilation and about twice as quickly as pressure-support ventilation. Multiple daily trials of spontaneous breathing were equally successful.	LOYOLA UNIV, CHICAGO, IL 60611 USA; EDWARD HINES JR VET ADM HOSP, HINES, IL USA; HOSP DEL MAR, BARCELONA, SPAIN; HOSP SANTA CRUZ & SAN PABLO, E-08025 BARCELONA, SPAIN; HOSP PARC TAULI, SABADELL, SPAIN; HOSP GERMANS TRIAS & PUJOL, BADALONA, SPAIN; COMPLEJO HOSP LEON, LEON, SPAIN; HOSP GEN SEGOVIA, SEGOVIA, SPAIN; HOSP RIO ORTEGA, VALLADOLID, SPAIN	Loyola University Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Autonomous University of Barcelona; Parc Tauli Hospital Universitari; Hospital Germans Trias i Pujol; Universidad de Leon; Hospital de Leon	ESTEBAN, A (corresponding author), HOSP UNIV GETAFE, SERV CUIDADOS INTENS, CTRA TOLEDO KM 12500, E-28905 GETAFE, SPAIN.		Fernandez, Rafael/A-9586-2010	Fernandez, Rafael/0000-0001-5711-5317; benito, salvador/0000-0002-6333-5823; Frutos-Vivar, Fernando/0000-0002-4648-9636				ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; BROCHARD L, 1991, ANESTHESIOLOGY, V75, P739, DOI 10.1097/00000542-199111000-00004; Brochard L, 1994, PRINCIPLES PRACTICE, P239; COX DR, 1972, J R STAT SOC B, V34, P187; DOWNS JB, 1973, CHEST, V64, P331, DOI 10.1378/chest.64.3.331; ESTEBAN A, 1994, CHEST, V106, P1188, DOI 10.1378/chest.106.4.1188; FAULKNER JA, 1985, LUNG BIOL HLTH DISEA, V29, P1329; GIBNEY RTN, 1982, CHEST, V82, P692, DOI 10.1378/chest.82.6.692; HASTINGS PR, 1980, ANESTHESIOLOGY, V53, P429; IMSAND C, 1994, ANESTHESIOLOGY, V80, P13, DOI 10.1097/00000542-199401000-00006; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LUCE JM, 1981, CHEST, V79, P678, DOI 10.1378/chest.79.6.678; MARINI JJ, 1988, AM REV RESPIR DIS, V138, P1169, DOI 10.1164/ajrccm/138.5.1169; NATHAN SD, 1993, CHEST, V103, P1215, DOI 10.1378/chest.103.4.1215; ROCHESTER DF, 1988, AM REV RESPIR DIS, V138, P516, DOI 10.1164/ajrccm/138.3.516; SASSOON CSH, 1994, PRINCIPLES PRACTICE, P221; SCHACHTER EN, 1981, JAMA-J AM MED ASSOC, V246, P1210, DOI 10.1001/jama.246.11.1210; TOBIN MJ, 1994, NEW ENGL J MED, V330, P1056, DOI 10.1056/NEJM199404143301507; Tobin MJ, 1994, PRINCIPLES PRACTICE, P1177; TOMLINSON JR, 1989, CHEST, V96, P348, DOI 10.1378/chest.96.2.348; VENUS B, 1987, CRIT CARE MED, V15, P530, DOI 10.1097/00003246-198705000-00017	23	817	867	0	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 9	1995	332	6					345	350		10.1056/NEJM199502093320601	http://dx.doi.org/10.1056/NEJM199502093320601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF300	7823995				2022-12-28	WOS:A1995QF30000001
J	WHALEN, CM; HOCKIN, JC; RYAN, A; ASHTON, F				WHALEN, CM; HOCKIN, JC; RYAN, A; ASHTON, F			THE CHANGING EPIDEMIOLOGY OF INVASIVE MENINGOCOCCAL-DISEASE IN CANADA, 1985 THROUGH 1992 - EMERGENCE OF A VIRULENT CLONE OF NEISSERIA-MENINGITIDIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DECEMBER 1991; FEBRUARY 1992; INFLUENZA-A; INFECTIONS; OUTBREAK; AGE	Objective.-To describe the occurrence of invasive meningococcal disease (IMD) in Canada with respect to demographic variables and characteristics of the isolated strains of Neisseria meningitidis. Design.-National surveillance case series. Setting.-Canada, 1985 through 1992. Outcome Measures.-Morbidity and mortality. Main Results.-The incidence of IMD averaged 1.38 per 100 000 person-years, with considerable regional variation. In 1988, serogroup C organisms became more common, with one strain of the electrophoretic type 37 (ET-37) complex of N meningitidis,termed ET-15, the predominant group C strain identified. With the increase in group C disease, a greater proportion of cases were older than 5 years. By 1991, ET-15 was the most common strain identified in most parts of the country. Electrophoretic type 15 had a case fatality of 17.8% vs 8.1% for all other IMD (P<.001). Among cases 20 years and older the case fatality for ET-15 was 22.4%. Conclusions.-The group C, ET-15 strain of N meningitidis, first identified in Canada, was more virulent than other prevalent strains during this period, Active surveillance, rapid identification, and typing of N meningitidis will assist public health decision making in the control of emerging strains.	HLTH & WELF CANADA,HLTH PROTECT BRANCH,LAB CTR DIS CONTROL,BUR COMMUNICABLE DIS EPIDEMIOL,OTTAWA,ON K1A 0L2,CANADA; HLTH & WELF CANADA,HLTH PROTECT BRANCH,LAB CTR DIS CONTROL,BUR MICROBIOL,NATL LAB BACTERIOL,OTTAWA,ON K1A 0L2,CANADA; UNIV OTTAWA,DEPT EPIDEMIOL & COMMUNITY MED,OTTAWA,ON,CANADA	University of Ottawa								ASHTON FE, 1991, J CLIN MICROBIOL, V29, P2489, DOI 10.1128/JCM.29.11.2489-2493.1991; BAKER CJ, 1983, PEDIATRICS, V71, P923; BOUCHARD F, 1992, CAN J PUBLIC HEALTH, V83, P131; CARTWRIGHT KAV, 1991, LANCET, V338, P554, DOI 10.1016/0140-6736(91)91112-8; CORBETTFEENEY G, 1991, IRISH J MED SCI, V160, P134, DOI 10.1007/BF02965936; EDWARDS EA, 1977, SCAND J INFECT DIS, V9, P105, DOI 10.3109/inf.1977.9.issue-2.09; FALLON RJ, 1988, J MED MICROBIOL, V26, P161; FARLEY JD, 1992, CAN J PUBLIC HEALTH, V83, P138; GEMMILL I, 1992, CAN J PUBLIC HEALTH, V83, P134; GOLD R, 1992, CAN J PUBLIC HEALTH, V83, P5; HOCKIN J, 1993, 3RD NAT M CAN SOC EP; HUBERT B, 1992, J INFECT DIS, V166, P542, DOI 10.1093/infdis/166.3.542; HUME SE, 1992, JAMA-J AM MED ASSOC, V267, P1833, DOI 10.1001/jama.267.13.1833; JAFARI H, 1993, 33RD P INT C ANT AG; Jones D M, 1988, J Med Microbiol, V26, P165; Jones D M, 1994, Commun Dis Rep CDR Rev, V4, pR97; KRANSINSKI K, 1987, AM J EPIDEMIOL, V125, P499; LABIN LL, 1978, STATISTICS MODERN BU, P561; Le Saux N, 1992, Can J Infect Dis, V3, P60; MOORE PS, 1990, JAMA-J AM MED ASSOC, V264, P1271, DOI 10.1001/jama.264.10.1271; PELTOLA H, 1982, LANCET, V2, P595; REILLY S, 1991, LANCET, V338, P1143, DOI 10.1016/0140-6736(91)91999-B; SCHWARTZ B, 1989, CLIN MICROBIOL REV, V2, pS118, DOI 10.1128/CMR.2.Suppl.S118-S124.1989; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P837; STROFFOLINI T, 1989, J INFECTION, V19, P69, DOI 10.1016/S0163-4453(89)94980-3; SWEET L, 1992, CAN J PUBLIC HEALTH, V83, P129; Varughese P V, 1989, Can Dis Wkly Rep, V15, P89; VARUGHESE PV, 1987, EVOLUTION MENINGOCOC, V1, P47; Varughese PV, 1983, CAN DIS WKLY REP, V9, P177; WANG JF, 1993, J INFECT DIS, V167, P1320, DOI 10.1093/infdis/167.6.1320; WHITE K, 1992, CAN J PUBLIC HEALTH, V83, P141; YOUNG LS, 1972, NEW ENGL J MED, V287, P5, DOI 10.1056/NEJM197207062870102; 1985, 84208 DEP SUPPL SERV; 1991, NOTIFIABLE DISEASES; 1994, CAN COMMUNICABLE DIS, V20, P17; 1994, B INFORM MALAD INFEC, V1, P5; 1993, CAN COMMUNICABLE DIS, V19, P184; 1991, CAN DIS WKLY REP, V17, P295; 1991, CAN DIS WKLY REP, V17, P293; 1992, CAN COMMUNICABLE DIS, V18, P137; 1991, CAN DIS WKLY REP S3, V17, P24; 1994, 1993 DEP SUPPL SERV; 1989, CAN MED ASSOC J, V141, P567	43	147	150	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	1995	273	5					390	394		10.1001/jama.273.5.390	http://dx.doi.org/10.1001/jama.273.5.390			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QD203	7823384				2022-12-28	WOS:A1995QD20300023
J	MADRENAS, J; WANGE, RL; WANG, JL; ISAKOV, N; SAMELSON, LE; GERMAIN, RN				MADRENAS, J; WANGE, RL; WANG, JL; ISAKOV, N; SAMELSON, LE; GERMAIN, RN			ZETA-PHOSPHORYLATION WITHOUT ZAP-70 ACTIVATION-INDUCED BY TCR ANTAGONISTS OR PARTIAL AGONISTS	SCIENCE			English	Article							T-CELL-RECEPTOR; ANTIGEN-PRESENTING CELLS; TYROSINE PHOSPHORYLATION; CYTOCHROME-C; COMPLEX; CHAIN; LIGAND; COMPONENTS; ANALOG; KINASE	Small changes in the peptide-major histocompatibility complex (MHC) molecule ligands recognized by antigen-specific T cell receptors (TCRs) can convert fully activating complexes into partially activating or even inhibitory ones, This study examined early TCR-dependent signals induced by such partial agonists or antagonists, In contrast to typical agonist ligands, both an antagonist and several partial agonists stimulated a distinct pattern of zeta chain phosphorylation and failed to activate associated ZAP-70 kinase, These results identify a specific step in the early tyrosine phosphorylation cascade that is altered after TCR engagement with modified peptide-MHC molecule complexes, This finding may explain the different biological responses to TCR occupancy by these variant ligands.	NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	MADRENAS, J (corresponding author), NIAID, IMMUNOL LAB, LYMPHOCYTE BIOL SECT, BLDG 10, BETHESDA, MD 20892 USA.		Madrenas, Quim/P-5008-2019; Germain, Ronald/ABE-7090-2020; Germain, Ronald N./Z-1945-2019	Wange, Ronald/0000-0001-9593-3572; Isakov, Noah/0000-0002-1412-0957				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BERGMAN RN, 1978, J BIOL CHEM, V253, P3238; BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHO EA, 1993, J IMMUNOL, V151, P20; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; DING L, 1993, J IMMUNOL, V151, P1224; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; FRANCO A, 1994, EUR J IMMUNOL, V24, P940, DOI 10.1002/eji.1830240424; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GERMAIN RN, 1993, CURR BIOL, V3, P586, DOI 10.1016/0960-9822(93)90004-8; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; HSI ED, 1989, J BIOL CHEM, V264, P10836; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; KLAUSNER RD, 1987, J BIOL CHEM, V262, P12654; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; KUCHROO VK, 1994, J IMMUNOL, V153, P3326; MADRENAS J, UNPUB; MATIS LA, 1983, J IMMUNOL, V130, P1527; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; PAGE DM, 1994, P NATL ACAD SCI USA, V91, P4057, DOI 10.1073/pnas.91.9.4057; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PLOEGH H, 1993, NATURE, V364, P16, DOI 10.1038/364016d0; QIAN DP, 1993, J BIOL CHEM, V268, P4488; RACIOPPI L, 1993, J EXP MED, V177, P1047, DOI 10.1084/jem.177.4.1047; RACIOPPI L, 1991, J IMMUNOL, V147, P3718; RONCHESE F, 1987, NATURE, V329, P254, DOI 10.1038/329254a0; RUPPERT J, 1993, P NATL ACAD SCI USA, V90, P2671, DOI 10.1073/pnas.90.7.2671; SAMELSON LE, 1987, J IMMUNOL, V139, P2708; SAMELSON LE, 1992, ADV EXP MED BIOL, V323, P9; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SCHWARTZ RH, 1985, J IMMUNOL, V135, P2598; SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANOERS NSC, 1994, IMMUNITY, V1, P675, DOI 10.1016/1074-7613(94)90038-8; VIGNALI DAA, 1994, J EXP MED, V179, P1945, DOI 10.1084/jem.179.6.1945; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YOON ST, 1994, IMMUNITY, V1, P563	49	505	511	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	1995	267	5197					515	518		10.1126/science.7824949	http://dx.doi.org/10.1126/science.7824949			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD403	7824949				2022-12-28	WOS:A1995QD40300039
J	EMANUEL, EJ; STEINER, D				EMANUEL, EJ; STEINER, D			INSTITUTIONAL CONFLICT-OF-INTEREST	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							OF-INTEREST; CLINICAL-TRIAL; ISSUES		HARVARD UNIV,SCH MED,BOSTON,MA 02115; ROPES & GRAY,BOSTON,MA 02110; HARVARD UNIV,CAMBRIDGE,MA 02138	Harvard University; Harvard Medical School; Harvard University	EMANUEL, EJ (corresponding author), CHILDRENS HOSP,DANA FARBER CANC INST,BOSTON,MA 02115, USA.							ANDERSON C, 1993, SCIENCE, V259, P300, DOI 10.1126/science.8419997; [Anonymous], 1986, HIST THEORY INFORM C; APPELBAUM P, 1987, INFORMED CONSENT LEG; BARINAGA M, 1992, SCIENCE, V257, P616, DOI 10.1126/science.1496372; BLUMENTHAL D, 1992, JAMA-J AM MED ASSOC, V268, P3344, DOI 10.1001/jama.268.23.3344; BOOTH W, 1988, SCIENCE, V242, P1497, DOI 10.1126/science.3201233; BROAD WJ, 1982, SCIENCE, V215, P874, DOI 10.1126/science.7058339; CULLITON BJ, 1989, SCIENCE, V245, P1034, DOI 10.1126/science.2772654; CULLITON BJ, 1983, SCIENCE, V220, P31, DOI 10.1126/science.6828878; CURRAN WJ, 1991, NEW ENGL J MED, V324, P998, DOI 10.1056/NEJM199104043241419; Emanuel EJ, 1991, ENDS HUMAN LIFE MED, P9; HEALY B, 1989, NEW ENGL J MED, V320, P949, DOI 10.1056/NEJM198904063201432; HILLMAN AL, 1991, NEW ENGL J MED, V324, P1362, DOI 10.1056/NEJM199105093241911; HUNNEWELL S, 1993, HARVARD MAG, V96, P34; KASSIRER JP, 1993, NEW ENGL J MED, V329, P570, DOI 10.1056/NEJM199308193290810; MARSHALL E, 1990, SCIENCE, V248, P152, DOI 10.1126/science.2326628; MARSHALL E, 1990, SCIENCE, V248, P153, DOI 10.1126/science.248.4952.153; MARSHALL E, 1990, SCIENCE, V248, P154; PERRY CB, 1994, AM J MED, V96, P375, DOI 10.1016/0002-9343(94)90069-8; Relman A S, 1983, Health Aff (Millwood), V2, P5, DOI 10.1377/hlthaff.2.2.5; RELMAN AS, 1980, NEW ENGL J MED, V303, P963, DOI 10.1056/NEJM198010233031703; RELMAN AS, 1984, NEW ENGL J MED, V310, P1182, DOI 10.1056/NEJM198405033101809; RODWIN M, 1993, MED MONEY MORALS; RODWIN MA, 1989, NEW ENGL J MED, V321, P1405, DOI 10.1056/NEJM198911163212010; ROTHMAN KJ, 1993, JAMA-J AM MED ASSOC, V269, P2782, DOI 10.1001/jama.269.21.2782; SHIMM DS, 1991, ANN INTERN MED, V115, P148, DOI 10.7326/0003-4819-115-2-148; THOMPSON DF, 1993, NEW ENGL J MED, V329, P573, DOI 10.1056/NEJM199308193290812; TOPOL EJ, 1992, J AM COLL CARDIOL, V19, P1123, DOI 10.1016/0735-1097(92)90312-B; 1992, FACULTY POLICIES INT; 1992, ANN INTERN MED, V117, P947; 1990, ACAD MED, V65, P487; 1994, FED REGISTER, V59, P48708; 1992, JAMA-J AM MED ASSOC, V267, P2366; 1994, HARVARD MED CTR GUID; 1990, JAMA-J AM MED ASSOC, V263, P2790; 1990, POLICY CONFLICTS INT	36	58	59	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	1995	332	4					262	267		10.1056/NEJM199501263320412	http://dx.doi.org/10.1056/NEJM199501263320412			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC270	7808495				2022-12-28	WOS:A1995QC27000012
J	NORMAN, P				NORMAN, P			VAGINAL BIRTH AFTER CESAREAN-SECTION	LANCET			English	Editorial Material							CESAREAN-SECTION; MORBIDITY				NORMAN, P (corresponding author), MT SINAI HOSP,TORONTO,ON,CANADA.							CLARK L, 1991, BRIT J OBSTET GYNAEC, V98, P519, DOI 10.1111/j.1471-0528.1991.tb10362.x; ERIKSEN NL, 1989, AM J PERINAT, V6, P375, DOI 10.1055/s-2007-999621; MCCLAIN CS, 1990, SOC SCI MED, V31, P203, DOI 10.1016/0277-9536(90)90062-W; MILLER DA, 1994, OBSTET GYNECOL, V84, P255; MILLER JM, 1988, OBSTET GYN CLIN N AM, V15, P629; PETTITI DB, 1982, OBSTET GYNECOL, V59, P6; ROSEN MG, 1991, OBSTET GYNECOL, V77, P465; STAFFORD RS, 1990, AM J PUBLIC HEALTH, V80, P313, DOI 10.2105/AJPH.80.3.313; 1986, CAN MED ASSOC J, V134, P1348; 1988, STAT B METRP INSUR C, V69, P18; 1991, APPROPRIATE USE CESA	11	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					142	142		10.1016/S0140-6736(95)90163-9	http://dx.doi.org/10.1016/S0140-6736(95)90163-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QC550	7823667				2022-12-28	WOS:A1995QC55000006
J	SUNG, JJY; CHUNG, SCS; LING, TKW; YUNG, MY; LEUNG, VKS; NG, EKW; LI, MKK; CHENG, AFB; LI, AKC				SUNG, JJY; CHUNG, SCS; LING, TKW; YUNG, MY; LEUNG, VKS; NG, EKW; LI, MKK; CHENG, AFB; LI, AKC			ANTIBACTERIAL TREATMENT OF GASTRIC-ULCERS ASSOCIATED WITH HELICOBACTER-PYLORI	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTIINFLAMMATORY DRUG-USE; CAMPYLOBACTER-PYLORI; INFECTION	Background. There is a strong association between infection with Helicobacter pylori and gastric ulcers that are unrelated to the use of nonsteroidal antiinflammatory medications. We studied the efficacy of antibacterial therapy without medication to suppress gastric acid for the treatment of patients with H. pylori infection and gastric ulcers unrelated to the use of nonsteroidal agents. Methods. Patients with gastric ulcers seen on endoscopy and with H. pylori infection confirmed by smear or culture were randomly assigned to receive either a one-week course of antibacterial agents (120 mg of bismuth subcitrate, 500 mg of tetracycline, and 400 mg of metronidazole, each given orally four times a day) or a four-week course of omeprazole (20 mg orally per day). Follow-up endoscopies were performed after five and nine weeks. The patients and their physicians were aware of the treatment assignments, but the endoscopists were not. Results. A total of 100 patients were randomly assigned to treatment, and 85 completed the trial, At five weeks, H. pylori had been eradicated in 41 of the 45 patients in the antibacterial-treatment group (91.1 percent; 95 percent confidence interval, 82.9 to 99.3) and in 5 of the 40 in the omeprazole group (12.5 percent; 95 percent confidence interval, 2.3 to 22.7; P<0.001). The gastric ulcers were healed in 38 of the patients treated with antibacterial drugs (84.4 percent; 95 percent confidence interval, 73.9 to 95.0) and in 29 of those treated with omeprazole (72.5 percent; 95 percent confidence interval, 58.6 to 86.4; P=0.28). At nine weeks, ulcer healing was confirmed in 43 of the patients receiving antibacterial therapy and in 37 of those receiving omeprazole (P=1.0). The mean (+/-SD) duration of pain during the first week of treatment was 1.9+/-2.6 days in the omeprazole group, as compared with 3.6+/-3.0 days in the antibacterial-treatment group (P=0.004). One year after treatment, recurrent gastric ulcers were detected in 1 of 22 patients (4.5 percent) in the antibacterial-treatment group and in 12 of 23 (52.2 percent) in the omeprazole group (P=0.001). H. pylori was detected in the 1 patient with a recurrent ulcer who had received antibacterial treatment and in 10 of the 12 patients with recurrent ulcers who had received omeprazole. Conclusions. In patients with H. pylori infection and gastric ulcers unrelated to the use of nonsteroidal antiinflammatory drugs, one week of antibacterial therapy without acid suppression heals the ulcers as well as omeprazole and reduces the rate of their recurrence.	PRINCE WALES HOSP,DEPT SURG,SHA TIN,HONG KONG; PRINCE WALES HOSP,DEPT MICROBIOL,SHA TIN,HONG KONG; CHINESE UNIV HONG KONG,HONG KONG,HONG KONG	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong	SUNG, JJY (corresponding author), PRINCE WALES HOSP,DEPT MED,SHA TIN,HONG KONG.		Sung, Joseph J. Y./R-3203-2018; Ng, Enders Kwok Wai/E-8276-2016	Sung, Joseph J. Y./0000-0003-3125-5199; 				BAYERDORFFER E, 1993, GASTROENTEROLOGY, V104, pA40; DANIEL WW, 1987, BIOSTATISTICS F ANAL; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1653, DOI 10.1016/0016-5085(91)90665-8; GRAHAM DY, 1992, ANN INTERN MED, V116, P705, DOI 10.7326/0003-4819-116-9-705; HOSKING SW, 1994, LANCET, V343, P508, DOI 10.1016/S0140-6736(94)91460-5; LABENZ J, 1994, GUT, V35, P19, DOI 10.1136/gut.35.1.19; LAINE L, 1992, AM J GASTROENTEROL, V87, P1398; LEUNG KM, 1992, AM J CLIN PATHOL, V98, P569, DOI 10.1093/ajcp/98.6.569; LOEB DS, 1992, GASTROENTEROLOGY, V102, P1899, DOI 10.1016/0016-5085(92)90311-L; MARSHALL BJ, 1984, LANCET, V1, P1311; MISIEWICZ JJ, 1990, 1990 WORLD C GASTR 2, P1; MONTGOMERY EA, 1988, AM J CLIN PATHOL, V90, P606, DOI 10.1093/ajcp/90.5.606; PARSONNET J, 1988, J CLIN MICROBIOL, V26, P948, DOI 10.1128/JCM.26.5.948-949.1988; RAUWS EA, 1988, GASTROENTEROLOGY, V94, P33, DOI 10.1016/0016-5085(88)90606-3; SEPPALA K, 1993, NOV HEL PYL BAS MECH; SIPPONEN P, 1990, SCAND J GASTROENTERO, V25, P193, DOI 10.1080/00365521.1990.12067090; TYTGAT GNJ, 1990, GASTROENTEROL CLIN N, V19, P183	17	292	295	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 19	1995	332	3					139	142		10.1056/NEJM199501193320302	http://dx.doi.org/10.1056/NEJM199501193320302			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB160	7800005				2022-12-28	WOS:A1995QB16000002
J	DAVIDSON, RJ				DAVIDSON, RJ			THE COMMUNITY - WHERE REFORM ROLLS ON	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											DAVIDSON, RJ (corresponding author), AMER HOSP ASSOC,325 7TH ST SW,WASHINGTON,DC 20004, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					255	255						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QB234	7807677				2022-12-28	WOS:A1995QB23400042
J	APPELGREN, P; RANSJO, U; BINDSLEV, L; LARM, O				APPELGREN, P; RANSJO, U; BINDSLEV, L; LARM, O			DOES SURFACE HEPARINIZATION REDUCE BACTERIAL-COLONIZATION OF CENTRAL VENOUS CATHETERS	LANCET			English	Letter							BINDING		KAROLINSKA SJUKHUSET,DEPT CLIN MICROBIOL,STOCKHOLM,SWEDEN; KAROLINSKA SJUKHUSET,DEPT ANESTHESIOL,STOCKHOLM,SWEDEN; MEDICARB AB,BROMMA,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	APPELGREN, P (corresponding author), KAROLINSKA SJUKHUSET,DEPT INTERNAL MED,INFECT DIS UNIT,S-17176 STOCKHOLM,SWEDEN.							ARNANDER C, 1987, BIOMATERIALS, V8, P496, DOI 10.1016/0142-9612(87)90088-3; BINDSLEV L, 1987, ANESTHESIOLOGY, V67, P117, DOI 10.1097/00000542-198707000-00024; GOLDMANN DA, 1993, CLIN MICROBIOL REV, V6, P176, DOI 10.1128/CMR.6.2.176-192.1993; LARM O, 1983, BIOMATER ARTIF CELL, V11, P161, DOI 10.3109/10731198309118804; NILSSON UR, 1993, SCAND J IMMUNOL, V37, P349, DOI 10.1111/j.1365-3083.1993.tb02564.x	5	16	16	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					130	130		10.1016/S0140-6736(95)90097-7	http://dx.doi.org/10.1016/S0140-6736(95)90097-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815870				2022-12-28	WOS:A1995QB80400048
J	WETTERVIK, C; CLAES, G; DROTT, C; EMANUELSSON, H; LOMSKY, M; RADBERG, G; TYGESEN, H				WETTERVIK, C; CLAES, G; DROTT, C; EMANUELSSON, H; LOMSKY, M; RADBERG, G; TYGESEN, H			ENDOSCOPIC TRANSTHORACIC SYMPATHICOTOMY FOR SEVERE ANGINA	LANCET			English	Note							SYMPATHETIC CHAIN; PAIN	We evaluated the antianginal effects of endoscopic transthoracic sympathicotomy (ETS) in 24 patients not eligible for coronary bypass surgery or angioplasty. In this procedure, the sympathetic chain is electrocoagulated under general anaesthesia. No major surgical complications occurred. The frequency of anginal attacks was significantly reduced (p=0.001). The mean increase in maximum exercise capacity was 13 (SD 21) W (p=0.009). ST depression at maximum comparable workload was reduced by 0.052 (0.10) mV (p=0.005). Global ejection fraction during exercise and metaiodobenzylguanidine uptake were unchanged. Heart rate variability analysis showed a reduction of the ratio between low and high frequencies at tilt test (-1.00 [0.96]; p<0.001). We conclude that ETS can be done without major complications, alleviates angina, and increases maximum working capacity in patients with advanced coronary disease.	SAHLGRENS UNIV HOSP,DIV CARDIOL,S-41345 GOTHENBURG,SWEDEN; SAHLGRENS UNIV HOSP,DIV CLIN PHYSIOL,S-41345 GOTHENBURG,SWEDEN; SAHLGRENS UNIV HOSP,DIV THORAC SURG,S-41345 GOTHENBURG,SWEDEN; BORAS CTY HOSP,DEPT MED,BORAS,SWEDEN; BORAS CTY HOSP,DEPT SURG,BORAS,SWEDEN	Sahlgrenska University Hospital; Sahlgrenska University Hospital; Sahlgrenska University Hospital								AKSELROD S, 1985, AM J PHYSIOL, V249, pH867, DOI 10.1152/ajpheart.1985.249.4.H867; BLOMBERG S, 1989, ANESTH ANALG, V69, P558; BLOMBERG S, 1990, ANESTHESIOLOGY, V74, P840; CLAES G, 1991, BRIT J SURG, V78, P760, DOI 10.1002/bjs.1800780634; DROTT C, 1993, ARCH SURG-CHICAGO, V128, P237; FAGRET D, 1993, J NUCL MED, V34, P57; KOCK M, 1992, ANESTH ANALG, V71, P625; LINDGREN I, 1950, ACTA MED SCAND, P1; MASERI A, 1992, PROG CARDIOVASC DIS, V35, P1, DOI 10.1016/0033-0620(92)90031-T; TOFT P, 1987, INTENS CARE MED, V13, P388	10	51	55	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					97	98		10.1016/S0140-6736(95)90065-9	http://dx.doi.org/10.1016/S0140-6736(95)90065-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815891				2022-12-28	WOS:A1995QB80400012
J	EILERS, J; AUGUSTINE, GJ; KONNERTH, A				EILERS, J; AUGUSTINE, GJ; KONNERTH, A			SUBTHRESHOLD SYNAPTIC CA2+ SIGNALING IN FINE DENDRITES AND SPINES OF CEREBELLAR PURKINJE NEURONS	NATURE			English	Article							GLUTAMATE-RECEPTOR CHANNELS; CENTRAL-NERVOUS-SYSTEM; CALCIUM TRANSIENTS; CELLS; CURRENTS; INVITRO; ACTIVATION; SLICES	THE conventional view of synaptic integration is that it results from the simple summation of electrical signals produced by each active synapse innervating a given neuron(1). However, because synaptic action can go beyond the production of postsynaptic electrical signals, to include intracellular biochemical events such as the generation of second messengers, it is possible that synaptic integration could occur at another level(2). We have considered this possibility by examining changes in the dendritic concentration of the second messenger, calcium, resulting from subthreshold excitatory synaptic activity in cerebellar Purkinje neurons. We report here clear evidence that such non-electrical synaptic integration occurs and that it takes place in restricted dendritic compartments consisting of spines and adjacent fine dendrites.	UNIV SAARLAND,INST PHYSIOL 1,D-66421 HOMBURG,GERMANY; DUKE UNIV,MED CTR,DEPT NEUROBIOL,DURHAM,NC 27710	Saarland University; Duke University			Augustine, George James/J-9228-2013; Eilers, Jens/E-6251-2012	Eilers, Jens/0000-0003-0497-5625				ALFORD S, 1993, J PHYSIOL-LONDON, V469, P693, DOI 10.1113/jphysiol.1993.sp019838; BARBOUR B, 1993, NEURON, V11, P759, DOI 10.1016/0896-6273(93)90085-6; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; ECCLES JC, 1964, PHYSL SYNAPSES, V4, P101; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; Eilers Jens, 1995, P213; HILLMAN D, 1991, P NATL ACAD SCI USA, V88, P7076, DOI 10.1073/pnas.88.16.7076; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; Ito M, 1991, Curr Opin Neurobiol, V1, P616, DOI 10.1016/S0959-4388(05)80038-8; ITO M, 1984, CEREBELLUM NEURAL CO, P36; KANO M, 1992, NATURE, V356, P601, DOI 10.1038/356601a0; KONNERTH A, 1992, P NATL ACAD SCI USA, V89, P7051, DOI 10.1073/pnas.89.15.7051; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; LLINAS R, 1976, P NATL ACAD SCI USA, V73, P2520, DOI 10.1073/pnas.73.7.2520; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P197, DOI 10.1113/jphysiol.1980.sp013358; LLINAS RR, 1990, SYNAPTIC ORG BRAIN, P214; MIDTGAARD J, 1993, J NEUROPHYSIOL, V70, P2455, DOI 10.1152/jn.1993.70.6.2455; MIYAKAWA H, 1992, J NEUROPHYSIOL, V68, P1178, DOI 10.1152/jn.1992.68.4.1178; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; MURPHY TH, 1994, SCIENCE, V263, P529, DOI 10.1126/science.7904774; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; PALAY SL, 1974, CEREBELLAR CORTEX, P79; ROSS WN, 1987, J PHYSIOL-LONDON, V389, P319, DOI 10.1113/jphysiol.1987.sp016659; SCHNEGGENBURGER R, 1993, NEURON, V11, P133, DOI 10.1016/0896-6273(93)90277-X; SUGIMORI M, 1990, P NATL ACAD SCI USA, V87, P5084, DOI 10.1073/pnas.87.13.5084; TANK DW, 1988, SCIENCE, V242, P773, DOI 10.1126/science.2847315; USOWICZ MM, 1992, NEURON, V9, P1185, DOI 10.1016/0896-6273(92)90076-P	29	235	239	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					155	158		10.1038/373155a0	http://dx.doi.org/10.1038/373155a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7816097				2022-12-28	WOS:A1995QB06300060
J	CHEN, GH; HOFFMAN, AS				CHEN, GH; HOFFMAN, AS			GRAFT-COPOLYMERS THAT EXHIBIT TEMPERATURE-INDUCED PHASE-TRANSITIONS OVER A WIDE-RANGE OF PH	NATURE			English	Article							DRUG DELIVERY; POLYMERS; HYDROGELS; NETWORKS; RELEASE; GELS; ACID	THERE are many potential applications of 'intelligent' aqueous polymer systems(1-8) in medicine, biotechnology, industry and in environmental problems(9-13). Many of these polymer systems undergo reversible phase transitions-for example, abrupt changes in volume-in response to external stimuli such as temperature, pH or the nature of the solvent. Most of the polymers studied previously are responsive to only one kind of stimulus. But for some applications, independent responsiveness to several factors, such as temperature and pH, may be required. Here we describe a polymer that undergoes marked solubility changes in water in response to temperature and/or pH changes, The polymer is prepared by grafting temperature-sensitive side chains onto a pH-sensitive backbone, We also find that block copolymers, in which the temperature- and pH-sensitive units alternate along the chain, show similar behaviour.	UNIV WASHINGTON,CTR BIOENGN,SEATTLE,WA 98195	University of Washington; University of Washington Seattle								BAE YH, 1988, MAKROMOL CHEM-RAPID, V9, P185; CHEN GH, 1993, BIOCONJUGATE CHEM, V4, P509, DOI 10.1021/bc00024a013; DONG LC, 1990, J CONTROL RELEASE, V13, P21, DOI 10.1016/0168-3659(90)90071-Z; DONG LC, 1991, J CONTROL RELEASE, V15, P141, DOI 10.1016/0168-3659(91)90072-L; Dusek K., 1993, RESPONSIVE GELS VOLU, VII; FREITAS RFS, 1987, CHEM ENG SCI, V42, P97, DOI 10.1016/0009-2509(87)80213-0; Heskins M., 1968, J MACROMOL SCI CHEM, V2, P1441, DOI DOI 10.1080/10601326808051910; HOFFMAN A S, 1987, Journal of Controlled Release, V6, P297, DOI 10.1016/0168-3659(87)90083-6; HOFFMAN AS, 1991, MRS BULL, V16, P42, DOI 10.1557/S0883769400056049; KATONO H, 1991, J CONTROL RELEASE, V16, P215, DOI 10.1016/0168-3659(91)90045-F; KISHI R, 1991, POLYMER GELS, P205; KLIER J, 1990, MACROMOLECULES, V23, P4944, DOI 10.1021/ma00225a011; KUNGWATCHAKUN D, 1988, MAKROMOL CHEM-RAPID, V9, P243; MONJI N, 1987, APPL BIOCHEM BIOTECH, V14, P107, DOI 10.1007/BF02798429; OKANO T, 1990, J CONTROL RELEASE, V11, P255, DOI 10.1016/0168-3659(90)90138-J; PARK TG, 1993, MACROMOLECULES, V26, P5045, DOI 10.1021/ma00071a010; PRIEST JH, 1987, ACS SYM SER, V350, P255; SUZUKI M, 1991, POLYMER GELS, P221; TANAKA T, 1979, POLYMER, V20, P1404, DOI 10.1016/0032-3861(79)90281-7; TAYLOR LD, 1970, J POLYM SCI A, V8, P3405	20	1162	1244	9	332	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 5	1995	373	6509					49	52		10.1038/373049a0	http://dx.doi.org/10.1038/373049a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800038				2022-12-28	WOS:A1995QA23900050
J	OLESEN, F; JOLLEYS, JV				OLESEN, F; JOLLEYS, JV			OUT-OF-HOURS SERVICE - THE DANISH SOLUTION EXAMINED	BRITISH MEDICAL JOURNAL			English	Article								In Denmark the provision of out of hours care by general practitioners came under increasing pressure in the 1980s because of growing demand for services by the public and increasing complaints from rural doctors about their heavy workload and disproportionately low remuneration in comparison with urban doctors. As a result, the out of hours service was reformed at the start of 1992: locally negotiated rota systems were replaced with county based services. Each county now has a coordination centre, where all patients' calls are received by a team of doctors. The doctors may give a telephone consultation, advise the patient to attend one of the emergency clinics strategically placed about the county, or arrange for a home visit. Doctors on home visiting duty are located at bases throughout the county and keep in touch with the coordination centre with mobile telephones. Graded fees mean that doctors are encouraged to give telephone consultations rather than arrange for clinic consultations or home visits. The reforms have reduced doctors' out of hours workload and the number of home visits made and have proved acceptable to patients, doctors, and administrators.	AARHUS UNIV,INST FAMILY MED,GEN PRACTICE RES UNIT,AARHUS,DENMARK; UNIV NOTTINGHAM,SCH MED,DEPT GEN PRACTICE,NOTTINGHAM,ENGLAND	Aarhus University; University of Nottingham								HALLAM L, 1994, BRIT MED J, V308, P249, DOI 10.1136/bmj.308.6923.249; WARDEN J, 1993, BRIT MED J, V307, P1234; WHITEHEAD M, 1994, BRIT MED J, V308, P1284, DOI 10.1136/bmj.308.6939.1284; 1994, NATIONAL HLTH INSURA; 1992, PATIENTERS OPLEVELSE; 1994, BRIT MED J, V308, P1387; 1994, UGESKRIFT LAEGER, V156, P1676	7	58	58	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1624	1626		10.1136/bmj.309.6969.1624	http://dx.doi.org/10.1136/bmj.309.6969.1624			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819945	Green Published			2022-12-28	WOS:A1994PY22000027
J	BAGGALEY, R; GODFREYFAUSSETT, P; MSISKA, R; CHILANGWA, D; CHITU, E; PORTER, J; KELLY, M				BAGGALEY, R; GODFREYFAUSSETT, P; MSISKA, R; CHILANGWA, D; CHITU, E; PORTER, J; KELLY, M			IMPACT OF HIV-INFECTION ON ZAMBIAN BUSINESSES	BRITISH MEDICAL JOURNAL			English	Article									MINIST HLTH,NATL AIDS CONTROL PROGRAMME,LUSAKA,ZAMBIA; UNIV LUSAKA,TEACHING HOSP,DEPT MED,ZAMBART PROJECT,LUSAKA,ZAMBIA; LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	BAGGALEY, R (corresponding author), KARA COUNSELLING & TRAINING TRUST,POB 37559,LUSAKA,ZAMBIA.							BUVE A, IN PRESS AIDS; ELLIOTT AM, 1990, BRIT MED J, V301, P412, DOI 10.1136/bmj.301.6749.412; MURRAY CJL, 1992, HLTH ADULTS DEV WORL, P23; NKOWANE BM, 1991, AIDS, V5, pS7; PIOT P, 1992, AIDS AFRICA MANUAL P	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 10	1994	309	6968					1549	1550		10.1136/bmj.309.6968.1549	http://dx.doi.org/10.1136/bmj.309.6968.1549			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX564	7819895	Green Published			2022-12-28	WOS:A1994PX56400021
J	WALD, N; LAW, M; MEADE, T; MILLER, G; ALBERMAN, E; DICKINSON, J				WALD, N; LAW, M; MEADE, T; MILLER, G; ALBERMAN, E; DICKINSON, J			USE OF PERSONAL MEDICAL RECORDS FOR RESEARCH PURPOSES	BRITISH MEDICAL JOURNAL			English	Article							ALPHA-FETOPROTEIN MEASUREMENT	The established practice of doctors using medical records for research purposes is threatened by the recent proposed guidelines from the Department of Health, the BMA, and the European Commission. The European Commission has explicit consent should be obtained patient before his or her medical records can be used; the proposals from the Department of Health and the BMA would require all research that needs access to personal medical records to be submitted to an ethics committee. We believe that these proposals would seriously impair an entire category of research and suggest therefore that another set of guidelines, proposed by a Royal College of Physicians' working group, should be used to modify the proposals. The guidelines of the working group encourage the use of medical records for research and ensure that such use can be made in a confidential manner without causing harm.			WALD, N (corresponding author), UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,WOLFSON INST PREVENT MED,LONDON EC1M 6BQ,ENGLAND.		Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					BEALES D, 1994, BRIT MED J, V309, P360, DOI 10.1136/bmj.309.6951.360a; BERAL V, 1980, BRIT MED J, V281, P1098, DOI 10.1136/bmj.281.6248.1098; BROWN WMC, 1965, BRIT MED J, V2, P1327, DOI 10.1136/bmj.2.5474.1327; BROWN WMC, 1957, LEUKAEMIA APLASTIC A; CUCKLE HS, 1984, LANCET, V1, P926; FIRTH HV, 1994, LANCET, V343, P1069, DOI 10.1016/S0140-6736(94)90182-1; VESSEY MP, 1968, BMJ-BRIT MED J, V2, P199, DOI 10.1136/bmj.2.5599.199; WALD NJ, 1974, LANCET, V1, P765; WALD NJ, 1983, LANCET, V2, P246; 1994, J R COLL PHYSICIANS, V28, P439; 1994, CONSULTATION DOCUMEN	11	28	28	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1994	309	6966					1422	1424		10.1136/bmj.309.6966.1422	http://dx.doi.org/10.1136/bmj.309.6966.1422			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7819855	Green Published			2022-12-28	WOS:A1994PU76400030
J	GALLERANI, M; MANFREDINI, R; CARACCIOLO, S; SCAPOLI, C; MOLINARI, S; FERSINI, C				GALLERANI, M; MANFREDINI, R; CARACCIOLO, S; SCAPOLI, C; MOLINARI, S; FERSINI, C			SERUM-CHOLESTEROL CONCENTRATIONS IN PARASUICIDE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PLASMA-CHOLESTEROL; PRIMARY PREVENTION; TERM MORTALITY; LOWERING DRUGS; MEN; TRIGLYCERIDES; POPULATION; AGGRESSION; SEROTONIN; VIOLENCE	Objective-To evaluate whether people who have committed parasuicide have low serum cholesterol concentrations. Design-Results of blood tests in subjects admitted to hospital for parasuicide compared with those of a control group of non-suicidal subjects; comparison in subgroup of parasuicide subjects of two sets of blood test results (one set from admission for parasuicide and the other from admission for some other illness). Setting-General hospital, Ferrara, Italy. Subjects-331 parasuicide subjects aged 44 (SD 21) years (109 with two sets of blood test results) and 331 controls. Main outcome measures-Serum cholesterol concentrations and possible association with parasuicide, considering sex, violence of method of parasuicide, and underlying psychiatric disorder. Results-Lower serum cholesterol concentrations (4.96 (SD 1.16) mmol/l) were found in the parasuicide subjects than in the controls (5.43 (1.30); P<0.001), regardless of sex and degree of violence of parasuicide method. Both men and women with two sets of blood test results had lower cholesterol concentrations after parsuicide. Linear regression analysis showed that the difference in cholesterol concentrations was significantly related to the length of time between the taking of the two sets of blood samples. Conclusion-The study showed low cholesterol concentrations after parasuicide. This finding agrees with previous studies, which suggest an association between low cholesterol concentration and suicide.	UNIV FERRARA, SCH MED, INST INTERNAL MED 1, FERRARA, ITALY; UNIV FERRARA, SCH MED, DEPT PSYCHOL, FERRARA, ITALY; UNIV FERRARA, DEPT BIOL, FERRARA, ITALY	University of Ferrara; University of Ferrara; University of Ferrara	GALLERANI, M (corresponding author), ST ANNA HOSP, DEPT EMERGENCY, CORSO GIOVECCA 203, I-44100 FERRARA, ITALY.		Scapoli, Chiara/E-2268-2015; Scapoli, Chiara/N-3372-2019; Manfredini, Roberto/A-3471-2008; Manfredini, Roberto/N-3859-2019; Manfredini, Roberto/AAJ-5442-2020	Scapoli, Chiara/0000-0003-4058-4787; Scapoli, Chiara/0000-0003-4058-4787; Manfredini, Roberto/0000-0002-8364-2601; Manfredini, Roberto/0000-0002-8364-2601; 				ALLAIN CC, 1974, CLIN CHEM, V20, P470; BOTTIGER LE, 1972, BRIT MED J, V32, P87; Brown G L, 1986, Ann N Y Acad Sci, V487, P175, DOI 10.1111/j.1749-6632.1986.tb27897.x; BROWN SL, 1994, BRIT MED J, V308, P1328, DOI 10.1136/bmj.308.6940.1328; CARLSON LA, 1985, ACTA CHIR SCAND, P87; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; COCCARO EF, 1989, BRIT J PSYCHIAT, V155, P52, DOI 10.1192/S0007125000291769; CUMMINGS P, 1994, ANN INTERN MED, V120, P848, DOI 10.7326/0003-4819-120-10-199405150-00006; ENGELBERG H, 1992, LANCET, V339, P727, DOI 10.1016/0140-6736(92)90609-7; FOWKES FGR, 1992, LANCET, V340, P995, DOI 10.1016/0140-6736(92)93009-C; HORROBIN DF, 1989, BRIT J PSYCHIAT, V154, P882, DOI 10.1192/bjp.154.6.882b; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; LINDBERG G, 1992, BRIT MED J, V305, P277, DOI 10.1136/bmj.305.6848.277; LINNOILA M, 1983, LIFE SCI, V33, P2609, DOI 10.1016/0024-3205(83)90344-2; MELTZER H, 1989, BRIT J PSYCHIAT, V155, P25, DOI 10.1192/S0007125000291733; MORGAN RE, 1993, LANCET, V341, P75, DOI 10.1016/0140-6736(93)92556-9; MULDOON MF, 1992, ARCH INTERN MED, V152, P775, DOI 10.1001/archinte.152.4.775; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; OLIVER MF, 1988, J AM COLL CARDIOL, V12, P814, DOI 10.1016/0735-1097(88)90327-0; PEKKANEN J, 1989, ARCH INTERN MED, V149, P1589, DOI 10.1001/archinte.149.7.1589; PLATT S, 1992, ACTA PSYCHIAT SCAND, V85, P97, DOI 10.1111/j.1600-0447.1992.tb01451.x; ROY A, 1988, ACTA PSYCHIAT SCAND, V78, P529, DOI 10.1111/j.1600-0447.1988.tb06380.x; RYDER REJ, 1984, BRIT MED J, V289, P1651, DOI 10.1136/bmj.289.6459.1651; SAMPSON EJ, 1975, CLIN CHEM, V21, P1983; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; STRANDBERG TE, 1991, JAMA-J AM MED ASSOC, V266, P1225, DOI 10.1001/jama.266.9.1225; VARTIAINEN E, 1994, BRIT MED J, V309, P445, DOI 10.1136/bmj.309.6952.445; VIRKKUNEN M, 1979, NEUROPSYCHOBIOLOGY, V5, P27, DOI 10.1159/000117660; VIRKKUNEN M, 1989, ARCH GEN PSYCHIAT, V46, P604; WYSOWSKI DK, 1990, ARCH INTERN MED, V150, P2169, DOI 10.1001/archinte.150.10.2169	31	67	67	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 24	1995	310	6995					1632	1636		10.1136/bmj.310.6995.1632	http://dx.doi.org/10.1136/bmj.310.6995.1632			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF698	7795448	Green Published			2022-12-28	WOS:A1995RF69800018
J	EBERT, DA; HECKERLING, PS				EBERT, DA; HECKERLING, PS			COMMUNICATION WITH DEAF PATIENTS - KNOWLEDGE, BELIEFS, AND PRACTICES OF PHYSICIANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							SERVICES	Objective.-To assess physicians' knowledge and beliefs regarding communication with deaf people and compare their knowledge and beliefs with their methods of communicating with deaf patients in their practices. Design.-Survey. Setting.-University medical center. Subjects.-Attending physicians in an internal medicine department. Interventions.-Physicians were surveyed regarding prior contacts with deaf patients and with deaf people outside the medical setting, and regarding their knowledge and beliefs concerning methods of communicating with deaf people. Physicians were asked to estimate the fraction of encounters in which they communicated with deaf patients by lipreading, writing, translation by a relative or friend, a sign language interpreter, or other methods. Results.-Writing was the method used most frequently in communicating with deaf patients. Although 63% of physicians knew that signing should be the initial method of communicating with deaf patients who sign, only 22% used sign language interpreters more frequently than other methods in their practices. Past contact with deaf people (P=.05), belief that communication by signing was the best means of communication (P=.04), and knowledge of the inefficiency of lipreading (P=.04) were predictors of the use of sign language interpreters for deaf patients. Physicians who used sign language interpreters more frequently than other methods believed that much more time and effort were involved in caring for deaf than for hearing patients compared with those who used interpreters less frequently (P=.08). Conclusion.-Although most physicians believed that use of sign language interpreters was preferable, only a minority used them in their practices. Greater recognition of the advantages of signing over other methods and greater availability of sign language interpreters should read to more effective communication between deaf patients and physicians.			EBERT, DA (corresponding author), UNIV ILLINOIS,DEPT MED,GEN INTERNAL MED SECT,M-C 787,840 S WOOD ST,CHICAGO,IL 60612, USA.							DAVENPORT SLH, 1977, J FAM PRACTICE, V4, P1065; DIPIETRO LJ, 1981, AM ANN DEAF, V126, P106, DOI 10.1353/aad.2012.1505; ENGELMAN L, 1988, BMDP STATISTICAL SOF, P941; GOLDEN P, 1978, HOSPITALS, V52, P86; HAFFNER L, 1992, WESTERN J MED, V157, P255; KLINE F, 1980, AM J PSYCHIAT, V137, P1530; LASS LG, 1978, AM ANN DEAF, V123, P960; MCENTEE MK, 1993, AM ANN DEAF, V138, P26, DOI 10.1353/aad.2012.0569; MCEWEN E, 1988, J FAM PRACTICE, V26, P289; MINDEL ED, 1971, THEY GROW SILENCE, P96; REISMAN G, 1977, JAMA-J AM MED ASSOC, V237, P2397; SCHEIN JD, 1980, DEAF AM, V32, P5; VERNON M, 1970, REHABIL LIT, V31, P258; WARNER HC, 1986, AM ANN DEAF, V131, P365, DOI 10.1353/aad.2012.1033	14	76	76	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					227	229						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QB234	7807662				2022-12-28	WOS:A1995QB23400027
J	COPI, CJ; SCHRAMM, DN; TURNER, MS				COPI, CJ; SCHRAMM, DN; TURNER, MS			BIG-BANG NUCLEOSYNTHESIS AND THE BARYON DENSITY OF THE UNIVERSE	SCIENCE			English	Article							METAL-DEFICIENT DWARFS; PRIMORDIAL NUCLEOSYNTHESIS; DARK-MATTER; GALACTIC HALO; IRAS GALAXIES; STARS; ABUNDANCES; BERYLLIUM; LITHIUM; ORIGIN	For almost 30 years, the predictions of big-bang nucleosynthesis have been used to test the big-bang model to within a fraction of a second of the bang. The agreement between the predicted and observed abundances of deuterium, helium-3, helium-4, and lithium-7 confirms the standard cosmology model and allows accurate determination of the baryon density, between 1.7 x 10(-31) and 4.1 x 10(-31) grams per cubic centimeter (corresponding to about 1 to 15 percent of the critical density). This measurement of the density of ordinary matter is pivotal to the establishment of two dark-matter problems: (i) most of the baryons are dark, and (ii) if the total mass density is greater than about 15 percent of the critical density, as many determinations indicate, the bulk of the dark matter must be ''nonbaryonic,'' composed of elementary particles left from the earliest moments.	FERMILAB NATL ACCELERATOR LAB, NASA, FERMILAB ASTROPHYS CTR, BATAVIA, IL 60510 USA; UNIV CHICAGO, ENRICO FERMI INST, DEPT ASTRON & ASTROPHYS, CHICAGO, IL 60637 USA	National Aeronautics & Space Administration (NASA); United States Department of Energy (DOE); University of Chicago; Fermi National Accelerator Laboratory; University of Chicago	COPI, CJ (corresponding author), UNIV CHICAGO, DEPT PHYS, CHICAGO, IL 60637 USA.							ALCOCK C, 1993, NATURE, V365, P621, DOI 10.1038/365621a0; ALPHER RA, 1949, PHYS REV, V75, P1089, DOI 10.1103/PhysRev.75.1089; ALPHER RA, 1948, PHYS REV, V73, P803, DOI 10.1103/PhysRev.73.803; APPLEGATE JH, 1988, ASTROPHYS J, V329, P572, DOI 10.1086/166404; AUBOURG E, 1993, NATURE, V365, P623, DOI 10.1038/365623a0; BALSER DS, 1994, 1994 P ESO M LIGHT E; BLACK DC, 1972, GEOCHIM COSMOCHIM AC, V36, P347, DOI 10.1016/0016-7037(72)90028-2; BOYD RN, 1989, ASTROPHYS J, V336, pL55, DOI 10.1086/185360; BRUNE CR, 1994, PHYS REV C, V50, P2205, DOI 10.1103/PhysRevC.50.2205; CARSWELL RF, 1994, MON NOT R ASTRON SOC, V268, pL1, DOI 10.1093/mnras/268.1.L1; CARSWELL RF, COMMUNICATION; CHARBONNEL C, 1992, ASTRON ASTROPHYS, V265, P55; DAVIDSON K, 1985, ASTROPHYS J SUPPL S, V58, P321, DOI 10.1086/191044; DEARBORN DSP, 1986, ASTROPHYS J, V302, P35, DOI 10.1086/163969; DEKEL A, 1994, ANNU REV ASTRON ASTR, V32, P371; DODELSON S, 1994, PHYS REV D, V49, P5068, DOI 10.1103/PhysRevD.49.5068; DUNCAN DK, 1992, ASTROPHYS J, V401, P584, DOI 10.1086/172088; EDVARDSSON B, 1989, GEOCHIM COSMOCHIM AC, V53, P197; EPSTEIN RI, 1976, NATURE, V263, P198, DOI 10.1038/263198a0; FABER SM, 1979, ANNU REV ASTRON ASTR, V17, P135, DOI 10.1146/annurev.aa.17.090179.001031; FOWLER WA, 1962, GEOPHYS J ROY ASTR S, V6, P148, DOI 10.1111/j.1365-246X.1962.tb02977.x; GAMOW G, 1946, PHYS REV, V70, P527; GEISS J, 1972, ASTRON ASTROPHYS, V18, P126; Geiss J., 1993, ORIGIN EVOLUTION ELE, V89; GILMORE G, 1992, NATURE, V357, P379, DOI 10.1038/357379a0; GILMORE G, 1991, ASTROPHYS J, V378, P17, DOI 10.1086/170402; HOBBS LM, 1994, ASTROPHYS J, V428, pL25, DOI 10.1086/187384; HOBBS LM, 1988, ASTROPHYS J, V326, pL23, DOI 10.1086/185115; HOYLE F, 1964, NATURE, V203, P1108, DOI 10.1038/2031108a0; IBEN I, 1978, ASTROPHYS J, V220, P980, DOI 10.1086/155986; JAKOBSEN P, 1994, NATURE, V370, P35, DOI 10.1038/370035a0; JEDAMZIK K, 1994, ASTROPHYS J, V422, P423, DOI 10.1086/173738; KAISER N, 1991, MON NOT R ASTRON SOC, V252, P1; KAWASAKI M, 1994, NUCL PHYS B, V419, P105, DOI 10.1016/0550-3213(94)90359-X; KERNAN PJ, 1994, PHYS REV LETT, V72, P3309, DOI 10.1103/PhysRevLett.72.3309; Kurki-Suonio H., 1990, Astrophysical Journal, V353, P406, DOI 10.1086/168626; LIDDLE AR, 1993, PHYS REP, V231, P1, DOI 10.1016/0370-1573(93)90114-S; LINSKY JL, 1993, ASTROPHYS J, V402, P694, DOI 10.1086/172170; MALANEY RA, 1993, PHYS REP, V229, P147; MAMPE W, 1993, JETP LETT+, V57, P82; MATHER JC, 1994, ASTROPHYS J, V420, P439, DOI 10.1086/173574; MONTANET L, 1994, PHYS REV D, V50, P1680; OLIVE KA, IN PRESS ASTROPHYS S; OSTRIKER JP, 1993, ANNU REV ASTRON ASTR, V31, P689; PAGEL BEJ, 1992, MON NOT R ASTRON SOC, V255, P325, DOI 10.1093/mnras/255.2.325; PEEBLES PJE, 1966, ASTROPHYS J, V146, P542, DOI 10.1086/148918; PINSONNEAULT MH, 1992, ASTROPHYS J SUPPL S, V78, P179, DOI 10.1086/191624; PISONNEAULT MH, 1992, ASTROPHYS J SUPL SER, V78, P179; REBOLO R, 1988, ASTRON ASTROPHYS, V193, P193; REBOLO R, 1988, ASTRON ASTROPHYS, V192, P192; REEVES H, 1970, NATURE, V226, P727, DOI 10.1038/226727a0; REEVES H, 1973, ASTROPHYS J, V179, P909, DOI 10.1086/151928; REIMERS D, 1993, ASTRON ASTROPHYS, V276, pL13; ROGERSON JB, 1973, ASTROPHYS J, V186, pL95, DOI 10.1086/181366; RYAN SG, 1990, ASTROPHYS J, V348, pL57, DOI 10.1086/185630; RYAN SG, 1992, ASTROPHYS J, V388, P184, DOI 10.1086/171141; SASSELOV D, IN PRESS ASTROPHYS J; SATO K, 1991, PHYS SCR TOP ISSUES, V136, P60; SKILLMAN ED, 1993, ASTROPHYS J, V411, P655, DOI 10.1086/172868; SKILLMAN ED, 1993, ANN NY ACAD SCI, V688, P739, DOI 10.1111/j.1749-6632.1993.tb43965.x; SKILLMAN ED, IN PRESS ASTROPHYS J; SKILLMAN ED, IN PRESS; SMITH MS, 1993, ASTROPHYS J SUPPL S, V85, P219, DOI 10.1086/191763; SMITH PF, 1990, PHYS REP, V187, P203, DOI 10.1016/0370-1573(90)90081-C; SMITH VV, 1993, ASTROPHYS J, V408, P262, DOI 10.1086/172585; SONGAILA A, 1994, NATURE, V368, P599, DOI 10.1038/368599a0; SPITE F, 1982, ASTRON ASTROPHYS, V115, P357; SPITE M, 1984, ASTRON ASTROPHYS, V141, P56; STEIGMAN G, 1994, MON NOT R ASTRON SOC, V269, pL53, DOI 10.1093/mnras/269.1.L53; STEIGMAN G, 1993, ASTROPHYS J, V415, pL35, DOI 10.1086/187026; STEIGMAN G, 1977, PHYS LETT B, V66, P202, DOI 10.1016/0370-2693(77)90176-9; STRAUSS MA, 1992, ASTROPHYS J, V397, P395, DOI 10.1086/171796; THOMAS D, 1993, ASTROPHYS J, V406, P569, DOI 10.1086/172469; TURNER MS, 1993, P NATL ACAD SCI USA, V90, P4827, DOI 10.1073/pnas.90.11.4827; TYTLER D, COMMUNICATION; UDALSKI A, 1993, ACTA ASTRONOM, V43, P289; VANGIONIFLAM E, 1994, ASTROPHYS J, V427, P618, DOI 10.1086/174171; WAGONER RV, 1967, ASTROPHYS J, V148, P3, DOI 10.1086/149126; WALKER TP, 1991, ASTROPHYS J, V376, P51, DOI 10.1086/170255; WHITE SDM, 1993, NATURE, V366, P429, DOI 10.1038/366429a0; WILSON TL, 1983, P ESO WORKSHOP PRIMO, P379; WITTEN E, 1984, PHYS REV D, V30, P272, DOI 10.1103/PhysRevD.30.272; YANG J, 1984, ASTROPHYS J, V281, P493, DOI 10.1086/162123	84	347	349	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 13	1995	267	5195					192	199		10.1126/science.7809624	http://dx.doi.org/10.1126/science.7809624			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7809624				2022-12-28	WOS:A1995QB15300023
J	MURGUIA, JR; BELLES, JM; SERRANO, R				MURGUIA, JR; BELLES, JM; SERRANO, R			A SALT-SENSITIVE 3'(2'),5'-BISPHOSPHATE NUCLEOTIDASE INVOLVED IN SULFATE ACTIVATION	SCIENCE			English	Article							FUNCTIONAL EXPRESSION; TRANSGENIC TOBACCO; TOLERANCE; LITHIUM; ION; INHIBITION; PROTEINS; GENETICS; YEAST; CROPS	Overexpression of a yeast gene, HAL2, allows the cells to tolerate higher than normal extracellular salt concentrations. HAL2 encodes a 3'(2')5'-bisphosphate nucleotidase that serves to remove the end products of sulfate transfer during cellular metabolism. The enzyme is inhibited by lithium and sodium and is activated by potassium. Metabolic systems that are sensitive to salt, as well as those governing osmolyte synthesis and ion transport, offer routes by which genetic engineering can be used to improve the tolerance of various organisms to salt.	UNIV POLITECN VALENCIA, CSIC, Inst Biol Mol & Celular Plantas, Camino Vera, E-46022 VALENCIA, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); Universitat Politecnica de Valencia; CSIC-UPV - Instituto de Biologia Molecular y Celular de Plantas (IBMCP)	SERRANO, R (corresponding author), UNIV POLITECN VALENCIA, CSIC, Inst Biol Mol & Celular Plantas, Camino Vera, E-46022 VALENCIA, SPAIN.		Bellés, José María/H-4734-2015; Murguia, Jose R./H-4419-2015	Bellés, José María/0000-0003-0362-9616; Murguia, Jose R./0000-0001-9364-4603				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BONE R, 1992, P NATL ACAD SCI USA, V89, P10031, DOI 10.1073/pnas.89.21.10031; BRUNNGRABER EG, 1958, J BIOL CHEM, V233, P472; DOWNTON WJS, 1984, CRC CR REV PLANT SCI, V1, P183, DOI 10.1080/07352688409382177; EPSTEIN E, 1980, SCIENCE, V210, P399, DOI 10.1126/science.210.4468.399; GAXIOLA R, 1992, EMBO J, V11, P3157, DOI 10.1002/j.1460-2075.1992.tb05392.x; GLASER HU, 1993, EMBO J, V12, P3105, DOI 10.1002/j.1460-2075.1993.tb05979.x; GREENWAY H, 1980, ANNU REV PLANT PHYS, V31, P149, DOI 10.1146/annurev.pp.31.060180.001053; HALLCHER LM, 1980, J BIOL CHEM, V255, P896; HEDRICH R, 1989, ANNU REV PLANT PHYS, V40, P539, DOI 10.1146/annurev.pp.40.060189.002543; INHORN RC, 1987, J BIOL CHEM, V262, P15946; JONES RGW, 1986, OUTLOOK AGR, V15, P33; JONES RGW, 1983, ENCY PLANT PHYSL, V15, pCH4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYH TS, 1993, CRIT REV BIOCHEM MOL, V28, P515, DOI 10.3109/10409239309085137; LI F, 1989, J CHROMATOGR, V461, P353, DOI 10.1016/S0021-9673(00)94302-4; MCCUE KF, 1990, TRENDS BIOTECHNOL, V8, P358, DOI 10.1016/0167-7799(90)90225-M; METZLER DE, 1977, BIOCHEMISTRY-US, P636; NAHORSKI SR, 1991, TRENDS PHARMACOL SCI, V12, P297, DOI 10.1016/0165-6147(91)90581-C; NEUWALD AF, 1991, FEBS LETT, V294, P16, DOI 10.1016/0014-5793(91)81332-3; RAMASWAMY SG, 1987, J BIOL CHEM, V262, P10044; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; SERRANO R, 1994, CRIT REV PLANT SCI, V13, P121, DOI 10.1080/713608057; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; STAPLES RC, 1984, SALINITY TOLERANCE C; TAL M, 1985, PLANT SOIL, V89, P199, DOI 10.1007/BF02182243; TARCZYNSKI MC, 1992, P NATL ACAD SCI USA, V89, P2600, DOI 10.1073/pnas.89.7.2600; TARCZYNSKI MC, 1993, SCIENCE, V259, P508, DOI 10.1126/science.259.5094.508; THOMAS D, 1992, J GEN MICROBIOL, V138, P2021, DOI 10.1099/00221287-138-10-2021; TSANG MLS, 1976, EUR J BIOCHEM, V65, P113; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; 1992, ENZYME NOMENCLATURE, P318	34	167	178	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 13	1995	267	5195					232	234						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7809627				2022-12-28	WOS:A1995QB15300033
J	LOMBILLO, VA; STEWART, RJ; MCINTOSH, JR				LOMBILLO, VA; STEWART, RJ; MCINTOSH, JR			MINUS-END-DIRECTED MOTION OF KINESIN-COATED MICROSPHERES DRIVEN BY MICROTUBULE DEPOLYMERIZATION	NATURE			English	Article							CYTOPLASMIC DYNEIN; MITOTIC SPINDLE; MOVEMENT; IDENTIFICATION; MICROSCOPY; INVITRO; PROTEIN	DYNAMIC changes in microtubule (MT) length have long been thought to contribute to intracellular motility(1). Both the polymerization(2) and depolymerization(3-5) of tubulin have been shown to do work in vitro, but the biochemical complexity of objects moved, such as chromosomes, has complicated the identification of proteins that couple MT dynamics with motility. Work with MTs grown from and tethered to pellicles of lysed Tetrahymena has shown that disassembly-dependent movement of chromosomes in vitro can be inhibited with antibodies against the motor domain of kinesin(6). To study proteins that can function in disassembly-dependent motion, we have refined this motility assay, replacing chromosomes with protein-coated latex microspheres. We report here the ability of several enzymes, including kinesin, to support in vitro motility of latex microspheres on disassembling Mts (Fig. 1a). The polarity of kinesin's motor activity can be reversed by MT disassembly and interactions between a motor and a MT end can either slow or speed the rate of tubulin depolymerization.	UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309; ROWLAND INST SCI INC,CAMBRIDGE,MA 02142	University of Colorado System; University of Colorado Boulder			McIntosh, Richard/GLN-3533-2022					COUE M, 1991, J CELL BIOL, V112, P1165, DOI 10.1083/jcb.112.6.1165; DAVIS A, 1994, SCIENCE, V264, P839, DOI 10.1126/science.8171338; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; INOUE S, 1981, J CELL BIOL, V91, pS131, DOI 10.1083/jcb.91.3.131s; KOONCE MP, 1990, CELL MOTIL CYTOSKEL, V15, P51, DOI 10.1002/cm.970150108; KOSHLAND DE, 1988, NATURE, V331, P499, DOI 10.1038/331499a0; LOMBILLO VA, IN PRESS J CELL BIOL; LOMBILLO VA, 1993, METHOD CELL BIOL, V39, P148; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; MIYAMOTO H, 1988, P TANAGUICHI INT S, V14, P220; PORTER ME, 1988, J BIOL CHEM, V263, P6759; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1989, CELL, V59, P915, DOI 10.1016/0092-8674(89)90614-4; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437	16	164	166	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					161	164		10.1038/373161a0	http://dx.doi.org/10.1038/373161a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7816099				2022-12-28	WOS:A1995QB06300062
J	RICHARDSON, RE; BOURNAS, N; MAGOS, AL				RICHARDSON, RE; BOURNAS, N; MAGOS, AL			IS LAPAROSCOPIC HYSTERECTOMY A WASTE OF TIME	LANCET			English	Article							ASSISTED VAGINAL HYSTERECTOMY; ABDOMINAL HYSTERECTOMY; STAPLER	Laparoscopic hysterectomy (LH) is a way to avoid laparotomy. However, there is evidence that most women treated by abdominal hysterectomy are suitable for vaginal surgery. To test this hypothesis, and to determine the relative merits of laparoscopic and vaginal hysterectomy (VH) and the best technique for LH, we prospectively studied 98 women who had relative contraindications for vaginal surgery by traditional criteria. 75 underwent LH and 23 VH. The LH group included 22 women who had been assigned to this route of surgery as part of a prospective randomised controlled comparison with VH (23 women). Surgery was completed with the intended technique in 93.9% of cases. 5 women in the LH group (6.7%) and 2 in the VH group required laparotomy or additional procedures. In the prospective randomised study LH took longer than VH (mean duration 131 vs 77 min). VH was the faster procedure, irrespective of uterine size and need for oophorectomy. With LH, the operative time increased as more of the hysterectomy was carried out with laparoscopic rather than vaginal dissection. Complication rates, blood loss, analgesia requirements, and recovery were similar for the two techniques. Our study confirms that most hysterectomies could be performed vaginally, and that LH is a much slower procedure. If LH is done, it should be converted to a vaginal procedure as early as possible to reduce the overall operating time. LH does seem to be a waste of time for most patients.	UNIV LONDON ROYAL FREE HOSP,DEPT OBSTET & GYNAECOL,MINAMALLY INVAS THERAPY UNIT,LONDON NW3 2QG,ENGLAND; UNIV LONDON ROYAL FREE HOSP,DEPT OBSTET & GYNAECOL,CTR ENDOSCOPY TRAINING,LONDON NW3 2QG,ENGLAND	University of London; University College London; University of London; University College London								AMSO NN, 1992, GYNAECOL ENDOSC, V1, P85; BRILL HM, 1951, AM J OBSTET GYNECOL, V62, P528, DOI 10.1016/0002-9378(51)91151-9; BROADBENT JA, 1992, CONT REV OBSTET GYNE, V4, P154; CAPEN CV, 1983, J REPROD MED, V28, P589; CLINCH J, 1994, BRIT J OBSTET GYNAEC, V101, P253, DOI 10.1111/j.1471-0528.1994.tb13121.x; COULAM CB, 1973, AM J OBSTET GYNECOL, V116, P252, DOI 10.1016/0002-9378(73)91060-0; DICKER RC, 1982, AM J OBSTET GYNECOL, V144, P841, DOI 10.1016/0002-9378(82)90362-3; GRODY MHT, 1989, J GYNECOL SURG, V5, P301, DOI 10.1089/gyn.1989.5.301; HANCOCK KW, 1993, BRIT J OBSTET GYNAEC, V100, P262, DOI 10.1111/j.1471-0528.1993.tb15240.x; Heaney NS, 1934, AM J OBSTET GYNECOL, V28, P751, DOI 10.1016/S0002-9378(34)90071-5; HOFFMAN MS, 1990, AM J OBSTET GYNECOL, V162, P1269, DOI 10.1016/0002-9378(90)90033-4; HOFFMAN MS, 1992, AM J OBSTET GYNECOL, V165, P407; JOHNS DA, 1993, ENDOSCOPIC SURG GYNE, P179; KADAR N, 1994, AM J OBSTET GYNECOL, V170, P47; KADAR N, 1993, AM J OBSTET GYNECOL, V168, P1493, DOI 10.1016/S0002-9378(11)90787-X; KOVAC SR, 1986, OBSTET GYNECOL, V67, P131; KOVAC SR, 1990, J GYNECOL SURG, V6, P185, DOI 10.1089/gyn.1990.6.185; MAGOS AL, IN PRESS MIN INVAS T; MAGOS AL, IN PRESS AM J OBSTET; MAHER P, 1994, GYNAECOL ENDOSC, V3, P129; NEZHAT C, 1990, J GYNECOL SURG, V6, P287, DOI 10.1089/gyn.1990.6.287; NEZHAT C, 1994, OBSTET GYNECOL, V83, P713; NEZHAT F, 1992, J REPROD MED, V37, P247; PHIPPS JH, 1993, BRIT J OBSTET GYNAEC, V100, P698, DOI 10.1111/j.1471-0528.1993.tb14246.x; PHIPPS JH, 1993, GYNAECOL ENDOSC, V2, P7; PRUITT AB, 1992, J S CAROLINA MED SEP, P433; REICH H, 1989, J GYNECOL SURG, V5, P213, DOI 10.1089/gyn.1989.5.213; REINER IJ, 1988, OBSTET GYNECOL, V71, P416; SAYE WB, 1993, SURG LAPAROSC ENDOSC, V3, P88; SEMM K, 1991, GEBURTSH FRAUENHEILK, V51, P996, DOI 10.1055/s-2008-1026252; STOVALL TG, 1992, OBSTET GYNECOL, V80, P145; SUMMITT RL, 1992, OBSTET GYNECOL, V80, P895; VESSEY MP, 1992, BRIT J OBSTET GYNAEC, V99, P402, DOI 10.1111/j.1471-0528.1992.tb13758.x; WOODLAND MB, 1992, AM J OBSTET GYNECOL, V167, P756, DOI 10.1016/S0002-9378(11)91584-1; WRIGHT RC, 1974, AM J OBSTET GYNECOL, V120, P759, DOI 10.1016/0002-9378(74)90578-X	35	201	206	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					36	41		10.1016/S0140-6736(95)91158-8	http://dx.doi.org/10.1016/S0140-6736(95)91158-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799707				2022-12-28	WOS:A1995QA29000016
J	SCHEFFNER, M; NUBER, U; HUIBREGTSE, JM				SCHEFFNER, M; NUBER, U; HUIBREGTSE, JM			PROTEIN UBIQUITINATION INVOLVING AN E1-E2-E3 ENZYME UBIQUITIN THIOESTER CASCADE	NATURE			English	Article							N-END RULE; ACTIVATING ENZYME; CONJUGATING ENZYME; E6 ONCOPROTEIN; P53; E6-AP; DEGRADATION; BINDING; LIGASE; YEAST	UBIQUITINATION Of proteins involves the concerted action of the El ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzymes and E3 ubiquitin-protein ligases(1-3). It has been proposed that E3s function as 'docking proteins', specifically binding substrate proteins and specific E2s, and that ubiquitin is then transferred directly from E2s to substrates(1-5). We show here that formation of a ubiquitin thioester on E6-AP, an E3 involved in the human papillomavirus EB-induced ubiquitination of p53 (refs 6-10), is an intermediate step in E6-AP-dependent ubiquitination. The order of ubiquitin transfer is from E1 to E2, from E2 to E6-AP, and finally from E6-AP to a substrate. This cascade of ubiquitin thioester complexes suggests that E3s have a defined enzymatic activity and do not function simply as docking proteins. The cysteine residue of E6-AP responsible for ubiquitin thioester formation was mapped to a region that is highly conserved among several proteins of unknown function, suggesting that these proteins share the ability to form thioesters with ubiquitin.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	SCHEFFNER, M (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM,NEUENHEIMER FELD 242,D-69120 HEIDELBERG,GERMANY.		Scheffner, Martin/K-2940-2012	Scheffner, Martin/0000-0003-2229-0128				BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BERLETH ES, 1992, J BIOL CHEM, V267, P16403; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; GIROD PA, 1993, PLANT J, V3, P545, DOI 10.1046/j.1365-313X.1993.03040545.x; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HATFIELD PM, 1992, J BIOL CHEM, V267, P14799; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V13, P4129; JENTSCH S, 1992, ANNU REV GENET, V26, P177; MULLER D, 1992, NUCLEIC ACIDS RES, V20, P1471, DOI 10.1093/nar/20.7.1471; PASCOLO S, 1992, YEAST, V8, P987, DOI 10.1002/yea.320081109; PICKART CM, 1985, J BIOL CHEM, V260, P1573; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SUNG P, 1991, J MOL BIOL, V221, P745, DOI 10.1016/0022-2836(91)80169-U; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WATKINS JF, 1993, GENE DEV, V7, P250, DOI 10.1101/gad.7.2.250	22	714	748	4	85	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 5	1995	373	6509					81	83		10.1038/373081a0	http://dx.doi.org/10.1038/373081a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800044	Green Submitted			2022-12-28	WOS:A1995QA23900061
J	COMAI, L; ZOMERDIJK, JCBM; BECKMANN, H; ZHOU, S; ADMON, A; TJIAN, R				COMAI, L; ZOMERDIJK, JCBM; BECKMANN, H; ZHOU, S; ADMON, A; TJIAN, R			RECONSTITUTION OF TRANSCRIPTION FACTOR SL1 - EXCLUSIVE BINDING OF TBP BY SL1 OR TFIID SUBUNITS	SCIENCE			English	Article							RNA POLYMERASE-I; RIBOSOMAL-RNA; DNA-BINDING; MOLECULAR-CLONING; III PROMOTERS; TATA-LESS; PROTEIN; EXPRESSION; SPECIFICITY; COMPLEX	RNA polymerase I and II transcription factors SL1 and TFIID, respectively, are composed of the TATA-binding protein (TBP) and a set of TBP-associated factors (TAFs) responsible for promoter recognition. How the universal transcription factor TBP becomes committed to a TFIID or SL1 complex has not been known. Complementary DNAs encoding each of the three TAF(I)s that are integral components of SL1 have now been isolated. Analysis of subunit interactions indicated that the three TAF(I)s can bind individually and specifically to TBP. In addition, these TAF(I)s interact with each other to form a stable TBP-TAF complex. When TBP was bound first by either TAF(I)110, 63, or 48, subunits of TFIID such as TAF(II)250 and 150 did not bind TBP. Conversely, if TBP first formed a complex with TAF(II)250 or 150, the subunits of SL1 did not bind TBP. These results suggest that a mutually exclusive binding specificity for TBP intrinsic to SL1 and TFIID subunits directs the formation of promoter- and RNA polymerase-selective TBP-TAF complexes.	UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley			Comai, Lucio/L-5905-2019; Comai, Lucio/H-9524-2019; Zomerdijk, Joost/A-5142-2008	Comai, Lucio/0000-0003-3109-1841; Admon, Arie/0000-0003-0504-3950; Zomerdijk, Joost/0000-0003-1865-729X				BECKMANN H, UNPUB; BELL SG, UNPUB; BELL SP, 1989, CELL, V59, P489, DOI 10.1016/0092-8674(89)90032-9; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; COMAI L, UNPUB; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EBERHARD D, 1993, NUCLEIC ACIDS RES, V21, P4180, DOI 10.1093/nar/21.18.4180; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JANZEN HM, 1992, GENE DEV, V6, P1950; KEYS DA, 1994, GENE DEV, V8, P2349, DOI 10.1101/gad.8.19.2349; KIM K, 1994, J BIOL CHEM, V269, P4891; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; KOKUBO T, 1993, P NATL ACAD SCI USA, V90, P5896, DOI 10.1073/pnas.90.13.5896; KOKUBO T, 1993, MOL CELL BIOL, V13, P7859, DOI 10.1128/MCB.13.12.7859; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REEDER RH, 1992, REGULATION TRANSCRIP, V1, P315; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUDLOFF U, 1994, EMBO J, V13, P2611, DOI 10.1002/j.1460-2075.1994.tb06551.x; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TANESE N, 1992, GENES DEV, V5; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	45	128	134	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 23	1994	266	5193					1966	1972		10.1126/science.7801123	http://dx.doi.org/10.1126/science.7801123			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801123				2022-12-28	WOS:A1994PZ26700023
J	BAXTER, DN				BAXTER, DN			PERTUSSIS IMMUNIZATION OF CHILDREN WITH HISTORIES OF NEUROLOGICAL PROBLEMS	BRITISH MEDICAL JOURNAL			English	Article											BAXTER, DN (corresponding author), UNIV MANCHESTER,SCH MED,SCH EPIDEMIOL & HLTH SCI,MANCHESTER M13 9PT,LANCS,ENGLAND.							BAXTER DN, 1990, PUBLIC HEALTH, V104, P267, DOI 10.1016/S0033-3506(05)80476-7; MILLER D, 1988, Tokai Journal of Experimental and Clinical Medicine, V13, P145; 1990, IMMUNIZATION INFECTI; 1987, PEDIATRICS, V80, P743	4	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1619	1619		10.1136/bmj.309.6969.1619	http://dx.doi.org/10.1136/bmj.309.6969.1619			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819939	Green Published			2022-12-28	WOS:A1994PY22000020
J	MCMURRAY, J; RANKIN, A				MCMURRAY, J; RANKIN, A			CARDIOLOGY .2. TREATMENT OF HEART-FAILURE AND ATRIAL-FIBRILLATION AND ARRHYTHMIAS	BRITISH MEDICAL JOURNAL			English	Article							IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; RADIOFREQUENCY CATHETER ABLATION; ACUTE MYOCARDIAL-INFARCTION; VENTRICULAR TACHYARRHYTHMIAS; CARDIAC-ARREST; DRUG EFFICACY; PLACEBO; TRIAL; TACHYCARDIA; METOPROLOL		UNIV GLASGOW,ROYAL INFIRM,DEPT MED CARDIOL,GLASGOW G31 2ER,LANARK,SCOTLAND	Royal Infirmary of Edinburgh; University of Glasgow	MCMURRAY, J (corresponding author), WESTERN GEN HOSP,DEPT CARDIOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		mcmurray, John/B-2467-2013	mcmurray, John/0000-0002-6317-3975				ADLER SW, 1993, CIRCULATION, V88, P1348, DOI 10.1161/01.CIR.88.3.1348; AKHTAR M, 1993, CIRCULATION, V88, P282, DOI 10.1161/01.CIR.88.1.282; [Anonymous], 1994, LANCET, V343, P687; BARDY GH, 1993, CIRCULATION, V88, P543, DOI 10.1161/01.CIR.88.2.543; CALKINS H, 1994, AM J CARDIOL, V73, P353, DOI 10.1016/0002-9149(94)90007-8; CHEN SA, 1993, CIRCULATION, V88, P578, DOI 10.1161/01.CIR.88.2.578; CHOUE CW, 1994, AM J CARDIOL, V73, P1075, DOI 10.1016/0002-9149(94)90286-0; COGGINS DL, 1994, J AM COLL CARDIOL, V23, P1333, DOI 10.1016/0735-1097(94)90375-1; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; DOMANSKI MJ, 1993, AM J CARDIOL, V72, P455, DOI 10.1016/0002-9149(93)91140-D; DOVAL HC, 1994, LANCET, V334, P493; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; EPSTEIN LM, 1994, J AM COLL CARDIOL, V23, P1356, DOI 10.1016/0735-1097(94)90377-8; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FITZPATRICK AP, 1994, CIRCULATION, V89, P2503, DOI 10.1161/01.CIR.89.6.2503; GARFUICHEVIDH JJ, 1993, REV FED ARG CADIAL, V22, P73; GARRATT CJ, 1994, BRIT HEART J, V71, P307; HAISSAGUERRE M, 1994, J CARDIOVASC ELECTR, V5, P532, DOI 10.1111/j.1540-8167.1994.tb01293.x; HAISSAGUERRE M, 1994, EUR HEART J, V15, P200, DOI 10.1093/oxfordjournals.eurheartj.a060476; HINTRINGER F, 1994, EUR HEART J, V15, P858; KATRITSIS D, 1994, EUR HEART J, V15, P339, DOI 10.1093/oxfordjournals.eurheartj.a060500; KIM SG, 1993, AM J CARDIOL, V72, P1263, DOI 10.1016/0002-9149(93)90294-M; KIM YH, 1994, CIRCULATION, V89, P1094, DOI 10.1161/01.CIR.89.3.1094; KUGLER JD, 1994, NEW ENGL J MED, V330, P1481, DOI 10.1056/NEJM199405263302103; LESH MD, 1994, CIRCULATION, V89, P1074, DOI 10.1161/01.CIR.89.3.1074; MANOLIS AS, 1994, ARCH INTERN MED, V154, P617, DOI 10.1001/archinte.154.6.617; MASON JW, 1993, NEW ENGL J MED, V329, P452, DOI 10.1056/NEJM199308123290702; MASON JW, 1993, NEW ENGL J MED, V329, P445, DOI 10.1056/NEJM199308123290701; MCMURRAY J, 1994, BMJ-BRIT MED J, V309, P1343, DOI 10.1136/bmj.309.6965.1343; MORADY F, 1993, CIRCULATION, V87, P363, DOI 10.1161/01.CIR.87.2.363; NADAMANEE K, 1993, CIRCULATION, V88, P764; NAKAGAWA H, 1993, CIRCULATION, V88, P2607, DOI 10.1161/01.CIR.88.6.2607; NAVARROLOPEZ F, 1993, AM J CARDIOL, V72, P1243, DOI 10.1016/0002-9149(93)90291-J; NEWMAN D, 1992, AM J CARDIOL, V69, P899, DOI 10.1016/0002-9149(92)90789-2; NICKLAS JM, 1991, AM HEART J, V122, P1016, DOI 10.1016/0002-8703(91)90466-U; ONUNAIN S, 1993, LANCET, V341, P1641, DOI 10.1016/0140-6736(93)90770-H; PACKER M, 1993, NEW ENGL J MED, V329, P1, DOI 10.1056/NEJM199307013290101; PETERSEN P, 1989, LANCET, V1, P175; POWELL AC, 1993, CIRCULATION, V88, P1083, DOI 10.1161/01.CIR.88.3.1083; ROWE PM, 1994, LANCET, V344, P123, DOI 10.1016/S0140-6736(94)91304-8; SCHWARTZ PJ, 1994, EUR HEART J, V15, P620, DOI 10.1093/oxfordjournals.eurheartj.a060557; SINGER DE, 1992, AM HEART J, V124, P1567, DOI 10.1016/0002-8703(92)90074-6; TEO KK, 1993, JAMA-J AM MED ASSOC, V270, P1589, DOI 10.1001/jama.270.13.1589; URETSKY BF, 1993, J AM COLL CARDIOL, V22, P955, DOI 10.1016/0735-1097(93)90403-N; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R; WARD DE, 1993, NEW ENGL J MED, V329, P498, DOI 10.1056/NEJM199308123290710; WEN MS, 1994, CIRCULATION, V89, P1690, DOI 10.1161/01.CIR.89.4.1690; ZAREMBSKI DG, 1993, ARCH INTERN MED, V153, P2661, DOI 10.1001/archinte.153.23.2661; ZIPES DP, 1994, CIRCULATION, V89, P2934, DOI 10.1161/01.CIR.89.6.2934; 1993, AM J CARDIOL, V72, P280; 1992, ANN INTERN MED, V116, P6; 1991, CIRCULATION, V84, P527; 1994, J AM COLL CARDIOL, V23, P1521; 1993, LANCET, V342, P1255; 1990, NEW ENGL J MED, V323, P1505; 1992, ANN INTERN MED, V116, P1	56	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1631	1635		10.1136/bmj.309.6969.1631	http://dx.doi.org/10.1136/bmj.309.6969.1631			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819948	Green Published			2022-12-28	WOS:A1994PY22000032
J	BRUSTER, S; JARMAN, B; BOSANQUET, N; WESTON, D; ERENS, R; DELBANCO, TL				BRUSTER, S; JARMAN, B; BOSANQUET, N; WESTON, D; ERENS, R; DELBANCO, TL			NATIONAL SURVEY OF HOSPITAL PATIENTS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To Survey patients' opinions of their experiences in hospital in order to produce data that can help managers and doctors to identify and solve problems. Design-Random sample of 36 NHS hospitals, stratified by size of hospital (number of beds), area (north, midlands, south east, south west), and type of hospital (teaching or non-teaching, trust or directly managed). From each hospital a random sample of, on average, 143 patients was interviewed at home or the place of discharge two to four weeks after discharge by means of a structured questionnaire about their treatment in hospital. Subjects-5150 randomly chosen NHS patients recently discharged from acute hospitals in England. Subjects had been patients on medical and surgical wards apart from paediatric, maternity, psychiatric, and geriatric wards. Main outcome measures-Patients' responses to direct questions about preadmission procedures, admission, communication with staff, physical care, tests and operations, help from staff, pain management, and discharge planning. Patients' responses to general questions about their degree of satisfaction in hospitals. Results-Problems were reported by patients, particularly with regard to communication with staff (56% (2824/5020) had not been given written or printed information); pain management (33% (1042/ 3162) of those suffering pain were in pain all or most of the time); and discharge planning (70% (3599/ 5124) had not been told about warning signs and 62% (3177/5119) had not been told when to resume normal activities). Hospitals failed to reach the standards of the Patient's Charter-for example, in explaining the treatment proposed and giving patients the option of not taking part in student training. Answers to questions about patient satisfaction were, however, highly positive but of little use to managers. Conclusions-This survey has highlighted several problems with treatment in NHS hospitals. Asking patients direct questions about what happened rather than how satisfied they were with treatment can elucidate the problems that exist and so enable them to be solved.	ST MARYS HOSP,SCH MED,LISSON GROVE HLTH CTR,DEPT GEN PRACTICE,LONDON NW8 8EG,ENGLAND; SOCIAL & COMMUNITY PLANNING RES,LONDON EC1V 0AX,ENGLAND; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,PICKER COMMONWEALTH PATIENT CENTERED CARE PROGRAM,BOSTON,MA 02215	Imperial College London; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School								CHARLES C, 1994, CAN MED ASSOC J, V150, P1813; CLEARY PD, 1991, HEALTH AFFAIR, V10, P254, DOI 10.1377/hlthaff.10.4.254; DELBANCO TL, 1992, ANN INTERN MED, V116, P414, DOI 10.7326/0003-4819-116-5-414; DIXON P, 1989, NHS ITS CUSTOMERS, V3; EARDLEY A, 1974, PATIENTS SPEAK SURVE; FITZPATRICK R, 1991, BRIT MED J, V302, P887, DOI 10.1136/bmj.302.6781.887; HEYDEN V, 1993, HLTH SERVICE J, V103, P21; Raftery J, 1990, Health Serv J, V100, P1692; Richardson J, 1990, Health Serv J, V100, P435; STEELE K, 1992, PUBLIC MONEY MANAGEM, V12, P31; Wickings I, 1989, Health Serv J, V99, P1070; 1988, PATIENTS THEIR HOSPI; 1988, WHAT DO THEY KNOW IT; 1989, CMND555; 1993, HOSPITAL PERSONAL SO; 1992, PATIENTS CHARTER	16	207	208	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 10	1994	309	6968					1542	1546		10.1136/bmj.309.6968.1542	http://dx.doi.org/10.1136/bmj.309.6968.1542			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX564	7819893	Green Published			2022-12-28	WOS:A1994PX56400019
J	SIMPSON, DM; TAGLIATI, M				SIMPSON, DM; TAGLIATI, M			NEUROLOGIC MANIFESTATIONS OF HIV-INFECTION	ANNALS OF INTERNAL MEDICINE			English	Review							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; CENTRAL-NERVOUS-SYSTEM; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; IMMUNE-DEFICIENCY SYNDROME; AIDS DEMENTIA COMPLEX; EPSTEIN-BARR-VIRUS; POLYMERASE CHAIN-REACTION; BLOOD-BRAIN-BARRIER; PHASE-I TRIAL; PLACEBO-CONTROLLED TRIAL	Purpose: To review the clinical features, pathogenetic mechanisms, and management of neurologic manifestations of human immunodeficiency virus (HIV) infection. Data Sources: Studies published from 1983 to 1994 identified by MEDLINE literature search; Centers for Disease Control and Prevention reports; recent communications and abstracts; and authors' published and unpublished data. Study Selection: We selected studies that described the clinical characteristics of neurologic disorders in the acquired immunodeficiency syndrome (AIDS), basic science studies addressing the mechanisms of direct or indirect neurologic damage in HIV infection, and clinical trials investigating the effects of therapeutic agents on the neurologic complications of AIDS. Data Extraction: We evaluated information and data on epidemiologic characteristics, clinical manifestations, pathogenetic mechanisms, and therapy for neurologic complications of HIV disease and outlined a practical approach to assess and manage these disorders. Data Synthesis: In the past decade, basic and clinical studies have provided considerable information about neurologic manifestations of AIDS. Dementia is the most important ''primary'' neurologic complication of HIV infection. Focal lesions of the central nervous system include cerebral toxoplasmosis, lymphoma, and progressive multifocal leukoencephalopathy. Other opportunistic infections include cytomegalovirus encephalitis, cryptococcal meningitis, and neurosyphilis. Various peripheral neuropathies and myopathies may occur in association with HIV infection or as toxic effects of antiretroviral agents. Conclusions: The prevalence of neurologic complications associated with HIV disease will increase as more effective therapies allow persons with AIDS to live longer. Early recognition and treatment of these disorders substantially affect patients' quality of life and survival.			SIMPSON, DM (corresponding author), MT SINAI MED CTR, DEPT NEUROL, BOX 1052, 1 GUSTAVE L LEVY PL, NEW YORK, NY 10029 USA.			Tagliati, Michele/0000-0002-6722-8208	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028630] Funding Source: NIH RePORTER; NCRR NIH HHS [5M01 RR00071] Funding Source: Medline; NINDS NIH HHS [R01-NS28630] Funding Source: Medline; PHS HHS [UO1-A1-27667] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAIR JC, 1987, ARCH NEUROL-CHICAGO, V44, P548, DOI 10.1001/archneur.1987.00520170074026; AKSAMIT AJ, 1990, NEUROLOGY, V40, P1073, DOI 10.1212/WNL.40.7.1073; ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5; AYLWARD EH, 1993, NEUROLOGY, V43, P2099, DOI 10.1212/WNL.43.10.2099; BAILEY RO, 1988, NEUROLOGY, V38, P886, DOI 10.1212/WNL.38.6.886; BASHIR RM, 1989, NEUROLOGY, V39, P813, DOI 10.1212/WNL.39.6.813; BAUMGARTNER JE, 1990, J NEUROSURG, V73, P206, DOI 10.3171/jns.1990.73.2.0206; BEHAR R, 1987, NEUROLOGY, V37, P557, DOI 10.1212/WNL.37.4.557; BELEC L, 1991, AIDS, V5, P234, DOI 10.1097/00002030-199102000-00022; BERGER AR, 1993, NEUROLOGY, V43, P358, DOI 10.1212/WNL.43.2.358; BERGER JR, 1991, ARCH NEUROL-CHICAGO, V48, P700, DOI 10.1001/archneur.1991.00530190046014; BERGER JR, 1987, ANN INTERN MED, V107, P78, DOI 10.7326/0003-4819-107-1-78; BERGER JR, 1988, NEUROLOGY, V38, P1060, DOI 10.1212/WNL.38.7.1060; BESSEN LJ, 1988, NEW ENGL J MED, V318, P708; BISHBURG E, 1986, ANN INTERN MED, V105, P210, DOI 10.7326/0003-4819-105-2-210; BLUM A, 1993, NEUROLOGY, V43, pA190; BONI J, 1993, NEUROLOGY, V43, P1813, DOI 10.1212/WNL.43.9.1813; Borggreve F, 1993, Funct Neurol, V8, P95; BOTZEL K, 1993, NERVENARZT, V64, P282; BOZZETTE SA, 1991, NEW ENGL J MED, V324, P580, DOI 10.1056/NEJM199102283240902; BREW BJ, 1989, NEUROLOGY, V39, P830, DOI 10.1212/WNL.39.6.830; BREW BJ, 1990, ANN NEUROL, V28, P556, DOI 10.1002/ana.410280413; BRITTON CB, 1985, NEUROLOGY, V35, P1071, DOI 10.1212/WNL.35.7.1071; BRITTON CB, 1992, NEUROSCIENCE HIV INF; BROWNE MJ, 1993, J INFECT DIS, V167, P21, DOI 10.1093/infdis/167.1.21; Budka H, 1991, BRAIN PATHOL, V1, P143, DOI 10.1111/j.1750-3639.1991.tb00653.x; CARBONE LG, 1988, AM J KIDNEY DIS, V12, P72, DOI 10.1016/S0272-6386(88)80076-3; CHAD DA, 1990, ANN NEUROL, V28, P579, DOI 10.1002/ana.410280418; CHALMERS AC, 1991, NEUROLOGY, V41, P1181, DOI 10.1212/WNL.41.8.1181; CHAPPELL ET, 1992, NEUROSURGERY, V30, P825, DOI 10.1227/00006123-199206000-00001; CHARIOT P, 1993, ANN NEUROL, V34, P561, DOI 10.1002/ana.410340409; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHUCK SL, 1989, NEW ENGL J MED, V321, P794, DOI 10.1056/NEJM198909213211205; CHUPP GL, 1993, CLIN INFECT DIS, V16, P15, DOI 10.1093/clinids/16.1.15; CINQUE P, 1993, LANCET, V342, P398, DOI 10.1016/0140-6736(93)92814-A; CIRICILLO SF, 1990, J NEUROSURG, V73, P720, DOI 10.3171/jns.1990.73.5.0720; CIRICILLO SF, 1991, J NEUROSURG, V74, P1029; CLARK RA, 1990, REV INFECT DIS, V12, P768; CLIFFORD DB, 1993, NEUROLOGY, V43, P75, DOI 10.1212/WNL.43.1_Part_1.75; COHN JA, 1989, AM J MED, V86, P521, DOI 10.1016/0002-9343(89)90378-1; COKER RJ, 1991, J ANTIMICROB CHEMOTH, V28, P105, DOI 10.1093/jac/28.suppl_B.105; CONWAY B, 1990, REV INFECT DIS, V12, P479; COOLEY TP, 1990, NEW ENGL J MED, V322, P1340, DOI 10.1056/NEJM199005103221902; CORNBLATH DR, 1987, ANN NEUROL, V21, P32, DOI 10.1002/ana.410210107; CORNBLATH DR, 1988, ANN NEUROL, V23, pS88, DOI 10.1002/ana.410230723; CVETKOVICH TA, 1992, P NATL ACAD SCI USA, V89, P5162, DOI 10.1073/pnas.89.11.5162; DALAKAS M, 1994, NEUROLOGY, V44, P360, DOI 10.1212/WNL.44.2.360-b; DALAKAS MC, 1988, ANN NEUROL, V23, pS38, DOI 10.1002/ana.410230713; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DALPAN GJ, 1992, NEUROLOGY, V42, P2125, DOI 10.1212/WNL.42.11.2125; DANNEMANN B, 1992, ANN INTERN MED, V116, P33, DOI 10.7326/0003-4819-116-1-33; DEGANS J, 1988, BMJ-BRIT MED J, V296, P339, DOI 10.1136/bmj.296.6618.339; DEGANS J, 1992, J ACQ IMMUN DEF SYND, V5, P137; DEGANS J, 1990, AIDS, V4, P421, DOI 10.1097/00002030-199005000-00007; DEGANS J, 1992, AIDS, V6, P185, DOI 10.1097/00002030-199202000-00007; DELAMONTE SM, 1988, ANN NEUROL, V23, P485, DOI 10.1002/ana.410230510; DENNING DW, 1989, ARCH INTERN MED, V149, P2301, DOI 10.1001/archinte.149.10.2301; DERIX MMA, 1990, CLIN NEUROL NEUROSUR, V92, P215, DOI 10.1016/0303-8467(90)90023-X; DISMUKES WE, 1987, NEW ENGL J MED, V317, P334, DOI 10.1056/NEJM198708063170602; DISMUKES WE, 1988, J INFECT DIS, V157, P624, DOI 10.1093/infdis/157.4.624; DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646; DUBINSKY RM, 1989, MUSCLE NERVE, V12, P856, DOI 10.1002/mus.880121012; EIDELBERG D, 1986, NEUROLOGY, V36, P912, DOI 10.1212/WNL.36.7.912; EPSTEIN LG, 1993, ANN NEUROL, V33, P429, DOI 10.1002/ana.410330502; EVANS DL, 1990, CURRENT OPINION PSYC, V3, P96; EVERALL IP, 1991, LANCET, V337, P1119, DOI 10.1016/0140-6736(91)92786-2; FABER DW, 1992, INVEST OPHTH VIS SCI, V33, P2345; FALANGOLA MF, 1993, NEUROLOGY, V43, P2035, DOI 10.1212/WNL.43.10.2035; FEIDEN W, 1993, ACTA NEUROL SCAND, V87, P228; FERARU ER, 1990, NEUROLOGY, V40, P541, DOI 10.1212/WNL.40.3_Part_1.541; FIALA M, 1988, REV INFECT DIS, V10, P250; FORMENTI SC, 1989, CANCER, V63, P1101, DOI 10.1002/1097-0142(19890315)63:6<1101::AID-CNCR2820630611>3.0.CO;2-R; FREDERICK WP, 1988, INTERSCIENCE C ANTIM; FULLER GN, 1989, J NEUROL NEUROSUR PS, V52, P975, DOI 10.1136/jnnp.52.8.975; GAL AA, 1987, DIAGN MICR INFEC DIS, V7, P249, DOI 10.1016/0732-8893(87)90139-8; GALETTO G, 1993, JAMA-J AM MED ASSOC, V269, P92, DOI 10.1001/jama.269.1.92; GARDNER HAR, 1991, NEUROLOGY, V41, P1993, DOI 10.1212/WNL.41.12.1993; GARROTE FJ, 1990, REV CLIN ESP, V187, P404; GELMAN BB, 1993, ANN NEUROL, V34, P65, DOI 10.1002/ana.410340112; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; GHERARDI R, 1992, ANN NEUROL, V32, P535, DOI 10.1002/ana.410320409; GILL PS, 1985, AM J MED, V78, P742, DOI 10.1016/0002-9343(85)90277-3; GLASS JD, 1993, NEUROLOGY, V43, P2230, DOI 10.1212/WNL.43.11.2230; GOLDSTICK L, 1985, NEUROLOGY, V35, P103, DOI 10.1212/WNL.35.1.103; GONZALES MF, 1988, NEUROPATH APPL NEURO, V14, P345, DOI 10.1111/j.1365-2990.1988.tb01138.x; GOTZCHE PC, 1992, BRIT MED J, V304, P13; GOUDSMIT J, 1986, LANCET, V2, P177; GOZLAN J, 1992, J INFECT DIS, V166, P1416, DOI 10.1093/infdis/166.6.1416; GRAFE MR, 1989, ANN NEUROL, V25, P561, DOI 10.1002/ana.410250606; GRANT I, 1987, ANN INTERN MED, V107, P828, DOI 10.7326/0003-4819-107-6-828; GRAU JM, 1993, ANN NEUROL, V34, P206, DOI 10.1002/ana.410340217; GRAY F, 1991, LANCET, V337, P852, DOI 10.1016/0140-6736(91)92560-O; GRIFFIN DE, 1991, NEUROLOGY, V41, P69, DOI 10.1212/WNL.41.1.69; GRIFFIN J W, 1991, Neurology, V41, P374; GRIFFIN JW, 1993, NEUROLOGY, V43, pA232; GRIMALDI LME, 1991, ANN NEUROL, V29, P21, DOI 10.1002/ana.410290106; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HAMILTONDUTOIT SJ, 1991, AM J PATHOL, V138, P149; HASSETT J, 1994, NEUROLOGY, V44, pA250; HELBERT M, 1988, LANCET, V2, P689; HENGGE UR, 1993, ANTIMICROB AGENTS CH, V37, P1010, DOI 10.1128/AAC.37.5.1010; HERSKOVITZ S, 1989, NEUROLOGY, V39, P1552, DOI 10.1212/WNL.39.11.1552; HERZBERG NH, 1992, MUSCLE NERVE, V15, P706, DOI 10.1002/mus.880150613; HEYES MP, 1991, ANN NEUROL, V29, P202, DOI 10.1002/ana.410290215; HEYES MP, 1989, ANN NEUROL, V26, P275; HEYES MP, 1990, ANN NEUROL, V27, P666, DOI 10.1002/ana.410270614; HO DD, 1985, NEW ENGL J MED, V313, P1493, DOI 10.1056/NEJM198512123132401; HO HW, 1989, J NEUROPATH EXP NEUR, V48, P382, DOI 10.1097/00005072-198905000-00250; HOFFMAN JM, 1993, J NUCL MED, V34, P567; HOLLAND NR, 1994, NEUROLOGY, V44, P507, DOI 10.1212/WNL.44.3_Part_1.507; HOROWITZ SL, 1982, ANN NEUROL, V12, P80; JANSSEN RS, 1992, NEUROLOGY, V42, P1472, DOI 10.1212/WNL.42.8.1472; JOHNS DR, 1987, NEW ENGL J MED, V316, P1569, DOI 10.1056/NEJM198706183162503; JOHNSON JD, 1993, J INFECTION, V26, P147, DOI 10.1016/0163-4453(93)92788-X; JOHNSTON SRD, 1992, J INFECTION, V24, P185, DOI 10.1016/0163-4453(92)92954-H; KARAHALIOS D, 1992, J ACQ IMMUN DEF SYND, V5, P1030; KATZ DA, 1989, ARCH NEUROL-CHICAGO, V46, P895, DOI 10.1001/archneur.1989.00520440085024; KETZLER S, 1990, ACTA NEUROPATHOL, V80, P92, DOI 10.1007/BF00294228; KIEBURTZ KD, 1992, J ACQ IMMUN DEF SYND, V5, P60; KIEBURTZ KD, 1991, ARCH NEUROL-CHICAGO, V48, P312, DOI 10.1001/archneur.1991.00530150082023; KIM YS, 1993, CLIN INFECT DIS, V17, P32, DOI 10.1093/clinids/17.1.32; LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901; LAMPERTH L, 1991, LAB INVEST, V65, P742; LANGE DJ, 1988, ARCH NEUROL-CHICAGO, V45, P1084, DOI 10.1001/archneur.1988.00520340038008; LANSKA MJ, 1988, NEUROLOGY, V38, P1297, DOI 10.1212/WNL.38.8.1297; LARSEN RA, 1990, ANN INTERN MED, V113, P183, DOI 10.7326/0003-4819-113-3-183; LEGER JM, 1992, J NEUROL, V239, P132, DOI 10.1007/BF00833911; LEGER JM, 1989, J NEUROL NEUROSUR PS, V52, P1369, DOI 10.1136/jnnp.52.12.1369; LEPORT C, 1989, J INFECT DIS, V160, P557, DOI 10.1093/infdis/160.3.557; LEPORT C, 1988, AM J MED, V84, P94, DOI 10.1016/0002-9343(88)90014-9; LEVINE AM, 1991, J NATL CANCER I, V83, P662, DOI 10.1093/jnci/83.10.662; LEVY RM, 1985, J NEUROSURG, V62, P475, DOI 10.3171/jns.1985.62.4.0475; LEVY RM, 1988, J ACQ IMMUN DEF SYND, V1, P41; LIPKIN WI, 1985, NEUROLOGY, V35, P1479, DOI 10.1212/WNL.35.10.1479; LIPTON SA, 1992, TRENDS NEUROSCI, V15, P75, DOI 10.1016/0166-2236(92)90013-X; LIPTON SA, 1991, NEURON, V7, P111, DOI 10.1016/0896-6273(91)90079-F; LUFT BJ, 1984, JAMA-J AM MED ASSOC, V252, P913, DOI 10.1001/jama.252.7.913; LUFT BJ, 1992, CLIN INFECT DIS, V15, P211, DOI 10.1093/clinids/15.2.211; LUFT BJ, 1993, NEW ENGL J MED, V329, P995, DOI 10.1056/NEJM199309303291403; LUKEHART SA, 1988, ANN INTERN MED, V109, P855, DOI 10.7326/0003-4819-109-11-855; MAH V, 1988, ANN NEUROL, V24, P713, DOI 10.1002/ana.410240604; MAHIEUX F, 1989, J NEUROL NEUROSUR PS, V52, P270, DOI 10.1136/jnnp.52.2.270; MALAMUT R I, 1992, Neurology, V42, P335; MANJI H, 1993, J NEUROL, V240, P479, DOI 10.1007/BF00874117; MANJI H, 1992, GENITOURIN MED, V68, P192; MARK AS, 1989, RADIOLOGY, V173, P517, DOI 10.1148/radiology.173.2.2798883; MASLIAH E, 1992, ANN NEUROL, V32, P321, DOI 10.1002/ana.410320304; MASTAGLIA FL, 1985, ANN NEUROL, V17, P317, DOI 10.1002/ana.410170402; MCARTHUR JC, 1989, ANN NEUROL, V26, P601, DOI 10.1002/ana.410260504; MCARTHUR JC, 1987, MEDICINE, V66, P407, DOI 10.1097/00005792-198711000-00001; MCARTHUR JC, 1993, NEUROLOGY, V43, P2245, DOI 10.1212/WNL.43.11.2245; MCARTHUR JC, 1988, ANN NEUROL, V23, pS34, DOI 10.1002/ana.410230712; MCARTHUR JC, 1992, NEUROLOGY, V42, P1707, DOI 10.1212/WNL.42.9.1707; MEEKER TC, 1991, AIDS, V5, P669, DOI 10.1097/00002030-199106000-00005; MHIRI C, 1991, ANN NEUROL, V29, P606, DOI 10.1002/ana.410290607; Michaels J, 1988, Immunodefic Rev, V1, P71; MILLER RG, 1988, MUSCLE NERVE, V11, P857, DOI 10.1002/mus.880110810; MILLER RG, 1991, NEUROLOGY, V41, P1603, DOI 10.1212/WNL.41.10.1603; MILLER RG, 1990, NEUROLOGY, V40, P569, DOI 10.1212/WNL.40.4.569; MORGELLO S, 1994, MUSCLE NERVE, V17, P176, DOI 10.1002/mus.880170208; MORGELLO S, 1988, ARCH PATHOL LAB MED, V112, P173; MORGELLO S, 1987, HUM PATHOL, V18, P289, DOI 10.1016/S0046-8177(87)80012-6; MORGELLO S, 1992, AM J PATHOL, V141, P441; MORGELLO S, 1989, HUM PATHOL, V20, P808, DOI 10.1016/0046-8177(89)90078-6; MUSHER DM, 1991, J INFECT DIS, V163, P1201, DOI 10.1093/infdis/163.6.1201; MUSHER DM, 1990, ANN INTERN MED, V113, P872, DOI 10.7326/0003-4819-113-11-872; NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603; NAVIA BA, 1986, ANN NEUROL, V19, P224, DOI 10.1002/ana.410190303; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; NAVIA BA, 1990, SUBCORTICAL DEMENTIA, P181; NICOLI F, 1992, LANCET, V339, P306, DOI 10.1016/0140-6736(92)91376-J; NISCE LZ, 1992, JAMA-J AM MED ASSOC, V267, P1921, DOI 10.1001/jama.1992.03480140047026; NOVAK I S, 1989, Neurology, V39, P379; OLSEN WL, 1988, RADIOLOGY, V169, P445, DOI 10.1148/radiology.169.2.3174991; PADGETT BL, 1971, LANCET, V1, P1257; PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0; PELUSO R, 1985, VIROLOGY, V147, P231, DOI 10.1016/0042-6822(85)90246-6; PERT CB, 1988, ANN NEUROL, V23, pS71, DOI 10.1002/ana.410230719; PETITO CK, 1992, ANN NEUROL, V32, P658, DOI 10.1002/ana.410320509; PETITO CK, 1986, J NEUROPATH EXP NEUR, V45, P635, DOI 10.1097/00005072-198611000-00003; PETITO CK, 1985, NEW ENGL J MED, V312, P874, DOI 10.1056/NEJM198504043121402; PIKE IM, 1993, CLIN INFECT DIS, V16, pS63, DOI 10.1093/clinids/16.Supplement_1.S63; PIZZO PA, 1988, NEW ENGL J MED, V319, P889, DOI 10.1056/NEJM198810063191401; PLUDA JM, 1990, ANN INTERN MED, V113, P276, DOI 10.7326/0003-4819-113-4-276; PONS VG, 1988, AIDS NERVOUS SYSTEM, P263; PORTEGIES P, 1989, BRIT MED J, V299, P819, DOI 10.1136/bmj.299.6703.819; PORTEGIES P, 1991, LANCET, V337, P680, DOI 10.1016/0140-6736(91)92504-U; PORTEGIES P, 1993, AIDS, V7, P669, DOI 10.1097/00002030-199305000-00010; PORTER SB, 1992, NEW ENGL J MED, V327, P1643, DOI 10.1056/NEJM199212033272306; POST MJD, 1988, AM J ROENTGENOL, V151, P373, DOI 10.2214/ajr.151.2.373; POST MJD, 1986, AM J ROENTGENOL, V146, P1229, DOI 10.2214/ajr.146.6.1229; POWDERLY WG, 1992, NEW ENGL J MED, V326, P793, DOI 10.1056/NEJM199203193261203; POWDERLY WG, 1993, CLIN INFECT DIS, V17, P837, DOI 10.1093/clinids/17.5.837; POWER C, 1993, ANN NEUROL, V34, P339, DOI 10.1002/ana.410340307; QUINNAN GV, 1984, JAMA-J AM MED ASSOC, V252, P72, DOI 10.1001/jama.252.1.72; REMINGTON JS, 1989, INFECT DIS, P89; REYES MG, 1992, NEUROLOGY, V42, P1251; ROBERTSON KR, 1993, ARCH NEUROL-CHICAGO, V50, P807, DOI 10.1001/archneur.1993.00540080018007; ROSEMBERG S, 1992, NEUROLOGY, V42, P640, DOI 10.1212/WNL.42.3.640; ROSENBERG NL, 1986, ANN NEUROL, V20, P98, DOI 10.1002/ana.410200118; ROSENBLUM M, 1989, NEUROLOGY, V39, P892, DOI 10.1212/WNL.39.7.892; RUSKIN J, 1976, ANN INTERN MED, V84, P193, DOI 10.7326/0003-4819-84-2-193; SAAG MS, 1992, NEW ENGL J MED, V326, P83, DOI 10.1056/NEJM199201093260202; SAHAI J, 1988, AM J MED, V84, P791, DOI 10.1016/0002-9343(88)90124-6; SAID G, 1991, ANN NEUROL, V29, P139, DOI 10.1002/ana.410290205; SAITO Y, 1994, NEUROLOGY, V44, P474, DOI 10.1212/WNL.44.3_Part_1.474; SCHMITT FA, 1988, NEW ENGL J MED, V319, P1573, DOI 10.1056/NEJM198812153192404; SCHOONDERMARKVANDEVEN E, 1993, CLIN INFECT DIS, V16, P661, DOI 10.1093/clind/16.5.661; SEILHEAN D, 1993, NEUROLOGY, V43, P1492, DOI 10.1212/WNL.43.8.1492; SELNES OA, 1992, NEUROLOGY, V42, P1924, DOI 10.1212/WNL.42.10.1924; SHAW GM, 1985, SCIENCE, V227, P177, DOI 10.1126/science.2981429; SHEPP DH, 1985, ANN INTERN MED, V103, P368, DOI 10.7326/0003-4819-103-3-368; SIDTIS JJ, 1993, ANN NEUROL, V33, P343, DOI 10.1002/ana.410330403; SIDTIS JJ, 1990, NEUROLOGY, V40, P323, DOI 10.1212/WNL.40.2.323; SIDTIS JJ, 1988, J CLIN EXP NEUROPSYC, V10, P76; SIMPSON D, 1994, IN PRESS J AIDS; SIMPSON D, 1994, MUSCLE NERVE, V17, P1113; SIMPSON D, 1993, PERIPHERAL NEUROPATH; SIMPSON DM, 1988, ANN NEUROL, V24, P79, DOI 10.1002/ana.410240114; SIMPSON DM, 1991, AIDS, V5, P917, DOI 10.1097/00002030-199108000-00001; SIMPSON DM, 1990, NEUROLOGY, V40, P535, DOI 10.1212/WNL.40.3_Part_1.535; SIMPSON DM, 1994, NEUROLOGY, V44, pA249; SIMPSON DM, 1993, NEUROLOGY, V43, P971, DOI 10.1212/WNL.43.5.971; SIMPSON DM, 1993, CLIN NEUROPATHOL S1, V12, pS220; SNIDER WD, 1983, ANN NEUROL, V14, P403, DOI 10.1002/ana.410140404; SO YT, 1986, ANN NEUROL, V20, P566, DOI 10.1002/ana.410200503; SO YT, 1994, ANN NEUROL, V35, P53, DOI 10.1002/ana.410350109; SO YT, 1988, ARCH NEUROL-CHICAGO, V45, P945, DOI 10.1001/archneur.1988.00520330023005; SO YT, 1991, NEUROLOGY S1, V41, P375; STERN JJ, 1988, AM J MED, V85, P477, DOI 10.1016/S0002-9343(88)80081-0; TAGLIATI M, 1994, NEUROLOGY, V44, pA367; TAN SV, 1993, ANN NEUROL, V34, P619, DOI 10.1002/ana.410340418; TORNATORE C, 1992, ANN NEUROL, V31, P454, DOI 10.1002/ana.410310426; TORNATORE C, 1994, NEUROLOGY, V44, P481, DOI 10.1212/WNL.44.3_Part_1.481; TOUCHETTE N, 1993, J NIH RES, V5, P33; TROSS S, 1988, AIDS, V2, P81, DOI 10.1097/00002030-198804000-00002; TROTOT PM, 1990, J NEURORADIOLOGY, V17, P233; TYOR WR, 1993, NEUROLOGY, V43, P1002, DOI 10.1212/WNL.43.5.1002; VAGO L, 1991, LANCET, V337, P1488, DOI 10.1016/0140-6736(91)93186-D; VANGORP WG, 1994, NEUROLOGY, V44, P929, DOI 10.1212/WNL.44.5.929; VENDRELL J, 1987, NEUROLOGY, V37, P544, DOI 10.1212/WNL.37.3.544-a; VINTERS HV, 1989, BRAIN, V112, P245, DOI 10.1093/brain/112.1.245; VONEINSIEDEL RW, 1993, J NEUROL, V240, P391; WALKER RW, 1992, NEUROLOGY, V42, P2005, DOI 10.1212/WNL.42.10.2005; WEIDENHEIM KM, 1992, HUM PATHOL, V23, P581, DOI 10.1016/0046-8177(92)90137-R; WEISSMAN JD, 1992, NEUROLOGY, V42, P619, DOI 10.1212/WNL.42.3.619; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; WESSELINGH SL, 1993, NEUROLOGY, V43, pA291; WHITEMAN MLH, 1993, RADIOLOGY, V187, P233, DOI 10.1148/radiology.187.1.8451420; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; WOLF DG, 1992, J INFECT DIS, V166, P1412, DOI 10.1093/infdis/166.6.1412; WRZOLEK MA, 1990, MUSCLE NERVE, V13, P508, DOI 10.1002/mus.880130607; YARCHOAN R, 1990, LANCET, V336, P526, DOI 10.1016/0140-6736(90)92085-V; YARCHOAN R, 1987, LANCET, V1, P132, DOI 10.1016/S0140-6736(87)91968-4; ZIMMER C, 1992, J NEUROL, V239, P394; ZUGER A, 1986, ANN INTERN MED, V104, P234, DOI 10.7326/0003-4819-104-2-234	256	158	169	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1994	121	10					769	785		10.7326/0003-4819-121-10-199411150-00008	http://dx.doi.org/10.7326/0003-4819-121-10-199411150-00008			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ928	7794311				2022-12-28	WOS:A1994PQ92800008
J	STEINBERG, W; TENNER, S				STEINBERG, W; TENNER, S			MEDICAL PROGRESS - ACUTE-PANCREATITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DOUBLE-BLIND TRIAL; ACUTE ALCOHOLIC PANCREATITIS; HEMORRHAGIC-NECROTIZING PANCREATITIS; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; NONALCOHOLIC ACUTE-PANCREATITIS; ENHANCED COMPUTED-TOMOGRAPHY; ACUTE FULMINANT PANCREATITIS; PROSPECTIVE RANDOMIZED TRIAL; TOTAL PARENTERAL-NUTRITION; CONTROLLED CLINICAL-TRIAL		GEORGE WASHINGTON UNIV, MED CTR, DEPT HLTH CARE SCI, DIV GASTROENTEROL, WASHINGTON, DC 20037 USA	George Washington University	STEINBERG, W (corresponding author), GEORGE WASHINGTON UNIV, MED CTR, DEPT MED, DIV GASTROENTEROL, 2150 PENN AVE, WASHINGTON, DC 20037 USA.							Agarwal N, 1986, Pancreas, V1, P69, DOI 10.1097/00006676-198601000-00013; ALDRIDGE MC, 1989, BRIT J SURG, V76, P362, DOI 10.1002/bjs.1800760416; [Anonymous], 1977, Lancet, V2, P632; BALLDIN G, 1987, ACUTE PANCREATITIS, P63; BALTHAZAR EJ, 1989, RADIOL CLIN N AM, V27, P19; BANERJEE AK, 1989, MED TOXICOL ADV DRUG, V4, P186, DOI 10.1007/BF03259996; BANK S, 1983, AM J GASTROENTEROL, V78, P637; BARTHOLOMEW C, 1970, BMJ-BRIT MED J, V1, P666, DOI 10.1136/bmj.1.5697.666; BEDFORD RA, 1993, GASTROINTEST ENDOSC, V39, P315; BEGER HG, 1988, BRIT J SURG, V75, P207, DOI 10.1002/bjs.1800750306; BEGER HG, 1991, HEPATO-GASTROENTEROL, V38, P92; BEGER HG, 1986, GASTROENTEROLOGY, V91, P433, DOI 10.1016/0016-5085(86)90579-2; BENNETT IL, 1953, MEDICINE, V32, P431, DOI 10.1097/00005792-195312000-00002; BIRD NC, 1989, BRIT J SURG, V76, P731, DOI 10.1002/bjs.1800760728; BITTNER R, 1987, DIGEST DIS SCI, V32, P1082, DOI 10.1007/BF01300192; BIVINS BA, 1978, ARCH SURG-CHICAGO, V113, P751; BLAMEY SL, 1984, GUT, V25, P1340, DOI 10.1136/gut.25.12.1340; BLOCK S, 1986, GUT, V27, P1035, DOI 10.1136/gut.27.9.1035; BOON P, 1991, CLIN NEUROL NEUROSUR, V93, P137, DOI 10.1016/0303-8467(91)90055-T; BOURKE JB, 1975, LANCET, V2, P967; BRADLEY EL, 1991, AM J SURG, V161, P19, DOI 10.1016/0002-9610(91)90355-H; BRAGG LE, 1985, AM J SURG, V150, P694, DOI 10.1016/0002-9610(85)90411-8; BROE PJ, 1982, SURG GYNECOL OBSTET, V154, P13; BUCHLER M, 1992, GASTROENTEROLOGY, V103, P1902; BUCHLER M, 1993, GASTROENTEROLOGY, V104, P1165; BUCHLER M, 1989, GASTROENTEROLOGY, V97, P1521; BUGGY BP, 1983, AM J GASTROENTEROL, V78, P810; BUNTAIN WL, 1978, J PEDIATR SURG, V13, P143, DOI 10.1016/S0022-3468(78)80008-6; CAMERON JL, 1979, SURG GYNECOL OBSTET, V148, P206; CAMERON JL, 1973, ANN SURG, V177, P483, DOI 10.1097/00000658-197304000-00017; Cappell Mitchell S., 1993, Practical Gastroenterology, V17, P18; CAVALLINI G, 1987, ACUTE PANCREATITIS, P25; CHOI TK, 1989, GUT, V30, P223, DOI 10.1136/gut.30.2.223; CLAVIEN PA, 1989, ANN SURG, V210, P614, DOI 10.1097/00000658-198911000-00008; CLAVIEN PA, 1988, AM J SURG, V155, P457, DOI 10.1016/S0002-9610(88)80113-2; CORFIELD AP, 1985, LANCET, V2, P403; COTTON PB, 1974, BRIT MED J, V1, P608, DOI 10.1136/bmj.1.5908.608; COTTON PB, 1985, GASTROENTEROLOGY, V89, P1431, DOI 10.1016/0016-5085(85)90667-5; CRAIG RM, 1975, ANN INTERN MED, V83, P831, DOI 10.7326/0003-4819-83-6-831; CUSCHIERI A, 1983, BRIT J SURG, V70, P710, DOI 10.1002/bjs.1800701205; DEGIDIO A, 1991, BRIT J SURG, V78, P133, DOI 10.1002/bjs.1800780204; DEMMY TL, 1988, AM J SURG, V156, P492, DOI 10.1016/S0002-9610(88)80537-3; DOWELL SF, 1990, MODERN PATHOL, V3, P49; DURR HK, 1978, GUT, V19, P175, DOI 10.1136/gut.19.3.175; Elman R, 1929, ARCH SURG-CHICAGO, V19, P943, DOI 10.1001/archsurg.1929.01150060005001; FAN ST, 1993, NEW ENGL J MED, V328, P228, DOI 10.1056/NEJM199301283280402; FELDSTEIN JD, 1974, ANN SURG, V180, P85, DOI 10.1097/00000658-197407000-00012; FERNANDEZDELCASTILLO C, 1991, NEW ENGL J MED, V325, P382; FIGARELLA C, 1987, ACUTE PANCREATITIS R, P53; FINCH WT, 1976, ANN SURG, V183, P667, DOI 10.1097/00000658-197606000-00008; Fitz RH, 1889, BOSTON MED SURG J, V120, P229; Fitz RH, 1889, BOSTON MED SURG J, V70, P181, DOI DOI 10.1056/NEJM188902211200801; Fitz RH, 1889, BOSTON MED SURG J, V120, P205; FOULIS AK, 1982, GUT, V23, P656, DOI 10.1136/gut.23.8.656; FOULIS AK, 1982, J CLIN PATHOL, V35, P1244, DOI 10.1136/jcp.35.11.1244; FUNNELL IC, 1993, BRIT J SURG, V80, P484, DOI 10.1002/bjs.1800800426; GAFTER U, 1976, JAMA-J AM MED ASSOC, V235, P2004, DOI 10.1001/jama.235.18.2004; GERZOF SG, 1987, GASTROENTEROLOGY, V93, P1315, DOI 10.1016/0016-5085(87)90261-7; GOEBELL H, 1979, SCAND J GASTROENTERO, V14, P881, DOI 10.3109/00365527909181420; GOLDBERG PB, 1980, GASTROENTEROLOGY, V78, P1041; GRIFFIN M, 1981, GASTROENTEROLOGY, V81, P345; GROSS V, 1990, DIGEST DIS SCI, V35, P97, DOI 10.1007/BF01537230; GUDGEON AM, 1990, LANCET, V335, P4, DOI 10.1016/0140-6736(90)90135-R; GULLO L, 1984, ACUTE PANCREATITIS, P87; GUMASTE V, 1992, AM J MED, V92, P239, DOI 10.1016/0002-9343(92)90070-R; GUMASTE VV, 1991, GASTROENTEROLOGY, V101, P1361, DOI 10.1016/0016-5085(91)90089-4; GWOZDZ GP, 1990, CLIN CHIM ACTA, V187, P243, DOI 10.1016/0009-8981(90)90109-6; HABER CJ, 1986, GASTROENTEROLOGY, V91, P982, DOI 10.1016/0016-5085(86)90703-1; HOWES R, 1975, J SURG RES, V18, P197, DOI 10.1016/0022-4804(75)90016-5; IHSE I, 1986, ANN SURG, V204, P122, DOI 10.1097/00000658-198608000-00004; IMRIE CW, 1977, GUT, V18, P53, DOI 10.1136/gut.18.1.53; IMRIE CW, 1978, BRIT J SURG, V65, P337, DOI 10.1002/bjs.1800650514; IMRIE CW, 1975, BRIT J SURG, V62, P490, DOI 10.1002/bjs.1800620615; IZSAK EM, 1980, GASTROENTEROLOGY, V79, P555; JOE L, 1989, SOUTHERN MED J, V82, P1444, DOI 10.1097/00007611-198911000-00029; JORDAN SC, 1977, J PEDIATR-US, V91, P211, DOI 10.1016/S0022-3476(77)80814-7; KARIMGANI I, 1992, GASTROENTEROLOGY, V103, P1636, DOI 10.1016/0016-5085(92)91189-B; KATTWINKEL J, 1973, PEDIATRICS, V51, P55; KELLY TR, 1988, SURGERY, V104, P600; KHUROO MS, 1992, BRIT J SURG, V79, P1335, DOI 10.1002/bjs.1800791231; KIVILAAKSO E, 1984, ANN SURG, V199, P426, DOI 10.1097/00000658-198404000-00009; KIVISAARI L, 1983, SCAND J GASTROENTERO, V18, P39, DOI 10.3109/00365528309181556; KIVISAARI L, 1984, GASTROINTEST RADIOL, V9, P27, DOI 10.1007/BF01887796; KLAR E, 1990, BRIT J SURG, V77, P1205, DOI 10.1002/bjs.1800771104; KRONBORG O, 1980, AM J GASTROENTEROL, V73, P423; LANKISCH PG, 1990, GASTROENTEROLOGY, V98, P509, DOI 10.1016/0016-5085(90)90848-U; LANKISCH PG, 1989, AM J GASTROENTEROL, V84, P1391; LANKISCH PG, 1991, AM J GASTROENTEROL, V86, P322; LANS JI, 1992, GASTROINTEST ENDOSC, V38, P430, DOI 10.1016/S0016-5107(92)70471-4; LARVIN M, 1989, LANCET, V2, P201; LARVIN M, 1992, Gastroenterology, V102, pA274; LEACH SD, 1990, ANN SURG, V212, P109, DOI 10.1097/00000658-199007000-00014; Lee H S, 1989, Singapore Med J, V30, P599; LEE SP, 1992, NEW ENGL J MED, V326, P589, DOI 10.1056/NEJM199202273260902; LEESE T, 1988, ANN ROY COLL SURG, V70, P227; LEESE T, 1987, BRIT J SURG, V74, P907, DOI 10.1002/bjs.1800741012; LEFOR AT, 1992, ARCH SURG-CHICAGO, V127, P1225; LEGGE DA, 1971, GASTROENTEROLOGY, V61, P834; LERCH MM, 1993, GASTROENTEROLOGY, V104, P1768, DOI 10.1016/0016-5085(93)90658-Y; LEVANT JA, 1974, JAMA-J AM MED ASSOC, V229, P51, DOI 10.1001/jama.229.1.51; LIN A, 1990, ANN INTERN MED, V113, P166, DOI 10.7326/0003-4819-113-2-166; LOIUDICE TA, 1984, AM J GASTROENTEROL, V79, P553; LONDON NJM, 1991, BRIT J SURG, V78, P1452, DOI 10.1002/bjs.1800781216; LONDON NJM, 1989, BRIT J SURG, V76, P268, DOI 10.1002/bjs.1800760317; LOPEZ MCS, 1991, AM J GASTROENTEROL, V86, P764; MACHADO MCC, 1986, DIGEST DIS SCI, V31, pS25; MALLORY A, 1980, GASTROENTEROLOGY, V78, P813, DOI 10.1016/0016-5085(80)90689-7; MARKS IN, 1984, PANCREATITIS CONCEPT, P371; MAXSON CJ, 1992, AM J GASTROENTEROL, V87, P708; MAYER AD, 1985, NEW ENGL J MED, V312, P399, DOI 10.1056/NEJM198502143120703; MAYER AD, 1985, SURG GYNECOL OBSTET, V160, P507; MCKAY AJ, 1982, BRIT J SURG, V69, P369, DOI 10.1002/bjs.1800690704; MCKAY JW, 1958, GASTROENTEROLOGY, V35, P256; MCLATCHIE GR, 1981, DIGESTION, V21, P13, DOI 10.1159/000198513; MCMAHON MJ, 1980, ACTA CHIR SCAND, V146, P171; MEISELMAN MS, 1988, J CLIN GASTROENTEROL, V10, P537, DOI 10.1097/00004836-198810000-00012; MESHKINPOUR H, 1979, GASTROENTEROLOGY, V77, P687; MIXTER CG, 1962, NEW ENGL J MED, V266, P265, DOI 10.1056/NEJM196202082660601; MOFENSON HC, 1991, J TOXICOL-CLIN TOXIC, V29, P223, DOI 10.3109/15563659109038615; MOODY FG, 1993, GASTROENTEROLOGY, V104, P927, DOI 10.1016/0016-5085(93)91034-F; MORANTE AL, 1986, POSTGRAD MED J, V62, P407, DOI 10.1136/pgmj.62.727.407; Moynihan B, 1925, ANN SURG, V81, P132; NAEIJE R, 1978, BRIT MED J, V2, P659, DOI 10.1136/bmj.2.6138.659; NEOPTOLEMOS JP, 1984, BRIT J SURG, V71, P230, DOI 10.1002/bjs.1800710324; NEOPTOLEMOS JP, 1988, LANCET, V2, P979, DOI 10.1016/S0140-6736(88)90740-4; NEVALAINEN TJ, 1987, ACUTE PANCREATITIS, P71; NUUTINEN P, 1988, PANCREAS, V3, P53, DOI 10.1097/00006676-198802000-00010; Opie EL, 1901, AM J MED SCI, V121, P27, DOI 10.1097/00000441-190101000-00002; PATTI MG, 1990, SURG CLIN N AM, V70, P1277; PEDERZOLI P, 1993, SURG GYNECOL OBSTET, V176, P480; PEZZILLI R, 1993, DIGEST DIS SCI, V38, P1265, DOI 10.1007/BF01296077; PIEPERBIGELOW C, 1990, GASTROENTEROL CLIN N, V19, P793; PUOLAKKAINEN PA, 1989, ACTA CHIR SCAND, V155, P25; RANSON JHC, 1976, SURG GYNECOL OBSTET, V143, P209; RANSON JHC, 1982, AM J GASTROENTEROL, V77, P633; RANSON JHC, 1985, ANN SURG, V201, P656, DOI 10.1097/00000658-198505000-00016; RANSON JHC, 1977, SURGERY, V82, P99; RANSON JHC, 1974, SURG GYNECOL OBSTET, V139, P69; RANSON JHC, 1990, ANN SURG, V211, P708, DOI 10.1097/00000658-199006000-00009; RATTNER DW, 1992, AM J SURG, V163, P105, DOI 10.1016/0002-9610(92)90261-O; RENNER IG, 1985, DIGEST DIS SCI, V30, P1005, DOI 10.1007/BF01308298; ROS E, 1991, GASTROENTEROLOGY, V101, P1701, DOI 10.1016/0016-5085(91)90410-M; SAARIO IA, 1983, AM J SURG, V145, P349, DOI 10.1016/0002-9610(83)90198-8; SAX HC, 1987, AM J SURG, V153, P117, DOI 10.1016/0002-9610(87)90211-X; SCHRODER T, 1991, ANN SURG, V214, P663, DOI 10.1097/00000658-199112000-00004; SCHWARTZ MS, 1989, AM J GASTROENTEROL, V84, P459; SEMLACHER EA, 1993, AM J GASTROENTEROL, V88, P756; SENN J, 1886, SURGERY PANCREAS, P71; SHEARER MG, 1986, BRIT J SURG, V73, P282, DOI 10.1002/bjs.1800730412; SHERMAN S, 1990, GASTROINTEST ENDOSC, V36, P462, DOI 10.1016/S0016-5107(90)71115-7; SHERMAN S, 1991, PANCREAS, V6, P350, DOI 10.1097/00006676-199105000-00013; SHERMAN S, 1992, PANCREAS, V7, P402; SIMPSON WG, 1990, SOUTH MED J, V83, P417, DOI 10.1097/00007611-199004000-00014; SINGH M, 1990, GASTROENTEROLOGY, V98, P1051, DOI 10.1016/0016-5085(90)90033-W; SKYRING A, 1965, BRIT MED J, V2, P627, DOI 10.1136/bmj.2.5462.627; STEINBERG WM, 1985, ANN INTERN MED, V102, P576, DOI 10.7326/0003-4819-102-5-576; STEINBERG WM, 1987, GASTROENTEROLOGY, V93, P1420, DOI 10.1016/0016-5085(87)90275-7; STEINBERG WM, 1990, GASTROENTEROL CLIN N, V19, P849; STEINBERG WM, 1985, HOSP PRACT, V20, P95; STONE HH, 1981, ANN SURG, V194, P305, DOI 10.1097/00000658-198109000-00008; Symmers WSC, 1917, DUBLIN J MED SCI, V143, P244; TAM PKH, 1985, J PEDIATR SURG, V20, P58, DOI 10.1016/S0022-3468(85)80393-6; TENNER SM, 1992, AM J GASTROENTEROL, V87, P1755; THOMSON SR, 1987, BRIT J SURG, V74, P398, DOI 10.1002/bjs.1800740526; TOSKES PP, 1990, GASTROENTEROL CLIN N, V19, P783; TRAN DD, 1992, AM J GASTROENTEROL, V87, P604; TRAPNELL JE, 1974, BRIT J SURG, V61, P177, DOI 10.1002/bjs.1800610303; TRAPNELL JE, 1967, AM J DIG DIS, V12, P409, DOI 10.1007/BF02241945; USADEL KH, 1985, DIGEST DIS SCI, V30, P992; VALDERRAMA R, 1992, DIGESTION, V51, P65, DOI 10.1159/000200877; VENU RP, 1989, DIGEST DIS SCI, V34, P56, DOI 10.1007/BF01536154; Wall A J, 1965, Med J Aust, V2, P281; WARSHAW AL, 1975, ANN SURG, V181, P314, DOI 10.1097/00000658-197503000-00012; WATERWOR.MW, 1974, LANCET, V1, P1231; WEIZMAN Z, 1988, J PEDIATR-US, V113, P24, DOI 10.1016/S0022-3476(88)80523-7; WHICHER JT, 1982, GUT, V23, P944, DOI 10.1136/gut.23.11.944; WHITE TT, 1970, AM J SURG, V120, P132, DOI 10.1016/S0002-9610(70)80100-3; WILCOX CM, 1990, GASTROENTEROLOGY, V99, P263, DOI 10.1016/0016-5085(90)91257-7; WILSON C, 1988, INT J PANCREATOL, V3, P273; WILSON C, 1990, BRIT J SURG, V77, P1260, DOI 10.1002/bjs.1800771120; WILSON C, 1989, BRIT J SURG, V76, P177, DOI 10.1002/bjs.1800760224; WILSON C, 1988, BRIT J SURG, V75, P1119, DOI 10.1002/bjs.1800751123; WILSON C, 1990, BRIT J SURG, V77, P731, DOI 10.1002/bjs.1800770705; WILSON RH, 1991, BRIT J SURG, V78, P1196, DOI 10.1002/bjs.1800781017; ZIEGLER DW, 1988, ANN SURG, V207, P257, DOI 10.1097/00000658-198803000-00006; 1989, VITALHLTH STAT 13, V100, P1; 1987, DHHS PHS871101 PUBL	187	740	767	0	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 28	1994	330	17					1198	1210		10.1056/NEJM199404283301706	http://dx.doi.org/10.1056/NEJM199404283301706			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG586	7811319				2022-12-28	WOS:A1994NG58600006
J	MCDANIEL, R; EBERTKHOSLA, S; HOPWOOD, DA; KHOSLA, C				MCDANIEL, R; EBERTKHOSLA, S; HOPWOOD, DA; KHOSLA, C			RATIONAL DESIGN OF AROMATIC POLYKETIDE NATURAL-PRODUCTS BY RECOMBINANT ASSEMBLY OF ENZYMATIC SUBUNITS	NATURE			English	Article							STREPTOMYCES-COELICOLOR A3(2); NUCLEOTIDE-SEQUENCE; ENGINEERED BIOSYNTHESIS; HYBRID ANTIBIOTICS; DEDUCED FUNCTION; SYNTHASE GENE; ACTINORHODIN; GLAUCESCENS; CLUSTER	Recent advances in understanding of bacterial aromatic polyketide biosynthesis allow the development of a set of design rules for the rational manipulation of chain synthesis, reduction of keto groups and early cyclization steps by genetic engineering. The concept of rational design is illustrated by the preparation of Streptomyces strains that produce two new polyketides by expression of combinations of appropriate enzymatic subunits from naturally occurring polyketide synthases. The potential for generating molecular diversity within this class of molecules by genetic engineering is enormous.	STANFORD UNIV,DEPT CHEM ENGN,STANFORD,CA 94305; JOHN INNES CTR,DEPT GENET,NORWICH NR4 7UH,NORFOLK,ENGLAND	Stanford University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center				Khosla, Chaitan/0000-0001-6529-495X				AOYAMA T, 1992, J ANTIBIOT, V45, P1767, DOI 10.7164/antibiotics.45.1767; BECK J, 1990, EUR J BIOCHEM, V192, P487, DOI 10.1111/j.1432-1033.1990.tb19252.x; BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; BIBB MJ, 1994, GENE, V142, P31, DOI 10.1016/0378-1119(94)90351-4; CARTER GT, 1989, J ORG CHEM, V54, P4321, DOI 10.1021/jo00279a018; DAVIS NK, 1990, MOL MICROBIOL, V4, P1679, DOI 10.1111/j.1365-2958.1990.tb00545.x; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; DONADIO S, 1992, GENE, V115, P97, DOI 10.1016/0378-1119(92)90546-2; FERNANDEZMORENO MA, 1992, J BIOL CHEM, V267, P19278; Fu H, 1994, Chem Biol, V1, P205, DOI 10.1016/1074-5521(94)90012-4; FU H, 1994, J AM CHEM SOC, V116, P4166, DOI 10.1021/ja00089a003; FU H, 1994, BIOCHEMISTRY-US, V33, P9321, DOI 10.1021/bi00197a036; FU H, 1994, J AM CHEM SOC, V116, P6443, DOI 10.1021/ja00093a058; GRIFFIN DA, 1984, J CHEM SOC PERK T 1, P1035, DOI 10.1039/p19840001035; HALLAM SE, 1988, GENE, V74, P305, DOI 10.1016/0378-1119(88)90165-5; HOPWOOD DA, 1985, NATURE, V314, P642, DOI 10.1038/314642a0; KAO CM, 1994, SCIENCE, V265, P509, DOI 10.1126/science.8036492; KAO CM, 1994, J AM CHEM SOC, V116, P11612, DOI 10.1021/ja00104a069; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; KHOSLA C, 1993, J BACTERIOL, V175, P2197, DOI 10.1128/JB.175.8.2197-2204.1993; MALPARTIDA F, 1987, NATURE, V325, P818, DOI 10.1038/325818a0; MCDANIEL R, 1994, P NATL ACAD SCI USA, V91, P11542, DOI 10.1073/pnas.91.24.11542; MCDANIEL R, 1993, J AM CHEM SOC, V115, P11671, DOI 10.1021/ja00078a002; MCDANIEL R, 1994, J AM CHEM SOC, V116, P10855, DOI 10.1021/ja00103a001; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MCDANIEL R, IN PRESS J AM CHEM S; OHagan D., 1991, POLYKETIDE METABOLIT; SHERMAN DH, 1989, EMBO J, V8, P2717, DOI 10.1002/j.1460-2075.1989.tb08413.x; SUMMERS RG, 1992, J BACTERIOL, V174, P1810, DOI 10.1128/jb.174.6.1810-1820.1992; TOKIWA Y, 1992, J AM CHEM SOC, V114, P4107, DOI 10.1021/ja00037a011; YU TW, 1994, J BACTERIOL, V176, P2627, DOI 10.1128/JB.176.9.2627-2634.1994; ZHANG HL, 1990, J ORG CHEM, V55, P1682, DOI 10.1021/jo00292a053	32	238	249	1	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					549	554		10.1038/375549a0	http://dx.doi.org/10.1038/375549a0			6	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791871				2022-12-28	WOS:A1995RD28700041
J	CHIU, ES; AUSTIN, JHM				CHIU, ES; AUSTIN, JHM			ACUPUNCTURE NEEDLE FRAGMENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											CHIU, ES (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,NEW YORK,NY 10032, USA.								0	10	10	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 2	1995	332	5					304	304		10.1056/NEJM199502023320505	http://dx.doi.org/10.1056/NEJM199502023320505			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD396	7816066				2022-12-28	WOS:A1995QD39600005
J	KIMBALL, HR; YOUNG, PR				KIMBALL, HR; YOUNG, PR			EDUCATIONAL RESOURCE SHARING AND COLLABORATIVE TRAINING IN FAMILY-PRACTICE AND INTERNAL-MEDICINE - A STATEMENT FROM THE AMERICAN-BOARD-OF-INTERNAL-MEDICINE AND THE AMERICAN-BOARD-OF-FAMILY-PRACTICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESIDENCY		AMER BOARD FAMILY PRACTICE,LEXINGTON,KY		KIMBALL, HR (corresponding author), AMER BOARD INTERNAL MED,OFF PRESIDENT,3624 MARKET ST,PHILADELPHIA,PA 19104, USA.							CHRISTIANSEN RG, 1986, JAMA-J AM MED ASSOC, V255, P2628, DOI 10.1001/jama.255.19.2628; KIMBALL HR, 1994, JAMA-J AM MED ASSOC, V271, P315, DOI 10.1001/jama.271.4.315; ODELL DV, 1992, ACAD MED, V67, P88, DOI 10.1097/00001888-199202000-00006; RIVO ML, 1994, JAMA-J AM MED ASSOC, V271, P1499, DOI 10.1001/jama.271.19.1499; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WENNBERG JE, 1993, HEALTH AFFAIR, V12, P89, DOI 10.1377/hlthaff.12.2.89; 1994, US PHS4TH HLTH RES S; 1994, 1994 PHYS PAYM REV C; 1994, J GEN INTERN MED S1, V9, pS1; 1993, RECRUITMENT EXPERIEN	10	17	17	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	1995	273	4					320	322		10.1001/jama.273.4.320	http://dx.doi.org/10.1001/jama.273.4.320			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QC057	7815661				2022-12-28	WOS:A1995QC05700032
J	KOSTER, T; BLANN, AD; BRIET, E; VANDENBROUCKE, JP; ROSENDAAL, FR				KOSTER, T; BLANN, AD; BRIET, E; VANDENBROUCKE, JP; ROSENDAAL, FR			ROLE OF CLOTTING FACTOR-VIII IN EFFECT OF VON-WILLEBRAND-FACTOR ON OCCURRENCE OF DEEP-VEIN THROMBOSIS	LANCET			English	Article							POOR ANTICOAGULANT RESPONSE; ISCHEMIC-HEART-DISEASE; ACTIVATED PROTEIN-C; BLOOD GROUP-A; VONWILLEBRAND-FACTOR; VENOUS THROMBOSIS; RISK-FACTORS; GROUP-B; ATHEROSCLEROSIS; THROMBOPHILIA	To elucidate the roles of the ABO blood group, von Willebrand factor (vWF), and clotting factor VIII in the process of deep-vein thrombosis we undertook a population-based patient-control study in which 301 consecutive patients younger than 70 with a first, objectively diagnosed episode of venous thrombosis and without an underlying malignant disorder were compared with 301 healthy controls matched for age and sex. In univariate analysis, blood group, vWF concentration, and factor VIII concentrations were all related to deep-vein thrombosis. The risk of thrombosis increased with increasing vWF or factor VIII concentration and was higher in subjects of non-O blood groups than in those of group O. In multivariate analysis only factor VIII remained as a risk factor, and the dose-response relation between factor VIII concentration and risk of thrombosis persisted (subjects with factor VIII concentrations above 1500 IU/L had an adjusted odds ratio of 4.8 [95% CI 2.3-10.0]). By contrast, the adjusted odds ratio for each vWF stratum did not differ from 1, and that for blood group was 1.5 (1.0-2.2). Our findings point to an effect on thrombosis risk of vWF and blood group, the former fully and the latter at least partly mediated through factor VIII. The 25% prevalence of factor VIII concentrations above 1500 IU/L among unselected consecutive thrombosis patients and the high adjusted relative risk for thrombosis lead to the conclusion that high factor VIII concentrations are common and represent a clear increase in risk of thrombosis, similar to the risks conferred by deficiencies of the coagulation-inhibiting proteins and activated protein C resistance.	UNIV LEIDEN HOSP,CTR HEMOSTASIS & THROMBOSIS RES,LEIDEN,NETHERLANDS; UNIV S MANCHESTER HOSP,DEPT SURG,MANCHESTER,LANCS,ENGLAND	Leiden University; Leiden University Medical Center (LUMC); Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	KOSTER, T (corresponding author), UNIV LEIDEN HOSP,DEPT CLIN EPIDEMIOL,BLDG 1 CO-P-43,POB 9600,2300 RC LEIDEN,NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020; Rosendaal, Frits/Q-3842-2017	Vandenbroucke, Jan/0000-0001-5668-6716; Rosendaal, Frits/0000-0003-2558-7496				ALLAART CF, 1993, LANCET, V341, P134, DOI 10.1016/0140-6736(93)90003-Y; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BLANN AD, 1993, INT J OBESITY, V17, P723; BLANN AD, 1994, EUR J VASCULAR SURG, P10; CAEKEBEKEPEERLI.KM, 1989, BRIT J HAEMATOL, V73, P217; CONLAN MG, 1993, THROMB HAEMOSTASIS, V70, P380; CUCUIANU MP, 1983, THROMB RES, V30, P487, DOI 10.1016/0049-3848(83)90183-4; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; GILL JC, 1987, BLOOD, V69, P1691; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; HIRSH J, 1986, J AM COLL CARDIOL, V8, pB104, DOI 10.1016/S0735-1097(86)80012-2; KINGSBURY KJ, 1971, LANCET, V1, P199; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LOELIGER EA, 1984, ANTICOAGULANTS MYOCA, P157; MATSUI T, 1992, J BIOL CHEM, V267, P8723; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MEDALIE JH, 1981, NEW ENGL J MED, V285, P1348; MILETICH JP, 1993, CELL, V72, P477, DOI 10.1016/0092-8674(93)90063-V; OBRIEN JR, 1990, THROMB RES, V59, P221, DOI 10.1016/0049-3848(90)90288-N; ROSENDAAL FR, 1990, BRIT J HAEMATOL, V75, P525, DOI 10.1111/j.1365-2141.1990.tb07793.x; ROSENDAAL FR, 1989, BRIT J HAEMATOL, V71, P71, DOI 10.1111/j.1365-2141.1989.tb06277.x; SHORT PE, 1982, MED LAB SCI, V32, P351; SODETZ JM, 1979, J BIOL CHEM, V254, P754; TALBOT S, 1970, LANCET, V1, P1257; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; WEISS HJ, 1977, J CLIN INVEST, V60, P390, DOI 10.1172/JCI108788	26	940	957	0	21	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					152	155		10.1016/S0140-6736(95)90166-3	http://dx.doi.org/10.1016/S0140-6736(95)90166-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7823669				2022-12-28	WOS:A1995QC55000009
J	HO, DD; NEUMANN, AU; PERELSON, AS; CHEN, W; LEONARD, JM; MARKOWITZ, M				HO, DD; NEUMANN, AU; PERELSON, AS; CHEN, W; LEONARD, JM; MARKOWITZ, M			RAPID TURNOVER OF PLASMA VIRIONS AND CD4 LYMPHOCYTES IN HIV-1 INFECTION	NATURE			English	Article							CELLS; AIDS; INDIVIDUALS; PCR	Treatment of infected patients with ABT-538, an inhibitor of the protease of human immunodeficiency virus type 1 (HIV-1), causes plasma HIV-1 levels to decrease exponentially (mean half-life, 2.1 +/- 0.4 days) and CD4 lymphocyte counts to rise substantially. Minimum estimates of HIV-1 production and clearance and of CD4 lymphocyte turnover indicate that replication of HIV-1 in vivo is continuous and highly productive, driving the rapid turnover of CD4 lymphocytes.	SANTA FE INST,SANTA FE,NM 87501; LOS ALAMOS NATL LAB,DIV THEORET,LOS ALAMOS,NM 87545; ABBOTT LABS,DIV PHARMACEUT PROD,ABBOTT PK,IL 60064	The Santa Fe Institute; United States Department of Energy (DOE); Los Alamos National Laboratory; Abbott Laboratories	HO, DD (corresponding author), NYU,SCH MED,AARON DIAMOND AIDS RES CTR,455 1ST AVE,NEW YORK,NY 10016, USA.		Perelson, Alan S/Z-1959-2019	Perelson, Alan S/0000-0002-2455-0002				AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; CAO Y, IN PRESS AIDS RES HU; COFFIN JM, 1992, CURR TOP MICROBIOL, V176, P143; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; GRODY WW, 1985, AM J CLIN PATHOL, V84, P85, DOI 10.1093/ajcp/84.1.85; HAASE AT, 1994, ANN NY ACAD SCI, V724, P75, DOI 10.1111/j.1749-6632.1994.tb38897.x; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KEMPF D, IN PRESS P NATN ACAD; MARKOWITZ M, IN PRESS J VIROL; PACHL C, IN PRESS J AIDS; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PATTERSON BK, 1993, SCIENCE, V260, P976, DOI 10.1126/science.8493534; PAUL WE, 1985, FUNDAMENTAL IMMUNOLO; PERELSON AS, 1993, MATH BIOSCI, V114, P81, DOI 10.1016/0025-5564(93)90043-A; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; WAINHOBSON S, 1993, NATURE, V366, P22, DOI 10.1038/366022b0; WAINHOBSON S, 1993, CURR OPIN GENET DEV, V3, P878, DOI 10.1016/0959-437X(93)90008-D; WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571	20	3708	3790	4	232	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					123	126		10.1038/373123a0	http://dx.doi.org/10.1038/373123a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7816094				2022-12-28	WOS:A1995QB06300049
J	RADZICKA, A; WOLFENDEN, R				RADZICKA, A; WOLFENDEN, R			A PROFICIENT ENZYME	SCIENCE			English	Article							TRANSITION-STATE STABILIZATION; STAPHYLOCOCCAL NUCLEASE; DECARBOXYLASE; ACID; CATALYSIS; MECHANISM; RATES; 5'-PHOSPHATE; PURIFICATION; SPECIFICITY	Orotic acid is decarboxylated with a half-time (t(1/2)) of 78 million years in neutral aqueous solution at room temperature, as indicated by reactions in quartz tubes at elevated temperatures. Spontaneous hydrolysis of phosphodiester bonds, such as those present in the backbone of DNA, proceeds even more slowly at high temperatures, but the heat of activation is less positive, so that dimethyl phosphate is hydrolyzed with a t(1/2) of 130,000 years in neutral solution at room temperature. These values extend the known range of spontaneous rate constants for reactions that are also susceptible to catalysis by enzymes to more than 14 orders of magnitude. Values of the second-order rate constant k(cat)/K-m for the corresponding enzyme reactions are confined to a range of only 600-fold, in contrast. Orotidine 5'-phosphate decarboxylase, an extremely proficient enzyme, enhances the rate of reaction by a factor of 10(17) and is estimated to bind the altered substrate in the transition state with a dissociation constant of less than 5 x 10(-24) M.			RADZICKA, A (corresponding author), UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599, USA.				NIGMS NIH HHS [GM-18325] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018325, R37GM018325] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHESON SA, 1990, BIOCHEMISTRY-US, V29, P3198, DOI 10.1021/bi00465a007; ALBERTY RA, 1958, J PHYS CHEM-US, V62, P154, DOI 10.1021/j150560a005; ANDREWS PR, 1973, BIOCHEMISTRY-US, V12, P3492, DOI 10.1021/bi00742a022; BEAK P, 1976, J AM CHEM SOC, V98, P3601, DOI 10.1021/ja00428a035; BELL JB, 1991, J BIOL CHEM, V266, P12662; BUNTON CA, 1960, J CHEM SOC, P3293, DOI 10.1039/jr9600003293; BURGNER JW, 1984, BIOCHEMISTRY-US, V23, P3636, DOI 10.1021/bi00311a010; DEWOLF WE, 1979, J BIOL CHEM, V254, P868; DUMAS DP, 1989, J BIOL CHEM, V264, P19659; FOX JJ, 1957, BIOCHIM BIOPHYS ACTA, V23, P295, DOI 10.1016/0006-3002(57)90331-1; FRICK L, 1987, BIOORG CHEM, V15, P100, DOI 10.1016/0045-2068(87)90011-3; GARRETT ER, 1972, J AM CHEM SOC, V94, P8532, DOI 10.1021/ja00779a040; GRATHWOHL C, 1981, BIOPOLYMERS, V20, P2623, DOI 10.1002/bip.1981.360201209; HALL A, 1975, BIOCHEMISTRY-US, V14, P4348, DOI 10.1021/bi00690a032; HAWKINSON DC, 1991, BIOCHEMISTRY-US, V30, P10849, DOI 10.1021/bi00109a007; HUNT SW, 1982, J BIOL CHEM, V257, P14240; JOHNSON FH, 1954, KINETIC BASIS MOLECU, P187; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; LAIDLER KJ, 1965, CHEMICAL KINETICS, P488; LEVINE HL, 1980, BIOCHEMISTRY-US, V19, P4993, DOI 10.1021/bi00563a010; MIHEL I, 1979, J AM CHEM SOC, V101, P4349, DOI 10.1021/ja00509a050; NOBLE WJL, 1967, PROGR PHYS ORG CHEM, V5, P207; POLLACK RM, 1989, J AM CHEM SOC, V111, P6419, DOI 10.1021/ja00198a066; PUTMAN SJ, 1972, BIOCHEM J, V129, P301, DOI 10.1042/bj1290301; Roughton FJW, 1941, J AM CHEM SOC, V63, P2930, DOI 10.1021/ja01856a018; SERPERSU EH, 1986, BIOCHEMISTRY-US, V25, P68, DOI 10.1021/bi00349a011; SMILEY JA, 1991, BIOCHEMISTRY-US, V30, P6216, DOI 10.1021/bi00239a020; SMILEY JA, 1994, P NATL ACAD SCI USA, V91, P8319, DOI 10.1073/pnas.91.18.8319; SMILEY JA, 1992, BIOCHEMISTRY-US, V31, P12162, DOI 10.1021/bi00163a027; STEINER H, 1975, EUR J BIOCHEM, V59, P253, DOI 10.1111/j.1432-1033.1975.tb02449.x; TUCKER PW, 1978, MOL CELL BIOCHEM, V22, P67, DOI 10.1007/BF00496235; WHITAKER JR, 1986, BIOCHEMISTRY-US, V5, P386; WOLFENDEN R, 1976, ANNU REV BIOPHYS BIO, V5, P271, DOI 10.1146/annurev.bb.05.060176.001415	33	697	709	3	175	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 6	1995	267	5194					90	93		10.1126/science.7809611	http://dx.doi.org/10.1126/science.7809611			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA235	7809611				2022-12-28	WOS:A1995QA23500036
J	THUT, CJ; CHEN, JL; KLEMM, R; TJIAN, R				THUT, CJ; CHEN, JL; KLEMM, R; TJIAN, R			P53 TRANSCRIPTIONAL ACTIVATION MEDIATED BY COACTIVATORS TAF(II)40 AND TAF(II)60	SCIENCE			English	Article							WILD-TYPE; BINDING PROTEIN; MDM-2 ONCOGENE; DOMAIN; GENE; EXPRESSION; INVITRO; DNA; SUPPRESSION; MUTATIONS	The tumor suppressor protein p53 is a transcriptional regulator that enhances the expression of proteins that control cellular proliferation. The multisubunit transcription factor IID (TFIID) is thought to be a primary target for site-specific activators of transcription. Here, a direct interaction between the activation domain of p53 and two subunits of the TFIID complex, TAF(II)40 and TAF(II)60, is reported. A double point mutation in the activation domain of p53 impaired the ability of this domain to activate transcription and, simultaneously, its ability to interact with both TAF(II)40 and TAF(II)60. Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAF(II)250, dTAF(II)60, and dTAF(II)40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAF(II)40 and TAF(II)60 did not. Together, these results suggest that TAF(II)40 and TAF(II)60 are important targets for transmitting activation signals between p53 and the initiation complex.			THUT, CJ (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,401 BARKER HALL,BERKELEY,CA 94720, USA.							BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DYNALECHT BD, 1991, CELL, V66, P563; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH JA, 1994, CURR OPIN CELL BIOL, V6, P403; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HOEY T, 1993, CELL, V72, P274; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KLEMM RA, UNPUB; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MILLER C W, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P386; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THUT CJ, UNPUB; TONG X, IN PRESS J VIROL; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	41	419	422	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 6	1995	267	5194					100	104		10.1126/science.7809597	http://dx.doi.org/10.1126/science.7809597			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA235	7809597				2022-12-28	WOS:A1995QA23500039
J	UNWIN, N				UNWIN, N			ACETYLCHOLINE-RECEPTOR CHANNEL IMAGED IN THE OPEN STATE	NATURE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; DELTA-SUBUNIT; LIGAND-BINDING; ION CHANNELS; AMINO-ACIDS; H-3 CHLORPROMAZINE; CRYSTAL-STRUCTURE; TUBULAR CRYSTALS; GAMMA-SUBUNIT; AGONIST	The structure of the open-channel form of the acetylcholine receptor has been determined from electron images of Torpedo ray postsynaptic membranes activated by brief (<5 ms) mixing with droplets containing acetylcholine. Comparison with the closed-channel form shows that acetylcholine Initiates small rotations of the subunits in the extracellular domain, which trigger a change in configuration of a-helices lining the membrane-spanning pore. The open pore tapers towards the intracellular membrane face, where it is shaped by a 'barrel' of a-helices having a pronounced right-handed twist.			UNWIN, N (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.							AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; BERRIMAN J, 1994, ULTRAMICROSCOPY, V56, P241, DOI 10.1016/0304-3991(94)90012-4; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BRISSON A, 1984, J CELL BIOL, V99, P1202, DOI 10.1083/jcb.99.4.1202; CHANGEUX JP, 1992, Q REV BIOPHYS, V25, P395, DOI 10.1017/S0033583500004352; CHARNET P, 1990, NEURON, V2, P497; COHEN BN, 1992, J GEN PHYSIOL, V100, P373, DOI 10.1085/jgp.100.3.373; COLQUHOUN D, 1988, J PHYSIOL-LONDON, V395, P131, DOI 10.1113/jphysiol.1988.sp016912; COLQUHOUN D, 1985, J PHYSIOL-LONDON, V369, P501, DOI 10.1113/jphysiol.1985.sp015912; CZAJKOWSKI C, 1991, J BIOL CHEM, V266, P22603; DANI JA, 1989, J NEUROSCI, V9, P844; DEROSIER DJ, 1968, NATURE, V217, P130, DOI 10.1038/217130a0; DILGER JP, 1990, BIOPHYS J, V57, P723, DOI 10.1016/S0006-3495(90)82593-5; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; GERSTEIN M, 1993, J MOL BIOL, V229, P494, DOI 10.1006/jmbi.1993.1048; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GORNETSCHELNOKOW U, 1994, EMBO J, V13, P338, DOI 10.1002/j.1460-2075.1994.tb06266.x; HERZ JM, 1989, J BIOL CHEM, V264, P12439; Hille B., 1992, IONIC CHANNELS EXCIT; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; IMOTO K, 1991, FEBS LETT, V289, P193, DOI 10.1016/0014-5793(91)81068-J; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JACKSON MB, 1989, P NATL ACAD SCI USA, V86, P2219; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; KUBALEK E, 1987, J CELL BIOL, V105, P9, DOI 10.1083/jcb.105.1.9; LADENSTEIN R, 1988, J MOL BIOL, V203, P1045, DOI 10.1016/0022-2836(88)90128-3; LEE YH, 1994, BIOPHYS J, V66, P646, DOI 10.1016/S0006-3495(94)80838-0; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; MATSUBARA N, 1992, BIOCHEMISTRY-US, V31, P5507, DOI 10.1021/bi00139a012; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; POPOT JL, 1984, PHYSIOL REV, V64, P1162, DOI 10.1152/physrev.1984.64.4.1162; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; SINE SM, 1991, J BIOL CHEM, V266, P19369; SINE SM, 1984, BIOPHYS J, V46, P277, DOI 10.1016/S0006-3495(84)84022-9; SINE SM, 1990, J GEN PHYSIOL, V96, P395, DOI 10.1085/jgp.96.2.395; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; STEIN PE, 1994, STRUCTURE, V2, P45, DOI 10.1016/S0969-2126(00)00007-1; TOYOSHIMA C, 1990, J CELL BIOL, V111, P2623, DOI 10.1083/jcb.111.6.2623; TOYOSHIMA C, 1988, NATURE, V336, P247, DOI 10.1038/336247a0; TOYOSHIMA C, 1988, ULTRAMICROSCOPY, V25, P279, DOI 10.1016/0304-3991(88)90003-4; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; UNWIN PNT, 1975, J MOL BIOL, V94, P425, DOI 10.1016/0022-2836(75)90212-0; VALENZUELA CF, 1994, BIOPHYS J, V66, P674, DOI 10.1016/S0006-3495(94)80841-0; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012; WHITE BH, 1992, J BIOL CHEM, V267, P15770	49	886	896	0	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 5	1995	373	6509					37	43		10.1038/373037a0	http://dx.doi.org/10.1038/373037a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800037				2022-12-28	WOS:A1995QA23900047
J	SCOTT, R; SCOTT, H				SCOTT, R; SCOTT, H			CROCODILE BITES AND TRADITIONAL BELIEFS IN KOROGWE DISTRICT, TANZANIA	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To investigate why fatal crocodile bites are increasing in a Tanzanian district and the importance of traditional beliefs and superstitions in determining the residents' response to the crocodiles. Design-Information about beliefs was obtained by interview of Korogwe residents. Human and crocodile fatality statistics were obtained from the Korogwe Department of Natural Resources. Setting-Villages within Korogwe District. Subjects-Population of Korogwe District. Results-Crocodiles have been responsible for 51 deaths in the 52 months from January 1990 to April 1994. Of these, 18 deaths occurred in the first four months of 1994. Conclusions-Local beliefs and superstitions about crocodiles include those about the taming of animals, with implications concerning the choice of victim and the penalties that may ensue if a crocodile is killed. The recent rise in human fatalities is thought to relate to increasing river pollution reducing the fish supply, together with a change in social mores at the riverside which has increased the crocodiles' displeasure. A reliable pumped water supply would reduce the need to draw water and bathe in the river, and eradication of superstition would empower the villagers in the fight against a common enemy.			SCOTT, R (corresponding author), ST RAPHAELS HOSP,POB 35,TANGA,TANZANIA.								0	13	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1691	1692		10.1136/bmj.309.6970.1691	http://dx.doi.org/10.1136/bmj.309.6970.1691			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819989	Green Published			2022-12-28	WOS:A1994PY71700015
J	STILLER, CA				STILLER, CA			POPULATION-BASED SURVIVAL RATES FOR CHILDHOOD-CANCER IN BRITAIN, 1980-91	BRITISH MEDICAL JOURNAL			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; NEURO-BLASTOMA; NEUROBLASTOMA; CHEMOTHERAPY; CHILDREN; LYMPHOMA; THERAPY; PROTOCOL; UKCCSG; TRIALS	Objectives-To investigate the survival of children with cancer diagnosed during 1980-91 in order to assess the impact of developments in medical care on a Population basis. Design-Retrospective cohort study. Setting-Great-Britain. Subjects-14973 children with cancer diagnosed during 1980-91 and included in the population based National Registry of Childhood Tumours. Main outcome measures-Actuarial survival rates. Results-For all cancers combined, two year survival increased from 66% to 76% between 1980-2 and 1989-91, and five year survival increased from 57% to 65% between 1980-2 and 1986-8. Significant increases in survival rates occurred among children with acute lymphoblastic leukaemia, acute nonlymphocytic leukaemia, retinoblastoma, osteosarcoma, Ewing's sarcoma, rhabdomyosarcoma, and malignant gonadal germ cell tumours. No trend in survival was seen for children with Hodgkin's disease, central nervous system tumours, neuroblastoma, or Wilms's tumour. Conclusions-Nearly two. thirds of children who have cancer diagnosed can now expect to survive at least 10 years.			STILLER, CA (corresponding author), UNIV OXFORD,DEPT PAEDIAT,CHILDHOOD CANC RES GRP,OXFORD OX2 6HJ,ENGLAND.			Stiller, Charles/0000-0002-3006-7869				BERTHOLD F, 1991, AM J PEDIAT HEMATOL, V13, P8; BIRCH JM, 1987, INT J CANCER, V40, P620, DOI 10.1002/ijc.2910400508; BRAMWELL VHC, 1992, J CLIN ONCOL, V10, P1579, DOI 10.1200/JCO.1992.10.10.1579; CHESSELLS JM, 1992, LEUKEMIA, V6, P157; DUNST J, 1991, CANCER, V67, P2818, DOI 10.1002/1097-0142(19910601)67:11<2818::AID-CNCR2820671118>3.0.CO;2-Y; EDEN QB, 1992, BRIT J HAEMATOL, V82, P310, DOI 10.1111/j.1365-2141.1992.tb06423.x; HAAF H, 1993, JAHRESBERICHT 1992 D; HANAWA Y, 1990, MED PEDIATR ONCOL, V18, P472, DOI 10.1002/mpo.2950180607; HANN IM, 1990, BRIT J HAEMATOL, V76, P359, DOI 10.1111/j.1365-2141.1990.tb06368.x; HARTMANN O, 1988, J CLIN ONCOL, V6, P44, DOI 10.1200/JCO.1988.6.1.44; HAWKINS MM, 1991, J NATL CANCER I, V83, P1643, DOI 10.1093/jnci/83.22.1643; HAWKINS MM, 1987, BRIT J CANCER, V56, P339, DOI 10.1038/bjc.1987.200; JONES PHM, 1991, BRIT J CANCER, V64, P1; KELLIE SJ, 1988, EUR J CANCER CLIN ON, V24, P903, DOI 10.1016/0277-5379(88)90200-3; MANN JR, 1989, CANCER-AM CANCER SOC, V63, P1657; MILLER BA, 1992, NIH922789 US DEP HLT; NAITO H, 1990, J PEDIATR SURG, V25, P245, DOI 10.1016/0022-3468(90)90410-B; Neglia J P, 1991, J Pediatr Oncol Nurs, V8, P59, DOI 10.1177/104345429100800207; PINKERTON CR, 1991, BRIT J CANCER, V64, P583, DOI 10.1038/bjc.1991.354; PINKERTON CR, 1990, BRIT J CANCER, V62, P319, DOI 10.1038/bjc.1990.286; PRITCHARD J, 1989, BRIT MED J, V299, P835, DOI 10.1136/bmj.299.6703.835; ROBERTSON CM, 1994, BRIT MED J, V309, P162, DOI 10.1136/bmj.309.6948.162; SANDERS BM, 1988, BRIT J OPHTHALMOL, V72, P576, DOI 10.1136/bjo.72.8.576; SANKILA R, 1993, EUR J CANCER, V29A, P122, DOI 10.1016/0959-8049(93)90588-7; SHAFFORD EA, 1993, BRIT J CANCER, V68, P1199, DOI 10.1038/bjc.1993.504; STEVENS M, 1993, MED PEDIATR ONCOL, V21, P554; STEVENS RF, 1992, LEUKEMIA, V6, P55; STILLER CA, 1988, ARCH DIS CHILD, V63, P23, DOI 10.1136/adc.63.1.23; STILLER CA, 1990, BRIT J CANCER, V62, P806, DOI 10.1038/bjc.1990.383; STILLER CA, 1994, ARCH DIS CHILD, V70, P219, DOI 10.1136/adc.70.3.219; STILLER CA, 1989, ARCH DIS CHILD, V64, P657, DOI 10.1136/adc.64.5.657; 1991, PEDIATRICS, V89, P597	32	120	120	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1612	1616		10.1136/bmj.309.6969.1612	http://dx.doi.org/10.1136/bmj.309.6969.1612			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819936	Green Published			2022-12-28	WOS:A1994PY22000016
J	GODLEE, F				GODLEE, F			THE WORLD-HEALTH-ORGANIZATION - THE REGIONS - TOO MUCH POWER, TOO LITTLE EFFECT	BRITISH MEDICAL JOURNAL			English	Article								WHO's regional offices make it structurally one of the most decentralised of all United Nations agencies. But at what cost and to what effect? This article argues that too often the regions give only the illusion of decentralisation while wresting power from WHO's governing body and prolonging the time taken for resources to reach the point of need.										DAES EIA, 1994, DECENTRALISATION O 3; WALT G, 1992, DRUGS POLICY DEV WOR, P40; 1991, EFFECTIVENESS MULTIL; 1994, FINANCIAL REPORT AUD	4	18	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 10	1994	309	6968					1566	1570		10.1136/bmj.309.6968.1566	http://dx.doi.org/10.1136/bmj.309.6968.1566			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX564	7819902	Green Published			2022-12-28	WOS:A1994PX56400028
J	BARTLEY, M; BLANE, D				BARTLEY, M; BLANE, D			APPROPRIATENESS OF DEPRIVATION INDEXES MUST BE ENSURED	BRITISH MEDICAL JOURNAL			English	Note									CHARING CROSS & WESTMINSTER MED SCH,ACAD DEPT PSYCHIAT,LONDON W6 8RP,ENGLAND	Imperial College London	BARTLEY, M (corresponding author), UNIV OXFORD NUFFIELD COLL,OXFORD OX1 1NF,ENGLAND.							Holtermann S., 1975, SOCIAL TRENDS, V6, P33	1	26	26	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 3	1994	309	6967					1479	1479		10.1136/bmj.309.6967.1479	http://dx.doi.org/10.1136/bmj.309.6967.1479			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW053	7804050	Green Published			2022-12-28	WOS:A1994PW05300023
J	BLACKMAN, PH				BLACKMAN, PH			FIREARM VIOLENCE AND PUBLIC-HEALTH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											BLACKMAN, PH (corresponding author), NATL RIFLE ASSOC AMER,FAIRFAX,VA, USA.							ADLER KP, 1994, JAMA-J AM MED ASSOC, V271, P1281, DOI 10.1001/jama.271.16.1281; Kleck G., 1991, POINT BLANK GUNS VIO; Wright J.D., 1986, ARMED CONSIDERED DAN; 1977, CONCENTRATED URBAN E; 1978, HANDGUN CONTROL EFFE	5	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	1994	272	18					1406	1407		10.1001/jama.272.18.1406	http://dx.doi.org/10.1001/jama.272.18.1406			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PP690	7818662				2022-12-28	WOS:A1994PP69000015
J	KENT, DL; HAYNOR, DR; LONGSTRETH, WT; LARSON, EB				KENT, DL; HAYNOR, DR; LONGSTRETH, WT; LARSON, EB			CLINICAL EFFICACY OF MAGNETIC-RESONANCE-IMAGING IN NEUROIMAGING	ANNALS OF INTERNAL MEDICINE			English	Review							DEGENERATIVE DISK DISEASE; HEALTHY ELDERLY SUBJECTS; CAROTID-ARTERY STENOSIS; TEMPORAL-LOBE EPILEPSY; CERVICAL-SPINE TRAUMA; CONTRAST-ENHANCED MR; WHITE-MATTER LESIONS; T2 SIGNAL INTENSITY; MINOR HEAD-INJURY; MULTIPLE-SCLEROSIS	Purpose: To assess the clinical efficacy of magnetic resonance imaging (MRI) for neuroimaging and to provide guidelines for clinical practice. Study Selection: After a comprehensive literature search, studies of the diagnostic accuracy of MRI alone or compared with other tests and of any impact on therapeutic choices or patient outcomes were reviewed by independent readers, followed by discussion to reach consensus conclusions. Data Extraction: Of 3125 citations retrieved, 156 studies with original data could be rated according to methodologic criteria for study design. One article contributed grade A quality information about diagnostic accuracy, 28 were graded B or C, and 113 were graded D. One randomized trial and 2 comparison studies contributed grade B or C information about the impact on therapeutic choices. Only 2 studies surveyed health status before and after magnetic resonance scanning. Results: For most abnormalities, the sensitivity of MRI is equal to or better than competing technologies. Magnetic resonance imaging shows greater contrast and detail than computed tomography (CT) but also shows more clinically silent abnormalities or incidental findings. A few studies found a modest impact on therapeutic choices but no impact on quality of life or disability. Costs for MRI are high. Computed tomography is sufficient for initial diagnosis of most mass lesions or intracranial hemorrhages requiring immediate intervention. Magnetic resonance imaging is more accurate in the temporal lobes, posterior fossa, brainstem, and spinal cord. For lumbar radiculopathy, MRI and plain spinal CT are as accurate as postmyelographic CT and are less invasive. The role of magnetic resonance angiography for carotid artery stenosis is being studied. Conclusions: Although suggestions for appropriate use of MRI in clinical practice can be made, the supporting evidence in published studies is weak. Firm guidelines for appropriate use of MRI should be based on further clinical research using more rigorous methods.	UNIV WASHINGTON, SCH MED, DEPT RADIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT NEUROL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, MED CTR, SCH MED, SEATTLE, WA 98195 USA; DEPT VET AFFAIRS MED CTR, SEATTLE, WA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					AHRQ HHS [HS-06344] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ACKERMAN RH, 1992, AM J NEURORADIOL, V13, P1005; ADLER CH, 1992, ANN NEUROL, V32, P502, DOI 10.1002/ana.410320404; ALGRA PR, 1991, RADIOGRAPHICS, V11, P219, DOI 10.1148/radiographics.11.2.2028061; ALMKVIST O, 1992, ARCH NEUROL-CHICAGO, V49, P626, DOI 10.1001/archneur.1992.00530300062011; Anderson C, 1992, AM J NEURORADIOL, V13, P1005; ANDERSON CM, 1992, AM J NEURORADIOL, V13, P989; ATLAS SW, 1993, RADIOLOGY, V186, P319, DOI 10.1148/radiology.186.2.8421727; AUBIN ML, 1987, J NEURORADIOLOGY, V14, P313; AUSTROM MG, 1990, J AM GERIATR SOC, V38, P1133, DOI 10.1111/j.1532-5415.1990.tb01377.x; Awad Issam A., 1992, Neurological Research, V14, P360; BASSI P, 1990, NEURORADIOLOGY, V31, P486, DOI 10.1007/BF00340127; BECK RW, 1993, ARCH NEUROL-CHICAGO, V50, P841, DOI 10.1001/archneur.1993.00540080050013; BLATTER DD, 1992, RADIOLOGY, V183, P379, DOI 10.1148/radiology.183.2.1561338; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P403, DOI 10.2106/00004623-199072030-00013; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P1178, DOI 10.2106/00004623-199072080-00008; BOZZAO A, 1992, RADIOLOGY, V185, P135, DOI 10.1148/radiology.185.1.1523297; BRADLEY WG, 1991, RADIOLOGY, V179, P319, DOI 10.1148/radiology.179.2.2014270; BREIDAHL W H, 1991, Australasian Radiology, V35, P306, DOI 10.1111/j.1440-1673.1991.tb03035.x; BRONEN RA, 1991, MAGN RESON IMAGING, V9, P501, DOI 10.1016/0730-725X(91)90036-L; BROOKS BS, 1990, AM J ROENTGENOL, V154, P577, DOI 10.2214/ajr.154.3.2106225; BROWN BM, 1988, AM J ROENTGENOL, V151, P1205, DOI 10.2214/ajr.151.6.1205; BROWN BW, 1977, STATISTICS BIOM INTR, P29; BRYAN RN, 1991, AM J NEURORADIOL, V12, P611; BUCHFELDER M, 1993, AM J NEURORADIOL, V14, P1183; BUNDSCHUH CV, 1988, AM J ROENTGENOL, V150, P923, DOI 10.2214/ajr.150.4.923; CAILLET H, 1990, J NEURORADIOLOGY, V17, P289; CARMODY RF, 1989, RADIOLOGY, V173, P225, DOI 10.1148/radiology.173.1.2675185; CHAMBERLAIN MC, 1990, NEUROLOGY, V40, P435, DOI 10.1212/WNL.40.3_Part_1.435; CIRICILLO SF, 1990, J NEUROSURG, V73, P720, DOI 10.3171/jns.1990.73.5.0720; CLARFIELD AM, 1988, ANN INTERN MED, V109, P476, DOI 10.7326/0003-4819-109-6-476; COHEN WA, 1992, AM J NEURORADIOL, V13, P1231; COLLETTI PM, 1991, MAGN RESON IMAGING, V9, P349, DOI 10.1016/0730-725X(91)90422-I; COOK JD, 1992, J CHILD NEUROL, V7, pS51, DOI 10.1177/08830738920070010811; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DAVIS SM, 1989, AUST NZ J MED, V19, P219, DOI 10.1111/j.1445-5994.1989.tb00249.x; DAWSON DL, 1991, AM J SURG, V161, P619, DOI 10.1016/0002-9610(91)90913-X; DAY JJ, 1990, AGE AGEING, V19, P144, DOI 10.1093/ageing/19.2.144; DeCandido P, 1988, J Spinal Disord, V1, P9; DEGREEF G, 1992, AM J NEURORADIOL, V13, P835; Diem K, 1970, DOCUMENTA GEIGY SCI, P85; DIXON AK, 1991, BRIT MED J, V302, P79, DOI 10.1136/bmj.302.6768.79; DOEZEMA D, 1991, ANN EMERG MED, V20, P1281, DOI 10.1016/S0196-0644(05)81065-0; DOWLING R J, 1989, Australasian Radiology, V33, P337, DOI 10.1111/j.1440-1673.1989.tb03307.x; DRAYER BP, 1992, CLIN NEUR, V38, P87; DUGUID JR, 1986, ANN NEUROL, V20, P744, DOI 10.1002/ana.410200618; DUVOISIN B, 1991, EUR J RADIOL, V13, P96, DOI 10.1016/0720-048X(91)90088-D; EARNEST F, 1986, RADIOLOGY, V161, P132; EDELMAN RR, 1993, AM J ROENTGENOL, V161, P1, DOI 10.2214/ajr.161.1.8517285; EHRICKE HH, 1992, COMPUT MED IMAG GRAP, V16, P65, DOI 10.1016/0895-6111(92)90119-T; ELSTER AD, 1992, AM J NEURORADIOL, V13, P1309; ELSTER AD, 1991, AM J NEURORADIOL, V12, P165; ELSTER AD, 1989, RADIOLOGY, V173, P231, DOI 10.1148/radiology.173.1.2781014; ERKINJUNTTI T, 1993, ARCH NEUROL-CHICAGO, V50, P305, DOI 10.1001/archneur.1993.00540030069017; FAZEKAS F, 1989, EUR NEUROL, V29, P164, DOI 10.1159/000116401; FEIN G, 1990, ARCH GEN PSYCHIAT, V47, P220; FELBER S, 1992, NEURORADIOLOGY, V34, P413, DOI 10.1007/BF00596504; FERBERT A, 1991, STROKE, V22, P1010, DOI 10.1161/01.STR.22.8.1010; FLANDERS AE, 1990, RADIOLOGY, V177, P25, DOI 10.1148/radiology.177.1.2399326; FRANCIS DA, 1987, J NEUROL NEUROSUR PS, V50, P758, DOI 10.1136/jnnp.50.6.758; FRANKEN EA, 1986, RADIOLOGY, V161, P377, DOI 10.1148/radiology.161.2.3763904; FREDERIKSEN JL, 1992, ACTA NEUROL SCAND, V86, P317, DOI 10.1111/j.1600-0404.1992.tb05093.x; FREDERIKSEN JL, 1991, ACTA NEUROL SCAND, V83, P343, DOI 10.1111/j.1600-0404.1991.tb04713.x; FROCRAIN L, 1989, RADIOLOGY, V170, P531, DOI 10.1148/radiology.170.2.2911682; FUKUSHIMA T, 1991, SPINE, V16, pS534, DOI 10.1097/00007632-199110001-00016; FUMEYA H, 1991, Neurologia Medico-Chirurgica, V31, P650, DOI 10.2176/nmc.31.650; GANGAROSA RE, 1987, MAGN RESON IMAGING, V5, P287, DOI 10.1016/0730-725X(87)90006-3; GEANMARTON AD, 1991, RADIOLOGY, V180, P215, DOI 10.1148/radiology.180.1.2052698; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GERARD G, 1987, COMPUT RADIOL, V11, P223, DOI 10.1016/0730-4862(87)90002-3; GODERSKY JC, 1987, NEUROSURGERY, V21, P676, DOI 10.1227/00006123-198711000-00013; GOLDBERG AL, 1991, CLIN IMAG, V15, P47, DOI 10.1016/0899-7071(91)90048-Z; GOLDBERG AL, 1988, SKELETAL RADIOL, V17, P89, DOI 10.1007/BF00365133; GOLDSTEIN HA, 1990, RADIOLOGY, V174, P17, DOI 10.1148/radiology.174.1.2403679; GOLOMB J, 1993, ARCH NEUROL-CHICAGO, V50, P967, DOI 10.1001/archneur.1993.00540090066012; GRECO A, 1990, RADIOLOGY, V176, P451, DOI 10.1148/radiology.176.2.2195593; HANKEY GJ, 1990, STROKE, V21, P209, DOI 10.1161/01.STR.21.2.209; HARDJASUDARMA M, 1992, J CAN ASSOC RADIOL, V43, P100; HARRIS JO, 1991, ANN NEUROL, V29, P548, DOI 10.1002/ana.410290515; HAUGHTON VM, 1988, RADIOLOGY, V166, P829, DOI 10.1148/radiology.166.3.3340779; HAUGHTON VM, 1986, RADIOLOGY, V160, P751, DOI 10.1148/radiology.160.3.3737914; HAYMAN LA, 1991, AM J NEURORADIOL, V12, P899; HEINZ ER, 1989, AM J ROENTGENOL, V152, P347, DOI 10.2214/ajr.152.2.347; HENDRIE HC, 1989, AM J NEURORADIOL, V10, P703; HOFFMAN RM, 1991, SPINE, V16, P623, DOI 10.1097/00007632-199106000-00005; HOMMEL M, 1990, STROKE, V21, P546, DOI 10.1161/01.STR.21.4.546; HOROWITZ AL, 1989, AM J NEURORADIOL, V10, P303; HUSAIN MM, 1991, PSYCHIAT RES-NEUROIM, V40, P95, DOI 10.1016/0925-4927(91)90001-7; HUSTON J, 1993, RADIOLOGY, V186, P339, DOI 10.1148/radiology.186.2.8421731; HUTCHINS LG, 1990, RADIOLOGY, V175, P837, DOI 10.1148/radiology.175.3.2343134; IGARASHI H, 1991, CEPHALALGIA, V11, P69, DOI 10.1046/j.1468-2982.1991.1102069.x; JACK CR, 1992, NEUROLOGY, V42, P183, DOI 10.1212/WNL.42.1.183; JACK CR, 1992, ANN NEUROL, V31, P138, DOI 10.1002/ana.410310204; JACKSON GD, 1990, NEUROLOGY, V40, P1869, DOI 10.1212/WNL.40.12.1869; JACKSON RP, 1989, SPINE, V14, P1362, DOI 10.1097/00007632-198912000-00013; JACOBS L, 1991, NEUROLOGY, V41, P15, DOI 10.1212/WNL.41.1.15; JENKINS A, 1988, J NEUROSURG, V68, P731, DOI 10.3171/jns.1988.68.5.0731; JENSEN MC, 1993, AM J ROENTGENOL, V160, P153, DOI 10.2214/ajr.160.1.8416615; JOHNSEN DE, 1991, RADIOGRAPHICS, V11, P727, DOI 10.1148/radiographics.11.5.1947311; KANAL E, 1990, RADIOLOGY, V176, P593, DOI 10.1148/radiology.176.3.2202008; KATAYAMA H, 1990, RADIOLOGY, V175, P621, DOI 10.1148/radiology.175.3.2343107; KAWAMOTO A, 1991, CLIN EXP PHARMACOL P, V18, P605, DOI 10.1111/j.1440-1681.1991.tb01633.x; KENT DL, 1994, ANN INTERN MED, V120, P872; KENT DL, 1992, AM J ROENTGENOL, V158, P1135, DOI 10.2214/ajr.158.5.1533084; KENT DL, 1992, INVEST RADIOL, V27, P245, DOI 10.1097/00004424-199203000-00014; KENT DL, 1988, ANN INTERN MED, V108, P402, DOI 10.7326/0003-4819-108-3-402; KERTESZ A, 1987, NEUROLOGY, V37, P1580, DOI 10.1212/WNL.37.10.1580; KIDO D, 1993, AJNR AM J NEORORADIO; KIDO DK, 1990, MED DECIS MAKING, V10, P331; KIDO DK, 1991, ARCH NEUROL-CHICAGO, V48, P484, DOI 10.1001/archneur.1991.00530170044019; KILPATRICK CJ, 1991, EPILEPSIA, V32, P358, DOI 10.1111/j.1528-1157.1991.tb04664.x; KIRSCH SJ, 1992, NEUROSCI LETT, V134, P187, DOI 10.1016/0304-3940(92)90513-7; KROL G, 1988, AM J ROENTGENOL, V151, P583, DOI 10.2214/ajr.151.3.583; KUCHARCZYK W, 1986, RADIOLOGY, V161, P761, DOI 10.1148/radiology.161.3.3786729; KUZNIECKY R, 1987, ANN NEUROL, V22, P341, DOI 10.1002/ana.410220310; KUZNIECKY R, 1993, ARCH NEUROL-CHICAGO, V50, P65, DOI 10.1001/archneur.1993.00540010059018; LARSON EB, 1986, ARCH INTERN MED, V146, P1917, DOI 10.1001/archinte.146.10.1917; LARSON EB, 1984, ANN INTERN MED, V100, P417, DOI 10.7326/0003-4819-100-3-417; LASTER RE, 1993, AM J NEURORADIOL, V14, P681; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVITT MA, 1991, AM J EMERG MED, V9, P131, DOI 10.1016/0735-6757(91)90173-H; LEVY RM, 1990, J ACQ IMMUN DEF SYND, V3, P461; LHUILLIER FM, 1992, NEURORADIOLOGY, V34, P144, DOI 10.1007/BF00588162; LONERAGAN R, 1989, Australasian Radiology, V33, P47, DOI 10.1111/j.1440-1673.1989.tb03234.x; Lunsford L D, 1986, Acta Radiol Suppl, V369, P154; LYNCH SG, 1990, NEUROLOGY, V40, P900, DOI 10.1212/WNL.40.6.900; MARUYAMA Y, 1984, RADIOLOGY, V152, P177, DOI 10.1148/radiology.152.1.6729108; MASCIOCCHI C, 1990, Chirurgia degli Organi di Movimento, V75, P141; MATSUMURA K, 1990, SURG NEUROL, V34, P71, DOI 10.1016/0090-3019(90)90100-4; MCFARLAND HF, 1992, ANN NEUROL, V32, P758, DOI 10.1002/ana.410320609; MEHALIC TF, 1990, NEUROSURGERY, V26, P217, DOI 10.1227/00006123-199002000-00006; MILLER DH, 1988, J NEUROL NEUROSUR PS, V51, P1569, DOI 10.1136/jnnp.51.12.1569; MILLER DH, 1991, J NEUROL NEUROSUR PS, V54, P683, DOI 10.1136/jnnp.54.8.683; MION CC, 1991, PSYCHIAT RES-NEUROIM, V40, P157, DOI 10.1016/0165-1781(91)90155-I; MODIC MT, 1988, RADIOLOGY, V166, P193, DOI 10.1148/radiology.166.1.3336678; MOSCA LJ, 1992, CLIN RES, V40, pA561; MOULOPOULOS LA, 1992, RADIOLOGY, V185, P833, DOI 10.1148/radiology.185.3.1438772; MUSHLIN A, 1994, IN PRESS ARCH NEUROL; MUSHLIN AI, 1993, JAMA-J AM MED ASSOC, V269, P3146, DOI 10.1001/jama.269.24.3146; NIENDORF HP, 1988, 2ND P EUR C NMR MED, P50; NOORBEHESHT B, 1987, NEURORADIOLOGY, V29, P512, DOI 10.1007/BF00350432; NORRIS JW, 1982, LANCET, V1, P328; OFFENBACHER H, 1993, NEUROLOGY, V43, P905, DOI 10.1212/WNL.43.5.905; OFFENBACHER H, 1992, WIEN KLIN WOCHENSCHR, V104, P589; OGAWA T, 1993, RADIOLOGY, V186, P345, DOI 10.1148/radiology.186.2.8421732; Ogawa T, 1992, Acta Neurochir Suppl (Wien), V55, P8; OJALA M, 1988, ACTA NEUROL SCAND, V78, P26, DOI 10.1111/j.1600-0404.1988.tb03614.x; ORRISON WW, 1991, RADIOLOGY, V181, P121, DOI 10.1148/radiology.181.1.1887020; OSBORN RE, 1991, AM J NEURORADIOL, V12, P521; PALMER F J, 1988, Australasian Radiology, V32, P426, DOI 10.1111/j.1440-1673.1988.tb02770.x; PAN XM, 1992, J VASC SURG, V16, P609, DOI 10.1016/0741-5214(92)90168-8; PANNIZZO F, 1992, MAGNET RESON MED, V24, P90, DOI 10.1002/mrm.1910240110; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; PAVONE P, 1992, RADIOLOGY, V184, P401, DOI 10.1148/radiology.184.2.1620836; PHILLIPS ME, 1990, J COMPUT ASSIST TOMO, V14, P536, DOI 10.1097/00004728-199007000-00007; PILLAY P K, 1991, Neurological Research, V13, P3; POLAK JF, 1993, RADIOLOGY, V186, P333, DOI 10.1148/radiology.186.2.8421730; POSER S, 1991, ACTA NEUROL SCAND, V83, P172, DOI 10.1111/j.1600-0404.1991.tb04671.x; POST MJD, 1988, AM J ROENTGENOL, V151, P373, DOI 10.2214/ajr.151.2.373; POST MJD, 1991, RHEUM DIS CLIN N AM, V17, P773; POST MJD, 1991, RADIOLOGY, V178, P131, DOI 10.1148/radiology.178.1.1984291; Riela A R, 1987, Electroencephalogr Clin Neurophysiol Suppl, V39, P161; RIZZOLO SJ, 1991, SPINE, V16, pS187, DOI 10.1097/00007632-199106001-00002; ROSS JS, 1990, AM J ROENTGENOL, V155, P159, DOI 10.2214/ajr.155.1.2112839; ROSS JS, 1990, AM J ROENTGENOL, V155, P867, DOI 10.2214/ajr.155.4.2119123; RUDICK RA, 1992, ARCH NEUROL-CHICAGO, V49, P685, DOI 10.1001/archneur.1992.00530310027007; Ruggieri P M, 1991, Top Magn Reson Imaging, V3, P23; RUGGIERI PM, 1992, STROKE, V23, P774, DOI 10.1161/01.STR.23.5.774; RUNGE VM, 1991, RADIOLOGY, V181, P701, DOI 10.1148/radiology.181.3.1947085; RUNGE VM, 1992, INVEST RADIOL, V27, pS22; RUSSELL EJ, 1989, AM J ROENTGENOL, V152, P813, DOI 10.2214/ajr.152.4.813; SACKETT DL, 1989, CHEST, V95, pS2, DOI 10.1378/chest.95.2.2S; SCHAEFER DM, 1992, J NEUROSURG, V76, P218, DOI 10.3171/jns.1992.76.2.0218; SCHORNER W, 1990, NEURORADIOLOGY, V32, P12, DOI 10.1007/BF00593935; SCHUBEUS P, 1990, NEURORADIOLOGY, V32, P467, DOI 10.1007/BF02426457; SCHWARTZ JS, 1982, ANN INTERN MED, V96, P246, DOI 10.7326/0003-4819-96-2-246; SEINES OA, 1990, NEUROLOGY, V40, P204; SHAH SA, 1992, ACTA PSYCHIAT SCAND, V85, P474, DOI 10.1111/j.1600-0447.1992.tb03214.x; SHELLOCK F G, 1989, Magnetic Resonance Quarterly, V5, P243; SHELLOCK FG, 1993, RADIOLOGY, V189, P587, DOI 10.1148/radiology.189.2.8210394; SHUAIB A, 1992, NEUROLOGY, V42, P816, DOI 10.1212/WNL.42.4.816; SHUMAN WP, 1987, AM J ROENTGENOL, V148, P595, DOI 10.2214/ajr.148.3.595; SHUMAN WP, 1985, RADIOLOGY, V156, P143, DOI 10.1148/radiology.156.1.4001401; SIU AL, 1991, ANN INTERN MED, V115, P122, DOI 10.7326/0003-4819-115-2-122; SMITH AS, 1991, AM J NEURORADIOL, V12, P175; SMITH R R, 1992, Comprehensive Therapy, V18, P7; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; SORBY WA, 1989, MED J AUSTRALIA, V151, P8, DOI 10.5694/j.1326-5377.1989.tb128446.x; SOX H, 1990, MED DECISION MAKING; SPENCER SS, 1993, NEUROLOGY, V43, P2117, DOI 10.1212/WNL.43.10.2117; STERN MB, 1989, NEUROLOGY, V39, P1524, DOI 10.1212/WNL.39.11.1524; STRATHAM PF, 1991, J NEUROL NEUROSUR PS, V54, P484; SWARTZ BE, 1992, EPILEPSIA, V33, P624, DOI 10.1111/j.1528-1157.1992.tb02338.x; SZCZEPURA AK, 1991, BRIT MED J, V303, P1435, DOI 10.1136/bmj.303.6815.1435; SZE G, 1989, AM J NEURORADIOL, V10, P965; SZE G, 1991, RADIOLOGY, V181, P693, DOI 10.1148/radiology.181.3.1947084; SZE G, 1990, AM J NEURORADIOL, V11, P785; SZE G, 1988, RADIOLOGY, V168, P187, DOI 10.1148/radiology.168.1.3380956; SZE G, 1992, AM J ROENTGENOL, V159, P149, DOI 10.2214/ajr.159.1.1609689; TAKAHASHI M, 1989, RADIOLOGY, V173, P219, DOI 10.1148/radiology.173.1.2781011; TASH R, 1991, AM J NEURORADIOL, V12, P839; TEASDALE G, 1992, J NEUROTRAUM, V9, pS249; TEASDALE GM, 1989, BRIT MED J, V299, P349, DOI 10.1136/bmj.299.6695.349; TENHAKEN RK, 1992, RADIOTHER ONCOL, V25, P121, DOI 10.1016/0167-8140(92)90018-P; TERESI LM, 1987, RADIOLOGY, V164, P83, DOI 10.1148/radiology.164.1.3588931; THORNBURY JR, 1993, RADIOLOGY, V186, P731, DOI 10.1148/radiology.186.3.8267688; THORNTON AF, 1992, INT J RADIAT ONCOL, V24, P767, DOI 10.1016/0360-3016(92)90727-Y; THRUSH A, 1990, AM J NEURORADIOL, V11, P1171; TRACY PT, 1989, SPINE, V14, P292, DOI 10.1097/00007632-198903000-00009; TRUYEN L, 1991, J NEUROL SCI, V106, P35, DOI 10.1016/0022-510X(91)90191-9; TUITE M, 1993, AM J NEURORADIOL, V14, P257; VALK J, 1987, ACTA RADIOL, V28, P659; VALK J, 1987, NEUROSURG REV, V10, P87, DOI 10.1007/BF01741443; WAKHLOO AK, 1991, ACTA NEUROCHIR, V111, P119, DOI 10.1007/BF01400499; WALLACE CJ, 1992, AM J ROENTGENOL, V158, P849, DOI 10.2214/ajr.158.4.1546605; WARACH S, 1992, RADIOLOGY, V182, P41, DOI 10.1148/radiology.182.1.1727307; WEINREB JC, 1989, RADIOLOGY, V170, P125, DOI 10.1148/radiology.170.1.2521192; WEINSHENKER BG, 1987, CAN J NEUROL SCI, V14, P255, DOI 10.1017/S0317167100026573; WEISZ GM, 1988, INT ORTHOP, V12, P331, DOI 10.1007/BF00317833; WESBEY GE, 1992, J VASC SURG, V16, P619, DOI 10.1016/0741-5214(92)90169-9; WHITE LJ, 1988, ANN INTERN MED, V108, P474, DOI 10.7326/0003-4819-108-3-474; WILLIAMS MP, 1989, J COMPUT ASSIST TOMO, V13, P211, DOI 10.1097/00004728-198903000-00004; WILSON DW, 1991, NEUROSURGERY, V28, P175, DOI 10.1227/00006123-199102000-00001; Wilson JMG, 1968, PRINCIPLES PRACTICE; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; YAMASHITA Y, 1989, ACTA RADIOL, V30, P135; YAMASHITA Y, 1991, BRIT J RADIOL, V64, P201, DOI 10.1259/0007-1285-64-759-201; YETKIN FZ, 1993, AM J ROENTGENOL, V161, P855, DOI 10.2214/ajr.161.4.7980728; YETKIN FZ, 1991, RADIOLOGY, V178, P447, DOI 10.1148/radiology.178.2.1987607; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007; YOUSEM DM, 1992, J COMPUT ASSIST TOMO, V16, P345, DOI 10.1097/00004728-199205000-00002; YOUSEM DM, 1991, AM J NEURORADIOL, V12, P229; ZIMMERMAN RD, 1988, AM J ROENTGENOL, V150, P651, DOI 10.2214/ajr.150.3.651; 1987, MRI ASSESSMENT PROGR	234	131	131	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1994	120	10					856	871		10.7326/0003-4819-120-10-199405150-00007	http://dx.doi.org/10.7326/0003-4819-120-10-199405150-00007			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK458	7818632				2022-12-28	WOS:A1994NK45800007
J	FRIEDEN, TR; FUJIWARA, PI; WASHKO, RM; HAMBURG, MA				FRIEDEN, TR; FUJIWARA, PI; WASHKO, RM; HAMBURG, MA			TUBERCULOSIS IN NEW-YORK-CITY - TURNING THE TIDE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RESISTANT MYCOBACTERIUM-TUBERCULOSIS; INFECTION; CHEMOTHERAPY	Background. From 1978 through 1992, the number of patients with tuberculosis in New York City nearly tripled, and the proportion of such patients who had drug-resistant isolates of Mycobacterium tuberculosis more than doubled. Methods. We reviewed, confirmed, and analyzed data obtained during the surveillance of patients with tuberculosis. Results. From 1992 through 1994, there was a 21 percent decrease in reported cases of tuberculosis in New York City. An evaluation of the surveillance system revealed very few unreported cases. The number of cases decreased by more than 20 percent among blacks and Hispanics, persons with documented human immunodeficiency virus infection, homeless persons, and patients with multidrug-resistant tuberculosis; in all these groups, tuberculosis is likely to result from recent transmission. In contrast, the number of cases of tuberculosis increased among elderly and foreign-born persons, in whom the disease is likely to result from the reactivation of an infection acquired many years earlier. Enrollment in a program of directly observed therapy, in which health workers watch patients take their medications, increased from fewer than 100 patients to nearly 1300, with more than 32,000 patient-months of observation from 1992 through 1994. Conclusions. Epidemiologic patterns strongly suggest that the decrease in cases resulted from an interruption in the ongoing spread of M. tuberculosis infection, primarily because of better rates of completion of treatment and expanded use of directly observed therapy. Another contributing factor may have been efforts to reduce the spread of tuberculosis in institutional settings, such as hospitals, shelters, and jails. Expansion of measures to prevent and control tuberculosis and support of international control efforts are needed to ensure continued progress.	NEW YORK CITY DEPT HLTH, NEW YORK, NY 10013 USA; CTR DIS CONTROL & PREVENT, NATL CTR PREVENT SERV, DIV TB ELIMINAT, ATLANTA, GA 30341 USA; CTR DIS CONTROL & PREVENT, DIV FIELD EPIDEMIOL, EPIDEMIOL PROGRAM OFF, ATLANTA, GA 30341 USA	New York City Department of Health & Mental Hygiene; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; [Anonymous], 1990, MMWR Recomm Rep, V39, P1; [Anonymous], 1994, MMWR MORB MORTAL WKL; Arno P S, 1993, J Law Med Ethics, V21, P317, DOI 10.1111/j.1748-720X.1993.tb01256.x; AZMEH W, 1993, 33RD INT C ANT AG CH, P229; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; BELLIN EY, 1993, JAMA-J AM MED ASSOC, V269, P2228, DOI 10.1001/jama.269.17.2228; BIGGS HM, 1908, BRIEF HIST CAMPAIGN; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; BRICKNER PW, 1993, TUBERCULOSIS COMPREH, P433; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P585; COMBS DL, 1990, ANN INTERN MED, V112, P397, DOI 10.7326/0003-4819-76-3-112-6-397; COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131, DOI 10.1093/oxfordjournals.aje.a121593; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; ISEMAN MD, 1993, NEW ENGL J MED, V329, P784, DOI 10.1056/NEJM199309093291108; JARLAIS DCD, 1994, JAMA-J AM MED ASSOC, V271, P121, DOI 10.1001/jama.271.2.121; KIM SJ, 1992, TUBERCLE LUNG DIS, V73, P219, DOI 10.1016/0962-8479(92)90090-7; LOWELL AM, 1961, TUBERCULOSIS NEW YOR; MALONEY SA, 1995, ANN INTERN MED, V122, P90, DOI 10.7326/0003-4819-122-2-199501150-00002; MURRAY CJL, 1991, LANCET, V338, P1305, DOI 10.1016/0140-6736(91)92600-7; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; STYBLO K, 1991, SELECTED PAPERS ROYA, V24, P52; VALWAY S, 1993, 33RD INT C ANT AG CH, P230; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; 1994, WHOTB94177; 1992, NEW YORK CITY TASK F; 1993, TUBERCULOSIS NEW YOR; 1990, MMWR-MORBID MORTAL W, V39, P9; 1995, MMWR-MORBID MORTAL W, V44, P81; 1994, AIDS SURVEILLANCE UP	35	580	593	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 27	1995	333	4					229	233		10.1056/NEJM199507273330406	http://dx.doi.org/10.1056/NEJM199507273330406			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK423	7791840				2022-12-28	WOS:A1995RK42300006
J	PEARSON, VAH; OWEN, MR; PHILLIPS, DR; GRAY, DJP; MARSHALL, MN				PEARSON, VAH; OWEN, MR; PHILLIPS, DR; GRAY, DJP; MARSHALL, MN			PREGNANT TEENAGERS KNOWLEDGE AND USE OF EMERGENCY CONTRACEPTION	BRITISH MEDICAL JOURNAL			English	Article									UNIV EXETER,INST POPULAT STUDIES,EXETER EX4 6DT,DEVON,ENGLAND; UNIV EXETER,POSTGRAD MED SCH,INST GEN PRACTICE,EXETER EX2 5DW,DEVON,ENGLAND	University of Exeter; University of Exeter	PEARSON, VAH (corresponding author), EXETER & N DEVON HLTH AUTHOR,SOUTHERNHAY E,EXETER EX1 1PQ,DEVON,ENGLAND.			PEREIRA GRAY, DENIS/0000-0001-7917-3841				BROMHAM DR, 1993, BRIT MED J, V306, P556, DOI 10.1136/bmj.306.6877.556; Bury J., 1984, TEENAGE PREGNANCY BR; DUNCAN G, 1990, BRIT J FAM PLANN, V15, P112; MELLANBY A, 1993, BRIT MED J, V307, P25, DOI 10.1136/bmj.307.6895.25; 1992, FMI21 OFF POP CENS S	5	47	49	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 24	1995	310	6995					1644	1644		10.1136/bmj.310.6995.1644	http://dx.doi.org/10.1136/bmj.310.6995.1644			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RF698	7795453	Green Published			2022-12-28	WOS:A1995RF69800025
J	CASES, O; SEIF, I; GRIMSBY, J; GASPAR, P; CHEN, K; POURNIN, S; MULLER, U; AGUET, M; BABINET, C; SHIH, JC; DEMAEYER, E				CASES, O; SEIF, I; GRIMSBY, J; GASPAR, P; CHEN, K; POURNIN, S; MULLER, U; AGUET, M; BABINET, C; SHIH, JC; DEMAEYER, E			AGGRESSIVE-BEHAVIOR AND ALTERED AMOUNTS OF BRAIN-SEROTONIN AND NOREPINEPHRINE IN MICE LACKING MAOA	SCIENCE			English	Article							MONOAMINE OXIDASE-A; RAT-BRAIN; ORGANIZATION; EXPRESSION; GENES; IMMUNOCYTOCHEMISTRY; SEQUENCE; CORTEX; LIVER; MOTOR	Deficiency in monoamine oxidase A (MAOA), an enzyme that degrades serotonin and norepinephrine, has recently been shown to be associated with aggressive behavior in men of a Dutch family. A line of transgenic mice was isolated in which transgene integration caused a deletion in the gene encoding MAOA, providing an animal model of MAOA deficiency, in pup brains, serotonin concentrations were increased up to ninefold, and serotonin-like immunoreactivity was present. in catecholaminergic neurons, In pup and adult brains, norepinephrine concentrations were increased up to twofold, and I cytoarchitectural changes were observed in the somatosensory cortex. Pup behavioral alterations, including trembling, difficulty in righting, and fearfulness were reversed by the serotonin synthesis inhibitor parachlorophenylalanine. Adults manifested a distinct behavioral syndrome, including enhanced aggression in males.	INST CURIE,CNRS,URA 1343,F-91405 ORSAY,FRANCE; UNIV SO CALIF,DEPT MOLEC PHARMACOL & TOXICOL,LOS ANGELES,CA 90033; HOP LA PITIE SALPETRIERE,INSERM,U106,F-75651 PARIS,FRANCE; INST PASTEUR,CNRS,URA 361,F-75724 PARIS,FRANCE; UNIV ZURICH,INST MOLEC BIOL 1,CH-8093 ZURICH,SWITZERLAND; GENENTECH INC,S SAN FRANCISCO,CA 94080	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Southern California; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Zurich; Roche Holding; Genentech			cases, olivier/G-4882-2017; Gaspar, Patricia/G-8892-2011	cases, olivier/0000-0002-5678-7362; Gaspar, Patricia/0000-0003-4217-5717	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH037020, K05MH000796, R37MH039085] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH 37020, K05 MH 00796, R37 MH039085-23, R37 MH039085, R37 MH 39085] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; BARINAGA M, 1994, SCIENCE, V264, P1690, DOI 10.1126/science.8209247; BENEDETTI MS, 1992, DEV PHARMACOL THERAP, V18, P191, DOI 10.1159/000480622; BENNETTCLARKE CA, 1993, P NATL ACAD SCI USA, V90, P153, DOI 10.1073/pnas.90.1.153; BORSINI F, 1988, PSYCHOPHARMACOLOGY, V94, P147; BROWN SDM, 1993, MAMM GENOME, V4, pS269, DOI 10.1007/BF00360846; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; CASES O, UNPUB; CHEN C, 1994, SCIENCE, V266, P291, DOI 10.1126/science.7939668; CHEN ZY, 1992, GENOMICS, V14, P75, DOI 10.1016/S0888-7543(05)80286-1; COLLINS FA, 1992, AM J MED GENET, V42, P127, DOI 10.1002/ajmg.1320420126; DAMATO RJ, 1987, P NATL ACAD SCI USA, V84, P4322, DOI 10.1073/pnas.84.12.4322; GERSON SC, 1980, LIFE SCI, V27, P1435, DOI 10.1016/0024-3205(80)90368-9; GRIMSBY J, 1991, P NATL ACAD SCI USA, V88, P3637, DOI 10.1073/pnas.88.9.3637; HAEFELY WE, 1990, ADV NEUROL, V53, P505; KOIDE Y, 1984, NEUROCHEM RES, V9, P595, DOI 10.1007/BF00964506; KOLB B, 1983, CAN J PSYCHOL, V37, P211, DOI 10.1037/h0080724; KUWAHARA T, 1990, AGR BIOL CHEM TOKYO, V54, P253, DOI 10.1080/00021369.1990.10869903; LEVITT P, 1982, P NATL ACAD SCI-BIOL, V79, P6385, DOI 10.1073/pnas.79.20.6385; LICHTENSTEIGER W, 1967, J NEUROCHEM, V14, P489, DOI 10.1111/j.1471-4159.1967.tb09548.x; MANN CC, 1994, SCIENCE, V264, P1686, DOI 10.1126/science.8209246; Maxson Stephen C., 1992, V8, P349; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; OCHMAN H, 1988, GENETICS, V120, P621; OSTERHELDHAAS MC, 1994, DEV BRAIN RES, V77, P189, DOI 10.1016/0165-3806(94)90196-1; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; RHOADES RW, 1990, J COMP NEUROL, V293, P190, DOI 10.1002/cne.902930204; SAUDOU F, 1994, SCIENCE, V265, P1875, DOI 10.1126/science.8091214; SEIF I, 1991, J VIROL, V65, P664, DOI 10.1128/JVI.65.2.664-671.1991; SHASKAN EG, 1970, J PHARMACOL EXP THER, V175, P404; STEINBUSCH HWM, 1982, CYTOCHEMICAL METHODS, P407; TSANG D, 1986, DEV NEUROSCI-BASEL, V8, P243, DOI 10.1159/000112258; WALLACE JA, 1982, BRAIN RES BULL, V9, P117, DOI 10.1016/0361-9230(82)90127-7; WESTLUND KN, 1985, SCIENCE, V230, P181, DOI 10.1126/science.3875898; WHISHAW IQ, 1981, J COMP PHYSIOL PSYCH, V95, P85, DOI 10.1037/h0077760; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X; WU HF, 1993, MOL PHARMACOL, V43, P888	38	932	967	5	142	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1763	1766		10.1126/science.7792602	http://dx.doi.org/10.1126/science.7792602			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792602	Green Accepted			2022-12-28	WOS:A1995RE66800045
J	SMITH, MD; CASSIDY, JM; SOUTHER, S; MORRIS, EJ; SAPIN, PM; JOHNSON, SB; KEARNEY, PA				SMITH, MD; CASSIDY, JM; SOUTHER, S; MORRIS, EJ; SAPIN, PM; JOHNSON, SB; KEARNEY, PA			TRANSESOPHAGEAL ECHOCARDIOGRAPHY IN THE DIAGNOSIS OF TRAUMATIC RUPTURE OF THE AORTA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BLUNT CHEST TRAUMA; THORACIC AORTA; ANATOMIC CORRELATIONS; CLINICAL-APPLICATIONS; 10-YEAR EXPERIENCE; DISSECTION; TRANSECTION; ANGIOGRAPHY; RADIOGRAPHY; INJURY	Background. Rupture of the aorta is a major cause of death after motor vehicle accidents. Survival depends on early diagnosis, and emergency aortography is the standard imaging method. Although transesophageal echocardiography is noninvasive and can provide high-resolution images of the aorta, information about its value in patients with trauma is limited. We conducted this study to assess prospectively the value of transesophageal echocardiography in the emergency evaluation of patients at risk for aortic injury. Methods. Transesophageal echocardiography of the aorta was attempted in 101 patients admitted to the emergency room with a diagnosis of possible traumatic rupture of the aorta. Echocardiography and aortography personnel were notified simultaneously of the arrival of the patient, and the two tests were performed sequentially by operators who were blinded to the results of the other test. The sensitivity and specificity of transesophageal echocardiography were calculated on the basis of the results of aortography of the arch, surgery, or topsy. tempted in 101 patients. The study was successfully performed in 93 patients but could not be completed in 8 because of lack of cooperation on the part of the patient (7 patients) or maxillofacial trauma (1 patient). Despite a high injury-severity score (mean, 29.6), transesophageal echocardiography was performed without complications, and within a mean (+/-SD) of 29+/-12 minutes. Eleven of the 93 studies (12 percent) demonstrated rupture of the aorta near the isthmus. The findings were confirmed in 10 of the 11 patients by aortography (9 patients), surgery (9 patients), or autopsy (1 patient), yielding a sensitivity of 100 percent and specificity of 98 percent for the detection of injury to the aorta. There was one false positive echocardiogram. Conclusions. Transesophageal echocardiography is a highly sensitive and specific method of detecting injury to the thoracic aorta. This technique can be used safely and quickly in critically injured patients with suspected traumatic rupture of the aorta and compares favorably with arch aortography.	UNIV KENTUCKY,DEPT INTERNAL MED,DIV CARDIOVASC MED,LEXINGTON,KY; UNIV KENTUCKY,DEPT SURG,TRAUMA & CRIT CARE SECT,LEXINGTON,KY; VET AFFAIRS MED CTR,LEXINGTON,KY	University of Kentucky; University of Kentucky; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center								AKINS CW, 1981, ANN THORAC SURG, V31, P305, DOI 10.1016/S0003-4975(10)60955-1; AYELLA RJ, 1977, J TRAUMA, V17, P199, DOI 10.1097/00005373-197703000-00002; BARCIA TC, 1983, RADIOLOGY, V147, P15, DOI 10.1148/radiology.147.1.6338561; BROOKS SW, 1992, J TRAUMA, V32, P761, DOI 10.1097/00005373-199206000-00015; BROOKS SW, 1991, J TRAUMA, V31, P841, DOI 10.1097/00005373-199106000-00016; BURNEY RE, 1984, CHEST, V85, P605, DOI 10.1378/chest.85.5.605; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; EAGLE KA, 1986, AM J CARDIOL, V57, P322, DOI 10.1016/0002-9149(86)90912-4; ERBEL R, 1989, LANCET, V1, P457; GALVIN IF, 1991, ANN THORAC SURG, V51, P310, DOI 10.1016/0003-4975(91)90811-4; GREENDYKE RM, 1966, J AMER MED ASSOC, V195, P527, DOI 10.1001/jama.195.7.527; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; GUNDRY SR, 1983, INVEST RADIOL, V18, P230, DOI 10.1097/00004424-198305000-00003; JACKSON DH, 1984, CHEST, V85, P585, DOI 10.1378/chest.85.5.585-b; KEARNEY PA, 1993, J TRAUMA, V34, P696, DOI 10.1097/00005373-199305000-00012; KIRSH MM, 1976, ANN SURG, V184, P308, DOI 10.1097/00000658-197609000-00008; LABERGE JM, 1987, RADIOLOGY, V165, P36; LIVONI JP, 1982, RADIOLOGY, V145, P31, DOI 10.1148/radiology.145.1.6750686; LOCKE TJ, 1991, J THORAC CARDIOV SUR, V101, P555; MARNOCHA KE, 1985, AM J ROENTGENOL, V144, P19, DOI 10.2214/ajr.144.1.19; MARSH DG, 1976, ANN THORAC SURG, V21, P337, DOI 10.1016/S0003-4975(10)64323-8; MIRVIS SE, 1987, RADIOLOGY, V163, P487, DOI 10.1148/radiology.163.2.3562831; MIRVIS SE, 1987, INVEST RADIOL, V22, P187, DOI 10.1097/00004424-198703000-00001; NIENABER CA, 1992, CIRCULATION, V85, P434, DOI 10.1161/01.CIR.85.2.434; OH JK, 1990, AM J CARDIOL, V66, P1492, DOI 10.1016/0002-9149(90)90541-8; PARMLEY LF, 1958, CIRCULATION, V17, P1086, DOI 10.1161/01.CIR.17.6.1086; SEFCZEK DM, 1983, AM J ROENTGENOL, V141, P1259, DOI 10.2214/ajr.141.6.1259; SEWARD JB, 1990, MAYO CLIN PROC, V65, P1193, DOI 10.1016/S0025-6196(12)62744-X; SEWARD JB, 1988, MAYO CLIN PROC, V63, P649, DOI 10.1016/S0025-6196(12)65529-3; SHAPIRO MJ, 1991, J TRAUMA, V31, P835, DOI 10.1097/00005373-199106000-00015; SPARKS MB, 1991, ARCH SURG-CHICAGO, V126, P711; SYMBAS PN, 1973, ANN SURG, V178, P6, DOI 10.1097/00000658-197307000-00002; TAAMS MA, 1988, EUR HEART J, V9, P1308, DOI 10.1093/oxfordjournals.eurheartj.a062448; TUNICK PA, 1991, ANN INTERN MED, V115, P423, DOI 10.7326/0003-4819-115-6-423; WEISS J P, 1991, Emergency Medicine Clinics of North America, V9, P789; WOODRING JH, 1984, ANN THORAC SURG, V37, P171, DOI 10.1016/S0003-4975(10)60311-6	36	188	190	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 9	1995	332	6					356	362		10.1056/NEJM199502093320603	http://dx.doi.org/10.1056/NEJM199502093320603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF300	7823997				2022-12-28	WOS:A1995QF30000003
J	CARACENI, P; VANTHIEL, DH				CARACENI, P; VANTHIEL, DH			ACUTE LIVER-FAILURE	LANCET			English	Article							FULMINANT HEPATIC-FAILURE; INTRACRANIAL-PRESSURE; CONTROLLED TRIAL; CHARCOAL HEMOPERFUSION; BACTERIAL-INFECTION; BIOARTIFICIAL LIVER; OXYGEN-TRANSPORT; N-ACETYLCYSTEINE; CEREBRAL EDEMA; TRANSPLANTATION		BAPTIST MED CTR,OKLAHOMA TRANSPLANTAT INST,OKLAHOMA CITY,OK 73112									[Anonymous], 1979, GUT, V20, P620; BERNUAU J, 1993, LANCET, V342, P252, DOI 10.1016/0140-6736(93)91809-Z; BERNUAU J, 1991, HEPATOLOGY, V14, pA49; BERNUAU J, 1986, SEMIN LIVER DIS, V6, P97, DOI 10.1055/s-2008-1040593; BERNUAU J, 1990, HEPATOLOGY, V12, pA373; BIHARI D, 1985, CRIT CARE MED, V13, P1034, DOI 10.1097/00003246-198512000-00010; BIHARI DJ, 1986, SEMIN LIVER DIS, V6, P119, DOI 10.1055/s-2008-1040595; BISMUTH H, 1987, ANN INTERN MED, V107, P337, DOI 10.7326/0003-4819-107-2-337; BLEI AT, 1993, LANCET, V341, P157, DOI 10.1016/0140-6736(93)90016-A; CANALESE J, 1982, GUT, V23, P625, DOI 10.1136/gut.23.7.625; CASTELLS A, 1993, GASTROENTEROLOGY, V105, P532, DOI 10.1016/0016-5085(93)90731-Q; DAVENPORT A, 1990, CRIT CARE MED, V18, P286, DOI 10.1097/00003246-199003000-00008; Ede R, 1982, Gastroenterol Jpn, V17, P163; EDE RJ, 1986, J HEPATOL, V2, P43, DOI 10.1016/S0168-8278(86)80007-1; ELLIS AJ, 1994, HEPATOLOGY, V20, pA140; FORBES A, 1989, HEPATOLOGY, V10, P306, DOI 10.1002/hep.1840100309; GAZZARD BG, 1975, GUT, V16, P617, DOI 10.1136/gut.16.8.617; GIMSON AES, 1986, HEPATOLOGY, V6, P288, DOI 10.1002/hep.1840060222; GIMSON AES, 1982, LANCET, V2, P681; GISLASON GT, 1994, ARTIF ORGANS, V18, P385, DOI 10.1111/j.1525-1594.1994.tb02220.x; HARRISON PM, 1990, LANCET, V335, P1572, DOI 10.1016/0140-6736(90)91388-Q; HARRISON PM, 1991, NEW ENGL J MED, V324, P1852, DOI 10.1056/NEJM199106273242604; HARRISON PM, 1990, J HEPATOL, V10, P332, DOI 10.1016/0168-8278(90)90141-D; JAREGUI HO, 1992, ARTIF ORGANS, V16, P209; KEAYS RT, 1993, J HEPATOL, V18, P205, DOI 10.1016/S0168-8278(05)80247-8; KENNING JA, 1981, SURG NEUROL, V15, P148, DOI 10.1016/0090-3019(81)90037-9; KONDRUP J, 1992, INT J ARTIF ORGANS, V15, P669, DOI 10.1177/039139889201501110; LEE WM, 1993, NEW ENGL J MED, V329, P1862, DOI 10.1056/NEJM199312163292508; LIDOFSKY SD, 1992, HEPATOLOGY, V16, P1, DOI 10.1002/hep.1840160102; MACDOUGALL BRD, 1977, LANCET, V1, P617; MUNOZ SJ, 1990, HEPATOLOGY, V13, P209; OGRADY JG, 1988, Q J MED, V69, P817; OGRADY JG, 1993, LANCET, V342, P273; OGRADY JG, 1988, GASTROENTEROLOGY, V94, P1186, DOI 10.1016/0016-5085(88)90011-X; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; PAUWELS A, 1993, J HEPATOL, V17, P124, DOI 10.1016/S0168-8278(05)80532-X; PRESCOTT LF, 1979, BRIT MED J, V2, P1097, DOI 10.1136/bmj.2.6198.1097; RAKELA J, 1979, GASTROENTEROLOGY, V76, P1297; ROLANDO N, 1991, J HEPATOL, V12, P1, DOI 10.1016/0168-8278(91)90900-V; ROLANDO N, 1990, HEPATOLOGY, V11, P49, DOI 10.1002/hep.1840110110; ROLANDO N, 1993, HEPATOLOGY, V17, P196, DOI 10.1016/0270-9139(93)90076-Y; ROLANDO N, 1994, HEPATOLOGY, V20, pA125; ROZGA J, 1993, HEPATOLOGY, V17, P258, DOI 10.1016/0270-9139(93)90086-3; SALMERON JM, 1992, J HEPATOL, V14, P280, DOI 10.1016/0168-8278(92)90171-K; SHATFORD RA, 1992, J SURG RES, V53, P549, DOI 10.1016/0022-4804(92)90253-V; SHEINER P, 1992, HEPATOLOGY, V16, pA88; SMILKSTEIN MJ, 1988, NEW ENGL J MED, V319, P1557, DOI 10.1056/NEJM198812153192401; SUSSMAN NL, 1994, ARTIF ORGANS, V18, P390, DOI 10.1111/j.1525-1594.1994.tb02221.x; TREY C, 1970, Progress in Liver Diseases, P282; VICKERS C, 1988, J HEPATOL, V7, P143, DOI 10.1016/S0168-8278(88)80475-6; WARE AJ, 1974, AM J GASTROENTEROL, V62, P130; WENDON JA, 1992, HEPATOLOGY, V15, P1067, DOI 10.1002/hep.1840150616	52	89	94	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					163	169		10.1016/S0140-6736(95)90171-X	http://dx.doi.org/10.1016/S0140-6736(95)90171-X			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7823674				2022-12-28	WOS:A1995QC55000014
J	BUTLER, SM				BUTLER, SM			WHAT TO DO NOW ON HEALTH-CARE SYSTEM REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											BUTLER, SM (corresponding author), HERITAGE FDN,214 MASSACHUSETTS AVE NE,WASHINGTON,DC 20002, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					253	254		10.1001/jama.273.3.253	http://dx.doi.org/10.1001/jama.273.3.253			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QB234	7807676				2022-12-28	WOS:A1995QB23400041
J	MAYER, A; NEUPERT, W; LILL, R				MAYER, A; NEUPERT, W; LILL, R			MITOCHONDRIAL PROTEIN IMPORT - REVERSIBLE BINDING OF THE PRESEQUENCE AT THE TRANS SIDE OF THE OUTER-MEMBRANE DRIVES PARTIAL TRANSLOCATION AND UNFOLDING	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; C HEME LYASE; PRECURSOR PROTEINS; INTERMEMBRANE SPACE; RECEPTOR COMPLEX; INNER MEMBRANE; CYTOCHROME-C; INSERTION; YEAST; MATRIX	The mechanism of translocation of matrix-targeted, cleavable preproteins across the mitochondrial outer membrane was studied using purified outer membrane vesicles. The N-terminal presequence interacts in a sequential and reversible fashion with two specific binding sites. The first one is provided by protease-sensitive receptors on the surface of the membrane (cis site); the second one is located at the inner face of the outer membrane (trans site). Binding to the trans site drives translocation of the N-terminal portion of the preprotein and, at the same time, unfolding of its mature part. We suggest that the outer membrane protein import machinery forms a translocation channel that permits reversible sliding of preproteins and prevents their lateral aggregation in the membrane. Although translocation can be initiated by the outer membrane, its completion requires coupling to the energetic system of the inner membrane. Our data assign an essential role to the presequence, not only for efficient targeting, but also for the translocation step.	UNIV MUNICH, INST PHYSIOL CHEM PHYS BIOCHMEM & ZELLBIOL, D-80336 MUNICH, GERMANY	University of Munich			Mayer, Andreas/AAE-4315-2020	Mayer, Andreas/0000-0001-6131-313X; Lill, Roland/0000-0002-8345-6518				ARKOWITZ RA, 1993, EMBO J, V12, P243, DOI 10.1002/j.1460-2075.1993.tb05650.x; ARRETZ M, 1994, J BIOL CHEM, V269, P4959; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; DOBBERSTEIN B, 1994, NATURE, V367, P599, DOI 10.1038/367599a0; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; GLICK B, 1991, ANNU REV GENET, V25, P21; Glick B, 1991, Trends Cell Biol, V1, P99, DOI 10.1016/0962-8924(91)90037-A; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; HARKNESS TAA, 1994, J CELL BIOL, V124, P637, DOI 10.1083/jcb.124.5.637; HWANG S, 1989, J CELL BIOL, V109, P487, DOI 10.1083/jcb.109.2.487; HWANG ST, 1991, J BIOL CHEM, V266, P21083; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; MAYER A, 1994, CELL BIOL LABORATORY; NEUPERT W, 1993, PHILOS T ROY SOC B, V339, P355, DOI 10.1098/rstb.1993.0034; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; NICHOLSON DW, 1987, EUR J BIOCHEM, V164, P147, DOI 10.1111/j.1432-1033.1987.tb11006.x; NUNNARI J, 1992, Current Opinion in Cell Biology, V4, P573, DOI 10.1016/0955-0674(92)90074-M; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFALLER R, 1989, J BIOL CHEM, V264, P34; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; PFANNER N, 1991, TRENDS BIOCHEM SCI, V16, P63, DOI 10.1016/0968-0004(91)90026-R; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RASSOW J, 1991, FEBS LETT, V293, P85, DOI 10.1016/0014-5793(91)81157-4; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; SEGUIREAL B, 1992, FEBS LETT, V313, P2, DOI 10.1016/0014-5793(92)81171-H; SEQUIREAL B, 1993, EMBO J, V12, P2211, DOI 10.1002/j.1460-2075.1993.tb05869.x; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533	43	144	144	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 13	1995	80	1					127	137		10.1016/0092-8674(95)90457-3	http://dx.doi.org/10.1016/0092-8674(95)90457-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813008	Bronze			2022-12-28	WOS:A1995QB91000016
J	MITNIK, L; HELLER, C; PROST, J; VIOVY, JL				MITNIK, L; HELLER, C; PROST, J; VIOVY, JL			SEGREGATION IN DNA SOLUTIONS INDUCED BY ELECTRIC-FIELDS	SCIENCE			English	Article							ELECTROPHORESIS	DNA solutions subjected to an electric field exhibit an instability that leads to DNA segregation in aggregates tilted with regard to the field. With the use of epifluorescence videomicroscopy, the evolution of DNA patterns in capillaries as a function of DNA concentration, DNA size, field strength, and field frequency was studied. The field threshold for segregation was decreased when the frequency was lowered or when the DNA molecular weight or concentration was increased. Aggregation is attributed to an electrohydrodynamic instability triggered by the dipole-dipole interaction. This phenomenon explains the failure of earlier attempts to separate large DNA in capillaries.	ECOLE SUPER PHYS & CHIM IND VILLE PARIS, CNRS, UA 1382, PHYSICOCHIM THEOR LAB, F-75231 PARIS 05, FRANCE; ECOLE SUPER PHYS & CHIM IND VILLE PARIS, CNRS, UA 278, PHYSICOCHIM STRUCT & MACROMOLEC LAB, F-75231 PARIS 05, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)				Viovy, Jean-Louis/0000-0002-8223-4040; Heller, Christoph/0000-0002-9434-8192				BROCHARDWYART F, 1988, CR ACAD SCI II, V307, P1497; Colburn J.C., 1992, CAPILLARY ELECTROPHO; GUSZCZYNSKI T, 1993, ELECTROPHORESIS, V14, P523, DOI 10.1002/elps.1150140180; HJERTEN S, 1991, FEB HIGH PERF CAP EL; HU Y, 1994, J CHEM PHYS, V100, P4674, DOI 10.1063/1.466250; JONSSON M, 1993, J CHEM SOC FARADAY T, V89, P2791, DOI 10.1039/ft9938902791; KRATKY O, 1949, RECL TRAV CHIM PAY B, V68, P1106; Mandel M, 1977, Ann N Y Acad Sci, V303, P74, DOI 10.1111/j.1749-6632.1977.tb55921.x; POHL HA, 1978, DIELECTROPHORESIS, P135; SONG L, 1991, J BIOMOL STRUCT DYN, V9, P87, DOI 10.1080/07391102.1991.10507895; WANG ZL, 1990, MACROMOLECULES, V23, P790, DOI 10.1021/ma00205a016	11	79	80	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 13	1995	267	5195					219	222		10.1126/science.7809626	http://dx.doi.org/10.1126/science.7809626			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7809626				2022-12-28	WOS:A1995QB15300029
J	RANGELFRAUSTO, MS; PITTET, D; COSTIGAN, M; HWANG, T; DAVIS, CS; WENZEL, RP				RANGELFRAUSTO, MS; PITTET, D; COSTIGAN, M; HWANG, T; DAVIS, CS; WENZEL, RP			THE NATURAL-HISTORY OF THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) - A PROSPECTIVE-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-DISTRESS SYNDROME; CONTROLLED CLINICAL-TRIAL; GRAM-NEGATIVE BACTEREMIA; SEPTIC SHOCK; SEPSIS SYNDROME; MONOCLONAL-ANTIBODY; ENDOTOXIN; DISEASE	Objective.-Define the epidemiology of the four recently classified syndromes describing the biologic response to infection: systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, and septic shock. Design.-Prospective cohort study with a follow-up of 28 days or until discharge if earlier. Setting.-Three intensive care units and three general wards in a tertiary health care institution. Methods.-Patients were included if they met at least two of the criteria for SI RS: fever or hypothermia, tachycardia, tachypnea, or abnormal white blood cell count. Main Outcomes Measures.-Development of any stage of the biologic response to infection: sepsis, severe sepsis, septic shock, end-organ dysfunction, and death. Results.-During the study period 3708 patients were admitted to the survey units, and 2527 (68%) met the criteria for SIRS. The incidence density rates for SIRS in the surgical, medical, and cardiovascular intensive care units were 857, 804, and 542 episodes per 1000 patient-days, respectively, and 671, 495, and 320 per 1000 patient-days for the medical, cardiothoracic, and general surgery wards, respectively. Among patients with SIRS, 649 (26%) developed sepsis, 467 (18%) developed severe sepsis, and 110 (4%) developed septic shock. The median interval from SIRS to sepsis was inversely correlated with the number of SIRS criteria (two, three, or all four) that the patients met. As the population of patients progressed from SIRS to septic shock, increasing proportions had adult respiratory distress syndrome, disseminated intravascular coagulation, acute renal failure, and shock. Positive blood cultures were found in 17% of patients with sepsis, in 25% with severe sepsis, and in 69% with septic shock, There were also stepwise increases in mortality rates in the hierarchy from SIRS, sepsis, severe sepsis, and septic shock: 7%, 16%, 20%, and 46%, respectively. Of interest, we also observed equal numbers of patients who appeared to have sepsis, severe sepsis, and septic shock but who had negative cultures. They had been prescribed empirical antibiotics for a median of 3 days, The cause of the systemic inflammatory response in these culture-negative populations is unknown, but they had similar morbidity and mortality rates as the respective culture-positive populations. Conclusions.-This prospective epidemiologic study of SIRS and related conditions provides, to our knowledge, the first evidence of a clinical progression from SIRS to sepsis to severe sepsis and septic shock.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,DIV GEN MED CLIN EPIDEMIOL & HLTH SERV RES,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PREVENT MED,DIV BIOSTAT,IOWA CITY,IA 52242; UNIV HOSP GENEVA,DEPT INTERNAL MED,DIV INFECT DIS,INFECT CONTROL GRP,GENEVA,SWITZERLAND	University of Iowa; University of Iowa; University of Geneva								[Anonymous], 1992, CRIT CARE MED, V20, P864; Bone R C, 1991, Infect Dis Clin North Am, V5, P793; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; BONE RC, 1991, ANN INTERN MED, V114, P332, DOI 10.7326/0003-4819-114-4-332; BRODERICK A, 1990, AM J EPIDEMIOL, V131, P734, DOI 10.1093/oxfordjournals.aje.a115558; EXLEY AR, 1990, LANCET, V335, P1275, DOI 10.1016/0140-6736(90)91337-A; FREEMAN J, 1980, AM J EPIDEMIOL, V112, P707, DOI 10.1093/oxfordjournals.aje.a113043; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P10; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MCCABE WR, 1962, ARCH INTERN MED, V110, P856, DOI 10.1001/archinte.1962.03620240038007; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; NIEDERMAN MS, 1990, CLIN CHEST MED, V11, P633; OPAL SM, 1992, OCT INT C ANT AG CHE, P372; OWENS WD, 1978, ANESTHESIOLOGY, V49, P239, DOI 10.1097/00000542-197810000-00003; PARKER MM, 1983, JAMA-J AM MED ASSOC, V250, P3324, DOI 10.1001/jama.250.24.3324; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; PITTET D, 1991, SEP INT C ANT AG CHE, P232; PITTET D, 1993, OCT INT C ANT AG CHE, P358; TEASDALE G, 1974, LANCET, V2, P81; WENZEL RP, 1992, NEW ENGL J MED, V326, P1151, DOI 10.1056/NEJM199204233261710; WHERRY J, 1993, OCT INT C ANT AG CHE, P246; WOOLSON RF, 1987, STATISTICAL METHODS, P252; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; 1993, MONTHLY VITAL STAT R, V41, P5; 1990, SAS STAT USERS GUIDE, V2	29	1408	1514	1	81	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 11	1995	273	2					117	123		10.1001/jama.273.2.117	http://dx.doi.org/10.1001/jama.273.2.117			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ687	7799491				2022-12-28	WOS:A1995PZ68700024
J	APPLETON, DR				APPLETON, DR			CROSS WORDS	BRITISH MEDICAL JOURNAL			English	Editorial Material											APPLETON, DR (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MED STAT,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1737	1738		10.1136/bmj.309.6970.1737	http://dx.doi.org/10.1136/bmj.309.6970.1737			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7820007	Green Published			2022-12-28	WOS:A1994PY71700038
J	SAAB, M; RANA, PSJB				SAAB, M; RANA, PSJB			ITS NOT CRICKET	BRITISH MEDICAL JOURNAL			English	Note											SAAB, M (corresponding author), ST PETERS HOSP,DEPT ACCID & EMERGENCY,CHERTSEY KT16 0PZ,SURREY,ENGLAND.								0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1747	1747						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7820012				2022-12-28	WOS:A1994PY71700046
J	DOOLEY, CT; CHUNG, NN; WILKES, BC; SCHILLER, PW; BIDLACK, JM; PASTERNAK, GW; HOUGHTEN, RA				DOOLEY, CT; CHUNG, NN; WILKES, BC; SCHILLER, PW; BIDLACK, JM; PASTERNAK, GW; HOUGHTEN, RA			AN ALL D-AMINO-ACID OPIOID PEPTIDE WITH CENTRAL ANALGESIC ACTIVITY FROM A COMBINATORIAL LIBRARY	SCIENCE			English	Article							OPIATE RECEPTOR; LIGANDS	A synthetic combinatorial library containing 52,128,400 D-amino acid hexapeptides was used to identify a ligand for the mu opioid receptor. The peptide, Ac-rfwink-NH2, bears no resemblance to any known opioid peptide. Simulations using molecular dynamics, however, showed that three amino acid moieties have the same spatial orientation as the corresponding pharmacophoric groups of the opioid peptide PLO17. Ac-rfwink-NH2 was shown to be a potent agonist at the mu receptor and induced long-lasting analgesia in mice. Analgesia produced by intraperitoneally administered Ac-rfwink-NH2 was blocked by intracerebroventricular administration of naloxone, demonstrating that this peptide may cross the blood-brain barrier.	TORREY PINES INST MOLEC STUDIES,SAN DIEGO,CA 92121; HOUGHTEN PHARMACEUT INC,SAN DIEGO,CA 92121; CLIN RES INST MONTREAL,CHEM BIOL & PEPTIDE RES LAB,MONTREAL,PQ H2W 1R7,CANADA; UNIV ROCHESTER,MED CTR,DEPT PHARMACOL,ROCHESTER,NY 14642; MEM SLOAN KETTERING CANC CTR,DEPT NEUROL,NEW YORK,NY 10021	Torrey Pines Institute for Molecular Studies, California; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Rochester; Memorial Sloan Kettering Cancer Center					NIDA NIH HHS [DA-000138, DA-03742, DA-02615] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002615, R01DA003742, R56DA002615] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; CLARK JA, 1988, MOL PHARMACOL, V34, P308; CLARK JA, 1989, J PHARMACOL EXP THER, V251, P461; DIMAIO J, 1982, J MED CHEM, V25, P1432, DOI 10.1021/jm00354a008; DOOLEY CT, 1993, P NATL ACAD SCI USA, V90, P10811, DOI 10.1073/pnas.90.22.10811; DOOLEY CT, 1993, LIFE SCI, V52, P1509, DOI 10.1016/0024-3205(93)90113-H; HENDERSON G, 1972, BRIT J PHARMACOL, V46, P764, DOI 10.1111/j.1476-5381.1972.tb06901.x; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HOUGHTEN RA, 1992, BIOTECHNIQUES, V13, P412; HOUGHTEN RA, 1993, BIOORG MED CHEM LETT, V3, P405, DOI 10.1016/S0960-894X(01)80222-5; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; JIANG Q, 1992, J PHARMACOL EXP THER, V262, P526; KOSTERLITZ HW, 1968, BRIT J PHARMACOL, V33, P266, DOI 10.1111/j.1476-5381.1968.tb00988.x; PATON WDM, 1957, BRIT J PHARM CHEMOTH, V12, P119, DOI 10.1111/j.1476-5381.1957.tb01373.x; SCHILLER PW, 1978, BIOCHEM BIOPH RES CO, V85, P1332, DOI 10.1016/0006-291X(78)91149-X; SCHILLER PW, 1983, PEPTIDES STRUCTURE F, P269; VAUGHN LK, 1993, LIFE SCI, V52, P1509; YAMAZAKI T, 1993, J MED CHEM, V36, P708, DOI 10.1021/jm00058a007; ZUKIN RS, 1988, P NATL ACAD SCI USA, V85, P4061, DOI 10.1073/pnas.85.11.4061	19	144	186	1	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					2019	2022		10.1126/science.7801131	http://dx.doi.org/10.1126/science.7801131			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801131				2022-12-28	WOS:A1994PZ26700037
J	MOGFORD, N; PALLETT, A; GEORGE, C				MOGFORD, N; PALLETT, A; GEORGE, C			ERYTHROMYCIN DEAFNESS AND CIMETIDINE TREATMENT	BRITISH MEDICAL JOURNAL			English	Letter											MOGFORD, N (corresponding author), SOUTHAMPTON GEN HOSP,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.							WATKINS PB, 1987, J CLIN INVEST, V80, P1029, DOI 10.1172/JCI113156	1	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1620	1620		10.1136/bmj.309.6969.1620c	http://dx.doi.org/10.1136/bmj.309.6969.1620c			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819942	Green Published			2022-12-28	WOS:A1994PY22000025
J	JULIOUS, SA; MULLEE, MA				JULIOUS, SA; MULLEE, MA			CONFOUNDING AND SIMPSONS PARADOX	BRITISH MEDICAL JOURNAL			English	Article											JULIOUS, SA (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.							CHARIG CR, 1986, BRIT MED J, V292, P879, DOI 10.1136/bmj.292.6524.879; GATLING W, 1989, PRACTICAL DIABETES, V5, P104; HAND DJ, 1979, BRIT J PSYCHIAT, V135, P90, DOI 10.1192/bjp.135.1.90b; SIMPSON EH, 1951, J ROY STAT SOC B, V13, P238; WEATHERALL DJ, 1987, OXFORD TXB MED, V9, P54	5	90	95	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 3	1994	309	6967					1480	1481		10.1136/bmj.309.6967.1480	http://dx.doi.org/10.1136/bmj.309.6967.1480			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW053	7804052	Green Published			2022-12-28	WOS:A1994PW05300024
J	EVANS, KL				EVANS, KL			DIAGNOSIS AND MANAGEMENT OF SINUSITIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ENDOSCOPIC ENDONASAL SURGERY; PARA-NASAL SINUSES; MAXILLARY SINUSITIS; FUNGAL SINUSITIS; RECURRING RHINOSINUSITIS; PHYSICAL-EXAMINATION; CHILDREN; COMPLICATIONS; INFECTION; PATIENT				EVANS, KL (corresponding author), GLOUCESTERSHIRE ROYAL HOSP, GLOUCESTER GL1 3NN, ENGLAND.							AXELSSON A, 1970, ACTA OTO-LARYNGOL, V69, P302, DOI 10.3109/00016487009123368; BERGOGNEBEREZIN E, 1985, INT J CLIN PHARM RES, V5, P341; CALHOUN K, 1992, OTOLARYNG HEAD NECK, V107, P850, DOI 10.1177/019459989210700607.2; CAMACHO AE, 1992, AM J MED, V93, P271, DOI 10.1016/0002-9343(92)90232-Z; CASIANO RR, 1991, AM J MED, V91, pS27, DOI 10.1016/0002-9343(91)90398-H; CHO SY, 1979, AM J CLIN PATHOL, V72, P617; DRUCE HM, 1992, J ALLERGY CLIN IMMUN, V90, P436, DOI 10.1016/0091-6749(92)90165-X; DRUCE HM, 1991, ANN ALLERGY, V66, P132; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; Gamble RC, 1933, ARCH OPHTHALMOL-CHIC, V10, P483; GILL FF, 1989, AM J RHINOL, V3, P13; GODOFSKY EW, 1992, AM J MED, V93, P163, DOI 10.1016/0002-9343(92)90046-E; GRANT A, 1993, GENITOURIN MED, V69, P208; HAVAS TE, 1988, ARCH OTOLARYNGOL, V114, P856; HUERTER JV, 1992, OTOLARYNG CLIN N AM, V25, P231; Jannert M, 1982, Acta Otolaryngol Suppl, V389, P1; KAVANAGH KT, 1991, ANN OTO RHINOL LARYN, V100, P331, DOI 10.1177/000348949110000413; KENNEDY DW, 1990, OTOLARYNG HEAD NECK, V103, P884, DOI 10.1177/01945998901030S509; KENNEDY DW, 1985, ARCH OTOLARYNGOL, V111, P576; KOVATCH AL, 1984, PEDIATRICS, V73, P306; KULBER DA, 1991, AM SURGEON, V57, P775; LANZA DC, 1992, J ALLERGY CLIN IMMUN, V90, P505, DOI 10.1016/0091-6749(92)90175-2; LIN P-T, 1991, Ear Nose and Throat Journal, V70, P488; Lund V J, 1988, J Laryngol Otol Suppl, V15, P1; MABRY RL, 1991, AM J RHINOL, V5, P121; MACKAY IS, 1988, BRIT J DIS CHEST, V82, P1, DOI 10.1016/0007-0971(88)90002-2; MCMAHAN JT, 1990, OTOLARYNG CLIN N AM, V23, P1169; MELEN I, 1986, ACTA OTO-LARYNGOL, V101, P494, DOI 10.3109/00016488609108636; Messerklinger W, 1967, Acta Otolaryngol, V63, P176, DOI 10.3109/00016486709128748; Messerklinger W., 1978, ENDOSCOPY NOSE; MUNTZ HR, 1991, ARCH OTOLARYNGOL, V117, P179; OHASHI Y, 1983, ACTA OTO-LARYNGOL, P3; OHASHI Y, 1983, ACTA OTO-LARYNGOL, P11; PATT BS, 1991, OTOLARYNG HEAD NECK, V104, P789, DOI 10.1177/019459989110400604; PFLEIDERER AG, 1984, CLIN OTOLARYNGOL, V9, P335, DOI 10.1111/j.1365-2273.1984.tb01517.x; Qvarnberg Yrjo, 1992, Rhinology (Utrecht), V30, P103; REILLY JS, 1990, OTOLARYNG HEAD NECK, V103, P856, DOI 10.1177/01945998901030S504; SCHWIETZ LA, 1992, ALLERGY PROC, V13, P3, DOI 10.2500/108854192778878980; SHANKAR L, 1994, ATLAS IMAGING PARANA; SHAPIRO MD, 1989, RADIOL CLIN N AM, V27, P447; SLAVIN RG, 1988, J ALLERGY CLIN IMMUN, V81, P284, DOI 10.1016/0091-6749(88)90700-2; SLAVIN RG, 1988, J ALLERGY CLIN IMMUN, V81, P1028, DOI 10.1016/0091-6749(88)90174-1; SOM PM, 1988, RADIOLOGY, V167, P803, DOI 10.1148/radiology.167.3.3363145; SPECTOR SL, 1981, J ALLERGY CLIN IMMUN, V67, P22, DOI 10.1016/0091-6749(81)90040-3; STAMMBERGER H, 1986, OTOLARYNG HEAD NECK, V94, P147, DOI 10.1177/019459988609400203; STAMMBERGER H, 1986, OTOLARYNG HEAD NECK, V94, P143, DOI 10.1177/019459988609400202; STAMMBERGER H, 1988, ANN OTO RHINOL LARYN, V97, P3, DOI 10.1177/00034894880970S501; STAMMBERGER H, 1991, FUNCTIONAL ENDOSCOPI, P398; Stammberger H., 1991, FUNCTIONAL ENDOSCOPI; STANKIEWICZ JA, 1987, LARYNGOSCOPE, V97, P1270, DOI 10.1288/00005537-198711000-00004; WALD ER, 1981, NEW ENGL J MED, V304, P749, DOI 10.1056/NEJM198103263041302; WIGAND ME, 1990, ENDOSCOPIC SINUS SUR, P101; WILLIAMS JW, 1992, ANN INTERN MED, V117, P705, DOI 10.7326/0003-4819-117-9-705; WILSON NW, 1988, AM J RHINOL, V2, P55; WILSON R, 1986, THORAX, V41, P453, DOI 10.1136/thx.41.6.453; WILSON R, 1987, THORAX, V42, P631, DOI 10.1136/thx.42.8.631; WINTHER B, 1990, OTOLARYNG HEAD NECK, V103, P876, DOI 10.1177/01945998901030S507; YONKERS A J, 1992, Ear Nose and Throat Journal, V71, P258; ZINREICH J, 1993, OTOLARYNG CLIN N AM, V26, P535; ZINREICH SJ, 1988, J COMPUT ASSIST TOMO, V12, P1014, DOI 10.1097/00004728-198811000-00019; ZINREICH SJ, 1990, OTOLARYNG HEAD NECK, V103, P863, DOI 10.1177/01945998901030S505; ZINREICH SJ, 1988, RADIOLOGY, V169, P439, DOI 10.1148/radiology.169.2.3174990; 1984, NIH DATA BOOK, P57; 1971, DIGEST HLTH STATISTI; 1993, MAKING BEST USE DEP	65	45	47	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 26	1994	309	6966					1415	1422		10.1136/bmj.309.6966.1415	http://dx.doi.org/10.1136/bmj.309.6966.1415			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7819854	Green Published			2022-12-28	WOS:A1994PU76400029
J	LIM, WA; RICHARDS, FM; FOX, RO				LIM, WA; RICHARDS, FM; FOX, RO			STRUCTURAL DETERMINANTS OF PEPTIDE-BINDING ORIENTATION AND OF SEQUENCE SPECIFICITY IN SH3 DOMAINS	NATURE			English	Article							CRYSTAL-STRUCTURE; TYROSINE KINASES; PROTEIN; SOS; ASSOCIATION; SEVENLESS; EXCHANGE; GRB2	THE Src-homology-3 (SH3) domains of the Caenorhabditis elegans protein SEM-5 and its human and Drosophila homologues, Grb2 and Drk (refs 1-4), bind proline-rich sequences found in the nucleotide-exchange factor Sos as part of their proposed function linking receptor tyrosine kinase activation to Ras activation(5-7). Here we report the crystal structure at 2.0 Angstrom resolution of the carboxy-terminal SH3 domain from SEM-5 complexed to the mSos-derived amino-acid sequence PPPVPPRRR. The peptide is found to bind in an orientation ('minus') that is precisely opposite to that observed previously ('plus' orientation) in other SH3-peptide complexes(8,9). This novel ability of peptide-recognition proteins to recognize peptides in two distinct modes may play an important role in the signalling specificity of pathways involving SH3 domains. Comparison of this structure with other SH3 complexes reveals how a conserved binding face can be used to recognize peptides in different orientations, and why the Sos peptide binds in this particular orientation.	YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06520	Howard Hughes Medical Institute; Yale University	LIM, WA (corresponding author), YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,POB 6666,NEW HAVEN,CT 06520, USA.							BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DUNBRACK RL, 1993, J MOL BIOL, V230, P542; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; LI N, 1993, NATURE, V363, P83; LIM WA, 1994, PROTEIN SCI, V3, P1261, DOI 10.1002/pro.5560030812; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NAVAZA J, 1987, ACTA CRYSTALLOGR A, V43, P645, DOI 10.1107/S0108767387098787; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICHARDS FM, 1993, Q REV BIOPHYS, V26, P423, DOI 10.1017/S0033583500002845; ROZAKISADOCK M, 1993, NATURE, V363, P79; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; TERASAWA H, IN PRESS NATURE STRU; WITTEKIND M, IN PRESS BIOCHEMISTR; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZVELEBIL MJJM, 1993, Q REV BIOPHYS, V26, P333, DOI 10.1017/S0033583500002870	28	475	482	1	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					375	379		10.1038/372375a0	http://dx.doi.org/10.1038/372375a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7802869				2022-12-28	WOS:A1994PU28700059
J	ENDERS, G; MILLER, E; CRADOCKWATSON, J; BOLLEY, I; RIDEHALGH, M				ENDERS, G; MILLER, E; CRADOCKWATSON, J; BOLLEY, I; RIDEHALGH, M			CONSEQUENCES OF VARICELLA AND HERPES-ZOSTER IN PREGNANCY - PROSPECTIVE-STUDY OF 1739 CASES	LANCET			English	Article							VIRUS-INFECTIONS; ZOSTER VIRUS	In a joint prospective study in Germany and the United Kingdom between 1980 and 1993, 1373 women who had varicella and 366 who had herpes tester during the first 36 weeks of gestation were followed up.	PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,DIV IMMUNISAT,LONDON NW9 5EQ,ENGLAND; INST VIROL INFEKTIOL & EPIDEMIOL,D-70192 STUTTGART,GERMANY; WITHINGTON HOSP,PUBL HLTH LAB,MANCHESTER M20 8LR,LANCS,ENGLAND	Public Health England								ALKALAY AL, 1987, J PEDIATR-US, V111, P320, DOI 10.1016/S0022-3476(87)80447-X; CRADOCKWATSON JE, 1991, CURRENT TOPICS CLIN, P1; DASILVA O, 1990, PEDIATR INFECT DIS J, V9, P854; ENDERS G, 1985, POSTGRAD MED J, V61, P23; GOTTARDI H, 1991, GEBURTSH FRAUENHEILK, V51, P63, DOI 10.1055/s-2008-1026335; HAAKE DA, 1990, REV INFECT DIS, V12, P788; HIGA K, 1987, OBSTET GYNECOL, V69, P214; KANGRO HO, 1988, EPIDEMIOL INFECT, V101, P187, DOI 10.1017/S0950268800029344; LAFORET EG, 1947, NEW ENGL J MED, V236, P534, DOI 10.1056/NEJM194704102361504; MEHRAEIN Y, 1991, GEBURTSH FRAUENHEILK, V51, P984, DOI 10.1055/s-2008-1026249; MICHIE CA, 1992, PEDIATR INFECT DIS J, V11, P1050, DOI 10.1097/00006454-199211120-00012; Miller E., 1993, Reviews in Medical Microbiology, V4, P222; MILLER E, 1989, LANCET, V2, P371; MILLER E, 1993, LANCET, V341, P308, DOI 10.1016/0140-6736(93)92663-E; PUCHHAMMERSTOCK.E, 1994, IN PRESS J PERINAT M, V22; SCHARF A, 1990, J PERINAT MED, V18, P317	16	336	357	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 18	1994	343	8912					1548	1551		10.1016/S0140-6736(94)92943-2	http://dx.doi.org/10.1016/S0140-6736(94)92943-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR329	7802767				2022-12-28	WOS:A1994NR32900013
J	CRAIG, AM; WYBORSKI, RJ; BANKER, G				CRAIG, AM; WYBORSKI, RJ; BANKER, G			PREFERENTIAL ADDITION OF NEWLY SYNTHESIZED MEMBRANE-PROTEIN AT AXONAL GROWTH CONES	NATURE			English	Article							SIMPLEX VIRUS AMPLICON; HIPPOCAMPAL-NEURONS; POLARITY ORIENTATION; PLASMA-MEMBRANE; GROWING AXONS; BREFELDIN-A; CULTURE; MICROTUBULES; DIFFUSION; MOVEMENT	THE addition of plasma membrane proteins to a growing axon could occur by preferential insertion at the tip (the growth cone), by uniform insertion along the axon, or by insertion at the cell body and bulk flow along the axon. To differentiate between these possibilities we used a defective herpesvirus vector to express an exogenous protein, the lymphocyte transmembrane protein CD8 alpha, in cultured rat hippocampal neurons. The newly synthesized protein first appeared on the axonal surface almost exclusively at the growth cone. Preferential addition at the growth cone was also observed in minor processes (immature dendrites), but not in mature dendrites. Over several hours, CD8 alpha reached a uniform distribution over the entire neuronal surface, presumably by diffusion within the membrane and possibly endocytic recycling. As well as providing materials for axonal growth, the selective addition of membrane vesicles at the growth cone may contribute to the polarized distribution of axonal surface molecules(1).	UNIV VIRGINIA,SCH MED,DEPT NEUROSCI,CHARLOTTESVILLE,VA 22908; PARKE DAVIS RES,DEPT BIOTECHNOL,ANN ARBOR,MI 48106	University of Virginia; Pfizer			Craig, Ann Marie/M-2054-2014					BAAS PW, 1989, J CELL BIOL, V109, P3085, DOI 10.1083/jcb.109.6.3085; BAAS PW, 1988, P NATL ACAD SCI USA, V85, P8335, DOI 10.1073/pnas.85.21.8335; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BRAY D, 1970, P NATL ACAD SCI USA, V65, P905, DOI 10.1073/pnas.65.4.905; DELUCA NA, 1985, J VIROL, V56, P558, DOI 10.1128/JVI.56.2.558-570.1985; DOTTI CG, 1988, J NEUROSCI, V8, P1454; DOTTI CG, 1990, CELL, V62, P62; FELDMAN EL, 1981, J NEUROBIOL, V12, P591, DOI 10.1002/neu.480120607; FUTERMAN AH, 1993, NATURE, V362, P119, DOI 10.1038/362119a0; GELLER AI, 1988, SCIENCE, V241, P1667, DOI 10.1126/science.2843986; GOSLIN K, 1991, CULTURING NERVE CELL, P207; GRIFFIN JW, 1981, J CELL BIOL, V88, P205, DOI 10.1083/jcb.88.1.205; JUNG LJ, 1991, SCIENCE, V251, P1330, DOI 10.1126/science.2003219; KAPLITT M G, 1991, Molecular and Cellular Neuroscience, V2, P320, DOI 10.1016/1044-7431(91)90062-S; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KODA LY, 1976, J NEUROBIOL, V7, P157, DOI 10.1002/neu.480070208; KWONG AD, 1985, VIROLOGY, V142, P421, DOI 10.1016/0042-6822(85)90351-4; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MUNDIGL O, 1993, J CELL BIOL, V122, P1207, DOI 10.1083/jcb.122.6.1207; OKABE S, 1992, J CELL BIOL, V117, P105, DOI 10.1083/jcb.117.1.105; PFENNINGER KH, 1981, J CELL BIOL, V89, P547, DOI 10.1083/jcb.89.3.547; POPOV S, 1993, SCIENCE, V259, P244, DOI 10.1126/science.7678471; REINSCH SS, 1991, J CELL BIOL, V115, P365, DOI 10.1083/jcb.115.2.365; ROIZMAN B, 1990, VIROLOGY, V2, P1795; SMALL RK, 1984, J CELL BIOL, V98, P1434, DOI 10.1083/jcb.98.4.1434; SPAETE RR, 1982, CELL, V30, P295, DOI 10.1016/0092-8674(82)90035-6	26	154	155	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					592	594		10.1038/375592a0	http://dx.doi.org/10.1038/375592a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791876				2022-12-28	WOS:A1995RD28700052
J	CUENOUD, B; SZOSTAK, JW				CUENOUD, B; SZOSTAK, JW			A DNA METALLOENZYME WITH DNA-LIGASE ACTIVITY	NATURE			English	Article							HUMAN THROMBIN; RNA; BINDING; APTAMER; SELECTION; MOLECULES; INVITRO	SINGLE-STRANDED DNA can fold into well-defined sequence-dependent tertiary structures that specifically bind a variety of target molecules(1-10), raising the possibility that some folded single-stranded DNAs might exhibit catalytic activities similar to those of ribozymes and protein enzymes. Derivatives of the hammerhead ribozyme that contain a majority of deoxyribonucleotides retain the ability to cleave RNA(11), and a 'deoxyribozyme' was generated by leaving all essential ribonucleotides of the hammerhead on the RNA 'substrate'(12). Recently in vitro selection has been used to isolate a DNA sequence that shows Pb2+-dependent RNA-cleaving activity(13). Here we report the isolation by in vitro selection(14-17) of a small single-stranded DNA that is a Zn2+/Cu2+-dependent metalloenzyme. The enzyme catalyses the formation of a new phosphodiester bond by the condensation of the 5'-hydroxyl of one oligodeoxynucleotide and a 3'-phosphorimidazolide on another oligodeoxynucleotide, and shows multiple turnover ligation.	HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital								Ahrland S., 1973, COMPREHENSIVE INORGA, V5; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BRATTY J, 1993, BIOCHIM BIOPHYS ACTA, V1216, P345, DOI 10.1016/0167-4781(93)90001-T; Breaker R R, 1994, Chem Biol, V1, P223, DOI 10.1016/1074-5521(94)90014-0; BREAKER RR, 1994, TRENDS BIOTECHNOL, V12, P268, DOI 10.1016/0167-7799(94)90138-4; CHAPMAN KB, 1994, CURR OPIN STRUC BIOL, V4, P618, DOI 10.1016/S0959-440X(94)90227-5; CHARTRAND P, 1994, RNA PROCESSING, V77; CHU BCF, 1986, NUCLEIC ACIDS RES, V14, P5591, DOI 10.1093/nar/14.14.5591; DAHM SC, 1993, BIOCHEMISTRY-US, V32, P13040, DOI 10.1021/bi00211a013; ELLINGTON AD, 1992, NATURE, V355, P850, DOI 10.1038/355850a0; Fersht A., 1985, ENZYME STRUCTURE MEC; HUIZENGA DE, 1995, BIOCHEMISTRY-US, V34, P656, DOI 10.1021/bi00002a033; JOYCE GF, 1994, CURR OPIN STRUC BIOL, V4, P331, DOI 10.1016/S0959-440X(94)90100-7; KAO TH, 1980, P NATL ACAD SCI-BIOL, V77, P3360, DOI 10.1073/pnas.77.6.3360; KARLIN KD, 1993, SCIENCE, V261, P701, DOI 10.1126/science.7688141; KHAN AS, 1988, SCIENCE, V241, P74, DOI 10.1126/science.2455342; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LUEBKE KJ, 1989, J AM CHEM SOC, V111, P8733, DOI 10.1021/ja00205a033; ORGEL LE, 1994, SCI AM, V271, P77, DOI 10.1038/scientificamerican1094-76; PABORSKY LR, 1993, J BIOL CHEM, V268, P20808; PADMANABHAN K, 1993, J BIOL CHEM, V268, P17651; PAN T, 1994, BIOCHEMISTRY-US, V33, P9561, DOI 10.1021/bi00198a023; PERREAULT JP, 1989, EUR J BIOCHEM, V186, P87, DOI 10.1111/j.1432-1033.1989.tb15181.x; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; SHABAROVA ZA, 1988, BIOCHIMIE, V70, P1323, DOI 10.1016/0300-9084(88)90003-X; SZOSTAK JW, 1992, TRENDS BIOCHEM SCI, V17, P89, DOI 10.1016/0968-0004(92)90242-2; WANG KY, 1993, BIOCHEMISTRY-US, V32, P11285, DOI 10.1021/bi00093a004; WILSON C, 1995, NATURE, V374, P777, DOI 10.1038/374777a0; WYATT JR, 1994, P NATL ACAD SCI USA, V91, P1356, DOI 10.1073/pnas.91.4.1356	30	342	370	6	126	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 15	1995	375	6532					611	614		10.1038/375611a0	http://dx.doi.org/10.1038/375611a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791880				2022-12-28	WOS:A1995RD28700057
J	NOUSBAUM, JB; POL, S; NALPAS, B; LANDAIS, P; BERTHELOT, P; BRECHOT, C; GIGOU, M; FERAY, C; THIERS, V; OKAMOTO, H; MISHIRO, S; POUSSIN, K; PATERLINI, P; RUMI, M; COLOMBO, M				NOUSBAUM, JB; POL, S; NALPAS, B; LANDAIS, P; BERTHELOT, P; BRECHOT, C; GIGOU, M; FERAY, C; THIERS, V; OKAMOTO, H; MISHIRO, S; POUSSIN, K; PATERLINI, P; RUMI, M; COLOMBO, M			HEPATITIS-C VIRUS TYPE-1B(II) INFECTION IN FRANCE AND ITALY	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS C VIRUS; HEPATITIS C; GENOTYPE; DNA, VIRAL; POLYMERASE CHAIN REACTION	RECOMBINANT INTERFERON-ALFA; POLYMERASE CHAIN-REACTION; HEPATOCELLULAR-CARCINOMA; B VIRUS; CONTROLLED TRIAL; GENOTYPES; SEQUENCE; LIVER; RNA; VARIABILITY	Objective: To analyze the distribution of hepatitis C virus (HCV) genotypes among patients positive for antibody to HCV (anti-HCV) according to age, severity of liver disease, and duration of infection; to investigate the influence of HCV genotypes on response to interferon-alpha therapy; and to study HCV viremia levels in relation to genotypes and severity of liver disease. Design: Cross-sectional study. Setting: 3 university hospitals and 2 research units. Patients: 3 groups of French and Italian patients with chronic HCV infection and detectable serum HCV RNA: Group 1 included 35 patients with hepatocellular carcinoma; group 2, 71 patients with cirrhosis who did not have hepatocellular carcinoma; and group 3, 114 patients with chronic active hepatitis. 106 of the patients with chronic hepatitis or cirrhosis were treated with interferon-alpha (3 MU subcutaneously 3 times/wk for greater than or equal to 6 months). Measurements: Genotyping by polymerase chain reaction with capsid-specific primers; serum HCV RNA by branched DNA (bDNA) signal amplification. Results: Hepatitis C virus genotype 1b (II) was the most prevalent genotype (61.8%). In a univariate analysis, it was associated with older age (<40 years, 47.4%; greater than or equal to 60 years, 80.4%; P = 0.001), longer duration of disease (less than or equal to 10 years, 40.4%; greater than or equal to 20 years, 86.7%; P = 0.005), and cirrhosis with or without hepatocellular carcinoma 78.4% compared with 53.8% for chronic hepatitis; P < 0.001). Viremia levels did not differ between patients infected with HCV type 1b (II) and those infected with other HCV genotypes. Patients with HCV type 1b (II) responded to interferon-alpha therapy significantly less than did patients with other HCV genotypes (P = 0.01). In a multivariate analysis, age and cirrhosis were independently associated with HCV genotype 1b (II). Genotype and HCV viremia level were independent predictors of response to interferon-alpha therapy. Conclusions: The prevalence of HCV genotypes in French and Italian patients has been changing; the prevalence of HCV type 1b (II) infection has progressively decreased, although it still accounts for most HCV-related cirrhosis and hepatocellular carcinoma. High HCV viremia levels and HCV genotype type 1b (II) are independent predictors for poor response to interferon-alpha therapy and should be considered in the management of patients with HCV infection.	HOP NECKER ENFANTS MALAD, F-75015 PARIS, FRANCE; INST PASTEUR, PARIS, FRANCE; JICHI MED SCH, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; UNIV MILAN, MILAN, ITALY; HOP P BROUSSE, PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Jichi Medical University; University of Milan			Okamoto, Hiroaki/H-4371-2011; Nalpas, Bertrand/M-4981-2018; Feray, Cyrille/S-2559-2018	Okamoto, Hiroaki/0000-0003-0827-0964; Nalpas, Bertrand/0000-0002-8215-2942				Brouwer J. T., 1993, Journal of Hepatology, V18, pS10; BUKH J, 1993, P NATL ACAD SCI USA, V90, P8234, DOI 10.1073/pnas.90.17.8234; CHA TA, 1992, P NATL ACAD SCI USA, V89, P7144, DOI 10.1073/pnas.89.15.7144; CHAN SW, 1992, J GEN VIROL, V73, P1131, DOI 10.1099/0022-1317-73-5-1131; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; COLLETT MS, 1989, J GEN VIROL, V70, P253, DOI 10.1099/0022-1317-70-2-253; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; ENOMOTO N, 1990, BIOCHEM BIOPH RES CO, V170, P1021, DOI 10.1016/0006-291X(90)90494-8; FERAY C, 1993, GASTROENTEROLOGY, V104, P549, DOI 10.1016/0016-5085(93)90425-C; KATO N, 1993, J VIROL, V67, P3923, DOI 10.1128/JVI.67.7.3923-3930.1993; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; LI JS, 1991, GENE, V105, P167; LOK ASF, 1990, HEPATOLOGY, V12, P582, DOI 10.1002/hep.1840120322; MCOMISH F, 1993, TRANSFUSION, V33, P7, DOI 10.1046/j.1537-2995.1993.33193142314.x; NAKAO T, 1991, J GEN VIROL, V72, P2105, DOI 10.1099/0022-1317-72-9-2105; OKADA S, 1992, HEPATOLOGY, V16, P619, DOI 10.1002/hep.1840160302; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; OKAMOTO H, 1992, VIROLOGY, V188, P331, DOI 10.1016/0042-6822(92)90762-E; OKAMOTO H, 1993, J GEN VIROL, V74, P2385, DOI 10.1099/0022-1317-74-11-2385; OKAMOTO H, 1992, VIROLOGY, V190, P894, DOI 10.1016/0042-6822(92)90933-G; PATERLINI P, 1993, HEPATOLOGY, V17, P20, DOI 10.1016/0270-9139(93)90186-Q; POZZATO G, 1991, LANCET, V338, P509, DOI 10.1016/0140-6736(91)90578-D; POZZATO G, 1992, Journal of Hepatology, V16, pS3; RAIMONDO G, 1988, VIROLOGY, V166, P103, DOI 10.1016/0042-6822(88)90151-1; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SHERMAN KE, 1993, J CLIN MICROBIOL, V31, P2679, DOI 10.1128/JCM.31.10.2679-2682.1993; SIMMONDS P, 1993, J GEN VIROL, V74, P661, DOI 10.1099/0022-1317-74-4-661; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1016/0270-9139(94)90887-7; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; TAKADA N, 1993, J HEPATOL, V17, P277, DOI 10.1016/S0168-8278(05)80205-3; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; Urdea M S, 1991, Nucleic Acids Symp Ser, P197; WEINER AJ, 1992, P NATL ACAD SCI USA, V89, P3468, DOI 10.1073/pnas.89.8.3468; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203	39	516	528	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1995	122	3					161	+		10.7326/0003-4819-122-3-199502010-00001	http://dx.doi.org/10.7326/0003-4819-122-3-199502010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD733	7810932				2022-12-28	WOS:A1995QD73300001
J	SCHILLING, RF				SCHILLING, RF			ESTIMATING THE RISK FOR SEPSIS AFTER SPLENECTOMY IN HEREDITARY SPHEROCYTOSIS	ANNALS OF INTERNAL MEDICINE			English	Note							INFECTIONS; ADULTS				SCHILLING, RF (corresponding author), UNIV WISCONSIN, DEPT MED, 1300 UNIV AVE, MADISON, WI 53706 USA.							Gardner M, 1989, BRIT MED J; GARDNER MJ, 1989, BRIT MED J, P52; KING H, 1952, ANN SURG, V136, P239, DOI 10.1097/00000658-195208000-00006; KONRADSEN HB, 1991, ACTA PAEDIATR SCAND, V80, P423, DOI 10.1111/j.1651-2227.1991.tb11877.x; MACKINNEY AA, 1962, J CLIN INVEST, V41, P554, DOI 10.1172/JCI104509; ONEAL BJ, 1981, ANN SURG, V194, P775, DOI 10.1097/00000658-198112000-00020; SCHILLING RF, 1976, SEMIN HEMATOL, V13, P169; SCHWARTZ PE, 1982, JAMA-J AM MED ASSOC, V248, P2279, DOI 10.1001/jama.248.18.2279; Singer D B, 1973, Perspect Pediatr Pathol, V1, P285; TEARE L, 1992, LANCET, V340, P1362, DOI 10.1016/0140-6736(92)92555-T; ZARRABI MH, 1984, ARCH INTERN MED, V144, P1421, DOI 10.1001/archinte.144.7.1421	11	65	67	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1995	122	3					187	188		10.7326/0003-4819-122-3-199502010-00005	http://dx.doi.org/10.7326/0003-4819-122-3-199502010-00005			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD733	7810936				2022-12-28	WOS:A1995QD73300005
J	SEWARD, PJ; TODD, JS				SEWARD, PJ; TODD, JS			HEALTH SYSTEM REFORM - WHITHER OR WHETHER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									AMER MED ASSOC,OFF CHAIR BOARD TRUSTEES,CHICAGO,IL 60610; AMER MED ASSOC,OFF EXECUT VICE PRESIDENT,CHICAGO,IL 60610	American Medical Association; American Medical Association								TODD JS, 1991, JAMA-J AM MED ASSOC, V265, P2503; 1993, MICRA INFORMATION; 1994, ADVOCACY INITIATIVE, P8; 1993, PRESERVING CHOICE MA	4	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					246	247						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB234	7807671				2022-12-28	WOS:A1995QB23400036
J	FRASER, DR				FRASER, DR			VITAMIN-D	LANCET			English	Article							D DEFICIENCY; RECEPTOR; 1,25-DIHYDROXYVITAMIN-D3; HYPERPARATHYROIDISM; RAT				FRASER, DR (corresponding author), UNIV SYDNEY, DEPT ANIM SCI, SYDNEY, NSW 2006, AUSTRALIA.			Fraser, David/0000-0003-2560-0750				BELL NH, 1991, ENDOCRIN METAB CLIN, V20, P645, DOI 10.1016/S0889-8529(18)30262-7; BELTON NR, 1986, ACTA PAEDIATR SCAND, P68; BRAIDMAN IP, 1985, CLIN ENDOCRINOL, V23, P445, DOI 10.1111/j.1365-2265.1985.tb01103.x; CHAPLIN H, 1951, AM J MED SCI, V221, P369, DOI 10.1097/00000441-195104000-00003; CLEMENTS MR, 1992, CLIN ENDOCRINOL, V37, P17, DOI 10.1111/j.1365-2265.1992.tb02278.x; CLEMENTS MR, 1987, NATURE, V325, P62, DOI 10.1038/325062a0; CLEMENTS MR, 1988, J CLIN INVEST, V81, P1768, DOI 10.1172/JCI113518; CLEMENTS MR, 1987, CLIN SCI, V73, P659, DOI 10.1042/cs0730659; CORLESS D, 1975, LANCET, V1, P1404; EISMAN JA, 1993, OSTEOPOROSIS INT, V3, pS56, DOI 10.1007/BF01621865; ELRADHI AS, 1982, J ROY SOC MED, V75, P884; ETHIER C, 1991, ENDOCR RES, V17, P421, DOI 10.1080/07435809109106818; FRASER DR, 1991, NESTLE NUTR WORKS SE, V21, P23; FREANEY R, 1993, AM J CLIN NUTR, V58, P187, DOI 10.1093/ajcn/58.2.187; GLOTH FM, 1991, J AM GERIATR SOC, V39, P137, DOI 10.1111/j.1532-5415.1991.tb01615.x; GREAVES JH, 1974, J HYG-CAMBRIDGE, V73, P341, DOI 10.1017/S0022172400042686; HAUSSLER MR, 1976, LIFE SCI, V18, P1049, DOI 10.1016/0024-3205(76)90137-5; HUGHES MR, 1976, J CLIN INVEST, V58, P61, DOI 10.1172/JCI108459; KAMPMAN E, 1994, AM J EPIDEMIOL, V139, P16, DOI 10.1093/oxfordjournals.aje.a116931; KRAGBALLE K, 1993, DERMATOL CLIN, V11, P137, DOI 10.1016/S0733-8635(18)30290-0; LEESON PM, 1966, LANCET, V1, P1182; MASSHEIMER V, 1992, MOL CELL ENDOCRINOL, V84, P15, DOI 10.1016/0303-7207(92)90066-F; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; MORRISON NA, 1992, P NATL ACAD SCI USA, V89, P6665, DOI 10.1073/pnas.89.15.6665; POLS HAP, 1990, J STEROID BIOCHEM, V37, P873, DOI 10.1016/0960-0760(90)90435-N; PUN KK, 1990, BONE, V11, P365, DOI 10.1016/8756-3282(90)90092-D; SANDGREN ME, 1991, BIOCHEM BIOPH RES CO, V181, P611, DOI 10.1016/0006-291X(91)91234-4; Scragg R, 1992, Ann Epidemiol, V2, P697; SPECKER BL, 1987, J PEDIATR-US, V110, P744, DOI 10.1016/S0022-3476(87)80016-1; SPECKER BL, 1994, AM J CLIN NUTR, V59, p484S, DOI 10.1093/ajcn/59.2.484S; STEPHENS WP, 1982, Q J MED, V51, P171; VIETH R, 1990, BONE MINER, V11, P267, DOI 10.1016/0169-6009(90)90023-9; VILLAREAL DT, 1991, J CLIN ENDOCR METAB, V72, P628, DOI 10.1210/jcem-72-3-628	33	158	162	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 14	1995	345	8942					104	107		10.1016/S0140-6736(95)90067-5	http://dx.doi.org/10.1016/S0140-6736(95)90067-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815853				2022-12-28	WOS:A1995QB80400014
J	JO, SA; ZHU, XJ; MARCHIONNI, MA; BURDEN, SJ				JO, SA; ZHU, XJ; MARCHIONNI, MA; BURDEN, SJ			NEUREGULINS ARE CONCENTRATED AT NERVE-MUSCLE SYNAPSES AND ACTIVATE ACH-RECEPTOR GENE-EXPRESSION	NATURE			English	Article							ACETYLCHOLINE-RECEPTOR; SUBUNIT GENE; TRANSGENIC MICE; EPSILON-SUBUNIT; BASAL LAMINA; FAMILY; PROTEIN; MEMBER; NEU; HER4/P180(ERBB4)	Two different signalling pathways mediate the localization of acetylcholine receptors (AChRs) to synaptic sites in skeletal muscle. The signal for one pathway is agrin, a protein that triggers a redistribution of previously unlocalized cell surface AChRs to synaptic sites(1). The signal for the other pathway is not known, but this signal stimulates transcription of AChR genes in myofibre nuclei near the synaptic site(2). Neuregulins, identified originally as a potential ligand for erbB2 (Neu differentiation factor, NDF)(3), stimulate proliferation of Schwann cells (glial growth factor, GGF)(4), increase the rate of AChR synthesis in cultured muscle cells (AChR-inducing activity)(5) and are expressed in motor neurons(4,5). These results raise the possibility that neuregulin is the signal that activates AChR genes in synaptic nuclei. Here we show that neuregulin activates AChR gene expression in C2 muscle cells and that the neuregulin response element in the AChR delta-subunit gene is contained in the same 181 base pairs that confer synapse-specific expression in transgenic mice. We use antibodies to show that neuregulins are concentrated at synaptic sites and that, like the extracellular signal that stimulates synapse-specific expression, neuregulins remain at synaptic sites in the absence of nerve and muscle. We show that C2 muscle cells contain erbB2 and erbB3 messenger RNA but little or no erbB4 mRNA, and that neuregulin stimulates tyrosine phosphorylation of erbB2 and erbB3, indicating that neuregulin signalling in skeletal muscle may be mediated by a complex of erbB2 and erbB3.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; CAMBRIDGE NEUROSCI INC,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	JO, SA (corresponding author), HARVARD UNIV,SCH MED,CTR BLOOD RES,200 LONGWOOD AVE,BOSTON,MA 02115, USA.			Burden, Steven/0000-0002-3550-6891				BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BRENNER HR, 1992, DEVELOPMENT, V116, P41; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; BURDEN SJ, 1993, TRENDS GENET, V9, P12, DOI 10.1016/0168-9525(93)90066-Q; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GOLDMAN D, 1991, NEURON, V7, P649, DOI 10.1016/0896-6273(91)90377-C; GUNDERSEN K, 1993, J CELL BIOL, V123, P1535, DOI 10.1083/jcb.123.6.1535; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JO SA, 1992, DEVELOPMENT, V115, P673; KLARSFELD A, 1991, EMBO J, V10, P625, DOI 10.1002/j.1460-2075.1991.tb07990.x; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARTINOU JC, 1991, P NATL ACAD SCI USA, V88, P7669, DOI 10.1073/pnas.88.17.7669; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; MUDGE AW, 1993, CURR BIOL, V3, P361, DOI 10.1016/0960-9822(93)90201-X; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; SANES JR, 1991, DEVELOPMENT, V113, P1181; SANES JR, 1983, COLD SPRING HARB SYM, V48, P667, DOI 10.1101/SQB.1983.048.01.070; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; SIMON AM, 1993, MOL CELL BIOL, V13, P5133, DOI 10.1128/MCB.13.9.5133; SIMON AM, 1992, DEVELOPMENT, V114, P545; TANG JC, 1994, DEVELOPMENT, V120, P1799; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	28	243	252	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					158	161						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7816098				2022-12-28	WOS:A1995QB06300061
J	PACKER, C; COLLINS, DA; SINDIMWO, A; GOODALL, J				PACKER, C; COLLINS, DA; SINDIMWO, A; GOODALL, J			REPRODUCTIVE CONSTRAINTS ON AGGRESSIVE COMPETITION IN FEMALE BABOONS	NATURE			English	Article							OLIVE BABOONS; PAPIO-ANUBIS; PRIMATES; AGE	COMPETITIVE interaction between females of the same social group is characteristic of most primate species(1-3). In old World monkeys, females of high social rank maintain priority of access to scarce resources and harass low-ranking companions(1-6). But different field studies have found differing correlations between female dominance and reproductive success: several populations show an advantage of rank whereas others do not(1,3,5,7). Although such variation may reflect divergent levels of predation, food availability or social stress in different environments, female competitive ability may also be balanced by significant reproductive costs and thus be subject to strong stabilizing selection, We report here that high-ranking female baboons (Papio cynocephalus anubis) at Gombe National Park, Tanzania, enjoy shorter interbirth intervals, improved infant survival, and accelerated maturation of their daughters. These advantages, however, are countered by a significantly higher probability of miscarriage, and a proportion of high-ranking females suffer from reduced fertility.	UNIV EDINBURGH,INST CELL ANIM & POPULAT BIOL,ASHWORTH LAB,EDINBURGH EH9 3JT,MIDLOTHIAN,SCOTLAND; GOMBE STREAM RES CTR,KIGOMA,TANZANIA	University of Edinburgh	PACKER, C (corresponding author), UNIV MINNESOTA,DEPT EEB,1987 UPPER BUFORD CIRCLE,ST PAUL,MN 55108, USA.							ABBOTT DH, 1987, J ZOOL, V213, P455, DOI 10.1111/j.1469-7998.1987.tb03720.x; Altmann J., 1988, P403; Altmann J., 1970, LAB ANIM DIG, V6, P7; BERCOVITCH FB, 1993, BEHAV ECOL SOCIOBIOL, V33, P313; Chapais Bernard, 1992, P29; Collins DA, 1984, INFANTICIDE COMP EVO, P193; FAIRBANKS LA, 1986, ANIM BEHAV, V34, P1710, DOI 10.1016/S0003-3472(86)80258-5; Glickman Stephen E., 1993, Perspectives in Ethology, V10, P87; Goodall J, 1986, CHIMPANZEES GOMBE, DOI DOI 10.1002/AJPA.1330730313; Goy R W, 1972, Recent Prog Horm Res, V28, P707; HAUSFATER G, 1982, SCIENCE, V217, P752, DOI 10.1126/science.217.4561.752; HAUSFATER G, 1975, DOMINANCE REPRODUCTI; LEE PC, 1987, J ZOOL, V213, P409, DOI 10.1111/j.1469-7998.1987.tb03717.x; NASH LT, 1976, AM J PHYS ANTHROPOL, V44, P63, DOI 10.1002/ajpa.1330440109; OWENS NW, 1976, BEHAVIOUR, V57, P241, DOI 10.1163/156853976X00541; PACKER C, 1979, ANIM BEHAV, V27, P1, DOI 10.1016/0003-3472(79)90126-X; PACKER C, 1975, NATURE, V255, P219, DOI 10.1038/255219a0; Ransom TW., 1981, BEACH TROOP GOMBE; SACKETT GP, 1975, 5TH P INT C INT PRIM; Silk J.B., 1987, P318; SMUTS B, 1989, AM J PRIMATOL, V19, P229, DOI 10.1002/ajp.1350190405; STRUM SC, 1982, AM J PRIMATOL, V3, P61, DOI 10.1002/ajp.1350030106; vom Saal F S, 1989, J Reprod Fertil, V86, P457, DOI 10.1530/jrf.0.0860457; Walters J.R., 1987, P306; Wasser S.K., 1983, P349; WASSER SK, 1993, BEHAV ECOL SOCIOBIOL, V32, P273; YALCINKAYA TM, 1993, SCIENCE, V260, P1929, DOI 10.1126/science.8391165	27	136	139	2	47	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 5	1995	373	6509					60	63		10.1038/373060a0	http://dx.doi.org/10.1038/373060a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800039				2022-12-28	WOS:A1995QA23900054
J	FARRELL, M				FARRELL, M			BARTLETT,ADELAIDE AND THE PIMLICO MYSTERY	BRITISH MEDICAL JOURNAL			English	Article								In 1886 Adelaide Bartlett stood trial at the Old Bailey for the murder of her husband, Thomas Edwin Bartlett. The court witnessed sensational evidence and the case left questions which remain unanswered.											0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1720	1723		10.1136/bmj.309.6970.1720	http://dx.doi.org/10.1136/bmj.309.6970.1720			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7820001	Green Published			2022-12-28	WOS:A1994PY71700031
J	KOSSEREV, I; CRAWSHAW, R				KOSSEREV, I; CRAWSHAW, R			MEDICINE AND THE GULAG	BRITISH MEDICAL JOURNAL			English	Article							NAZI DOCTORS	The nature of the medical treatment of prisoners in the Gulag has emerged from accounts published by survivors. Over a period of 70 years some doctors entrusted with the medical care of prisoners failed to discharge their ethical duties, contributing to the prisoners' neglect and suffering. The medical profession must carefully examine what occurred and properly assign responsibility for ethical as well as unethical medical acts. Understanding the history of these ominous events will alert doctors worldwide to the importance of medical autonomy in the support of imprisoned patients.	IM SECHENOV MED ACAD,MOSCOW,RUSSIA; RUSSIAN ACAD NAT SCI,MOSCOW,RUSSIA	Sechenov First Moscow State Medical University; Russian Academy of Sciences								Anisimov E. V., 1993, REFORMS PETER GREAT, P217; Annas George J., 1992, NAZI DOCTORS NUREMBE; BENATAR S, J MED HUMANITIES, V14, P137; CONQUEST R, 1968, GREAT TERROR STALINS, P699; CRAWSHAW R, 1987, PHAROS, V50, P41; DROBNIEWSKI F, 1993, J ROY SOC MED, V86, P541; FISCHER L, 1964, LIFE LENIN, P31; GALTON DJ, 1989, J ROY COLL PHYS LOND, V23, P189; GELLER JJ, 1989, BRIT MED J, V299, P1601, DOI 10.1136/bmj.299.6715.1601; GLASER K, 1979, VICTIMS POLITICS STA, P342; LISIZYIN P, 1993, KENNEDY I ETHICS J, V3, P419; MARCHENKO A, 1969, MY TESTIMONY, P10; Medvedev Roy A., 1980, SOVIET DISSENT; PARES B, 1962, RUSSIA REFORM REVOLU, P300; PIRGOV NL, 1991, QUESTIONS LIFE DIARY; PODRABINEK AP, 1979, FUNITIVE MED; PROSS C, 1991, J MED ETHICS, V17, P13, DOI 10.1136/jme.17.Suppl.13; SHALMOV V, 1989, NOVII MIR        DEC, P42; SOLZHENITSYN A, 1990, ONE DAY IN LIFE OF I; SOLZHENITSYN AI, 1973, GULAG ARCHIPELAGO 19, P207; TSAREGORODTSEV GI, 1989, J MED PHILOS, V14, P301, DOI 10.1093/jmp/14.3.301; VOLKOV O, 1989, POGRUZHENIYE VO TMO, P366	22	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1726	1730		10.1136/bmj.309.6970.1726	http://dx.doi.org/10.1136/bmj.309.6970.1726			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7820004	Green Published			2022-12-28	WOS:A1994PY71700034
J	SCOTT, CM; SINGH, J				SCOTT, CM; SINGH, J			CHOCOLATE BARS IN EYE	BRITISH MEDICAL JOURNAL			English	Note											SCOTT, CM (corresponding author), PRINCESS ALEXANDRA EYE PAVIL,EDINBURGH EH3 9H,MIDLOTHIAN,SCOTLAND.								0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1748	1748						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7820015				2022-12-28	WOS:A1994PY71700048
J	HIRSCH, S; MUCKEL, E; HEEMEYER, F; VONHEIJNE, G; SOLL, J				HIRSCH, S; MUCKEL, E; HEEMEYER, F; VONHEIJNE, G; SOLL, J			A RECEPTOR COMPONENT OF THE CHLOROPLAST PROTEIN TRANSLOCATION MACHINERY	SCIENCE			English	Article							OUTER ENVELOPE MEMBRANE; SPINACH-CHLOROPLASTS; IMPORT APPARATUS; PEA-CHLOROPLASTS; CONTACT SITES; LOCALIZATION; IDENTIFICATION; MITOCHONDRIAL; POLYPEPTIDE; TRANSPORT	The chloroplast outer envelope protein OEP86 functions as a receptor in precursor protein translocation into chloroplasts. Sequence analysis suggests that the precursor of OEP86 is directed to the chloroplast outer envelope by a cleavable, negatively charged, and unusually long amino-terminal peptide. This presequence is unlike other potential targeting signals and suggests the existence of another membrane insertion pathway. insertion of precursor OEP86 required the hydrolysis of adenosine triphosphate and the existence of surface exposed chloroplast membrane components, and it was not competed by another precursor protein destined for the internal plastid compartments.	CHRISTIAN ALBRECHTS UNIV KIEL, INST BOT, D-24098 KIEL, GERMANY; KAROLINSKA INST, NOVUM, CTR STRUCT BIOCHEM, S-14157 HUDDINGE, SWEDEN	University of Kiel; Karolinska Institutet			von Heijne, Gunnar/AAH-9389-2019; von Heijne, Gunnar/F-5576-2011	von Heijne, Gunnar/0000-0002-4490-8569				ALEFSEN H, 1994, J PLANT PHYSIOL, V144, P339, DOI 10.1016/S0176-1617(11)81196-X; BLOCK MA, 1983, J BIOL CHEM, V258, P3281; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; FLUGGE UI, 1991, NATURE, V353, P364, DOI 10.1038/353364a0; HARLOW E, 1989, ANTIBODIES LABORATOR; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; JOYARD J, 1983, J BIOL CHEM, V258, P1; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; KLEIN RR, 1992, PLANT PHYSIOL, V98, P546, DOI 10.1104/pp.98.2.546; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; SCHINDLER C, 1987, Z NATURFORSCH C, V42, P103; SCHNELL DJ, 1990, J CELL BIOL, V111, P1825, DOI 10.1083/jcb.111.5.1825; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; SEEDORF M, IN PRESS PLANT J; SOLL J, 1989, PLANTA, V177, P393, DOI 10.1007/BF00403598; SOLL J, 1992, PLANT J, V2, P253, DOI 10.1111/j.1365-313X.1992.00253.x; SOLL J, 1993, PHYSIOL PLANTARUM, V87, P433, DOI 10.1111/j.1399-3054.1993.tb01752.x; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x; WAEGEMANN K, 1992, PLANTA, V187, P89, DOI 10.1007/BF00201628; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; WAEGEMANN K, 1993, NATO ASI SERIES H, V74, P101	29	196	208	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					1989	1992		10.1126/science.7801125	http://dx.doi.org/10.1126/science.7801125			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801125	Green Submitted			2022-12-28	WOS:A1994PZ26700029
J	SHEARD, S				SHEARD, S			GAGGING PUBLIC-HEALTH DOCTORS	BRITISH MEDICAL JOURNAL			English	Article											SHEARD, S (corresponding author), UNIV LIVERPOOL,DEPT PUBL HLTH,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.			Sheard, Sally/0000-0001-8116-9120				RUE R, 1987, COMMUNITY PHYSI 0711, P92; 1993, MANAGING NEW NHS BAC; 1988, CMND289; 1847, PUNCH, V11, P44	4	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1643	1644		10.1136/bmj.309.6969.1643	http://dx.doi.org/10.1136/bmj.309.6969.1643			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PY220	7819950	Green Published			2022-12-28	WOS:A1994PY22000036
J	CHRISTIAN, TF; MILLER, TD; BAILEY, KR; GIBBONS, RJ				CHRISTIAN, TF; MILLER, TD; BAILEY, KR; GIBBONS, RJ			EXERCISE TOMOGRAPHIC TL-201 IMAGING IN PATIENTS WITH SEVERE CORONARY-ARTERY DISEASE AND NORMAL ELECTROCARDIOGRAMS	ANNALS OF INTERNAL MEDICINE			English	Article						CORONARY DISEASE; EXERCISE TESTS; THALLIUM RADIOISOTOPES; TOMOGRAPHY, RADIO-NUCLIDE COMPUTED; COST-BENEFIT ANALYSIS	MYOCARDIAL PERFUSION SCINTIGRAPHY; PROGNOSTIC VALUE; NONINVASIVE IDENTIFICATION; RADIONUCLIDE ANGIOGRAPHY; CHEST PAIN; HEART-DISEASE; TL-201; INFARCTION; DIAGNOSIS; HISTORY	Objective: To assess the incremental value and cost-effectiveness of exercise tomographic thallium-201 imaging compared with clinical and exercise electrocardiographic variables for detecting three-vessel or left main coronary artery disease in patients with normal at-rest electrocardiograms. Design: Prospective cohort study. Participants: 411 patients (77 [19%] had three-vessel or left main disease) with normal at-rest electrocardiograms who underwent exercise tomographic thallium-201 studies and subsequently had coronary angiography. Measurements: Clinical, exercise, and thallium-201 variables; univariate followed by multivariate logistic regression analysis to determine predictors of three-vessel or left main disease (clinical variables; clinical and exercise electrocardiographic variables; and clinical, exercise, and thallium-201 variables). Patients were classified by each of these models into low-, intermediate-, and high-risk groups. Setting: A tertiary referral center. Results: Among the clinical variables, diabetes mellitus, sex, age, and typical angina were independently associated with severe coronary disease (46% of patients were correctly classified into low- or high-risk groups). The peak exercise heart rate-blood pressure product and the magnitude of the exercise-induced ST depression added independent information to clinical variables. Among the thallium variables, the change in the global thallium-201 score (a measure of redistribution) added independent information to clinical and exercise variables, resulting in only 3% of the patients being reclassified regarding their predicted risk for severe coronary disease. The cost per additional reclassification was estimated to be $20 550. Twenty-one cardiac events occurred (7 cardiac deaths and 14 myocardial infarctions) after thallium study (follow-up, 2.8 +/- 1.0 years). Event-free survival was 94% to 97% regardless of the predicted probability of developing three-vessel or left main coronary artery disease by any model. Conclusions: When the at-rest electrocardiogram is normal, thallium-201 scintigraphy adds little information to clinical and exercise variables in identifying patients with severe coronary artery disease. The high cost of this information may not justify the routine use of sophisticated imaging for this purpose.			CHRISTIAN, TF (corresponding author), MAYO CLIN & MAYO FDN, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							BOTVINICK EH, 1978, AM J CARDIOL, V41, P43, DOI 10.1016/0002-9149(78)90130-3; BOUCHER CA, 1980, AM J CARDIOL, V46, P189, DOI 10.1016/0002-9149(80)90057-0; BROWN KA, 1983, J AM COLL CARDIOL, V1, P994, DOI 10.1016/S0735-1097(83)80100-4; CHRISTIAN TF, 1992, AM J CARDIOL, V70, P14, DOI 10.1016/0002-9149(92)91382-E; CONNOLLY DC, 1984, MAYO CLIN PROC, V59, P247, DOI 10.1016/S0025-6196(12)61257-9; DEPASQUALE EE, 1988, CIRCULATION, V77, P316, DOI 10.1161/01.CIR.77.2.316; DIAMOND GA, 1988, AM J CARDIOL, V62, P806, DOI 10.1016/0002-9149(88)91227-1; DIAMOND GA, 1989, J AM COLL CARDIOL, V14, pA12, DOI 10.1016/0735-1097(89)90157-5; EDWARDS WD, 1981, MAYO CLIN PROC, V56, P479; FAGAN LF, 1992, AM J CARDIOL, V69, P607, DOI 10.1016/0002-9149(92)90150-W; GIBBONS RJ, 1988, J AM COLL CARDIOL, V11, P28, DOI 10.1016/0735-1097(88)90162-3; GIBBONS RJ, 1990, ANN INTERN MED, V112, P743, DOI 10.7326/0003-4819-112-10-743; HUBBARD BL, 1992, ARCH INTERN MED, V152, P309, DOI 10.1001/archinte.152.2.309; ISKANDRIAN AS, 1980, AM J CARDIOL, V46, P553, DOI 10.1016/0002-9149(80)90502-0; KAUL S, 1988, J AM COLL CARDIOL, V12, P25, DOI 10.1016/0735-1097(88)90351-8; LADENHEIM ML, 1986, J AM COLL CARDIOL, V7, P464, DOI 10.1016/S0735-1097(86)80454-5; LADENHEIM ML, 1987, AM J CARDIOL, V59, P270, DOI 10.1016/0002-9149(87)90798-3; MAHMARIAN JJ, 1990, J AM COLL CARDIOL, V15, P318, DOI 10.1016/S0735-1097(10)80055-5; MORISE AP, 1992, J AM COLL CARDIOL, V20, P1187, DOI 10.1016/0735-1097(92)90377-Y; OKEEFE JH, 1989, AM J MED, V86, P658, DOI 10.1016/0002-9343(89)90439-7; POLLOCK SG, 1992, CIRCULATION, V85, P237, DOI 10.1161/01.CIR.85.1.237; Principal Investigators of CASS and Associates, 1981, CIRCULATION S1, V63, pI1; PRYOR DB, 1991, AM J MED, V90, P553; PRYOR DB, 1993, ANN INTERN MED, V118, P81, DOI 10.7326/0003-4819-118-2-199301150-00001; RITCHIE JL, 1977, CIRCULATION, V56, P66, DOI 10.1161/01.CIR.56.1.66; RITCHIE JL, 1982, AM J CARDIOL, V50, P1236, DOI 10.1016/0002-9149(82)90455-6; ROZANSKI A, 1985, NEW ENGL J MED, V308, P518; SIMARI RD, 1991, AM J CARDIOL, V67, P573, DOI 10.1016/0002-9149(91)90894-Q; TAMAKI N, 1984, EUR J NUCL MED, V9, P99, DOI 10.1007/BF00253509; VARNAUSKAS E, 1985, CIRCULATION, V72, P90; WEISS AT, 1987, J AM COLL CARDIOL, V9, P752; [No title captured]; 1983, SAS SUPPLEMENTED LIB	33	85	84	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1994	121	11					825	832		10.7326/0003-4819-121-11-199412010-00001	http://dx.doi.org/10.7326/0003-4819-121-11-199412010-00001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT628	7794314				2022-12-28	WOS:A1994PT62800001
J	GLAZER, M; SAGAR, VV				GLAZER, M; SAGAR, VV			BONY METASTASES	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									MED CTR DELAWARE,NEWARK,DE 19718		GLAZER, M (corresponding author), UNIV CHICAGO,CHICAGO,IL 60637, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 9	1995	332	6					370	370		10.1056/NEJM199502093320606	http://dx.doi.org/10.1056/NEJM199502093320606			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF300	7823999				2022-12-28	WOS:A1995QF30000006
J	COFFIN, JM				COFFIN, JM			HIV POPULATION-DYNAMICS IN-VIVO - IMPLICATIONS FOR GENETIC-VARIATION, PATHOGENESIS, AND THERAPY	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RETROVIRAL SHUTTLE VECTOR; SINGLE REPLICATION CYCLE; REVERSE-TRANSCRIPTASE; T-CELL; INSITU HYBRIDIZATION; MUTATIONAL HOTSPOTS; BROAD-SPECTRUM; INFECTION; TYPE-1	Several recent reports indicate that the long, clinically latent phase that characterizes human immunodeficiency virus (HIV) infection of humans is not a period of viral inactivity, but an active process in which cells are being infected and dying at a high rate and in large numbers. These results lead to a simple steady-state model in which infection, cell death, and cell replacement are in balance, and imply that the unique feature of HIV is the extraordinarily large number of replication cycles that occur during infection of a single individual. This turnover drives both the pathogenic process and (even more than mutation rate) the development of genetic variation. This variation includes the inevitable and, in principle, predictable accumulation of mutations such as those conferring resistance to antiviral drugs whose presence before therapy must be considered in the design of therapeutic strategies,			COFFIN, JM (corresponding author), TUFTS UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,136 HARRISON AVE,BOSTON,MA 02111, USA.				NATIONAL CANCER INSTITUTE [R35CA044385] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA 44385] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURNS DPW, 1991, J VIROL, V65, P1843, DOI 10.1128/JVI.65.4.1843-1854.1991; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; Coffin J M, 1980, Ann N Y Acad Sci, V354, P410, DOI 10.1111/j.1749-6632.1980.tb27982.x; COFFIN JM, 1992, CURR TOP MICROBIOL, V176, P143; COFFIN JP, UNPUB; CRISE B, 1992, J VIROL, V66, P2296, DOI 10.1128/JVI.66.4.2296-2301.1992; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DOOLITTLE RF, 1990, CURR TOP MICROBIOL, V157, P1; DOUGHERTY JP, 1988, J VIROL, V62, P2817, DOI 10.1128/JVI.62.8.2817-2822.1988; ELGEN M, 1990, AIDS S1, V4, P585; ELGEN M, 1988, RNA GENETICS, V3, P3; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; EMBRETSON J, 1993, P NATL ACAD SCI USA, V90, P357, DOI 10.1073/pnas.90.1.357; EVANS LA, 1993, HIV MOL ORG PATHOGEN, P29; FAUCI AS, 1993, J ACQ IMMUN DEF SYND, V6, P655; FENYO EM, 1988, J VIROL, V62, P4414; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FOLKS T, 1986, SCIENCE, V231, P600, DOI 10.1126/science.3003906; GAO Q, 1992, J VIROL, V66, P12, DOI 10.1128/JVI.66.1.12-19.1992; GOJOBORI T, 1990, P NATL ACAD SCI USA, V87, P10015, DOI 10.1073/pnas.87.24.10015; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOLLAND JJ, 1992, CURR TOP MICROBIOL, V176, P1; JOHNSON PR, 1991, VIROLOGY, V185, P217, DOI 10.1016/0042-6822(91)90769-8; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; KOZAL MJ, 1993, J INFECT DIS, V167, P526, DOI 10.1093/infdis/167.3.526; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; LINETTE GP, 1988, SCIENCE, V241, P573, DOI 10.1126/science.2899908; LOVEDAY C, COMMUNICATION; MERRILL JE, 1989, J VIROL, V63, P4404, DOI 10.1128/JVI.63.10.4404-4408.1989; MERRILL JE, 1992, CLIN IMMUNOL IMMUNOP, V64, P23, DOI 10.1016/0090-1229(92)90054-R; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; MOHRI H, 1993, P NATL ACAD SCI USA, V90, P25, DOI 10.1073/pnas.90.1.25; MONK RJ, 1992, J VIROL, V66, P3683, DOI 10.1128/JVI.66.6.3683-3689.1992; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; MYERS G, 1992, RETROVIRIDAE, P51; NAJERA I, 1995, J VIROL, V69, P23; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9839; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6024, DOI 10.1073/pnas.87.16.6024; PATTERSON BK, 1993, SCIENCE, V260, P976, DOI 10.1126/science.8493534; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; RICCHETTI M, 1990, EMBO J, V9, P1583, DOI 10.1002/j.1460-2075.1990.tb08278.x; RICHMAN D, COMMUNICATION; RICHMAN DD, 1992, CURR TOP MICROBIOL, V176, P131; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; SAKSELA K, 1994, P NATL ACAD SCI USA, V91, P1104, DOI 10.1073/pnas.91.3.1104; SALSELA K, 1993, J VIROL, V67, P7423; SCHINAZI R, 1994, INT ANTIVIRAL NEWS, V2, P72; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHUURMANN R, UNPUB; SCHWARTZ S, 1989, P NATL ACAD SCI USA, V86, P7200, DOI 10.1073/pnas.86.18.7200; SMITH TF, 1988, NATURE, V333, P573, DOI 10.1038/333573a0; TANTILLO J, 1994, J MOL BIOL, V243, P364; TARPLEY WG, COMMUNICATION; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; VARELAECHAVARRIA A, 1992, J BIOL CHEM, V267, P24681; WAINHOBSON S, 1992, CURR TOP MICROBIOL, V176, P181; WEI X, 1995, NATURE, V373, P17; WOLINSKY SM, COMMUNICATION; 1994, LANCET, V343, P871	69	1631	1705	3	111	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 27	1995	267	5197					483	489		10.1126/science.7824947	http://dx.doi.org/10.1126/science.7824947			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD403	7824947				2022-12-28	WOS:A1995QD40300031
J	HOFNUNG, M				HOFNUNG, M			AN INTELLIGENT CHANNEL (AND MORE)	SCIENCE			English	Editorial Material							BACTERIOPHAGE-LAMBDA RECEPTOR; ESCHERICHIA-COLI; OUTER-MEMBRANE; MALTOSE TRANSPORT; MALTOPORIN; BINDING; PROTEIN; MUTATIONS; DOMINANCE; MUTANTS				HOFNUNG, M (corresponding author), INST PASTEUR,UNITE PROGRAMMAT MOLEC & TOXICOL GENET BIOTECHNOL,25 RUE DR ROUX,F-75015 PARIS,FRANCE.							CHARBIT A, 1991, J BACTERIOL, V173, P262, DOI 10.1128/jb.173.1.262-275.1991; CHARBIT A, 1988, J MOL BIOL, V201, P487, DOI 10.1016/0022-2836(88)90630-4; CHARBIT A, 1994, J BACTERIOL, V176, P3204, DOI 10.1128/jb.176.11.3204-3209.1994; DARGENT B, 1988, J MOL BIOL, V201, P497, DOI 10.1016/0022-2836(88)90632-8; DEATH A, 1993, J BACTERIOL, V175, P1475, DOI 10.1128/JB.175.5.1475-1483.1993; FERENCI T, 1989, J BACTERIOL, V171, P855, DOI 10.1128/jb.171.2.855-861.1989; Ghuysen J.-M., 1994, BACTERIAL CELL WALL; HEINE HG, 1988, J BACTERIOL, V170, P1730, DOI 10.1128/jb.170.4.1730-1738.1988; KLEBBA PE, 1994, EMBO J, V13, P4670, DOI 10.1002/j.1460-2075.1994.tb06790.x; MARCHAL C, 1983, EMBO J, V2, P81, DOI 10.1002/j.1460-2075.1983.tb01385.x; Newton S. L., UNPUB; NIKAIDO H, 1992, SCIENCE, V258, P936, DOI 10.1126/science.1279804; RANDALLHAZELBAU.L, 1973, J BACTERIOL, V116, P1436; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; SCHIRMER T, 1993, PROTEIN SCI, V2, P1361, DOI 10.1002/pro.5560020820; Schulz GE, 1993, CURR OPIN CELL BIOL, V5, P701, DOI 10.1016/0955-0674(93)90143-E; SZMELCMAN S, 1975, J BACTERIOL, V124, P112, DOI 10.1128/JB.124.1.112-118.1975; THIRION JP, 1972, GENETICS, V71, P207; WANDERSMAN C, 1979, J BACTERIOL, V140, P1	19	23	23	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 27	1995	267	5197					473	474		10.1126/science.7824946	http://dx.doi.org/10.1126/science.7824946			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD403	7824946				2022-12-28	WOS:A1995QD40300028
J	SCHIRMER, T; KELLER, TA; WANG, YF; ROSENBUSCH, JP				SCHIRMER, T; KELLER, TA; WANG, YF; ROSENBUSCH, JP			STRUCTURAL BASIS FOR SUGAR TRANSLOCATION THROUGH MALTOPORIN CHANNELS AT 3.1-ANGSTROM RESOLUTION	SCIENCE			English	Article							OUTER-MEMBRANE PROTEIN; ESCHERICHIA-COLI; LAMBDA RECEPTOR; MALTOSE-BINDING; TRANSPORT; SELECTIVITY; SITES; GENE; CRYSTALLIZATION; DIFFUSION	Trimeric maltoporin (LamB protein) facilitates the diffusion of maltodextrins across the outer membrane of Gram-negative bacteria. The crystal structure of maltoporin from Escherichia coli, determined to a resolution of 3.1 angstroms, reveals an 18-stranded, antiparallel beta-barrel that forms the framework of the channel. Three inwardly folded loops contribute to a constriction about halfway through the channel. Six contingent aromatic residues line the channel and form a path from the vestibule to the periplasmic outlet. Soaking of a crystal with maltotriose revealed binding of the sugar to this hydrophobic track across the constriction, which suggests that maltose and linear oligosaccharides may be translocated across the membrane by guided diffusion along this path.	UNIV BASEL,BIOZENTRUM,DEPT MICROBIOL,CH-4056 BASEL,SWITZERLAND	University of Basel	SCHIRMER, T (corresponding author), UNIV BASEL,BIOZENTRUM,DEPT BIOL STRUCT,CH-4056 BASEL,SWITZERLAND.							BENZ R, 1987, J MEMBRANE BIOL, V100, P21, DOI 10.1007/BF02209137; Brtinger A. T., 1990, X PLOR VERSION 2 1; BUEHLER LK, 1991, J BIOL CHEM, V266, P24446; CHARBIT A, 1991, J BACTERIOL, V173, P262, DOI 10.1128/jb.173.1.262-275.1991; CHARBIT A, 1988, J MOL BIOL, V201, P487, DOI 10.1016/0022-2836(88)90630-4; CLEMENT JM, 1981, CELL, V27, P507, DOI 10.1016/0092-8674(81)90392-5; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DARGENT B, 1987, FEBS LETT, V220, P136, DOI 10.1016/0014-5793(87)80891-8; FERENCI T, 1989, BIOESSAYS, V10, P3; FERENCI T, 1982, J MOL BIOL, V160, P431, DOI 10.1016/0022-2836(82)90306-0; FREUNDLIEB S, 1988, J BIOL CHEM, V263, P314; GARAVITO RM, 1984, J BIOL CHEM, V259, P4254; GEHRING K, 1991, J BACTERIOL, V173, P1873, DOI 10.1128/jb.173.6.1873-1878.1991; GOLDSMITH E, 1982, J MOL BIOL, V156, P411, DOI 10.1016/0022-2836(82)90336-9; HEINE HG, 1987, GENE, V53, P287, DOI 10.1016/0378-1119(87)90018-7; JONES TA, 1991, O MANUAL; KELLER TA, 1994, BIOCHEM BIOPH RES CO, V199, P767, DOI 10.1006/bbrc.1994.1295; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KREUSCH A, 1994, PROTEIN SCI, V3, P58; LESK AM, 1989, PROTEINS, V5, P139, DOI 10.1002/prot.340050208; LUCKEY M, 1980, P NATL ACAD SCI-BIOL, V77, P167, DOI 10.1073/pnas.77.1.167; NEUHAUS JM, 1983, EMBO J, V2, P1987, DOI 10.1002/j.1460-2075.1983.tb01689.x; PAUPTIT RA, 1991, J STRUCT BIOL, V107, P136, DOI 10.1016/1047-8477(91)90017-Q; RANDALLHAZELBAU.L, 1973, J BACTERIOL, V116, P1436; ROSSMANN MG, 1964, ACTA CRYSTALLOGR, V17, P338, DOI 10.1107/S0365110X64000822; SCHIRMER T, 1993, PROTEIN SCI, V2, P1361, DOI 10.1002/pro.5560020820; Schwartz M, 1987, ESCHERICHIA COLI SAL, P1482; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; STAUFFER KA, 1990, J MOL BIOL, V211, P297, DOI 10.1016/0022-2836(90)90351-L; WANDERSMAN C, 1979, J BACTERIOL, V140, P1; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242	31	402	408	0	26	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 27	1995	267	5197					512	514		10.1126/science.7824948	http://dx.doi.org/10.1126/science.7824948			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD403	7824948				2022-12-28	WOS:A1995QD40300038
J	SVEJSTRUP, JQ; WANG, ZG; FEAVER, WJ; WU, XH; BUSHNELL, DA; DONAHUE, TF; FRIEDBERG, EC; KORNBERG, RD				SVEJSTRUP, JQ; WANG, ZG; FEAVER, WJ; WU, XH; BUSHNELL, DA; DONAHUE, TF; FRIEDBERG, EC; KORNBERG, RD			DIFFERENT FORMS OF TFIIH FOR TRANSCRIPTION AND DNA-REPAIR - HOLO-TFIIH AND A NUCLEOTIDE EXCISION REPAIROSOME	CELL			English	Article							RNA POLYMERASE-II; FACTOR-B; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; CTD KINASE; DHFR GENE; YEAST; PURIFICATION; RECOMBINATION; DOMAIN	Yeast TFIIH that is active in transcription can be dissociated into three components: a 5-subunit core, the SSL2 gene product, and a complex of 47 kDa, 45 kDa, and 33 kDa polypeptides that possesses protein kinase activity directed towards the C-terminal repeat domain of RNA polymerase II. These three components can reconstitute fully functional TFIIH, and all three are required for transcription in vitro. By contrast, TFIIH that is highly active in nucleotide excision repair (NER) lacks the kinase complex and instead contains the products of all other genes known to be required for NER in yeast: RAD1, RAD2, RAD4, RAD10, and RAD14. This repairosome is not active in reconstituted transcription in vitro and is significantly more active than any of the constituent polypeptides in correcting defective repair in extracts from strains mutated in NER genes.	STANFORD UNIV,SCH MED,DEPT BIOL STRUCT,STANFORD,CA 94305; UNIV TEXAS,SW MED CTR,DEPT PATHOL,MOLEC PATHOL LAB,DALLAS,TX 75235; INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405	Stanford University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Indiana University System; Indiana University Bloomington				Svejstrup, Jesper/0000-0003-4964-6147	NATIONAL CANCER INSTITUTE [R01CA012428, R37CA012428] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036659, R01GM032263, R01GM036659] Funding Source: NIH RePORTER; NCI NIH HHS [CA12428] Funding Source: Medline; NIGMS NIH HHS [GM36659, GM32263] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL AJ, 1994, MOL CELL BIOL, V14, P3569, DOI 10.1128/MCB.14.6.3569; BARDWELL L, 1994, P NATL ACAD SCI USA, V91, P3926, DOI 10.1073/pnas.91.9.3926; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CLEAVER JE, 1994, CELL, V76, P1, DOI 10.1016/0092-8674(94)90165-1; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FLORES O, 1992, J BIOL CHEM, V267, P2786; Friedberg E.C., 1991, MOL CELLULAR BIOL TE, P147; GERARD M, 1991, J BIOL CHEM, V266, P20940; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HANAWALT PC, 1994, CURR BIOL, V4, P518, DOI 10.1016/S0960-9822(00)00112-3; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; NAEGELI H, 1992, BIOCHEMISTRY-US, V32, P613; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; Qui H., 1993, GENE DEV, V7, P2161; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIMON M, 1986, EMBO J, V5, P2697, DOI 10.1002/j.1460-2075.1986.tb04553.x; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; SONG JM, 1990, J BACTERIOL, V172, P6620, DOI 10.1128/jb.172.12.6620-6630.1990; SUNG P, 1984, P NATL ACAD SCI USA, V84, P8951; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; TANAKA K, 1994, TRENDS BIOCHEM SCI, V19, P83, DOI 10.1016/0968-0004(94)90040-X; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; VANGOOL AJ, 1994, IN PRESS EMBO J; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WANG ZG, 1993, P NATL ACAD SCI USA, V90, P4907, DOI 10.1073/pnas.90.11.4907	55	248	252	0	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					21	28		10.1016/0092-8674(95)90447-6	http://dx.doi.org/10.1016/0092-8674(95)90447-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813015	Bronze			2022-12-28	WOS:A1995QB91000006
J	SAKIMURA, K; KUTSUWADA, T; ITO, I; MANABE, T; TAKAYAMA, C; KUSHIYA, E; YAGI, T; AIZAWA, S; INOUE, Y; SUGIYAMA, H; MISHINA, M				SAKIMURA, K; KUTSUWADA, T; ITO, I; MANABE, T; TAKAYAMA, C; KUSHIYA, E; YAGI, T; AIZAWA, S; INOUE, Y; SUGIYAMA, H; MISHINA, M			REDUCED HIPPOCAMPAL LTP AND SPATIAL-LEARNING IN MICE LACKING NMDA RECEPTOR EPSILON-1 SUBUNIT	NATURE			English	Article							LONG-TERM POTENTIATION; II MUTANT MICE; CHANNEL; CLONING; ANTAGONIST; EXPRESSION; MODULATION; NEURONS	THE NMDA (N-methyl-D-aspartate) receptor channel is important for synaptic plasticity, which is thought to underlie learning, memory and development(1,2). The NMDA receptor channel is formed by at least two members of the glutamate receptor (GluR) channel subunit families, the GluR epsilon (NR2) and GluR zeta (NR1) subunit families(3-8). The four epsilon subunits are distinct in distribution, properties and regulation(5-14). On the basis of the Mg2+ sensitivity and expression patterns, we have proposed that the epsilon 1 (NR2A) and epsilon 2 (NR2B) subunits play a role in synaptic plasticity(6,14). Here we show that targeted disruption of the mouse epsilon 1 subunit gene resulted in significant reduction of the NMDA receptor channel current and long-term potentiation at the hippocampal CA1 synapses. The mutant mice also showed a moderate deficiency in spatial learning. These results support the notion that the NMDA receptor channel-dependent synaptic plasticity is the cellular basis of certain forms of learning.	UNIV TOKYO,FAC MED,DEPT PHARMACOL,BUNKYO KU,TOKYO 113,JAPAN; NIIGATA UNIV,BRAIN RES INST,DEPT NEUROPHARMACOL,NIIGATA 951,JAPAN; KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN; UNIV TOKYO,FAC MED,INST BRAIN RES,DEPT NEUROPHYSIOL,TOKYO 113,JAPAN; HOKKAIDO UNIV,SCH MED,DEPT ANAT,SAPPORO,HOKKAIDO 060,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC ONCOL LAB,TSUKUBA,IBARAKI 305,JAPAN	University of Tokyo; Niigata University; Kyushu University; University of Tokyo; Hokkaido University; RIKEN								ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; ARAKI K, 1993, BIOCHEM BIOPH RES CO, V197, P1267, DOI 10.1006/bbrc.1993.2614; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; COLEMAN PA, 1989, J NEUROPHYSIOL, V61, P218, DOI 10.1152/jn.1989.61.1.218; DAVIS S, 1992, J NEUROSCI, V12, P21; GRANT SG, 1992, SCIENCE, V259, P1903; IKEDA K, 1992, FEBS LETT, V313, P34, DOI 10.1016/0014-5793(92)81178-O; ISHII T, 1993, J BIOL CHEM, V268, P2836; ITO I, 1991, NEUROREPORT, V2, P333, DOI 10.1097/00001756-199106000-00008; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MISHINA M, 1993, ANN NY ACAD SCI, V707, P136, DOI 10.1111/j.1749-6632.1993.tb38049.x; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORI H, 1993, NEUROREPORT, V4, P519, DOI 10.1097/00001756-199305000-00014; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; WATANABE M, 1993, J COMP NEUROL, V338, P337; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; YAMAZAKI M, 1992, FEBS LETT, V300, P39, DOI 10.1016/0014-5793(92)80160-I; ZHANG YX, 1994, BRAIN RES, V658, P127, DOI 10.1016/S0006-8993(09)90018-X	30	659	679	1	41	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					151	155		10.1038/373151a0	http://dx.doi.org/10.1038/373151a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7816096				2022-12-28	WOS:A1995QB06300059
J	DYDA, F; HICKMAN, AB; JENKINS, TM; ENGELMAN, A; CRAIGIE, R; DAVIES, DR				DYDA, F; HICKMAN, AB; JENKINS, TM; ENGELMAN, A; CRAIGIE, R; DAVIES, DR			CRYSTAL-STRUCTURE OF THE CATALYTIC DOMAIN OF HIV-1 INTEGRASE - SIMILARITY TO OTHER POLYNUCLEOTIDYL TRANSFERASES	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE; ESCHERICHIA-COLI; DNA INTEGRATION; ANGSTROM RESOLUTION; NUCLEOTIDE-SEQUENCE; PROTEIN INVITRO; RIBONUCLEASE-H; AIDS VIRUS; IDENTIFICATION	HIV integrase is the enzyme responsible for inserting the viral DNA into the host chromosome; it is essential for HIV replication. The crystal structure of the catalytically active core domain (residues 50 to 212) of HIV-7 integrase was determined at 2.5 Angstrom resolution. The central feature of the structure is a five-stranded beta sheet flanked by helical regions. The overall topology reveals that this domain of integrase belongs to a superfamily of polynucleotidyl transferases that includes ribonuclease H and the Holliday junction resolvase RuvC. The active site region is identified by the position of two of the conserved carboxylate residues essential for catalysis, which are located at similar positions in ribonuclease H. In the crystal, two molecules form a dimer with an extensive solvent-inaccessible interface of 1300 Angstrom(2) per monomer.	NIDDK,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								[Anonymous], COMMUNICATION; ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; ARTYMIUK PJ, 1993, FEBS LETT, V324, P15, DOI 10.1016/0014-5793(93)81523-3; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BAKER TA, 1994, GENE DEV, V8, P2416, DOI 10.1101/gad.8.20.2416; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CARTEAU S, 1993, BIOCHEM BIOPH RES CO, V192, P1409, DOI 10.1006/bbrc.1993.1573; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CRAIGIE R, 1991, NUCLEIC ACIDS RES, V19, P2729, DOI 10.1093/nar/19.10.2729; CROUCH R J, 1990, New Biologist, V2, P771; Crouch R. J., 1982, NUCLEASES, P211; CUSHMAN M, 1992, BIOCHEM BIOPH RES CO, V185, P85, DOI 10.1016/S0006-291X(05)80958-1; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DAVIES JF, 1994, CELL, V7623, P1123; Doublie S., 1992, CRYSTALLIZATION NUCL, P311; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; FAYET O, 1990, MOL MICROBIOL, V4, P1771, DOI 10.1111/j.1365-2958.1990.tb00555.x; FESEN MR, 1993, P NATL ACAD SCI USA, V90, P2399, DOI 10.1073/pnas.90.6.2399; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; FUREY W, 1990, AM CRYSTALLOGRAPHIC; GOFF SP, 1992, ANNU REV GENET, V26, P527, DOI 10.1146/annurev.ge.26.120192.002523; HAZUDA DJ, 1994, NUCLEIC ACIDS RES, V22, P1121, DOI 10.1093/nar/22.6.1121; HICKMAN AB, 1994, J BIOL CHEM, V269, P29279; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JENKINS TC, UNPUB; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KATAYANAGI K, 1993, PROTEINS, V17, P337, DOI 10.1002/prot.340170402; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREMENSTOVA E, COMMUNICATION; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LEAVITT AD, 1993, J BIOL CHEM, V268, P2113; LIN TH, 1991, PROTEIN ENG, V4, P435, DOI 10.1093/protein/4.4.435; MAZUMDER A, 1994, P NATL ACAD SCI USA, V91, P5771, DOI 10.1073/pnas.91.13.5771; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MUESING MA, 1985, NATURE, V313, P450, DOI 10.1038/313450a0; MULLER HP, 1994, EMBO J, V13, P4704, DOI 10.1002/j.1460-2075.1994.tb06794.x; MURZIN AG, 1992, CURR OPIN STRUC BIOL, V2, P895; NUCLEASES, 1967, DAVI, P93; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; RADSTROM P, 1994, J BACTERIOL, V176, P3257, DOI 10.1128/jb.176.11.3257-3268.1994; RAMAKRISHNAN V, 1993, NATURE, V262, P219; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; ROWLAND SJ, 1990, MOL MICROBIOL, V4, P961, DOI 10.1111/j.1365-2958.1990.tb00669.x; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SCHAUER M, 1992, BIOCHEM BIOPH RES CO, V185, P874, DOI 10.1016/0006-291X(92)91708-X; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; SHERRATT D, 1989, MOBILE DNA, P163; STARNES MC, 1989, J BIOL CHEM, V264, P7073; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; VINCENT KA, 1993, J VIROL, V67, P425, DOI 10.1128/JVI.67.1.425-437.1993; VINCENT KA, 1990, NUCLEIC ACIDS RES, V18, P6045, DOI 10.1093/nar/18.20.6045; VINK C, 1991, J VIROL, V65, P4636, DOI 10.1128/JVI.65.9.4636-4644.1991; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; VINK C, 1994, NUCLEIC ACIDS RES, V22, P2176, DOI 10.1093/nar/22.11.2176; VINK C, 1991, NUCLEIC ACIDS RES, V19, P6691, DOI 10.1093/nar/19.24.6691; VINK C, 1990, J VIROL, V64, P5626, DOI 10.1128/JVI.64.11.5626-5627.1990; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551; WOERNER AM, 1993, NUCLEIC ACIDS RES, V21, P3507, DOI 10.1093/nar/21.15.3507; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	81	680	712	0	33	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					1981	1986		10.1126/science.7801124	http://dx.doi.org/10.1126/science.7801124			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801124				2022-12-28	WOS:A1994PZ26700027
J	MODRICH, P				MODRICH, P			MISMATCH REPAIR, GENETIC STABILITY, AND CANCER	SCIENCE			English	Editorial Material							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; COLORECTAL-CANCER; INSTABILITY; MECHANISM; MUTATIONS; EXTRACTS; MUTANTS; HOMOLOG; CELLS		DUKE UNIV,HOWARD HUGHES MED INST,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute	MODRICH, P (corresponding author), DUKE UNIV,DEPT BIOCHEM,DURHAM,NC 27710, USA.			Modrich, Paul/0000-0001-8708-9885				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; AU KG, 1992, J BIOL CHEM, V267, P12142; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; COX EC, 1976, ANNU REV GENET, V10, P135, DOI 10.1146/annurev.ge.10.120176.001031; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; ESHLEMAN JR, IN PRESS ONCOGENE; FANG WH, 1993, J BIOL CHEM, V268, P11838; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; HAN HJ, 1993, CANCER RES, V53, P5087; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; MESELSON M, 1988, RECOMBINATION GENETI, P91; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PETIT MA, 1991, GENETICS, V129, P327; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; REENAN RAG, 1992, GENETICS, V132, P963; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; UMAR A, 1994, J BIOL CHEM, V269, P14367; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238	29	380	410	0	26	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					1959	1960		10.1126/science.7801122	http://dx.doi.org/10.1126/science.7801122			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801122				2022-12-28	WOS:A1994PZ26700021
J	SALLES, FJ; LIEBERFARB, ME; WREDEN, C; GERGEN, JP; STRICKLAND, S				SALLES, FJ; LIEBERFARB, ME; WREDEN, C; GERGEN, JP; STRICKLAND, S			COORDINATE INITIATION OF DROSOPHILA DEVELOPMENT BY REGULATED POLYADENYLATION OF MATERNAL MESSENGER-RNAS	SCIENCE			English	Article							XENOPUS OOCYTE MATURATION; RECEPTOR TYROSINE KINASE; CYTOPLASMIC POLYADENYLATION; TRANSLATIONAL CONTROL; MEIOTIC MATURATION; ANTERIOR PATTERN; MOUSE OOCYTES; BODY PATTERN; EMBRYO; GENE	Pattern formation in Drosophila depends initially on the translational activation of maternal messenger RNAs (mRNAs) whose protein products determine cell fate. Three mRNAs that dictate anterior, dorsoventral, and terminal specification-bicoid, Toll, and torso, respectively-showed increases in polyadenylate [poly(A)] tail length concomitant with translation. In contrast, posteriorly localized nanos mRNA, although also translationally activated, was not regulated by poly(A) status. These results implicate at least two mechanisms of mRNA activation in flies. Studies with bicoid mRNA showed that cytoplasmic polyadenylation is necessary for translation, establishing this pathway as essential for embryogenesis. Combined, these experiments identify a regulatory pathway that can coordinate initiation of maternal pattern formation systems in Drosophila.	SUNY STONY BROOK, MED CTR, DEPT PHARMACOL, STONY BROOK, NY 11794 USA; SUNY STONY BROOK, DEPT BIOCHEM & CELL BIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NIGMS NIH HHS [GM51584] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051584] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHVAROVA RF, 1992, CELL, V69, P895, DOI 10.1016/0092-8674(92)90606-D; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; DRIEVER W, 1989, NATURE, V342, P149, DOI 10.1038/342149a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1990, DEVELOPMENT, V109, P811; EPHRUSSI A, COMMUNICATION; FERRANDON D, IN PRESS CELL; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GAVIS ER, 1994, NATURE, V369, P315, DOI 10.1038/369315a0; GAY NJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P290, DOI 10.1016/0167-4781(92)90163-T; GOTTLIEB E, 1992, P NATL ACAD SCI USA, V89, P7164, DOI 10.1073/pnas.89.15.7164; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HUARTE J, 1987, GENE DEV, V1, P1201, DOI 10.1101/gad.1.10.1201; HUARTE J, 1992, CELL, V69, P1021, DOI 10.1016/0092-8674(92)90620-R; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; KUHN R, 1991, MECH DEVELOP, V35, P143, DOI 10.1016/0925-4773(91)90064-D; MACDONALD PM, 1991, GENE DEV, V5, P2455, DOI 10.1101/gad.5.12b.2455; MARTIN JR, 1994, NATURE, V367, P741, DOI 10.1038/367741a0; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; MCGREW LL, 1990, EMBO J, V9, P3743, DOI 10.1002/j.1460-2075.1990.tb07587.x; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; PARIS J, 1990, MOL CELL BIOL, V10, P5634, DOI 10.1128/MCB.10.11.5634; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; SALLES F, UNPUB; SALLES FJ, 1992, GENE DEV, V6, P1202, DOI 10.1101/gad.6.7.1202; SCHAFER M, 1990, EMBO J, V9, P4519, DOI 10.1002/j.1460-2075.1990.tb07903.x; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; Standart Nancy, 1992, Seminars in Developmental Biology, V3, P367; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STJOHNSTON D, 1992, CELL, V68, P201; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; VERROTTI AC, UNPUB; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WHARTON RP, 1992, SEMINARS DEV BIOL, V3, P391; WICKENS M, 1992, SEM DEV BIOL, V3, P399; WNAG LK, 1994, DEV DYNAM, V199, P103	43	205	208	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 23	1994	266	5193					1996	1999		10.1126/science.7801127	http://dx.doi.org/10.1126/science.7801127			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801127				2022-12-28	WOS:A1994PZ26700031
J	CRAGG, D; HALLAM, L				CRAGG, D; HALLAM, L			QUALITY STANDARDS FOR DEPUTIZING SERVICES	BRITISH MEDICAL JOURNAL			English	Article									UNIV MANCHESTER,RUSHOLME HLTH CTR,CTR PRIMARY CARE RES,MANCHESTER M14 5NP,LANCS,ENGLAND	University of Manchester	CRAGG, D (corresponding author), UNIV MANCHESTER,RUSHOLME HLTH CTR,DEPT GEN PRACTICE,MANCHESTER M14 5NP,LANCS,ENGLAND.							BOLLAM MJ, 1988, BRIT MED J, V296, P829, DOI 10.1136/bmj.296.6625.829; DIXON RA, 1977, BRIT MED J, V1, P560, DOI 10.1136/bmj.1.6060.560; HALLAM L, 1994, BRIT MED J, V309, P1621, DOI 10.1136/bmj.309.6969.1621; 1989, GENERAL PRACTICE NAT; 1984, DHSS FP84 DEP HLTH S	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1630	1630						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819947				2022-12-28	WOS:A1994PY22000030
J	ROUJEAU, JC; STERN, RS				ROUJEAU, JC; STERN, RS			SEVERE ADVERSE CUTANEOUS REACTIONS TO DRUGS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TOXIC EPIDERMAL NECROLYSIS; STEVENS-JOHNSON SYNDROME; INDUCED SKIN NECROSIS; CONVERTING-ENZYME-INHIBITORS; SULFONAMIDE HYPERSENSITIVITY REACTIONS; SYSTEMIC LUPUS-ERYTHEMATOSUS; HUMAN-IMMUNODEFICIENCY-VIRUS; SICKNESS-LIKE ILLNESS; PROTEIN-C DEFICIENCY; SERUM SICKNESS		HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT DERMATOL, BOSTON, MA 02215 USA; UNIV PARIS 12, HOP HENRI MONDOR, DEPT DERMATOL, F-94010 CRETEIL, FRANCE	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP								ALANKO K, 1989, ACTA DERM-VENEREOL, V69, P223; ANDERSON MW, 1990, J ALLERGY CLIN IMMUN, V85, P856, DOI 10.1016/0091-6749(90)90068-F; [Anonymous], 1991, Lancet, V337, P1308; ASKMARK H, 1990, ACTA NEUROL SCAND, V81, P131; BASTUJIGARIN S, 1993, ARCH DERMATOL, V129, P92, DOI 10.1001/archderm.129.1.92; BAUER KA, 1993, ARCH DERMATOL, V129, P766, DOI 10.1001/archderm.129.6.766; BERAN RG, 1993, EPILEPSIA, V34, P163, DOI 10.1111/j.1528-1157.1993.tb02392.x; BERGOEND H, 1968, ANN DERMATOL SYPHIL, V95, P481; BIELORY L, 1992, ALLERGY PROC, V13, P85, DOI 10.2500/108854192778878845; BIELORY L, 1985, J AM ACAD DERMATOL, V13, P411, DOI 10.1016/S0190-9622(85)70182-X; BIGBY M, 1986, JAMA-J AM MED ASSOC, V256, P3358; BILLINGHAM RE, 1968, ARCH DERMATOL, V98, P528, DOI 10.1001/archderm.98.5.528; Binaghi M, 1988, Ophtalmologie, V2, P121; BOCHNER BS, 1991, NEW ENGL J MED, V324, P1785, DOI 10.1056/NEJM199106203242506; BOTTIGER LE, 1975, ACTA MED SCAND, V198, P229; BRASILE L, 1989, AM J MED, V87, P74; BRUNET P, 1992, AM J KIDNEY DIS, V19, P444, DOI 10.1016/S0272-6386(12)80952-8; BRUYNZEEL DP, 1987, SEMIN DERMATOL, V6, P119; BURGE SM, 1985, J AM ACAD DERMATOL, V13, P665, DOI 10.1016/S0190-9622(85)80447-3; CALABRESE LH, 1990, ARTHRITIS RHEUM, V33, P1108; CARRASCO MD, 1987, ARCH INTERN MED, V147, P1677, DOI 10.1001/archinte.147.9.1677; CHAN HL, 1990, ARCH DERMATOL, V126, P43, DOI 10.1001/archderm.126.1.43; CHOSIDOW O, 1991, LANCET, V337, P928, DOI 10.1016/0140-6736(91)90273-R; COMP PC, 1993, DRUG SAFETY, V8, P128, DOI 10.2165/00002018-199308020-00003; COOPMAN SA, 1993, NEW ENGL J MED, V328, P1670, DOI 10.1056/NEJM199306103282304; CORRE KA, 1988, ANN EMERG MED, V17, P145, DOI 10.1016/S0196-0644(88)80300-7; CORREIA O, 1993, ARCH DERMATOL, V129, P466, DOI 10.1001/archderm.129.4.466; DANGELO SV, 1986, J CLIN INVEST, V77, P416, DOI 10.1172/JCI112319; DCRUZ D, 1992, BRIT MED J, V304, P269, DOI 10.1136/bmj.304.6822.269; DEMLING RH, 1985, NEW ENGL J MED, V313, P1389, DOI 10.1056/NEJM198511283132205; DOLMAN KM, 1993, LANCET, V342, P651, DOI 10.1016/0140-6736(93)91761-A; DUBOST JJ, 1991, BAILLIERE CLIN RHEUM, V5, P119, DOI 10.1016/S0950-3579(05)80299-7; DWYER JM, 1989, LANCET, V2, P494; EKENSTAM AE, 1984, ARCH DERMATOL, V120, P484; FALK RJ, 1988, NEW ENGL J MED, V318, P1651, DOI 10.1056/NEJM198806233182504; FAUCI AS, 1978, ANN INTERN MED, V89, P660, DOI 10.7326/0003-4819-89-5-660; GENNIS MA, 1991, AM J MED, V91, P631, DOI 10.1016/0002-9343(91)90216-K; GRIMAUDO V, 1989, BRIT MED J, V298, P233, DOI 10.1136/bmj.298.6668.233; GUPTA A, 1992, CLIN PHARMACOL THER, V51, P56, DOI 10.1038/clpt.1992.8; HALEBIAN PH, 1986, ANN SURG, V204, P503, DOI 10.1097/00000658-198611000-00001; HARUDA F, 1979, NEUROLOGY, V29, P1480, DOI 10.1212/WNL.29.11.1480; HECKBERT SR, 1990, AM J EPIDEMIOL, V132, P336, DOI 10.1093/oxfordjournals.aje.a115663; HEDNER T, 1992, BRIT MED J, V304, P941, DOI 10.1136/bmj.304.6832.941; HEIMBACH DM, 1987, JAMA-J AM MED ASSOC, V258, P1894; HEIMBACH DM, 1987, JAMA-J AM MED ASSOC, V257, P2171; HELLGREN U, 1987, BRIT MED J, V295, P365, DOI 10.1136/bmj.295.6594.365-a; HENG MCY, 1991, J AM ACAD DERMATOL, V25, P778, DOI 10.1016/S0190-9622(08)80969-3; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; HORAN RF, 1992, JAMA-J AM MED ASSOC, V268, P2858, DOI 10.1001/jama.268.20.2858; HORTON RC, 1989, LANCET, V2, P568; HOUSE RA, 1992, J OCCUP ENVIRON MED, V34, P135; HUFF JC, 1983, J AM ACAD DERMATOL, V8, P763; HUMINER D, 1989, BRIT MED J, V299, P303, DOI 10.1136/bmj.299.6694.303; Ives T J, 1992, Arch Fam Med, V1, P241, DOI 10.1001/archfami.1.2.241; JORDAN M H, 1991, Journal of Burn Care and Rehabilitation, V12, P579, DOI 10.1097/00004630-199111000-00015; KAMANABROO D, 1985, ARCH DERMATOL, V121, P1548, DOI 10.1001/archderm.121.12.1548; KELLY RA, 1981, JAMA-J AM MED ASSOC, V246, P1582, DOI 10.1001/jama.246.14.1582; KELTON JG, 1988, BLOOD, V72, P925; KESSLER DA, 1993, JAMA-J AM MED ASSOC, V269, P2765, DOI 10.1001/jama.269.21.2765; Kim PS, 1983, J BURN CARE REHABIL, V4, P91; KRAMER MS, 1979, JAMA-J AM MED ASSOC, V242, P623, DOI 10.1001/jama.242.7.623; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LIVINGSTON S, 1967, J AMER MED ASSOC, V200, P204, DOI 10.1001/jama.200.3.204; LOUIK C, 1985, CLIN PHARMACOL THER, V38, P183, DOI 10.1038/clpt.1985.156; LUPTON GP, 1979, J AM ACAD DERMATOL, V1, P365, DOI 10.1016/S0190-9622(79)70031-4; LYELL A, 1956, BRIT J DERMATOL, V68, P355, DOI 10.1111/j.1365-2133.1956.tb12766.x; MACLEAN JA, 1990, ANN ALLERGY, V65, P254; MAGUIRE JH, 1987, BRIT J CLIN PHARMACO, V24, P554, DOI 10.1111/j.1365-2125.1987.tb03212.x; MARKS J, 1982, CLIN EXP DERMATOL, V7, P415, DOI 10.1111/j.1365-2230.1982.tb02450.x; MCDONALD BJ, 1992, ANN PHARMACOTHER, V26, P34, DOI 10.1177/106002809202600109; MEGERIAN CA, 1992, LARYNGOSCOPE, V102, P256; MELISH ME, 1970, NEW ENGL J MED, V282, P1114, DOI 10.1056/NEJM197005142822002; MEROT Y, 1986, ARCH DERMATOL, V122, P455, DOI 10.1001/archderm.122.4.455; MILETICH J, 1987, NEW ENGL J MED, V317, P991, DOI 10.1056/NEJM198710153171604; MILLER KD, 1986, AM J TROP MED HYG, V35, P451, DOI 10.4269/ajtmh.1986.35.451; MOORE N, 1985, LANCET, V2, P1056; MURPHY JM, 1991, NEUROLOGY, V41, P144, DOI 10.1212/WNL.41.1.144; MUTASIM DF, 1993, DERMATOL CLIN, V11, P473, DOI 10.1016/S0733-8635(18)30244-4; NALDI L, 1990, ARCH DERMATOL, V126, P1103, DOI 10.1001/archderm.1990.01670320127028; NETHERCOTT JR, 1985, DERMATOLOGICA, V171, P383, DOI 10.1159/000249463; NOEL J, 1987, AM HEART J, V113, P395, DOI 10.1016/0002-8703(87)90287-0; PARKER WA, 1979, NEUROLOGY, V29, P175, DOI 10.1212/WNL.29.2.175; PARNES EL, 1991, KIDNEY INT, V40, P1148, DOI 10.1038/ki.1991.327; PECK GL, 1972, LANCET, V2, P1151; PELEKANOS J, 1991, EPILEPSIA, V32, P554, DOI 10.1111/j.1528-1157.1991.tb04692.x; PELLOCK JM, 1987, EPILEPSIA, V28, pS64, DOI 10.1111/j.1528-1157.1987.tb05780.x; PIRMOHAMED M, 1991, BRIT J CLIN PHARMACO, V32, P741; PLATT R, 1988, J INFECT DIS, V158, P474, DOI 10.1093/infdis/158.2.474; PORTEOUS DM, 1991, ARCH DERMATOL, V127, P740, DOI 10.1001/archderm.127.5.740; PRENDIVILLE JS, 1989, J PEDIATR-US, V115, P881, DOI 10.1016/S0022-3476(89)80736-X; PUYANA J, 1990, ALLERGY, V45, P313, DOI 10.1111/j.1398-9995.1990.tb00502.x; RAPP RP, 1983, NEUROSURGERY, V13, P272, DOI 10.1227/00006123-198309000-00010; RAYCHAUDHURI K, 1989, NEUROLOGY, V39, P436, DOI 10.1212/WNL.39.3.436; RENFRO L, 1989, INT J DERMATOL, V28, P441, DOI 10.1111/j.1365-4362.1989.tb02502.x; RESSLER C, 1987, ANN ALLERGY, V59, P167; REVUZ J, 1987, ARCH DERMATOL, V123, P1160, DOI 10.1001/archderm.123.9.1160; RIEDER MJ, 1991, CLIN PHARMACOL THER, V49, P13, DOI 10.1038/clpt.1991.3; RIEDER MJ, 1989, ANN INTERN MED, V110, P286, DOI 10.7326/0003-4819-110-4-286; RIJLAARSDAM U, 1991, J AM ACAD DERMATOL, V24, P216, DOI 10.1016/0190-9622(91)70029-2; ROSENTHAL CJ, 1982, CANCER, V49, P2305, DOI 10.1002/1097-0142(19820601)49:11<2305::AID-CNCR2820491118>3.0.CO;2-G; ROUJEAU JC, 1991, ARCH DERMATOL, V127, P1333, DOI 10.1001/archderm.127.9.1333; ROUJEAU JC, 1990, ARCH DERMATOL, V126, P37, DOI 10.1001/archderm.126.1.37; ROUJEAU JC, 1987, ARCH DERMATOL, V123, P1171, DOI 10.1001/archderm.123.9.1171; ROUPE G, 1986, INT ARCH ALLER A IMM, V80, P145, DOI 10.1159/000234043; RUIZMALDONADO R, 1985, J AM ACAD DERMATOL, V13, P623, DOI 10.1016/S0190-9622(85)70207-1; RZANY B, 1993, ARCH DERMATOL, V129, P1059, DOI 10.1001/archderm.129.8.1059; RZANY B, 1991, ACTA DERM-VENEREOL, V71, P171; SAIAG P, 1992, J AM ACAD DERMATOL, V26, P567, DOI 10.1016/0190-9622(92)70082-Q; SANCHEZ NP, 1985, ARCH DERMATOL, V121, P220, DOI 10.1001/archderm.121.2.220; Schick Bela, 1951, SERUM SICKNESS; SCHOPF E, 1991, ARCH DERMATOL, V127, P839, DOI 10.1001/archderm.127.6.839; SCHRAMM W, 1993, ARCH DERMATOL, V129, P753, DOI 10.1001/archderm.129.6.753; SERRE H, 1976, ANN MED INTERNE, V127, P552; SHEAR NH, 1990, ARCH DERMATOL, V126, P94, DOI 10.1001/archderm.126.1.94; SHEAR NH, 1988, J CLIN INVEST, V82, P1826, DOI 10.1172/JCI113798; SHEAR NH, 1986, ANN INTERN MED, V105, P179, DOI 10.7326/0003-4819-105-2-179; SHERERTZ EF, 1985, J AM ACAD DERMATOL, V12, P178, DOI 10.1016/S0190-9622(85)80012-8; SLATER EE, 1988, JAMA-J AM MED ASSOC, V260, P967, DOI 10.1001/jama.260.7.967; SPIELBERG SP, 1981, NEW ENGL J MED, V305, P722, DOI 10.1056/NEJM198109243051302; SPIELBERG SP, 1991, ANN INTERN MED, V114, P720, DOI 10.7326/0003-4819-114-9-720; STERN RS, 1989, J AM ACAD DERMATOL, V21, P317, DOI 10.1016/S0190-9622(89)70176-6; Stevens AM, 1922, AM J DIS CHILD, V24, P526, DOI 10.1001/archpedi.1922.04120120077005; STROM BL, 1991, ARCH DERMATOL, V127, P831, DOI 10.1001/archderm.127.6.831; TAYLOR RJ, 1991, J ALLERGY CLIN IMMUN, V87, P889, DOI 10.1016/0091-6749(91)90139-F; TEEPE RGC, 1986, ARCH DERMATOL, V122, P1408, DOI 10.1001/archderm.122.12.1408; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; THOMPSON T, 1993, LARYNGOSCOPE, V103, P10; TIMSIT JF, 1992, INTENS CARE MED, V18, P42, DOI 10.1007/BF01706425; TOMECKI KJ, 1981, ARCH DERMATOL, V117, P38, DOI 10.1001/archderm.117.1.38; TUNEU A, 1985, J AM ACAD DERMATOL, V12, P1072, DOI 10.1016/S0190-9622(85)70135-1; Turner W M, 1984, Drug Inf J, V18, P259; VANHALE HM, 1986, J AM ACAD DERMATOL, V15, P665, DOI 10.1016/S0190-9622(86)70222-3; VARGA J, 1992, ANN INTERN MED, V116, P140, DOI 10.7326/0003-4819-116-2-140; VERRESEN L, 1990, LANCET, V336, P1360, DOI 10.1016/0140-6736(90)92904-V; VILLADA G, 1990, J AM ACAD DERMATOL, V23, P870, DOI 10.1016/0190-9622(90)70307-4; VILLADA G, 1992, ARCH DERMATOL, V128, P50, DOI 10.1001/archderm.128.1.50; WARRINGTON RJ, 1987, J ALLERGY CLIN IMMUN, V79, P605, DOI 10.1016/S0091-6749(87)80156-2; WERNER MC, 1989, AM J MED SCI, V297, P216, DOI 10.1097/00000441-198904000-00003; WESTLY ED, 1984, ARCH DERMATOL, V120, P721, DOI 10.1001/archderm.120.6.721; WESTON WL, 1989, PEDIATR DERMATOL, V6, P229; WILKINS J, 1992, DERMATOL CLIN, V10, P571; WILSON JT, 1978, BRIT MED J, V1, P1583, DOI 10.1136/bmj.1.6127.1583; WINTROUB BU, 1985, J AM ACAD DERMATOL, V13, P167, DOI 10.1016/S0190-9622(85)70156-9; YEN MC, 1983, POSTGRAD MED, V74, P291, DOI 10.1080/00325481.1983.11698473	144	1145	1201	2	53	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 10	1994	331	19					1272	1285		10.1056/NEJM199411103311906	http://dx.doi.org/10.1056/NEJM199411103311906			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP752	7794310				2022-12-28	WOS:A1994PP75200006
J	PAICE, E				PAICE, E			FORTNIGHTLY REVIEW - REFLEX SYMPATHETIC DYSTROPHY	BRITISH MEDICAL JOURNAL			English	Article							REGIONAL INTRAVENOUS GUANETHIDINE; ALGODYSTROPHY; CROSSOVER; DISEASE; TRIAL; HAND				PAICE, E (corresponding author), WHITTINGTON HOSP,LONDON N19 5NF,ENGLAND.							AMADIO PC, 1991, PLAST RECONSTR SURG, V87, P371, DOI 10.1097/00006534-199102000-00023; Bonica J. J., 1979, ADV PAIN RES THER, V3, P141; CASALE R, 1992, J AUTONOM NERV SYST, V41, P215, DOI 10.1016/0165-1838(92)90061-K; CHRISTENSEN K, 1983, SCAND J RHEUMATOL, V12, P263, DOI 10.3109/03009748309098547; De Vilder J, 1992, Acta Orthop Belg, V58 Suppl 1, P252; DIETZ FR, 1989, CLIN ORTHOP RELAT R, V258, P225; DOURY P, 1988, CLIN RHEUMATOL, V7, P173, DOI 10.1007/BF02204451; DRUMMOND PD, 1991, BRAIN, V114, P2025, DOI 10.1093/brain/114.5.2025; EGLE UT, 1990, PSYCHOTHER PSYCH MED, V40, P123; EULRY F, 1991, CLIN RHEUMATOL, V10, P377, DOI 10.1007/BF02206656; EULRY F, 1990, REV RHUM, V57, P351; Fialka V, 1992, Fortschr Med, V110, P146; FIELD J, 1993, J HAND SURG-BRIT EUR, V18B, P339, DOI 10.1016/0266-7681(93)90058-N; GENANT HK, 1975, RADIOLOGY, V117, P21, DOI 10.1148/117.1.21; GOLDSMITH DP, 1989, ARTHRITIS RHEUM, V32, P480, DOI 10.1002/anr.1780320419; HANNA MH, 1989, PAIN, V38, P145, DOI 10.1016/0304-3959(89)90232-7; HANNINGTONKIFF JG, 1991, LANCET, V338, P1125, DOI 10.1016/0140-6736(91)91974-Y; HANNINGTONKIFF JG, 1974, LANCET, V1, P1019; HOOSHMAND H, 1993, CHRONIC PAIN REFLEX, P13; HORD AH, 1992, ANESTH ANALG, V74, P818; KOZIN F, 1992, CLIN EXP RHEUMATOL, V10, P401; LIVINGSTON WK, 1947, PAIN MECHANISMS; LYNCH ME, 1992, PAIN, V49, P337, DOI 10.1016/0304-3959(92)90241-3; Marchettini P, 1989, Funct Neurol, V4, P135; Mitchell SW., 1864, GUNSHOT WOUNDS OTHER; NIELSEN F B, 1992, Ugeskrift for Laeger, V154, P1500; OCHOA JL, 1992, CLIN J PAIN, V8, P363, DOI 10.1097/00002508-199212000-00012; POPLAWSKI ZJ, 1983, J BONE JOINT SURG AM, V65, P642, DOI 10.2106/00004623-198365050-00010; ROCCO AG, 1989, CLIN J PAIN, V5, P205, DOI 10.1097/00002508-198909000-00002; SARANGI PP, 1993, J BONE JOINT SURG BR, V75, P450, DOI 10.1302/0301-620X.75B3.8496220; Schott G, 1989, Funct Neurol, V4, P131; SCHUTZER SF, 1984, J BONE JOINT SURG AM, V66A, P625, DOI 10.2106/00004623-198466040-00025; SILBER TJ, 1988, AM J DIS CHILD, V142, P1325, DOI 10.1001/archpedi.1988.02150120079045; Solarova P, 1990, Vutr Boles, V29, P102; SUDECK P, 1900, ARCH KLIN CHIR, V62, P147; VANHOUDENHOVE B, 1992, CLIN J PAIN, V8, P300; VELDMAN PHJM, 1993, LANCET, V342, P1012, DOI 10.1016/0140-6736(93)92877-V; WERNER R, 1989, J HAND SURG-AM, V14A, P520, DOI 10.1016/S0363-5023(89)80016-4; WILDER RT, 1992, J BONE JOINT SURG AM, V74A, P910, DOI 10.2106/00004623-199274060-00013; 1986, PAIN S, V3, pS28	40	34	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 24	1995	310	6995					1645	1648		10.1136/bmj.310.6995.1645	http://dx.doi.org/10.1136/bmj.310.6995.1645			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF698	7795454	Green Published			2022-12-28	WOS:A1995RF69800026
J	BLUMENTHAL, D				BLUMENTHAL, D			HEALTH-CARE REFORM - PAST AND FUTURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											BLUMENTHAL, D (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA.							BLUMENTHAL D, 1988, RENEWING PROMISE MED, P3; CLYMER R, 1994, NY TIMES        1003, pA12; Corning Peter A, 1969, EVOLUTION MEDICARE; DAVID S, 1985, DIGNITY SEARCH MEDIC; DOLE R, 1994, BOSTON GLOBE    1002, P74; EASTERBROOK G, 1994, BOSTON GLOBE    1009, P74; HARRIS R, 1969, SACRED TRUST; PEAR RG, 1994, NY TIMES        1009, P4; REINHARDT U, 1994, JUL M DORS S BEAV CR; WILKIE C, 1994, BOSTON GLOBE    1003, P3; 1994, UNHEALTHY MONEY, V12	11	23	23	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 16	1995	332	7					465	468		10.1056/NEJM199502163320711	http://dx.doi.org/10.1056/NEJM199502163320711			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF770	7824020				2022-12-28	WOS:A1995QF77000011
J	ISSARAGRISIL, S; VISUTHISAKCHAI, S; SUVATTE, V; TANPHAICHITR, VS; CHANDANAYINGYONG, D; SCHREINER, T; KANOKPONGSAKDI, S; SIRITANARATKUL, N; PLANKIJAGUM, A				ISSARAGRISIL, S; VISUTHISAKCHAI, S; SUVATTE, V; TANPHAICHITR, VS; CHANDANAYINGYONG, D; SCHREINER, T; KANOKPONGSAKDI, S; SIRITANARATKUL, N; PLANKIJAGUM, A			TRANSPLANTATION OF CORD-BLOOD STEM-CELLS INTO A PATIENT WITH SEVERE THALASSEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							MARROW TRANSPLANTATION; HEMATOPOIETIC STEM; PROGENITOR CELLS; FANCONIS ANEMIA; THERAPY; DISEASE		MAHIDOL UNIV,SIRIRAJ HOSP,CHULABHORN BONE MARROW TRANSPLANT CTR,BANGKOK 10700,THAILAND; MAHIDOL UNIV,SIRIRAJ HOSP,DEPT PEDIAT,BANGKOK 10700,THAILAND; MAHIDOL UNIV,SIRIRAJ HOSP,DEPT TRANSFUS MED,BANGKOK 10700,THAILAND; MAHIDOL UNIV,SIRIRAJ HOSP,DEPT OBSTET & GYNECOL,BANGKOK 10700,THAILAND; UNIV ULM,DEPT TRANSFUS MED,W-7900 ULM,GERMANY	Chulabhorn Research Institute; Mahidol University; Mahidol University; Mahidol University; Mahidol University; Ulm University	ISSARAGRISIL, S (corresponding author), MAHIDOL UNIV,SIRIRAJ HOSP,DEPT MED,2 PRANNOK,BANGKOK 10700,THAILAND.		Brugnara, Carlo/A-8041-2010	Brugnara, Carlo/0000-0001-8192-8713; Issaragrisil, Surapol/0000-0002-8924-0646				BROXMEYER HE, 1992, BONE MARROW TRANSPL, V9, P7; BROXMEYER HE, 1989, P NATL ACAD SCI USA, V86, P3828, DOI 10.1073/pnas.86.10.3828; BROXMEYER HE, 1991, BLOOD CELLS, V17, P313; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; GLUCKMAN E, 1990, NOUV REV FR HEMATOL, V32, P423; ISSARAGRISIL S, 1983, AM J CLIN PATHOL, V80, P865, DOI 10.1093/ajcp/80.6.865; ISSARAGRISIL S, 1993, BONE MARROW TRANSP S, V1, P42; LUCARELLI G, 1993, NEW ENGL J MED, V329, P840, DOI 10.1056/NEJM199309163291204; LUCARELLI G, 1990, NEW ENGL J MED, V322, P417, DOI 10.1056/NEJM199002153220701; LUCARELLI G, 1987, NEW ENGL J MED, V316, P1050, DOI 10.1056/NEJM198704233161703; MANNA M, 1993, BONE MARROW TRANS S1, V1, P70; PARK MS, 1993, CLIN TRANSPLANTS 199, P475; SCHREINER T, 1994, J IMMUNOL METHODS, V168, P183, DOI 10.1016/0022-1759(94)90053-1; STORB R, 1986, BLOOD, V68, P119; THOMAS ED, 1982, LANCET, V2, P227; TYNAN KM, 1989, J MOL EVOL, V28, P212, DOI 10.1007/BF02102478; VILMER E, 1992, TRANSPLANTATION, V53, P1155; VOWELS MR, 1993, NEW ENGL J MED, V329, P1623, DOI 10.1056/NEJM199311253292205; WAGNER JE, 1992, BLOOD, V79, P1874; WAGNER JE, 1993, BLOOD, V82, pA86; WASI P, 1981, CLIN HAEMATOL, V10, P707; WASI P, 1987, OXFORD TXB MED, V2, P266; WINICHAGOON P, IN PRESS SE ASIAN J	23	76	85	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 9	1995	332	6					367	369		10.1056/NEJM199502093320605	http://dx.doi.org/10.1056/NEJM199502093320605			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF300	7823998				2022-12-28	WOS:A1995QF30000005
J	CHESSELLS, JM; BAILEY, C; RICHARDS, SM; EDEN, OB; BARBOR, PRH; BARRETT, A; BARTON, C; BROADBENT, V; DEMPSEY, SI; DURRANT, J; EMERSON, P; EVANS, DIK; FENNELLY, JJ; GALTON, DAG; GIBSON, B; GRAY, R; HANN, IM; HARDISTY, RM; HILL, FGH; KERNAHAN, J; KING, DJ; LILLEYMAN, JS; MANN, J; MARTIN, J; MCELWAIN, TJ; MELLOR, ST; JONES, PHM; OAKHILL, A; PETO, J; RADFORD, M; REES, JKH; STEVENS, RF; SUMMERFIELD, GP; THOMPSON, EN				CHESSELLS, JM; BAILEY, C; RICHARDS, SM; EDEN, OB; BARBOR, PRH; BARRETT, A; BARTON, C; BROADBENT, V; DEMPSEY, SI; DURRANT, J; EMERSON, P; EVANS, DIK; FENNELLY, JJ; GALTON, DAG; GIBSON, B; GRAY, R; HANN, IM; HARDISTY, RM; HILL, FGH; KERNAHAN, J; KING, DJ; LILLEYMAN, JS; MANN, J; MARTIN, J; MCELWAIN, TJ; MELLOR, ST; JONES, PHM; OAKHILL, A; PETO, J; RADFORD, M; REES, JKH; STEVENS, RF; SUMMERFIELD, GP; THOMPSON, EN			INTENSIFICATION OF TREATMENT AND SURVIVAL IN ALL CHILDREN WITH LYMPHOBLASTIC-LEUKEMIA - RESULTS OF UK MEDICAL-RESEARCH-COUNCIL TRIAL UKALL-X	LANCET			English	Article							PEDIATRIC-ONCOLOGY-GROUP; CANCER-STUDY-GROUP; PRESENTING FEATURES; PROGNOSTIC FACTORS; HIGH-RISK; NON-T; LEUKEMIA; CHILDHOOD; THERAPY; METHOTREXATE	The UK Medical Research Council trial MRC UKALL X was designed to investigate the benefit of one or two courses of additional intensification therapy in children with acute lymphoblastic leukaemia receiving standard treatment. From 1985 to 1990 1612 children, comprising more than 90% of eligible cases in the UK, were treated with intensive induction therapy, central nervous system directed therapy with cranial irradiation and intrathecal methotrexate, and continuing treatment for 2 years. 1171 children were randomised to receive additional intensification therapy at 5 weeks, 20 weeks, both, or neither. At follow-up of at least 3 years disease-free survival for all children at 5 years was 62% (95% confidence interval [Cl] 60.0-64.4), a significant improvement over the 56% (53.0.59.6) found in the preceding MRC UKALL trial. The 5-year disease-free survival was 71% (65.5-76.1) for children randomised to two blocks of intensification therapy, this being significantly better than the 62% (56.6-68.0), 61% (55.7-67.1), and 57% (50.9-62.7) rates for the groups randomised to one intensification block at 5 weeks, one at 20 weeks, and no intensification, respectively. The benefits of intensification therapy were seen irrespective of clinical factors known to influence outcome such as age, sex, and initial leucocyte count. We conclude that the addition of two courses of intensification therapy has produced a 14% improvement in disease-free survival and an 11% improvement in overall survival for the randomised patients. This additional treatment is of benefit to all children with acute lymphoblastic leukaemia, even those traditionally deemed at lower risk of relapse.	ST JAMES UNIV HOSP, PAEDIAT ONCOL DAY HOSP, LEEDS, W YORKSHIRE, ENGLAND; RADCLIFFE INFIRM, CLIN TRIAL SERV UNIT, OXFORD, ENGLAND	Saint James's University Hospital; Radcliffe Infirmary; University of Oxford	CHESSELLS, JM (corresponding author), INST CHILD HLTH, DEPT HAEMATOL & ONCOL, GUILFORD ST, LONDON WC1N 1EH, ENGLAND.							BLEYER WA, 1983, J CLIN ONCOL, V1, P317, DOI 10.1200/JCO.1983.1.5.317; BLOOMFIELD CD, 1986, BLOOD, V67, P415; CAMITTA B, 1989, J CLIN ONCOL, V7, P1539, DOI 10.1200/JCO.1989.7.10.1539; CHESSELLS JM, 1992, LANCET, V340, P565, DOI 10.1016/0140-6736(92)92103-M; CHESSELLS JM, IN PRESS BR J HAEMAT; CLAVELL LA, 1986, NEW ENGL J MED, V315, P657, DOI 10.1056/NEJM198609113151101; COX D, 1991, CANCER, V67, P2428, DOI 10.1002/1097-0142(19910515)67:10<2428::AID-CNCR2820671004>3.0.CO;2-J; EDEN OB, 1991, BRIT J HAEMATOL, V78, P187, DOI 10.1111/j.1365-2141.1991.tb04415.x; EDEN OB, 1990, BRIT J HAEMATOL, V75, P496, DOI 10.1111/j.1365-2141.1990.tb07788.x; GAYNON PS, 1993, J CLIN ONCOL, V11, P2234, DOI 10.1200/JCO.1993.11.11.2234; GOLDIE JH, 1984, CANCER RES, V44, P3643; HALE JP, 1991, ARCH DIS CHILD, V66, P462, DOI 10.1136/adc.66.4.462; Henze G, 1990, Haematol Blood Transfus, V33, P483; KRANCE RA, 1991, CANCER-AM CANCER SOC, V67, P550, DOI 10.1002/1097-0142(19910201)67:3<550::AID-CNCR2820670303>3.0.CO;2-#; LIPSHULTZ SE, 1991, NEW ENGL J MED, V324, P808, DOI 10.1056/NEJM199103213241205; MILLER DR, 1989, J CLIN ONCOL, V7, P1807, DOI 10.1200/JCO.1989.7.12.1807; MILLER DR, 1983, CANCER, V51, P1041, DOI 10.1002/1097-0142(19830315)51:6<1041::AID-CNCR2820510612>3.0.CO;2-G; NIEMEYER CM, 1991, ANN ONCOL, V2, P745, DOI 10.1093/oxfordjournals.annonc.a057856; NORTON L, 1977, CANCER TREAT REP, V61, P1307; PETO J, 1986, LANCET, V1, P408; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PINKERTON CR, 1987, ARCH DIS CHILD, V62, P12, DOI 10.1136/adc.62.1.12; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; Riehm H, 1987, Haematol Blood Transfus, V30, P139; RIVERA GK, 1994, BAILLIERE CLIN HAEM, V7, P273, DOI 10.1016/S0950-3536(05)80203-3; RIVERA GK, 1993, NEW ENGL J MED, V329, P1289, DOI 10.1056/NEJM199310283291801; RIVERA GK, 1991, LANCET, V337, P61, DOI 10.1016/0140-6736(91)90733-6; RIVERA GK, 1987, SEMIN HEMATOL, V24, P12; RUBIN CM, 1991, J CLIN ONCOL, V9, P2183, DOI 10.1200/JCO.1991.9.12.2183; TUBERGEN DG, 1993, J CLIN ONCOL, V11, P527, DOI 10.1200/JCO.1993.11.3.527; WHITE SJ, 1978, BRIT J CANCER, V37, P849, DOI 10.1038/bjc.1978.124	31	246	249	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 21	1995	345	8943					143	148		10.1016/S0140-6736(95)90164-7	http://dx.doi.org/10.1016/S0140-6736(95)90164-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7823668				2022-12-28	WOS:A1995QC55000007
J	MCDERMOTT, J				MCDERMOTT, J			THE FIRST STEP	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											MCDERMOTT, J (corresponding author), US HOUSE REPRESENTATIVES,LONGWORTH HOUSE OFF BLDG 1707,WASHINGTON,DC 20515, USA.							DAVIS K, 1994, HEALTH AFFAIR, V13, P7, DOI 10.1377/hlthaff.13.2.7; HILZENRATH D, 1994, WASHINGTON POST 1031, P12; SCISM L, 1994, WALL STREET J   0527; SUMMER L, 1994, TRENDS HLTH INSURANC, P4; 1993, 1993 US BUR CENS CUR; 1994, AM MED NEWS     1114, V37, P27; 1993, FY1993 NAT ASS CHILD	7	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					251	253						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB234	7807675				2022-12-28	WOS:A1995QB23400040
J	NIELSEN, S; HAHLIN, M				NIELSEN, S; HAHLIN, M			EXPECTANT MANAGEMENT OF 1ST-TRIMESTER SPONTANEOUS-ABORTION	LANCET			English	Article							INDUCED 1ST-TRIMESTER ABORTION; PREGNANCY	Approximately 15% of registered pregnancies end in spontaneous abortion, and for 50 years or so dilatation and curettage (D&C) has been the usual management. In a prospective randomised trial we compared the clinical results after either expectant management or D&C, for miscarriages of less than 13 weeks' gestation in which transvaginal ultrasound examination showed intrauterine tissue and/or blood clots with a diameter 15-50 mm. 103 patients were randomised to expectant management and spontaneous resolution of pregnancy occurred within 3 days in 81 cases (79%). 52 patients were randomised to D&C. 3 infections were diagnosed among patients who underwent expectant management (3%); 5 infections and 1 case of postoperative anaemia were observed among patients randomised to D&C (11%). The duration of vaginal bleeding was a mean of 1.3 days longer in the expectant management group (p<0.02). Convalesence time, time during which patients experienced pain, and packed-cell volume 3 and 14 days after inclusion did not differ significantly between the groups. This study shows that expectant management of selected cases of spontaneous abortion has a similar outcome to D&C.			NIELSEN, S (corresponding author), GOTHENBURG UNIV, SAHLGRENS HOSP, DEPT OBSTET & GYNAECOL, S-41345 GOTHENBURG, SWEDEN.							CHUNG CS, 1982, AM J EPIDEMIOL, V115, P879, DOI 10.1093/oxfordjournals.aje.a113375; DILLON EH, 1993, RADIOLOGY, V186, P87, DOI 10.1148/radiology.186.1.8416592; FARRELL RG, 1982, ANN EMERG MED, V11, P652, DOI 10.1016/S0196-0644(82)80256-4; GOLDSTEIN SR, 1990, J CLIN ULTRASOUND, V18, P262, DOI 10.1002/jcu.1870180409; HAHLIN M, 1991, FERTIL STERIL, V55, P492; HAINES CJ, 1994, GYNECOL OBSTET INVES, V37, P14, DOI 10.1159/000292512; HAMMERSLOUGH CR, 1992, PUBLIC HEALTH REP, V107, P269; HEISTERBERG L, 1986, AM J OBSTET GYNECOL, V155, P76, DOI 10.1016/0002-9378(86)90082-7; HEISTERBERG L, 1987, ACTA OBSTET GYN SCAN, V66, P201, DOI 10.3109/00016348709020747; HENSHAW RC, 1993, BMJ-BRIT MED J, V306, P894, DOI 10.1136/bmj.306.6882.894; Hertig AT, 1944, NEW ENGL J MED, V230, P797; KURTZ AB, 1991, J ULTRAS MED, V10, P387; LAFERLA JJ, 1986, CLIN OBSTET GYNAECOL, V13, P105; LETTERIE GS, 1991, GYNECOL OBSTET INVES, V31, P176, DOI 10.1159/000293147; MANSUR MM, 1992, EUR J OBSTET GYN R B, V44, P65, DOI 10.1016/0028-2243(92)90315-P; MCKEE M, 1992, ARCH EMERG MED, V9, P290; MISHELL DR, 1966, AM J OBSTET GYNECOL, V96, P119, DOI 10.1016/S0002-9378(16)34650-6; RULIN MC, 1993, AM J OBSTET GYNECOL, V168, P12, DOI 10.1016/S0002-9378(12)90877-7; RUSSELL P B Jr, 1947, South Med J, V40, P314	19	174	176	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 14	1995	345	8942					84	86		10.1016/S0140-6736(95)90060-8	http://dx.doi.org/10.1016/S0140-6736(95)90060-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815886				2022-12-28	WOS:A1995QB80400007
J	KNOWLES, S				KNOWLES, S			A PASSAGE THROUGH GRIEF - THE WESTERN-AUSTRALIAN RURAL PREGNANCY LOSS TEAM	BRITISH MEDICAL JOURNAL			English	Article											KNOWLES, S (corresponding author), KING EDWARD MEM HOSP WOMEN,SUBIACO,WA 6008,AUSTRALIA.								0	11	11	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1705	1708		10.1136/bmj.309.6970.1705	http://dx.doi.org/10.1136/bmj.309.6970.1705			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819995	Green Published			2022-12-28	WOS:A1994PY71700024
J	LINDBACK, S; BROSTROM, C; KARLSSON, A; GAINES, H				LINDBACK, S; BROSTROM, C; KARLSSON, A; GAINES, H			DOES SYMPTOMATIC PRIMARY HIV-1 INFECTION ACCELERATE PROGRESSION TO CDC STAGE-IV DISEASE, CD4 COUNT BELOW 200 X 10(6)/1, AIDS, AND DEATH FROM AIDS	BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY VIRUS-INFECTION; BISEXUAL MEN; ILLNESS; SEROCONVERTERS; PREDICTORS; ANTIBODY; COHORT; RISK	Objective-To investigate the prognostic significance of symptomatic primary HIV-1 infection. Design-Prospective study of homosexual men seroconverting to HIV in 1985 and 1986. Patients were followed up at least three times yearly with clinical examinations and T cell subset determinations for an average of 7.2 years. Setting-Research project centred on attenders for treatment and screening for HIV at the Karolinska Institute, Stockholm. Subjects-19 patients presenting with a glandular-fever-like illness associated with seroconversion to HIV and 29 asymptomatic seroconverters. Main outcome measures-Progression to Centers for Disease Control and Prevention stage IV disease, CD4 cell count below 200 x 10(6)/1, AIDS, and death from AIDS. Results-Symptomatic seroconverters were significantly more likely to develop Centers for Disease Control and Prevention stage IV disease (95% v 66%), CD4 cell counts below 200 x 10(6)/1 (84% v 55%), and AIDS (58% v 28%) and die of AIDS (53% v 7%). Conclusion-A glandular-fever-like illness associated with seroconversion to HIV-1 predicts accelerated progression to AIDS and other HIV related diseases.	KAROLINSKA INST,HUDDINGE HOSP,DEPT INFECT DIS,STOCKHOLM,SWEDEN; KAROLINSKA INST,SODER SJUKHUSET,DEPT DERMATOVENEREOL,STOCKHOLM,SWEDEN; SWEDISH INST INFECT DIS CONTROL,DEPT CLIN IMMUNOL,STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska Institutet; Sodersjukhuset Hospital; Swedish Institute for Infectious Disease Control								ALBERT J, 1987, J MED VIROL, V23, P67, DOI 10.1002/jmv.1890230108; BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; COOPER DA, 1985, LANCET, V1, P537; GAINES H, 1987, LANCET, V1, P1249; GAINES H, 1988, BRIT MED J, V297, P1363, DOI 10.1136/bmj.297.6660.1363; GAINES H, 1990, AIDS, V4, P995, DOI 10.1097/00002030-199010000-00008; GAINES H, 1988, AIDS, V2, P11, DOI 10.1097/00002030-198802000-00002; HESSOL NA, 1989, AM J EPIDEMIOL, V130, P1167, DOI 10.1093/oxfordjournals.aje.a115445; JASON J, 1989, JAMA-J AM MED ASSOC, V261, P725, DOI 10.1001/jama.261.5.725; KEET IPM, 1993, AIDS, V7, P51, DOI 10.1097/00002030-199301000-00008; LANGE JMA, 1988, AIDS, V2, P31, DOI 10.1097/00002030-198802000-00005; LEARMONT J, 1992, LANCET, V340, P863, DOI 10.1016/0140-6736(92)93281-Q; MARCUS R, 1989, B WORLD HEALTH ORGAN, V67, P577; NIU MT, 1993, AIDS RES HUM RETROV, V9, P913, DOI 10.1089/aid.1993.9.913; PEDERSEN C, 1989, BRIT MED J, V299, P154, DOI 10.1136/bmj.299.6692.154; REZZA G, 1992, AIDS, V6, P421, DOI 10.1097/00002030-199204000-00010; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SIMMONDS P, 1991, LANCET, V338, P1159, DOI 10.1016/0140-6736(91)92029-2; SINICCO A, 1993, J ACQ IMMUN DEF SYND, V6, P575; TINDALL B, 1988, ARCH INTERN MED, V148, P945, DOI 10.1001/archinte.148.4.945; VONSYDOW M, 1988, BMJ-BRIT MED J, V296, P238, DOI 10.1136/bmj.296.6617.238; 1987, MMWR-MORBID MORTAL W, V36, P3; 1994, LANCET, V343, P871; 1986, MMWR-MORBID MORTAL W, V35, P334	24	77	77	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 10	1994	309	6968					1535	1537		10.1136/bmj.309.6968.1535	http://dx.doi.org/10.1136/bmj.309.6968.1535			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX564	7819891	Green Published			2022-12-28	WOS:A1994PX56400017
J	BHANDARI, N; BHAN, MK; SAZAWAL, S				BHANDARI, N; BHAN, MK; SAZAWAL, S			IMPACT OF MASSIVE DOSE OF VITAMIN-A GIVEN TO PRESCHOOL-CHILDREN WITH ACUTE DIARRHEA ON SUBSEQUENT RESPIRATORY AND DIARRHEAL MORBIDITY	BRITISH MEDICAL JOURNAL			English	Article							A SUPPLEMENTATION; CHILDHOOD MORTALITY; IMMUNE-RESPONSE; TRIAL; RISK; DEFICIENCY; MEASLES; INFECTIONS	Objective-To assess the impact of vitamin A supplementation on morbidity from acute respiratory tract infections and diarrhoea. Design-Double blind randomised placebo controlled field trial. Setting-An urban slum area in New Delhi, India. Subjects-900 children aged 12-60 months attending a local health facility for acute diarrhoea of less than seven days' duration randomly allocated to receive vitamin A 200 000 IU or placebo. Main outcome measures-Incidence and prevalence of acute lower respiratory tract infections and diarrhoea during the 90 days after termination of the enrolment diarrhoeal episode measured by twice weekly household surveillance. Results-The incidence (relative risk 1.07; 95% confidence interval 0.92 to 1.26) and average number of days spent with acute lower respiratory tract infections were similar in the vitamin A supplementation and placebo groups. Among children aged 23 months or less there was a significant reduction in the incidence of measles (relative risk 0.06; 95% confidence interval 0.01 to 0.48). The incidence of diarrhoea was also similar (relative risk 0.95; 0.86 to 1.05) in the two groups. There was a 36% reduction in the mean daily prevalence of diarrhoea associated with fever in the vitamin A supplemented children older than 23 months. Conclusions-Results were consistent with a lack of impact on acute lower respiratory tract related mortality after vitamin A supplementation noted in other trials and a possible reduction in the severity of diarrhoea.	ALL INDIA INST MED SCI,DEPT PAEDIAT,DIV GASTROENTEROL & ENTER INFECT,NEW DELHI 110029,INDIA	All India Institute of Medical Sciences (AIIMS) New Delhi								BARCLAY AJG, 1987, BMJ-BRIT MED J, V294, P294, DOI 10.1136/bmj.294.6567.294; BEATON GH, 1992, REPORT CIDA FACULTY, P1; BIERI JG, 1979, AM J CLIN NUTR, V32, P2143, DOI 10.1093/ajcn/32.10.2143; BLOEM MW, 1990, AM J EPIDEMIOL, V131, P332, DOI 10.1093/oxfordjournals.aje.a115502; CHUN TY, 1992, J NUTR, V122, P1062, DOI 10.1093/jn/122.5.1062; COUTSOUDIS A, 1991, AM J CLIN NUTR, V54, P890, DOI 10.1093/ajcn/54.5.890; DAULAIRE NMP, 1992, BMJ-BRIT MED J, V304, P207, DOI 10.1136/bmj.304.6821.207; DIBLEY MJ, 1992, FASEB J, V6, pA1787; ELBUSHRA HE, 1992, PEDIATR INFECT DIS J, V11, P380, DOI 10.1097/00006454-199205000-00008; FEACHEM RG, 1987, TROP DIS B, V84, P1; FRIEDMAN A, 1989, J NUTR, V119, P790, DOI 10.1093/jn/119.5.790; FRIEDMAN A, 1991, J NUTR, V121, P395, DOI 10.1093/jn/121.3.395; GARDNER MJ, 1989, STATISTICS CONFIDENC; HENDRY M, 1989, RADIOLOGY WORKING GR, P90; HUSSEY GD, 1990, NEW ENGL J MED, V323, P160, DOI 10.1056/NEJM199007193230304; ISLAM A, 1983, J PEDIATR, V103, P1000; LATHAM MC, 1993, LANCET, V342, P549, DOI 10.1016/0140-6736(93)91671-8; MILTON RC, 1987, AM J CLIN NUTR, V46, P823; Pocock SJ, 1986, CLIN TRIALS PRACTICA; RAHMATHULLAH L, 1990, NEW ENGL J MED, V323, P929, DOI 10.1056/NEJM199010043231401; REDDY V, 1986, B WORLD HEALTH ORGAN, V64, P721; SOMMER A, 1980, LANCET, V1, P557; SOMMER A, 1986, LANCET, V1, P1169; SOMMER A, 1984, AM J CLIN NUTR, V40, P1090, DOI 10.1093/ajcn/40.5.1090; STANSFIELD SK, 1993, LANCET, V342, P578, DOI 10.1016/0140-6736(93)91410-N; WEST KP, 1991, LANCET, V338, P69; 1989, STATE WORLDS CHILDRE; 1993, LANCET, V342, P7	28	61	65	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1994	309	6966					1404	1407		10.1136/bmj.309.6966.1404	http://dx.doi.org/10.1136/bmj.309.6966.1404			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7819847	Green Published			2022-12-28	WOS:A1994PU76400019
J	THAM, KY; EVANS, RJ; RUBYTHON, EJ; KINNAIRD, TD				THAM, KY; EVANS, RJ; RUBYTHON, EJ; KINNAIRD, TD			MANAGEMENT OF VENTRICULAR-FIBRILLATION BY DOCTORS IN CARDIAC-ARREST TEAMS	BRITISH MEDICAL JOURNAL			English	Article							RESUSCITATION SKILLS; CARDIOPULMONARY		CARDIFF ROYAL INFIRM,DEPT ACCID & EMERGENCY,CARDIFF CF2 1SZ,S GLAM,WALES	Cardiff Royal Infirmary								DAVID J, 1993, BRIT MED J, V306, P1578, DOI 10.1136/bmj.306.6892.1578; MORRIS F, 1991, BRIT MED J, V302, P626, DOI 10.1136/bmj.302.6777.626; TUNSTALLPEDOE H, 1992, BRIT MED J, V304, P1347, DOI 10.1136/bmj.304.6838.1347; 1992, RESUSCITATION, V24, P111; 1993, BRIT MED J, V306, P1589	5	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1994	309	6966					1408	1409		10.1136/bmj.309.6966.1408a	http://dx.doi.org/10.1136/bmj.309.6966.1408a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7819848	Green Published			2022-12-28	WOS:A1994PU76400021
J	UEDA, P; HALL, D				UEDA, P; HALL, D			GIANT COLONIC DIVERTICULUM	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											UEDA, P (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA.								0	6	7	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 27	1995	333	4					228	228		10.1056/NEJM199507273330405	http://dx.doi.org/10.1056/NEJM199507273330405			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK423	7791839				2022-12-28	WOS:A1995RK42300005
J	MIYASHITA, Y				MIYASHITA, Y			HOW THE BRAIN CREATES IMAGERY - PROJECTION TO PRIMARY VISUAL-CORTEX	SCIENCE			English	Editorial Material							ADULT OWL MONKEYS; MEMORY				MIYASHITA, Y (corresponding author), UNIV TOKYO,SCH MED,DEPT PHYSIOL,BUNKYO KU,7-3-1 HONGO,TOKYO 113,JAPAN.		Miyashita, Yasushi/B-7171-2019	Miyashita, Yasushi/0000-0003-3496-8637				ALAIN EAC, 1926, SYSTEME BEAUX ART, P342; CRAVERLEMLEY C, 1987, PERCEPTION, V16, P533; Damasio A. R., 1990, SEMIN NEUROSCI, V2, P287; FARAH MJ, 1985, J EXP PSYCHOL GEN, V114, P91, DOI 10.1037/0096-3445.114.1.91; FINKE RA, 1977, J EXP PSYCHOL HUMAN, V3, P599, DOI 10.1037/0096-1523.3.4.599; ISHAI A, 1995, SCIENCE, V268, P1772, DOI 10.1126/science.7792605; KARNI A, 1993, NATURE, V365, P250, DOI 10.1038/365250a0; KAUFMAN JH, 1981, PERCEPT PSYCHOPHYS, V30, P547, DOI 10.3758/BF03202008; KOSLYN SM, 1994, TRENDS NEUROSCI, V17, P290; Kosslyn S. M., 1994, IMAGE BRAIN; KOSSLYN SM, 1993, J COGNITIVE NEUROSCI, V5, P263, DOI 10.1162/jocn.1993.5.3.263; LEBIHAN D, 1993, P NATL ACAD SCI USA, V90, P11802, DOI 10.1073/pnas.90.24.11802; MIYASHITA Y, 1993, ANNU REV NEUROSCI, V16, P245, DOI 10.1146/annurev.ne.16.030193.001333; MOSCOVITCH M, 1994, TRENDS NEUROSCI, V17, P292, DOI 10.1016/0166-2236(94)90060-4; POLAT U, 1994, P NATL ACAD SCI USA, V91, P1206, DOI 10.1073/pnas.91.4.1206; PYLYSHYN Z, 1981, PSYCHOL REV, V87, P16; RECANZONE GH, 1993, J NEUROSCI, V13, P87; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1015, DOI 10.1152/jn.1992.67.5.1015; ROLAND PE, 1994, TRENDS NEUROSCI, V17, P281, DOI 10.1016/0166-2236(94)90057-4; ROLAND PE, 1985, J NEUROPHYSIOL, V53, P1219, DOI 10.1152/jn.1985.53.5.1219; SAKAI K, 1994, TRENDS NEUROSCI, V17, P287, DOI 10.1016/0166-2236(94)90058-2; SAKAI K, 1991, NATURE, V354, P152, DOI 10.1038/354152a0; Tye M., 1991, THE IMAGERY DEBATE; VANESSEN DC, 1992, SCIENCE, V255, P419, DOI 10.1126/science.1734518	24	38	38	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1719	1720		10.1126/science.7792596	http://dx.doi.org/10.1126/science.7792596			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RE668	7792596				2022-12-28	WOS:A1995RE66800032
J	NASSAR, M; HORN, G; HERRMANN, C; SCHERER, A; MCCORMICK, F; WITTINGHOFER, A				NASSAR, M; HORN, G; HERRMANN, C; SCHERER, A; MCCORMICK, F; WITTINGHOFER, A			THE 2.2-ANGSTROM CRYSTAL-STRUCTURE OF THE RAS-BINDING DOMAIN OF THE SERINE THREONINE KINASE C-RAF1 IN COMPLEX WITH RAP1A AND A GTP ANALOG	NATURE			English	Article							RAS-P21 GTPASE; GENE-PRODUCT; HA-RAS; PROTEIN; TARGET; RAF-1; RECOGNITION; INHIBITION; RESOLUTION; HYDROLYSIS	The X-ray crystal structure of the complex between the Ras-related protein Rap1A in the GTP-analogue (GppNHp) form and the pas-binding domain (RED) of the Ras effector molecule c-Raf1, a ser/Thr-specific protein kinase, has been solved to a resolution of 2.2 Angstrom. It shows that RED has the ubiquitin superfold and that the structure of Rap1A is very similar to that of Ras. The interaction between the two proteins is mediated by an apparent central antiparallel beta-sheet formed by strands B1-B2 from RED and strands beta 2-beta 3 from Rap1A. Complex formation is mediated by main-chain and side-chain interactions of the so-called effector residues in the switch I region of Rap1A.	MAX PLANCK INST MED RES,BIOPHYS ABT,D-69119 HEIDELBERG,GERMANY; ONYX PHARMACEUT,RICHMOND,CA 94806	Max Planck Society	NASSAR, M (corresponding author), MAX PLANCK INST MOLEK PHYSIOL,STRUKTURELLE BIOL ABT,POSTFACH 102664,D-44026 DORTMUND,GERMANY.							AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Barnard D, 1995, ONCOGENE, V10, P1283; BOKOCH G, 1993, GTPASES BIOL 1, V108, P377; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER TA, 1993, XPLOR VERSION 3 1; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; COOK S, 1993, EMBO J, V12, P3485; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; EMERSON SD, 1994, BIOCHEMISTRY-US, V33, P7745, DOI 10.1021/bi00191a001; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1994, CELL, V79, P193, DOI 10.1016/0092-8674(94)90189-9; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; HATA Y, 1990, J BIOL CHEM, V265, P7104; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LU XY, 1994, EMBO J, V13, P2592, DOI 10.1002/j.1460-2075.1994.tb06549.x; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; ORENGO CA, 1994, NATURE, V372, P631, DOI 10.1038/372631a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WHITE MA, 1995, CELL, V80, P1; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	49	549	564	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					554	560		10.1038/375554a0	http://dx.doi.org/10.1038/375554a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791872				2022-12-28	WOS:A1995RD28700042
J	LEDERMAN, MM				LEDERMAN, MM			HOST-DIRECTED AND IMMUNE-BASED THERAPIES FOR HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							TUMOR-NECROSIS-FACTOR; MULTIDRUG-RESISTANT TUBERCULOSIS; HIV-1 REVERSE-TRANSCRIPTASE; PLACEBO-CONTROLLED TRIAL; LONG TERMINAL REPEAT; AIDS-RELATED COMPLEX; T-CELLS; OPPORTUNISTIC INFECTIONS; GENE-EXPRESSION; ZIDOVUDINE AZT	This essay reviews the rationale underlying host-directed or immune-based therapeutic strategies for human immunodeficiency virus (HIV) infection and its complications. These approaches have seen only limited trial in the past 10 years, but as more is learned about the immunopathogenesis of HIV disease and as the limitations of virus-directed therapies become more apparent, the need to pursue other therapeutic avenues has become increasingly important. Moreover, properly designed trials of host-directed and immune-based therapies can provide key insights into the pathogenesis of HIV disease that may be otherwise unattainable through in vitro studies.	CASE WESTERN RESERVE UNIV, AIDS CLIN TRIALS UNIT, CLEVELAND, OH 44106 USA	Case Western Reserve University	LEDERMAN, MM (corresponding author), UNIV CLEVELAND HOSP, DEPT MED, DIV INFECT DIS, 11100 EUCLID AVE, CLEVELAND, OH 44106 USA.				NIAID NIH HHS [AI 25879] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025879] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BARDITCHCROVO P, 1993, 9TH INT C AIDS BERL; BISWAS DK, 1993, P NATL ACAD SCI USA, V90, P11044, DOI 10.1073/pnas.90.23.11044; BUHL R, 1989, LANCET, V2, P1294; CHOW YK, 1993, NATURE, V361, P650, DOI 10.1038/361650a0; CLERICI M, 1992, J INFECT DIS, V166, P723, DOI 10.1093/infdis/166.4.723; CLERICI M, 1993, SCIENCE, V262, P1721, DOI 10.1126/science.7903123; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEWOLF F, 1988, LANCET, V1, P373; DEZUBE BJ, 1993, J ACQ IMMUN DEF SYND, V6, P787; DORSETT BH, 1990, ARCH INTERN MED, V150, P1025, DOI 10.1001/archinte.150.5.1025; ECK HP, 1989, BIOL CHEM H-S, V370, P101, DOI 10.1515/bchm3.1989.370.1.101; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FLIRI H, 1993, ANN NY ACAD SCI, V696, P47; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; GULIZIA J, 1994, J VIROL, V68, P2021, DOI 10.1128/JVI.68.3.2021-2025.1994; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HAUBRICH RH, 1993, 9TH INT C AIDS BERL; HILDRETH JEK, 1989, SCIENCE, V244, P1075, DOI 10.1126/science.2543075; ISEMAN MD, 1993, NEW ENGL J MED, V329, P784, DOI 10.1056/NEJM199309093291108; ISRAELBIET D, 1990, CLIN EXP IMMUNOL, V81, P18, DOI 10.1111/j.1365-2249.1990.tb05285.x; KALEBIC T, 1991, P NATL ACAD SCI USA, V88, P986, DOI 10.1073/pnas.88.3.986; KOVACS JA, 1993, 9 INT C AIDS BERL; KUNDIG TM, 1993, SCIENCE, V262, P1059, DOI 10.1126/science.8235625; LAHDEVIRTA J, 1988, AM J MED, V85, P289, DOI 10.1016/0002-9343(88)90576-1; LANCY ED, 1989, J BACTERIOL, V171, P5572, DOI 10.1128/jb.171.10.5572-5580.1989; LANE HC, 1990, ANN INTERN MED, V112, P805, DOI 10.7326/0003-4819-112-11-805; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LEDERMAN MM, 1987, HUM IMMUNOL, V20, P279, DOI 10.1016/0198-8859(87)90019-X; LEDERMAN MM, 1989, P NATL ACAD SCI USA, V86, P4205, DOI 10.1073/pnas.86.11.4205; LEDERMAN MM, 1993, 9TH INT C AIDS BERL; LEDERMAN MM, 1988, AUTOIMMUNE ASPECTS H, P165; LEE TC, 1992, NEW BIOL, V4, P66; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; LUKE DR, 1993, INT J CLIN PHARM TH, V31, P343; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; MALIM MH, 1992, J EXP MED, V176, P1197, DOI 10.1084/jem.176.4.1197; MALIM MH, 1993, MOL CELL BIOL, V13, P6180, DOI 10.1128/MCB.13.10.6180; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MILES SA, 1990, ANN INTERN MED, V112, P582, DOI 10.7326/0003-4819-112-8-582; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; MOLE L, 1994, J ACQ IMMUN DEF SYND, V7, P519; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; OJWANG JO, 1992, P NATL ACAD SCI USA, V89, P10802, DOI 10.1073/pnas.89.22.10802; PAIETTA E, 1986, ANN INTERN MED, V104, P890, DOI 10.7326/0003-4819-104-6-890_2; PEARSON L, 1990, P NATL ACAD SCI USA, V87, P5079, DOI 10.1073/pnas.87.13.5079; PHILLIPS A, 1989, CAN MED ASSOC J, V140, P1456; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; POLI G, 1992, AIDS RES HUM RETROV, V8, P191, DOI 10.1089/aid.1992.8.191; REDDY EP, 1992, PATHOBIOLOGY, V60, P219; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; ROEDERER M, 1990, P NATL ACAD SCI USA, V87, P4884, DOI 10.1073/pnas.87.12.4884; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SAAG MS, 1993, NEW ENGL J MED, V329, P1065, DOI 10.1056/NEJM199310073291502; SALLAFRANQUEANDREOLA ML, 1989, EUR J BIOCHEM, V184, P367, DOI 10.1111/j.1432-1033.1989.tb15028.x; SCHACKER T, 1994, J INFECT DIS, V169, P37, DOI 10.1093/infdis/169.1.37; SCHMIDT A, 1990, J VIROL, V64, P4037, DOI 10.1128/JVI.64.8.4037-4041.1990; SILICIANO RF, 1988, CELL, V54, P561, DOI 10.1016/0092-8674(88)90078-5; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N; TAKASHIMA T, 1990, INFECT IMMUN, V58, P3286, DOI 10.1128/IAI.58.10.3286-3292.1990; TEPPLER H, 1993, J EXP MED, V177, P483, DOI 10.1084/jem.177.2.483; TYLER DS, 1989, J IMMUNOL, V142, P1177; VANHAM G, 1990, CLIN EXP IMMUNOL, V82, P3, DOI 10.1111/j.1365-2249.1990.tb05395.x; WILDE MI, 1993, DRUGS, V46, P515, DOI 10.2165/00003495-199346030-00010; YARCHOAN R, 1986, LANCET, V1, P575	74	14	15	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1995	122	3					218	222		10.7326/0003-4819-122-3-199502010-00010	http://dx.doi.org/10.7326/0003-4819-122-3-199502010-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD733	7810941				2022-12-28	WOS:A1995QD73300010
J	FERRICK, DA; SCHRENZEL, MD; MULVANIA, T; HSIEH, B; FERLIN, WG; LEPPER, H				FERRICK, DA; SCHRENZEL, MD; MULVANIA, T; HSIEH, B; FERLIN, WG; LEPPER, H			DIFFERENTIAL PRODUCTION OF INTERFERON-GAMMA AND INTERLEUKIN-4 IN RESPONSE TO TH1-STIMULATING AND TH2-STIMULATING PATHOGENS BY GAMMA-DELTA T-CELLS IN-VIVO	NATURE			English	Article							ALPHA-BETA; LISTERIA-MONOCYTOGENES; PROTECTIVE IMMUNITY; INFECTION; CYTOKINES; MICE; TUBERCULOSIS; EOSINOPHILIA; APPEARANCE; ELEVATION	EXPOSURE to various pathogens can stimulate at least two patterns of cytokine production by CD4-positive T cells(1-4) Responses that result in secretion of interferon-gamma (IFN-gamma), lymphotoxin and interleukin-2 (IL-2) are classified as T-helper-1 (Th1)(5,6); CD4(+) T-cell production of IL-4, IL-5, IL-9, IL-10 and IL-13 is called a T-helper-2 response (Th2)(5,6). Differentiation of CD4(+) T cells into either Th1 or Th2 cells is influenced by the cytokine milieu in which the initial antigen priming occurs(7-9). Here we use flow cytometry to identify the presence of intracellular cytokines (cytoflow) and analyse T-cell production of IFN-gamma and IL-4 from mice infected with Listeria monocytogenes or Nippostrongylus brasiliensis. We show that T cells bearing ya receptors discriminate early in infection between these two pathogens by producing cytokines associated with the appropriate T-helper response. Our results demonstrate that gamma delta T cells are involved in establishing primary immune responses.			FERRICK, DA (corresponding author), UNIV CALIF DAVIS,SCH VET MED,DEPT PATHOL MICROBIOL & IMMUNOL,DAVIS,CA 95616, USA.							BARNES PF, 1992, J INFECT DIS, V165, P506, DOI 10.1093/infdis/165.3.506; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; ENSOR JE, 1994, AM J PHYSIOL, V266, P967; FU YX, 1994, J IMMUNOL, V153, P3101; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; HIROMATSU K, 1992, J EXP MED, V175, P49, DOI 10.1084/jem.175.1.49; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; KATONA IM, 1988, J IMMUNOL, V140, P3206; KELSO A, 1988, P NATL ACAD SCI USA, V85, P9189, DOI 10.1073/pnas.85.23.9189; LOCKSLEY RM, 1994, J EXP MED, V179, P1405, DOI 10.1084/jem.179.5.1405; MOMBAERTS P, 1993, NATURE, V365, P53, DOI 10.1038/365053a0; MOSER R, 1993, J LAB CLIN MED, V122, P567; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; OBRIEN RL, 1989, CELL, V57, P667, DOI 10.1016/0092-8674(89)90135-9; OHGA S, 1990, EUR J IMMUNOL, V20, P533, DOI 10.1002/eji.1830200311; REINER SL, 1994, J EXP MED, V179, P447, DOI 10.1084/jem.179.2.447; ROCKEN M, 1992, J IMMUNOL, V148, P1031; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; SCOTT P, 1991, IMMUNOL TODAY, V12, P346, DOI 10.1016/0167-5699(91)90063-Y; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SHER A, 1992, IMMUNOL REV, V127, P183, DOI 10.1111/j.1600-065X.1992.tb01414.x; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; SVETIC A, 1993, J IMMUNOL, V150, P3434; TWOMEY BM, 1993, CLIN EXP IMMUNOL, V93, P178; URBAN JF, 1992, IMMUNOL REV, V127, P205, DOI 10.1111/j.1600-065X.1992.tb01415.x; WEN L, 1994, NATURE, V369, P654, DOI 10.1038/369654a0; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582	30	590	599	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					255	257		10.1038/373255a0	http://dx.doi.org/10.1038/373255a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816142				2022-12-28	WOS:A1995QC27800067
J	MARTINEZ, FD; WRIGHT, AL; TAUSSIG, LM; HOLBERG, CJ; HALONEN, M; MORGAN, WJ; BEAN, J; BIANCHI, H; CURTISS, J; EY, J; SANGUINETI, A; SMITH, B; VONDRAK, T; WEST, N; MCLELLAN, M				MARTINEZ, FD; WRIGHT, AL; TAUSSIG, LM; HOLBERG, CJ; HALONEN, M; MORGAN, WJ; BEAN, J; BIANCHI, H; CURTISS, J; EY, J; SANGUINETI, A; SMITH, B; VONDRAK, T; WEST, N; MCLELLAN, M			ASTHMA AND WHEEZING IN THE FIRST 6 YEARS OF LIFE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIRUS-SPECIFIC IGE; RESPIRATORY ILLNESS; PULMONARY-FUNCTION; LUNG-FUNCTION; SERUM IGE; AIRWAY RESPONSIVENESS; 1ST YEAR; CHILDREN; SUBSEQUENT; CHILDHOOD	Background. Many young children wheeze during viral respiratory infections, but the pathogenesis of these episodes and their relation to the development of asthma later in life are not well understood. Methods. In a prospective study, we investigated the factors affecting wheezing before the age of three years and their relation to wheezing at six years of age. Of 1246 newborns in the Tucson, Arizona, area enrolled between May 1980 and October 1984, follow-up data at both three and six years of age were available for 826. For these children, assessments in infancy included measurement of cord-serum IgE levels (measured in 750 children), pulmonary-function testing before any lower respiratory tract illness had occurred (125), measurement of serum IgE levels at nine months of age (672), and questionnaires completed by the children's parents when the children were one year old (800), Assessments at six years of age included measurement of serum IgE levels (in 460), pulmonary-function testing (526), and skin allergy testing (629). Results. At the age of six years, 425 children (51.5 percent) had never wheezed, 164 (19.9 percent) had had at least one lower respiratory tract illness with wheezing during the first three years of life but had no wheezing at six years of age, 124 (15.0 percent) had no wheezing before the age of three years but had wheezing at the age of six years, and 113 (13.7 percent) had wheezing both before three years of age and at six years of age. The children who had wheezing before three years of age but not at the age of six had diminished airway function (length-adjusted maximal expiratory flow at functional residual capacity [V(max)FRC]) both before the age of one year and at the age of six years, were more likely than the other children to have mothers who smoked but not mothers with asthma, and did not have elevated serum IgE levels or skin-test reactivity. Children who started wheezing in early life and continued to wheeze at the age of six were more likely than the children who never wheezed to have mothers with a history of asthma (P<0.001), to have elevated serum IgE levels (P<0.01) and normal lung function in the first year of life, and to have elevated serum IgE levels (P<0.001) and diminished values for V(max)FRC (P<0.01) at six years of age. Conclusions. The majority of infants with wheezing have transient conditions associated with diminished airway function at birth and do not have increased risks of asthma or allergies later in life, In a substantial minority of infants, however, wheezing episodes are probably related to a predisposition to asthma.	UNIV ARIZONA, COLL MED, DEPT PEDIAT, TUCSON, AZ USA	University of Arizona	MARTINEZ, FD (corresponding author), UNIV ARIZONA, ARIZONA HLTH SCI CTR, COLL MED, CTR RESP SCI, 1501 N CAMPBELL AVE, TUCSON, AZ 85724 USA.			Halonen, Marilyn/0000-0001-9606-935X	NHLBI NIH HHS [HL14136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMITAGE P, 1987, STATISTICAL METHODS; BERBERICH MA, 1993, AM REV RESPIR DIS, V148, P1105; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; HALONEN M, 1992, AM REV RESPIR DIS, V146, P866, DOI 10.1164/ajrccm/146.4.866; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518, DOI 10.1164/ajrccm/138.3.518; MARTINEZ FD, 1991, AM REV RESPIR DIS, V143, P312, DOI 10.1164/ajrccm/143.2.312; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; MARTINEZ FD, 1994, 5 P BRONCH INT S GRO, P161; MERKUS PJFM, 1993, AM REV RESPIR DIS, V148, P1484, DOI 10.1164/ajrccm/148.6_Pt_1.1484; PATTEMORE PK, 1993, CLIN EXP ALLERGY, V23, P886, DOI 10.1111/j.1365-2222.1993.tb00273.x; REDLINE S, 1989, AM REV RESPIR DIS, V140, P179, DOI 10.1164/ajrccm/140.1.179; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; SAMET JM, 1983, AM REV RESPIR DIS, V127, P508, DOI 10.1164/arrd.1983.127.4.508; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; TAGER IB, 1993, AM REV RESPIR DIS, V147, P811, DOI 10.1164/ajrccm/147.4.811; TAUSSIG LM, 1989, AM J EPIDEMIOL, V129, P1219, DOI 10.1093/oxfordjournals.aje.a115242; TAUSSIG LM, 1977, AM REV RESPIR DIS, V116, P1031; TEPPER RS, 1987, AM REV RESPIR DIS, V136, P800; WEISS ST, 1992, AM REV RESPIR DIS, V145, P58, DOI 10.1164/ajrccm/145.1.58; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; WELLIVER RC, 1993, PEDIATR PULM, V15, P19, DOI 10.1002/ppul.1950150104; WELLIVER RC, 1982, J PEDIATR-US, V101, P889, DOI 10.1016/S0022-3476(82)80005-X; Woolf B, 1954, ANN HUM GENET, V19, P251; WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232, DOI 10.1093/oxfordjournals.aje.a115243	24	2827	2905	7	286	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 19	1995	332	3					133	138		10.1056/NEJM199501193320301	http://dx.doi.org/10.1056/NEJM199501193320301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB160	7800004				2022-12-28	WOS:A1995QB16000001
J	HARPER, CL; NYQUIST, LE; BANSAL, B; WIESMANN, H; SHIH, CY				HARPER, CL; NYQUIST, LE; BANSAL, B; WIESMANN, H; SHIH, CY			RAPID ACCRETION AND EARLY DIFFERENTIATION OF MARS INDICATED BY ND-142 ND-144 IN SNC METEORITES	SCIENCE			English	Article							ND ISOTOPIC EVOLUTION; SM-ND; MARTIAN ORIGIN; PB SYSTEMATICS; SHERGOTTITES; PLANET; AGE; ACHONDRITES; CHONDRITES; ABUNDANCES	Small differences in the ratio of neodymium-142 to neodymium-144 in early formed mantle reservoirs in planetary bodies are the result of in situ decay of the extinct radionuclide samarium-146 and can be used to constrain early planetary differentiation and therefore the time scale of planetary accretion. The martian meteorite Nakhla (similar to 1.3 billion years old), the type sample of the nakhlite subgroup of the Shergottite-Nakhlite-Chassigny (SNC) meteorites, exhibits a 59 +/- 13 parts per million excess in the ratio of neodymium-142 to neodymium-144 relative to normal neodymium. This anomaly records differentiation in the martian mantle before 4539 million years ago and implies that Mars experienced no giant impacts at any time later than 27 million years after the origin of the solar system.	NASA, LYNDON B JOHNSON SPACE CTR, HOUSTON, TX 77058 USA; LOCKHEED ENGN & SCI CO, HOUSTON, TX 77058 USA	National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; Lockheed Martin	HARPER, CL (corresponding author), HARVARD UNIV, DEPT EARTH & PLANETARY SCI, 20 OXFORD ST, CAMBRIDGE, MA 02138 USA.							AARSETH SJ, 1993, ASTROPHYS J, V403, P351, DOI 10.1086/172208; BOGARD DD, 1984, GEOCHIM COSMOCHIM AC, V48, P1723, DOI 10.1016/0016-7037(84)90028-0; BOGARD DD, 1977, GEOPHYS RES LETT, V4, P69, DOI 10.1029/GL004i002p00069; BOGARD DD, 1979, METEORITICS, V14, P356; CHEN JH, 1986, GEOCHIM COSMOCHIM AC, V50, P955, DOI 10.1016/0016-7037(86)90376-5; DONES L, 1993, ICARUS, V103, P67, DOI 10.1006/icar.1993.1059; GALE NH, 1975, EARTH PLANET SC LETT, V26, P195, DOI 10.1016/0012-821X(75)90087-4; GOPEL C, 1994, EARTH PLANET SC LETT, V121, P153, DOI 10.1016/0012-821X(94)90038-8; HARPER CL, 1992, NATURE, V360, P728, DOI 10.1038/360728a0; HARPER CL, UNPUB; HARPER CL, 1994, LPS, V25, P509; HARPER CL, 1993, LUNAR PLANET SCI, V24, P607; JACOBSEN SB, 1980, EARTH PLANET SC LETT, V50, P139, DOI 10.1016/0012-821X(80)90125-9; JACOBSEN SB, 1984, EARTH PLANET SC LETT, V67, P137, DOI 10.1016/0012-821X(84)90109-2; JAGOUTZ E, 1991, SPACE SCI REV, V56, P13, DOI 10.1007/BF00178386; JAGOUTZ E, 1989, GEOCHIM COSMOCHIM AC, V53, P2429, DOI 10.1016/0016-7037(89)90363-3; JONES JH, 1986, GEOCHIM COSMOCHIM AC, V50, P969, DOI 10.1016/0016-7037(86)90377-7; JONES JH, 1989, P LUNAR PLANET SCI C, V19, P465; JONES JH, 1990, 9004 LUN PLAN I TECH, P35; LARSON RB, 1989, FORMATION EVOLUTION, P31; Lee T, 1974, GEOPHYS RES LETT, V1, P225, DOI 10.1029/GL001i006p00225; LISSAUER JJ, 1993, ANNU REV ASTRON ASTR, V31, P129, DOI 10.1146/annurev.aa.31.090193.001021; LISSAUER JJ, 1987, ICARUS, V69, P249, DOI 10.1016/0019-1035(87)90104-7; LISSAUER JJ, 1991, ICARUS, V93, P288, DOI 10.1016/0019-1035(91)90213-D; LISSAUER JJ, IN PRESS NEPTUNE TRI; LONGHI J, 1991, P LUNAR PLANET SCI, V21, P695; MCSWEEN HY, 1985, REV GEOPHYS, V23, P391, DOI 10.1029/RG023i004p00391; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; MOUGINISMARK PJ, 1992, J GEOPHYS RES-PLANET, V97, P10213, DOI 10.1029/92JE00612; MUSSELWHITE DS, 1991, NATURE, V352, P697, DOI 10.1038/352697a0; NAKAMURA N, 1982, GEOCHIM COSMOCHIM AC, V46, P1555, DOI 10.1016/0016-7037(82)90314-3; NAKAMURA N, 1982, METEORITICS, V17, P257; NORMAN MD, 1992, LUNAR PLANET SCI, V23, P999; NYQUIST LE, 1990, GEOCHIM COSMOCHIM AC, V54, P2195, DOI 10.1016/0016-7037(90)90045-M; NYQUIST LE, 1994, METEORITICS, V29, P872, DOI 10.1111/j.1945-5100.1994.tb01102.x; NYQUIST LE, 1991, METEORITICS, V26, P381; NYQUIST LE, 1994, LUNAR PLANET SCI, V25, P1017; NYQUIST LE, UNPUB; OTT U, 1988, GEOCHIM COSMOCHIM AC, V52, P1937, DOI 10.1016/0016-7037(88)90017-8; PAL DK, 1986, GEOCHIM COSMOCHIM AC, V50, P2405, DOI 10.1016/0016-7037(86)90022-0; PODOSEK FA, 1973, EARTH PLANET SC LETT, V19, P135, DOI 10.1016/0012-821X(73)90108-8; PRINZHOFER A, 1992, GEOCHIM COSMOCHIM AC, V56, P797, DOI 10.1016/0016-7037(92)90099-5; SHIH CY, 1982, GEOCHIM COSMOCHIM AC, V46, P2323, DOI 10.1016/0016-7037(82)90205-8; SLEEP NH, 1994, J GEOPHYS RES-PLANET, V99, P5639, DOI 10.1029/94JE00216; SPAUTE D, 1991, ICARUS, V92, P147, DOI 10.1016/0019-1035(91)90041-Q; STEVENSON DJ, 1988, ICARUS, V75, P146, DOI 10.1016/0019-1035(88)90133-9; STEWART BW, 1994, GEOCHIM COSMOCHIM AC, V58, P3487, DOI 10.1016/0016-7037(94)90100-7; TONKS WB, 1993, J GEOPHYS RES-PLANET, V98, P5319, DOI 10.1029/92JE02726; WADHWA M, 1994, GEOCHIM COSMOCHIM AC, V58, P4213, DOI 10.1016/0016-7037(94)90274-7; WASSERBURG GJ, 1981, GEOCHIM COSMOCHIM AC, V45, P2311, DOI 10.1016/0016-7037(81)90085-5; Wetherill G. W, 1986, ORIGIN MOON, P519; WETHERILL GW, 1990, ANNU REV EARTH PL SC, V18, P205, DOI 10.1146/annurev.ea.18.050190.001225; WETHERILL GW, 1989, ICARUS, V77, P330, DOI 10.1016/0019-1035(89)90093-6; WETHERILL GW, 1992, ICARUS, V100, P307, DOI 10.1016/0019-1035(92)90103-E; WIENS RC, 1986, EARTH PLANET SC LETT, V77, P149, DOI 10.1016/0012-821X(86)90156-1; [No title captured]; [No title captured]; [No title captured]	59	131	131	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 13	1995	267	5195					213	217		10.1126/science.7809625	http://dx.doi.org/10.1126/science.7809625			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7809625				2022-12-28	WOS:A1995QB15300027
J	ANDERSON, T				ANDERSON, T			EVIDENCE OF BIRTH DEFORMITIES IN 16TH-CENTURY KENT	BRITISH MEDICAL JOURNAL			English	Note											ANDERSON, T (corresponding author), CANTERBURY ARCHAEOLOG TRUST,CANTERBURY CT1 2LU,KENT,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1748	1748						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7820016				2022-12-28	WOS:A1994PY71700047
J	BRYDEN, DJ; SIMMS, DL				BRYDEN, DJ; SIMMS, DL			MARSHALL,JOHN - THE MAKING OF TRUE SPECTACLES	BRITISH MEDICAL JOURNAL			English	Article								In 1693 John Marshall of London devised a novel method of grinding batches of identical, good quality, lenses of a specified focal length. Its commendation by the Royal Society led to a trade war between Marshall and rivals in the Worshipful Company of Spectacle Makers. Despite initial opposition the method was rapidly adopted by London opticians and, though much modified, it forms the unrecognised basis of present day practice.			BRYDEN, DJ (corresponding author), NATL MUSEUMS SCOTLAND,DEPT SCI TECHNOL & WORKING LIFE,EDINBURGH EH1 2JF,MIDLOTHIAN,SCOTLAND.							BRYDEN DJ, 1993, ANN SCI, V50, P1, DOI 10.1080/00033799300200101	1	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1713	1714		10.1136/bmj.309.6970.1713	http://dx.doi.org/10.1136/bmj.309.6970.1713			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819998	Green Published			2022-12-28	WOS:A1994PY71700028
J	PINK, G				PINK, G			THE PRICE OF TRUTH	BRITISH MEDICAL JOURNAL			English	Article																			0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1700	1705		10.1136/bmj.309.6970.1700	http://dx.doi.org/10.1136/bmj.309.6970.1700			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819994	Green Published			2022-12-28	WOS:A1994PY71700023
J	PAZIN, MJ; KAMAKAKA, RT; KADONAGA, JT				PAZIN, MJ; KAMAKAKA, RT; KADONAGA, JT			ATP-DEPENDENT NUCLEOSOME RECONFIGURATION AND TRANSCRIPTIONAL ACTIVATION FROM PREASSEMBLED CHROMATIN TEMPLATES	SCIENCE			English	Article							RNA POLYMERASE-II; GAL4 DERIVATIVES; DROSOPHILA EMBRYOS; DNA-REPLICATION; DISRUPTION; INVITRO; YEAST; GAL4-VP16; ANTIREPRESSION; MECHANISM	GAL4-VP16-mediated nucleosome reconfiguration and transcriptional activation were observed with preassembled chromatin templates that contained regular and physiological nucleosome spacing. Both processes were dependent on adenosine triphosphate (ATP), although binding of GAL4-VP16 to the chromatin was ATP-independent. Factor-mediated nucleosome reconfiguration was not, however, sufficient for transcriptional activation. These experiments recreate in vitro the active participation of nucleosomal cores in the regulation of transcription that occurs in vivo, and they suggest a multistep pathway for transcriptional activation in which factor- and ATP-dependent nucleosome reconfiguration is followed by facilitation by the DNA-bound activator of transcription from the repressed chromatin template.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR GENET MOLEC,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego			Kamakaka, Rohinton/K-3140-2019	Kamakaka, Rohinton/0000-0003-1931-7000; Pazin, Michael/0000-0002-7561-3640				AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; Bulger M., 1994, METH MOL G, V5, P241; BULGER MD, UNPUB; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CAVILLI G, 1993, EMBO J, V12, P4603; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; FEDOR MJ, 1989, MOL CELL BIOL, V9, P1721, DOI 10.1128/MCB.9.4.1721; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; GRALLA JD, 1985, P NATL ACAD SCI USA, V82, P3078, DOI 10.1073/pnas.82.10.3078; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; IMBALZANO AN, 1991, NATURE, V370, P481; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KAMAKAKA RT, 1991, P NATL ACAD SCI USA, V88, P1024, DOI 10.1073/pnas.88.3.1024; KAMAKAKA RT, 1994, METHOD CELL BIOL, V44, P225, DOI 10.1016/S0091-679X(08)60916-4; KAMAKAKA RT, UNPUB; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAYBOURN PJ, 1992, SCIENCE, V257, P1682, DOI 10.1126/science.1388287; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MORGAN JE, 1992, P NATL ACAD SCI USA, V89, P11622, DOI 10.1073/pnas.89.23.11622; MORSE RH, 1993, SCIENCE, V262, P1563, DOI 10.1126/science.8248805; NEDOSPASOV SA, 1980, BIOCHEM BIOPH RES CO, V92, P532, DOI 10.1016/0006-291X(80)90366-6; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PAZIN MJ, UNPUB; REIK A, 1991, EMBO J, V10, P2569, DOI 10.1002/j.1460-2075.1991.tb07797.x; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; WALLRATH LL, 1994, BIOESSAYS, V16, P165, DOI 10.1002/bies.950160306; WOLFFE AP, 1994, CURR OPIN GENET DEV, V4, P245, DOI 10.1016/S0959-437X(05)80051-6; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0	41	135	137	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					2007	2011		10.1126/science.7801129	http://dx.doi.org/10.1126/science.7801129			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801129				2022-12-28	WOS:A1994PZ26700034
J	BOSCH, X; SANS, M; MARTINEZOROZCO, F; URBANOMARQUEZ, A				BOSCH, X; SANS, M; MARTINEZOROZCO, F; URBANOMARQUEZ, A			PAROTITIS INDUCED BY CHLORMETHIAZOLE	BRITISH MEDICAL JOURNAL			English	Letter											BOSCH, X (corresponding author), HOSP CLIN BARCELONA,E-08036 BARCELONA,SPAIN.							BOSCH X, 1992, BRIT MED J, V304, P882, DOI 10.1136/bmj.304.6831.882-a; CHEN JH, 1977, JAMA-J AM MED ASSOC, V238, P1399, DOI 10.1001/jama.238.13.1399; DOLLERY C, 1991, THERAPEUTC DRUGS, V1, pC184; MARDH PA, 1974, ACTA MED SCAND, V195, P333; PELLINEN TJ, 1982, BRIT MED J, V285, P344, DOI 10.1136/bmj.285.6338.344	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1620	1620		10.1136/bmj.309.6969.1620b	http://dx.doi.org/10.1136/bmj.309.6969.1620b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819943	Green Published			2022-12-28	WOS:A1994PY22000024
J	ADLER, KP; BARONDESS, JA; COHEN, JJ; FARBER, SJ; FOREMAN, S; GAMBUTI, G; HAMBURG, M; KASE, NG; MESSITE, J; MICHELS, R; NEWMAN, RG; PARDES, H; PURPURA, DP; ROSENFIELD, A; ROWE, JW; SCHWARZ, RH; SKINNER, DB; SPECK, WT; TONKEL, JR				ADLER, KP; BARONDESS, JA; COHEN, JJ; FARBER, SJ; FOREMAN, S; GAMBUTI, G; HAMBURG, M; KASE, NG; MESSITE, J; MICHELS, R; NEWMAN, RG; PARDES, H; PURPURA, DP; ROSENFIELD, A; ROWE, JW; SCHWARZ, RH; SKINNER, DB; SPECK, WT; TONKEL, JR			FIREARM VIOLENCE AND PUBLIC-HEALTH - LIMITING THE AVAILABILITY OF GUNS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									NEW YORK ACAD MED,OFF PUBL HLTH,NEW YORK,NY 10029; NEW YORK MED COLL,VALHALLA,NY 10595; SUNY STONY BROOK,HLTH SCI CTR,COLL MED,STONY BROOK,NY 11794; NYU,SCH MED,NEW YORK,NY; MONTEFIORE MED CTR,BRONX,NY 10467; ST LUKES ROOSEVELT HOSP,NEW YORK,NY; NEW YORK CITY DEPT HLTH,NEW YORK,NY 10013; CUNY,MT SINAI SCH MED,NEW YORK,NY 10021; CORNELL UNIV,SCH MED,NEW YORK,NY 10021; BETH ISRAEL MED CTR,NEW YORK,NY 10003; COLUMBIA UNIV,COLL PHYS & SURG,NEW YORK,NY; ALBERT EINSTEIN COLL MED,BRONX,NY 10467; COLUMBIA UNIV,SCH PUBL HLTH,NEW YORK,NY; MT SINAI MED CTR,NEW YORK,NY 10029; SUNY HLTH SCI CTR,COLL MED,BROOKLYN,NY 11203; NEW YORK HOSP,NEW YORK,NY 10021; PRESBYTERIAN HOSP,NEW YORK,NY; ST VINCENTS HOSP & MED CTR,NEW YORK,NY 10011	New York Academy of Medicine; New York Medical College; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; New York University; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Mount Sinai St. Luke's; Mount Sinai West; New York City Department of Health & Mental Hygiene; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Cornell University; Harvard University; Beth Israel Deaconess Medical Center; Columbia University; Yeshiva University; Albert Einstein College of Medicine; Columbia University; Icahn School of Medicine at Mount Sinai; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; NewYork-Presbyterian Hospital; NewYork-Presbyterian Hospital; Saint Vincents Hospital Manhattan								Baker SP, 1992, THE INJURY FACT BOOK, V2nd; CALLAHAN CM, 1992, JAMA-J AM MED ASSOC, V267, P3038, DOI 10.1001/jama.267.22.3038; COOK PJ, 1993, AM J PREV MED, V9, P33, DOI 10.1016/S0749-3797(18)30676-7; FREEMAN LN, 1993, J AM ACAD CHILD PSY, V32, P419, DOI 10.1097/00004583-199303000-00025; KELLERMANN AL, 1992, NEW ENGL J MED, V327, P467, DOI 10.1056/NEJM199208133270705; KELLERMANN AL, 1993, NEW ENGL J MED, V329, P1084, DOI 10.1056/NEJM199310073291506; KOOP CE, 1992, JAMA-J AM MED ASSOC, V267, P3075, DOI 10.1001/jama.267.22.3075; MAX M, 1993, HLTH AFF, V12, P171; Rice DP, 1989, COST INJURY US REPOR; TERET SP, 1992, JAMA-J AM MED ASSOC, V267, P3073, DOI 10.1001/jama.267.22.3073; 1993, MMWR MORB MORTAL WKL, V42, P773; 1991, HOW MANY GUNS; 1994, WASHINGTON POST 0104, P8; 1993, 1992 FED BUR INV UN; 1994, MMWR MORB MORTAL WKL, V43, P37	15	27	27	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 27	1994	271	16					1281	1283		10.1001/jama.271.16.1281	http://dx.doi.org/10.1001/jama.271.16.1281			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NG362	7818630				2022-12-28	WOS:A1994NG36200030
J	MARTIN, K; TROUCHE, D; HAGEMEIER, C; SORENSEN, TS; LATHANGUE, NB; KOUZARIDES, T				MARTIN, K; TROUCHE, D; HAGEMEIER, C; SORENSEN, TS; LATHANGUE, NB; KOUZARIDES, T			STIMULATION OF E2F1/DP1 TRANSCRIPTIONAL ACTIVITY BY MDM2 ONCOPROTEIN	NATURE			English	Article							BINDING PROTEIN; RETINOBLASTOMA PROTEIN; ACTIVATION DOMAIN; GENE-PRODUCT; P53; TRANSACTIVATION; EXPRESSION; E2F-1; COMPLEX; FORMS	THE MDM2 proto-oncogene is found amplified in a variety of tumours(1). The oncogenic capacity of the MDM2 protein is attributed to its ability to bind the p53 tumour-suppressor protein and mask its transcriptional activation potential(2,3). Here we show that MDM2 makes a functional contact with two cooperating transcription factors, E2F1 and DP1 (refs 4, 5), which are involved in S-phase progression(6). MDM2 contacts the activation domain of E2F1 using residues conserved in the activation domain of p53. However, in contrast to its repression of p53 activity, MDM2 stimulates the activation capacity of E2F1/DP1. These results indicate that MDM2 not only releases a proliferative block by silencing the tumour suppressor p53, it also positively augments proliferation by stimulating the S-phase inducing transcription factors E2F1/DP1.	WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE,ENGLAND; NATL INST MED RES,MRC,LONDON NW7 1AA,ENGLAND	University of Cambridge; MRC National Institute for Medical Research			Trouche, Didier/B-2854-2008	Kouzarides, Tony/0000-0002-8918-4162; Trouche, Didier/0000-0003-1398-6481	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	22	446	466	1	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 22	1995	375	6533					691	694		10.1038/375691a0	http://dx.doi.org/10.1038/375691a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791903				2022-12-28	WOS:A1995RE57600063
J	GILSTRAP, LC; CHRISTENSEN, R; CLEWELL, WH; DALTON, ME; DAVIDSON, EC; ESCOBEDO, MB; GJERDINGEN, DK; GODDARDFINEGOLD, J; GOLDENBERG, RK; GRIMES, DA; HANSEN, TN; KAUFFMAN, RE; KEELER, EB; OH, W; SUSMAN, EJ; VOGEL, MG; AVERY, ME; BALLARD, PL; BALLARD, RA; CROWLEY, P; GARITE, T; GOLDENBERG, RL; HANKINS, GDV; JOBE, AH; KOPPE, JG; MAHER, JE; MERKATZ, IR; SHANKARAN, S; SIMPSON, KN; SINCLAIR, JC; SLOTKIN, TA; TAEUSCH, HW; WRIGHT, LL; ALEXANDER, D; BERBERICH, MA; BRACKEN, M; COOPER, L; CULPEPPER, L; ELLIOTT, JM; FERGUSON, JH; FRIGOLETTO, F; GAIL, DB; HALL, WH; JONES, MD; MEDOFFCOOPER, B; MERENSTEIN, GB; WHALEN, JM				GILSTRAP, LC; CHRISTENSEN, R; CLEWELL, WH; DALTON, ME; DAVIDSON, EC; ESCOBEDO, MB; GJERDINGEN, DK; GODDARDFINEGOLD, J; GOLDENBERG, RK; GRIMES, DA; HANSEN, TN; KAUFFMAN, RE; KEELER, EB; OH, W; SUSMAN, EJ; VOGEL, MG; AVERY, ME; BALLARD, PL; BALLARD, RA; CROWLEY, P; GARITE, T; GOLDENBERG, RL; HANKINS, GDV; JOBE, AH; KOPPE, JG; MAHER, JE; MERKATZ, IR; SHANKARAN, S; SIMPSON, KN; SINCLAIR, JC; SLOTKIN, TA; TAEUSCH, HW; WRIGHT, LL; ALEXANDER, D; BERBERICH, MA; BRACKEN, M; COOPER, L; CULPEPPER, L; ELLIOTT, JM; FERGUSON, JH; FRIGOLETTO, F; GAIL, DB; HALL, WH; JONES, MD; MEDOFFCOOPER, B; MERENSTEIN, GB; WHALEN, JM			EFFECT OF CORTICOSTEROIDS FOR FETAL MATURATION ON PERINATAL OUTCOMES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To develop a consensus on the use of antenatal corticosteroids for fetal maturation in preterm infants. Participants.-A nonfederal, nonadvocate, 16-member consensus panel including representatives from neonatology, obstetrics, family medicine, behavioral medicine, psychology, biostatistics, and the public; 19 experts in neonatology, obstetrics, and pharmacology presented data to the consensus panel and a conference audience of approximately 500. Evidence.-An extensive bibliography of references was produced for the consensus panel and the conference audience using a variety of on-line databases including MEDLINE. The consensus panel met several times prior to the conference to review the literature. It also commissioned an updated meta-analysis, a neonatal registry review, and an economic analysis that were presented at the conference. The experts prepared abstracts for distribution at the conference, presented data, and answered questions from the panel and audience. The panel evaluated the strength of the scientific evidence using the grading system developed by the Canadian Task Force on the Periodic Health Examination and adapted by the US Preventive Services Task Force, Consensus.-The consensus panel, answering predefined consensus questions, developed their conclusions based on the scientific evidence presented in open forum and the scientific literature. Consensus Statement.-The consensus panel composed a draft statement that was read in its entirety at the conference for comment. The panel released a revised statement at the end of the conference and finalized the revisions a few weeks after the conference. Conclusions.-Antenatal corticosteroid therapy is indicated for women at risk of premature delivery with few exceptions and will result in a substantial decrease in neonatal morbidity and mortality, as well as substantial savings in health care costs, The use of antenatal corticosteroids for fetal maturation is a rare example of a technology that yields substantial cost savings in addition to improving health.	UNIV FLORIDA,COLL MED,GAINESVILLE,FL; PHOENIX PERINATAL ASSOCIATES,DEPT MATERNAL FETAL MED,PHOENIX,AZ; TUFTS UNIV,NEW ENGLAND MED CTR,DEPT OBSTET & GYNECOL,BOSTON,MA 02111; MARTIN LUTHER KING JR CHARLES R DREW UNIV,LOS ANGELES,CA; UNIV TEXAS,HLTH SCI CTR,DIV NEONATOL,SAN ANTONIO,TX; UNIV MINNESOTA,DEPT FAMILY PRACTICE & COMMUNITY HLTH,ST PAUL,MN 55108; BAYLOR COLL MED,DEPT PEDIAT & PATHOL,DIV PEDIAT NEUROL,HOUSTON,TX 77030; UNIV ALABAMA,SCH MED,CTR OBSTET RES,BIRMINGHAM,AL; UNIV ALABAMA,SCH MED,DEPT OBSTET & GYNECOL,BIRMINGHAM,AL; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; WAYNE STATE UNIV,CHILDRENS HOSP MICHIGAN,DEPT PEDIAT & PHARMACOL,DETROIT,MI; RAND CORP,DEPT SOCIAL POLICY,SANTA MONICA,CA 90406; BROWN UNIV,WOMEN & INFANTS HOSP,SCH MED,DEPT PEDIAT,PROVIDENCE,RI; PENN STATE UNIV,BIOBEHAV HLTH PROGRAM,UNIVERSITY PK,PA 16802; SCH DIST HATBORO HORSHAM,ELKINS PK,PA; NICHHD,BETHESDA,MD 20892; UNIV PENN,SCH MED,DEPT PEDIAT,DIV NEONATOL,PHILADELPHIA,PA 19104; CHILDRENS HOSP PHILADELPHIA,PHILADELPHIA,PA 19104; NHLBI,DIV LUNG DIS,CELL & DEV BIOL BRANCH,BETHESDA,MD 20892; YALE UNIV,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT 06520; NINR,DIV EXTRAMURAL PROGRAMS,BETHESDA,MD; BROWN UNIV,MEM HOSP RHODE ISL,DEPT FAMILY MED,PAWTUCKET,RI 02860; NIH,OFF MED APPLICAT RES,BETHESDA,MD 20892; MASSACHUSETTS GEN HOSP,VINCENT MEM HOSP,DIV OBSTET,BOSTON,MA 02114; UNIV TEXAS,SW MED CTR,DEPT OBSTET & GYNECOL,DALLAS,TX 75235; UNIV CALIF LOS ANGELES,HARBOR MED CTR,SCH MED,WALTER P MARTIN RES CTR,TORRANCE,CA 90509; UNIV COLORADO,SCH MED,DEPT PEDIAT,DENVER,CO; CHILDRENS HOSP,DENVER,CO 80218; UNIV PENN,SCH NURSING,PHILADELPHIA,PA 19104; UNIV COLORADO,CHILDRENS HOSP,SCH MED,DEPT PEDIAT,DENVER,CO 80202; NICHHD,OFF SCI POLICY & ANAL,BETHESDA,MD 20892; NICHHD,CTR RES MOTHERS & CHILDREN,BETHESDA,MD 20892	State University System of Florida; University of Florida; Tufts Medical Center; Tufts University; Charles R. Drew University of Medicine & Science; University of Texas System; University of Texas Health San Antonio; University of Minnesota System; University of Minnesota Twin Cities; Baylor College of Medicine; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Baylor College of Medicine; Children's Hospital of Michigan; Wayne State University; RAND Corporation; Brown University; Women & Infants Hospital Rhode Island; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Yale University; National Institutes of Health (NIH) - USA; NIH National Institute of Nursing Research (NINR); Brown University; National Institutes of Health (NIH) - USA; Harvard University; Massachusetts General Hospital; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Children's Hospital Colorado; University of Pennsylvania; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	GILSTRAP, LC (corresponding author), UNIV TEXAS,SW MED CTR,DEPT OBSTET & GYNECOL,DALLAS,TX 75235, USA.		Hansen, Thomas/GWZ-2858-2022; Maher, James/H-3342-2017	Maher, James/0000-0002-6226-4082					0	713	732	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	1995	273	5					413	418		10.1001/jama.1995.03520290065031	http://dx.doi.org/10.1001/jama.1995.03520290065031			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD203	7823388				2022-12-28	WOS:A1995QD20300027
J	FORREST, D				FORREST, D			PATTERNS OF ABUSE IN SIKH ASYLUM-SEEKERS	LANCET			English	Note								Many slates practise or condone torture to control dissident groups in their population. Most techniques used and the resulting injuries are common to all cultures. 31 male Sikh asylum-seekers, examined between December, 1991, and May, 1994, showed a pattern of abuse that included features particular to their region of origin. All gave a persuasive history of serious abuse and ail showed long-term mental and physical effects that could be convincingly attributed to their experiences.			FORREST, D (corresponding author), MED FDN CARE VICTIMS TORTURE,96-98 GRAFTON RD,LONDON NW5 3EJ,ENGLAND.							MALIK GH, 1993, NEPHRON, V63, P434, DOI 10.1159/000187248; 1992, MED BETRAYAL; 1994, DEAD SILENCE LEGACY; 1992, ASA200692 AMN INT; 1991, ASA201191 AMN INT	5	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 28	1995	345	8944					225	226		10.1016/S0140-6736(95)90225-2	http://dx.doi.org/10.1016/S0140-6736(95)90225-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QD532	7823716				2022-12-28	WOS:A1995QD53200011
J	KEMPIN, SA; SAVIDGE, B; YANOFSKY, MF				KEMPIN, SA; SAVIDGE, B; YANOFSKY, MF			MOLECULAR-BASIS OF THE CAULIFLOWER PHENOTYPE IN ARABIDOPSIS	SCIENCE			English	Article							HOMEOTIC GENE; FLOWER DEVELOPMENT; INFLORESCENCE DEVELOPMENT; THALIANA; APETALA1; LEAFY	Genetic studies demonstrate that two Arabidopsis genes, CAULIFLOWER and APETALA1, encode partially redundant activities involved in the formation of floral meristems, the first step in the development of flowers. Isolation of the CAULIFLOWER gene from Arabidopsis reveals that it is closely related in sequence to APETALA1. Like APETALA1, CAULIFLOWER is expressed in young flower primordia and encodes a MADS-domain, indicating that it may function as a transcription factor. Analysis of the cultivated garden variety of cauliflower (Brassica oleracea var. botrytis) reveals that its CAULIFLOWER gene homolog is not functional, suggesting a molecular basis for one of the oldest recognized flower abnormalities.	UNIV CALIF SAN DIEGO,DEPT BIOL,SAN DIEGO,CA; UNIV CALIF SAN DIEGO,CTR GENET MOLEC,SAN DIEGO,CA	University of California System; University of California San Diego; University of California System; University of California San Diego					NIGMS NIH HHS [GM07313] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOWMAN JL, 1993, DEVELOPMENT, V119, P721; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; GUSTAFSONBROWN C, 1994, CELL, V76, P131, DOI 10.1016/0092-8674(94)90178-3; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MANDEL M, UNPUB; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; RIETER RS, 1992, P NATL ACAD SCI USA, V89, P1477; SADIK S, 1962, AM J BOT, V49, P290, DOI 10.2307/2439552; SAVIDGE B, UNPUB; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SHANNON S, 1993, PLANT CELL, V5, P639, DOI 10.1105/tpc.5.6.639; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WILLIAMS PH, 1986, SCIENCE, V232, P1385, DOI 10.1126/science.232.4756.1385; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0; YARNELL SH, 1956, BOT REV, V22, P81, DOI 10.1007/BF02872468	20	393	437	2	82	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 27	1995	267	5197					522	525		10.1126/science.7824951	http://dx.doi.org/10.1126/science.7824951			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD403	7824951				2022-12-28	WOS:A1995QD40300041
J	LEVINSON, W				LEVINSON, W			WORK MAY BE GOOD MEDICINE	LANCET			English	Editorial Material							ACADEMIC MEDICINE				LEVINSON, W (corresponding author), LEGACY GOOD SAMARITAN HOSP,DEPT MED,PORTLAND,OR 97209, USA.							FEIN OT, 1991, ACAD MED, V66, P694, DOI 10.1097/00001888-199111000-00014; LEVINSON W, 1993, ANN INTERN MED, V119, P220, DOI 10.7326/0003-4819-119-3-199308010-00008; LEVINSON W, 1989, NEW ENGL J MED, V321, P1511, DOI 10.1056/NEJM198911303212205; MASON NA, 1991, AM J HOSP PHARM, V48, P85, DOI 10.1093/ajhp/48.1.85; NASSAR S, 1994, NY TIMES        1201; OLSEN A, 1994, PEDIATRICS, V94, P363; Wheeler R, 1990, J Am Med Womens Assoc (1972), V45, P47	7	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					140	141		10.1016/S0140-6736(95)90161-2	http://dx.doi.org/10.1016/S0140-6736(95)90161-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7823665				2022-12-28	WOS:A1995QC55000004
J	COHEN, JJ				COHEN, JJ			ACADEMIC MEDICINE - FACING CHANGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											COHEN, JJ (corresponding author), ASSOC AMER MED COLL,2450 N ST NW,WASHINGTON,DC 20057, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					245	246						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB234	7807670				2022-12-28	WOS:A1995QB23400035
J	TRACEY, KJ				TRACEY, KJ			TNF AND WEST,MAE OR - DEATH FROM TOO MUCH OF A GOOD THING	LANCET			English	Editorial Material							TUMOR-NECROSIS-FACTOR; PLASMODIUM-FALCIPARUM; FACTOR-ALPHA; CACHECTIN; SHOCK; INTERLEUKIN-1; INFECTION; RECEPTOR; MALARIA; SERUM		PICOWER INST MED RES,MANHASSET,NY	Northwell Health	TRACEY, KJ (corresponding author), N SHORE UNIV HOSP,DEPT SURG,BIOMED SCI LAB,MANHASSET,NY 11030, USA.							BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; CLARK IA, 1992, LANCET, V340, P894, DOI 10.1016/0140-6736(92)93295-X; GIRARDIN E, 1988, NEW ENGL J MED, V319, P397, DOI 10.1056/NEJM198808183190703; JACOB CO, 1990, P NATL ACAD SCI USA, V87, P1233, DOI 10.1073/pnas.87.3.1233; KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5; MARANO MA, 1990, SURG GYNECOL OBSTET, V170, P32; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; MOLVIG J, 1988, SCAND J IMMUNOL, V27, P705, DOI 10.1111/j.1365-3083.1988.tb02404.x; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PICOT F, 1993, EUR J IMMUNOL, V23, P224; Tracey K.J., 1992, TUMOR NECROSIS FACTO, P255; TRACEY KJ, 1989, LANCET, V1, P1122; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; WILSON AG, 1994, BR J RHEUMATOL S1, V33, P89	15	33	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					75	76		10.1016/S0140-6736(95)90055-1	http://dx.doi.org/10.1016/S0140-6736(95)90055-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815882				2022-12-28	WOS:A1995QB80400002
J	HARWOOD, AJ; PLYTE, SE; WOODGETT, J; STRUTT, H; KAY, RR				HARWOOD, AJ; PLYTE, SE; WOODGETT, J; STRUTT, H; KAY, RR			GLYCOGEN-SYNTHASE KINASE-3 REGULATES CELL FATE IN DICTYOSTELIUM	CELL			English	Article							CYCLIC-AMP; GENE-EXPRESSION; STALK-CELL; PRESTALK CELLS; DISCOIDEUM; DIFFERENTIATION; INDUCTION; PRESPORE; PHOSPHORYLATION; TRANSFORMATION	Extracellular cyclic AMP (cAMP) induces the formation of prespore cells in Dictyostelium but inhibits stalk cell formation. We have cloned gskA, which encodes the Dictyostelium homolog of glycogen synthase kinase 3 (GSK-3), and discovered that it is required for both cAMP effects. Disruption of gskA creates a mutant that aggregates but forms few spores and an abnormally high number of stalk cells. These stalk cells probably arise from an expanded prestalk B (pstB) cell population, which normally produces the basal disc of the fruiting body. In cultured mutant cells, cAMP neither inhibits pstB cell differentiation nor induces efficient prespore cell differentiation. We propose that cAMP acts through a common pathway that requires GSK-3 and determines the proportion of prespore and pstB cells.	PRINCESS MARGARET HOSP,ONTARIO CANC INST,TORONTO,ON M4X 1K9,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	HARWOOD, AJ (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Harwood, Adrian/A-4350-2010; Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797; Strutt, Helen/0000-0003-4365-2271; Kay, Robert R/0000-0001-9836-7967; Harwood, Adrian/0000-0003-3124-5169				BARKLIS E, 1983, CELL, V32, P1139, DOI 10.1016/0092-8674(83)90297-0; BERKS M, 1988, DEV BIOL, V126, P108, DOI 10.1016/0012-1606(88)90244-8; BERKS M, 1990, DEVELOPMENT, V110, P977; BIANCHI MW, 1993, GENE, V134, P51, DOI 10.1016/0378-1119(93)90173-Z; BIANCHI MW, 1994, MOL GEN GENET, V242, P337, DOI 10.1007/BF00280424; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CECCARELLI A, 1991, CELL, V65, P983, DOI 10.1016/0092-8674(91)90550-I; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DEGROOT RP, 1993, ONCOGENE, V8, P841; DIAZBENJUMEE F, 1994, GENE, V85, P353; EARLY AE, 1987, GENE, V59, P99, DOI 10.1016/0378-1119(87)90270-8; EARLY AE, 1988, DEVELOPMENT, V103, P519; EARLY AE, 1993, DEVELOPMENT, V118, P353; HANKS S, 1991, METHOD ENZYMOL, V300, P38; HARLOW E, 1988, ANTIBODIES LABORATOR; HARWOOD AJ, 1991, DIFFERENTIATION, V46, P7, DOI 10.1111/j.1432-0436.1991.tb00860.x; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; JERMYN KA, 1991, DEVELOPMENT, V111, P779; JERMYN KA, 1989, NATURE, V340, P144, DOI 10.1038/340144a0; JOLY E, 1993, TRENDS GENET, V9, P157, DOI 10.1016/0168-9525(93)90152-8; KAY RR, 1992, BIOCHEM J, V281, P155, DOI 10.1042/bj2810155; KAY RR, 1978, NATURE, V271, P58, DOI 10.1038/271058a0; KAY RR, 1983, NATURE, V303, P242, DOI 10.1038/303242a0; KAY RR, 1989, DEVELOPMENT, V105, P753; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; KOPACHIK WJ, 1985, DIFFERENTIATION, V28, P209, DOI 10.1111/j.1432-0436.1985.tb00827.x; KUSPA A, 1992, P NATL ACAD SCI USA, V89, P8803, DOI 10.1073/pnas.89.18.8803; MANN SKO, 1987, MOL CELL BIOL, V7, P458, DOI 10.1128/MCB.7.1.458; MEHDY MC, 1983, CELL, V32, P763, DOI 10.1016/0092-8674(83)90062-4; MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0; NELLEN W, 1984, MOL CELL BIOL, V4, P2890, DOI 10.1128/MCB.4.12.2890; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; PUZISS JW, 1994, MOL CELL BIOL, V14, P831, DOI 10.1128/MCB.14.1.831; SAXE CL, 1991, DEV GENET, V12, P6, DOI 10.1002/dvg.1020120104; SCHAAP P, 1986, DEV BIOL, V118, P52, DOI 10.1016/0012-1606(86)90072-2; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1990, NATURE, V354, P825; SIMPSON P, 1993, DEVELOPMENT, P29; STERNFELD J, 1982, DEV BIOL, V93, P111, DOI 10.1016/0012-1606(82)90244-5; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; THEISEN H, 1994, DEVELOPMENT, V120, P347; TOWN CD, 1976, NATURE, V262, P717, DOI 10.1038/262717a0; WILLIAMS JG, 1989, CELL, V59, P1157, DOI 10.1016/0092-8674(89)90771-X; WILLIAMS JG, 1987, CELL, V49, P185, DOI 10.1016/0092-8674(87)90559-9; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x	49	180	188	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					139	148		10.1016/0092-8674(95)90458-1	http://dx.doi.org/10.1016/0092-8674(95)90458-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813009	Bronze			2022-12-28	WOS:A1995QB91000017
J	RAMACHANDRAN, VS; COBB, S				RAMACHANDRAN, VS; COBB, S			VISUAL-ATTENTION MODULATES METACONTRAST MASKING	NATURE			English	Article							MOTION PERCEPTION; CORTEX	HOW does the human visual system 'bind' different fragments in the visual scene to create enduring representations of objects(1-5)? A visual illusion known as 'metacontrast'(6-9) or backward masking provides compelling evidence that perception is not instantaneous and that it occurs sequentially in distinct stages, If a solid white target square is displayed for 50 ms in a tachistoscope, switched off, and followed by a 50 ms display of two flanking mask squares, remarkably, subjects report seeing only the two flanking squares: the first square is simply not 'seen'. By plotting the magnitude of masking as a function of the delay between the target and mask (the stimulus onset asynchrony), one can obtain a characteristic 'U'-shaped function(7) with optimum masking occurring at about 50 ms, and no masking with synchronous target and mask presentations or at delays higher than 300 ms. The illusion is also highly sensitive to elementary stimulus dimensions such as colour, orientation and spatial frequency(8), and it has been suggested(10) that it is based on 'low level' autonomous visual mechanisms rather than cognitive processes, Here we describe a novel visual stimulus that demonstrates that metacontrast can be strongly modulated by 'top down' influences such as voluntary visual attention.			RAMACHANDRAN, VS (corresponding author), UNIV CALIF SAN DIEGO,CTR RES BRAIN & COGNIT,BRAIN & PERCEPT LAB,0109,LA JOLLA,CA 92093, USA.							BREITMEYER BG, 1977, VISION RES, V17, P861, DOI 10.1016/0042-6989(77)90130-4; CAVANAGH P, 1992, SCIENCE, V257, P1563, DOI 10.1126/science.1523411; COBB S, 1994, SOC NEUR ABSTR, V20, P1667; Crick F., 1990, Seminars in the Neurosciences, V2, P263; DAMASIO AR, 1990, COLD SH Q B, V55, P1039; Dennett D.C., 1991, CONSCIOUSNESS EXPLAI; DILOLLO V, 1993, PSYCHOL SCI, V4, P260, DOI 10.1111/j.1467-9280.1993.tb00272.x; FINKEL LH, 1994, AM SCI, V82, P224; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; KAHNEMAN D, 1968, PSYCHOL BULL, V62, P404; LOGOTHETIS NK, 1989, SCIENCE, V245, P761, DOI 10.1126/science.2772635; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; RAMACHANDRAN VS, 1983, NATURE, V304, P529, DOI 10.1038/304529a0; RAMACHANDRAN VS, 1986, SCI AM, V254, P102, DOI 10.1038/scientificamerican0686-102; Stigler R, 1910, PFLUG ARCH GES PHYS, V134, P365, DOI 10.1007/BF01680352; TREISMAN A, 1986, SCI AM, V225, P114; WILLIAMS MC, 1991, VISION RES, V31, P2017, DOI 10.1016/0042-6989(91)90196-C	17	107	107	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 5	1995	373	6509					66	68		10.1038/373066a0	http://dx.doi.org/10.1038/373066a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800040				2022-12-28	WOS:A1995QA23900056
J	WYATT, JP				WYATT, JP			SQUIRREL BITES	BRITISH MEDICAL JOURNAL			English	Article											WYATT, JP (corresponding author), ROYAL HOSP SICK CHILDREN,EDINBURGH EH9 1LF,MIDLOTHIAN,SCOTLAND.							BRACKENBURY PH, 1989, ARCH EMERG MED, V6, P251; LAWTON J, 1990, NATURE, V343, P595, DOI 10.1038/343595a0; MAGEE JS, 1989, PEDIATR INFECT DIS J, V8, P123; RUSSO PK, 1981, NEW ENGL J MED, V304, P1166, DOI 10.1056/NEJM198105073041911	4	6	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1694	1694		10.1136/bmj.309.6970.1694	http://dx.doi.org/10.1136/bmj.309.6970.1694			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819992	Green Published			2022-12-28	WOS:A1994PY71700018
J	HANAWALT, PC				HANAWALT, PC			TRANSCRIPTION-COUPLED REPAIR AND HUMAN-DISEASE	SCIENCE			English	Editorial Material							DNA-REPAIR; COCKAYNES-SYNDROME; EXCISION-REPAIR; ACTIVE GENE; XERODERMA-PIGMENTOSUM; PREFERENTIAL REPAIR; DHFR GENE; STRAND; REMOVAL; DAMAGE				HANAWALT, PC (corresponding author), STANFORD UNIV,DEPT SCI BIOL,STANFORD,CA 94305, USA.							BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; BOYCE RP, 1964, P NATL ACAD SCI USA, V51, P293, DOI 10.1073/pnas.51.2.293; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; DELBRUCK M., 1949, TRANS CONNECTICUT ACAD ARTS SCI, V38, P173; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; HANAWALT P, 1993, CURR BIOL, V3, P67, DOI 10.1016/0960-9822(93)90156-I; HANAWALT PC, 1994, CURR BIOL, V4, P518, DOI 10.1016/S0960-9822(00)00112-3; KOROGODIN VI, 1991, YEAST, V7, P105, DOI 10.1002/yea.320070204; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; LEHMANN AR, 1979, CANCER RES, V39, P4237; LIU B, 1993, NATURE, V366, P33, DOI 10.1038/366033a0; MAYNE L, 1982, CANCER RES, V42, P473; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MOUNKES LC, 1992, CELL, V71, P925, DOI 10.1016/0092-8674(92)90389-T; PETTIJOHN DE, 1964, J MOL BIOL, V9, P395, DOI 10.1016/S0022-2836(64)80216-3; Qui H., 1993, GENE DEV, V7, P2161; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SATOH MS, 1993, P NATL ACAD SCI USA, V90, P6335, DOI 10.1073/pnas.90.13.6335; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1990, J BIOL CHEM, V265, P21330; SETLOW RB, 1964, P NATL ACAD SCI USA, V51, P226, DOI 10.1073/pnas.51.2.226; SWEDER KS, 1994, J BIOL CHEM, V269, P1852; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707	31	454	461	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					1957	1958		10.1126/science.7801121	http://dx.doi.org/10.1126/science.7801121			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801121				2022-12-28	WOS:A1994PZ26700020
J	SLOGGETT, A; JOSHI, H				SLOGGETT, A; JOSHI, H			HIGHER MORTALITY IN DEPRIVED AREAS - COMMUNITY OR PERSONAL DISADVANTAGE	BRITISH MEDICAL JOURNAL			English	Article							DEPRIVATION	Objective-To investigate the association between level of social deprivation in electoral wards and premature mortality among residents, before and after allowing for levels of personal deprivation. Design-Longitudinal study of the Office of Population Censuses and Surveys. Setting-England. Subjects-Random sample of nearly 300 000 people aged between 16 and 65 at the 1981 census and followed up for nearly nine years. Main outcome measure-Death from all causes between ages of 16 and 70. Results-Without allowance for personal disadvantage, both sexes showed a clear, significant, and roughly linear positive relation between degree of deprivation of the ward of residence in 1981 and premature death before 1990. For men, this association was effectively explained away once allowance was made for individual socioeconomic circumstances. For women living in wards of above average deprivation, the association was also effectively removed, but the situation for other women was less clear. Conclusion-The excess mortality associated with residence in areas designated as deprived by census based indicators is wholly explained by the concentration in those areas of people with adverse personal or household socioeconomic factors. Health policy needs to target people as well as places.	CITY UNIV LONDON,LONDON EC1V 0HB,ENGLAND	City University London	SLOGGETT, A (corresponding author), LONDON SCH HYG & TROP MED,CTR POPULAT STUDIES,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 6AZ,ENGLAND.							ARBER S, 1989, HLTH INEQUALITIES EU, P250; CARSTAIRS V, 1989, COMMUNITY MED, V11, P210, DOI 10.1093/oxfordjournals.pubmed.a042469; DAVIES H, IN PRESS J ROYAL STA; EAMES M, 1993, BRIT MED J, V307, P1097, DOI 10.1136/bmj.307.6912.1097; GOLDBLATT P, 1990, LONGITUDINAL STUD LS, V6, P67; GOLDBLATT P, 1990, LONGITUDINAL STUD LS, V6, P164; HAAN M, 1987, AM J EPIDEMIOL, V125, P989, DOI 10.1093/oxfordjournals.aje.a114637; Holtermann S., 1975, SOCIAL TRENDS, V6, P33; MORRIS R, 1991, J PUBLIC HEALTH MED, V13, P318; SLOGGETT A, 1994, ENV POPULATION CHANG, P393; TOWNSEND P, 1989, HLTH DEPRIVATION; WEATHERALL R, 1992, COMP MORTALITY MEASU; WETHERALL R, 1994, SOC SCI MED, V38, P285; 1989, MORTALITY STATISTICS	14	273	275	0	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 3	1994	309	6967					1470	1474		10.1136/bmj.309.6967.1470	http://dx.doi.org/10.1136/bmj.309.6967.1470			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PW053	7804047	Green Published			2022-12-28	WOS:A1994PW05300018
J	MULLINS, PD; CHOUDHURY, SL				MULLINS, PD; CHOUDHURY, SL			ENALAPRIL AND BULLOUS ERUPTIONS	BRITISH MEDICAL JOURNAL			English	Letter							CAPTOPRIL				MULLINS, PD (corresponding author), COUNTESS CHESTER HOSP,CHESTER CH2 1BQ,CHESHIRE,ENGLAND.							GAVRAS I, 1983, ANN INTERN MED, V98, P556, DOI 10.7326/0003-4819-98-4-556_2; MANN RD, 1987, ADVERSE DRUG REACT, P5; SHELTON RM, 1991, J AM ACAD DERMATOL, V24, P503, DOI 10.1016/S0190-9622(08)80079-5; WILKIN JK, 1980, ARCH DERMATOL, V116, P902; WILLIAMS GH, 1988, NEW ENGL J MED, V319, P1517	5	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1994	309	6966					1411	1411		10.1136/bmj.309.6966.1411a	http://dx.doi.org/10.1136/bmj.309.6966.1411a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7819851	Green Published			2022-12-28	WOS:A1994PU76400025
J	ALLEN, K; BLASCOVICH, J				ALLEN, K; BLASCOVICH, J			EFFECTS OF MUSIC ON CARDIOVASCULAR REACTIVITY AMONG SURGEONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							RESPONSES; STRESS	Objective.-To determine the effects of surgeon-selected and experimenter-selected music on performance and autonomic responses of surgeons during a standard laboratory psychological stressor. Design.-Within-subjects laboratory experiment. Setting.-Hospital psychophysiology laboratory. Participants.-A total of 50 male surgeons aged 31 to 61 years, who reported that they typically listen to music during surgery, volunteered for the study. Main Outcome Measurements.-Cardiac responses, hemodynamic measures, electrodermal autonomic responses, task speed, and accuracy. Results.-Autonomic reactivity for all physiological measures was significantly less in the surgeon-selected music condition than in the experimenter-selected music condition, which in turn was significantly less than in the no-music control condition. Likewise, speed and accuracy of task performance were significantly better in the surgeon-selected music condition than in the experimenter-selected music condition, which was also significantly better than the no-music control condition. Conclusion.-Surgeon-selected music was associated with reduced autonomic reactivity and improved performance of a stressful nonsurgical laboratory task in study participants.	SUNY BUFFALO,DEPT PSYCHOL,AMHERST,NY	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	ALLEN, K (corresponding author), SUNY BUFFALO,CTR STUDY BIOBEHAV & SOCIAL ASPECTS HLTH,PK HALL,AMHERST,NY 14260, USA.							ALLEN KM, 1991, J PERS SOC PSYCHOL, V61, P582, DOI 10.1037/0022-3514.61.4.582; ALLEN MT, 1987, PSYCHOPHYSIOLOGY, V24, P648, DOI 10.1111/j.1469-8986.1987.tb00345.x; BARGER DA, 1979, J MUSIC THER, V16, P158, DOI 10.1093/jmt/16.4.158; Beck S L, 1991, Oncol Nurs Forum, V18, P1327; BLASCOVICH J, 1992, J PERS SOC PSYCHOL, V63, P164, DOI 10.1037/0022-3514.63.1.164; BLASCOVICH J, 1993, J PERS SOC PSYCHOL, V64, P165, DOI 10.1037/0022-3514.64.2.165; CHETTA HD, 1981, J MUSIC THER, V18, P74, DOI 10.1093/jmt/18.2.74; DAINOW E, 1977, J RES MUSIC EDUC, V25, P211, DOI 10.2307/3345305; DAVISROLLINS C, 1987, HEART LUNG, V19, P29; DEGOOD DE, 1976, BIOFEEDBACK SELF-REG, V1, P373; GUZZETTA CE, 1989, HEART LUNG, V18, P606; Heitz L, 1992, J Post Anesth Nurs, V7, P22; Katkin E. S., 1993, CARDIOVASCULAR REACT; KELSEY RM, 1991, PSYCHOPHYSIOLOGY, V28, P619, DOI 10.1111/j.1469-8986.1991.tb01005.x; LANDRETH JE, 1974, J RES MUSIC EDUC, V22, P4, DOI 10.2307/3344613; LEVY O, 1964, TWILIGHT IDOLS, V16, P6; LOCSIN RGRAC, 1981, J ADV NURS, V6, P19, DOI 10.1111/j.1365-2648.1981.tb03091.x; MATTHEWS KA, 1986, HDB STRESS REACTIVIT; ORNSTEIN R, 1989, HLTH PLEASURES; OYAMA T, 1987, MUSIK MED MUSIC MED, P223; PERETTI PO, 1975, J PSYCHOL, V89, P183, DOI 10.1080/00223980.1975.9915750; PERETTI PO, 1974, J RES MUSIC EDUC, V22, P278, DOI 10.2307/3344765; RAUSCHER FH, 1993, NATURE, V365, P6; SHAPIRO AG, 1987, MUSIK MED, P227; SIFER KJ, 1991, AJR AM J ROENTGENOL, V156, P403; STEVENS K, 1990, J ADV NURS, V15, P1045, DOI 10.1111/j.1365-2648.1990.tb01985.x; STOUDENMIRE J, 1975, J CLIN PSYCHOL, V31, P490, DOI 10.1002/1097-4679(197507)31:3<490::AID-JCLP2270310328>3.0.CO;2-E; TANIOKA F, 1987, MUSIK MED, P199; Thayer J., 1983, PSYCHOMUSICOLOGY, V3, P44, DOI DOI 10.1037/H0094256; TOMAKA J, 1993, J PERS SOC PSYCHOL, V65, P248, DOI 10.1037/0022-3514.65.2.248; TOMAKA J, 1992, PERS SOC PSYCHOL B, V18, P616, DOI 10.1177/0146167292185012; Turner J., 1992, INDIVIDUAL DIFFERENC; UPDIKE PA, 1987, ANN PLAS SURG, V19, P29, DOI 10.1097/00000637-198707000-00004; WEBSTER C, 1973, AUST OCCUP THER J, V20, P9; Whipple B, 1992, Sch Inq Nurs Pract, V6, P43; ZIMNY GH, 1963, AM J PSYCHOL, V76, P311, DOI 10.2307/1419170	36	120	120	1	27	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 21	1994	272	11					882	884		10.1001/jama.272.11.882	http://dx.doi.org/10.1001/jama.272.11.882			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PG182	7811324				2022-12-28	WOS:A1994PG18200028
J	PATEL, P; MENDALL, MA; KHULUSI, S; MOLINEAUX, N; LEVY, J; MAXWELL, JD; NORTHFIELD, TC				PATEL, P; MENDALL, MA; KHULUSI, S; MOLINEAUX, N; LEVY, J; MAXWELL, JD; NORTHFIELD, TC			SALIVARY ANTIBODIES TO HELICOBACTER-PYLORI - SCREENING DYSPEPTIC PATIENTS BEFORE ENDOSCOPY	LANCET			English	Note								Diagnostic tests on saliva have advantages compared with those on serum. In 119 consecutive dyspeptic patients referred for endoscopy we developed and validated an enzyme-linked immunosorbent assay to detect salivary immunoglobulins to Helicobacter pylori. Salivary IgG distinguished positive and negative cases (p < 0.0001), but salivary IgA did not. The optimum performance of salivary IgG (85%) was similar to that of serum IgG (90%) and better than that of salivary IgA. Using our assay and a history of regular use of non-steroidal anti-inflammatories in screening patients under 45 years, we detected all peptic ulcers while saving 39% of endoscopies.	UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT MED,LONDON SW17 0RE,ENGLAND	St Georges University London								ALEMOHAMMAD MM, 1993, J CLIN MICROBIOL, V31, P2174, DOI 10.1128/JCM.31.8.2174-2177.1993; HOLDSTOCK G, 1979, BRIT MED J, V1, P457, DOI 10.1136/bmj.1.6161.457; MARSHALL BJ, 1984, LANCET, V1, P1311; MENDALL MA, 1992, EUR J GASTROEN HEPAT, V4, P713; PARRY JV, 1987, LANCET, V2, P72, DOI 10.1016/S0140-6736(87)92737-1; PATEL P, 1993, GUT, V34, pS36; RATHBONE BJ, 1986, GUT, V27, P642, DOI 10.1136/gut.27.6.642; WILLIAMS B, 1988, LANCET, V2, P1349; 1993, LANCET, V341, P1359; 1988, LANCET, V1, P576	10	95	96	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 20	1994	344	8921					511	512		10.1016/S0140-6736(94)91899-6	http://dx.doi.org/10.1016/S0140-6736(94)91899-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7802777				2022-12-28	WOS:A1994PC53500010
J	BENOWITZ, NL; HENNINGFIELD, JE				BENOWITZ, NL; HENNINGFIELD, JE			ESTABLISHING A NICOTINE THRESHOLD FOR ADDICTION - THE IMPLICATIONS FOR TOBACCO REGULATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CIGARETTE-SMOKING; CARBON-MONOXIDE; TAR; YIELDS; EXPOSURE; BIOAVAILABILITY; SMOKERS		UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94110; NATL INST DRUG ABUSE,BALTIMORE,MD 21224	University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)					NIDA NIH HHS [DA01696, DA02277] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA002277, P50DA001696, R01DA002277] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		[Anonymous], 1994, PREVENTING TOBACCO U; BENOWITZ NL, 1982, CLIN PHARMACOL THER, V32, P758, DOI 10.1038/clpt.1982.233; BENOWITZ NL, 1983, NEW ENGL J MED, V309, P139, DOI 10.1056/NEJM198307213090303; BENOWITZ NL, 1984, CLIN PHARMACOL THER, V35, P499, DOI 10.1038/clpt.1984.67; BENOWITZ NL, 1986, NEW ENGL J MED, V315, P1310, DOI 10.1056/NEJM198611203152102; BENOWITZ NL, 1991, CLIN PHARMACOL THER, V49, P270, DOI 10.1038/clpt.1991.28; BENOWITZ NL, IN PRESS CLIN PHARM; COULTAS DB, 1993, AM REV RESPIR DIS, V148, P435, DOI 10.1164/ajrccm/148.2.435; FIORE MC, 1992, MED CLIN N AM, V76, P289, DOI 10.1016/S0025-7125(16)30354-6; GORI GB, 1985, REGUL TOXICOL PHARM, V5, P314, DOI 10.1016/0273-2300(85)90045-5; GUYATT AR, 1989, PSYCHOPHARMACOLOGY, V99, P80, DOI 10.1007/BF00634457; HENNINGFIELD JE, 1990, BRIT J ADDICT, V85, P279; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; ROBINSON JH, 1992, PSYCHOPHARMACOLOGY, V108, P466, DOI 10.1007/BF02247423; ROBINSON JH, 1992, PSYCHOPHARMACOLOGY, V108, P397, DOI 10.1007/BF02247412; RUSSELL MAH, 1976, BRIT MED J, V1, P1430, DOI 10.1136/bmj.1.6023.1430; RUSSELL MAH, 1982, BRIT J ADDICT, V77, P145; SHIFFMAN S, 1989, PSYCHOPHARMACOLOGY, V97, P539, DOI 10.1007/BF00439561; SHIFFMAN S, 1990, ARCH GEN PSYCHIAT, V47, P333; STEPNEY R, 1980, BRIT J ADDICT, V75, P81; 1988, DHHS PHS CDC888406 P	21	378	387	0	28	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 14	1994	331	2					123	125		10.1056/NEJM199407143310212	http://dx.doi.org/10.1056/NEJM199407143310212			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NW712	7818638				2022-12-28	WOS:A1994NW71200012
J	ROBERTS, RJ; SANDIFER, QD; EVANS, MR; NOLANFARRELL, MZ; DAVIS, PM				ROBERTS, RJ; SANDIFER, QD; EVANS, MR; NOLANFARRELL, MZ; DAVIS, PM			REASONS FOR NON-UPTAKE OF MEASLES, MUMPS, AND RUBELLA CATCH-UP IMMUNIZATION IN A MEASLES EPIDEMIC AND SIDE-EFFECTS OF THE VACCINE	BRITISH MEDICAL JOURNAL			English	Article							IMMUNIZATION; CHILDREN; OUTBREAK; TRANSMISSION; POPULATION; COLLEGE	Objectives-To investigate the reasons for poor uptake of immunisation (non-immunisation) and the possible side effects of measles, mumps, and rubella vaccine in a catch up immunisation campaign during a community outbreak of measles. Design-Descriptive study of reasons for non-immunisation and retrospective cohort study of side effects of the vaccine. Setting-Secondary schools in South Glamorgan. Subjects-Random cluster sample of the parents of 500 children targeted but not immunised and a randomised sample of 2866 of the children targeted. Main outcome measures-Reasons for non-immunisation; symptoms among immunised and non-immunised children. Results-Immunisation coverage of the campaign was only 43.4% (7633/17 595). The practical problems experienced included non-return of consent forms (6698/17 595), refusal of immunisation (2061/10 897 forms returned), and absence from school on day of immunisation (1203/8836 children with consent for immunisation). The most common reasons cited for non-immunisation were previous measles infection (145/232), previous immunisation against measles (78/232), and concern about side effects (55/232). Symptoms were equally common among immunised and non-immunised subjects. However, significantly more immunised boys than non-immunised boys reported fever (relative risk 2.31 (95% confidence interval 1.36 to 3.93)), rash (2.00 (1.10 to 3.64), joint symptoms (1.58; 1.05 to 2.38), and headache (1.31 (1.04 to 1.65)). Conclusions-Many of the objections raised by parents could be overcome by emphasising that primary immunisation does not necessarily confer immunity and that diagnosis of measles is unreliable. Measles, mumps, and rubella vaccine is safe in children aged 11-15.	S GLAMORGAN HLTH AUTHOR,DEPT PUBL HLTH MED,CARDIFF CF1 3NW,S GLAM,WALES; LANSDOWNE HOSP,CARDIFF COMMUNITY HLTH CARE,CARDIFF CF1 8UL,S GLAM,WALES		ROBERTS, RJ (corresponding author), CTR COMMUNICABLE DIS SURVEILLANCE,PUBL HLTH LAB SERV,WELSH UNIT,ABTON HOUSE,CARDIFF CF4 3QX,S GLAM,WALES.		Morgan, Maria/D-3379-2009; Evans, Meirion/C-2990-2008	Evans, Meirion/0000-0003-3578-1866; Morgan, Maria/0000-0002-5182-7222				BARRETT G, 1993, BRIT MED J, V307, P681, DOI 10.1136/bmj.307.6905.681-b; BAXTER DN, 1990, PUBLIC HEALTH, V104, P267, DOI 10.1016/S0033-3506(05)80476-7; BENJAMIN CM, 1992, BMJ-BRIT MED J, V304, P1075, DOI 10.1136/bmj.304.6834.1075; BROWN DWG, 1994, BRIT MED J, V308, P1015, DOI 10.1136/bmj.308.6935.1015; Calvert N, 1994, Commun Dis Rep CDR Rev, V4, pR70; CHEN RT, 1991, VACCINE, V9, P297, DOI 10.1016/0264-410X(91)90053-9; CHEN RT, 1989, AM J EPIDEMIOL, V129, P173, DOI 10.1093/oxfordjournals.aje.a115106; Dean A. G., 1990, EPI INFO VERSION 5 W; GUSTAFSON TL, 1987, NEW ENGL J MED, V316, P771, DOI 10.1056/NEJM198703263161303; HERSH BS, 1991, AM J PUBLIC HEALTH, V81, P360, DOI 10.2105/AJPH.81.3.360; HULL D, 1987, J ROY COLL PHYS LOND, V21, P28; KLEIN N, 1989, BRIT MED J, V298, P1687, DOI 10.1136/bmj.298.6689.1687; LI J, 1993, BRIT MED J, V307, P168, DOI 10.1136/bmj.307.6897.168; LOCHHEAD YJ, 1991, J ADV NURS, V16, P130, DOI 10.1111/j.1365-2648.1991.tb01616.x; LYONS R, IN PRESS EPIDEMIOL I; MARKOWITZ LE, 1989, NEW ENGL J MED, V320, P75, DOI 10.1056/NEJM198901123200202; MILLER C, 1989, PRACTITIONER, V223, P69; MORGANCAPNER P, 1988, BRIT MED J, V297, P770, DOI 10.1136/bmj.297.6651.770; PELTOLA H, 1986, LANCET, V1, P939; Richardson J A, 1994, Commun Dis Rep CDR Rev, V4, pR73; SEAGER C, 1994, VACCINE, V82, P1018; SPRUANCE SL, 1977, ARTHRITIS RHEUM, V20, P741, DOI 10.1002/art.1780200216; 1994, COMMUN DIS REP CDR W, V4, P147; 1980, MMWR-MORBID MORTAL W, V29, P549; 1994, INFECTIOUS DISEASES	25	39	39	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 24	1995	310	6995					1629	1632		10.1136/bmj.310.6995.1629	http://dx.doi.org/10.1136/bmj.310.6995.1629			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF698	7795447	Green Published			2022-12-28	WOS:A1995RF69800017
J	SOMMERVILLE, A				SOMMERVILLE, A			REMEMBRANCE OF CONVERSATIONS PAST - ORAL ADVANCE STATEMENTS ABOUT MEDICAL-TREATMENT	BRITISH MEDICAL JOURNAL			English	Article								Polls show increasing public interest in advance statements or directives about medical treatment (''living wills'') but that few people, apart from Jehovah's Witnesses, carry such documents. Patients' firm, witnessed oral decisions are often sufficient to aid clinical decision making but should still be recorded in medical notes. Without documentation, dilemmas arise when others claim to know patients' views on the basis of past unrecorded conversations and demand withdrawal of treatment when patients are not terminally ill and cannot speak for themselves. Legal and ethical considerations oblige doctors to act in the best interests of an incapacitated patient; these considerations are now formally defined in draft legislation as including consideration of the patient's past wishes. The practicalities of ascertaining the strength and validity of such wishes from conversations reported second hand are complex. The paucity of legal and ethical guidance on reported oral advance statements makes debate imperative and renders the alternative of having designated surrogate decision makers increasingly attractive.			SOMMERVILLE, A (corresponding author), BRITISH MED ASSOC,DEPT ETH AUDIT & CAREER DEV,BMA HOUSE,TAVISTOCK SQ,LONDON WC1H 9JP,ENGLAND.							[Anonymous], 1995, ADV STATEMENTS MED T; Gostin L, 1991, Law Med Health Care, V19, P9; HERR SS, 1994, JAMA-J AM MED ASSOC, V271, P1017, DOI 10.1001/jama.271.13.1017; SCHNEIDERMAN LJ, 1992, ANN INTERN MED, V117, P599, DOI 10.7326/0003-4819-117-7-599; 1995, 231 LAW COMM DOC	5	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 24	1995	310	6995					1663	1665						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF698	7795460				2022-12-28	WOS:A1995RF69800036
J	BARTEL, B; FINK, GR				BARTEL, B; FINK, GR			ILR1, AN AMIDOHYDROLASE THAT RELEASES ACTIVE INDOLE-3-ACETIC-ACID FROM CONJUGATES	SCIENCE			English	Article							ARABIDOPSIS-THALIANA; RESISTANT MUTANTS; AUXIN; TISSUES; CLONING; GROWTH; YEAST	In plants, the growth regulator indole-3-acetic acid (IAA) is found both free and conjugated to a variety of amino acids, peptides, and carbohydrates. IAA conjugated to leucine has effects in Arabidopsis thaliana similar to those of free IAA. The ilr1 mutant is insensitive to exogenous IAA-Leu and was used to positionally clone the Arabidopsis ILR1 gene. ILR1 encodes a 48-kilodalton protein that cleaves IAA-amino acid conjugates in vitro and is homologous to bacterial amidohydrolase enzymes. DNA sequences similar to that of ILR1 are found in other plant species.	MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)			Bartel, Bonnie/O-8119-2019; Bartel, Bonnie/D-3550-2011	Bartel, Bonnie/0000-0002-6367-346X; Bartel, Bonnie/0000-0002-6367-346X				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BARTEL B, UNPUB; BEDNAREK SY, 1992, PLANT MOL BIOL, V20, P133, DOI 10.1007/BF00029156; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; BIALEK K, 1983, PLANT PHYSIOL, V73, P130, DOI 10.1104/pp.73.1.130; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; COHEN JD, 1982, ANNU REV PLANT PHYS, V33, P403, DOI 10.1146/annurev.pp.33.060182.002155; COHEN JD, 1988, BIOMECHANISMS REGULA, P229; Davies P. J., 1987, PLANT HORMONES THEIR; ESTELLE MA, 1987, MOL GEN GENET, V206, P200, DOI 10.1007/BF00333575; HANI EK, 1995, J BACTERIOL, V177, P2396, DOI 10.1128/jb.177.9.2396-2402.1995; HAUGHN GW, 1986, MOL GEN GENET, V204, P430, DOI 10.1007/BF00331020; HERMANSON GG, 1991, NUCLEIC ACIDS RES, V19, P4943, DOI 10.1093/nar/19.18.4943; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; JAKUBOWSKA A, 1993, J PLANT PHYSIOL, V142, P61, DOI 10.1016/S0176-1617(11)80108-2; Koncz C., 1992, METHODS ARABIDOPSIS; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; LIU CM, 1993, PLANT CELL, V5, P621, DOI 10.1105/tpc.5.6.621; MAHER EP, 1980, BIOCHEM GENET, V18, P1041, DOI 10.1007/BF00484337; MINET M, 1992, PLANT J, V2, P417; NORMANLY J, 1993, P NATL ACAD SCI USA, V90, P10355, DOI 10.1073/pnas.90.21.10355; SAKANYAN V, 1993, APPL ENVIRON MICROB, V59, P3878, DOI 10.1128/AEM.59.11.3878-3888.1993; STASINOPOULOS TC, 1990, PLANT PHYSIOL, V93, P1365, DOI 10.1104/pp.93.4.1365; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SZERSZEN JB, 1994, SCIENCE, V265, P1699, DOI 10.1126/science.8085154; WILSON AK, 1990, MOL GEN GENET, V222, P377, DOI 10.1007/BF00633843	26	196	200	5	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 23	1995	268	5218					1745	1748		10.1126/science.7792599	http://dx.doi.org/10.1126/science.7792599			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792599				2022-12-28	WOS:A1995RE66800041
J	SUDHOF, TC				SUDHOF, TC			THE SYNAPTIC VESICLE CYCLE - A CASCADE OF PROTEIN-PROTEIN INTERACTIONS	NATURE			English	Review							FROG NEUROMUSCULAR-JUNCTION; LONG-TERM POTENTIATION; SERIAL ELECTRON-MICROSCOPY; BRAIN COATED VESICLES; SYNAPSIN-I; TRANSMITTER RELEASE; CAENORHABDITIS-ELEGANS; BIOPHYSICAL CHARACTERISTICS; BUNDLING PROTEIN; DENDRITIC SPINES	The synaptic vesicle cycle at the nerve terminal consists of vesicle exocytosis with neurotransmitter release, endocytosis of empty vesicles, and regeneration of fresh vesicles. Of all cellular transport pathways, the synaptic vesicle cycle is the fastest and the most tightly regulated. A convergence of results now allows formulation of molecular models for key steps of the cycle. These developments may form the basis for a mechanistic understanding of higher neural function.	UNIV TEXAS,HLTH SCI CTR,SW MED SCH,HOWARD HUGHES MED INST,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	SUDHOF, TC (corresponding author), UNIV TEXAS,HLTH SCI CTR,SW MED SCH,DEPT MOLEC GENET,DALLAS,TX 75235, USA.							ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; Akert K., 1972, P67; ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BAINES AJ, 1986, NATURE, V319, P145, DOI 10.1038/319145a0; BAINES AJ, 1985, NATURE, V315, P410, DOI 10.1038/315410a0; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; CALAKOS N, 1994, J BIOL CHEM, V269, P24534; CECCARELLI B, 1980, J CELL BIOL, V87, P297, DOI 10.1083/jcb.87.1.297; CECCARELLI B, 1980, PHYSIOL REV, V60, P396, DOI 10.1152/physrev.1980.60.2.396; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DANTONIO A, 1994, NEURON, V12, P909; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DAVIETOV BA, 1994, J BIOL CHEM, V269, P28547; DAVIETOV BA, 1993, J BIOL CHEM, V268, P26386; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; DREYER F, 1983, BRAIN RES, V270, P373, DOI 10.1016/0006-8993(83)90617-0; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GREENGARD P, 1987, MOL NEUROBIOL, V1, P81, DOI 10.1007/BF02935265; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HARRIS KM, 1989, J NEUROSCI, V9, P2982; HARRIS KM, 1988, J NEUROSCI, V8, P4455; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HILLBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; HOSONO R, 1987, J NEUROCHEM, V49, P1820, DOI 10.1111/j.1471-4159.1987.tb02442.x; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; INUI M, 1994, J NEUROCHEM, V63, P1917; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; JOHNSTON PA, 1990, J BIOL CHEM, V265, P8869; Katz B., 1969, RELEASE NEURAL TRANS; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; KOENIG JH, 1989, J NEUROSCI, V9, P3844; KOH S, 1993, J NEUROCYTOL, V22, P995, DOI 10.1007/BF01218356; LACEY ML, 1992, J BIOL CHEM, V267, P4793; LANDIS DMD, 1988, NEURON, V1, P201, DOI 10.1016/0896-6273(88)90140-7; LAWRENCE GW, 1994, EUR J BIOCHEM, V222, P325, DOI 10.1111/j.1432-1033.1994.tb18871.x; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LIMBACH JA, 1994, NEURON, V13, P899; LINDNER R, 1992, J BIOL CHEM, V267, P16567; LITTLETON JT, 1994, P NATL ACAD SCI USA, V91, P10888, DOI 10.1073/pnas.91.23.10888; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; LLINAS R, 1991, J PHYSIOL-LONDON, V463, P257; LLOYD DPC, 1960, HDB PHYSL 1, V2, P929; MAGAZANIK LG, 1992, NEUROSCIENCE, V46, P181, DOI 10.1016/0306-4522(92)90017-V; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MAYCOX PR, 1992, J CELL BIOL; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MILLER TM, 1984, J CELL BIOL, V98, P685, DOI 10.1083/jcb.98.2.685; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; MULLER KJ, 1974, J PHYSIOL-LONDON, V238, P357, DOI 10.1113/jphysiol.1974.sp010529; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PETRENKO AG, 1991, NATURE, V351, P411; PETRUCCI TC, 1987, J CELL BIOL, V105, P1355, DOI 10.1083/jcb.105.3.1355; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PFEFFER SR, 1985, CELL, V40, P949, DOI 10.1016/0092-8674(85)90355-1; RASTAAD M, 1992, EUR J NEUROSCI, V4, P113; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; ROTHMAN JE, 1986, CELL, V46, P5, DOI 10.1016/0092-8674(86)90852-4; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; SCHAEFFER E, 1994, P NATL ACAD SCI USA, V91, P3882, DOI 10.1073/pnas.91.9.3882; SCHIAVO G, 1994, ANN NY ACAD SCI, V710, P65, DOI 10.1111/j.1749-6632.1994.tb26614.x; SCHULZE KL, 1995, CELL, V80, P311, DOI 10.1016/0092-8674(95)90414-X; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; SENG ZH, 1994, NEURON, V13, P1303; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V363, P318; STAHL B, 1994, J BIOL CHEM, V269, P24770; STEINER JP, 1987, J BIOL CHEM, V262, P905; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; SUDHOF TC, 1993, CELL, V75, P1; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; SUDHOF TC, 1991, NEURON, V6, P146; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; THOMAS P, 1994, J CELL BIOL, V124, P667, DOI 10.1083/jcb.124.5.667; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; ULLRICH U, 1994, NEURON, V13, P1281; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USUKURA J, 1987, CELL TISSUE RES, V247, P483, DOI 10.1007/BF00215740; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VONGERSDORFF H, 1994, NATURE, V370, P652, DOI 10.1038/370652a0; VONMOLLARD GF, 1994, J BIOL CHEM, V269, P10971; VONMOLLARD GF, 1994, EUR J CELL BIOL, V65, P319; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; WEISSKOPF MG, 1993, NATURE, V362, P423, DOI 10.1038/362423a0; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WICKELGREN WO, 1985, J NEUROSCI, V5, P1188; YOSHIDA A, 1992, J BIOL CHEM, V267, P25925; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	119	1753	1784	2	216	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 22	1995	375	6533					645	653		10.1038/375645a0	http://dx.doi.org/10.1038/375645a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791897				2022-12-28	WOS:A1995RE57600050
J	XIAO, ZX; CHEN, JD; LEVINE, AJ; MODJTAHEDI, N; XING, J; SELLERS, WR; LIVINGSTON, DM				XIAO, ZX; CHEN, JD; LEVINE, AJ; MODJTAHEDI, N; XING, J; SELLERS, WR; LIVINGSTON, DM			INTERACTION BETWEEN THE RETINOBLASTOMA PROTEIN AND THE ONCOPROTEIN MDM2	NATURE			English	Article							GENE-PRODUCT; TRANSCRIPTION FACTOR; GROWTH SUPPRESSION; COMPLEX-FORMATION; P53; TRANSACTIVATION; IDENTIFICATION; AMPLIFICATION; EXPRESSION; REPRESSION	INACTIVATION of tumour-suppressor genes leads to deregulated cell proliferation and is a key factor in human tumorigenesis. Both p53 and retinoblastoma genes are frequently mutated in human cancers(1,2), and the simultaneous inactivation of RB and p53 is frequently observed in a variety of naturally occurring human tumours(3). Furthermore, three distinct DNA tumour virus groups papovaviruses, adenoviruses and human papillomaviruses-transform cells by targeting and inactivating certain functions of both the p53 and retinoblastoma proteins(1,2). The cellular oncoprotein, Mdm2, binds to and downmodulates p53 function(4-6); its human homologue, MDM2, is amplified in certain human tumours, including sarcomas(7-9) and gliomas(10). Overproduction of Mdm2 is both tumorigenic(4) and capable of immortalizing primary rat embryo fibroblasts(11). Here we show that MDM2 interacts physically and functionally with pRB and, as with p53, inhibits pRB growth regulatory function. Therefore, both pRB and p53 can be subjected to negative regulation by the product of a single cellular proto-oncogene.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Harvard University; Harvard Medical School; Princeton University	XIAO, ZX (corresponding author), DANA FARBER CANC INST,BOSTON,MA 02115, USA.		MODJTAHEDI, Nazanine/D-4377-2017					CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CORDONCARDO C, 1994, CANCER RES, V54, P794; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; HAMEL PA, 1992, ONCOGENE, V7, P693; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LEACH FS, 1993, CANCER RES, V53, P2231; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; WEINBERG R, 1993, NEURON, V11, P191, DOI 10.1016/0896-6273(93)90177-S; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	30	548	568	1	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 22	1995	375	6533					694	698		10.1038/375694a0	http://dx.doi.org/10.1038/375694a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791904				2022-12-28	WOS:A1995RE57600064
J	FEAGAN, BG; ROCHON, J; FEDORAK, RN; IRVINE, EJ; WILD, G; SUTHERLAND, L; STEINHART, AH; GREENBERG, GR; GILLIES, R; HOPKINS, M; HANAUER, SB; MCDONALD, JWD				FEAGAN, BG; ROCHON, J; FEDORAK, RN; IRVINE, EJ; WILD, G; SUTHERLAND, L; STEINHART, AH; GREENBERG, GR; GILLIES, R; HOPKINS, M; HANAUER, SB; MCDONALD, JWD			METHOTREXATE FOR THE TREATMENT OF CROHNS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFLAMMATORY BOWEL-DISEASE; LOW-DOSE METHOTREXATE; RHEUMATOID-ARTHRITIS; INDUCED OSTEOPOROSIS; DRUG-TREATMENT; ACTIVITY INDEX; DOUBLE-BLIND; THERAPY; TRIAL; MANAGEMENT	Background. Although corticosteroids are highly effective in improving symptoms of Crohn's disease, they may have substantial toxicity. In some patients, attempts to discontinue corticosteroids are unsuccessful. Methods. We conducted a double-blind, placebo-controlled multicenter study of weekly injections of methotrexate in patients who had chronically active Crohn's disease despite a minimum of three months of prednisone therapy. Patients were randomly assigned to treatment with intramuscular methotrexate (25 mg once weekly) or placebo for 16 weeks. The patients also received prednisone (20 mg once a day), which was tapered over a period of 10 weeks unless their condition worsened. The primary outcome measure was clinical remission at the end of the 16-week trial. Remission was defined by the discontinuation of prednisone and a score of less than or equal to 150 points on the Crohn's Disease Activity Index. Results. A total of 141 patients were randomly assigned in a 2:1 ratio to methotrexate (94 patients) or placebo (47 patients). After 16 weeks, 37 patients (39.4 percent) were in clinical remission in the methotrexate group, as compared with 9 patients (19.1 percent) in the placebo group (P=0.025; relative risk, 1.95; 95 percent confidence interval, 1.09 to 3.48). The patients in the methotrexate group received less prednisone overall than those in the placebo group (P=0.026). The mean (+/-SE) score on the Crohn's Disease Activity Index after 16 weeks of treatment was significantly lower in the methotrexate group (162+/-12) than in the placebo group (204+/-17, P=0.002). The changes in quality-of-life scores and serum orosomucoid concentrations were similar. In the methotrexate group, 16 patients (17 percent) withdrew from treatment because of adverse events (including asymptomatic elevation of serum aminotransferase in 7 and nausea in 6), as compared with 1 patient (2 percent) in the placebo group. Conclusions, In a group of patients with chronically active Crohn's disease, methotrexate was more effective than placebo in improving symptoms and reducing requirements for prednisone.	UNIV CALGARY,DEPT MED,DIV GASTROENTEROL,CALGARY,AB,CANADA; UNIV CHICAGO,DEPT MED,GASTROENTEROL SECT,CHICAGO,IL 60637; UNIV ALBERTA,DEPT MED,DIV GASTROENTEROL,EDMONTON,AB,CANADA; MCMASTER UNIV,DEPT MED,DIV GASTROENTEROL,HAMILTON,ON,CANADA; UNIV WESTERN ONTARIO,DEPT MED,LONDON,ON,CANADA; UNIV WESTERN ONTARIO,DEPT BIOSTAT & EPIDEMIOL,LONDON,ON,CANADA; MCGILL UNIV,DEPT MED,DIV GASTROENTEROL,MONTREAL,PQ,CANADA; UNIV TORONTO,DEPT MED,DIV GASTROENTEROL,TORONTO,ON,CANADA; UNIV OTTAWA,FAC MED,OTTAWA,ON,CANADA	University of Calgary; University of Chicago; University of Alberta; McMaster University; Western University (University of Western Ontario); Western University (University of Western Ontario); McGill University; University of Toronto; University of Ottawa			Feagan, Brian/G-3292-2011; Feagan, Brian G/M-4283-2015; Greenberg, Gordon/C-4620-2015	Fedorak, Richard/0000-0002-7382-0080				ADACHI JD, 1993, SEMIN ARTHRITIS RHEU, V22, P375, DOI 10.1016/S0049-0172(05)80029-0; ALAWADHI A, 1993, J RHEUMATOL, V20, P1121; BEST WR, 1979, GASTROENTEROLOGY, V77, P843; BEST WR, 1976, GASTROENTEROLOGY, V70, P439; BINDER V, 1985, GUT, V26, P146, DOI 10.1136/gut.26.2.146; BLACK RL, 1964, JAMA-J AM MED ASSOC, V189, P743; BRICK JE, 1989, SEMIN ARTHRITIS RHEU, V19, P31, DOI 10.1016/0049-0172(89)90085-1; BRYNSKOV J, 1989, NEW ENGL J MED, V321, P845, DOI 10.1056/NEJM198909283211301; CALDWELL JR, 1991, SEMIN ARTHRITIS RHEU, V21, P1, DOI 10.1016/0049-0172(91)90051-Z; FEAGAN BG, 1994, NEW ENGL J MED, V330, P1846, DOI 10.1056/NEJM199406303302602; GREENBERG GR, 1994, NEW ENGL J MED, V331, P836, DOI 10.1056/NEJM199409293311303; GUYATT G, 1989, GASTROENTEROLOGY, V96, P804, DOI 10.1016/0016-5085(89)90905-0; IRVINE EJ, 1994, GASTROENTEROLOGY, V106, P287, DOI 10.1016/0016-5085(94)90585-1; JENNRICH RI, 1986, BIOMETRICS, V42, P805, DOI 10.2307/2530695; JEWELL DP, 1994, EUR J GASTROEN HEPAT, V6, P499, DOI 10.1097/00042737-199406000-00009; JOHANSSON BA, 1992, DOC OPHTHALMOL, V79, P91, DOI 10.1007/BF00160135; KLIPPEL JH, 1985, NEW ENGL J MED, V312, P853, DOI 10.1056/NEJM198503283121310; KOZAREK RA, 1989, ANN INTERN MED, V110, P353, DOI 10.7326/0003-4819-110-5-353; KOZLOWSKI RD, 1990, AM J MED, V88, P589, DOI 10.1016/0002-9343(90)90522-F; KREMER JM, 1994, ARTHRITIS RHEUM-US, V37, P316, DOI 10.1002/art.1780370304; LEWIS JH, 1988, AM J GASTROENTEROL, V83, P1337; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; MALCHOW H, 1984, GASTROENTEROLOGY, V86, P249; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; PRESENT DH, 1989, ANN INTERN MED, V111, P641, DOI 10.7326/0003-4819-111-8-641; SACHAR DB, 1994, NEW ENGL J MED, V331, P873, DOI 10.1056/NEJM199409293311311; SEARLES G, 1987, J RHEUMATOL, V14, P1164; SINGLETON JW, 1979, GASTROENTEROLOGY, V77, P870; SINGLETON JW, 1993, GASTROENTEROLOGY, V104, P1293, DOI 10.1016/0016-5085(93)90337-C; STURDEVANT RAL, 1979, GASTROENTEROLOGY, V77, P883; SUMMERS RW, 1979, GASTROENTEROLOGY, V77, P847; TRIPATHI RC, 1992, GASTROENTEROLOGY, V102, P1957, DOI 10.1016/0016-5085(92)90319-T; WEINBLATT ME, 1985, NEW ENGL J MED, V312, P818, DOI 10.1056/NEJM198503283121303; WHITINGOKEEFE QE, 1991, AM J MED, V90, P711; WILLKENS RF, 1984, ARTHRITIS RHEUM-US, V27, P376, DOI 10.1002/art.1780270403; WRIGHT JP, 1987, DIGEST DIS SCI, V32, P164, DOI 10.1007/BF01297104; 1991, ALPHA1 ACID GLYCOPRO; 1990, SAS PROCEDURES GUIDE	38	738	761	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 2	1995	332	5					292	297		10.1056/NEJM199502023320503	http://dx.doi.org/10.1056/NEJM199502023320503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD396	7816064				2022-12-28	WOS:A1995QD39600003
J	LEE, HH; CHERNESKY, MA; SCHACHTER, J; BURCZAK, JD; ANDREWS, WW; MULDOON, S; LECKIE, G; STAMM, WE				LEE, HH; CHERNESKY, MA; SCHACHTER, J; BURCZAK, JD; ANDREWS, WW; MULDOON, S; LECKIE, G; STAMM, WE			DIAGNOSIS OF CHLAMYDIA-TRACHOMATIS GENITOURINARY INFECTION IN WOMEN BY LIGASE CHAIN-REACTION ASSAY OF URINE	LANCET			English	Article							SPECIMENS; MEN; ANTIGENS; SAMPLES; PLASMID; SWABS	Genitourinary infection with Chlamydia trachomatis is a common and potentially serious sexually transmitted disease. Diagnosis of C trachomatis infection in women relies on culture of endocervical swabs, an and expensive procedure. The ligase chain reaction (LCR) is an in-vitro nucleic acid amplification technique that exponentially amplifies selected DNA sequences. We have compared an LCR-based assay to detect C trachomatis plasmid DNA in first void urine with culture of endocervical swabs for matched specimens from 1937 women from four geographic regions. Discordant specimen pairs were further tested by direct fluorescent antibody staining for elementary bodies and an alternative LCR assay based on the chlamydial outer membrane protein gene. An ''expanded gold standard'' was defined to include all culture-positive as well as culture-negative, confirmed LCR-positive women. The sensitivity and specificity of the LCR assay with first void urine samples compared with the expanded gold standard were 93.8% and 99.9%, respectively; the corresponding Values for culture were 65.0% and 100%, respectively. Thus, an automated LCR assay of readily obtained urine samples showed a detection rate for infected women almost 30% greater than that of endocervical swab culture. The LCR assay was highly effective for the detection of C trachomatis in urine from women with or without signs or symptoms of chlamydial genitourinary tract infection.	MCMASTER UNIV, ST JOSEPHS HOSP, REG VIROL & CHLAMYDIOL LAB, HAMILTON, ON, CANADA; UNIV CALIF SAN FRANCISCO, DEPT LAB MED, SAN FRANCISCO, CA 94143 USA; UNIV ALABAMA, DEPT OBSTET & GYNECOL, BIRMINGHAM, AL 35294 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA USA	McGill University; McMaster University; University of California System; University of California San Francisco; University of Alabama System; University of Alabama Birmingham; University of Washington; University of Washington Seattle	LEE, HH (corresponding author), ABBOTT LABS, ABBOTT PK, IL 60064 USA.							BAUWENS JE, 1993, J CLIN MICROBIOL, V31, P3013, DOI 10.1128/JCM.31.11.3013-3016.1993; BLYTH MJ, 1988, J PEDIATR, V122, P1000; BRADLEY MG, 1985, GENITOURIN MED, V61, P371; BURCZAK JD, 1993, 6TH EUR C CLIN MICR; CHERNESKY M, 1990, J INFECT DIS, V161, P124; CHERNESKY MA, 1994, J CLIN MICROBIOL, V32, P2682, DOI 10.1128/JCM.32.11.2682-2685.1994; CHERNESKY MA, 1994, J INFECT DIS, V170, P1308, DOI 10.1093/infdis/170.5.1308; DILLE BJ, 1993, J CLIN MICROBIOL, V31, P729, DOI 10.1128/JCM.31.3.729-731.1993; HINKELMAN RM, 1990, MED DECIS MAKING, V10, P24; JANG D, 1992, SEX TRANSM DIS, V19, P315, DOI 10.1097/00007435-199211000-00003; JOHANNISSON G, 1989, OBSTET GYNECOL, V56, P671; JONES RB, 1986, J CLIN MICROBIOL, V24, P1029, DOI 10.1128/JCM.24.6.1029-1033.1986; LARSEN JH, 1986, EUR J CLIN MICROBIOL, V5, P554, DOI 10.1007/BF02017704; MAHONY JB, 1992, J CLIN MICROBIOL, V30, P2241, DOI 10.1128/JCM.30.9.2241-2245.1992; MAHONY JB, 1985, J CLIN MICROBIOL, V22, P865, DOI 10.1128/JCM.22.5.865-867.1985; MORRIS RE, 1993, SEX TRANSM DIS, V20, P198, DOI 10.1097/00007435-199307000-00004; PAAVONEN J, 1982, SCAND J INFECT DIS, P45; PALMER L, 1986, PLASMID, V16, P52, DOI 10.1016/0147-619X(86)90079-X; PETERSON EM, 1990, PLASMID, V23, P144, DOI 10.1016/0147-619X(90)90033-9; QUINN TC, 1990, CHLAMYDIAL INFECTION, P491; SCHACHTER J, 1989, NEW ENGL J MED, V320, P802, DOI 10.1056/NEJM198903233201210; SCHACHTER J, 1990, WESTERN J MED, V153, P523; SCHACHTER J, 1994, J CLIN MICROBIOL, V32, P2540, DOI 10.1128/JCM.32.10.2540-2543.1994; SCHACHTER J, 1988, DIAGN MICROBIOL INFE, V4, P185; SELLORS JW, 1991, J INFECT DIS, V164, P205, DOI 10.1093/infdis/164.1.205; SMITH TF, 1975, J CLIN MICROBIOL, V2, P134; STAMM WE, 1988, ANN INTERN MED, V108, P210; SVENSSON LO, 1991, GENITOURIN MED, V67, P117; TAM MR, 1984, NEW ENGL J MED, V310, P1146, DOI 10.1056/NEJM198405033101803; WALLIN JE, 1981, BRIT J VENER DIS, V57, P50	30	301	309	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 28	1995	345	8944					213	216		10.1016/S0140-6736(95)90221-X	http://dx.doi.org/10.1016/S0140-6736(95)90221-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7823713				2022-12-28	WOS:A1995QD53200007
J	BOZZETTE, SA; KANOUSE, DE; BERRY, S; DUAN, NH				BOZZETTE, SA; KANOUSE, DE; BERRY, S; DUAN, NH			HEALTH-STATUS AND FUNCTION WITH ZIDOVUDINE OR ZALCITABINE AS INITIAL THERAPY FOR AIDS - A RANDOMIZED CONTROLLED TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLACEBO-CONTROLLED TRIAL; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; QUALITY-OF-LIFE; MEDICAL OUTCOMES; HIV-INFECTION; ANTIHYPERTENSIVE THERAPY; AZIDOTHYMIDINE AZT; VIRUS INFECTION; DOUBLE-BLIND; PHASE-I	Objective.-To evaluate the functional and health status implications of prescribing zalcitabine or zidovudine for initial therapy of acquired immunodeficiency syndrome (AIDS). Design.-A substudy of a randomized controlled trial. Setting.-Private and public clinics and referral centers. Patients.-Had human immunodeficiency virus (HIV) infection, less than 0.20x10(9)/L (200 mu L) CD4(+) cells, and either a history of Pneumocystis carinii pneumonia or symptoms of HIV infection. Fifty-eight percent (338/668) of main study enrollees representing 90% of enrollees at participating sites were included in this substudy. Interventions.-Either zalcitabine at 0.75 mg every 8 hours plus inactive capsules identical in appearance to zidovudine or zidovudine at 200 mg (later 100 mg) every 4 hours plus inactive tablets identical in appearance to zalcitabine. Main Outcome Measures.-Results of a periodically completed self-report survey instrument containing specific questions about symptom impact, disability, work, functioning, and utilization as well as nine health and functioning scales adapted from the Medical Outcomes Study (MOS). Results.-Zalcitabine recipients were twice as likely to undergo an invasive procedure (P=.004) or be admitted to hospital(P=.01). Zalcitabine recipients reported greater than 40% more symptoms that interfered with activity (P=.001) and greater than 50% more disability days (P<.01). They also had a 7% lower employment rate and a 35% lower monthly income, Average observed health status scores were lower in zalcitabine recipients overall, but especially in the early portion of the study. New methods for combining survival and health status data showed that, over 76 weeks of study, a typical zidovudine recipient spent about 4 (10%) more weeks with at least the typical health state than did a typical zalcitabine recipient. Conclusions.-Zidovudine has substantial advantages over zalcitabine in initial monotherapy of AIDS in terms of functional outcomes such as symptom impact, disability, work, utilization, and health status. In this case, the differences in functional outcomes presaged differences in physiological and clinical measures. The inclusion of functional outcomes can greatly improve the information available from a clinical trial.	UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92103; VET AFFAIRS MED CTR,LA JOLLA,CA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	BOZZETTE, SA (corresponding author), RAND CORP,HLTH SCI PROGRAM,1700 MAIN ST,SANTA MONICA,CA 90407, USA.			Duan, Naihua/0000-0001-9411-2924	NIAID NIH HHS [AI-95030, AI-27670] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027670, N01AI095030] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMS DI, 1994, NEW ENGL J MED, V330, P657, DOI 10.1056/NEJM199403103301001; BERRY SH, 1994, RAND MR342NIAID PUBL; BOZZETTE SA, 1994, MED CARE, V32, P716, DOI 10.1097/00005650-199407000-00005; BOZZETTE SA, 1994, PSYCHOL HEALTH, V9, P143, DOI 10.1080/08870449408407465; BOZZETTE SA, 1991, 7 INT C AIDS FLOR; BOZZETTE SA, IN PRESS J ACQUIR IM; CHOI SS, 1993, ANN INTERN MED, V118, P674, DOI 10.7326/0003-4819-118-9-199305010-00003; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; CUNNINGHAM BE, IN PRESS MED CARE; Duan N., 1983, J BUS STAT, V1, P115, DOI DOI 10.2307/1391852; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; Fisher RA, 1935, DESIGN EXPT; GELBER RD, 1986, J CLIN ONCOL, V4, P1772, DOI 10.1200/JCO.1986.4.12.1772; Hays R D, 1992, Qual Life Res, V1, P91, DOI 10.1007/BF00439716; KAPLAN RM, 1989, MED CARE, V27, pS27, DOI 10.1097/00005650-198903001-00003; KAPLAN RM, 1994, PSYCHOL HEALTH, V9, P131, DOI 10.1080/08870449408407464; LEHMANN EL, 1975, NONPARAMETRICS; Lubeck D P, 1992, Qual Life Res, V1, P359, DOI 10.1007/BF00704430; MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13; MERIGAN TC, 1989, ANN INTERN MED, V110, P189, DOI 10.7326/0003-4819-110-3-189; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; SKOWRON G, 1993, ANN INTERN MED, V118, P321, DOI 10.7326/0003-4819-118-5-199303010-00001; Steward A., 1992, MEASURING FUNCTIONIN, P345; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; TESTA MA, 1993, NEW ENGL J MED, V328, P907, DOI 10.1056/NEJM199304013281302; WACHTEL T, 1992, ANN INTERN MED, V116, P129, DOI 10.7326/0003-4819-116-2-129; WARE JE, 1992, MED CARE, V30, P492; WU AW, 1990, J ACQ IMMUN DEF SYND, V3, P683; WU AW, 1993, J ACQ IMMUN DEF SYND, V6, P452; WU AW, 1991, MED CARE, V29, P786, DOI 10.1097/00005650-199108000-00011	33	46	46	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	1995	273	4					295	301						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QC057	7815656				2022-12-28	WOS:A1995QC05700027
J	JOUET, M; KENWRICK, S				JOUET, M; KENWRICK, S			GENE ANALYSIS OF L1 NEURAL CELL-ADHESION MOLECULE IN PRENATAL-DIAGNOSIS OF HYDROCEPHALUS	LANCET			English	Note							X-LINKED HYDROCEPHALUS	X-linked hydrocephalus is the most common form of inherited hydrocephalus, and is associated with severe neurological deficits and premature death. We have shown that mutations in the gene encoding L1 neural cell adhesion molecule result in X-linked hydrocephalus, which enables improved prenatal diagnosis and investigation of the role of this molecule in sporadic cases. Here we report two pedigrees with apparently sporadic hydrocephalus in which we demonstrated a disabling mutation in the L1 gene. This enabled us to provide definitive prenatal diagnosis at 10 weeks' gestation.	ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND	Addenbrooke's Hospital; University of Cambridge								COOPER DN, 1993, HUMAN GENE MUTATION, P239; HALLIDAY J, 1986, J MED GENET, V23, P23, DOI 10.1136/jmg.23.1.23; JOUET M, 1994, NAT GENET, V7, P402, DOI 10.1038/ng0794-402; RICHARDS B, 1991, NUCLEIC ACIDS RES, V19, P1944, DOI 10.1093/nar/19.8.1944; ROSENTHAL A, 1992, NAT GENET, V2, P107, DOI 10.1038/ng1092-107; SERVILLE F, 1993, PRENATAL DIAG, V13, P435, DOI 10.1002/pd.1970130603; WILLEMS PJ, 1987, AM J MED GENET, V27, P921, DOI 10.1002/ajmg.1320270419; WILLEMS PJ, 1992, AM J HUM GENET, V51, P307	8	38	38	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					161	162		10.1016/S0140-6736(95)90170-1	http://dx.doi.org/10.1016/S0140-6736(95)90170-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7823673				2022-12-28	WOS:A1995QC55000013
J	WAGNER, G				WAGNER, G			E-CADHERIN - A DISTANT MEMBER OF THE IMMUNOGLOBULIN SUPERFAMILY	SCIENCE			English	Editorial Material							DOMAIN				WAGNER, G (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,240 LONGWOOD AVE,BOSTON,MA 02115, USA.							ARULANANDAM ARN, 1993, P NATL ACAD SCI USA, V90, P11613, DOI 10.1073/pnas.90.24.11613; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; COTHIA C, 1985, J MOL BIOL, V186, P651; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; PIGOTT R, 1993, ADHESION MOL FACTS B; PILEWSKI JM, 1993, AM REV RESPIR DIS, V148, pS31, DOI 10.1164/ajrccm/148.6_Pt_2.S31; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Wilson HV, 1907, J EXP ZOOL, V5, P245, DOI 10.1002/jez.1400050204; WITHKA JM, 1993, STRUCTURE, V1, P69, DOI 10.1016/0969-2126(93)90009-6	12	22	23	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 20	1995	267	5196					342	342		10.1126/science.7824932	http://dx.doi.org/10.1126/science.7824932			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC273	7824932				2022-12-28	WOS:A1995QC27300025
J	GODLEE, F				GODLEE, F			WHO IN CRISIS	BRITISH MEDICAL JOURNAL			English	Article								Media attention has been focused on the leadership of the World Health Organisation, rather than on the real factors that limit WHO's effectiveness. These factors relate to the organisation's structure and also to its current priorities, methods, and management. This article examines the objectives and strategy of WHO in view of financial constraints and donor countries' demands; WHO's stated goal of integrated primary health care; staff morale; and the growing dislocation between the regions and headquarters.										DAES EIA, 1994, GENERAL ASSEMBLY O S, V34; TOLLISON RD, 1993, PUBLICATION SOCIAL A, V53; 1992, BASIC DOCUMENTS; 1991, EFFECTIVENESS MULTIL; 1994, 47 WORLD HLTH ASS; 1994, PREVENTION SEXUAL HA; 1993, 46TH WORLD HLTH ASS; 1993, REPORT EXECUTIVE BOA	8	61	64	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1994	309	6966					1424	1428		10.1136/bmj.309.6966.1424	http://dx.doi.org/10.1136/bmj.309.6966.1424			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7819856	Green Published			2022-12-28	WOS:A1994PU76400031
J	UPTON, C				UPTON, C			SLEEP DISTURBANCE IN CHILDREN TREATED WITH OFLOXACIN	BRITISH MEDICAL JOURNAL			English	Letter							CYSTIC-FIBROSIS				UPTON, C (corresponding author), NORFOLK & NORWICH HOSP,NORWICH NR1 3SR,NORFOLK,ENGLAND.							JENSEN T, 1987, J ANTIMICROB CHEMOTH, V20, P585, DOI 10.1093/jac/20.4.585; VALERIUS NH, 1991, LANCET, V338, P725, DOI 10.1016/0140-6736(91)91446-2; 1993, DRUG THER B, V31, P69	3	14	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1994	309	6966					1411	1411		10.1136/bmj.309.6966.1411	http://dx.doi.org/10.1136/bmj.309.6966.1411			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7819852	Green Published			2022-12-28	WOS:A1994PU76400024
J	MUIR, KW; SQUIRE, IB; ALWAN, W; LEES, KR				MUIR, KW; SQUIRE, IB; ALWAN, W; LEES, KR			ANTICARDIOLIPIN ANTIBODIES IN AN UNSELECTED STROKE POPULATION	LANCET			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTIPHOSPHOLIPID SYNDROME; CEREBRAL-ISCHEMIA; ANTI-CARDIOLIPIN; ASSOCIATION; THROMBOSIS; INFARCTION; COAGULATION; PREVALENCE; FEATURES	A pathogenetic role in thrombotic disease, particularly in young people, has been postulated for anticardiolipin antibody (ACA). We have carried out a prospective controlled study of 262 unselected patients with acute stroke and 226 controls to assess the prevalence and relation to age and vascular risk factors of ACA. Titres of IgG, IgA, or IgM ACA were above the upper normal limit in 38% of patients. The proportions of patients and controls with raised titres did not differ significantly (13 vs 8% IgG, 22 vs 29% IgA, 11 vs 7% IgM). IgG titres were higher among patients than among controls (mean 3.88 vs 2.86 u/mL [95% CI for difference 0.62-0.87], p=0.0004), whereas IgA and IgM titres were lower in patients than in controls (IgA 4.82 vs 5.98 u/mL [1.12-1.60], p = 0.01; IgM 3.00 vs 3.64 u/mL [1.01-1.45], p = 0.04). However, within age tertiles the only significant difference between patients and controls for IgG ACA was in the oldest tertile. Analysis by number of risk factors for stroke showed a significant difference between the groups only for subjects with one risk factor. IgA and IgM ACA titres were higher among controls only in those with no vascular risk factors.	UNIV GLASGOW,WESTERN INFIRM,DEPT IMMUNOL,GLASGOW G11 6NT,SCOTLAND	University of Glasgow	MUIR, KW (corresponding author), UNIV GLASGOW,WESTERN INFIRM,DEPT MED & THERAPEUT,GLASGOW G11 6NT,SCOTLAND.		Muir, Keith W/A-7670-2011	Muir, Keith W/0000-0001-9535-022X				ASHERSON RA, 1991, ANN RHEUM DIS, V50, P805, DOI 10.1136/ard.50.11.805; ASHERSON RA, 1992, ANN RHEUM DIS, V51, P147, DOI 10.1136/ard.51.2.147; BABIKIAN VL, 1990, STROKE, V21, P1268; BABIKIAN VL, 1992, STROKE S1, V23, P133; BAKIMER R, 1992, J CLIN INVEST, V89, P1558, DOI 10.1172/JCI115749; BREY RL, 1990, NEUROLOGY, V40, P1190, DOI 10.1212/WNL.40.8.1190; CHAKRAVARTY KK, 1991, Q J MED, V79, P397; CHANCELLOR AM, 1991, J NEUROL, V238, P401, DOI 10.1007/BF00319860; CZLONKOWSKA A, 1992, ACTA NEUROL SCAND, V86, P304, DOI 10.1111/j.1600-0404.1992.tb05090.x; GINSBURG KS, 1992, ANN INTERN MED, V117, P997, DOI 10.7326/0003-4819-117-12-997; GREAVES M, 1993, J NEUROL NEUROSUR PS, V56, P433, DOI 10.1136/jnnp.56.5.433; HAMSTEN A, 1986, LANCET, V1, P113; HARRIS E N, 1987, British Journal of Rheumatology, V26, P19; HARRIS EN, 1983, LANCET, V2, P1211; HARRIS EN, 1990, AM J CLIN PATHOL, V94, P476, DOI 10.1093/ajcp/94.4.476; HART RG, 1984, STROKE, V15, P114, DOI 10.1161/01.STR.15.1.114; HESS DC, 1991, NEUROLOGY, V41, P525, DOI 10.1212/WNL.41.4.525; HUGHES GRV, 1993, LANCET, V342, P341, DOI 10.1016/0140-6736(93)91477-4; KUSHNER MJ, 1990, STROKE, V21, P295, DOI 10.1161/01.STR.21.2.295; LEVINE SR, 1990, NEUROLOGY, V40, P1181, DOI 10.1212/WNL.40.8.1181; MANOUSSAKIS MN, 1987, CLIN EXP IMMUNOL, V69, P557; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; MONTALBAN J, 1991, STROKE, V22, P750, DOI 10.1161/01.STR.22.6.750; MUEH JR, 1980, ANN INTERN MED, V92, P156, DOI 10.7326/0003-4819-92-2-156; NENCINI P, 1992, STROKE, V23, P189, DOI 10.1161/01.STR.23.2.189; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; TRIMBLE M, 1990, AM J MED, V88, P593, DOI 10.1016/0002-9343(90)90523-G; VLACHOYIANNOPOULOS PG, 1992, EUR J CLIN INVEST, V22, P482, DOI 10.1111/j.1365-2362.1992.tb01494.x; 1993, STROKE S1, V24, P120	29	91	93	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 13	1994	344	8920					452	456		10.1016/S0140-6736(94)91775-2	http://dx.doi.org/10.1016/S0140-6736(94)91775-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7818647				2022-12-28	WOS:A1994PB76100015
J	HARPER, R; ENNIS, CN; SHERIDAN, B; ATKINSON, AB; JOHNSTON, GD; BELL, PM				HARPER, R; ENNIS, CN; SHERIDAN, B; ATKINSON, AB; JOHNSTON, GD; BELL, PM			EFFECTS OF LOW-DOSE VERSUS CONVENTIONAL-DOSE THIAZIDE DIURETIC ON INSULIN ACTION IN ESSENTIAL-HYPERTENSION	BRITISH MEDICAL JOURNAL			English	Article							DEPENDENT DIABETES-MELLITUS; GLUCOSE-INTOLERANCE; LIPID-METABOLISM; CLINICAL-TRIAL; RESISTANCE; DISEASE; HYDROCHLOROTHIAZIDE; MORTALITY; TURNOVER; THERAPY	Objective-To see whether low dose thiazide diuretics given to patients with essential hypertension might avoid the adverse metabolic consequences seen with conventional doses. Design-Double blind randomised crossover study of two 12 week treatment periods with either low dose (1.25 mg) or conventional dose (5.0 mg) bendrofluazide given after a six week placebo run in period. Setting-Outpatient clinics serving the greater Belfast area. Subjects-16 white non-diabetic patients (9 male) under 65 with essential hypertension recruited from general practices within the greater Belfast area. Main outcome measures-Systolic and diastolic blood pressure and peripheral and hepatic insulin action. Results-One man failed to complete the study. There were no differences between doses in their effects on systolic and diastolic blood pressure. Bendrofluazide 1.25 mg had substantially less effect on serum potassium concentration than the 5.0 mg dose. There were no intertreatment differences in fasting glucose, insulin, cholesterol, and triglyceride concentrations. Bendrofluazide 5.0 mg significantly increased postabsorptive endogenous glucose production compared with baseline (mean 10.9 (SD 1.2) v 10.0 (0.8) mu mol/kg/min), whereas bendrofluazide 1.25 mg did not. Postabsorptive endogenous glucose production was significantly higher with bendrofluazide 5.0 mp compared with 1.25 mg (10.9 (1.2) v 9.9 (0.8) mu mol/kg/min) but was suppressed to a similar extent after insulin (bendrofluazide 5.0 mg 2.8 (1.5) mu mol/kg/min v bendroffuazide 1.25 mg 2.2 (1.5) mu mol/kg/min). Exogenous glucose infusion rates required to maintain euglycaemia were not significantly different between doses and were similar to baseline. Conclusions-Bendrofluazide 1.25 mg is as effective as conventional doses but has less adverse metabolic effect. In contrast with conventional doses, low dose bendrofluazide has no effect on hepatic insulin action. There is no difference between low and conventional doses of bendrofluazide in their effect on peripheral insulin sensitivity.	ROYAL VICTORIA HOSP,SIR GEORGE E CLARK METAB UNIT,BELFAST BT12 6BA,NORTH IRELAND; ROYAL VICTORIA HOSP,REG ENDOCRINE LAB,BELFAST BT12 6BA,NORTH IRELAND; QUEENS UNIV BELFAST,DEPT THERAPEUT & PHARMACOL,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND	Queens University Belfast								AMES RP, 1976, AM J MED, V61, P748, DOI 10.1016/0002-9343(76)90156-X; BEARDWOO.DM, 1965, METABOLIS, V14, P561, DOI 10.1016/S0026-0495(65)80016-6; BENGTSSON C, 1984, BMJ-BRIT MED J, V289, P1495, DOI 10.1136/bmj.289.6457.1495; BOWEN HF, 1973, J CLIN INVEST, V52, P3033, DOI 10.1172/JCI107502; BURRIS JF, 1990, JAMA-J AM MED ASSOC, V263, P1507, DOI 10.1001/jama.263.11.1507; CARLSEN JE, 1990, BRIT MED J, V300, P975, DOI 10.1136/bmj.300.6730.975; DEBODO RC, 1963, RECENT PROG HORM RES, V19, P445; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; DEFRONZO RA, 1992, DIABETOLOGIA, V35, P389, DOI 10.1007/BF00401208; DUCIMETIERE P, 1980, DIABETOLOGIA, V19, P205, DOI 10.1007/BF00275270; FAJANS SS, 1966, J CLIN INVEST, V45, P481, DOI 10.1172/JCI105362; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FIRTH RG, 1986, J CLIN INVEST, V77, P1525, DOI 10.1172/JCI112467; FUH MMT, 1987, ARCH INTERN MED, V147, P1035, DOI 10.1001/archinte.147.6.1035; FULLER JH, 1980, LANCET, V1, P1373; GERICH JE, 1991, DIABETOLOGIA, V34, P607, DOI 10.1007/BF00400282; GRIMM RH, 1981, ANN INTERN MED, V94, P7, DOI 10.7326/0003-4819-94-1-7; HALES CN, 1963, BIOCHEM J, V88, P137, DOI 10.1042/bj0880137; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; HOLLANDER W, 1957, BOSTON MED Q, V8, P68; KAPLAN NM, 1986, AM J NEPHROL, V6, P1, DOI 10.1159/000167045; KNOCHEL JP, 1984, AM J MED, V77, P18, DOI 10.1016/S0002-9343(84)80004-2; MACMAHON SW, 1986, PROG CARDIOVASC DIS, V29, P99, DOI 10.1016/0033-0620(86)90038-1; MACMAHON SW, 1985, ARTERIOSCLEROSIS, V5, P391, DOI 10.1161/01.ATV.5.4.391; MCVEIGH G, 1988, BRIT MED J, V297, P95, DOI 10.1136/bmj.297.6641.95; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; MURPHY MB, 1982, LANCET, V2, P1293; NEELY RDG, 1990, DIABETOLOGIA, V33, P681, DOI 10.1007/BF00400570; NEELY RDG, 1992, AM J PHYSIOL, V263, pE980, DOI 10.1152/ajpendo.1992.263.5.E980; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; RAPAPORT MI, 1964, ARCH INTERN MED, V113, P405; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROONEY DP, 1992, METABOLISM, V41, P317, DOI 10.1016/0026-0495(92)90278-I; SOMOGYI M, 1945, J BIOL CHEM, V160, P69; STEELE R, 1956, AM J PHYSIOL, V187, P15, DOI 10.1152/ajplegacy.1956.187.1.15; WEINBERGER MH, 1985, ARCH INTERN MED, V145, P1103; 1980, LANCET, V1, P1261; 1985, BRIT MED J, V291, P97	38	57	59	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1994	309	6949					226	230		10.1136/bmj.309.6949.226	http://dx.doi.org/10.1136/bmj.309.6949.226			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ180	7818648	Green Published			2022-12-28	WOS:A1994NZ18000014
J	COYLE, A; MCGRELLIS, S				COYLE, A; MCGRELLIS, S			STRATEGIES FOR DEALING WITH PROBLEMS ASSOCIATED WITH USE OF SERVICES FOR HIV-INFECTION AND AIDS OUT OF REGION - VIEWS OF PROVIDERS AND USERS	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONER	Objectives-To identify reasons why people with HIV infection and AIDS living within the former South West Thames Regional Health Authority use HIV and AIDS services outside the region, and to identify strategies for dealing with the problems associated with such use. Design-Qualitative study consisting of interviews with individual subjects and focus groups. Setting-Providers of services for patients with HIV infection and AIDS in South West Thames, central London, and Brighten. Users of such services resident in South West Thames. Subjects-Thirty four South West Thames residents with HIV infection and AIDS who use or used services outside the former region; and 70 providers of services within and beyond South West Thames. Results-Principal reasons for use of services out of the region were accessibility (15) and negative appraisals of local services (14). Three main strategies for dealing with the problems of such use were suggested by providers. These entailed introducing users of services outside the region to services in their locality (16); sharing the responsibility for care between providers in specialist centres and in the person's locality (10); and involving the person's general practitioner in their care (12). These strategies were deemed acceptable by 29, 30, and 20 service users respectively. Conclusion-The reasons underlying use of services for patients with HIV infection and AIDS outside the region offer suggestions for developing services in areas with a high incidence of such use. The suggestions advanced by service providers offer an acceptable framework for dealing with the problems.			COYLE, A (corresponding author), UNIV SURREY,DEPT NURSING & MIDWIFERY,GUILDFORD GU2 5XH,SURREY,ENGLAND.			Coyle, Adrian/0000-0002-5340-9817				ADLER M, 1993, BRIT MED J, V307, P1010, DOI 10.1136/bmj.307.6910.1010; BEARDSELL S, 1995, HIV TESTING SERVICES; COYLE A, 1993, NEED LISTEN SERVICE; KING MB, 1988, BRIT MED J, V297, P182, DOI 10.1136/bmj.297.6642.182; Krueger R. A., 1988, FOCUS GROUPS PRACTIC; MANSFIELD SJ, 1989, J ROY COLL GEN PRACT, V39, P104; Miles M., 2013, QUALITATIVE DATA ANA; SAUNDERS P, 1994, BRIT MED J, V308, P2, DOI 10.1136/bmj.308.6920.2; SMITH S, 1993, BRIT MED J, V307, P801, DOI 10.1136/bmj.307.6907.801-c; 1993, HIV AIDS 1992 1993 S	10	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 24	1995	310	6995					1636	1638		10.1136/bmj.310.6995.1636	http://dx.doi.org/10.1136/bmj.310.6995.1636			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF698	7795449	Green Published			2022-12-28	WOS:A1995RF69800019
J	NOOR, MA				NOOR, MA			SPECIATION DRIVEN BY NATURAL-SELECTION IN DROSOPHILA	NATURE			English	Article							GENE FLOW; REINFORCEMENT	REINFORCEMENT is the process by which natural selection strengthens sexual isolation between incipient species, reducing the frequency of maladaptive hybridization and hence completing reproductive isolation. Although this model of speciation was once widely accepted(1,2), its plausibility(3,4) and experimental support(5-7) have been recently attacked. Here we provide an example of speciation by reinforcement, in the North American fruitfly Drosophila pseudoobscura. The results suggest that females of D. pseudoobscura evolved increased sexual isolation from their sibling species, D. persimilis, by natural selection against maladaptive hybridization.			NOOR, MA (corresponding author), UNIV CHICAGO,DEPT ECOL & EVOLUT,1101 E 57TH ST,CHICAGO,IL 60637, USA.			Noor, Mohamed/0000-0002-5400-4408				BROWN RGB, 1963, BEHAVIOUR, V23, P61; Butlin R., 1989, P158; BUTLIN R, 1987, TRENDS ECOL EVOL, V2, P8, DOI 10.1016/0169-5347(87)90193-5; COYNE JA, 1987, AM NAT, V129, P847, DOI 10.1086/284679; COYNE JA, 1992, NATURE, V355, P511, DOI 10.1038/355511a0; DOBZHANSKY T, 1973, AM NAT, V107, P312, DOI 10.1086/282833; Dobzhansky T., 1935, PHILOS SCI, V2, P344, DOI DOI 10.1086/286379; Dobzhansky T., 1951, COPEIA; Dobzhansky T., 1975, INVERTEBRATES GENETI, P537; HOWARD DJ, 1993, HYBRID ZONES AND THE EVOLUTIONARY PROCESS, P46; Lewontin RC, 1974, GENETIC BASIS EVOLUT; MAYR E, 1946, P NATL ACAD SCI USA, V32, P128, DOI 10.1073/pnas.32.5.128; Mayr E, 1942, SYSTEMATICS ORIGIN S; Noor M.A., 1994, Drosophila Information Service, V75, P67; NOOR MA, 1995, PAN-PAC ENTOMOL, V71, P71; POWELL JR, 1983, P NATL ACAD SCI-BIOL, V80, P492, DOI 10.1073/pnas.80.2.492; SANDERSON N, 1989, EVOLUTION, V43, P1223, DOI [10.2307/2409358, 10.1111/j.1558-5646.1989.tb02570.x]; SCHAEFFER SW, 1992, GENETICS, V132, P471; SPENCER HG, 1986, AM NAT, V128, P241, DOI 10.1086/284557; TAKAHATA N, 1984, P NATL ACAD SCI-BIOL, V81, P1764, DOI 10.1073/pnas.81.6.1764; TEMPLETON AR, 1981, ANNU REV ECOL SYST, V12, P23, DOI 10.1146/annurev.es.12.110181.000323	21	262	266	0	41	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 22	1995	375	6533					674	675		10.1038/375674a0	http://dx.doi.org/10.1038/375674a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791899				2022-12-28	WOS:A1995RE57600057
J	GOOD, GR; DINUBILE, MJ				GOOD, GR; DINUBILE, MJ			CYCLIC FEVER IN HODGKINS-DISEASE (PEL-EBSTEIN FEVER)	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											GOOD, GR (corresponding author), UNIV MED & DENT NEW JERSEY,COOPER HOSP,MED CTR,CAMDEN,NJ 08103, USA.								0	9	9	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 16	1995	332	7					436	436		10.1056/NEJM199502163320705	http://dx.doi.org/10.1056/NEJM199502163320705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF770	7824016				2022-12-28	WOS:A1995QF77000005
J	PANTALEO, G; MENZO, S; VACCAREZZA, M; GRAZIOSI, C; COHEN, OJ; DEMAREST, JF; MONTEFIORI, D; ORENSTEIN, JM; FOX, C; SCHRAGER, LK; MARGOLICK, JB; BUCHBINDER, S; GIORGI, JV; FAUCI, AS				PANTALEO, G; MENZO, S; VACCAREZZA, M; GRAZIOSI, C; COHEN, OJ; DEMAREST, JF; MONTEFIORI, D; ORENSTEIN, JM; FOX, C; SCHRAGER, LK; MARGOLICK, JB; BUCHBINDER, S; GIORGI, JV; FAUCI, AS			STUDIES IN SUBJECTS WITH LONG-TERM NONPROGRESSIVE HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOLLICULAR DENDRITIC CELLS; PRIMARY HIV-1 INFECTION; TYPE-1 INFECTION; LYMPH-NODES; AIDS; LYMPHADENOPATHY; LYMPHOCYTES; RESERVOIRS; VIREMIA; RNA	Background. In a small percentage of persons infected with human immunodeficiency Virus type 1 (HIV-1), there is no progression of disease and CD4+ T-cell counts remain stable for many years. Studies of the histopathological, virologic, and immunologic characteristics of these persons may provide insight into the pathogenic mechanisms that lead to HIV disease and the protective mechanisms that prevent progression to overt disease. Methods and Results. We studied 15 subjects with long-term nonprogressive HIV infection and 18 subjects with progressive HIV disease. Nonprogressive infection was defined as seven or more years of documented HIV infection, with more than 600 CD4+ T cells per cubic millimeter, no antiretroviral therapy, and no HIV-related disease. Lymph nodes from the subjects with nonprogressive infection had significantly fewer of the hyperplastic features, and none of the involuted features, characteristic of nodes from subjects with progressive disease. Plasma levels of HIV-1 RNA and the viral burden in peripheral-blood mononuclear cells were both significantly lower in the subjects with nonprogressive infection than in those with progressive disease (P = 0.003 and P = 0.015, respectively). HIV could not be isolated from the plasma of the former, who also had significantly higher titers of neutralizing antibodies than the latter. There was viral replication, however, in the subjects with nonprogressive infection, and virus was consistently cultured from mononuclear cells from the lymph nodes. In the lymph nodes virus ''trapping'' varied with the degree of formation of germinal centers, and few cells expressing virus were found by in situ hybridization. HIV-specific cytotoxic activity was detected in ail seven subjects with nonprogressive infection who were tested. Conclusions. in persons who remain free of disease for many years despite HIV infection the Viral load is low, but viral replication persists. Lymph-node architecture and immune function appear to remain intact.	NIAID,DIV AIDS,BETHESDA,MD 20892; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED CELLULAR IMMUNOL & CYTOMETRY,LOS ANGELES,CA; DUKE UNIV,MED CTR,CTR AIDS RES,DEPT SURG,DURHAM,NC; GEORGE WASHINGTON UNIV,DEPT PATHOL,WASHINGTON,DC; MOLEC HISTOL INC,GAITHERSBURG,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT ENVIRONM HLTH SCI,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT IMMUNOL & INFECT DIS,BALTIMORE,MD; DEPT PUBL HLTH,AIDS OFF,RES BRANCH,SAN FRANCISCO,CA; UNIV ANCONA,SCH MED,INST MICROBIOL,ANCONA,ITALY	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Duke University; George Washington University; Johns Hopkins University; Johns Hopkins University; Marche Polytechnic University	PANTALEO, G (corresponding author), NIAID,IMMUNOREGULAT LAB,BLDG 10,RM 11B13,10 CTR DR,MSC 1876,BETHESDA,MD 20892, USA.		graziosi, cecilia/M-1882-2019; Pantaleo, Giuseppe/K-6163-2016; VACCAREZZA, Mauro/S-9637-2019; menzo, stefano/AAL-2521-2020	Menzo, Stefano/0000-0002-4425-3750; VACCAREZZA, Mauro/0000-0003-3060-318X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035043, U01AI035042, U01AI035039] Funding Source: NIH RePORTER; NIAID NIH HHS [U01-AI-35039, U01-AI-35043, U01-AI-35042] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMSTRONG JA, 1985, IMMUNOL TODAY, V6, P121, DOI 10.1016/0167-5699(85)90076-3; ARMSTRONG JA, 1991, ACCESSORY CELLS IN HIV AND OTHER RETROVIRAL INFECTIONS, P69; BAGNARELLI P, 1992, J VIROL, V66, P7328, DOI 10.1128/JVI.66.12.7328-7335.1992; BIBERFELD P, 1987, ACTA PATH MICRO IM A, V95, P47; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; BUCHBINDER SP, 1994, AIDS, V8, P1123, DOI 10.1097/00002030-199408000-00014; BURKE AP, 1994, HUM PATHOL, V25, P248, DOI 10.1016/0046-8177(94)90196-1; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DONALDSON YK, 1994, J VIROL, V68, P5991, DOI 10.1128/JVI.68.9.5991-6005.1994; EASTERBROOK PJ, 1994, AIDS, V8, P1179, DOI 10.1097/00002030-199408000-00023; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; EMILIE D, 1990, J CLIN INVEST, V86, P148, DOI 10.1172/JCI114678; FAUCI AS, 1991, ANN INTERN MED, V114, P678, DOI 10.7326/0003-4819-114-8-678; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; GRAZIOSI C, 1993, P NATL ACAD SCI USA, V90, P6405, DOI 10.1073/pnas.90.14.6405; LEVY JA, 1993, AIDS, V7, P1401, DOI 10.1097/00002030-199311000-00001; LIFSON AR, 1991, J INFECT DIS, V163, P959, DOI 10.1093/infdis/163.5.959; MENZO S, 1992, J CLIN MICROBIOL, V30, P1752, DOI 10.1128/JCM.30.7.1752-1757.1992; MONTEFIORI DC, 1988, J CLIN MICROBIOL, V26, P231, DOI 10.1128/JCM.26.2.231-235.1988; PANTALEO G, 1990, P NATL ACAD SCI USA, V87, P4818, DOI 10.1073/pnas.87.12.4818; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; REIMANN KA, 1994, J VIROL, V68, P2362, DOI 10.1128/JVI.68.4.2362-2370.1994; SAFRIT JT, 1994, J EXP MED, V179, P463, DOI 10.1084/jem.179.2.463; SHEPPARD HW, 1993, AIDS, V7, P1159, DOI 10.1097/00002030-199309000-00002; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; SPIEGEL H, 1992, AM J PATHOL, V140, P15; TENNERRACZ K, 1986, AM J PATHOL, V123, P9; TENNERRACZ K, 1985, LANCET, V1, P105; WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; [No title captured]	35	657	674	1	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	1995	332	4					209	216		10.1056/NEJM199501263320402	http://dx.doi.org/10.1056/NEJM199501263320402			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC270	7808486				2022-12-28	WOS:A1995QC27000002
J	GLASSON, J; PLOWS, CW; CLARKE, OW; RUFF, V; FULLER, D; KLIGER, CH; WILKINS, GT; COSGRIFF, JH; TENNERY, RM; JOHNSON, KB; ORENTLICHER, D; HARWOOD, KM; LESLIE, J				GLASSON, J; PLOWS, CW; CLARKE, OW; RUFF, V; FULLER, D; KLIGER, CH; WILKINS, GT; COSGRIFF, JH; TENNERY, RM; JOHNSON, KB; ORENTLICHER, D; HARWOOD, KM; LESLIE, J			ETHICAL ISSUES IN MANAGED CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HEALTH MAINTENANCE ORGANIZATION; PROSPECTIVE PAYMENT SYSTEM; OUTCOMES; QUALITY		AMER MED ASSOC, COUNCIL ETH & JUDICIAL AFFAIRS, CHICAGO, IL 60610 USA	American Medical Association								BETTMANN MA, 1990, RADIOLOGY, V175, P616, DOI 10.1148/radiology.175.3.2343105; CLEMENT DG, 1994, JAMA-J AM MED ASSOC, V271, P1487, DOI 10.1001/jama.271.19.1487; EMANUEL EJ, 1993, NEW ENGL J MED, V329, P879, DOI 10.1056/NEJM199309163291213; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; IGLEHART JK, 1992, NEW ENGL J MED, V327, P742, DOI 10.1056/NEJM199209033271029; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1984, DOI 10.1001/jama.264.15.1984; KASSIRER JP, 1989, NEW ENGL J MED, V320, P1489, DOI 10.1056/NEJM198906013202211; KATAYAMA H, 1990, RADIOLOGY, V175, P621, DOI 10.1148/radiology.175.3.2343107; KOSECOFF J, 1990, JAMA-J AM MED ASSOC, V264, P1980, DOI 10.1001/jama.264.15.1980; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; MORREIM EH, 1988, HASTINGS CENT REP, V18, P20, DOI 10.2307/3563044; MORREIM EH, 1991, ARCH INTERN MED, V151, P443, DOI 10.1001/archinte.151.3.443; Pelligrino E D, 1986, J Contemp Health Law Policy, V2, P23; PETERS WP, 1994, NEW ENGL J MED, V330, P473, DOI 10.1056/NEJM199402173300707; POVAR G, 1988, ANN INTERN MED, V109, P419, DOI 10.7326/0003-4819-109-5-419; RAMSEY PG, 1993, JAMA-J AM MED ASSOC, V269, P1655, DOI 10.1001/jama.269.13.1655; RELMAN AS, 1993, NEW ENGL J MED, V329, P1574, DOI 10.1056/NEJM199311183292113; RUBENSTEIN LV, 1990, JAMA-J AM MED ASSOC, V264, P1974, DOI 10.1001/jama.264.15.1974; WARE JE, 1986, LANCET, V1, P1017; 1994, CODE MED ETHICS CURR; 1990, CODE MED ETHICS REPO, V1, P130; 1994, JAMA-J AM MED ASSOC, V272, P1056; 1993, PRINCIPLES MANAGED C; 1992, FED REGISTER, V57, P59024; 1988, JAMA-J AM MED ASSOC, V259, P1360; 1982, JAMA-J AM MED ASSOC, V248, P981; 1994, PHYSICIAN HLTH PLANS; 1988, MEDICARE PHYSICIAN I, P23; 1991, 140TH P HOUS DEL AM, P121	29	146	146	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	1995	273	4					330	335		10.1001/jama.1995.03520280076044	http://dx.doi.org/10.1001/jama.1995.03520280076044			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC057	7815663				2022-12-28	WOS:A1995QC05700034
J	KOMIYAMA, NH; MIYAZAKI, G; TAME, J; NAGAI, K				KOMIYAMA, NH; MIYAZAKI, G; TAME, J; NAGAI, K			TRANSPLANTING A UNIQUE ALLOSTERIC EFFECT FROM CROCODILE INTO HUMAN HEMOGLOBIN	NATURE			English	Article							ESCHERICHIA-COLI; CARBON-DIOXIDE; HEMOGLOBIN; BINDING	CROCODILES are able to remain under water for more than one hour without surfacing to breathe(1,2) and often kill their prey by drowning it. How do crocodiles stay under water for a long time? When they hold their breath, bicarbonate ions, the final product of respiration, accumulate and drastically reduce the oxygen affinity of haemoglobin, releasing it large fraction of haemoglobin-bound oxygen into the tissues(3,4). We have now located the bicarbonate-ion-binding site at the alpha(1) beta(2)-subunit interface by making various human-crocodile chimaeric haemoglobins. Furthermore, we have been able to transplant the bicarbonate effect into human haemoglobin by replacing only a few residues, even though the amino-acid sequence identity between crocodile (Crocodylus niloticus) and human haemoglobins is only 68% for the alpha- and 51% for the beta-subunit(5). These results indicate that an entirely new function which enables species to adapt to a new environment could evolve in a protein by a relatively small number of amino-acid substitutions in key positions(6).	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; OSAKA UNIV,FAC ENGN SCI,DEPT BIOPHYS,TOYONAKA,OSAKA 560,JAPAN	MRC Laboratory Molecular Biology; Osaka University				Tame, Jeremy/0000-0002-9341-7280				ANDERSEN HT, 1961, ACTA PHYSIOL SCAND, V53, P23, DOI 10.1111/j.1748-1716.1961.tb02261.x; BAUER C, 1977, NATURE, V269, P825, DOI 10.1038/269825a0; BAUER C, 1981, J BIOL CHEM, V256, P8429; COTT H. B., 1961, TRANS ZOOL SOC LONDON, V29, P211; FEMI G, 1981, ATLAS MOL STRUCTURE, V2; GRIGG GC, 1993, J EXP BIOL, V175, P15; HOFFMAN SJ, 1990, P NATL ACAD SCI USA, V87, P8521, DOI 10.1073/pnas.87.21.8521; IKEMURA T, 1982, J MOL BIOL, V158, P573, DOI 10.1016/0022-2836(82)90250-9; Imai K, 1981, Methods Enzymol, V76, P438; KIMURA M, 1971, SCI AM, V241, P94; KOMIYAMA NH, 1991, NATURE, V352, P349, DOI 10.1038/352349a0; Kooyman G.L., 1989, DIVERSE DIVERS PHYSL; LECLERCQ F, 1981, H-S Z PHYSIOL CHEM, V362, P1151; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1981, NATURE, V291, P682, DOI 10.1038/291682a0; PERUTZ MF, 1983, MOL BIOL EVOL, V1, P1; TAME JRH, 1989, THESIS U CAMBRIDGE; WELLS JA, 1985, GENE, V34, P315, DOI 10.1016/0378-1119(85)90140-4	19	72	73	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					244	246		10.1038/373244a0	http://dx.doi.org/10.1038/373244a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816138				2022-12-28	WOS:A1995QC27800063
J	FRIEDMAN, E				FRIEDMAN, E			WELCOME TO YEAR-83	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Evans R W, 1992, Health Manage Q, V14, P14; FRIEDMAN E, 1994, JAMA-J AM MED ASSOC, V271, P875; GEARON CJ, 1994, AHA NEWS, V30, P1; Harris Richard, 1966, SACRED TRUST; JORDAN S, 1994, NATIONS HLTH, V24, P4; Schlesinger Jr A., 1986, CYCLES AM HIST; Starr P, 1982, SOCIAL TRANSFORMATIO; 1994, HLTH BENEFITS 1993; 1994, SOURCES HLTH INSURAN	9	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					256	257						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB234	7807678				2022-12-28	WOS:A1995QB23400043
J	SPRAY, JG; THOMPSON, LM				SPRAY, JG; THOMPSON, LM			FRICTION MELT DISTRIBUTION IN A MULTIRING IMPACT BASIN	NATURE			English	Article							SUDBURY STRUCTURE; VREDEFORT DOME; COESITE	IT is generally accepted that multi-ring basins are the consequence of very large impacts, but the mechanism by which they form is still a matter of contention(1,2). Most of what is currently known about multi-ring basins is based on remote studies of the Moon(3-5) and, to a lesser extent, Mars and Mercury(4,6). But at least two multi-ring impact basins have been recognized on Earth(7)-the Sudbury(8) (Canada) and Vredefort(9) (South Africa) impact structures-providing an opportunity to study their properties directly. Here we describe the distribution of friction melt (pseudotachylyte) in the floor of the Sudbury impact basin. Although the veins and dykes of pseudotachylyte decrease in both thickness and frequency of occurrence towards the basin periphery, the greatest volumes of friction melt appear to define four rings around the central impact melt sheet. Field evidence indicates that the rings originated as zones of large displacement, which facilitated localized frictional melting of the basin floor during the modification (collapse) stage of the cratering process. By analogy, we argue that the rings of other multi-ring impact basins are also likely to be the remnants of such large-displacement fault zones.			SPRAY, JG (corresponding author), UNIV NEW BRUNSWICK,DEPT GEOL,FREDERICTON,NB E3B 5A3,CANADA.		Spray, John/J-7504-2013	Spray, John/0000-0003-3418-6862				[Anonymous], 1984, ONTARIO GEOLOGICAL S, V1, P97; Baldwin R. B., 1972, Physics of the Earth and Planetary Interiors, V6, P327, DOI 10.1016/0031-9201(72)90056-8; Baldwin R. B., 1963, MEASURE MOON, P488; BUTLER HR, IN PRESS LARGE METEO; CHUBB PT, IN PRESS CAN J EARTH; Dence M.R., 1977, IMPACT EXPLOSION CRA, P247; DENCE MR, 1972, SPEC PAP GEOL ASS CA, V10, P7; DIETZ RS, 1964, J GEOL, V72, P412, DOI 10.1086/626999; Dressler B.O., 1987, RES TERRESTRIAL IMPA, P39; DRESSLER BO, 1984, GEOL ORE DEPOSIT+, P97; DRESSLER BO, 1980, 196 ONT MIN NAT RES; FAGGART BE, 1985, SCIENCE, V230, P436, DOI 10.1126/science.230.4724.436; Grieve R. B., 1981, Proceedings of the Heartworm Symposium '80, Dallas, Texas, 23-24 February 1980., P37; GRIEVE RAF, 1991, J GEOPHYS RES-PLANET, V96, P22753, DOI 10.1029/91JE02513; Hartmann W. K., 1971, Moon, V3, P3, DOI 10.1007/BF00620390; Hartmann W.K., 1962, COMMUN LUNAR PLANET, V1, P51; HARTMANN WK, 1969, SKY TELESCOPE, V37, P4; HODGES CA, 1978, ICARUS, V34, P294, DOI 10.1016/0019-1035(78)90169-0; LAMBERT P, 1981, P LUNAR PLANET SCI, V12, P59; MARTINI JEJ, 1992, J METAMORPH GEOL, V10, P517, DOI 10.1111/j.1525-1314.1992.tb00102.x; MARTINI JEJ, 1991, EARTH PLANET SC LETT, V103, P285, DOI 10.1016/0012-821X(91)90167-G; Melosh H. J, 1989, IMPACT CRATERING GEO, DOI DOI 10.1103/PHYSREVB.46.10411; MELOSH HJ, 1978, GEOPHYS RES LETT, V5, P985, DOI 10.1029/GL005i011p00985; MELOSH HJ, 1979, J GEOPHYS RES, V84, P7513, DOI 10.1029/JB084iB13p07513; MILKEREIT B, 1992, GEOLOGY, V20, P807, DOI 10.1130/0091-7613(1992)020<0807:DGOTSS>2.3.CO;2; PEREDERY WV, 1984, GEOLOGY ORE DEPOSITS, P491; PIKE RJ, 1987, EARTH MOON PLANETS, V39, P129, DOI 10.1007/BF00054060; Shand S.J., 1916, Q J GEOL SOC, V72, P198, DOI [10.1144/GSL.JGS.1916.072.01-04.12, DOI 10.1144/GSL.JGS.1916.072.01-04.12]; SHANKS WS, 1991, CAN J EARTH SCI, V28, P1677, DOI 10.1139/e91-149; SPEERS EC, 1947, J GEOL, V65, P497; SPRAY JG, 1993, J GEOPHYS RES-SOL EA, V98, P8053, DOI 10.1029/93JB00020; SPRAY JG, 1992, TECTONOPHYSICS, V204, P205, DOI 10.1016/0040-1951(92)90308-S; SPRAY JG, 1987, J STRUCT GEOL, V7, P49; SPUDIS PD, 1993, GEOLOGY MULTIRING IM, P263; THOMPSON LM, 1993, EOS, V74, P389; WICHMAN RW, 1993, METEORITICS, V28, P222, DOI 10.1111/j.1945-5100.1993.tb00760.x; Wood C.A., 1976, P LUNAR PLANET SCI C, P3629	37	116	117	1	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					130	132		10.1038/373130a0	http://dx.doi.org/10.1038/373130a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7816095				2022-12-28	WOS:A1995QB06300051
J	SEUFERT, W; FUTCHER, B; JENTSCH, S				SEUFERT, W; FUTCHER, B; JENTSCH, S			ROLE OF A UBIQUITIN-CONJUGATING ENZYME IN DEGRADATION OF S-PHASE AND M-PHASE CYCLINS	NATURE			English	Article							YEAST-CELL CYCLE; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; PROTEOLYSIS; ENCODES; KINASE; CDC28; ANAPHASE; PATHWAY; MITOSIS	CELL cycle progression in eukaryotes is controlled by the p34(cdc2/CDC28) protein kinase and its short-lived, phase-specific regulatory subunits called cyclins(1,2). In Xenopus oocytes, degradation of M-phase (B-type) cyclins is required for exit from mitosis and is mediated by the ubiquitin-dependent proteolytic system(3). Here we show that B-type-cyclin degradation in yeast involves an essential nuclear ubiquitin-conjugating enzyme, UBC9. Repression of UBC9 synthesis prevents cell cycle progression at the G2 or early M phase, causing the accumulation of large budded cells with a single nucleus, a short spindle and replicated DNA. In ubc9 mutants both CLB5, an S-phase cyclin(4,5), and CLB2, an M-phase cyclin(6,7), are stabilized. In wild-type cells the CLB5 protein is unstable throughout the cell cycle, whereas CLB2 turnover occurs only at a specific cell-cycle stage(8). Thus distinct degradation signals or regulated interaction,vith the ubiquitin-protein ligase system may determine the cell-cycle specificity of cyclin proteolysis.	MAX PLANCK GESELL,FRIEDRICH MIESCHER LAB,D-72076 TUBINGEN,GERMANY; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Eberhard Karls University of Tubingen; Max Planck Society; Cold Spring Harbor Laboratory			Seufert, Wolfgang/F-7136-2019	Seufert, Wolfgang/0000-0001-8938-9064				AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Ausubel FM, 1994, CURRENT PROTOCOLS MO; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; ELLISON KS, 1991, J BIOL CHEM, V266, P24116; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1992, ANNU REV GENET, V26, P177; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0	30	440	454	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 5	1995	373	6509					78	81		10.1038/373078a0	http://dx.doi.org/10.1038/373078a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800043				2022-12-28	WOS:A1995QA23900060
J	SUGAWARA, N; IVANOV, EL; FISHMANLOBELL, J; RAY, BL; WU, X; HABER, JE				SUGAWARA, N; IVANOV, EL; FISHMANLOBELL, J; RAY, BL; WU, X; HABER, JE			DNA STRUCTURE-DEPENDENT REQUIREMENTS FOR YEAST RAD GENES IN GENE CONVERSION	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; MATING-TYPE; NUCLEOTIDE-SEQUENCE; REPAIR; RECOMBINATION; CASSETTE; PROTEIN	IN Saccharomyces cerevisiae, HO endonuclease-induced mating-type (MAT) switching is a specialized mitotic recombination event in which MAT sequences are replaced by those copied from a distant, unexpressed donor (HML or HMR)(1,2). The donors have a chromatin structure inaccessible for both transcription and HO cleavage(1,2). Here we use physical monitoring of DNA to show that MAT switching is completely blocked at an early step in recombination in strains deleted for the DNA repair genes RAD51, RAD52, RAD54, RAD55 or RAD57. We find, however, that only RAD52 is required when the donor sequence is simultaneously not silenced and located on a plasmid. RAD51, RAD54, RAD55 and RAD57 are still required when the same transcribed donor is on the chromosome. We conclude that recombination in vivo occurs between DNA molecules in chromatin, whose structure significantly influences the outcome. RAD51, RAD54, RAD55 and RAD57 are all required to facilitate strand invasion into otherwise inaccessible donor sequences.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254	Brandeis University; Brandeis University				Haber, James/0000-0002-1878-0610				ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; BANG DD, 1992, NUCLEIC ACIDS RES, V20, P3925, DOI 10.1093/nar/20.15.3925; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; BRAND AH, 1985, CELL, P41; COLLINS I, 1994, MOL CELL BIOL, V14, P3524, DOI 10.1128/MCB.14.5.3524; EMERY HS, 1991, GENE, V104, P103, DOI 10.1016/0378-1119(91)90473-O; FISHMANLOBELL J, 1992, MOL CELL BIOL, V12, P1292, DOI 10.1128/MCB.12.3.1292; HABER JE, 1993, P NATL ACAD SCI USA, V90, P3363, DOI 10.1073/pnas.90.8.3363; HABER JE, 1992, TRENDS GENET, V8, P446, DOI 10.1016/0168-9525(92)90329-3; IVANOV EL, 1994, MOL CELL BIOL, V14, P3414, DOI 10.1128/MCB.14.5.3414; JENSEN RE, 1984, COLD SPRING HARB SYM, V49, P97, DOI 10.1101/SQB.1984.049.01.013; KANS JA, 1991, GENE, V105, P139, DOI 10.1016/0378-1119(91)90527-I; LOVETT ST, 1994, GENE, V142, P103, DOI 10.1016/0378-1119(94)90362-X; LOVETT ST, 1987, GENETICS, V116, P547; MAHONEY DJ, 1989, MOL CELL BIOL, V9, P4621, DOI 10.1128/MCB.9.11.4621; MALONE RE, 1980, P NATL ACAD SCI-BIOL, V77, P503, DOI 10.1073/pnas.77.1.503; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; NICKOLOFF JA, 1989, J MOL BIOL, V207, P527, DOI 10.1016/0022-2836(89)90462-2; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; RATTRAY A, IN PRESS GENETICS; RAVEH D, 1989, MOL GEN GENET, V220, P33; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, P202; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SIMPSON RT, 1993, PROGR NUCLEIC ACIDS, V40, P1896; STRATHERN JN, 1989, GENETIC RECOMBINATIO, P445; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; VERHAGE R, 1994, MOL CELL BIOL, V14, P6135, DOI 10.1128/MCB.14.9.6135; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; [No title captured]	30	160	164	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 5	1995	373	6509					84	86		10.1038/373084a0	http://dx.doi.org/10.1038/373084a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800045				2022-12-28	WOS:A1995QA23900062
J	WADE, MJ; CHANG, NW				WADE, MJ; CHANG, NW			INCREASED MALE-FERTILITY IN TRIBOLIUM-CONFUSUM BEETLES AFTER INFECTION WITH THE INTRACELLULAR PARASITE WOLBACHIA	NATURE			English	Article							CYTOPLASMIC INCOMPATIBILITY; DROSOPHILA-SIMULANS; FLOUR BEETLES; INHERITANCE; POPULATIONS; SPECIATION; SYMBIONT; SPREAD	THE cytoplasmically inherited microorganism Wolbachia pipientis behaves like a sexually selected trait in its host, the flour beetle Tribolium confusum, enhancing male fertility at the expense of female fecundity. Here we show that infected females have fewer offspring than uninfected females but infected males have a large fertility advantage over uninfected males within multiply-inseminated infected or uninfected females. The male fertility effect accelerates the spread of the Wolbachia through the host population and expands the initial opportunity for hitch-hiking of host nuclear genes. Sperm competition in a host, mediated by endosymbionts, has not been previously described.			WADE, MJ (corresponding author), UNIV CHICAGO,DEPT ECOL & EVOLUT,1101 E 57TH ST,CHICAGO,IL 60637, USA.							Breeuwer J.A.J., 1992, Insect Molecular Biology, V1, P25, DOI 10.1111/j.1365-2583.1993.tb00074.x; BREEWUER JAJ, 1990, NATURE, V348, P558; HOFFMANN AA, 1988, GENETICS, V119, P435; HOLDEN PR, 1993, GENET RES, V62, P23, DOI 10.1017/S0016672300031529; KAMBHAMPATI S, 1993, EVOLUTION, V47, P673, DOI [10.2307/2410079, 10.1111/j.1558-5646.1993.tb02121.x]; LANDE R, 1981, P NATL ACAD SCI-BIOL, V78, P3721, DOI 10.1073/pnas.78.6.3721; MONTCHAMPMOREAU C, 1991, GENETICS, V129, P399; MORAN N, 1994, TRENDS ECOL EVOL, V9, P15, DOI 10.1016/0169-5347(94)90226-7; ONEILL SL, 1990, NATURE, V348, P178, DOI 10.1038/348178a0; ONEILL SL, 1992, P NATL ACAD SCI USA, V89, P2649; PARK T, 1933, EXP ZOOL, V65, P17; RICHARDSON PM, 1987, J INVERTEBR PATHOL, V50, P176, DOI 10.1016/0022-2011(87)90080-2; ROBINSON T, 1994, HEREDITY, V73, P155, DOI 10.1038/hdy.1994.114; ROUSSET F, 1991, TRENDS ECOL EVOL, V6, P54, DOI 10.1016/0169-5347(91)90123-F; ROUSSET F, 1993, HEREDITY, V72, P325; STEVENS L, 1990, GENETICS, V124, P367; STEVENS L, 1993, ANIM BEHAV, V46, P305, DOI 10.1006/anbe.1993.1191; STOUTHAMER R, 1993, NATURE, V361, P66, DOI 10.1038/361066a0; SUBBARAO SK, RECENT DEV GENETICS, P313; THOMPSON JN, 1987, BIOL J LINN SOC, V32, P385, DOI 10.1111/j.1095-8312.1987.tb00439.x; TRPIS MJ, 1993, J HERED, V72, P313; TURELLI M, 1992, GENETICS, V132, P713; TURELLI M, 1991, NATURE, V353, P440, DOI 10.1038/353440a0; WADE MJ, 1985, SCIENCE, V227, P527, DOI 10.1126/science.3966160; WADE MJ, 1994, J THEOR BIOL, V167, P81, DOI 10.1006/jtbi.1994.1052; WADE MJ, 1994, HEREDITY, V72, P163, DOI 10.1038/hdy.1994.23; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443	28	102	108	1	25	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 5	1995	373	6509					72	74		10.1038/373072a0	http://dx.doi.org/10.1038/373072a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800041				2022-12-28	WOS:A1995QA23900058
J	ZHAO, C; EMMONS, SW				ZHAO, C; EMMONS, SW			A TRANSCRIPTION FACTOR CONTROLLING DEVELOPMENT OF PERIPHERAL SENSE-ORGANS IN C-ELEGANS	NATURE			English	Article							CAENORHABDITIS-ELEGANS; DROSOPHILA-MELANOGASTER; NERVOUS-SYSTEM; CELL LINEAGES; MYC HOMOLOGY; DNA-BINDING; GENE; NEMATODE; ACHAETE; REGION	THE basic-helix-loop-helix (bHLH) proteins constitute a class of transcription factors thought to be important in the control of cell-type determination(1). These transcription factors are believed to activate the expression of cell-type-specific genes to generate stable differentiated cell types(2). The expression of bHLH proteins, in turn, is regulated by spatial cues, so that switches in cell type occur in a reproducible pattern(3). We report here that the lin-32 gene of Caenorhabditis elegans, which encodes a bHLH protein of the Drosophila achaete-scute family of transcription factors, is necessary and in some cells sufficient for specification of the neuroblast cell fate. Similarity in the function and structure of the lin-32 protein (LIN-32) to transcription factors of the achaete-scute gene family in Drosophila and vertebrates implies that this class of transcription factors functioned in a primitive ancestral form to specify neuronal cell fate, supporting the proposition that certain basic mechanisms of cell-type determination have been conserved through metazoan evolution(1).			ZHAO, C (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC GENET,1300 MORRIS PK AVE,BRONX,NY 10461, USA.							ALBERTSON DG, 1993, GENETICS, V134, P211; AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; BAIRD SE, 1991, DEVELOPMENT, V113, P515; BEGLEY CG, 1989, P NATL ACAD SCI USA, V88, P10128; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; CHALFIE M, 1989, SCIENCE, V243, P1027, DOI 10.1126/science.2646709; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; GONZALEZ F, 1989, EMBO J, V8, P3553, DOI 10.1002/j.1460-2075.1989.tb08527.x; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; HODGKIN J, 1983, NATURE, V304, P267, DOI 10.1038/304267a0; HORVITZ HR, 1983, COLD SPRING HARB SYM, V43, P453; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JARMAN AP, 1994, NATURE, V369, P398, DOI 10.1038/369398a0; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PALAZZOLO MJ, 1990, GENE, V88, P25, DOI 10.1016/0378-1119(90)90056-W; PLENEFISCH JD, 1989, GENETICS, V121, P57; RUVKUN G, 1989, GENETICS, V121, P501; SKEATH JB, 1992, GENE DEV, V6, P2606, DOI 10.1101/gad.6.12b.2606; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704	30	108	112	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 5	1995	373	6509					74	78		10.1038/373074a0	http://dx.doi.org/10.1038/373074a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800042				2022-12-28	WOS:A1995QA23900059
J	CURREY, J				CURREY, J			COME BACK DDT - ALL IS FORGIVEN	BRITISH MEDICAL JOURNAL			English	Article																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1692	1692		10.1136/bmj.309.6970.1692	http://dx.doi.org/10.1136/bmj.309.6970.1692			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819990	Green Published			2022-12-28	WOS:A1994PY71700016
J	BARRETT, J				BARRETT, J			ANISOCORIA ASSOCIATED WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS	BRITISH MEDICAL JOURNAL			English	Letter											BARRETT, J (corresponding author), MAUDSLEY HOSP & INST PSYCHIAT,LONDON SE5 8AZ,ENGLAND.								0	5	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1620	1620		10.1136/bmj.309.6969.1620a	http://dx.doi.org/10.1136/bmj.309.6969.1620a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819940	Green Published			2022-12-28	WOS:A1994PY22000023
J	KAKABADSE, A; SMYLLIE, H				KAKABADSE, A; SMYLLIE, H			EFFECTIVE TOP TEAMS - LUXURY OR NECESSITY	BRITISH MEDICAL JOURNAL			English	Article									TRENT HLTH AUTHOR,SHEFFIELD S10 3TH,S YORKSHIRE,ENGLAND		KAKABADSE, A (corresponding author), CRANFIELD SCH MANAGEMENT,CRANFIELD MK43 0AL,BEDS,ENGLAND.							KAKABADSE A, 1992, WEALTH CREATORS; 1987, J R COLL PHYSICIANS, V21, P175	2	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1653	1654		10.1136/bmj.309.6969.1653	http://dx.doi.org/10.1136/bmj.309.6969.1653			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819955	Green Published			2022-12-28	WOS:A1994PY22000043
J	HOLLEMAN, DR; SIMEL, DL				HOLLEMAN, DR; SIMEL, DL			DOES THE CLINICAL EXAMINATION PREDICT AIR-FLOW LIMITATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FORCED EXPIRATORY TIME; OBSTRUCTIVE AIRWAYS DISEASE; AIR-FLOW OBSTRUCTION; LUNG-FUNCTION; DIAGNOSIS; ASTHMA; SAMPLE		UNIV KENTUCKY,DEPT MED,LEXINGTON,KY 40506; VET AFFAIRS MED CTR,CTR HLTH SERV RES PRIMARY CARE,DURHAM,NC 27705; DUKE UNIV,CTR HLTH CARE POLICY RES & EDUC,DURHAM,NC	University of Kentucky; US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University	HOLLEMAN, DR (corresponding author), VET AFFAIRS MED CTR,MED SERV 111K,2250 LEESTOWN RD,LEXINGTON,KY 40511, USA.							BADGETT RG, 1993, AM J MED, V94, P188, DOI 10.1016/0002-9343(93)90182-O; BILGI C, 1977, CAN MED ASSOC J, V117, P1389; Bohadana A B, 1982, Indian J Chest Dis Allied Sci, V24, P133; BOHADANA AB, 1978, THORAX, V33, P345, DOI 10.1136/thx.33.3.345; CATLETT GF, 1969, AEROSPACE MED, V40, P1252; DODGE R, 1986, AM REV RESPIR DIS, V133, P981; FISHER M, 1989, GUIDE CLIN PREVENTIV; FLETCHER CM, 1952, P ROY SOC MED, V45, P577; FORGACS P, 1978, CHEST, V73, P399, DOI 10.1378/chest.73.3.399; FOXMAN B, 1982, RAND R226281HHS PUBL; GOVINDARAJ M, 1970, Indian Journal of Chest Diseases, V12, P110; HEPPER NG, 1969, ARCH ENVIRON HEALTH, V19, P806, DOI 10.1080/00039896.1969.10666934; HOLLEMAN DR, 1993, J GEN INTERN MED, V8, P63, DOI 10.1007/BF02599985; KERN DG, 1991, CHEST, V100, P636, DOI 10.1378/chest.100.3.636; KILBURN KH, 1969, ARCH INTERN MED, V123, P379, DOI 10.1001/archinte.123.4.379; KING DK, 1989, ANN INTERN MED, V110, P451, DOI 10.7326/0003-4819-110-6-451; LAL S, 1964, BRIT MED J, V1, P814, DOI 10.1136/bmj.1.5386.814; LEFCOE NM, 1970, CAN MED ASSOC J, V102, P381; MACDONALD JB, 1975, THORAX, V30, P554, DOI 10.1136/thx.30.5.554; MANNINO DM, 1993, ARCH INTERN MED, V153, P1892, DOI 10.1001/archinte.153.16.1892; MARINI JJ, 1979, AM REV RESPIR DIS, V120, P1069; MARKS A, 1960, South Med J, V53, P1211; MCNICOL KN, 1970, ARCH DIS CHILD, V45, P783, DOI 10.1136/adc.45.244.783; MULROW CD, 1986, J GEN INTERN MED, V1, P364, DOI 10.1007/BF02596418; NAIRN J R, 1969, British Journal of Diseases of the Chest, V63, P29, DOI 10.1016/S0007-0971(69)80041-0; PARDEE NE, 1980, CHEST, V77, P354, DOI 10.1378/chest.77.3.354; PARDEE NE, 1976, CHEST, V70, P341, DOI 10.1378/chest.70.3.341; REBUCK AS, 1985, CAN MED ASSOC J, V112, P710; SCHAPIRA RM, 1993, JAMA-J AM MED ASSOC, V270, P731, DOI 10.1001/jama.270.6.731; SCHEINHORN DJ, 1982, SOUTHERN MED J, V75, P434, DOI 10.1097/00007611-198204000-00014; SCHILLING RSF, 1955, BMJ-BRIT MED J, V1, P65, DOI 10.1136/bmj.1.4905.65; SHERRILL DL, 1991, AM REV RESPIR DIS, V144, P17, DOI 10.1164/ajrccm/144.1.17; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; SNIDER TH, 1959, JAMA-J AM MED ASSOC, V170, P1631, DOI 10.1001/jama.1959.03010140011004; STUBBING DG, 1982, AM REV RESPIR DIS, V125, P549, DOI 10.1164/arrd.1982.125.5.549; SUPRENANT EL, 1967, DIS CHEST, V52, P760; TEKLU B, 1990, J FAM PRACTICE, V31, P557; THACKER RE, 1982, CHEST, V81, P672, DOI 10.1378/chest.81.6.672; van Schayck C P, 1991, Scand J Prim Health Care, V9, P232, DOI 10.3109/02813439109018525; WILKINS RL, 1990, CHEST, V98, P886, DOI 10.1378/chest.98.4.886; WILLIAMS TJ, 1981, ARCH INTERN MED, V141, P878, DOI 10.1001/archinte.141.7.878; WORKUM P, 1982, AM REV RESPIR DIS, V126, P927; 1987, AM REV RESPIR DIS, V136, P225; 1991, AM REV RESPIR DIS, V144, P1202	44	134	135	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	1995	273	4					313	319		10.1001/jama.273.4.313	http://dx.doi.org/10.1001/jama.273.4.313			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC057	7815660				2022-12-28	WOS:A1995QC05700031
J	FRYER, CJH				FRYER, CJH			PELVIC RHABDOMYOSARCOMA - PAYING THE PRICE OF BLADDER PRESERVATION	LANCET			English	Editorial Material							SEQUELAE		BRITISH COLUMBIA CHILDRENS HOSP,VANCOUVER,BC,CANADA	BC Childrens Hospital; University of British Columbia	FRYER, CJH (corresponding author), UNIV BRITISH COLUMBIA,DIV PEDIAT HEMATOL ONCOL,VANCOUVER,BC,CANADA.							ATRA A, 1994, BRIT J CANCER, V70, P1004, DOI 10.1038/bjc.1994.438; DONALDSON S, 1994, MED PEDIATR ONCOL, V23, P3; FLAMANT F, 1990, J CLIN ONCOL, V8, P1847, DOI 10.1200/JCO.1990.8.11.1847; FONTANESI J, 1991, ENDOCURIETH HYPERTH, V7, P195; HAYS DM, IN PRESS AM J PEDIAT; HAYS DM, 1991, MED PEDIATR ONCOL, V19, P423; RANEY B, 1993, CANCER, V71, P2387, DOI 10.1002/1097-0142(19930401)71:7<2387::AID-CNCR2820710734>3.0.CO;2-A; YEUNG CK, 1994, BRIT J CANCER, V70, P1000, DOI 10.1038/bjc.1994.437	8	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					141	142		10.1016/S0140-6736(95)90162-0	http://dx.doi.org/10.1016/S0140-6736(95)90162-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7823666				2022-12-28	WOS:A1995QC55000005
J	FINZI, L; GELLES, J				FINZI, L; GELLES, J			MEASUREMENT OF LACTOSE REPRESSOR-MEDIATED LOOP FORMATION AND BREAKDOWN IN SINGLE DNA-MOLECULES	SCIENCE			English	Article							LAC REPRESSOR; OPERATORS; STABILITY; COMPLEX; PROTEIN; INVITRO; OPERON	In gene regulatory systems in which proteins bind to multiple sites on a DNA molecule, the characterization of chemical mechanisms and single-step reaction rates is difficult because many chemical species may exist simultaneously in a molecular ensemble. This problem was circumvented by detecting DNA looping by the lactose repressor protein of Escherichia coli in single DNA molecules. The looping was detected by monitoring the nanometer-scale Brownian motion of microscopic particles linked to the ends of individual DNA molecules. This allowed the determination of the rates of formation and breakdown of a protein-mediated DNA loop in vitro. The measurements reveal that mechanical strain stored in the loop does not substantially accelerate loop breakdown, and the measurements also show that subunit dissociation of tetrameric repressor is not the predominant loop breakdown pathway.	BRANDEIS UNIV,GRAD DEPT BIOCHEM,WALTHAM,MA 02254; BRANDEIS UNIV,CTR COMPLEX SYST,WALTHAM,MA 02254	Brandeis University; Brandeis University								BERLINER E, 1994, J BIOL CHEM, V269, P8610; BERLINER E, IN PRESS NATURE; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; BRENOWITZ M, 1990, BIOCHEMISTRY-US, V29, P3374, DOI 10.1021/bi00465a033; BRENOWITZ M, 1993, BIOCHEMISTRY-US, V32, P8693, DOI 10.1021/bi00084a041; BRENOWITZ M, 1991, BIOCHEMISTRY-US, V30, P5986, DOI 10.1021/bi00238a024; COLQUHOUN D, 1981, PROC R SOC SER B-BIO, V211, P205, DOI 10.1098/rspb.1981.0003; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; EISMANN E, 1987, J MOL BIOL, V195, P949, DOI 10.1016/0022-2836(87)90499-2; FINZI L, UNPUB; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HSIEH WT, 1987, J BIOL CHEM, V262, P14583; KRAMER H, 1987, EMBO J, V6, P1481, DOI 10.1002/j.1460-2075.1987.tb02390.x; MATTHEWS KS, 1992, MICROBIOL REV, V56, P123, DOI 10.1128/MMBR.56.1.123-136.1992; MOSSING MC, 1986, SCIENCE, V233, P889, DOI 10.1126/science.3090685; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; SCHAFER DA, 1991, NATURE, V352, P444, DOI 10.1038/352444a0; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; YIN H, 1994, BIOPHYS J, V67, P2468, DOI 10.1016/S0006-3495(94)80735-0	19	182	191	0	20	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 20	1995	267	5196					378	380		10.1126/science.7824935	http://dx.doi.org/10.1126/science.7824935			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC273	7824935				2022-12-28	WOS:A1995QC27300035
J	GLOVER, JNM; HARRISON, SC				GLOVER, JNM; HARRISON, SC			CRYSTAL-STRUCTURE OF THE HETERODIMERIC BZIP TRANSCRIPTION FACTOR C-FOS-C-JUN BOUND TO DNA	NATURE			English	Article							X-RAY STRUCTURE; LEUCINE ZIPPER; BASIC REGION; BINDING DOMAINS; COILED-COIL; PROTEIN; COMPLEX; RECOGNITION; SPECIFICITY; EXPRESSION	THE FOS and Jun families of eukaryotic transcription factors heterodimerize to form complexes capable of binding 5'-TGAGTCA-3' DNA elements. We have determined the X-ray crystal structure of a heterodimer of the bZIP regions of c-Fos and c-Jun bound to DNA. Both subunits form continuous alpha-helices. The carboxy-terminal regions form an asymmetric coiled-coil, and the amino-terminal regions make base-specific contacts with DNA in the major groove. Comparison of the two crystallographically distinct protein-DNA complexes show that the coiled-coil is flexibly joined to the basic regions and that the Fos-Jun heterodimer does not recognize the asymmetric 5'-TGAGTCA-3' recognition element in a unique orientation. There is an extensive network of electrostatic interactions between subunits within the coiled-coil, consistent with proposals that these interactions determine preferential formation of the heterodimer over either of the homodimers.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University	GLOVER, JNM (corresponding author), HARVARD UNIV,HOWARD HUGHES MED INST,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.							ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ABATE C, 1990, SCIENCE, V248, P1157; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; 1979, CCP 4 SUITE PROGRAMS	28	653	691	1	43	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					257	261		10.1038/373257a0	http://dx.doi.org/10.1038/373257a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816143				2022-12-28	WOS:A1995QC27800068
J	ADER, R; COHEN, N; FELTEN, D				ADER, R; COHEN, N; FELTEN, D			PSYCHONEUROIMMUNOLOGY - INTERACTIONS BETWEEN THE NERVOUS-SYSTEM AND THE IMMUNE-SYSTEM	LANCET			English	Review							CORTICOTROPIN-RELEASING FACTOR; CONDITIONED ENHANCEMENT; LYMPHOID ORGANS; STRESS; INTERLEUKIN-1; ARTHRITIS; CELLS; SUSCEPTIBILITY; SYMPATHECTOMY; INNERVATION		UNIV ROCHESTER, SCH MED & DENT, DEPT MICROBIOL & IMMUNOL, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT ANAT & NEUROBIOL, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, CTR PSYCHONEUROIMMUNOL RES, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	ADER, R (corresponding author), UNIV ROCHESTER, MED CTR, SCH MED & DENT, DEPT PSYCHIAT, ROCHESTER, NY 14642 USA.							ACKERMAN KD, 1991, PSYCHONEUROIMMUNOLOG, P71; ADER R, 1993, BRAIN BEHAV IMMUN, V7, P334, DOI 10.1006/brbi.1993.1033; ADER R, 1982, SCIENCE, V215, P1534, DOI 10.1126/science.7063864; ADER R, 1993, ANNU REV PSYCHOL, V44, P53, DOI 10.1146/annurev.ps.44.020193.000413; ADER R, 1991, PSYCHONEUROIMMUNOLOG, P685; Ader R, 1991, PSYCHONEUROIMMUNOLOG; Ader R., 1991, PSYCHONEUROIMMUNOLOG, V2nd Edn, P611; Ader R, 1987, PROG BRAIN RES <D>, V72, P79; BELLINGER DL, 1992, INT J IMMUNOPHARMACO, V14, P329, DOI 10.1016/0192-0561(92)90162-E; Berczi I, 1986, PITUITARY FUNCTION I; BERKENBOSCH F, 1987, SCIENCE, V238, P524, DOI 10.1126/science.2443979; BERNTON EW, 1991, PSYCHONEUROIMMUNOLOG, P403; BESEDOVSKY H, 1986, SCIENCE, V233, P652, DOI 10.1126/science.3014662; Besedovsky HO., 1991, PSYCHONEUROIMMUNOLOG, pp. 589, DOI [10.1159/000452902, DOI 10.1159/000452902]; BLALOCK JE, 1984, J IMMUNOL, V132, P1067; CHELMICKASCHORR E, 1988, J NEUROIMMUNOL, V17, P347, DOI 10.1016/0165-5728(88)90125-7; COE CL, 1985, PSYCHOBIOLOGY ATTACH, P163; COHEN S, 1993, J PERS SOC PSYCHOL, V64, P131, DOI 10.1037/0022-3514.64.1.131; COHEN S, 1991, PSYCHOL BULL, V109, P5, DOI 10.1037/0033-2909.109.1.5; DANTZER R, 1989, LIFE SCI, V44, P1995, DOI 10.1016/0024-3205(89)90345-7; DYCK DG, 1990, BRAIN BEHAV IMMUN, V4, P93, DOI 10.1016/0889-1591(90)90012-F; FELTEN DL, 1991, BRAIN BEHAV IMMUN, V5, P2, DOI 10.1016/0889-1591(91)90003-S; FELTEN DL, 1992, EUR J CLIN INVEST, V22, P37; FELTEN DL, 1991, NEUR CONT B, V6, P3; Felten S. Y., 1991, PSYCHONEUROIMMUNOLOG, P27, DOI DOI 10.1016/B978-0-12-043780-1.50006-3; FRIEDMAN H, 1991, PSYCHONEUROIMMUNOLOG, P931; GLASER R, 1987, Brain Behavior and Immunity, V1, P7, DOI 10.1016/0889-1591(87)90002-X; GORCZYNSKI RM, 1990, BRAIN BEHAV IMMUN, V4, P85, DOI 10.1016/0889-1591(90)90011-E; Heijnen C.J., 1991, PSYCHONEUROIMMUNOLOG, V2nd ed., P429; HEIJNEN CJ, 1991, IMMUNOL REV, V119, P41, DOI 10.1111/j.1600-065X.1991.tb00577.x; HERBERT TB, 1993, PSYCHOL BULL, V113, P472, DOI 10.1037/0033-2909.113.3.472; JEFFERIES WM, 1991, MED HYPOTHESES, V34, P198, DOI 10.1016/0306-9877(91)90212-H; Keller S, 1991, PSYCHONEUROIMMUNOLOG, P771; KELLEY KW, 1991, PSYCHONEUROIMMUNOLOG, P377; KOFF WC, 1986, J IMMUNOL, V136, P705; LEVINE JD, 1984, SCIENCE, V226, P547, DOI 10.1126/science.6208609; LEVINE S, 1962, P SOC EXP BIOL MED, V109, P294, DOI 10.3181/00379727-109-27183; LYCKE E, 1974, BRIT J PSYCHIAT, V124, P273, DOI 10.1192/bjp.124.3.273; LYSLE DT, 1988, LIFE SCI, V42, P2185, DOI 10.1016/0024-3205(88)90369-4; MADDEN KS, 1994, J NEUROIMMUNOL, V49, P67, DOI 10.1016/0165-5728(94)90182-1; MADDEN KS, 1991, PSYCHONEUROIMMUNOLOG, P283; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; OLNESS K, 1992, J DEV BEHAV PEDIATR, V13, P124, DOI 10.1097/00004703-199204000-00008; PAYAN DG, 1992, INFLAMMATION BASIC P, P177; Renoux G., 1991, PSYCHONEUROIMMUNOLOG, V2nd, P127; RETTORI V, 1987, J NEUROSCI RES, V18, P179, DOI 10.1002/jnr.490180125; SANDERS VM, 1992, J IMMUNOL, V148, P1822; SAPOLSKY R, 1987, SCIENCE, V238, P522, DOI 10.1126/science.2821621; SCHIFFER RB, 1991, PSYCHONEUROIMMUNOLOG, P1037; SHAVIT Y, 1991, PSYCHONEUROIMMUNOLOG, P789; SHERIDAN JF, 1994, CLIN MICROBIOL REV, V7, P200, DOI 10.1128/CMR.7.2.200-212.1994; SINGH U, 1985, CELL IMMUNOL, V93, P222, DOI 10.1016/0008-8749(85)90402-2; STERNBERG EM, 1989, P NATL ACAD SCI USA, V86, P4771, DOI 10.1073/pnas.86.12.4771; Weigent DA, 1994, NEUROPEPTIDES IMMUNO, P14; Weiner H., 1977, PSYCHOBIOLOGY HUMAN	55	585	621	2	72	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 14	1995	345	8942					99	103		10.1016/S0140-6736(95)90066-7	http://dx.doi.org/10.1016/S0140-6736(95)90066-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QB804	7815892				2022-12-28	WOS:A1995QB80400013
J	VRIELINK, H; VANDERPOEL, CL; REESINK, HW; ZAAIJER, HL; SCHOLTEN, E; KREMER, LCM; CUYPERS, HTM; LELIE, PN; VANOERS, MHJ				VRIELINK, H; VANDERPOEL, CL; REESINK, HW; ZAAIJER, HL; SCHOLTEN, E; KREMER, LCM; CUYPERS, HTM; LELIE, PN; VANOERS, MHJ			LOOK-BACK STUDY OF INFECTIVITY OF ANTI-HCV ELISA-POSITIVE BLOOD COMPONENTS	LANCET			English	Note							HEPATITIS-C VIRUS; RECOMBINANT IMMUNOBLOT ASSAY	The infectivity of blood components from donors who were later found to be anti-HCV ELISA-positive was investigated in recipients who were enrolled in a look-back programme. Recipients received ELISA-positive blood components from donors who were PCR-positive and/or RIBA-2-positive (n=22, group A) or PCR-negative and indeterminate or negative on RIBA-2 (n=105, group B). 26 of 32 (81%) recipients of group A donors and none of 140 of group B were HCV-infected. All stored serum samples of previous donations (n=172) of group A donors were anti-HCV-positive in RIBA-3, indicating a chronic carrier state of HCV in these donors.	NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam	VRIELINK, H (corresponding author), NETHERLANDS RED CROSS,BLOOD BANK AMSTERDAM,POSTBOX 9137,PLESMANLAAN 125,1066 CX AMSTERDAM,NETHERLANDS.			Kremer, Leontien/0000-0001-7422-3248				BUSCH MP, 1991, TRANSFUSION, V31, P655, DOI 10.1046/j.1537-2995.1991.31791368346.x; CUYPERS HTM, 1992, J CLIN MICROBIOL, V30, P3220, DOI 10.1128/JCM.30.12.3220-3224.1992; EBELING F, 1990, LANCET, V335, P982, DOI 10.1016/0140-6736(90)91055-F; SAMSON S, 1990, TRANSFUSION, V30, P214, DOI 10.1046/j.1537-2995.1990.30390194339.x; UYTTENDAELE S, 1994, VOX SANG, V66, P122, DOI 10.1111/j.1423-0410.1994.tb00293.x; VANDERPOEL C, 1991, TRANSFUSION, V31, P777; VANDERPOEL CL, 1991, LANCET, V337, P317, DOI 10.1016/0140-6736(91)90942-I; ZAAIJER HL, 1994, TRANSFUSION, V34, P603, DOI 10.1046/j.1537-2995.1994.34794330015.x	8	56	56	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					95	96		10.1016/S0140-6736(95)90063-2	http://dx.doi.org/10.1016/S0140-6736(95)90063-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815889				2022-12-28	WOS:A1995QB80400010
J	FAKLER, B; BRANDLE, U; GLOWATZKI, E; WEIDEMANN, S; ZENNER, HP; RUPPERSBERG, JP				FAKLER, B; BRANDLE, U; GLOWATZKI, E; WEIDEMANN, S; ZENNER, HP; RUPPERSBERG, JP			STRONG VOLTAGE-DEPENDENT INWARD RECTIFICATION OF INWARD RECTIFIER K+ CHANNELS IS CAUSED BY INTRACELLULAR SPERMINE	CELL			English	Article							GUINEA-PIG HEART; POTASSIUM CHANNEL; IK(A) CHANNELS; CELL-MEMBRANE; INACTIVATION; MAGNESIUM; IONS; POLYAMINES; EXPRESSION; COMPLEX	Inward rectifier K+ channels mediate the K+ conductance at resting potential in many types of cell. Since these K+ channels do not pass outward currents (inward rectification) when the cell membrane is depolarized beyond a trigger threshold, they play an important role in controlling excitability. Both a highly voltage-dependent block by intracellular Mg2+ and an endogenous gating process are presently assumed to underly inward rectification. It is shown that strong voltage dependence of rectification found under physiological conditions is predominantly due to the effect of intracellular spermine. Physiological concentrations of free spermine mediate strong rectification of IRK1 inward rectifier K+ channels even in the absence of free Mg2+ and in IRK1 mutant channels that have no endogenous rectification.	UNIV TUBINGEN HOSP, EAR NOSE & THROAT CLIN, DEPT SENSORY BIOPHYS, D-72076 TUBINGEN, GERMANY	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital				Glowatzki, Elisabeth/0000-0003-3135-658X				BOND CT, 1994, RECEPTOR CHANNEL, V2, P183; CHO SW, 1991, EUR J BIOCHEM, V202, P107, DOI 10.1111/j.1432-1033.1991.tb16350.x; ELAM TR, 1993, BIOPHYS J, V64, pA227; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FAKLER B, 1994, NEURON, V13, P1413, DOI 10.1016/0896-6273(94)90426-X; FAKLER B, 1994, FEBS LETT, V356, P199, DOI 10.1016/0014-5793(94)01258-X; GIANNAKOUROS T, 1990, MOL CELL BIOCHEM, V99, P9, DOI 10.1007/BF01261388; GUTTERIDGE JMC, 1990, BIOCHEM J, V269, P169, DOI 10.1042/bj2690169; HAGIWARA S, 1976, J GEN PHYSIOL, V67, P621, DOI 10.1085/jgp.67.6.621; HEBY O, 1981, DIFFERENTIATION, V19, P1, DOI 10.1111/j.1432-0436.1981.tb01123.x; HERLITZE S, 1990, GENE, V91, P143, DOI 10.1016/0378-1119(90)90177-S; HILGEMANN DW, 1991, NATURE, V352, P715, DOI 10.1038/352715a0; Hille B, 1992, IONIC CHANNELS EXCIT, P127; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; ISHIHARA K, 1989, J PHYSIOL-LONDON, V419, P297, DOI 10.1113/jphysiol.1989.sp017874; KELLY MEM, 1992, J MEMBRANE BIOL, V126, P171; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KURACHI Y, 1985, J PHYSIOL-LONDON, V366, P365, DOI 10.1113/jphysiol.1985.sp015803; LEECH CA, 1981, J PHYSIOL-LONDON, V319, P295, DOI 10.1113/jphysiol.1981.sp013909; LOPATIN AN, 1994, J PHYSL, V477, P86; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MATSUDA H, 1991, J PHYSIOL-LONDON, V435, P83, DOI 10.1113/jphysiol.1991.sp018499; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; RUPPERSBERG JP, 1991, NATURE, V353, P657, DOI 10.1038/353657a0; RUPPERSBERG JP, 1994, SEMIN NEUROSCI, V6, P87; SILVER MR, 1990, J GEN PHYSIOL, V96, P109, DOI 10.1085/jgp.96.1.109; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WATANABE S, 1991, J BIOL CHEM, V266, P20803	30	313	314	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 13	1995	80	1					149	154		10.1016/0092-8674(95)90459-X	http://dx.doi.org/10.1016/0092-8674(95)90459-X			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813010	Bronze			2022-12-28	WOS:A1995QB91000018
J	VONROENN, JH; ARMSTRONG, D; KOTLER, DP; COHN, DL; KLIMAS, NG; TCHEKMEDYIAN, NS; CONE, L; BRENNAN, PJ; WEITZMAN, SA				VONROENN, JH; ARMSTRONG, D; KOTLER, DP; COHN, DL; KLIMAS, NG; TCHEKMEDYIAN, NS; CONE, L; BRENNAN, PJ; WEITZMAN, SA			MEGESTROL-ACETATE IN PATIENTS WITH AIDS-RELATED CACHEXIA	ANNALS OF INTERNAL MEDICINE			English	Article						MEGESTROL; ACQUIRED IMMUNODEFICIENCY SYNDROME; CACHEXIA; WEIGHT GAIN; APPETITE	VIRUS HIV INFECTION; NUTRITIONAL-STATUS; CONTROLLED TRIAL; CANCER ANOREXIA; APPETITE; WEIGHT	Objectives: To compare the effects of oral suspensions of megestrol acetate, 800 mg/d, and placebo on body weight in patients with acquired immunodeficiency syndrome (AIDS)-related weight loss. Design: Randomized, double-blind, placebo-controlled trial. Setting: Outpatient community and university patient care setting. Patients: Consecutive patients with AIDS who had substantial weight loss and anorexia were enrolled. Of 271 patients, 270 and 195 were evaluable for safety and efficacy, respectively. Interventions: Patients were randomly assigned to receive placebo or megestrol acetate (100 mg, 400 mg, or 800 mg) daily for 12 weeks. Main Outcome Measures: The primary efficacy criterion was weight gain. Patients were evaluated at 4-week intervals for changes in weight and body composition, caloric intake, sense of well-being, toxic effects, and appetite. Results: For evaluable patients receiving 800 mg of megestrol acetate per day, 64.2% gained 2.27 kg (5 pounds) or more compared with 21.4% of patients receiving placebo (P < 0.001). An intent-to-treat analysis showed significant differences (P = 0.002) between those receiving placebo and those receiving 800 mg of megestrol acetate for the number of patients who gained 2.27 kg (5 pounds) or more (8 of 32 [25%] compared with 38 of 61 [62.3%], respectively). Compared with patients receiving placebo at the time of maximum weight change, evaluable patients receiving megestrol acetate, 800 mg/d, reported improvement in overall well-being and had an increase in mean weight gain (-0.725 compared with 3.54 kg [-1.6 compared with +7.8 pounds]; P < 0.001), lean body mass (-0.772 compared with +1.14 kg [-1.7 compared with +2.5 pounds]; P < 0.001), appetite grade (P < 0.001), and caloric intake (-107 compared with +645.6 calories/d; P = 0.001). Conclusions: In patients with AIDS-related weight loss, megestrol acetate can stimulate appetite, food intake, and statistically significant weight gain that is associated with a patient-reported improvement in an overall sense of well-being.										BENARD A, 1953, INDAGATIONES MATH, V15, P358; BRUERA E, 1990, CANCER, V66, P1279, DOI 10.1002/1097-0142(19900915)66:6&lt;1279::AID-CNCR2820660630&gt;3.0.CO;2-R; Centers for Disease Control and Prevention, 1987, MMWR-MORBID MORTAL W, V36, p1S; CHANDRA RK, 1980, AM J CLIN NUTR, V33, P2694, DOI 10.1093/ajcn/33.12.2694; Chelluri L, 1989, Nutr Clin Pract, V4, P16, DOI 10.1177/011542658900400116; Fleiss JL, 1981, STAT METHODS RATES P; FURTH PA, 1989, ANN INTERN MED, V110, P667, DOI 10.7326/0003-4819-110-8-667; GREGORY EJ, 1985, J CLIN ONCOL, V3, P155, DOI 10.1200/JCO.1985.3.2.155; KOTLER DP, 1989, AM J CLIN NUTR, V50, P444, DOI 10.1093/ajcn/50.3.444; LOPRINZI CL, 1990, JNCI-J NATL CANCER I, V82, P1127, DOI 10.1093/jnci/82.13.1127; LUKASKI HC, 1987, AM J CLIN NUTR, V46, P537, DOI 10.1093/ajcn/46.4.537; OSULLIVAN P, 1985, J AM DIET ASSOC, V85, P1483; SEGAL KR, 1988, AM J CLIN NUTR, V47, P7, DOI 10.1093/ajcn/47.1.7; TCHEKMEDYIAN NS, 1987, JAMA-J AM MED ASSOC, V257, P1195, DOI 10.1001/jama.257.9.1195; TCHEKMEDYIAN NS, 1986, SEMIN ONCOL, V13, P37; TCHEKMEDYIAN NS, 1992, CANCER, V69, P1268; VONROENN JH, 1988, ANN INTERN MED, V109, P840, DOI 10.7326/0003-4819-109-10-840; YSSELDYKE LL, 1991, J AM DIET ASSOC, V91, P217; Zar J.H., 1999, ZAR KUHR 5 2019, V4th	19	210	212	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1994	121	6					393	399		10.7326/0003-4819-121-6-199409150-00001	http://dx.doi.org/10.7326/0003-4819-121-6-199409150-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF337	7794302				2022-12-28	WOS:A1994PF33700001
J	GOSSEN, M; FREUNDLIEB, S; BENDER, G; MULLER, G; HILLEN, W; BUJARD, H				GOSSEN, M; FREUNDLIEB, S; BENDER, G; MULLER, G; HILLEN, W; BUJARD, H			TRANSCRIPTIONAL ACTIVATION BY TETRACYCLINES IN MAMMALIAN-CELLS	SCIENCE			English	Article							GENE	A transcriptional transactivator was developed that fuses the VP16 activation domain with a mutant Tet repressor from Escherichia coli. This transactivator requires certain tetracycline (Tc) derivatives for specific DNA binding. Thus, addition of doxycycline to HeLa cells that constitutively synthesized the transactivator and that contained an appropriate, stably integrated reporter unit rapidly induced gene expression more than a thousandfold. The specificity of the Tet repressor-operator-effector interaction and the pharmacological characteristics of Tc's make this regulatory system well suited for the control of gene activities in vivo, such as in transgenic animals and possibly in gene therapy.	UNIV ERLANGEN NURNBERG,INST MIKROBIOL & BIOCHEM,D-91058 ERLANGEN,GERMANY	University of Erlangen Nuremberg	GOSSEN, M (corresponding author), UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,NEUENHEIMER FELD 282,D-69120 HEIDELBERG,GERMANY.		Gossen, Manfred/K-9602-2013; Wilson, Matthew H/K-3193-2013	Gossen, Manfred/0000-0002-1761-4063				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1993, TRENDS BIOCHEM SCI, V18, P471, DOI 10.1016/0968-0004(93)90009-C; HECHT B, 1993, J BACTERIOL, V175, P1206, DOI 10.1128/JB.175.4.1206-1210.1993; HILLEN W, 1994, ANNU REV MICROBIOL, V48, P345, DOI 10.1146/annurev.mi.48.100194.002021; HINRICHS W, 1994, SCIENCE, V264, P418, DOI 10.1126/science.8153629; KISTNER A, UNPUB; MULLER G, 1995, THESIS U ERLANGEN NU; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sambrook J, 1989, MOL CLONING LABORATO; SCHLEICHER, 1984, P NATL ACAD SCI USA, V81, P1991; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WEINMANN P, 1994, PLANT J, V5, P559, DOI 10.1046/j.1365-313X.1994.5040559.x; Yarranton Geoffrey T., 1992, Current Opinion in Biotechnology, V3, P506, DOI 10.1016/0958-1669(92)90078-W	16	1963	2319	4	130	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1766	1769		10.1126/science.7792603	http://dx.doi.org/10.1126/science.7792603			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792603				2022-12-28	WOS:A1995RE66800046
J	TAUBES, G				TAUBES, G			INDIANA - WRONG ANSWERS - BUT NO RIGHT ONES	SCIENCE			English	Note																			0	2	2	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1707	1707		10.1126/science.7792590	http://dx.doi.org/10.1126/science.7792590			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792590				2022-12-28	WOS:A1995RE66800024
J	PATE, RR; PRATT, M; BLAIR, SN; HASKELL, WL; MACERA, CA; BOUCHARD, C; BUCHNER, D; ETTINGER, W; HEATH, GW; KING, AC; KRISKA, A; LEON, AS; MARCUS, BH; MORRIS, J; PAFFENBARGER, RS; PATRICK, K; POLLOCK, ML; RIPPE, JM; SALLIS, J; WILMORE, JH				PATE, RR; PRATT, M; BLAIR, SN; HASKELL, WL; MACERA, CA; BOUCHARD, C; BUCHNER, D; ETTINGER, W; HEATH, GW; KING, AC; KRISKA, A; LEON, AS; MARCUS, BH; MORRIS, J; PAFFENBARGER, RS; PATRICK, K; POLLOCK, ML; RIPPE, JM; SALLIS, J; WILMORE, JH			PHYSICAL-ACTIVITY AND PUBLIC-HEALTH - A RECOMMENDATION FROM THE CENTERS-FOR-DISEASE-CONTROL-AND-PREVENTION AND THE AMERICAN-COLLEGE-OF-SPORTS-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEPENDENT DIABETES-MELLITUS; CORONARY HEART-DISEASE; ALL-CAUSE MORTALITY; LEISURE-TIME; DESCRIPTIVE EPIDEMIOLOGY; ESSENTIAL-HYPERTENSION; EXERCISE BEHAVIOR; AEROBIC EXERCISE; FITNESS; MEN	Objective.-To encourage increased participation in physical activity among Americans of all ages by issuing a public health recommendation on the types and amounts of physical activity needed for health promotion and disease prevention. Participants.-A planning committee of five scientists was established by the Centers for Disease Control and Prevention and the American College of Sports Medicine to organize a workshop. This committee selected 15 other workshop discussants on the basis of their research expertise in issues related to the health implications of physical activity. Several relevant professional or scientific organizations and federal agencies also were represented. Evidence.-The panel of experts reviewed the pertinent physiological, epidemiologic, and clinical evidence, including primary research articles and recent review articles. Consensus Process.-Major issues related to physical activity and health were outlined, and selected members of the expert panel drafted sections of the paper from this outline. A draft manuscript was prepared by the planning committee and circulated to the full panel in advance of the 2-day workshop. During the workshop, each section of the manuscript was reviewed by the expert panel, Primary attention was given to achieving group consensus concerning the recommended types and amounts of physical activity. A concise ''public health message'' was developed to express the recommendations of the panel, During the ensuing months, the consensus statement was further reviewed and revised and was formally endorsed by both the Centers for Disease Control and Prevention and the American College of Sports Medicine. Conclusion.-Every US adult should accumulate 30 minutes or more of moderate-intensity physical activity on most, preferably all, days of the week.	CTR DIS CONTROL & PREVENT, ATLANTA, GA 30341 USA; COOPER INST AEROB RES, DALLAS, TX USA; UNIV LAVAL, PHYS ACT SCI LAB, QUEBEC CITY, PQ G1K 7P4, CANADA; STANFORD UNIV, MED CTR, SCH MED, STANFORD, CA 94305 USA; UNIV WASHINGTON, DEPT HLTH SERV, SEATTLE, WA 98195 USA; VET ADM MED CTR, SEATTLE, WA 98108 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, WINSTON SALEM, NC USA; UNIV PITTSBURGH, DEPT EPIDEMIOL, PITTSBURGH, PA 15261 USA; UNIV MINNESOTA, DEPT KINESIOL, MINNEAPOLIS, MN 55455 USA; BROWN UNIV, SCH MED, PROVIDENCE, RI 02912 USA; MIRIAM HOSP, PROVIDENCE, RI 02906 USA; LONDON SCH HYG & TROP MED, DEPT PUBL HLTH & POLICY, LONDON WC1, ENGLAND; STANFORD UNIV, DEPT HLTH RES & POLICY, STANFORD, CA 94305 USA; UNIV CALIF SAN DIEGO, GEN PREVENT MED RESIDENCY, SAN DIEGO, CA 92103 USA; SAN DIEGO STATE UNIV, SAN DIEGO, CA 92182 USA; UNIV FLORIDA, DEPT MED, GAINESVILLE, FL USA; UNIV FLORIDA, DEPT EXERCISE SCI, GAINESVILLE, FL USA; TUFTS UNIV, CTR CLIN & LIFESTYLE RES, MEDFORD, MA 02155 USA; SAN DIEGO STATE UNIV, DEPT PSYCHOL, SAN DIEGO, CA 92182 USA; UNIV TEXAS, DEPT KINESIOL & HLTH EDUC, AUSTIN, TX 78712 USA	Centers for Disease Control & Prevention - USA; Cooper Institute; Laval University; Stanford University; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Wake Forest University; Wake Forest Baptist Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Minnesota System; University of Minnesota Twin Cities; Brown University; Lifespan Health Rhode Island; Miriam Hospital; University of London; London School of Hygiene & Tropical Medicine; Stanford University; University of California System; University of California San Diego; California State University System; San Diego State University; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Tufts University; California State University System; San Diego State University; University of Texas System; University of Texas Austin	PATE, RR (corresponding author), UNIV S CAROLINA, SCH PUBL HLTH, DEPT EXERCISE SCI, COLUMBIA, SC 29208 USA.		Bouchard, Claude/A-7637-2009; Sallis, James F/D-3001-2014; Bouchard, Claude/AAE-2035-2019; Heath, Gregory Wayne/AAE-2464-2020	Bouchard, Claude/0000-0002-0048-491X; Sallis, James F/0000-0003-2555-9452; Heath, Gregory Wayne/0000-0003-2864-5225; Kriska, Andrea/0000-0002-3522-0869				AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; [Anonymous], 1990, MED SCI SPORT EXER, V22, P265; BLAIR SN, 1984, JAMA-J AM MED ASSOC, V252, P487, DOI 10.1001/jama.252.4.487; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; Bouchard C, 1993, Obes Res, V1, P133; BOUCHARD C, 1994, PHYSICAL ACTIVITY FI; CASPERSEN C J, 1992, Medicine and Science in Sports and Exercise, V24, pS26, DOI 10.1249/00005768-199205001-00153; CASPERSEN CJ, 1985, PUBLIC HEALTH REP, V100, P126; CASPERSEN CJ, 1986, PUBLIC HEALTH REP, V101, P587; CASPERSEN CJ, 1987, DHHS PHS881214 US DE, P30; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; DALSKY GP, 1988, ANN INTERN MED, V108, P824, DOI 10.7326/0003-4819-108-6-824; DEBUSK RF, 1990, AM J CARDIOL, V65, P1010, DOI 10.1016/0002-9149(90)91005-Q; DIPIETRO L, 1991, Medicine and Science in Sports and Exercise, V23, pS105; Dishman R., 1988, EXERCISE ADHERENCE; Dishman R., 1982, HEALTH PSYCHOL, V3, P237, DOI DOI 10.1037/0278-6133.1.3.237; Dishman R. K., 1992, EXERCISE DISEASE, V1, P179; Dishman RK., 1994, PHYS ACTIVITY FITNES, P214; DUNCAN JJ, 1985, JAMA-J AM MED ASSOC, V254, P2609, DOI 10.1001/jama.254.18.2609; EBISU T, 1985, Japanese Journal of Physical Education, V30, P37; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; FISHER M, 1989, GUIDE CLIN PREVENTIV; FLETCHER GF, 1992, CIRCULATION, V86, P340, DOI 10.1161/01.CIR.86.1.340; GODIN G, 1987, J BEHAV MED, V10, P145, DOI 10.1007/BF00846423; HAGBERG JM, 1990, EXERCISE, FITNESS, AND HEALTH, P455; HAGBERG JM, 1989, AM J CARDIOL, V64, P348, DOI 10.1016/0002-9149(89)90533-X; HAHN RA, 1990, JAMA-J AM MED ASSOC, V264, P2654, DOI 10.1001/jama.264.20.2654; HASKELL WL, 1986, ACTA MED SCAND, P25; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; IVY JL, 1987, EXERCISE SPORT SCI R, V15, P29; KING AC, 1993, HEALTH PSYCHOL, V12, P292, DOI 10.1037/0278-6133.12.4.292; KING AC, 1989, HEALTH PSYCHOL, V8, P305, DOI 10.1037/0278-6133.8.3.305; KOHL HW, 1988, AM J EPIDEMIOL, V127, P1228, DOI 10.1093/oxfordjournals.aje.a114915; KOHRT WM, 1991, J APPL PHYSIOL, V71, P2004, DOI 10.1152/jappl.1991.71.5.2004; KOIVISTO V A, 1986, Diabetes Metabolism Reviews, V1, P445; LEE IM, 1991, J NATL CANCER I, V83, P1324, DOI 10.1093/jnci/83.18.1324; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; LEON AS, 1981, AM HLTH F BOOK HLTH, P293; LEWIS BS, 1993, PREV MED, V22, P110, DOI 10.1006/pmed.1993.1008; Long B. J., 1994, Medicine and Science in Sports and Exercise, V26, pS4; MANSON JE, 1992, JAMA-J AM MED ASSOC, V268, P63, DOI 10.1001/jama.268.1.63; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; MARCUS R, 1992, MED SCI SPORT EXER, V24, pS301; MARTIN JE, 1982, J CONSULT CLIN PSYCH, V50, P1004, DOI 10.1037/0022-006X.50.6.1004; MCCARDLE WD, 1986, EXERCISE PHYSL ENERG, P642; MEREDITH CN, 1989, J APPL PHYSIOL, V66, P2844, DOI 10.1152/jappl.1989.66.6.2844; Moore S., 1994, Physical activity, fitness, and health: international proceedings and consensus statement., P570; MORRIS JN, 1966, LANCET, V2, P553, DOI 10.1016/S0140-6736(66)93034-0; MORRIS JN, 1990, BRIT HEART J, V63, P325; NEHLSENCANNARELLA SL, 1991, MED SCI SPORT EXER, V23, P64; Nieman DC, 1994, PYSICAL ACTIVITY FIT, P796; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PAFFENBARGER RS, 1983, AM J EPIDEMIOL, V117, P245, DOI 10.1093/oxfordjournals.aje.a113537; PARSONS D, 1992, Medicine and Science in Sports and Exercise, V24, pS21, DOI 10.1249/00005768-199205001-00125; PAVLOU KN, 1989, AM J CLIN NUTR, V49, P1115, DOI 10.1093/ajcn/49.5.1115; POLLOCK M. L., 1988, EXERCISE ADHERENCE I, P259; POLLOCK ML, 1974, ARCH PHYS MED REHAB, V55, P418; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; RAURAMAA R, 1994, PHYSICAL ACTIVITY FI, P471; Rogers M A, 1993, Exerc Sport Sci Rev, V21, P65; Sallis J F, 1990, Exerc Sport Sci Rev, V18, P307; SALLIS JF, 1992, PREV MED, V21, P237, DOI 10.1016/0091-7435(92)90022-A; SALLIS JF, 1989, PREV MED, V18, P20, DOI 10.1016/0091-7435(89)90051-0; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; SCHOENBORN CA, 1986, PUBLIC HEALTH REP, V101, P571; Snow-Harter C, 1991, Exerc Sport Sci Rev, V19, P351; STEPHENS T, 1985, PUBLIC HEALTH REP, V100, P147; STEPHENS T, 1987, RES Q EXERCISE SPORT, V58, P94, DOI 10.1080/02701367.1987.10605432; TAYLOR CB, 1985, PUBLIC HEALTH REP, V100, P195; TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9; Tipton C M, 1991, Exerc Sport Sci Rev, V19, P447; TUCKER LA, 1990, RES Q EXERCISE SPORT, V61, P315, DOI 10.1080/02701367.1990.10607493; WHITE CC, 1987, AM J PREV MED, V3, P304; WOOD PD, 1991, NEW ENGL J MED, V325, P461, DOI 10.1056/NEJM199108153250703; 1993, MMWR-MORBID MORTAL W, V42, P576; 1983, DHHS PHS831572 NAT C; 1993, MMWR-MORBID MORTAL W, V42, P669; 1991, US DHHS PHS9150212 P; 1992, PROJECT PACE PHYSICI; 1991, GUIDELINES EXERCISE; 1993, MED SCI SPORTS EXERC, V10, pR1	83	5075	5277	17	907	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	1995	273	5					402	407		10.1001/jama.273.5.402	http://dx.doi.org/10.1001/jama.273.5.402			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QD203	7823386				2022-12-28	WOS:A1995QD20300025
J	ARNOW, P; CHAMBERLIN, W				ARNOW, P; CHAMBERLIN, W			DEBUGGING COMPUTER-ASSISTED ANTIBIOTIC PRESCRIBING	LANCET			English	Editorial Material									MICHAEL REESE HOSP & MED CTR,CHICAGO,IL 60616	Michael Reese Hospital & Medical Center	ARNOW, P (corresponding author), UNIV CHICAGO HOSP & CLIN,DEPT MED,CHICAGO,IL 60637, USA.							EVANS RS, 1994, ARCH INTERN MED, V154, P878, DOI 10.1001/archinte.154.8.878; GARDNER FT, 1979, ARCH SURG-CHICAGO, V114, P883; GROSS PA, 1994, CLIN INFECT DIS, V18, P421, DOI 10.1093/clinids/18.3.421; HIRSCHMAN SZ, 1988, ARCH INTERN MED, V148, P2001, DOI 10.1001/archinte.148.9.2001; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; MOSS FM, 1981, LANCET, V2, P407; NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418, DOI 10.1164/ajrccm/148.5.1418; STURM AW, 1988, J ANTIMICROB CHEMOTH, V22, P257, DOI 10.1093/jac/22.2.257; YU VI, 1976, JAMA-J AM MED ASSOC, V242, P1279; YU VL, 1991, AM J MED SCI, V301, P165, DOI 10.1097/00000441-199103000-00003; 1994, J ANTIMICROB CHEMOTH, V34, P21	11	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 28	1995	345	8944					207	208		10.1016/S0140-6736(95)90219-8	http://dx.doi.org/10.1016/S0140-6736(95)90219-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7823711				2022-12-28	WOS:A1995QD53200005
J	WEST, S; MUNOZ, B; LYNCH, M; KAYONGOYA, A; CHILANGWA, Z; MMBAGA, BBO; TAYLOR, HR				WEST, S; MUNOZ, B; LYNCH, M; KAYONGOYA, A; CHILANGWA, Z; MMBAGA, BBO; TAYLOR, HR			IMPACT OF FACE-WASHING ON TRACHOMA IN KONGWA, TANZANIA	LANCET			English	Article							RISK	Observational studies have suggested that the prevalence of trachoma is lower in children with clean faces than in those with ocular or nasal discharge or flies on the face. We carried out a community-based randomised trial in three pairs of villages to assess the impact on trachoma of a face-washing intervention programme following a mass topical antibiotic treatment campaign. Six villages in Kongwa, Tanzania, were randomly assigned mass treatment plus the face-washing programme or treatment only. 1417 children aged 1-7 years in these villages were randomly selected and followed up for trachoma status and observations of facial cleanliness at baseline and 2, 6, and 12 months. At 12 months, children in the intervention villages were 60% more likely to have bad clean faces at two or more follow-up visits than children in the control villages. The odds of having severe trachoma in the intervention villages were 0.62 (95% CI 0.40-0.97) compared with control villages. A clean face at two or more follow-up visits was protective for any trachoma (odds ratio 0.58 [0.47-0.72]) and severe trachoma (0.35 [0.21-0.59]). This community-based participatory approach to face-washing intervention had variable penetration rates in the villages and was labour intensive. However, we found that, combined with topical treatment, community-based strategies for improving hygiene in children in trachoma-endemic villages can reduce the prevalence of trachoma.	JOHNS HOPKINS UNIV, DANA CTR PREVENT OPHTHALMOL, BALTIMORE, MD USA; CENT EYE HLTH FDN, DODOMA, TANZANIA; UNIV MELBOURNE, DEPT OPHTHALMOL, MELBOURNE, VIC, AUSTRALIA	Johns Hopkins University; University of Melbourne				Taylor, Hugh/0000-0002-9437-784X				LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LYNCH M, 1994, T ROY SOC TROP MED H, V88, P513, DOI 10.1016/0035-9203(94)90141-4; MABEY DCW, 1991, ANN TROP PAEDIATR, V11, P295, DOI 10.1080/02724936.1991.11747518; RAPOZA PA, 1991, INT OPHTHALMOL, V15, P123, DOI 10.1007/BF01046432; STANTON BF, 1987, AM J EPIDEMIOL, V125, P292, DOI 10.1093/oxfordjournals.aje.a114529; TAYLOR HR, 1989, ARCH OPHTHALMOL-CHIC, V107, P1821, DOI 10.1001/archopht.1989.01070020903037; THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477; WEST S, 1993, INVEST OPHTH VIS SCI, V34, P3194; WEST S, 1994, INT OPHTHALMOL, V18, P105, DOI 10.1007/BF00919249; WEST SK, 1991, ARCH OPHTHALMOL-CHIC, V109, P855, DOI 10.1001/archopht.1991.01080060119038; WEST SK, 1991, INT J EPIDEMIOL, V20, P1088, DOI 10.1093/ije/20.4.1088	11	170	175	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 21	1995	345	8943					155	158		10.1016/S0140-6736(95)90167-1	http://dx.doi.org/10.1016/S0140-6736(95)90167-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7823670	hybrid			2022-12-28	WOS:A1995QC55000010
J	CHEN, J; MAKINO, CL; PEACHEY, NS; BAYLOR, DA; SIMON, MI				CHEN, J; MAKINO, CL; PEACHEY, NS; BAYLOR, DA; SIMON, MI			MECHANISMS OF RHODOPSIN INACTIVATION IN-VIVO AS REVEALED BY A COOH-TERMINAL TRUNCATION MUTANT	SCIENCE			English	Article							DOMINANT RETINITIS-PIGMENTOSA; ROD OUTER SEGMENTS; COUPLED RECEPTOR KINASES; PHOSPHORYLATION SITES; TRANSGENIC MICE; PROTEIN; GENE; DESENSITIZATION; PHOTORECEPTORS; TRANSDUCTION	Although biochemical experiments suggest that rhodopsin and other receptors coupled to heterotrimeric guanosine triphosphate-binding proteins (G proteins) are inactivated by phosphorylation near the carboxyl (COOH)-terminus and the subsequent binding of a capping protein, little is known about the quenching process in vivo. Flash responses were recorded from rods of transgenic mice in which a fraction of the rhodopsin molecules lacked the COOH-terminal phosphorylation sites. In the single photon regime, abnormally prolonged responses, attributed to activation of individual truncated rhodopsins, occurred interspersed with normal responses. The occurrence of the prolonged responses suggests that phosphorylation is required for normal shutoff. Comparison of normal and prolonged single photon responses indicated that rhodopsin begins to be quenched before the peak of the electrical response and that quenching limits the response amplitude.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305; EDWARD HINES JR VET ADM HOSP,HINES,IL 60141; LOYOLA UNIV,STRITCH SCH MED,DEPT NEUROL,MAYWOOD,IL 60153	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Loyola University Chicago	CHEN, J (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.		Makino, Clint Lawrence/H-8428-2019; Peachey, Neal/G-5533-2010	Makino, Clint Lawrence/0000-0002-6005-9069; Peachey, Neal/0000-0002-4419-7226	NATIONAL EYE INSTITUTE [F32EY006405] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012288] Funding Source: NIH RePORTER; NEI NIH HHS [F32 EY06405, EY0570] Funding Source: Medline; NIA NIH HHS [AG12288] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H; APFELSTEDTSYLLA E, 1993, BRIT J OPHTHALMOL, V77, P495, DOI 10.1136/bjo.77.8.495; BAUMANN C, 1973, J PHYSIOL-LONDON, V235, P761, DOI 10.1113/jphysiol.1973.sp010415; BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; BENNETT N, 1980, BIOCHEM BIOPH RES CO, V96, P1695, DOI 10.1016/0006-291X(80)91369-8; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BRETON ME, 1994, INVEST OPHTH VIS SCI, V35, P295; CHEN J, 1993, INVEST OPHTH VIS SCI, V34, P768; CONE RA, 1969, NATURE, V221, P820, DOI 10.1038/221820a0; EBREY TG, 1968, VISION RES, V8, P965, DOI 10.1016/0042-6989(68)90071-0; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; HARGRAVE PA, 1992, INT REV CYTOL, V137B, P49; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HOOD DC, 1990, VISUAL NEUROSCI, V5, P379, DOI 10.1017/S0952523800000468; HORN M, 1992, HUM GENET, V90, P255; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KIM RY, 1993, ARCH OPHTHALMOL-CHIC, V111, P1518, DOI 10.1001/archopht.1993.01090110084030; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; MCDOWELL JH, 1985, INVEST OPHTH VIS SCI, V26, P291; MILLER JL, 1984, VISION RES, V24, P1509, DOI 10.1016/0042-6989(84)90313-4; NEWTON AC, 1991, J BIOL CHEM, V266, P17725; NEWTON AC, 1993, J BIOL CHEM, V268, P18181; OHGURO H, 1994, BIOCHEMISTRY-US, V33, P1023, DOI 10.1021/bi00170a022; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PEACHEY NS, UNPUB; PENN RD, 1969, NATURE, V223, P201, DOI 10.1038/223201a0; RESTAGNO G, 1993, HUM MOL GENET, V2, P207, DOI 10.1093/hmg/2.2.207; SUNG CH, 1994, J NEUROSCI, V14, P5818; VUONG TM, 1991, P NATL ACAD SCI USA, V88, P9813, DOI 10.1073/pnas.88.21.9813; WEHNER M, 1987, ADV BIOSCI, V62, P345; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; WILLIAMS DS, 1989, EXP EYE RES, V49, P439, DOI 10.1016/0014-4835(89)90052-3; WILSON CJ, 1993, CURR BIOL, V3, P683, DOI 10.1016/0960-9822(93)90068-Y	39	258	262	1	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 20	1995	267	5196					374	377		10.1126/science.7824934	http://dx.doi.org/10.1126/science.7824934			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC273	7824934				2022-12-28	WOS:A1995QC27300034
J	KATZ, AM				KATZ, AM			IMAGES IN CLINICAL MEDICINE - POST-TACHYCARDIA T-WAVE SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											KATZ, AM (corresponding author), UNIV CONNECTICUT,CTR HLTH,SCH MED,FARMINGTON,CT 06030, USA.								0	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 19	1995	332	3					161	161		10.1056/NEJM199501193320306	http://dx.doi.org/10.1056/NEJM199501193320306			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB160	7800008				2022-12-28	WOS:A1995QB16000006
J	KOPP, P; VANSANDE, J; PARMA, J; DUPREZ, L; GERBER, H; JOSS, E; JAMESON, JL; DUMONT, JE; VASSART, G				KOPP, P; VANSANDE, J; PARMA, J; DUPREZ, L; GERBER, H; JOSS, E; JAMESON, JL; DUMONT, JE; VASSART, G			BRIEF REPORT - CONGENITAL HYPERTHYROIDISM CAUSED BY A MUTATION IN THE THYROTROPIN-RECEPTOR GENE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							MCCUNE-ALBRIGHT SYNDROME; LUTEINIZING-HORMONE RECEPTOR; STIMULATORY G-PROTEIN; NEONATAL HYPERTHYROIDISM; PRECOCIOUS PUBERTY; THYROID ADENOMAS; GRAVES-DISEASE; CYCLIC-AMP; PREGNANCY; ONCOGENE		UNIV BERN, INSELSPITAL, DEPT INTERNAL MED, CH-3010 BERN, SWITZERLAND; UNIV BERN, INSELSPITAL, ENDOCRINOL LAB, CH-3010 BERN, SWITZERLAND; UNIV BERN, INSELSPITAL, PEDIAT CLIN, CH-3010 BERN, SWITZERLAND; FREE UNIV BRUSSELS, FAC MED, DEPT MED GENET, BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, FAC MED, INST RECH INTERDISCIPLINAIRE, BRUSSELS, BELGIUM	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	KOPP, P (corresponding author), NORTHWESTERN UNIV, CTR ENDOCRINOL METAB & MOLEC MED, TARRY 15, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA.			Jameson, James/0000-0001-9538-4059; Kopp, Peter A/0000-0001-5980-0529	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042144] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42144] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; HOLLINGSWORTH DR, 1976, AM J DIS CHILD, V130, P148, DOI 10.1001/archpedi.1976.02120030038008; HOLLINGSWORTH DR, 1972, J PEDIATR-US, V81, P446, DOI 10.1016/S0022-3476(72)80170-7; HOLLINGSWORTH DR, 1980, P SERONO S, V32, P169; HOLLINGSWORTH DR, 1985, PEDIATRIC THYROIDOLO, V14, P210; HOLLINGSWORTH DR, 1980, THYROID RES, V8, P587; HORTON GL, 1987, THESIS U LAUSANNE SW; KARGA H, 1991, J CLIN ENDOCR METAB, V73, P832, DOI 10.1210/jcem-73-4-832; KOPP P, 1994, J CLIN ENDOCR METAB, V79, P134, DOI 10.1210/jc.79.1.134; KOSUGI S, 1993, MOL ENDOCRINOL, V7, P1009, DOI 10.1210/me.7.8.1009; KREMER H, 1993, HUM MOL GENET, V2, P1779, DOI 10.1093/hmg/2.11.1779; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; OSULLIVAN C, 1991, MOL CARCINOGEN, V4, P345, DOI 10.1002/mc.2940040503; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; RAMSAY I, 1983, CLIN ENDOCRINOL, V18, P73, DOI 10.1111/j.1365-2265.1983.tb03188.x; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SCHWINDINGER WF, 1992, P NATL ACAD SCI USA, V89, P5152, DOI 10.1073/pnas.89.11.5152; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; THOMAS JL, 1982, ACTA ENDOCRINOL-COP, V100, P512, DOI 10.1530/acta.0.1000512; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; WILROY RS, 1971, J PEDIATR-US, V78, P625, DOI 10.1016/S0022-3476(71)80464-X; YOSHIMOTO M, 1991, ACTA PAEDIATR SCAND, V80, P984, DOI 10.1111/j.1651-2227.1991.tb11769.x; ZAKARIJA M, 1983, J CLIN ENDOCR METAB, V57, P1036, DOI 10.1210/jcem-57-5-1036; ZAKARIJA M, 1986, J CLIN ENDOCR METAB, V62, P368, DOI 10.1210/jcem-62-2-368; Zannolli R, 1989, Minerva Pediatr, V41, P33; 1987, DIAGNOSTIC STATISTIC	30	267	274	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 19	1995	332	3					150	154		10.1056/NEJM199501193320304	http://dx.doi.org/10.1056/NEJM199501193320304			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB160	7800007				2022-12-28	WOS:A1995QB16000004
J	HYNES, M; POULSEN, K; TESSIERLAVIGNE, M; ROSENTHAL, A				HYNES, M; POULSEN, K; TESSIERLAVIGNE, M; ROSENTHAL, A			CONTROL OF NEURONAL DIVERSITY BY THE FLOOR PLATE - CONTACT-MEDIATED INDUCTION OF MIDBRAIN DOPAMINERGIC-NEURONS	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; TYROSINE-HYDROXYLASE; CELL PATTERN; SUBSTANTIA-NIGRA; RAT; DIFFERENTIATION; EXPRESSION; SIGNALS; LOCALIZATION; RECEPTORS	The notochord and floor plate contribute to patterning the ventral neural tube in part by expressing a diffusible factor that induces motoneurons. To determine the mechanisms that direct the development of other classes of ventral neurons, we studied the development of dopaminergic neurons that reside near motoneurons in the ventral midbrain. We provide evidence that dopaminergic neurons develop in the vicinity of the floor plate and that they can be specified by the floor plate in vitro and in vivo. Unlike motoneurons, efficient induction of dopaminergic neurons requires contact with floor plate cells. These results suggest that neuronal diversification along the dorsal-ventral axis may be achieved partly through the concerted action of diffusible and contact-dependent signals from a single organizing center, the floor plate.	GENENTECH INC,DEPT NEUROSCI,S SAN FRANCISCO,CA 94080; UNIV CALIF SAN FRANCISCO,DEPT ANAT,PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,PROGRAM CELL BIOL,SAN FRANCISCO,CA 94143	Roche Holding; Genentech; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco				Hynes, Mary/0000-0001-6623-6727				ALTABA AR, 1993, J NEUROBIOL, V24, P1276, DOI 10.1002/neu.480241004; ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; ALTMAN J, 1981, J COMP NEUROL, V198, P677, DOI 10.1002/cne.901980409; BANERJEE SA, 1992, J NEUROSCI, V12, P4460; BAPTISTA CA, 1994, NEURON, V12, P243, DOI 10.1016/0896-6273(94)90268-2; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; DONIACH T, 1993, J NEUROBIOL, V24, P1256, DOI 10.1002/neu.480241003; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; GAO WQ, 1992, CELL, V68, P841, DOI 10.1016/0092-8674(92)90028-B; GAO WQ, 1991, NEURON, V6, P705, DOI 10.1016/0896-6273(91)90168-Y; GREENBERG D, 1974, SCIENCE, V184, P1243; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HIRSCH E, 1988, NATURE, V334, P345, DOI 10.1038/334345a0; JESSELL TM, 1992, HARVEY LECT, V86, P87; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAUDER JM, 1974, J COMP NEUROL, V155, P469, DOI 10.1002/cne.901550407; LUMSDEN A, 1994, DEVELOPMENT, V120, P1581; LUSKIN MB, 1993, J NEUROSCI, V13, P1730; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MARCHAND R, 1983, NEUROSCIENCE, V9, P373, DOI 10.1016/0306-4522(83)90300-7; MCCAFFERY P, 1994, P NATL ACAD SCI USA, V91, P7772, DOI 10.1073/pnas.91.16.7772; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; PICKEL VM, 1975, J HISTOCHEM CYTOCHEM, V23, P1, DOI 10.1177/23.1.234988; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PUELLES L, 1993, TRENDS NEUROSCI, V16, P472, DOI 10.1016/0166-2236(93)90080-6; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SASAKI H, 1993, DEVELOPMENT, V118, P47; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SEEMAN P, 1993, NATURE, V365, P441, DOI 10.1038/365441a0; SMITH JC, 1994, CELL, V76, P193, DOI 10.1016/0092-8674(94)90325-5; SPECHT LA, 1981, J COMP NEUROL, V199, P255, DOI 10.1002/cne.901990208; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; VOORN P, 1988, NEUROSCIENCE, V25, P857, DOI 10.1016/0306-4522(88)90041-3; WATANABE T, 1990, NEURON, V2, P461; YAGINUMA H, 1991, J COMP NEUROL, V304, P78, DOI 10.1002/cne.903040107; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	41	204	212	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					95	101		10.1016/0092-8674(95)90454-9	http://dx.doi.org/10.1016/0092-8674(95)90454-9			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813022	Bronze			2022-12-28	WOS:A1995QB91000013
J	STEINMAN, L				STEINMAN, L			ESCAPE FROM HORROR AUTOTOXICUS - PATHOGENESIS AND TREATMENT OF AUTOIMMUNE-DISEASE	CELL			English	Review							MYELIN BASIC-PROTEIN; GLUTAMIC-ACID DECARBOXYLASE; NONOBESE DIABETIC MICE; RHEUMATOID-ARTHRITIS; GENE; RECEPTOR; IMMUNE				STEINMAN, L (corresponding author), STANFORD UNIV,SCH MED,BECKMAN CTR MOLEC & GENET MED,DEPT NEUROL & NEUROL SCI,STANFORD,CA 94305, USA.			Steinman, Lawrence/0000-0002-2437-2250				AMAGAI M, 1992, CELL, V67, P869; CONRAD B, 1994, NATURE, V371, P351, DOI 10.1038/371351a0; CORNALL RJ, 1991, NATURE, V353, P262, DOI 10.1038/353262a0; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; ELIAS D, 1994, LANCET, V343, P704, DOI 10.1016/S0140-6736(94)91582-2; ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362; FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848; GAUR A, 1994, ADV IMMUNOL, V56, P219, DOI 10.1016/S0065-2776(08)60453-8; GOVERMAN J, 1993, CELL, V72, P551, DOI 10.1016/0092-8674(93)90074-Z; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; KIM J, 1994, J EXP MED, V180, P595, DOI 10.1084/jem.180.2.595; KOH DR, 1992, SCIENCE, V256, P1210, DOI 10.1126/science.256.5060.1210; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LAFAILLE JJ, 1994, CELL, V78, P399, DOI 10.1016/0092-8674(94)90419-7; MURYOI T, 1992, J EXP MED, V175, P1103, DOI 10.1084/jem.175.4.1103; NEPOM GT, 1991, ANNU REV IMMUNOL, V9, P493; OKSENBERG JR, 1993, NATURE, V362, P68, DOI 10.1038/362068a0; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; PETTE M, 1990, NEUROLOGY, V40, P1770, DOI 10.1212/WNL.40.11.1770; PRIBYL TM, 1993, P NATL ACAD SCI USA, V90, P10695, DOI 10.1073/pnas.90.22.10695; RAPOPORT MJ, 1993, J EXP MED, V178, P87, DOI 10.1084/jem.178.1.87; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; STEINMAN L, 1993, SCI AM, V269, P106, DOI 10.1038/scientificamerican0993-106; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; VINCENT A, 1994, IMMUNOLOGY NEUROMUSC, P1; WARREN KG, 1994, ANN NEUROL, V35, P280, DOI 10.1002/ana.410350307; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809	29	88	107	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					7	10		10.1016/0092-8674(95)90443-3	http://dx.doi.org/10.1016/0092-8674(95)90443-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813019	Bronze			2022-12-28	WOS:A1995QB91000002
J	COURIEL, JM				COURIEL, JM			GLUE EAR - PRESCRIBE, OPERATE, OR WAIT	LANCET			English	Editorial Material							CHILDREN				COURIEL, JM (corresponding author), BOOTH HALL CHILDRENS HOSP,DEPT MED,MANCHESTER,LANCS,ENGLAND.							BERMAN S, 1994, PEDIATRICS, V93, P353; BLACK NA, 1990, BRIT MED J, V300, P1551, DOI 10.1136/bmj.300.6739.1551; DEMELKER RA, 1993, BRIT MED J, V306, P5, DOI 10.1136/bmj.306.6869.5; GATES GA, 1987, NEW ENGL J MED, V317, P1441; MAW AR, 1994, CLIN OTOLARYNGOL, V19, P125, DOI 10.1111/j.1365-2273.1994.tb01195.x; MAW R, 1993, BMJ-BRIT MED J, V306, P756, DOI 10.1136/bmj.306.6880.756; Paradise J L, 1992, Adv Pediatr, V39, P157; 1992, EFFECTIVE HLTH CARE	8	7	7	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					3	4		10.1016/S0140-6736(95)91144-8	http://dx.doi.org/10.1016/S0140-6736(95)91144-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799705				2022-12-28	WOS:A1995QA29000003
J	BARRETT, TG; BOOTH, IW				BARRETT, TG; BOOTH, IW			SARTORIAL ELOQUENCE - DOES IT EXIST IN THE PEDIATRICIAN PATIENT RELATIONSHIP	BRITISH MEDICAL JOURNAL			English	Article							ATTIRE	Objective-To evaluate children's and parents' perceptions of hospital doctors' attire. Design-Questionnaire study asking children and parents to assign positive and negative attributes to five photographs of a male or female doctor dressed formally and informally. Setting-Outpatient department, Children's Hospital, Birmingham. Subjects-203 consecutive child-parent pairs attending outpatient clinics over three months. Main outcome measures-Children's and parents' preferences, assessed by comparing proportions. Results-70% (286/406) of children and parents rated doctors' dress as important; more children rated it ''very important'' (27% (54/203) v 14% (29/203), P < 0.01, 95% confidence interval for difference 5% to 21%). Of the 99 children responding, 44 regarded the man in white coat as most competent (44% v 20% expected by chance, P < 0.01, 34% to 54%) and most concerned (32% v 20%, P < 0.01, 23% to 41%), Children also regarded the woman in white coat as most competent; however, male and female doctors in white coats rated lower for friendliness. Asians and regular surgical attenders preferred doctors in white coats. The man in polo shirt and trousers was rated as most friendly (40% v 20% expected by chance, P < 0.01, 30% to 50%) and most gentle (37% v 20%, P < 0.01, 27% to 46%). The woman in tee shirt and slacks also rated most friendly and gentle; however, both casually dressed doctors rated lower for competence. Parents preferred more casual dress but expressed preferences less strongly, and they poorly predicted which outfits their children preferred. Conclusions-Children regard formally dressed doctors as competent but not friendly; they regard casual dress as friendly but not competent.	INST CHILD HLTH,BIRMINGHAM,W MIDLANDS,ENGLAND		BARRETT, TG (corresponding author), BIRMINGHAM MATERNITY HOSP,DEPT CLIN GENET,BIRMINGHAM B15 2TG,W MIDLANDS,ENGLAND.		Barrett, Timothy/F-1682-2010	Barrett, Timothy/0000-0002-6873-0750				BANNERJEE AK, 1988, MED J AUSTRALIA, V149, P168; BISHOP F, 1991, J ROY SOC MED, V84, P522, DOI 10.1177/014107689108400906; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; DUNN JJ, 1987, JAMA-J AM MED ASSOC, V257, P65, DOI 10.1001/jama.257.1.65; MARINO RV, 1991, J DEV BEHAV PEDIATR, V12, P98; STONE DH, 1993, BRIT MED J, V307, P1264, DOI 10.1136/bmj.307.6914.1264	6	40	43	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1710	1712		10.1136/bmj.309.6970.1710	http://dx.doi.org/10.1136/bmj.309.6970.1710			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819997	Green Published			2022-12-28	WOS:A1994PY71700027
J	EMSON, HE				EMSON, HE			CHRISTMAS WISHES	BRITISH MEDICAL JOURNAL			English	Editorial Material											EMSON, HE (corresponding author), ROYAL UNIV HOSP,SASKATOON,SK S7N 0X0,CANADA.								0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1738	1739		10.1136/bmj.309.6970.1738	http://dx.doi.org/10.1136/bmj.309.6970.1738			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7820008	Green Published			2022-12-28	WOS:A1994PY71700039
J	ZOMERDIJK, JCBM; BECKMANN, H; COMAI, L; TJIAN, R				ZOMERDIJK, JCBM; BECKMANN, H; COMAI, L; TJIAN, R			ASSEMBLY OF TRANSCRIPTIONALLY ACTIVE RNA-POLYMERASE-I INITIATION-FACTOR SL1 FROM RECOMBINANT SUBUNITS	SCIENCE			English	Article							FACTOR-TIF-IA; TATA-BINDING-PROTEIN; VACCINIA VIRUS; EXPRESSION SYSTEM; III TRANSCRIPTION; RIBOSOMAL DNA; MOUSE RDNA; PROMOTER; COMPLEX; SEQUENCES	Initiation of ribosomal RNA synthesis by RNA polymerase I requires the promoter selec tivity factor SL1, which consists of the TATA-binding protein, TBP, and three associated factors, TAF(I)s 110, 63, and 48. Here the in vivo and in vitro assembly of functional SL1 complexes from recombinant TAF(I)s and TBP are reported. Complexes containing TBP and all three TAF(I)s were as active in supporting transcription from the human ribosomal RNA gene promoter as endogenous SL1, whereas partial complexes without TBP did not efficiently direct transcription in vitro. These results suggest that TAF(I)s 110, 63, and 48, together with TBP, are necessary and sufficient to reconstitute a transcriptionally active SL1 complex.	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley			Comai, Lucio/H-9524-2019; Zomerdijk, Joost/A-5142-2008; Comai, Lucio/L-5905-2019	Comai, Lucio/0000-0003-3109-1841; Zomerdijk, Joost/0000-0003-1865-729X				BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; BUTTGEREIT D, 1985, NUCLEIC ACIDS RES, V13, P8165, DOI 10.1093/nar/13.22.8165; CAVANAUGH AH, 1985, NUCLEIC ACIDS RES, V13, P3357, DOI 10.1093/nar/13.9.3357; CLOS J, 1986, P NATL ACAD SCI USA, V83, P604, DOI 10.1073/pnas.83.3.604; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; MACKETT M, 1984, J VIROL, V49, P857, DOI 10.1128/JVI.49.3.857-864.1984; MCSTAY B, 1991, EMBO J, V10, P2297, DOI 10.1002/j.1460-2075.1991.tb07766.x; MISHIMA Y, 1982, NUCLEIC ACIDS RES, V10, P6659, DOI 10.1093/nar/10.21.6659; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; REEDER RH, 1992, REGULATION TRANSCRIP, V1, P315; SCHNAPP A, 1990, EMBO J, V9, P2857, DOI 10.1002/j.1460-2075.1990.tb07475.x; SCHNAPP A, 1993, MOL CELL BIOL, V13, P6723, DOI 10.1128/MCB.13.11.6723; SCHNAPP G, 1994, EMBO J, V13, P4028, DOI 10.1002/j.1460-2075.1994.tb06719.x; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; TOWER J, 1987, CELL, V50, P873, DOI 10.1016/0092-8674(87)90514-9; TOWER J, 1986, MOL CELL BIOL, V6, P3451, DOI 10.1128/MCB.6.10.3451	26	97	99	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					2015	2018		10.1126/science.7801130	http://dx.doi.org/10.1126/science.7801130			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801130				2022-12-28	WOS:A1994PZ26700036
J	MONTGOMERY, H; HUNTER, S; MORRIS, S; NAUNTONMORGAN, R; MARSHALL, RM				MONTGOMERY, H; HUNTER, S; MORRIS, S; NAUNTONMORGAN, R; MARSHALL, RM			INTERPRETATION OF ELECTROCARDIOGRAMS BY DOCTORS	BRITISH MEDICAL JOURNAL			English	Article									HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT CARDIOTHORAC SURG, LONDON W12 0HS, ENGLAND; ST GEORGE HOSP, DEPT VASC SURG, LONDON SW17 0RE, ENGLAND; OLDCHURCH HOSP, ROMFORD RM7 0BE, ESSEX, ENGLAND	Imperial College London; St Georges University London	MONTGOMERY, H (corresponding author), UCL HOSP NHS TRUST, DIV CARDIOL, HATTER INST CARDIOVASC STUDIES, LONDON WC1E 6DB, ENGLAND.		Montgomery, Hugh/L-1229-2019; Montgomery, Hugh/C-2592-2008	Montgomery, Hugh/0000-0001-8797-5019				BENNETT DH, 1985, CARDIAC ARRHYTHMIAS, P72; GANONG WF, 1991, REV MED PHYSL, P508; HOPE RA, 1989, OXFORD HDB CLIN MED, P264; MARRIOTT HJL, 1983, PRACTICAL ELECTROCAR, P16; SHAMROTH L, 1990, INTRO ELECTROPHYSIOL, P28	5	34	35	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 10	1994	309	6968					1551	1552		10.1136/bmj.309.6968.1551	http://dx.doi.org/10.1136/bmj.309.6968.1551			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX564	7819897	Green Published			2022-12-28	WOS:A1994PX56400023
J	MACRAE, K				MACRAE, K			SOCIOECONOMIC DEPRIVATION AND HEALTH AND THE ECOLOGICAL FALLACY	BRITISH MEDICAL JOURNAL			English	Note											MACRAE, K (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,REYNOLDS BLDG,LONDON W6 8RP,ENGLAND.							[Anonymous], 1980, INEQUALITIES HLTH RE; McCarron P, 1994, BMJ-BRIT MED J, V309; MCLEOONE P, 1994, BMJ, V309; MORGENSTERN H, 1982, AM J PUBLIC HEALTH, V72, P1336, DOI 10.2105/AJPH.72.12.1336; Robinson WS, 1950, AM SOCIOL REV, V15, P351, DOI 10.2307/2087176; SELVIN HC, 1958, AM J SOCIOL, V63, P607, DOI 10.1086/222356; SLOGGETT A, 1994, BMJ, V309; SMITH GD, 1990, BMJ-BRIT MED J, V301, P373, DOI 10.1136/bmj.301.6748.373	8	29	29	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 3	1994	309	6967					1478	1479		10.1136/bmj.309.6967.1478	http://dx.doi.org/10.1136/bmj.309.6967.1478			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PW053	7804049	Green Published			2022-12-28	WOS:A1994PW05300021
J	WRIGHT, N; CAPLAN, R; PAYNE, S				WRIGHT, N; CAPLAN, R; PAYNE, S			COMMUNITY SURVEY OF LONG-TERM DAYTIME USE OF BENZODIAZEPINES	BRITISH MEDICAL JOURNAL			English	Article									LINCOLN CTY HOSP,PETER HODGKINSON CTR,LINCOLN LN2 5QY,ENGLAND; MAPPERLEY HOSP,NOTTINGHAM NG3 6AA,ENGLAND									ASHTON H, 1989, BRIT J ADDICT, V84, P541; TAYLOR D, 1987, BENZODIAZEPINES CURR, P13; TYRER P, 1990, J AFFECT DISORDERS, V19, P53, DOI 10.1016/0165-0327(90)90009-W; Tyrer P J, 1984, Br Med J (Clin Res Ed), V288, P1101; 1988, CURRENT PROBLEMS, V21, P1	5	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 2	1994	309	6946					27	28		10.1136/bmj.309.6946.27	http://dx.doi.org/10.1136/bmj.309.6946.27			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NV891	7802775	Green Published			2022-12-28	WOS:A1994NV89100020
J	MECHANIC, D				MECHANIC, D			DILEMMAS IN RATIONING HEALTH-CARE SERVICES - THE CASE FOR IMPLICIT RATIONING	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL-CARE; CORONARY	With tension between the demand for health services and the cost of providing them, rationing is increasingly evident in all medical systems. Until recently, rationing was primarily through the ability to pay or achieved implicitly by doctors working within fixed budgets. Such forms of rationing are commonly alleged to be inequitable and inefficient and explicit rationing is advocated as more appropriate. Utilisation management in the United States and quasi-markets separating purchasing from provision in the United Kingdom are seen as ways of using resources more efficiently and are increasingly explicit. There is also advocacy to ration explicitly at the point of service. Mechanic reviews the implications of these developments and explains why explicit approaches are likely to focus conflict and dissatisfaction and be politically unstable. Explicit rationing is unlikely to be as equitable as its proponents argue and is likely to make dissatisfaction and perceived deprivation more salient. Despite its limitations, implicit rationing at the point of service is more sensitive to the complexity of medical decisions and the needs and personal and cultural preferences of patients. All systems use a mix of rationing devices, but the clinical allocation of services should substantially depend on the discretion of professionals informed by practice guidelines, outcomes research, and other informational aids.			MECHANIC, D (corresponding author), KINGS FUND INST,LONDON W2 4HT,ENGLAND.							AARON HJ, 1984, PAINFUL PRESCRIPTION; FRANKEL S, 1993, RATIONING RATIONALIT; HALL MA, 1993, MILBANK Q, V71, P645, DOI 10.2307/3350423; HALPER T, 1989, MISFORTUNES OTHER EN, P114; HILLMAN AL, 1987, NEW ENGL J MED, V317, P1743, DOI 10.1056/NEJM198712313172725; KLEIN R, 1993, BRIT MED J, V307, P309, DOI 10.1136/bmj.307.6899.309; KNAUS WA, 1991, SCIENCE, V254, P389, DOI 10.1126/science.1925596; MECHANIC D, 1978, NEW ENGL J MED, V298, P249, DOI 10.1056/NEJM197802022980505; MECHANIC D, 1990, INQUIRY-J HEALTH CAR, V27, P14; MECHANIC D, 1994, MILBANK Q, V72, P217, DOI 10.2307/3350294; MECHANIC D, 1992, U PENN LAW REV, V140, P1713, DOI 10.2307/3312429; MECHANIC D, 1994, INQUIRY-J HEALTH CAR, V31, P124; Mechanic D, 1986, ADVOCACY ALLOCATION; NAYLOR CD, 1990, LANCET, V335, P1070, DOI 10.1016/0140-6736(90)92640-4; NAYLOR CD, 1993, SOC SCI MED, V37, P61, DOI 10.1016/0277-9536(93)90318-X; REDMAYNE R, 1993, 11 NAT ASS HLTH AUTH; Rodwin M. A., 1993, MED MONEY MORALS PHY; Sheldon T, 1993, RATIONING ACTION, P3; SIMON HA, 1957, ADM BEHAVIOR	19	96	98	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 24	1995	310	6995					1655	1659		10.1136/bmj.310.6995.1655	http://dx.doi.org/10.1136/bmj.310.6995.1655			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RF698	7795458	Green Published			2022-12-28	WOS:A1995RF69800030
J	CABANILLAS, F; ARMITAGE, J; PUGH, WC; WEISENBURGER, D; DUVIC, M				CABANILLAS, F; ARMITAGE, J; PUGH, WC; WEISENBURGER, D; DUVIC, M			LYMPHOMATOID PAPULOSIS - A T-CELL DYSCRASIA WITH A PROPENSITY TO TRANSFORM INTO MALIGNANT-LYMPHOMA	ANNALS OF INTERNAL MEDICINE			English	Review							CUTANEOUS HODGKINS-DISEASE; KI-1 LYMPHOMA; SPECTRUM; SKIN	Objective: To describe the diagnostic difficulties, response to therapy, and clinical features of lymphomatoid papulosis and the cumulative frequency of transformation to lymphoma. Design: Case series. Setting: University hospitals. Methods: The records of 21 patients with lymphomatoid papulosis who were seen from 1986 to 1993 were retrieved from the archives of two institutions. The entry criteria for the study were lymphomatoid papulosis misdiagnosed at the time of original presentation or lymphomatoid papulosis that later developed into lymphoma. Results: When lymphomatoid papulosis tissues are pathologically examined, they are frequently confused with lymphoma, melanoma, or carcinoma. Eight of the 19 patients whose condition was misdiagnosed as malignant received either chemotherapy or radiotherapy. Although lymphomatoid papulosis responded to cytotoxic chemotherapy, the remissions were transient and promptly recurred after or during treatment. However, all five cases that became malignant responded to chemotherapy and have not recurred. Five of 21 patients (24%) developed lymphoma, but the cumulative risk for transformation after 15 years was 80%. Conclusions: Lymphomatoid papulosis can only be diagnosed accurately through a careful history in which the characteristic waxing and waning of the skin lesions is identified and through proper communication between clinicians and pathologists. Patients with lymphomatoid papulosis have an increased risk for developing lymphoma that is much higher than the 15% to 20% quoted in the literature. Patients who develop lymphoma respond well to cytotoxic chemotherapy and can be cured with appropriate therapy. Internists and oncologists need to be aware of lymphomatoid papulosis and its characteristic clinical features so that this disorder is accurately diagnosed and so that unnecessary and potentially hazardous treatment is avoided.	UNIV NEBRASKA, MED CTR, OMAHA, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	CABANILLAS, F (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, DEPT HEMATOL, 1515 HOLCOMBE BLVD, BOX 068, HOUSTON, TX 77030 USA.			Cabanillas, Fernando/0000-0001-9234-7893				AGNARSSON BA, 1989, HUM PATHOL, V20, P747, DOI 10.1016/0046-8177(89)90067-1; BANERJEE SS, 1991, J CLIN PATHOL, V44, P119, DOI 10.1136/jcp.44.2.119; BELJAARDS RC, 1992, BRIT J DERMATOL, V126, P596; Brehmer-Andersson E, 1976, Acta Derm Venereol Suppl (Stockh), V56, P3; CABANILLAS F, 1991, ANN ONCOL, V2, P31, DOI 10.1093/annonc/2.suppl_1.31; CHAN JKC, 1989, HISTOPATHOLOGY, V15, P11, DOI 10.1111/j.1365-2559.1989.tb03038.x; DAVIS TH, 1992, NEW ENGL J MED, V326, P1115, DOI 10.1056/NEJM199204233261704; KADIN ME, 1991, SEMIN DERMATOL, V10, P164; KADIN ME, 1986, BLOOD, V68, P1042; KADIN ME, 1993, ARCH DERMATOL, V129, P351, DOI 10.1001/archderm.129.3.351; KADIN ME, 1990, BLOOD S, V76, pA354; KAUDEWITZ P, 1991, BRIT J DERMATOL, V124, P465, DOI 10.1111/j.1365-2133.1991.tb00627.x; KLIMO P, 1985, ANN INTERN MED, V102, P596, DOI 10.7326/0003-4819-102-5-596; LEE R, 1986, J CLIN ONCOL, V4, P1455, DOI 10.1200/JCO.1986.4.10.1455; MACAULAY WL, 1968, ARCH DERMATOL, V97, P23, DOI 10.1001/archderm.97.1.23; MACAULAY WL, 1978, INT J DERMATOL, V17, P204, DOI 10.1111/j.1365-4362.1978.tb06061.x; SANCHEZ NP, 1983, J AM ACAD DERMATOL, V8, P81, DOI 10.1016/S0190-9622(83)70011-3; SZUR L, 1970, LANCET, V1, P1016; WANG HH, 1992, CANCER, V70, P2951, DOI 10.1002/1097-0142(19921215)70:12<2951::AID-CNCR2820701236>3.0.CO;2-7; WILLEMZE R, 1982, BRIT J DERMATOL, V107, P131, DOI 10.1111/j.1365-2133.1982.tb00331.x; WILLEMZE R, 1993, J AM ACAD DERMATOL, V28, P973, DOI 10.1016/0190-9622(93)70140-O	21	68	71	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1995	122	3					210	217		10.7326/0003-4819-122-3-199502010-00009	http://dx.doi.org/10.7326/0003-4819-122-3-199502010-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD733	7810940				2022-12-28	WOS:A1995QD73300009
J	MCNAMARA, RM; MONTI, S; KELLY, JJ				MCNAMARA, RM; MONTI, S; KELLY, JJ			REQUESTING CONSENT FOR AN INVASIVE PROCEDURE IN NEWLY DECEASED ADULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							INTUBATION; INFANTS; TEACH; DEAD	Objective.-Ethical concerns exist over the performance of medical procedures, such as endotracheal intubation, on newly deceased patients without family consent. This study examined the process of obtaining consent for the purpose of performing an invasive procedure in newly deceased adults. Design.-A prospective case series. Participants.-The families of patients who died during a 5-month period were requested to provide consent to perform wire-guided retrograde tracheal intubation. Main Outcome Measures.-Differences between success and failure in obtaining consent including information on the deceased, family reasons for their decision, and the experience of those requesting consent. Results.-Consent was requested from 44 families and 26 (59%) agreed to the procedure. This success rate was achieved despite the lack of a prior relationship with the family by the persons requesting consent. Consent was obtained more frequently in unexpected than expected deaths (77% vs 41%, P=.03). There were no differences in success rates for consent for age, race, sex, or do-not-resuscitate status of the deceased. Spouses consented more frequently than children (77% vs 50%, P=.25). The two physicians reported greater comfort in requesting consent than the nurse anesthetist investigator. In one instance, the consent process may have increased the emotional distress of the family. Conclusion.-Consent can frequently be obtained from families for an invasive procedure in newly deceased adults. Physicians should reconsider the practice of performing postmortem procedures without obtaining family consent.	MED COLL PENN,DEPT ANESTHESIOL,PHILADELPHIA,PA 19129	Drexel University	MCNAMARA, RM (corresponding author), MED COLL PENN,DEPT EMERGENCY MED,3300 HENRY AVE,PHILADELPHIA,PA 19129, USA.							BENFIELD DG, 1991, JAMA-J AM MED ASSOC, V265, P2360, DOI 10.1001/jama.265.18.2360; BURNS JP, 1994, NEW ENGL J MED, V331, P1652, DOI 10.1056/NEJM199412153312411; ISERSON KV, 1986, HASTINGS CENT REP, V16, P28, DOI 10.2307/3563273; ISERSON KV, 1993, J MED ETHICS, V19, P92, DOI 10.1136/jme.19.2.92; MCNAMARA RM, 1987, ANN EMERG MED, V16, P680, DOI 10.1016/S0196-0644(87)80071-9; MORHAIM D K, 1991, Journal of Emergency Medicine, V9, P515, DOI 10.1016/0736-4679(91)90233-6; ORLOWSKI JP, 1988, NEW ENGL J MED, V319, P439, DOI 10.1056/NEJM198808183190710; REITZ NN, 1993, J NATL MED ASSOC, V85, P353; SCHILLACI RF, 1976, NEW ENGL J MED, V295, P488, DOI 10.1056/NEJM197608262950907; TACHAKRA SS, 1991, JAMA-J AM MED ASSOC, V266, P1649, DOI 10.1001/jama.1991.03470120051027; TOLLE SW, 1984, ARCH INTERN MED, V144, P2389, DOI 10.1001/archinte.144.12.2389; TONKS A, 1992, BRIT MED J, V305, P332	12	47	47	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	1995	273	4					310	312		10.1001/jama.273.4.310	http://dx.doi.org/10.1001/jama.273.4.310			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC057	7815659				2022-12-28	WOS:A1995QC05700030
J	NIGHTINGALE, SL				NIGHTINGALE, SL			REQUEST FOR COMMENTS ON POLICY ON PROMOTION OF UNAPPROVED USES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1993, JAMA-J AM MED ASSOC, V269, P328; 1994, FED REGISTER, V59, P59820	2	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	1995	273	4					279	279						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC057	7815644				2022-12-28	WOS:A1995QC05700004
J	DWORKIN, RH; CORNBLATT, BA				DWORKIN, RH; CORNBLATT, BA			PREDICTING SCHIZOPHRENIA	LANCET			English	Editorial Material							SOCIAL DEFICITS; CHILDHOOD PRECURSORS; RISK; ADOLESCENTS; SYMPTOMS		COLUMBIA UNIV,COLL PHYS & SURG,DEPT PSYCHIAT,NEW YORK,NY; CUNY MT SINAI SCH MED,DEPT PSYCHIAT,NEW YORK,NY	Columbia University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	DWORKIN, RH (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT ANESTHESIOL,NEW YORK,NY, USA.							BELLACK AS, 1989, SCHIZOPHRENIA BULL, V15, P101, DOI 10.1093/schbul/15.1.101; BLEULER E, 1950, DEMENTIA PRAECOX GRO, P251; CORNBLATT BA, 1992, BRIT J PSYCHIAT, V161, P59, DOI 10.1192/S0007125000297067; DONE DJ, 1994, BRIT MED J, V309, P699, DOI 10.1136/bmj.309.6956.699; DWORKIN RH, 1993, SCHIZOPHRENIA BULL, V19, P563, DOI 10.1093/schbul/19.3.563; DWORKIN RH, 1992, SCHIZOPHRENIA BULL, V18, P59, DOI 10.1093/schbul/18.1.59; DWORKIN RH, 1991, AM J PSYCHIAT, V148, P1182; FISH B, 1992, ARCH GEN PSYCHIAT, V49, P221; FOERSTER A, 1991, BRIT J PSYCHIAT, V158, P171, DOI 10.1192/bjp.158.2.171; JONES P, 1994, LANCET, V344, P1398, DOI 10.1016/S0140-6736(94)90569-X; LENZENWEGER MF, 1991, SCHIZOPHRENIA BULL, V17, P515, DOI 10.1093/schbul/17.3.515; LIDDLE PF, 1987, BRIT J PSYCHIAT, V151, P145, DOI 10.1192/bjp.151.2.145; STRAUSS JS, 1974, SCHIZOPHRENIA B, V1, P61; WALKER EF, 1993, AM J PSYCHIAT, V150, P1654; WALKER EF, 1994, SCHIZOPHRENIA BULL, V20, P441, DOI 10.1093/schbul/20.3.441; WEINBERGER DR, 1987, ARCH GEN PSYCHIAT, V44, P660, DOI 10.1001/archpsyc.1987.01800190080012	16	6	6	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					139	140		10.1016/S0140-6736(95)90160-4	http://dx.doi.org/10.1016/S0140-6736(95)90160-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QC550	7823664				2022-12-28	WOS:A1995QC55000003
J	JOHNSON, RP; CRAIG, SW				JOHNSON, RP; CRAIG, SW			F-ACTIN BINDING-SITE MASKED BY THE INTRAMOLECULAR ASSOCIATION OF VINCULIN HEAD AND TAIL DOMAINS	NATURE			English	Article							SELF-ASSOCIATION; ESCHERICHIA-COLI; ALPHA-ACTININ; SMOOTH-MUSCLE; PURIFICATION; PROTEINS; METAVINCULIN; FILAMENTS; SEQUENCE; CDNA	ALTHOUGH vinculin is present at all sites of F-actin attachment to plasma membranes(1) acid is required for linkage of myofibrils to sarcolemma(2), it is unclear how it promotes attachment of actin to membranes. Because biochemical evidence for a direct interaction of vinculin with F-actin is controversial(3-9), current models of actin-membrane linkages depict only an indirect role for vinculin, as a tether for alpha-actinin(10). We demonstrate here that an intramolecular association between the 95K head and 30K tail domains of vinculin(11) masks an F-actin binding site present in the carboxyterminal tail domain. Cosedimentation and crosslinking assays, and direct visualization by transmission electron microscopy, reveal an interaction between F-actin and a bacterially expressed fusion protein containing amino acids 811-1066 of vinculin, and between F-actin and a proteolytic fragment of vinculin containing amino acids 858-1066. Vinculin itself neither cosediments with nor crosslinks F-actin. The amino-terminal 95K head fragment of vinculin, but not intact vinculin, inhibits both cosedimentation and crosslinking. We propose that assembly of vinculin into an adherens junction involves disruption of the head-tail interaction, revealing a site that mediates microfilament attachment.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University								BARSTEAD RJ, 1991, J CELL BIOL, V114, P715, DOI 10.1083/jcb.114.4.715; COUTU MD, 1988, P NATL ACAD SCI USA, V85, P8535, DOI 10.1073/pnas.85.22.8535; CRITCHLEY DR, 1991, BIOCHEM SOC T, V19, P1028, DOI 10.1042/bst0191028; EVANS RR, 1984, J BIOL CHEM, V259, P3916; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FRORATH B, 1992, BIOTECHNIQUES, V12, P558; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; GILMORE AP, 1993, J CELL BIOL, V122, P337, DOI 10.1083/jcb.122.2.337; GIMONA M, 1988, EMBO J, V7, P2329, DOI 10.1002/j.1460-2075.1988.tb03076.x; GROESCH ME, 1990, CELL MOTIL CYTOSKEL, V15, P41, DOI 10.1002/cm.970150107; JOCKUSCH BM, 1981, P NATL ACAD SCI-BIOL, V78, P3005, DOI 10.1073/pnas.78.5.3005; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; MENKEL AR, 1994, J CELL BIOL, V126, P1231, DOI 10.1083/jcb.126.5.1231; MENKEL AR, 1993, EUR J CELL BIOL S37, V60, P38; MILAM LM, 1985, J MOL BIOL, V184, P543, DOI 10.1016/0022-2836(85)90301-8; MOLONY L, 1985, J CELL BIOCHEM, V29, P31, DOI 10.1002/jcb.240290104; OTTO JJ, 1986, CELL MOTIL CYTOSKEL, V6, P48, DOI 10.1002/cm.970060107; PRICE GJ, 1987, BIOCHEM J, V245, P595, DOI 10.1042/bj2450595; PRICE GJ, 1989, BIOCHEM J, V259, P453, DOI 10.1042/bj2590453; RUHNAU K, 1988, FEBS LETT, V228, P105, DOI 10.1016/0014-5793(88)80595-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; WESTMEYER A, 1990, EMBO J, V9, P2071, DOI 10.1002/j.1460-2075.1990.tb07374.x; WILKINS JA, 1982, CELL, V28, P83, DOI 10.1016/0092-8674(82)90377-4; WILKINS JA, 1986, J CELL BIOL, V102, P1085, DOI 10.1083/jcb.102.3.1085	30	322	323	1	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					261	264		10.1038/373261a0	http://dx.doi.org/10.1038/373261a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816144				2022-12-28	WOS:A1995QC27800069
J	RHIND, NR; MILLER, LM; KOPCZYNSKI, JB; MEYER, BJ				RHIND, NR; MILLER, LM; KOPCZYNSKI, JB; MEYER, BJ			XOL-1 ACTS AS AN EARLY SWITCH IN THE C-ELEGANS MALE HERMAPHRODITE DECISION	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; SEX DETERMINATION SIGNAL; X-CHROMOSOME DOSAGE; GENE-EXPRESSION; DROSOPHILA; COMPENSATION; MORPHOGEN; DOMAINS	xol-1 is the earliest-acting gene in the known hierarchy that controls C. elegans sex determination and dosage compensation. We show that the primary sex-determining signal (the WA ratio) directs the choice of sexual fate by regulating xol-1 transcript levels: high xol-1 expression during gastrulation triggers male development, whereas low expression at that time permits hermaphrodite development. Inappropriately high xol-1 expression causes hermaphrodites to activate the male program of development and die from a disruption in dosage compensation. These results demonstrate that xol-1 functions as an early developmental switch to set the choice of sexual fate and suggest that assessment of the WA ratio occurs only early in embryogenesis to determine sex. Moreover, sdc-2, a gene that must be repressed by xol-1 to ensure male development, may be a direct target of negative regulation by xol-1.			RHIND, NR (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,229 STANLEY HALL,BERKELEY,CA 94720, USA.			Meyer, Barbara/0000-0002-6530-4588; Rhind, Nicholas/0000-0003-1758-7736	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030702, R37GM030702] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM030702, GM30702] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKERIB CC, 1994, GENETICS, V138, P1105; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BELOTE JM, 1983, DEV BIOL, V95, P512, DOI 10.1016/0012-1606(83)90054-4; Bull J.J., 1983, EVOLUTION SEX DETERM; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; CLINE TW, 1993, TRENDS GENET, V9, P385, DOI 10.1016/0168-9525(93)90138-8; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; HODGES D, 1994, ADV GENET, V31, P243; HODGKIN J, 1979, GENETICS, V91, P67; Hsu David R., 1993, Seminars in Developmental Biology, V4, P93, DOI 10.1006/sedb.1993.1012; HSU DR, 1994, GENETICS, V137, P999; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; KLEIN RD, 1993, CELL, V72, P349, DOI 10.1016/0092-8674(93)90113-5; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; KRAUSE M, 1989, J MOL BIOL, V208, P381, DOI 10.1016/0022-2836(89)90503-2; KUWABARA PE, 1992, TRENDS GENET, V8, P164, DOI 10.1016/0168-9525(92)90218-S; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MEYER BJ, 1986, CELL, V47, P871, DOI 10.1016/0092-8674(86)90802-0; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; Sambrook J, 1989, MOL CLONING LABORATO; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; VILLENEUVE AM, 1990, GENETICS, V124, P91	25	75	79	0	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					71	82		10.1016/0092-8674(95)90452-2	http://dx.doi.org/10.1016/0092-8674(95)90452-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813020	Bronze			2022-12-28	WOS:A1995QB91000011
J	RODGER, A; LEONARD, RCF; DIXON, JM				RODGER, A; LEONARD, RCF; DIXON, JM			LOCALLY ADVANCED BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article									MONASH UNIV,MELBOURNE,VIC 3004,AUSTRALIA; WESTERN GEN HOSP,DEPT CLIN ONCOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; ROYAL INFIRM,EDINBURGH,MIDLOTHIAN,SCOTLAND	Monash University; University of Edinburgh; Royal Infirmary of Edinburgh	RODGER, A (corresponding author), ALFRED HOSP,WILLIAM BUCKLAND RADIOTHERAPY CTR,MELBOURNE,VIC,AUSTRALIA.								0	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1994	309	6966					1431	1433		10.1136/bmj.309.6966.1431	http://dx.doi.org/10.1136/bmj.309.6966.1431			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7819859	Green Published			2022-12-28	WOS:A1994PU76400036
J	THOMSON, JA; DAVIES, DL; MCLAREN, EH; TEASDALE, GM				THOMSON, JA; DAVIES, DL; MCLAREN, EH; TEASDALE, GM			10-YEAR FOLLOW-UP OF MICROPROLACTINOMA TREATED BY TRANSSPHENOIDAL SURGERY	BRITISH MEDICAL JOURNAL			English	Article							HYPERPROLACTINEMIA; PROLACTINOMA		WESTERN INFIRM & ASSOCIATED HOSP,DEPT MED & THERAPEUT,GLASGOW G11 6NT,LANARK,SCOTLAND; STOBHILL GEN HOSP,DEPT MED,GLASGOW G21 3UW,LANARK,SCOTLAND; SO GEN HOSP,INST NEUROL SCI,GLASGOW G51 4TF,LANARK,SCOTLAND	University of Glasgow	THOMSON, JA (corresponding author), UNIV GLASGOW,GLASGOW ROYAL INFIRM,DEPT MED,GLASGOW G31 2ER,LANARK,SCOTLAND.							BEVAN JS, 1987, CLIN ENDOCRINOL, V26, P541, DOI 10.1111/j.1365-2265.1987.tb00809.x; SCANLON MF, 1985, BRIT MED J, V291, P1547, DOI 10.1136/bmj.291.6508.1547; SERRI O, 1983, NEW ENGL J MED, V309, P280, DOI 10.1056/NEJM198308043090505; SERRI O, 1993, NEW ENGL J MED, V329, P1357, DOI 10.1056/NEJM199310283291817; THOMSON JA, 1985, BRIT MED J, V291, P1550, DOI 10.1136/bmj.291.6508.1550	5	44	44	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1994	309	6966					1409	1410		10.1136/bmj.309.6966.1409	http://dx.doi.org/10.1136/bmj.309.6966.1409			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7819849	Green Published			2022-12-28	WOS:A1994PU76400022
J	LANDER, ES; BUDOWLE, B				LANDER, ES; BUDOWLE, B			DNA-FINGERPRINTING DISPUTE LAID TO REST	NATURE			English	Editorial Material							POPULATION-GENETICS; LOCI; NRC		MIT,DEPT BIOL,CAMBRIDGE,MA 02139; FED BUR INVEST ACAD,CTR FORENS SCI RES & TRAINING,FBI LAB,QUANTICO,VA 22135	Massachusetts Institute of Technology (MIT)	LANDER, ES (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.		Schneider, Peter M./A-6661-2011					ALDHOUS P, 1993, SCIENCE, V259, P755, DOI 10.1126/science.8430326; [Anonymous], 1992, DNA TECHNOLOGY FOREN; BALDING DJ, 1994, FORENSIC SCI INT, V64, P125, DOI 10.1016/0379-0738(94)90222-4; BUDOWIE B, IN PRESS J FORENSIC; BUDOWLE B, 1994, J FORENSIC SCI, V39, P988; BUDOWLE B, 1994, J FORENSIC SCI, V39, P319; CHAKRABORTY R, 1991, SCIENCE, V254, P1735, DOI 10.1126/science.1763323; DEVLIN B, 1993, SCIENCE, V259, P748, DOI 10.1126/science.8430323; DUNCAN GT, 1993, GENETICA, V88, P51, DOI 10.1007/BF02424451; EVETT IW, 1993, AM J HUM GENET, V52, P498; HUANG NE, IN PRESS J FORENSIC; KRANE DE, 1992, P NATL ACAD SCI USA, V89, P10583, DOI 10.1073/pnas.89.22.10583; LANDER ES, 1989, NATURE, V339, P501, DOI 10.1038/339501a0; LEWONTIN RC, 1991, SCIENCE, V254, P1745, DOI 10.1126/science.1845040; MORTON NE, 1992, P NATL ACAD SCI USA, V89, P2556, DOI 10.1073/pnas.89.7.2556; MORTON NE, 1993, P NATL ACAD SCI USA, V90, P1892, DOI 10.1073/pnas.90.5.1892; MORTON NE, IN PRESS GENETICA; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SILMOWITZ JR, 1993, AM J HUM GENET, V53, P314; TWERWILLIGER JD, 1994, HDB HUMAN GENETIC LI; WEIR BS, 1993, AM J HUM GENET, V52, P437; WEIR BS, 1992, P NATL ACAD SCI USA, V89, P11654, DOI 10.1073/pnas.89.24.11654; 1994, SCIENCE, V266, P201; 1993, VNTR POPULATION DATA	24	78	79	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 27	1994	371	6500					735	738		10.1038/371735a0	http://dx.doi.org/10.1038/371735a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP018	7818670				2022-12-28	WOS:A1994PP01800025
J	SYKES, JJW				SYKES, JJW			FORTNIGHTLY REVIEW - MEDICAL ASPECTS OF SCUBA DIVING	BRITISH MEDICAL JOURNAL			English	Review							DECOMPRESSION-SICKNESS; DIVERS				SYKES, JJW (corresponding author), INST NAVAL MED,GOSPORT PO12 2DL,HANTS,ENGLAND.							Bennett P, 1993, PHYSL MED DIVING; CRESSWELL JE, 1991, BRIT MED J, V302, P1590, DOI 10.1136/bmj.302.6792.1590; CROSS SJ, 1990, LANCET, V336, P568, DOI 10.1016/0140-6736(90)92125-2; Donald K, 1992, OXYGEN POISONING STU, V27, P207; EDMUNDS CW, 1981, DIVING SUBAQUATIC ME; Elliot D. H., 1993, PHYSL MED DIVING, P481; ELLIOTT DH, 1974, LANCET, V2, P1193; EVANS SA, 1993, SURVEY CLIN HYPERBAR; FRAMCOS TKR, 1993, PHYSL MED DIVING, P454; FRANCIS TJR, 1988, UNDERSEA BIOMED RES, V15, P403; FRANCIS TJR, 1991, DESCRIBING DYSBARISM; GOLDING F C, 1960, Br J Ind Med, V17, P167; HAMILTON FT, 1907, DEEP WATER DIVING; KELLEHER PC, 1993, UNDERSEA BIOOMED R S, V20, P18; Lungren CEG, 1965, BRIT MED J, V2, P511; MOON RE, 1989, LANCET, V1, P513; SMITH DJ, 1992, UNDERSEA BIOMED RES, V19, P40; Sykes J J, 1989, J R Nav Med Serv, V75, P69; WILMSHURST PT, 1989, LANCET, V2, P1302; WILMSHURST PT, 1989, LANCET, V1, P62	20	21	21	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 4	1994	308	6942					1483	1488		10.1136/bmj.308.6942.1483	http://dx.doi.org/10.1136/bmj.308.6942.1483			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ229	7802769	Green Published			2022-12-28	WOS:A1994NQ22900022
J	BROWN, EM; POLLAK, M; SEIDMAN, CE; SEIDMAN, JG; RICCARDI, D; HEBERT, SC				BROWN, EM; POLLAK, M; SEIDMAN, CE; SEIDMAN, JG; RICCARDI, D; HEBERT, SC			SEMINARS IN MEDICINE OF THE BETH-ISRAEL-HOSPITAL, BOSTON - CALCIUM-ION-SENSING CELL-SURFACE RECEPTORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BOVINE PARATHYROID CELLS; FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; SEVERE PRIMARY HYPERPARATHYROIDISM; BINDING-PROTEIN; ISOLATED HYPOPARATHYROIDISM; BENIGN HYPERCALCEMIA; EXTRACELLULAR CA-2+; GLUTAMATE RECEPTORS; GENE; PSEUDOHYPOPARATHYROIDISM		BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV RENAL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA USA; HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	BROWN, EM (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, DIV ENDOCRINE HYPERTENS, 221 LONGWOOD AVE, BOSTON, MA 02115 USA.		Riccardi, Daniela/A-4674-2010	Riccardi, Daniela/0000-0002-7322-3163	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041415, R01DK048330, R01DK044588] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44588, DK48330, DK41415] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS MD, 1989, J BIOL CHEM, V264, P15739; AHN TG, 1986, MEDICINE, V65, P73, DOI 10.1097/00005792-198603000-00001; Albright F, 1942, ENDOCRINOLOGY, V30, P922; ARNOLD A, 1990, J CLIN INVEST, V86, P1084, DOI 10.1172/JCI114811; ATTIE MF, 1983, J CLIN INVEST, V72, P667, DOI 10.1172/JCI111016; AURBACH GD, 1985, TXB ENDOCRINOLOGY, P1137; AUSTIN LA, 1981, NEW ENGL J MED, V304, P269, DOI 10.1056/NEJM198101293040505; BLACK BL, 1989, FASEB J, V3, P2653, DOI 10.1096/fasebj.3.14.2512193; BROWN E, 1987, FEBS LETT, V218, P113, DOI 10.1016/0014-5793(87)81029-3; Brown E M, 1993, Curr Opin Nephrol Hypertens, V2, P541, DOI 10.1097/00041552-199307000-00004; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1995, EUR J ENDOCRINOL, V132, P523, DOI 10.1530/eje.0.1320523; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; CHEN CJ, 1989, ENDOCRINOLOGY, V124, P233, DOI 10.1210/endo-124-1-233; CHOU YHW, 1992, NAT GENET, V1, P295, DOI 10.1038/ng0792-295; CHOU YHW, 1995, AM J HUM GENET, V56, P1075; CONKLIN BR, 1994, NATURE, V367, P22, DOI 10.1038/367022a0; COOPER L, 1986, PEDIATRICS, V78, P263; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; EASTELL R, 1992, DISORDERS BONE MINER, P571; EPSTEIN FH, 1968, AM J MED, V45, P700, DOI 10.1016/0002-9343(68)90206-4; ESTEP HL, 1981, 63RD ANN M END SOC C, P275; FARFEL Z, 1980, NEW ENGL J MED, V303, P237, DOI 10.1056/NEJM198007313030501; FINEGOLD DN, 1994, PEDIATR RES, V36, P414, DOI 10.1203/00006450-199409000-00024; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; FRIED RM, 1986, J BIOL CHEM, V261, P7669; HEATH H, 1993, AM J HUM GENET, V53, P193; HEATH H, 1994, J BONE MINER RES  S1, V9, pS414; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HUMES HD, 1978, J CLIN INVEST, V61, P32, DOI 10.1172/JCI108922; JUHLIN C, 1990, J BIOL CHEM, V265, P8275; KHOSLA S, 1993, J CLIN ENDOCR METAB, V76, P715, DOI 10.1210/jc.76.3.715; KUROKAWA K, 1994, KIDNEY INT, V45, pS97; LAW WM, 1985, ANN INTERN MED, V102, P511, DOI 10.7326/0003-4819-102-4-511; LEVINE MA, 1980, BIOCHEM BIOPH RES CO, V94, P1319, DOI 10.1016/0006-291X(80)90563-X; LUNDGREN S, 1994, EXP CELL RES, V212, P344, DOI 10.1006/excr.1994.1153; MARX SJ, 1985, AM J MED, V78, P15, DOI 10.1016/0002-9343(85)90455-3; MARX SJ, 1981, MEDICINE, V60, P397, DOI 10.1097/00005792-198111000-00002; MARX SJ, 1986, J CLIN ENDOCR METAB, V62, P445, DOI 10.1210/jcem-62-2-445; MCGRATH CM, 1984, IN VITRO CELL DEV B, V20, P652, DOI 10.1007/BF02619616; MEANS AR, 1980, NATURE, V285, P73, DOI 10.1038/285073a0; MOREL F, 1982, KIDNEY INT S, V11, pS55; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NEMETH EF, 1986, FEBS LETT, V203, P15, DOI 10.1016/0014-5793(86)81427-2; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; PEARCE SHS, 1994, J BONE MINER RES  S1, V9, pS145; Perry Y. M., 1994, American Journal of Human Genetics, V55, pA17; PIETROBON D, 1990, EUR J BIOCHEM, V193, P599, DOI 10.1111/j.1432-1033.1990.tb19378.x; POLLAK MR, 1994, J CLIN INVEST, V93, P1108, DOI 10.1172/JCI117062; POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194-303; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; QUAMME GA, 1989, AM J PHYSIOL, V256, pF197, DOI 10.1152/ajprenal.1989.256.2.F197; Racke FK, 1991, J BONE MINER RES, V6, pS118; REFETOFF S, 1982, AM J PHYSIOL, V243, pE88, DOI 10.1152/ajpendo.1982.243.2.E88; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SHOBACK DM, 1988, ENDOCRINOLOGY, V123, P382, DOI 10.1210/endo-123-1-382; Shoback DM, 1991, J BONE MINER RES, V6, pS135; STEWART AF, 1987, ENDOCRINOL METAB, P1317; SUKI WN, 1969, NEPHRON, V6, P50, DOI 10.1159/000179715; TAKAICHI K, 1988, J CLIN INVEST, V82, P1437, DOI 10.1172/JCI113749; TRUMP D, 1993, J BONE MINER RES, V8, pS167; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403	64	194	202	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 27	1995	333	4					234	240		10.1056/NEJM199507273330407	http://dx.doi.org/10.1056/NEJM199507273330407			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK423	7791841				2022-12-28	WOS:A1995RK42300007
J	ROACH, PL; CLIFTON, IJ; FULOP, V; HARLOS, K; BARTON, GJ; HAJDU, J; ANDERSSON, I; SCHOFIELD, CJ; BALDWIN, JE				ROACH, PL; CLIFTON, IJ; FULOP, V; HARLOS, K; BARTON, GJ; HAJDU, J; ANDERSSON, I; SCHOFIELD, CJ; BALDWIN, JE			CRYSTAL-STRUCTURE OF ISOPENICILLIN N-SYNTHASE IS THE FIRST FROM A NEW STRUCTURAL FAMILY OF ENZYMES	NATURE			English	Article							X-RAY-ABSORPTION; ACTIVE-SITE; SUBSTRATE; ISOZYMES; ERRORS; MAPS	PENICILLIN antibiotics are all produced from fermentation-derived penicillins because their chemical synthesis is not commercially viable. The key step in penicillin biosynthesis, in which both the beta-lactam and thiazolidine rings of the nucleus are created, is mediated by isopenicillin N synthase (IPNS), which binds ferrous iron-and uses dioxygen as a cosubstrate, In a unique enzymatic step, with no chemical precedent, IPNS catalyses the transfer of four hydrogen atoms from its tripeptide substrate to dioxygen forming, in a single reaction, the complete bicyclic nucleus of the penicillins(1). We now report the structure of IPNS complexed with manganese, which reveals the active site is unusually buried within a 'jelly-roll' motif and lined by hydrophobic residues, and suggest hem this structure permits the process of penicillin formation. Sequence analyses indicate IPNS, 1-aminocyclopropane-1-carboxylic acid oxidase and many of the 2-oxo-acid-dependent oxygenases contain a conserved jelly-roll motif, forming a new structural family of enzymes.	UNIV OXFORD, DYSON PERRINS LAB, OXFORD OX1 3QY, ENGLAND; SWEDISH UNIV AGR SCI, UPPSALA BIOMED CTR, DEPT BIOL MOLEC, S-75124 UPPSALA, SWEDEN; UNIV OXFORD, OXFORD CTR MOLEC SCI, OXFORD OX1 3QY, ENGLAND; UNIV OXFORD, LAB MOLEC BIOPHYS, OXFORD OX1 3QY, ENGLAND	University of Oxford; Swedish University of Agricultural Sciences; University of Oxford; University of Oxford			Roach, Peter/C-6248-2013; Roach, Peter/AAW-7071-2021; Barton, Geoffrey/N-1037-2019; Barton, Geoffrey J/C-6267-2011	Barton, Geoffrey/0000-0002-9014-5355; Schofield, Christopher/0000-0002-0290-6565				BALDWIN JE, 1991, TETRAHEDRON, V47, P5991, DOI 10.1016/S0040-4020(01)86491-7; BALDWIN JE, 1990, CHEM REV, V90, P1079, DOI 10.1021/cr00105a001; BALDWIN JE, 1992, CHEM BETA LACTAMS, pCH1; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHEN VJ, 1989, J BIOL CHEM, V264, P21677; COWTAN K, 1994, ACTA CRYSTALLOGR D, V50, P760; Crowfoot D., 1949, CHEM PENICILLIN, P310; FEIG AL, 1994, CHEM REV, V94, P759, DOI 10.1021/cr00027a011; Fleming A, 1929, BRIT J EXP PATHOL, V10, P226; FLOREY HW, 1949, ANTIBIOTICS, V2; FUJISHIMA Y, 1994, J MOL BIOL, V242, P712, DOI 10.1006/jmbi.1994.1622; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MARSH EN, 1992, BIOCHEMISTRY-US, V31, P12648, DOI 10.1021/bi00165a015; NORRIS GE, 1994, STRUCTURE, V2, P1049, DOI 10.1016/S0969-2126(94)00108-1; ORVILLE AM, 1992, BIOCHEMISTRY-US, V31, P4602, DOI 10.1021/bi00134a010; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; PANG CP, 1984, BIOCHEM J, V222, P789, DOI 10.1042/bj2220789; PRESCOTT AG, 1993, J EXP BOT, V44, P849, DOI 10.1093/jxb/44.5.849; RANDALL CR, 1993, BIOCHEMISTRY-US, V32, P6664, DOI 10.1021/bi00077a020; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RETEY J, 1990, ANGEW CHEM INT EDIT, V29, P355, DOI 10.1002/anie.199003551; ROACH PL, 1995, PROTEIN SCI, V4, P1007; SCOTT RA, 1992, BIOCHEMISTRY-US, V31, P4596, DOI 10.1021/bi00134a009; SRINIVASAN N, 1994, STRUCTURE, V2, P1017, DOI 10.1016/S0969-2126(94)00105-7; STUART D, 1993, CURR OPIN STRUC BIOL, V3, P167, DOI 10.1016/S0959-440X(05)80148-4; [No title captured]	30	373	386	0	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 22	1995	375	6533					700	704		10.1038/375700a0	http://dx.doi.org/10.1038/375700a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791906				2022-12-28	WOS:A1995RE57600066
J	YUSTE, R; DENK, W				YUSTE, R; DENK, W			DENDRITIC SPINES AS BASIC FUNCTIONAL UNITS OF NEURONAL INTEGRATION	NATURE			English	Article							CALCIUM; TRANSMISSION; POTENTIATION; RESPONSES; SLICES; BRAIN	MOST excitatory synaptic connections occur on dendritic spines(1). Calcium imaging experiments have suggested that spines constitute individual calcium compartments(2,3), but recent results have challenged this idea(4,5). Using two-photon microscopy(6) to image fluorescence with high resolution in strongly scattering tissue, we measured calcium dynamics in spines from CA1 pyramidal neurons in slices of rat hippocampus. Subthreshold synaptic stimulation and spontaneous synaptic events produced calcium accumulations that were localized to isolated spines, showed stochastic failure, and were abolished by postsynaptic blockers, Single somatic spikes induced fast-peaking calcium accumulation in spines throughout the cell. Pairing of spikes with synaptic stimulation was frequently cooperative, that is, it resulted in supralinear calcium accumulations. We conclude: (1) calcium channels exist in spine heads; (2) action potentials invade the spines; (3) spines are individual calcium compartments; and (4) spines can individually detect the temporal coincidence of pre- and postsynaptic activity, and thus serve as basic functional units of neuronal integration.	AT&T BELL LABS,BIOL COMPUTAT RES DEPT,MURRAY HILL,NJ 07974	AT&T; Nokia Corporation; Nokia Bell Labs			denk, winfried/I-6627-2012					ALFORD S, 1993, J PHYSIOL-LONDON, V469, P693, DOI 10.1113/jphysiol.1993.sp019838; ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; ANDERSEN P, 1977, NATURE, V266, P736, DOI 10.1038/266736a0; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P553, DOI 10.1113/jphysiol.1954.sp005128; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; DENK W, 1994, J NEUROSCI METH, V54, P151, DOI 10.1016/0165-0270(94)90189-9; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; EILERS J, 1995, NATURE, V373, P155, DOI 10.1038/373155a0; GAMBLE E, 1987, SCIENCE, V236, P1311, DOI 10.1126/science.3495885; Goppert-Mayer M., 1931, ANN PHYS-LEIPZIG, V401, P273, DOI DOI 10.1002/ANDP.19314010303; GUTHRIE PB, 1991, NATURE, V354, P78; JAFFE DB, 1994, J NEUROBIOL, V25, P220, DOI 10.1002/neu.480250303; LEVY WB, 1979, BRAIN RES, V175, P233, DOI 10.1016/0006-8993(79)91003-5; LEVY WB, 1985, ELECTRICAL ACTIVITY; LLANO I, 1994, NEURON, V12, P663, DOI 10.1016/0896-6273(94)90221-6; MAJOR G, 1993, BIOPHYS J, V65, P423, DOI 10.1016/S0006-3495(93)81037-3; Marty A., 1983, SINGLE CHANNEL RECOR, P107; MCNAUGHTON BL, 1977, J COMP NEUROL, V175, P439, DOI 10.1002/cne.901750404; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; MURPHY TH, 1994, NATURE, V263, P529; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; OTMAKHOV N, 1993, NEURON, V10, P1101, DOI 10.1016/0896-6273(93)90058-Y; Peters A., 1991, FINE STRUCTURE NERVO; SOBEL EC, 1994, SCIENCE, V263, P823, DOI 10.1126/science.263.5148.823; SPRUSTON N, 1995, SCIENCE, V268, P297, DOI 10.1126/science.7716524; SVAASAND LO, 1983, PHOTOCHEM PHOTOBIOL, V38, P293, DOI 10.1111/j.1751-1097.1983.tb02674.x; TANK DW, IN PRESS J NEUROSCI; YUSTE R, 1994, NEURON, V13, P23, DOI 10.1016/0896-6273(94)90457-X	31	689	706	0	52	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 22	1995	375	6533					682	684		10.1038/375682a0	http://dx.doi.org/10.1038/375682a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791901				2022-12-28	WOS:A1995RE57600060
J	MALMIVAARA, A; HAKKINEN, U; ARO, T; HEINRICHS, ML; KOSKENNIEMI, L; KUOSMA, E; LAPPI, S; PALOHEIMO, R; SERVO, C; VAARANEN, V; HERNBERG, S				MALMIVAARA, A; HAKKINEN, U; ARO, T; HEINRICHS, ML; KOSKENNIEMI, L; KUOSMA, E; LAPPI, S; PALOHEIMO, R; SERVO, C; VAARANEN, V; HERNBERG, S			THE TREATMENT OF ACUTE LOW-BACK-PAIN - BED REST, EXERCISES, OR ORDINARY ACTIVITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLINICAL-TRIAL; THERAPY	Background. Bed rest and back-extension exercises are often prescribed for patients with acute low back pain, but the effectiveness of these two competing treatments remains controversial. Methods. We conducted a controlled trial among employees of the city of Helsinki, Finland, who presented to an occupational health care center with acute, nonspecific low back pain. The patients were randomly assigned to one of three treatments: bed rest for two days (67 patients), back-mobilizing exercises (52 patients), or the continuation of ordinary activities as tolerated (the control group; 67 patients). Outcomes and costs were assessed after 3 and 12 weeks. Results. After 3 and 12 weeks, the patients in the control group had better recovery than those prescribed either bed rest or exercises. There were statistically significant differences favoring the control group in the duration of pain, pain intensity, lumbar flexion, ability to work as measured subjectively, Oswestry back-disability index, and number of days absent from work. Recovery was slowest among the patients assigned to bed rest. The overall costs of care did not differ significantly among the three groups. Conclusions. Among patients with acute low back pain, continuing ordinary activities within the limits permitted by the pain leads to more rapid recovery than either bed rest or back-mobilizing exercises.	NATL RES & DEV CTR WELF & HLTH,HELSINKI,FINLAND; CITY HELSINKI OCCUPAT HLTH CARE CTR,HELSINKI,FINLAND; INST OCCUPAT HLTH,DEPT EPIDEMIOL & BIOSTAT,HELSINKI,FINLAND	Finnish Institute of Occupational Health	MALMIVAARA, A (corresponding author), INST OCCUPAT HLTH,DEPT OCCUPAT MED,TOPELIUKSENKATU 41 AA,SF-00250 HELSINKI,FINLAND.							DEYO RA, 1986, NEW ENGL J MED, V315, P1064, DOI 10.1056/NEJM198610233151705; DEYO RA, 1987, SPINE, V12, P264, DOI 10.1097/00007632-198704000-00013; DEYO RA, 1991, CONT CONSERVATIVE CA, P169; DONELSON R, 1991, SPINE, V16, pS206, DOI 10.1097/00007632-199106001-00006; Drummond M F, 1991, Int J Technol Assess Health Care, V7, P561; FAAS A, 1993, SPINE, V18, P1388; Fairbank J C, 1980, Physiotherapy, V66, P271; GILBERT JR, 1985, BRIT MED J, V291, P791, DOI 10.1136/bmj.291.6498.791; KOES BW, 1991, BRIT MED J, V302, P1572, DOI 10.1136/bmj.302.6792.1572; NACHEMSON A, 1991, ONT RYGGEN ORSAKER D; Sintonen H, 1992, QUALITY LIFE ASSESSM, P185; STANKOVIC R, 1990, SPINE, V15, P120, DOI 10.1097/00007632-199002000-00014; Torrance GW, 1987, METHODS EC EVALUATIO; WADDELL G, 1987, SPINE, V12, P632, DOI 10.1097/00007632-198709000-00002; WIESEL SW, 1980, SPINE, V5, P324, DOI 10.1097/00007632-198007000-00006; 1993, EGRET INTUITIVE SOFT, P86; 1987, SPINE S, V12, pS22; 1987, SAS STAT GUIDE PERSO, P549	18	443	452	0	22	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 9	1995	332	6					351	355		10.1056/NEJM199502093320602	http://dx.doi.org/10.1056/NEJM199502093320602			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF300	7823996				2022-12-28	WOS:A1995QF30000002
J	ROY, N; MAHADEVAN, MS; MCLEAN, M; SHUTLER, G; YARAGHI, Z; FARAHANI, R; BAIRD, S; BESNERJOHNSTON, A; LEFEBVRE, C; KANG, XL; SALIH, M; AUBRY, H; TAMAI, K; GUAN, XP; IOANNOU, P; CRAWFORD, TO; DEJONG, PJ; SURH, L; IKEDA, JE; KORNELUK, RG; MACKENZIE, A				ROY, N; MAHADEVAN, MS; MCLEAN, M; SHUTLER, G; YARAGHI, Z; FARAHANI, R; BAIRD, S; BESNERJOHNSTON, A; LEFEBVRE, C; KANG, XL; SALIH, M; AUBRY, H; TAMAI, K; GUAN, XP; IOANNOU, P; CRAWFORD, TO; DEJONG, PJ; SURH, L; IKEDA, JE; KORNELUK, RG; MACKENZIE, A			THE GENE FOR NEURONAL APOPTOSIS INHIBITORY PROTEIN IS PARTIALLY DELETED IN INDIVIDUALS WITH SPINAL MUSCULAR-ATROPHY	CELL			English	Article							WERDNIG-HOFFMANN DISEASE; LINKAGE ANALYSIS; REGION; LOCUS; 5Q13; POLYMORPHISMS; CHROMOSOME-5; BACULOVIRUS; INTERVAL; MARKERS	The spinal muscular atrophies (SMAs), characterized by spinal cord motor neuron depletion, are among the most common autosomal recessive disorders. One model of SMA pathogenesis invokes an inappropriate persistence of normally occurring motor neuron apop tosis. Consistent with this hypothesis, the novel gene for neuronal apoptosis inhibitory protein (NAIP) has been mapped to the SMA region of chromosome 5q13.1 and is homologous with baculoviral apoptosis inhibitor proteins. The two first coding exons of this gene are deleted in approximately 67% of type I SMA chromosomes compared with 2% of non-SMA chromosomes. Furthermore, RT-PCR analysis reveals internally deleted and mutated forms of the NAIP transcript in type I SMA individuals and not in unaffected individuals. These findings suggest that mutations in the NAIP locus may lead to a failure of a normally occurring inhibition of motor neuron apoptosis resulting in or contributing to the SMA phenotype.	CHILDRENS HOSP EASTERN ONTARIO, GENET MOLEC LAB, OTTAWA, ON K1H 8L1, CANADA; UNIV OTTAWA, DEPT BIOCHEM, OTTAWA, ON K1H 8M5, CANADA; UNIV OTTAWA, DEPT PEDIAT, OTTAWA, ON K1H 8M5, CANADA; UNIV OTTAWA, IKEDA GENOSPHERE PROJECT, OTTAWA, ON K1H 8M5, CANADA; UNIV OTTAWA, DEPT MICROBIOL, OTTAWA, ON K1H 8M5, CANADA; UNIV OTTAWA, DEPT IMMUNOL, OTTAWA, ON K1H 8M5, CANADA; ROSWELL PK CANC INST, DEPT HUMAN GENET, BUFFALO, NY 14263 USA; JOHNS HOPKINS UNIV, DEPT NEUROL, BALTIMORE, MD 21205 USA; TOKAI UNIV, INST MED SCI, DEPT MED & MOLEC GENET, ISEHARA, KANAGAWA 25911, JAPAN	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; Roswell Park Cancer Institute; Johns Hopkins University; Tokai University			Crawford, Thomas/E-6307-2012; Tamai, Katsuyuki/F-4743-2013	Tamai, Katsuyuki/0000-0003-4094-3911	CSR NIH HHS [1R01RG01165-01] Funding Source: Medline	CSR NIH HHS		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3583; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; BRAHE C, 1994, HUM GENET, V93, P494, DOI 10.1007/BF00202811; BROOKE MH, 1986, CLIN VIEW NEUROMUSCU; BRZUSTOWICZ LM, 1992, GENOMICS, V13, P991, DOI 10.1016/0888-7543(92)90012-H; BRZUSTOWICZ LM, 1990, NATURE, V344, P540, DOI 10.1038/344540a0; BURGHES AHM, 1994, GENOMICS, V21, P394, DOI 10.1006/geno.1994.1282; BURGHES AHM, 1994, HUM GENET, V93, P305, DOI 10.1007/BF00212028; CHEN EY, 1993, GENOMICS, V17, P651, DOI 10.1006/geno.1993.1385; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; CLEM RJ, 1993, J VIROL, V67, P3730, DOI 10.1128/JVI.67.7.3730-3738.1993; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; CLEM RJ, 1994, APOPTOSIS, V2, P89; CLERMONT O, 1994, AM J HUM GENET, V54, P687; COLLIER S, 1993, NAT GENET, V3, P260, DOI 10.1038/ng0393-260; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; DIDONATO CJ, 1994, AM J HUM GENET, V55, P1218; Emery A E, 1991, Neuromuscul Disord, V1, P19, DOI 10.1016/0960-8966(91)90039-U; EVANS BA, 1985, EMBO J, V4, P133, DOI 10.1002/j.1460-2075.1985.tb02327.x; FRANCIS MJ, 1993, HUM MOL GENET, V2, P1161, DOI 10.1093/hmg/2.8.1161; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; GILLIAM TC, 1990, NATURE, V345, P823, DOI 10.1038/345823a0; GILLIAM TC, 1989, GENOMICS, V5, P940, DOI 10.1016/0888-7543(89)90138-9; GLATT K, 1994, GENOMICS, V19, P157, DOI 10.1006/geno.1994.1027; GLEESON R, 1991, NUCLEIC ACIDS RES, V19, P6491; HEDRICK PW, 1987, GENETICS, V117, P331; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; KLEYN PW, 1993, P NATL ACAD SCI USA, V90, P6801, DOI 10.1073/pnas.90.14.6801; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LIEN LL, 1991, P NATL ACAD SCI USA, V88, P7873, DOI 10.1073/pnas.88.17.7873; MACKENZIE A, 1993, HUM GENET, V90, P501; MCLEAN MD, 1994, HUM MOL GENET, V3, P1951; MELKI J, 1990, NATURE, V344, P767, DOI 10.1038/344767a0; MELKI J, 1994, SCIENCE, V264, P1474, DOI 10.1126/science.7910982; MURAYAMA S, 1991, ACTA NEUROPATHOL, V81, P408, DOI 10.1007/BF00293462; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PERESS NS, 1986, CLIN NEUROPATHOL, V5, P69; Podolsky L., 1994, American Journal of Human Genetics, V55, pA161; ROY N, 1995, IN PRESS GENOMICS; SARNAT HB, 1983, PROGR SPINAL MUSCULA, P91; SHETH P, 1991, AM J HUM GENET, V48, P764; SOARES VM, 1993, GENOMICS, V15, P365, DOI 10.1006/geno.1993.1069; THOMPSON TG, 1993, HUM MOL GENET, V2, P1169, DOI 10.1093/hmg/2.8.1169; TOWFIGHI J, 1985, ACTA NEUROPATHOL, V65, P270, DOI 10.1007/BF00687008; WEDELL A, 1993, HUM GENET, V91, P236; WIRTH B, 1993, GENOMICS, V15, P113, DOI 10.1006/geno.1993.1018; WIRTH B, 1994, GENOMICS, V20, P84, DOI 10.1006/geno.1994.1130; [No title captured]; [No title captured]	53	825	869	0	18	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 13	1995	80	1					167	178		10.1016/0092-8674(95)90461-1	http://dx.doi.org/10.1016/0092-8674(95)90461-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813013	hybrid			2022-12-28	WOS:A1995QB91000020
J	SAUNDERS, N				SAUNDERS, N			PELVIC EXAMINATION - BY WHOM AND FOR WHOM	LANCET			English	Editorial Material							EXENTERATION; RECURRENCE; CERVIX				SAUNDERS, N (corresponding author), PRINCESS ANNE HOSP,SOUTHAMPTON,HANTS,ENGLAND.							ANDERSEN BL, 1983, OBSTET GYNECOL, V61, P331; AVERETTE HE, 1984, AM J OBSTET GYNECOL, V150, P179, DOI 10.1016/S0002-9378(84)80013-7; BRUNSCHWIG A, 1948, CANCER, V1, P177, DOI 10.1002/1097-0142(194807)1:2<177::AID-CNCR2820010203>3.0.CO;2-A; MORELY GW, 1989, OBSTET GYNECOL, V74, P934; ORR JW, 1983, AM J OBSTET GYNECOL, V145, P325, DOI 10.1016/0002-9378(83)90719-6; PEREZ CA, 1983, CANCER, V51, P1393, DOI 10.1002/1097-0142(19830415)51:8<1393::AID-CNCR2820510812>3.0.CO;2-M; POPOVICH MJ, 1993, AM J ROENTGENOL, V160, P525, DOI 10.2214/ajr.160.3.8430546; ROBERTSON G, 1994, BRIT J OBSTET GYNAEC, V101, P529, DOI 10.1111/j.1471-0528.1994.tb13156.x; SHINGLETON HM, 1989, OBSTET GYNECOL, V73, P1027	9	20	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					5	6		10.1016/S0140-6736(95)91146-4	http://dx.doi.org/10.1016/S0140-6736(95)91146-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799711				2022-12-28	WOS:A1995QA29000005
J	GARDINER, PA				GARDINER, PA			THE LEAN AND SLIPPERED PANTALOON	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1709	1710		10.1136/bmj.309.6970.1709	http://dx.doi.org/10.1136/bmj.309.6970.1709			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819996	Green Published			2022-12-28	WOS:A1994PY71700026
J	CHOWIENCZYK, PJ; PARKIN, DH; LAWSON, CP; COCHRANE, GM				CHOWIENCZYK, PJ; PARKIN, DH; LAWSON, CP; COCHRANE, GM			DO ASTHMATIC-PATIENTS CORRECTLY RECORD HOME SPIROMETRY MEASUREMENTS	BRITISH MEDICAL JOURNAL			English	Article							DIARY		MICRO MED,CHATHAM,KENT,ENGLAND; GUYS HOSP,DEPT THORAC MED,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust	CHOWIENCZYK, PJ (corresponding author), ST THOMAS HOSP,DEPT CLIN PHARMACOL,LONDON SE1 7EH,ENGLAND.			Chowienczyk, Phil/0000-0003-4507-038X				BREWIS RAL, 1991, RESP MED, V85, P457, DOI 10.1016/S0954-6111(06)80262-3; CHOWIENCZYK PJ, 1992, LANCET, V339, P251, DOI 10.1016/0140-6736(92)90061-7; HYLAND ME, 1993, BRIT MED J, V306, P487, DOI 10.1136/bmj.306.6876.487; LISTER J, 1989, THORAX, V44, P343; 1993, J PHARM MED, V3, P217	5	51	51	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1618	1618		10.1136/bmj.309.6969.1618	http://dx.doi.org/10.1136/bmj.309.6969.1618			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819938	Green Published			2022-12-28	WOS:A1994PY22000019
J	MCLOONE, P; BODDY, FA				MCLOONE, P; BODDY, FA			DEPRIVATION AND MORTALITY IN SCOTLAND, 1981 AND 1991	BRITISH MEDICAL JOURNAL			English	Article							SUICIDE; HEALTH	Objective-To compare the mortality experience Scottish postcode sectors characterised by socioeconomic: census variables (Carstairs scores) in 1980-2 and 1990-2. Methods-Variables derived from the 1981 and 1991 censuses were combined according to the method devised by Carstairs and Morris(6) to obtain Carstairs scores for 1010 postcode sectors in Scotland in 1981 and 1001 sectors in 1991. For most analyses, these scores were grouped into seven deprivation categories ranging from affluent (category 1) to deprived (category 7) localities. Main outcome measures-Death rates and standardised mortality ratios for localities according to deprivation category. Results-Postcode sectors in Scotland that were categorised as deprived in 1981 were relatively more deprived at the time of the 1991 census; the mortality experience of deprived localities relative to either Scotland or affluent neighbourhoods worsened over this period, with a 162% difference between the most affluent and most deprived categories in 1991-2. Although the age and sex standardised mortality for ages 0-64 in Scotland declined by 22% during the 1980s, the reduction in the deprived categories was only about half that of the affluent groups. Increases in the death rate for men (29%) and women (11%) aged 20-29 in the deprived groups were largely attributable to an increase in the rates of suicide. Death rates from ischaemic heart disease and carcinoma of the lung and bronchus at ages 40-69 were lower in all deprivation categories in 1990-2, but the reduction was greater in more affluent areas; the difference in rates for these conditions between affluent. and deprived; groups therefore increased over the decade, The observed worsening of the standardised mortality ratio for Glasgow relative to Scotland could be explained on the basis of these mortality differentials and the concentration of deprived postcode sectors in Glasgow. Conclusions-Differences in mortality experience linked to relative poverty increased in the 10 years between 1981 and 1991 censuses. Although mortality for Scotland as 9 whole is improving, the Picture is one of an increasing distinction between the experience of the majority and that of a substantial minority of the population.			MCLOONE, P (corresponding author), UNIV GLASGOW,PUBL HLTH RES UNIT,GLASGOW G12 8RZ,LANARK,SCOTLAND.		McLoone, Philip/H-2353-2017	McLoone, Philip/0000-0003-0002-8700				Barker DJP, 1992, FETAL INFANT ORIGINS; BODDY FA, 1985, RECENT ADV COMMUNITY, P55; CARSTAIRS V, 1992, DEPRIVATION HLTH SCO; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; EAMES M, 1993, BRIT MED J, V307, P1097, DOI 10.1136/bmj.307.6912.1097; Forwell G, 1993, GLASGOWS HLTH OLD PR; FRISCHER M, 1993, J EPIDEMIOL COMMUN H, V47, P59, DOI 10.1136/jech.47.1.59; GOLDACRE M, 1993, LANCET, V342, P283, DOI 10.1016/0140-6736(93)91822-4; ILLSLEY R, 1960, PROFESSIONAL PUBLIC; JARMAN B, 1984, BRIT MED J, V289, P1587, DOI 10.1136/bmj.289.6458.1587; KELSEY JL, 1993, EPIDEMIOL REV, V15, P7, DOI 10.1093/oxfordjournals.epirev.a036118; KREITMAN N, 1994, HLTH B EDINB, V52, P300; MCLEONE P, 1992, CATEGORISING SMALL G; MCLOONE P, 1987, BMJ-BRIT MED J, V295, P629, DOI 10.1136/bmj.295.6599.629; McLoone P., 1994, CARSTAIRS SCORES SCO; MORRIS R, 1991, J PUBLIC HEALTH MED, V13, P318; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; PHILLIMORE P, 1994, BRIT MED J, V308, P1125, DOI 10.1136/bmj.308.6937.1125; SMITH GD, 1993, BRIT MED J, V307, P1085, DOI 10.1136/bmj.307.6912.1085; SMITH GD, 1994, EUR J PUBLIC HLTH, V4, P133; Townsend P., 1988, INEQUALITIES HLTH BL; Townsend PP., 1988, HLTH DEPRIVATION INE; Watt G C, 1993, Health Bull (Edinb), V51, P407; WATT GCM, 1992, J EPIDEMIOL COMMUNIT, V46, P184; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; WILKINSON RG, 1992, BRIT MED J, V305, P1239, DOI 10.1136/bmj.305.6864.1239; 1992, SCOTLANDS HLTH CHALL; 1992, HLTH NATION STRATEGY; 1992, SASPAC USER MANUAL, V1; 1993, FINAL MID 1991 POPUL	30	205	209	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 3	1994	309	6967					1465	1470		10.1136/bmj.309.6967.1465	http://dx.doi.org/10.1136/bmj.309.6967.1465			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW053	7804046	Green Published			2022-12-28	WOS:A1994PW05300017
J	WARDLAW, JM				WARDLAW, JM			CONTROVERSIES IN MANAGEMENT .12. IS ROUTINE COMPUTED-TOMOGRAPHY IN STROKES UNNECESSARY - COMPUTED-TOMOGRAPHY PROVIDES ACCURATE DIAGNOSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INTRACEREBRAL HEMORRHAGE; INFARCTION				WARDLAW, JM (corresponding author), WESTERN GEN HOSP, DEPT CLIN NEUROSCI, CREWE RD, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.		Wardlaw, Joanna M/Y-3456-2019; Hernandez, María/GYU-3543-2022	Wardlaw, Joanna M/0000-0002-9812-6642; 				ALLEN CMC, 1983, Q J MED, V52, P515; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; BARNFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16; DENNIS MS, 1987, BRIT MED J, V295, P379, DOI 10.1136/bmj.295.6594.379; DONNAN GA, 1992, LANCET, V339, P473, DOI 10.1016/0140-6736(92)91070-O; LAUPACIS A, 1993, LANCET, V342, P1251, DOI 10.1016/0140-6736(93)92353-U; LINDLEY RI, 1993, AGE AGEING S, V23, P4; POUNGVARIN N, 1991, BRIT MED J, V302, P1565, DOI 10.1136/bmj.302.6792.1565; SANDERCOCK P, 1985, BRIT MED J, V290, P193, DOI 10.1136/bmj.290.6463.193; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; 1988, BRIT MED J, V297, P126; 1933, STROKE CLIN UPDATES, V4, P1; 1990, J R COLL PHYS LOND, V24, P15	14	8	8	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 3	1994	309	6967					1498	1499		10.1136/bmj.309.6967.1498	http://dx.doi.org/10.1136/bmj.309.6967.1498			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW053	7804060	Green Published			2022-12-28	WOS:A1994PW05300034
J	TANG, WJ; GILMAN, AG				TANG, WJ; GILMAN, AG			CONSTRUCTION OF A SOLUBLE ADENYLYL-CYCLASE ACTIVATED BY G(S)ALPHA AND FORSKOLIN	SCIENCE			English	Article							GLUCOSE-TRANSPORT; ESCHERICHIA-COLI; GS-ALPHA; SITE; CAMP; RAT; ADIPOCYTES; INHIBITION	A soluble adenylyl cyclase was constructed by linkage of portions of the cytosolic domains of the mammalian type I and type II enzymes. The soluble enzyme was stimulated by both forskolin and the alpha subunit of the heterotrimeric guanine nucleotide-binding protein (G protein) G(s) (G(s) alpha). Expression of the construct complemented the catabolic defect in a strain of Escherichia coli that is deficient in adenylyl cyclase activity. The active, approximately 60-kilodalton enzyme accumulated in the cytoplasmic fraction of E. coli to yield activities in excess of 1 nanomole per minute per milligram of protein. The two sets of transmembrane helices of mammalian adenylyl cyclases are thus not necessary for the catalytic or the most characteristic regulatory activities of the enzyme. This system may be useful for both genetic and biochemical analysis of G protein-regulated adenylyl cyclases.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Tang, Wei-Jen/0000-0002-8267-8995	NIGMS NIH HHS [GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BEUVE A, 1990, J BACTERIOL, V172, P2614, DOI 10.1128/jb.172.5.2614-2621.1990; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DESSAUER C, UNPUB; FLORIO VA, 1983, MOL PHARMACOL, V24, P195; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HEUSCHNEIDER G, 1989, P NATL ACAD SCI USA, V86, P2938, DOI 10.1073/pnas.86.8.2938; HOSHI T, 1988, SCIENCE, V240, P1652, DOI 10.1126/science.2454506; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; JOOST HG, 1988, MOL PHARMACOL, V33, P449; KASHIWAGI A, 1983, J BIOL CHEM, V258, P3685; KNOLL LJ, 1993, J BIOL CHEM, V268, P4281; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MORRIS DI, 1994, MOL PHARMACOL, V46, P329; MORRIS DI, 1991, BIOCHEMISTRY-US, V30, P8371, DOI 10.1021/bi00098a014; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PERLMAN RL, 1969, BIOCHEM BIOPH RES CO, V37, P151, DOI 10.1016/0006-291X(69)90893-6; ROY A, 1982, MOL GEN GENET, V188, P465, DOI 10.1007/BF00330050; SEAMON KB, 1983, J MED CHEM, V26, P436, DOI 10.1021/jm00357a021; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SUTKOWSKI EM, 1994, BIOCHEMISTRY-US, V33, P12852, DOI 10.1021/bi00209a017; Tang W. J., UNPUB; TANG WJ, 1992, COLD SPRING HARB SYM, V57, P135, DOI 10.1101/SQB.1992.057.01.017; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; WADLER S, 1988, CANCER RES, V48, P539; WADZINSKI BE, 1990, BIOCHEM J, V272, P151, DOI 10.1042/bj2720151; WAGONER PK, 1988, SCIENCE, V240, P1655, DOI 10.1126/science.2454507	29	148	153	2	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 23	1995	268	5218					1769	1772		10.1126/science.7792604	http://dx.doi.org/10.1126/science.7792604			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792604				2022-12-28	WOS:A1995RE66800047
J	TAUBES, G				TAUBES, G			STANFORD - BRINGING IN THE BIG GUNS	SCIENCE			English	Note																			0	2	2	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1711	1711		10.1126/science.7792592	http://dx.doi.org/10.1126/science.7792592			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792592				2022-12-28	WOS:A1995RE66800026
J	TAUBES, G				TAUBES, G			IIT - SERVING UP ETHICS FOR LUNCH	SCIENCE			English	Note																			0	1	1	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1716	1716		10.1126/science.7792595	http://dx.doi.org/10.1126/science.7792595			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792595				2022-12-28	WOS:A1995RE66800031
J	BESSEN, RA; KOCISKO, DA; RAYMOND, GJ; NANDAN, S; LANSBURY, PT; CAUGHEY, B				BESSEN, RA; KOCISKO, DA; RAYMOND, GJ; NANDAN, S; LANSBURY, PT; CAUGHEY, B			NONGENETIC PROPAGATION OF STRAIN-SPECIFIC PROPERTIES OF SCRAPIE PRION PROTEIN	NATURE			English	Article							TRANSMISSIBLE MINK ENCEPHALOPATHY; DISEASES; BIOLOGY; MODEL; AGENT	THE infectious agents causing scrapie and other transmissible spongiform encephalopathies have been postulated to consist solely of the protease-resistant form of prion protein (PrPSc)(1-6). One unprecedented requirement of the protein-only model is that the 'inheritance' of pathogen strain differences must be mediated by stable variations in PrPSc structure(2,7,8), rather than mutations in an agent-specific nucleic acid(9). Strain differences in PrPSc structure have been described for the hyper (HY) and drowsy (DY) strains of hamster transmissible mink encephalopathy (TME)(7,8), a a scrapie-like disease originating in mink. Although HY and DY PrPSc are both post-translationally derived from the precursor prion protein (PrPc) they are cleaved at different amino-terminal sites by proteinase K (ref. 8). Here we investigate whether this strain-specific property of PrPSc is transmitted to PrPc during formation of new PrPSc. PrPSc from the HY and DY TME strains converted the protease-sensitive PrPc into two distinct sets of protease-resistant PrP products in a cell-free system. These data provide evidence that self-propagation of PrPSc polymers with distinct three-dimensional structures could be the molecular basis of scrapie strains.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	BESSEN, RA (corresponding author), NIAID,ROCKY MT LABS,PERSISTENT VIRAL DIS LAB,HAMILTON,MT 59840, USA.							BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1992, J GEN VIROL, V73, P329, DOI 10.1099/0022-1317-73-2-329; BESSEN RA, 1992, J VIROL, V66, P2096, DOI 10.1128/JVI.66.4.2096-2101.1992; BOLTON DC, 1988, CIBA F SYMP, V135, P164; BROWN P, 1991, LANCET, V337, P1019, DOI 10.1016/0140-6736(91)92670-W; BRUCE ME, 1987, J GEN VIROL, V68, P79, DOI 10.1099/0022-1317-68-1-79; CASPAR DLD, 1980, BIOPHYS J, V32, P101; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0	14	450	465	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 22	1995	375	6533					698	700		10.1038/375698a0	http://dx.doi.org/10.1038/375698a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791905				2022-12-28	WOS:A1995RE57600065
J	KELCE, WR; STONE, CR; LAWS, SC; GRAY, LE; KEMPPAINEN, JA; WILSON, EM				KELCE, WR; STONE, CR; LAWS, SC; GRAY, LE; KEMPPAINEN, JA; WILSON, EM			PERSISTENT DDT METABOLITE P,P'-DDE IS A POTENT ANDROGEN RECEPTOR ANTAGONIST	NATURE			English	Article							ESTROGENIC ACTIVITY; RAT; BINDING; PROSTATE; ANALOGS	THE increase in the number of reports of abnormalities in male sex development in wildlife and humans coincided with the introduction of 'oestrogenic' chemicals such as DDT (1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane) into the environment, Although these phenotypic alterations are thought to be mediated by the oestrogen receptor, they are also consistent with inhibition of androgen receptor-mediated events, Here we report that the major and persistent DDT metabolite, p,p'-DDE (1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene), has little ability to bind the oestrogen receptor, but inhibits androgen binding to the androgen receptor, androgen-induced transcriptional activity, and androgen action in developing, pubertal and adult male rats, The results suggest that abnormalities in male sex development induced by p,p'-DDE and related environmental chemicals may be mediated at the level of the androgen receptor.	UNIV N CAROLINA,REPROD BIOL LABS,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	KELCE, WR (corresponding author), US EPA,HLTH EFFECTS RES LAB,DIV DEV TOXICOL,REPROD TOXICOL BRANCH,RES TRIANGLE PK,NC 27711, USA.			gray jr, leon earl/0000-0002-1111-4754				BITMAN J, 1970, J AGR FOOD CHEM, V18, P1108, DOI 10.1021/jf60172a019; BOUWMAN H, 1991, J TOXICOL ENV HEALTH, V33, P141, DOI 10.1080/15287399109531514; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; CLEMENS LG, 1978, HORM BEHAV, V10, P40, DOI 10.1016/0018-506X(78)90023-5; CURLEY A, 1969, ARCH ENVIRON HEALTH, V19, P628, DOI 10.1080/00039896.1969.10666901; DURNBERGER H, 1980, CELL, V19, P465, DOI 10.1016/0092-8674(80)90521-8; Dustman E H, 1969, Ann N Y Acad Sci, V160, P162, DOI 10.1111/j.1749-6632.1969.tb15828.x; GELLERT RJ, 1972, ENDOCRINOLOGY, V91, P1095, DOI 10.1210/endo-91-4-1095; GRAY LE, 1994, TOXICOL APPL PHARM, V129, P46, DOI 10.1006/taap.1994.1227; GUILLETTE LJ, 1994, ENVIRON HEALTH PERSP, V102, P680, DOI 10.2307/3432198; IMPERATOMCGINLEY J, 1992, ENDOCRINOLOGY, V131, P1149, DOI 10.1210/en.131.3.1149; KELCE W R, 1988, Steroids, V52, P217, DOI 10.1016/0039-128X(88)90005-0; KELCE WR, 1994, TOXICOL APPL PHARM, V126, P276, DOI 10.1006/taap.1994.1117; KORENBROT CC, 1977, BIOL REPROD, V17, P298, DOI 10.1095/biolreprod17.2.298; KUPFER D, 1975, Critical Reviews in Toxicology, V4, P83; LEGER JG, 1988, PROSTATE, V13, P131, DOI 10.1002/pros.2990130205; MORGAN DP, 1971, ARCH ENVIRON HEALTH, V22, P301, DOI 10.1080/00039896.1971.10665848; NELSON J A, 1978, Journal of Toxicology and Environmental Health, V4, P325; NELSON JA, 1974, BIOCHEM PHARMACOL, V23, P447, DOI 10.1016/0006-2952(74)90436-5; Neumann F, 1970, Recent Prog Horm Res, V26, P337; PAGE MJ, 1982, MOL CELL ENDOCRINOL, V27, P343, DOI 10.1016/0303-7207(82)90099-5; ROBISON AK, 1985, J TOXICOL ENV HEALTH, V16, P493, DOI 10.1080/15287398509530758; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; STONE CR, 1995, J ANDROL S, V16, P42; WELCH RM, 1969, TOXICOL APPL PHARM, V14, P358, DOI 10.1016/0041-008X(69)90117-3; WILSON EM, 1976, J BIOL CHEM, V251, P5620; WOOLLEY DE, 1971, TOXICOL APPL PHARM, V18, P907, DOI 10.1016/0041-008X(71)90238-9; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115	29	1257	1317	7	187	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					581	585		10.1038/375581a0	http://dx.doi.org/10.1038/375581a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791873				2022-12-28	WOS:A1995RD28700049
J	WENGER, PN; OTTEN, J; BREEDEN, A; ORFAS, D; BECKSAGUE, CM; JARVIS, WR				WENGER, PN; OTTEN, J; BREEDEN, A; ORFAS, D; BECKSAGUE, CM; JARVIS, WR			CONTROL OF NOSOCOMIAL TRANSMISSION OF MULTIDRUG-RESISTANT MYCOBACTERIUM-TUBERCULOSIS AMONG HEALTH-CARE WORKERS AND HIV-INFECTED PATIENTS	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; OUTBREAK; RISK	From 1988 to 1990, an outbreak of multidrug-resistant tuberculosis (MDR-TB) among patients, and an increased number of tuberculin-skin-test conversions among healthcare workers, occurred on the HIV ward of Jackson Memorial Hospital, Miami, Florida, USA. Measures similar to those subsequently recommended in the 1990 Centers for Disease Control and Prevention guidelines were implemented on the HIV ward by June, 1990, and in September, 1992, we evaluated the efficacy of these control measures. Among MDR-TB patients and healthcare workers with tuberculin-skin-test conversions on the HIV ward, we looked for evidence of exposure to HIV ward MDR-TB patients positive for acid-fast bacilli in sputum during initial January-May, 1990) and follow-up (June, 1990-June, 1992) periods. Exposure before implementation of control measures to an infectious MDR-TB patient on the HIV ward was recorded in 12 of 15 (80%) MDR-TB patients during the initial period and 5 of 11(45%) MDR-TB patients during follow-up. After implementation of control measures, no episodes of MDR-TB could be traced to contact with infectious MDR-TB patients on the HIV ward. Skin-test conversions among workers on the HIV ward declined from 7 of 25 (28%) during the initial period to 3 of 17 (18%) in the early (June, 1990-February, 1998) and 0 of 23 in the late (March, 1991-June, 1992) follow-up periods (p<0.01). Skin-test conversions among healthcare workers were not associated with increased exposure to MDR-TB patients, and were not significantly higher among workers on the HIV ward than on a control ward without tuberculosis patients (3/27 vs 0/16). These data demonstrate that implementation of measures similar to the Centers for Disease Control and Prevention 1990 tuberculosis-control guidelines were effective in halting transmission of MDR-TB to healthcare workers and HIV-infected patients.	JACKSON MEM HOSP,OFF TB CONTROL,MIAMI,FL 33136; JACKSON MEM HOSP,OFF EMPLOYEE HLTH,MIAMI,FL 33136					Beck-Sague, Consuelo/0000-0001-9082-0165				BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; CATANZARO A, 1982, AM REV RESPIR DIS, V125, P559, DOI 10.1164/arrd.1982.125.5.559; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; EHRENKRA.NJ, 1972, ANN INTERN MED, V77, P377, DOI 10.7326/0003-4819-77-3-377; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; HALEY CE, 1989, INFECT CONT HOSP EP, V10, P204, DOI 10.1086/646003; HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540, DOI 10.1093/clind/15.3.540; JARVIS WR, 1993, RES MICROBIOL, V144, P117, DOI 10.1016/0923-2508(93)90025-W; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; KANTOR HS, 1988, AM J MED, V84, P833, DOI 10.1016/0002-9343(88)90060-5; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; RUDNIK J, 1993, 3RD ANN M SOC HOSP E; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; 1990, MMWR-MORBID MORTAL W, V39, P1; 1990, MMWR MORB MORTAL WKL, V39; 1990, AM REV RESPIR DIS, V142, P725; 1991, MMWR-MORBID MORTAL W, V40, P585	19	149	149	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 28	1995	345	8944					235	240		10.1016/S0140-6736(95)90228-7	http://dx.doi.org/10.1016/S0140-6736(95)90228-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7823719	Bronze			2022-12-28	WOS:A1995QD53200014
J	REDELMEIER, DA; SHAFIR, E				REDELMEIER, DA; SHAFIR, E			MEDICAL DECISION-MAKING IN SITUATIONS THAT OFFER MULTIPLE ALTERNATIVES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHOICE	Objective.-To determine whether situations involving multiple options can paradoxically influence people to choose an option that would have been declined if fewer options were available. Design.-Mailed survey containing medical scenarios formulated in one of two versions. Participants.-Two groups of physicians: members of the Ontario College of Family Physicians (response rate=77%; n=287) and neurologists and neurosurgeons affiliated with the North American Symptomatic Carotid Endarterectomy Trial (response rate=84%; n=352). One group of legislators belonging to the Ontario Provincial Parliament (response rate=32%; n=41). Intervention.-The basic version of each scenario presented a choice between two options. The expanded version presented three options: the original two plus a third. The two versions otherwise contained identical information and were randomly assigned. Outcome Measures.-Participants' treatment recommendations. Results.-ln one scenario involving a patient with osteoarthritis, family physicians were less likely to prescribe a medication when deciding between two medications than when deciding about only one medication (53% vs 72%; P<.005). Apparently, the difficulty in deciding between the two medications led some physicians to recommend not starting either. Similar discrepancies were found in decisions made by neurologists and neurosurgeons concerning carotid artery surgery and by legislators concerning hospital closures. Conclusions.-The introduction of additional options can increase decision difficulty and, hence, the tendency to choose a distinctive option or maintain the status quo. Awareness of this cognitive bias may lead to improved decision making in complex medical situations.	UNIV TORONTO,DEPT MED,TORONTO,ON,CANADA; PRINCETON UNIV,DEPT PSYCHOL,PRINCETON,NJ 08544	University of Toronto; Princeton University	REDELMEIER, DA (corresponding author), WELLESLEY COLL HOSP,RES INST,DIV CLIN EPIDEMIOL,JONES BLDG 123,160 WELLESLEY ST E,TORONTO,ON M4Y 1J3,CANADA.		Shafir, Eldar/H-9957-2014		NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH046885] Funding Source: NIH RePORTER; NIMH NIH HHS [1-R29-MH46885] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		[Anonymous], 1982, JUDGMENT UNCERTAINTY; BELL DE, 1982, OPER RES, V30, P961, DOI 10.1287/opre.30.5.961; Bell DE, 1988, DECISION MAKING; BORGEIL AEM, 1989, CAN MED ASSOC J, V140, P1085; DOWD AL, 1993, PHYSICIANS DESK REFE; FISCHHOFF B, 1975, J EXP PSYCHOL HUMAN, V41, P288; FONG GT, 1986, COGNITIVE PSYCHOL, V18, P253, DOI 10.1016/0010-0285(86)90001-0; Fuchs V., 1974, WHO SHALL LIVE; HELFAND M, 1990, ANN INTERN MED, V112, P840, DOI 10.7326/0003-4819-112-11-840; HUBER J, 1982, J CONSUM RES, V9, P90, DOI 10.1086/208899; Janis I. L., 1977, DECISION MAKING; NEIPP J, 1985, ADV HLTH EC HLTH SER; RANSOHOFF DF, 1991, ANN INTERN MED, V114, P177, DOI 10.7326/0003-4819-114-3-177; REDELMEIER DA, 1993, JAMA-J AM MED ASSOC, V270, P72, DOI 10.1001/jama.270.1.72; Samuelson W, 1988, J RISK UNCERTAINTY, V1, P7, DOI 10.1007/BF00055564; SHAFIR E, 1993, 101ST AM PSYCH ASS A, P35; SIMONSON I, 1992, J MARKETING RES, V29, P281, DOI 10.2307/3172740; SLOVIC P, 1983, AM ECON REV, V73, P596; TVERSKY A, 1992, PSYCHOL SCI, V3, P358, DOI 10.1111/j.1467-9280.1992.tb00047.x; TVERSKY A, 1986, KALEIDOSCOPE SCI; 1992, 1992 ONTARIO BUDGET; 1987, SPINE, V12, P522; 1991, NEW ENGL J MED, V325, P445	23	252	255	1	44	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	1995	273	4					302	305		10.1001/jama.273.4.302	http://dx.doi.org/10.1001/jama.273.4.302			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QC057	7815657				2022-12-28	WOS:A1995QC05700028
J	CHAPMAN, T; LIDDLE, LF; KALB, JM; WOLFNER, MF; PARTRIDGE, L				CHAPMAN, T; LIDDLE, LF; KALB, JM; WOLFNER, MF; PARTRIDGE, L			COST OF MATING IN DROSOPHILA-MELANOGASTER FEMALES IS MEDIATED BY MALE ACCESSORY-GLAND PRODUCTS	NATURE			English	Article							REPRODUCTIVE-BEHAVIOR; EXPRESSION; GENE; PEPTIDE; EXPOSURE; SPERM	FEMALE Drosophila melanogaster with environmentally(1-3) or genetically(4) elevated rates of mating die younger than controls. This cost of mating is not attributable to receipt of sperm(5). We demonstrate here that seminal fluid products from the main cells of the male accessory gland are responsible for the cost of mating in females, and that increasing exposure to these products increases female death rate. Main-cell products are also involved in elevating the rate of female egg-laying, in reducing female receptivity to further matings and in removing or destroying sperm of previous mates(6-12). The cost of mating to females may therefore represent a side-effect of evolutionary conflict between males(13).	UNIV LONDON UNIV COLL,DEPT GENET & BIOMETRY,LONDON NW1 2HE,ENGLAND; UNIV EDINBURGH,INST CELL ANIM & POPULAT BIOL,EDINBURGH EH9 3JT,MIDLOTHIAN,SCOTLAND; CORNELL UNIV,GENET & DEV SECT,ITHACA,NY 14853	University of London; University College London; University of Edinburgh; Cornell University			Partridge, Linda/A-5501-2010; Chapman, Tracey/E-5100-2011	Partridge, Linda/0000-0001-9615-0094				AGUADE M, 1992, GENETICS, V132, P755; AIGAKI T, 1991, NEURON, V7, P557, DOI 10.1016/0896-6273(91)90368-A; BALRATI A, 1970, DROSOPHILA INFORMATI, V45, P67; BERTRAM MJ, 1992, MECH DEVELOP, V38, P33, DOI 10.1016/0925-4773(92)90036-J; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; CAVENER DR, 1983, P NATL ACAD SCI-BIOL, V80, P6286, DOI 10.1073/pnas.80.20.6286; CHAPMAN T, 1994, J EVOLUTION BIOL, V7, P51, DOI 10.1046/j.1420-9101.1994.7010051.x; CHAPMAN T, 1992, J INSECT PHYSIOL, V38, P223, DOI 10.1016/0022-1910(92)90070-T; CHAPMAN T, 1993, P ROY SOC B-BIOL SCI, V253, P211, DOI 10.1098/rspb.1993.0105; CHEN PS, 1988, CELL, V54, P291, DOI 10.1016/0092-8674(88)90192-4; DIBENEDETTO AJ, 1990, DEV BIOL, V139, P134, DOI 10.1016/0012-1606(90)90284-P; DIXON WJ, 1988, BMDP STATISTICAL SOF, V2; FOWLER K, 1989, NATURE, V338, P760, DOI 10.1038/338760a0; HARSHMAN LG, IN PRESS EVOLUTION; HIHARA F, 1981, Zoological Magazine (Tokyo), V90, P307; KALB JM, 1993, P NATL ACAD SCI USA, V90, P8093, DOI 10.1073/pnas.90.17.8093; LUDWIG MZ, 1991, BIOCHEM GENET, V29, P215, DOI 10.1007/BF00590103; MANNING A, 1967, ANIM BEHAV, V15, P239, DOI 10.1016/0003-3472(67)90006-1; MEIKLE DB, 1990, J INSECT PHYSIOL, V36, P93, DOI 10.1016/0022-1910(90)90179-J; MONSMA SA, 1988, GENE DEV, V2, P1063, DOI 10.1101/gad.2.9.1063; PARTRIDGE L, 1990, J INSECT PHYSIOL, V36, P419, DOI 10.1016/0022-1910(90)90059-O; PARTRIDGE L, 1987, J INSECT PHYSIOL, V33, P745, DOI 10.1016/0022-1910(87)90060-6; RICE WR, 1989, EVOLUTION, V43, P223, DOI 10.1111/j.1558-5646.1989.tb04220.x; SCOTT D, 1987, ANIM BEHAV, V35, P142, DOI 10.1016/S0003-3472(87)80219-1; TREVITT S, 1988, J INSECT PHYSIOL, V34, P821, DOI 10.1016/0022-1910(88)90157-6; TREVITT S, 1989, THESIS U EDINBURGH; Trivers R. L., 1972, SEXUAL SELECTION DES, P136, DOI DOI 10.1002/AJPA.1330400226; VANVALEN LM, 1985, EVOL THEOR, V7, P93	28	1072	1093	1	248	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					241	244		10.1038/373241a0	http://dx.doi.org/10.1038/373241a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816137				2022-12-28	WOS:A1995QC27800062
J	DREVETS, WC; BURTON, H; VIDEEN, TO; SNYDER, AZ; SIMPSON, JR; RAICHLE, ME				DREVETS, WC; BURTON, H; VIDEEN, TO; SNYDER, AZ; SIMPSON, JR; RAICHLE, ME			BLOOD-FLOW CHANGES IN HUMAN SOMATOSENSORY CORTEX DURING ANTICIPATED STIMULATION	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; SOMATIC SENSORY TRANSMISSION; PET IMAGES; SELECTIVE ATTENTION; BRAIN; RESPONSES; MOVEMENT; PERFORMANCE; (H2O)-O-15; MODULATION	POSITRON emission tomography (PET) measurements of brain blood flow were used to monitor changes in the human primary and secondary somatosensory cortices during the period when somatosensory stimuli were expected. In anticipation of either focal or innocuous touching, or localized, painful shocks, blood flow decreased in parts of the primary somatosensory cortex map located outside the representation of the skin area that was the target of the expected stimulus. Specifically, attending to an impending stimulus to the fingers produced a significant decrease in blood flow in the somatosensory zones for the face, whereas attending to stimulation of the toe produced decreases in the zones for the fingers and face. Decreases were more prominent in the side ipsilateral to the location of the expected stimulus. No significant changes in blood flow occurred in the region of the cortex representing the skin locus of the awaited stimulation. These results are concurrent with a model of spatial attention in which potential signal enhancement may rely on, generalized suppression of background activity(1).	ST LOUIS UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110; ST LOUIS UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; ST LOUIS UNIV,SCH MED,DEPT NEUROL & NEUROL SURG NEUROL,ST LOUIS,MO 63110	Saint Louis University; Saint Louis University; Saint Louis University	DREVETS, WC (corresponding author), ST LOUIS UNIV,SCH MED,MALLINCKRODT INST RADIOL,DIV RADIAT SCI,ST LOUIS,MO 63110, USA.							BURTON H, 1993, SOMATOSENS MOT RES, V10, P297, DOI 10.3109/08990229309028839; CHAPIN JK, 1982, EXP NEUROL, V78, P654, DOI 10.1016/0014-4886(82)90082-6; CHAPIN JK, 1982, EXP NEUROL, V78, P670, DOI 10.1016/0014-4886(82)90083-8; CHAPMAN CE, 1988, EXP BRAIN RES, V72, P316; CHAPMAN CE, 1987, EXP BRAIN RES, V68, P516; CHAPMAN CE, 1991, EXP BRAIN RES, V87, P319; COQUERY J M, 1971, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V165, P1946; Coquery J-M, 1978, ACTIVE TOUCH MECHANI, P161; DREVETS WC, 1992, SCIENCE, V256, P1696, DOI 10.1126/science.256.5064.1696; FOX PT, 1985, J COMPUT ASSIST TOMO, V9, P141, DOI 10.1097/00004728-198501000-00025; FOX PT, 1989, J NUCL MED, V30, P141; FOX PT, 1988, J CEREBR BLOOD F MET, V8, P642, DOI 10.1038/jcbfm.1988.111; FOX PT, 1987, J NEUROSURG, V67, P34, DOI 10.3171/jns.1987.67.1.0034; HERSCOVITCH P, 1983, J NUCL MED, V14, P782; NELSON RJ, 1980, J COMP NEUROL, V192, P611, DOI 10.1002/cne.901920402; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; RAICHLE ME, 1983, J NUCL MED, V24, P790; ROLAND PE, 1981, J NEUROPHYSIOL, V46, P744, DOI 10.1152/jn.1981.46.4.744; SATHIAN K, 1991, PERCEPT PSYCHOPHYS, V50, P237, DOI 10.3758/BF03206747; SINCLAIR RJ, 1991, J NEUROPHYSIOL, V66, P153, DOI 10.1152/jn.1991.66.1.153; SPIELBERGER CD, 1970, MANUAL STATE TRAIT A; Talairach J., 1988, COPLANAR STEREOTAXIC, P1; WHANG KC, 1991, PERCEPT PSYCHOPHYS, V50, P157, DOI 10.3758/BF03212216; YAMAMOTO M, 1982, IEEE T NUCL SCI, V29, P529, DOI 10.1109/TNS.1982.4335901	24	231	238	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					249	252		10.1038/373249a0	http://dx.doi.org/10.1038/373249a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816140				2022-12-28	WOS:A1995QC27800065
J	MILLER, VT; LAROSA, J; BARNABEI, V; KESSLER, C; LEVIN, G; SMITHROTH, A; GRIFFIN, M; STOY, DB; BUSH, T; ZACUR, H; FOSTER, D; ANDERSON, J; MCKENZIE, A; MILLER, S; WOOD, PD; STEFANICK, ML; MARCUS, R; AKANA, A; HEINRICHS, L; KIRCHNER, C; OHANLAN, K; RUYLE, M; SHEEHAN, M; JUDD, HL; GREENDALE, G; BAYALOS, R; LOZANO, K; KAWAKAMI, K; BARRETTCONNOR, E; LANGER, R; KRITZSILVERSTEIN, D; CARRIONPETERSEN, ML; CAVERO, C; SCHROTT, HG; JOHNSON, SR; FEDDERSEN, DA; KRUTZFELDT, DL; BENDA, JA; PAUERSTEIN, C; TRABAL, J; SCHENKEN, R; STERN, MP; RODRIGUEZSIFUENTES, M; EASTON, C; WELLS, HB; ESPELAND, M; HOWARD, G; BYINGTON, R; LEGAULT, C; SHUMAKER, S; HOGAN, P; HIRE, D; WASILAUSKAS, C; JAMES, M; LANE, K; TERRELL, T; REECE, S; PIERCE, J; SNOW, M; ANTHONY, S; MEBANESIMS, IL; EINHORN, P; HUNSBERGER, S; WACLAWIW, M; LIPPEL, K; LUCAS, D; VERTER, J; JACKSON, S; KELAGHAN, J; PERLMAN, J; WOLF, P; MCGOWAN, J; GORDON, S; HEYSE, S; FRADKIN, J; SHERMAN, S; PAGE, L; SORENSON, A; HULKA, B; BRODY, B; BURKMAN, R; HEANEY, R; KRAUSS, R; ROBERTS, H; WITTES, J; RIGGS, L; MOSS, R; ALBERS, J; MARCOVINA, S; FINEBERG, SE; TRACY, RP; MERINO, M; SCULLY, R; LIVOLSI, V; KESSLER, G				MILLER, VT; LAROSA, J; BARNABEI, V; KESSLER, C; LEVIN, G; SMITHROTH, A; GRIFFIN, M; STOY, DB; BUSH, T; ZACUR, H; FOSTER, D; ANDERSON, J; MCKENZIE, A; MILLER, S; WOOD, PD; STEFANICK, ML; MARCUS, R; AKANA, A; HEINRICHS, L; KIRCHNER, C; OHANLAN, K; RUYLE, M; SHEEHAN, M; JUDD, HL; GREENDALE, G; BAYALOS, R; LOZANO, K; KAWAKAMI, K; BARRETTCONNOR, E; LANGER, R; KRITZSILVERSTEIN, D; CARRIONPETERSEN, ML; CAVERO, C; SCHROTT, HG; JOHNSON, SR; FEDDERSEN, DA; KRUTZFELDT, DL; BENDA, JA; PAUERSTEIN, C; TRABAL, J; SCHENKEN, R; STERN, MP; RODRIGUEZSIFUENTES, M; EASTON, C; WELLS, HB; ESPELAND, M; HOWARD, G; BYINGTON, R; LEGAULT, C; SHUMAKER, S; HOGAN, P; HIRE, D; WASILAUSKAS, C; JAMES, M; LANE, K; TERRELL, T; REECE, S; PIERCE, J; SNOW, M; ANTHONY, S; MEBANESIMS, IL; EINHORN, P; HUNSBERGER, S; WACLAWIW, M; LIPPEL, K; LUCAS, D; VERTER, J; JACKSON, S; KELAGHAN, J; PERLMAN, J; WOLF, P; MCGOWAN, J; GORDON, S; HEYSE, S; FRADKIN, J; SHERMAN, S; PAGE, L; SORENSON, A; HULKA, B; BRODY, B; BURKMAN, R; HEANEY, R; KRAUSS, R; ROBERTS, H; WITTES, J; RIGGS, L; MOSS, R; ALBERS, J; MARCOVINA, S; FINEBERG, SE; TRACY, RP; MERINO, M; SCULLY, R; LIVOLSI, V; KESSLER, G			EFFECTS OF ESTROGEN OR ESTROGEN/PROGESTIN REGIMENS ON HEART-DISEASE RISK-FACTORS IN POSTMENOPAUSAL WOMEN - THE POSTMENOPAUSAL ESTROGEN/PROGESTIN INTERVENTIONS (PEPI) TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE-REPLACEMENT THERAPY; DENSITY LIPOPROTEIN CHOLESTEROL; ATHEROSCLEROTIC VASCULAR-DISEASE; ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE; PROGESTOGEN REPLACEMENT; CARBOHYDRATE-METABOLISM; PLASMA-LIPOPROTEIN; INSULIN-RESISTANCE; SERUM-LIPIDS	Objective.-To assess pairwise differences between placebo, unopposed estrogen, and each of three estrogen/progestin regimens on selected heart disease risk factors in healthy postmenopausal women. Design.-A 3-year, multicenter, randomized, double-blind, placebo-controlled trial. Participants.-A total of 875 healthy postmenopausal women aged 45 to 64 years who had no known contraindication to hormone therapy. Intervention.-Participants were randomly assigned in equal numbers to the following groups: (1) placebo; (2) conjugated equine estrogen (CEE), 0.625 mg/d; (3) CEE, 0.625 mg/d plus cyclic medroxyprogesterone acetate (MPA), 10 mg/d for 12 d/mo; (4) CEE, 0.625 mg/d plus consecutive MPA, 2.5 mg/d; or (5) CEE, 0.625 mg/d plus cyclic micronized progesterone (MP), 200 mg/d for 12 d/mo. Primary Endpoints.-Four endpoints were chosen to represent four biological systems related to the risk of cardiovascular disease: (1) high-density lipoprotein cholesterol (HDL-C), (2) systolic blood pressure, (3) serum insulin, and (4) fibrinogen. Analysis.-Analyses presented are by intention to treat. P values for primary endpoints are adjusted for multiple comparisons; 95% confidence intervals around estimated effects were calculated without this adjustment. Results.-Mean changes in HDL-C segregated treatment regimens into three statistically distinct groups: (1) placebo (decrease of 0.03 mmol/L [1.2 mg/dL]); (2) MPA regimens (increases of 0.03 to 0.04 mmol/L [1.2 to 1.6 mg/dl]); and (3) CEE with cyclic MP (increase of 0.11 mmol/L [4.1 mg/dL]) and CEE alone (increase of 0.14 mmol/L [5.6 mg/dL]). Active treatments decreased mean low-density lipoprotein cholesterol (0.37 to 0.46 mmol/L [14.5 to 17.7 mg/dL]) and increased mean triglyceride (0.13 to 0.15 mmol/L [11.4 to 13.7 mg/dL]) compared with placebo. Placebo was associated with a significantly greater increase in mean fibrinogen than any active treatment (0.10 g/L compared with -0.02 to 0.06 g/L); differences among active treatments were not significant. Systolic blood pressure increased and postchallenge insulin levels decreased during the trial, but neither varied significantly by treatment assignment. Compared with other active treatments, unopposed estrogen was associated with a significantly increased risk of adenomatous or atypical hyperplasia (34% vs 1%) and of hysterectomy (6% vs 1%). No other adverse effect differed by treatment assignment or hysterectomy status. Conclusions.-Estrogen alone or in combination with a progestin improves lipoproteins and lowers fibrinogen levels without detectable effects on postchallenge insulin or blood pressure. Unopposed estrogen is the optimal regimen for elevation of HDL-C, but the high rate of endometrial hyperplasia restricts use to women without a uterus. In women with a uterus, CEE with cyclic MP has the most favorable effect on HDL-C and no excess risk of endometrial hyperplasia.	JOHNS HOPKINS UNIV,BALTIMORE,MD; STANFORD UNIV,STANFORD,CA; UNIV CALIF LOS ANGELES,LOS ANGELES,CA; UNIV CALIF SAN DIEGO,SAN DIEGO,CA; IOWA STATE UNIV SCI & TECHNOL,AMES,IA; UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX; BOWMAN GRAY SCH MED,WINSTON SALEM,NC; NICHHD,BETHESDA,MD; NIAMSD,BETHESDA,MD; NIDDKD,BETHESDA,MD; NIA,BETHESDA,MD; US PHS,CTR SUPPLY SERV,CTR DRUG DISTRIBUT,PERRY POINT,MD; NW LIPID RES CTR,LIPID LAB,SEATTLE,WA; WISHARD MEM HOSP,GLUCOSE INSULIN LAB,INDIANAPOLIS,IN; UNIV VERMONT,HEMOSTASIS LAB,BURLINGTON,VT; NCI,PATHOL LAB,BETHESDA,MD; MASSACHUSETTS GEN HOSP,BOSTON,MA; JEWISH HOSP ST LOUIS,ST LOUIS,MO; GEORGE WASHINGTON UNIV,WASHINGTON,DC; NHLBI,BETHESDA,MD 20892	Johns Hopkins University; Stanford University; University of California System; University of California Los Angeles; University of California System; University of California San Diego; Iowa State University; University of Texas System; University of Texas Health San Antonio; Wake Forest University; Wake Forest Baptist Medical Center; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); United States Public Health Service; University of Vermont; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Massachusetts General Hospital; Barnes-Jewish Hospital; George Washington University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			zacur, howard/W-2170-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL040154, U01HL040195, U01HL040185] Funding Source: NIH RePORTER; NHLBI NIH HHS [U01-HL40185, U01-HL40154, U01-HL40195] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bachorik P S, 1986, Methods Enzymol, V129, P78; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BARRETTCONNOR E, 1990, ARTERIOSCLEROSIS, V10, P531, DOI 10.1161/01.ATV.10.4.531; BARRETTCONNOR E, 1990, MENOPAUSE, P199; BASS KM, 1993, ARCH INTERN MED, V153, P2209, DOI 10.1001/archinte.153.19.2209; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; BUSH TL, 1990, MENOPAUSE BIOL CLIN, P211; CAGNACCI A, 1992, J CLIN ENDOCR METAB, V74, P1396, DOI 10.1210/jc.74.6.1396; CASTELLI WP, 1988, AM J OBSTET GYNECOL, V158, P1553, DOI 10.1016/0002-9378(88)90189-5; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; DECLEYN K, 1989, MATURITAS, V11, P235, DOI 10.1016/0378-5122(89)90216-8; EDWARDS AL, 1985, EXPT DESIGN PSYCHOL; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; GANGAR KF, 1993, BAILLIERE CLIN ENDOC, V7, P47, DOI 10.1016/S0950-351X(05)80270-8; GILLIGAN DM, 1994, CIRCULATION, V90, P786, DOI 10.1161/01.CIR.90.2.786; GLUECK CJ, 1994, J LAB CLIN MED, V123, P59; GODSLAND IF, 1993, METABOLISM, V42, P846, DOI 10.1016/0026-0495(93)90058-V; GOLDBOURT U, 1979, AM J EPIDEMIOL, V109, P296, DOI 10.1093/oxfordjournals.aje.a112683; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRUCHOW HW, 1988, AM HEART J, V115, P954, DOI 10.1016/0002-8703(88)90063-4; HAINLINE A, 1982, MANUAL LABORATORY OP; HASSAGER C, 1987, CIRCULATION, V76, P753, DOI 10.1161/01.CIR.76.4.753; HENDERSON BE, 1988, AM J OBSTET GYNECOL, V159, P312, DOI 10.1016/S0002-9378(88)80074-7; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; JENSEN J, 1987, AM J OBSTET GYNECOL, V156, P66, DOI 10.1016/0002-9378(87)90204-3; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; LAAKSO M, 1993, AM J EPIDEMIOL, V137, P959, DOI 10.1093/oxfordjournals.aje.a116768; LIP GYH, 1994, J HUM HYPERTENS, V8, P491; LOBO RA, 1991, J CLIN ENDOCR METAB, V73, P925, DOI 10.1210/jcem-73-5-925; LOBO RA, 1994, OBSTET GYNECOL, V84, P987; MASHCHAK CA, 1982, AM J OBSTET GYNECOL, V144, P511, DOI 10.1016/0002-9378(82)90218-6; MASHCHAK CA, 1985, J REPROD MED, V30, P805; Meilahn E N, 1992, Ann Epidemiol, V2, P445; MILLER VT, 1990, ENDOCRIN METAB CLIN, V19, P381, DOI 10.1016/S0889-8529(18)30331-1; MOORJANI S, 1991, J CLIN ENDOCR METAB, V73, P373, DOI 10.1210/jcem-73-2-373; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; NEWNHAM HH, 1993, BAILLIERE CLIN ENDOC, V7, P61, DOI 10.1016/S0950-351X(05)80271-X; PSATY BM, 1994, ARCH INTERN MED, V154, P1333, DOI 10.1001/archinte.154.12.1333; RAVNIKAR VA, 1993, LANCET, V342, P133; RIEDEL M, 1993, CLIN INVESTIGATOR, V71, P406; RIJPKEMA AHM, 1990, MATURITAS, V12, P259, DOI 10.1016/0378-5122(90)90007-S; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; Sacks Frank M., 1994, Current Opinion in Lipidology, V5, P236, DOI 10.1097/00041433-199405030-00012; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; Stevenson J C, 1994, Int J Fertil Menopausal Stud, V39 Suppl 1, P50; TIKKANEN MJ, 1986, MATURITAS, V8, P7, DOI 10.1016/0378-5122(86)90003-4; TIKKANEN MJ, 1993, CARDIOVASCULAR RISK, V3, P138; Trinder P., 1969, ANN CLIN BIOCHEM, V6, P24, DOI [10.1177/000456326900600108, DOI 10.1177/000456326900600108]; WALSH BW, 1993, J CLIN INVEST, V91, P2126, DOI 10.1172/JCI116437; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; Warnick G R, 1986, Methods Enzymol, V129, P101; 1992, SAS P229 SAS I INC T; 1978, J CHRON DIS, V31, P651; IN PRESS CONTROL CLI	58	2065	2093	0	49	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					199	208		10.1001/jama.1995.03520270033028	http://dx.doi.org/10.1001/jama.1995.03520270033028			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB234	7807658				2022-12-28	WOS:A1995QB23400023
J	GLICK, BS				GLICK, BS			CAN HSP70 PROTEINS ACT AS FORCE-GENERATING MOTORS	CELL			English	Review							MAJOR HEAT-SHOCK; MITOCHONDRIAL-MEMBRANES; TRANSLOCATION; IMPORT; MATRIX; COMPLEX				GLICK, BS (corresponding author), UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,920 E 58TH ST,CHICAGO,IL 60637, USA.			Glick, Benjamin/0000-0002-7921-1374				BRODSKY JL, 1994, BIOL HEAT SHOCK PROT, P85; Creighton T. E., 1993, PROTEINS STRUCTURES; DESHAIES RJ, 1988, TRENDS BIOCHEM SCI, V13, P384, DOI 10.1016/0968-0004(88)90180-6; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GLICK BS, 1993, PROTEIN SCI, V2, P1901, DOI 10.1002/pro.5560021112; Hannavy K, 1993, CURR OPIN CELL BIOL, V5, P694, DOI 10.1016/0955-0674(93)90142-D; Hightower LE, 1994, BIOL HEAT SHOCK PROT, P179; Holmes Ken C., 1993, Trends in Cell Biology, V3, P53, DOI 10.1016/0962-8924(93)90161-S; HWANG ST, 1991, J BIOL CHEM, V266, P21083; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P1177; JUNGNICKEL B, 1994, FEBS LETT, V346, P73, DOI 10.1016/0014-5793(94)00367-X; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; MCKAY DB, 1994, BIOL HEAT SHOCK PROT, P153; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; ROTHMAN JE, 1986, NATURE, V322, P209, DOI 10.1038/322209a0; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; VOOS W, 1993, J CELL BIOL, V123, P119, DOI 10.1083/jcb.123.1.119; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WALKER RA, 1993, ANNU REV BIOCHEM, V62, P429	30	224	227	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					11	14		10.1016/0092-8674(95)90444-1	http://dx.doi.org/10.1016/0092-8674(95)90444-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813006	Green Submitted, Bronze			2022-12-28	WOS:A1995QB91000003
J	ROONEY, CM; SMITH, CA; NG, CYC; LOFTIN, S; LI, CF; KRANCE, RA; BRENNER, MK; HESLOP, HE				ROONEY, CM; SMITH, CA; NG, CYC; LOFTIN, S; LI, CF; KRANCE, RA; BRENNER, MK; HESLOP, HE			USE OF GENE-MODIFIED VIRUS-SPECIFIC T-LYMPHOCYTES TO CONTROL EPSTEIN-BARR-VIRUS-RELATED LYMPHOPROLIFERATION	LANCET			English	Article							MARROW TRANSPLANT RECIPIENTS; BONE-MARROW; IMMUNITY	Reactivation of Epstein-Barr virus (EBV) after bone-marrow transplantation leads in many cases to lymphoproliferative disease that responds poorly to standard therapy and is usually fatal. To prevent or central this complication, we prepared EBV-specific cytotoxic T-lymphocyte (CTL) lines from donor leucocytes and infused them into ten allograft recipients. Three of the patients had shown signs of EBV reactivation, with or without overt lymphoproliferation, and the others received CTL infusions as prophylaxis. No patient developed any complication that could be attributed to the CTL infusions. in the three patients with EBV reactivation, EBV DNA concentrations (measured by semiquantitative polymerase chain reaction [PCR]), which had increased 1000-fold or more, returned to the control range within 3-4 weeks of immunotherapy. The most striking consequence was the resolution of immunoblastic lymphoma in a 17-year-old patient who received four CTL infusions (two 1x10(7)/m(2) and two 5x10(7)/m(2)). Because the CTL had been genetically marked before infusion, we were able to show by PCR analysis that they persisted for 10 weeks after administration. EBV-specific donor-type T-cell lines seem to offer safe and effective therapy for control of EBV-associated lymphoproliferation.	ST JUDE CHILDRENS RES HOSP, DEPT VIROL & MOLEC BIOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, DIV BONE MARROW TRANSPLANTAT, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, COLL MED, DEPT PATHOL, MEMPHIS, TN USA; UNIV TENNESSEE, COLL MED, DEPT MED, MEMPHIS, TN USA; UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center			Rooney, Cliona/ABD-5475-2021; Heslop, Helen/AAC-9500-2020; Brenner, Malcolm/Y-2509-2019		NATIONAL CANCER INSTITUTE [P30CA021765, R01CA061384, P01CA020180, U01CA061384] Funding Source: NIH RePORTER; NCI NIH HHS [CA 61384, CA 21765, CA 20180] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOURGAULT I, 1991, CLIN EXP IMMUNOL, V84, P501; BOYLE MJ, 1991, BLOOD, V78, P3004; BRENNER MK, 1993, LANCET, V342, P1134, DOI 10.1016/0140-6736(93)92122-A; BURROWS SR, 1994, J EXP MED, V179, P1155, DOI 10.1084/jem.179.4.1155; COHEN KI, 1991, P NATL ACAD SCI USA, V86, P9558; CRAWFORD DH, 1986, TRANSPLANTATION, V42, P50, DOI 10.1097/00007890-198607000-00010; DUNCOMBE AS, 1992, BLOOD, V79, P3059; FISCHER A, 1991, NEW ENGL J MED, V324, P1451, DOI 10.1056/NEJM199105233242102; HESLOP HE, 1994, BLOOD, V83, P1706, DOI 10.1182/blood.V83.6.1706b.bloodjournal8361706b; HESLOP HE, 1994, HUM GENE THER, V5, P381, DOI 10.1089/hum.1994.5.3-381; HESLOP HE, 1994, NEW ENGL J MED, V331, P679; JOSKE D, 1993, BLOOD REV, V7, P215, DOI 10.1016/0268-960X(93)90008-R; KHANNA R, 1992, J EXP MED, V176, P169, DOI 10.1084/jem.176.1.169; KLEIN G, 1994, CELL, V77, P791, DOI 10.1016/0092-8674(94)90125-2; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; LIEBERMAN J, 1994, NEW ENGL J MED, V330, P1231, DOI 10.1056/NEJM199404283301711; LIST AF, 1987, J CLIN ONCOL, V5, P1673, DOI 10.1200/JCO.1987.5.10.1673; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; PRENTICE HG, 1984, LANCET, V1, P472; RICKINSON AB, 1981, CANCER RES, V41, P4216; RIDDELL SR, 1992, SCIENCE, V257, P238; RIDDLER SA, 1994, BLOOD, V84, P972; ROONEY CM, IN PRESS BR J HAEMAT; SAVOIE A, 1994, BLOOD, V83, P2715; STRAUS SE, 1992, ANN INTERN MED, V118, P45; VANRHEE F, 1994, BLOOD, V83, P3377; Young L S, 1992, Semin Cancer Biol, V3, P273; ZIMBER U, 1986, VIROLOGY, V154, P56, DOI 10.1016/0042-6822(86)90429-0	29	951	985	1	24	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 7	1995	345	8941					9	13		10.1016/S0140-6736(95)91150-2	http://dx.doi.org/10.1016/S0140-6736(95)91150-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799740				2022-12-28	WOS:A1995QA29000008
J	STANLEY, P; PACKMAN, LC; KORONAKIS, V; HUGHES, C				STANLEY, P; PACKMAN, LC; KORONAKIS, V; HUGHES, C			FATTY ACYLATION OF 2 INTERNAL LYSINE RESIDUES REQUIRED FOR THE TOXIC ACTIVITY OF ESCHERICHIA-COLI HEMOLYSIN	SCIENCE			English	Article							NUCLEOTIDE-SEQUENCE; ACTINOBACILLUS-PLEUROPNEUMONIAE; CHROMOSOMAL HEMOLYSIN; VIRUS GLYCOPROTEINS; GENE; SECRETION; PROTEIN; PROHAEMOLYSIN; ACTIVATION; HLYC	Hemolysin of Escherichia coli is activated by fatty acylation of the protoxin, directed by the putative acyl transferase HlyC and by acyl carrier protein (ACP). Mass spectrometry and Edman degradation of proteolytic products from mature toxin activated in vitro with tritium-labeled acylACP revealed two fatty-acylated internal lysine residues, lysine 564 and lysine 690. Resistance of the acylation to chemical treatments suggested that fatty acid was amide linked. Substitution of the two lysines confirmed that they were the only sites of acylation and showed that although each was acylated in the absence of the other, both sites were required for in vivo toxin activity.	UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,ENGLAND; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND	University of Cambridge; University of Cambridge				Koronakis, Vassilis/0000-0002-1353-1092				CHANG YF, 1989, DNA-J MOLEC CELL BIO, V8, P635, DOI 10.1089/dna.1.1989.8.635; FELMLEE T, 1985, J BACTERIOL, V163, P94, DOI 10.1128/JB.163.1.94-105.1985; FORESTIER C, 1991, INFECT IMMUN, V59, P4212, DOI 10.1128/IAI.59.11.4212-4220.1991; FORESTIER C, 1990, INFECT IMMUN, V58, P828, DOI 10.1128/IAI.58.3.828-832.1990; FREY J, 1991, INFECT IMMUN, V59, P3026, DOI 10.1128/IAI.59.9.3026-3032.1991; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GYGI D, 1990, MOL MICROBIOL, V4, P123, DOI 10.1111/j.1365-2958.1990.tb02021.x; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; HARDIE KR, 1991, MOL MICROBIOL, V5, P1669, DOI 10.1111/j.1365-2958.1991.tb01914.x; HEDO JA, 1987, J BIOL CHEM, V262, P954; HESS J, 1986, FEMS MICROBIOL LETT, V34, P1, DOI 10.1016/0378-1097(86)90261-2; HUGHES C, 1992, BIOESSAYS, V14, P519, DOI 10.1002/bies.950140804; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; KORONAKIS V, 1989, EMBO J, V8, P595, DOI 10.1002/j.1460-2075.1989.tb03414.x; KORONAKIS V, 1988, NUCLEIC ACIDS RES, V16, P4789, DOI 10.1093/nar/16.11.4789; KRAIG E, 1990, INFECT IMMUN, V58, P920, DOI 10.1128/IAI.58.4.920-929.1990; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LO RYC, 1987, INFECT IMMUN, V55, P1987, DOI 10.1128/IAI.55.9.1987-1996.1987; MAGEE AI, 1984, BIOCHIM BIOPHYS ACTA, V798, P156, DOI 10.1016/0304-4165(84)90298-8; MCWHINNEY DR, 1992, J BACTERIOL, V174, P291, DOI 10.1128/jb.174.1.291-297.1992; OLSON EN, 1984, J BIOL CHEM, V259, P5364; PARKER MW, 1993, TRENDS BIOCHEM SCI, V18, P391, DOI 10.1016/0968-0004(93)90096-6; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; PELLETT S, 1990, INFECT IMMUN, V58, P822, DOI 10.1128/IAI.58.3.822-827.1990; PILLAI S, 1987, P NATL ACAD SCI USA, V84, P7654, DOI 10.1073/pnas.84.21.7654; ROWE GE, 1994, INFECT IMMUN, V62, P579, DOI 10.1128/IAI.62.2.579-588.1994; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT MFG, 1979, P NATL ACAD SCI USA, V76, P1687, DOI 10.1073/pnas.76.4.1687; STANLEY P, 1991, MOL MICROBIOL, V5, P2391, DOI 10.1111/j.1365-2958.1991.tb02085.x; STANLEY P, UNPUB; STANLEY PLD, 1993, MOL MICROBIOL, V10, P781, DOI 10.1111/j.1365-2958.1993.tb00948.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUTTORP N, 1990, INFECT IMMUN, V58, P3796, DOI 10.1128/IAI.58.11.3796-3801.1990	34	167	173	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					1992	1996		10.1126/science.7801126	http://dx.doi.org/10.1126/science.7801126			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801126				2022-12-28	WOS:A1994PZ26700030
J	CRAGG, DK; CAMPBELL, SM; ROLAND, MO				CRAGG, DK; CAMPBELL, SM; ROLAND, MO			OUT-OF-HOURS PRIMARY-CARE CENTERS - CHARACTERISTICS OF THOSE ATTENDING AND DECLINING TO ATTEND	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; HOURS CALLS; RATES	Objectives-To study the number, demography, and clinical derails of patients who agreed or refused to attend centralised primary care centres for out of hours medical care and to study the satisfaction with the service of those who attended. Design-Data collected by telephonists and doctors. Satisfaction questionnaires given to patients who attended. Setting-Five out of hours primary care centres in the United Kingdom. Subjects-All patients contacting the deputising service to request medical help out of hours who were asked to: attend a primary care centre. The study terminated when 1000 patients had agreed to attend (200 from each centre). 1000,patients not agreeing to attend were also sampled. Results-The attendance rate varied from:8.9% to 52.3% in the five centres. The overall standardised attendance rate was 22.4%. The attendance rate was highest in children under 5 (465/2380, 19.5%) and fell with increasing age. Of the 1000 sampled nonattenders, 403 said that they had no transport and 345 said that they were too ill to attend. Those who attended were seen by the doctor more quickly. There was no significant difference between the groups in the number who received a prescription (810 attenders v 820 non-attenders, P = 0.57) or who were admitted to hospital (59 v 52, P = 0.5). Satisfaction with the service among those who attended was very high; 95% (694/731) said that they would be prepared to attend under similar circumstances in the future. Conclusion-Most patients are not able or prepared to attend a central facility for primary care Out of hours. Substantial cultural change will be necessary and careful consideration given to planning if such centres are to provide a major part of out of hours care.			CRAGG, DK (corresponding author), UNIV MANCHESTER,RUSHOLME HLTH CTR,DEPT GEN PRACTICE,MANCHESTER M14 5NP,LANCS,ENGLAND.			Campbell, Stephen/0000-0002-2328-4136				BAIN DJG, 1984, BRIT MED J, V289, P471, DOI 10.1136/bmj.289.6443.471; BOLLAM MJ, 1988, BRIT MED J, V296, P829, DOI 10.1136/bmj.296.6625.829; CUBITT T, 1983, BRIT MED J, V287, P28, DOI 10.1136/bmj.287.6384.28; DIXON RA, 1988, BRIT MED J, V297, P1519, DOI 10.1136/bmj.297.6662.1519; DIXON RA, 1977, BRIT MED J, V1, P560, DOI 10.1136/bmj.1.6060.560; HOBBS FDR, 1991, BRIT MED J, V302, P329, DOI 10.1136/bmj.302.6772.329; Lockstone D R, 1976, J R Coll Gen Pract, V26, P68; MCCARTHY M, 1990, BRIT J GEN PRACT, V40, P19; MCKEE CM, 1990, BRIT J GEN PRACT, V40, P150; PITTS J, 1988, J ROY COLL GEN PRACT, V38, P2; SALISBURY C, 1993, BRIT MED J, V306, P762, DOI 10.1136/bmj.306.6880.762; SAWYER L, 1982, BRIT MED J, V284, P1531, DOI 10.1136/bmj.284.6328.1531; TULLOCH AJ, 1984, PRACTITIONER, V228, P663; WHITEHOUSE CR, 1985, BRIT MED J, V290, P359, DOI 10.1136/bmj.290.6465.359; 1984, CLASSIFICATION DISEA; 1994, BRIT NATIONAL FORMUL; 1992, CONSUMER SATISFACTIO	17	32	32	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1627	1629		10.1136/bmj.309.6969.1627	http://dx.doi.org/10.1136/bmj.309.6969.1627			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819946	Green Published			2022-12-28	WOS:A1994PY22000029
J	WILLIAMS, A; SHAW, WC; DEVLIN, HB				WILLIAMS, A; SHAW, WC; DEVLIN, HB			PROVISION OF SERVICES FOR CLEFT-LIP AND PALATE IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article									UNIV MANCHESTER,TURNER DENT SCH,DEPT ORAL HLTH & DEV,MANCHESTER M15 6FH,LANCS,ENGLAND	University of Manchester	WILLIAMS, A (corresponding author), ROYAL COLL SURGEONS ENGLAND,SURG AUDIT UNIT,LONDON WC2A 3PN,ENGLAND.							Congenital Malformations Worldwide, 1993, CONGENITAL MALFORMAT; DEVLIN HB, 1990, ANN R COLL SURG EN S, V73, P3; SHAW WC, 1994, FINAL REPORT REGIONA; SHAW WC, 1992, RECENT ADV PLASTICS, V4, P1; 1994, REPORT STANDING DENT	5	28	28	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 10	1994	309	6968					1552	1552		10.1136/bmj.309.6968.1552	http://dx.doi.org/10.1136/bmj.309.6968.1552			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX564	7819898	Green Published			2022-12-28	WOS:A1994PX56400024
J	WILSON, A; MCDONALD, P				WILSON, A; MCDONALD, P			COMPARISON OF PATIENT QUESTIONNAIRE, MEDICAL RECORD, AND AUDIO TAPE IN ASSESSMENT OF HEALTH PROMOTION IN GENERAL-PRACTICE CONSULTATIONS	BRITISH MEDICAL JOURNAL			English	Article							SATISFACTION	Objective-To determine what proportion of health promotion activities reported by the patient is recorded in the general practice notes and to compare these methods of assessing health promotion with audio tape analysis. Design-Secondary analysis of data obtained in a controlled trial of differing appointment lengths. After each consultation the medical record was examined and the patient invited to completed a questionnaire. A subsample of consultations was. audio taped. Setting-Nottinghamshire. Subjects-16 general practitioners from 10 practices. This report includes 3324 consultations with patients aged greater than or equal to 17, with data on measurement of blood pressure and advice about smoking and alcohol. Results-Data from questionnaire and;medical notes were available for 2281 consultations. Advice on smoking was recorded in the notes in 30.9% of cases in which a patient reported it (for alcohol and measurement of blood pressure, 44.4% and 82.7% of cases respectively). In 516 cases analysis of audio tape and review of records was performed. Advice on smoking was recorded in the patient's notes in 28.6% of cases hi which it was detected on audio tape (for alcohol, 31.1% of cases). In 335 consultations data from audio tape and questionnaire were available. Advice on smoking was reported by patients in 73.9% of cases in which it was detected on audio tape (for alcohol, 75.0% of cases). Conclusions-Review of the medical record is a reasonably accurate method of assessing measurement of blood pressure in the consultation but would lead to significant underestimation of advice about smoking and alcohol.	UNIV NOTTINGHAM,DEPT GEN PRACTICE,NOTTINGHAM NG7 2RD,ENGLAND	University of Nottingham	WILSON, A (corresponding author), LEICESTER GEN HOSP,DEPT GEN PRACTICE,GWENDOLEN RD,LEICESTER LE5 4PW,LEICS,ENGLAND.							BAKER R, 1990, BRIT J GEN PRACT, V40, P487; FITZPATRICK R, 1991, BMJ-BRIT MED J, V302, P1129, DOI 10.1136/bmj.302.6785.1129; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LEY P, 1973, PSYCHOL MED, V3, P217, DOI 10.1017/S0033291700048558; MAITLAND JM, 1991, BRIT J GEN PRACT, V41, P144; MANT D, 1989, BRIT MED J, V298, P1360, DOI 10.1136/bmj.298.6684.1360; PILL RM, 1989, J ROY COLL GEN PRACT, V39, P196; PRINGLE M, 1986, BRIT MED J, V293, P20, DOI 10.1136/bmj.293.6538.20; RETHANS JJ, 1994, BRIT J GEN PRACT, V44, P153; SILAGY C, 1992, BRIT MED J, V305, P871, DOI 10.1136/bmj.305.6858.871; WILSON A, 1992, BMJ-BRIT MED J, V304, P227, DOI 10.1136/bmj.304.6821.227; 1992, STATEMENT FEES ALLOW; 1994, BRIT MED J, V308, P313; 1994, BRIT MED J, V308, P308	14	68	68	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 3	1994	309	6967					1483	1485		10.1136/bmj.309.6967.1483	http://dx.doi.org/10.1136/bmj.309.6967.1483			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW053	7804055	Green Published			2022-12-28	WOS:A1994PW05300027
J	RAEBURN, JA				RAEBURN, JA			SCREENING FOR CARRIERS OF CYSTIC-FIBROSIS - SCREENING BEFORE PREGNANCY IS NEEDED	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY-CARE				RAEBURN, JA (corresponding author), CITY HOSP NOTTINGHAM,CTR GENET MED,NOTTINGHAM NG5 1PD,ENGLAND.							BEKKER H, 1993, BRIT MED J, V306, P1584, DOI 10.1136/bmj.306.6892.1584; MARTEAU TM, 1992, J MED GENET, V29, P24, DOI 10.1136/jmg.29.1.24; MATTHEWS P, 1993, INDEPENDENT SUND AUG, P42; MENNIE ME, 1992, LANCET, V340, P214, DOI 10.1016/0140-6736(92)90476-J; MODELL M, 1993, BRIT MED J, V307, P849, DOI 10.1136/bmj.307.6908.849; QURESHI N, 1993, BRIT MED J, V307, P816, DOI 10.1136/bmj.307.6908.816; SCRIVER CR, 1992, AM J HUM GENET, V51, P943; WALD NJ, 1993, LANCET, V342, P1307, DOI 10.1016/0140-6736(93)92403-G; 1993, GENETIC SCREENING ET, P15; 1992, CYSTIC FIBROSIS DNA	10	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1994	309	6966					1428	1429		10.1136/bmj.309.6966.1428	http://dx.doi.org/10.1136/bmj.309.6966.1428			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7819857	Green Published			2022-12-28	WOS:A1994PU76400032
J	KLINE, SE; HEDEMARK, LL; DAVIES, SF				KLINE, SE; HEDEMARK, LL; DAVIES, SF			OUTBREAK OF TUBERCULOSIS AMONG REGULAR PATRONS OF A NEIGHBORHOOD BAR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PULMONARY TUBERCULOSIS; ADULT; HOMELESS; SEQUENCE; SHELTER; COMPLEX	Background. Outbreaks of tuberculosis have been reported in prisons, nursing homes, urban homeless shelters, and other crowded settings. We report a nonresidential outbreak of tuberculosis that originated in a neighborhood bar. Methods. A homeless patient with highly infectious pulmonary tuberculosis was a regular patron of a neighborhood bar during a long symptomatic interval before diagnosis. We investigated 97 other regular customers and employees of the bar through interviews, tuberculin skin testing, and chest roentgenography, We performed DNA fingerprinting on isolates from the index patient and 11 other patients. Results. The index patient apparently infected 41 of 97 contacts (42 percent), resulting in 14 cases of active tuberculosis and 27 cases of infection but no disease (indicated by positive tuberculin skin tests). Four other cases of active tuberculosis occurred among regular customers of the bar who were missed by the contact investigation. There were also two secondary cases. Radiographic findings in active cases included upper-lobe disease in seven cases (three cavitary) and negative chest films at the time of diagnosis in four cases. All 12 culture isolates we tested had the same chromosomal-DNA restriction pattern. Conclusions. The spread of tuberculosis in a neighborhood bar can be a major public health problem. The high rate of infection and disease among the contacts was unexpected and was not due to coinfection with the human immunodeficiency virus. Possible explanations include heavy alcohol use among the contacts, high infectivity of the index case, or both. Sputum cultures must be performed in tuberculin-positive contacts who have symptoms, even if the chest films are normal.	HENNEPIN CTY MED CTR,DEPT MED,DIV PULM & CRIT CARE MED,MINNEAPOLIS,MN 55415; UNIV MINNESOTA,SCH MED,MINNEAPOLIS,MN 55455; TB CONTROL CLIN HENNEPIN CTY,MINNEAPOLIS,MN; UNIV MINNESOTA HOSP & CLIN,DEPT MED,DIV INFECT DIS,MINNEAPOLIS,MN	Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota Hospital								ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BARZA M, 1972, POSTGRAD MED, V51, P143, DOI 10.1080/00325481.1972.11698136; BROWN KE, 1961, BRIT J DIS CHEST, V55, P150, DOI 10.1016/S0007-0971(61)80109-5; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; CHOYKE PL, 1983, RADIOLOGY, V148, P357, DOI 10.1148/radiology.148.2.6867325; COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131, DOI 10.1093/oxfordjournals.aje.a121593; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; FEINGOLD AO, 1976, SOUTHERN MED J, V69, P1336, DOI 10.1097/00007611-197610000-00024; FRIEDMAN L H, 1992, American Review of Respiratory Disease, V145, pA107; FRIEDMAN LN, 1987, AM REV RESPIR DIS, V136, P1188, DOI 10.1164/ajrccm/136.5.1188; HADLOCK FP, 1980, AM J ROENTGENOL, V134, P1015, DOI 10.2214/ajr.134.5.1015; HUSEN L, 1971, CHEST, V60, P540, DOI 10.1378/chest.60.6.540; KHAN MA, 1977, AM J MED, V62, P31, DOI 10.1016/0002-9343(77)90346-1; MILLER W T, 1978, AJR (American Journal of Roentgenology), V130, P867; MILLER WT, 1993, SEMIN ROENTGENOL, V28, P109, DOI 10.1016/S0037-198X(05)80100-2; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; NOLAN CM, 1991, AM REV RESPIR DIS, V143, P257, DOI 10.1164/ajrccm/143.2.257; OLIN JS, 1966, CAN MED ASSOC J, V94, P999; PEDROBOTET J, 1992, AIDS, V6, P91, DOI 10.1097/00002030-199201000-00012; SCHMIDEK HH, 1967, CAN MED ASSOC J, V97, P178; SIDDIQUI F, 1989, BACTEC SYSTEM PRODUC; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; STEAD WW, 1981, ANN INTERN MED, V94, P606, DOI 10.7326/0003-4819-94-5-606; TABET SR, 1994, J INFECT DIS, V169, P189, DOI 10.1093/infdis/169.1.189; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578, DOI 10.1128/JCM.29.11.2578-2586.1991; WOODRING JH, 1986, AM J ROENTGENOL, V146, P497, DOI 10.2214/ajr.146.3.497; 1991, MMWR-MORBID MORTAL W, V40, P869; 1990, AM REV RESPIR DIS, V142, P725; 1990, AM REV RESPIR DIS, V142, P1470; 1992, MMWR-MORBID MORTAL W, V41, P507	31	186	187	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 27	1995	333	4					222	227		10.1056/NEJM199507273330404	http://dx.doi.org/10.1056/NEJM199507273330404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK423	7791838				2022-12-28	WOS:A1995RK42300004
J	LLOYDTHOMAS, AR; LAUDER, G				LLOYDTHOMAS, AR; LAUDER, G			REFLEX SYMPATHETIC DYSTROPHY IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article											LLOYDTHOMAS, AR (corresponding author), GREAT ORMOND ST HOSP CHILDREN NHS TRUST,DEPT PAEDIAT ANAESTHESIA,LONDON WC1N 3JH,ENGLAND.			Lauder, Gillian/0000-0001-6774-6120				BLUMBERG H, 1994, TXB PAIN, P685; COOKE ED, 1989, BRIT J RHEUMATOL, V28, P399; JANIG W, PAIN RES CLIN MANAGE, V4, P372; KARSTETTER KW, 1991, J AM PEDIATRIC ASS, V82, P198; WILDER RT, 1992, J BONE JOINT SURG AM, V74A, P910, DOI 10.2106/00004623-199274060-00013	5	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 24	1995	310	6995					1648	1649		10.1136/bmj.310.6995.1648	http://dx.doi.org/10.1136/bmj.310.6995.1648			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF698	7795455	Green Published			2022-12-28	WOS:A1995RF69800027
J	ZHONG, Y				ZHONG, Y			MEDIATION OF PACAP-LIKE NEUROPEPTIDE TRANSMISSION BY COACTIVATION OF RAS/RAF AND CAMP SIGNAL-TRANSDUCTION PATHWAYS IN DROSOPHILA	NATURE			English	Article							PROTEIN-TYROSINE KINASE; ADENYLATE-CYCLASE; RECEPTOR; RUTABAGA; CURRENTS; GENE; RAS1	MUCH work on the signal transduction mechanisms underlying neurotransmission has been directed towards studying the roles of the cyclic AMP and phosphoinositide pathways1-3. Upon ligand binding, the transmitter receptors interact with heterotrimeric G proteins, allowing G(alpha) and G(beta gamma) subunits to disengage(2,3). The free G(alpha) then modulates the activity of adenylyl cyclase and phospholipase C1-3. It has been suggested that the G(beta gamma), complex which is activated through muscarinic or neuropeptide receptors can stimulate mitogen-activated protein kinase (MAPK) via activation of the small guanine-nucleotide-binding protein Ras(4,5). Sequential activation of the intermediates in the Ras/Raf serine-threonine protein kinase/MAPK kinase/MAPK/transcription factor pathway has emerged as a central mechanism for controlling cell proliferation and differentiation in yeast, worms, fruitflies and mammals(6-11). Here we show, by analysis of Drosophila mutants, that synaptic current and modulation of K+ current, triggered by a pituitary adenylyl cyclase-activating polypeptide-like neuropeptide(12), are mediated by coactivation of the Ras/Raf and Rutabaga-adenylyl cyclase pathways. Thus the Ras/Raf pathway also appears to be essential for G-protein-coupled neurotransmission.			ZHONG, Y (corresponding author), COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724, USA.			Zhong, Yi/0000-0001-7810-9899; Zhong, Yi/0000-0002-7927-5976				ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EXTON JH, 1994, ANNU REV PHYSIOL, V56, P349; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; HAN PL, 1992, NEURON, V9, P619, DOI 10.1016/0896-6273(92)90026-A; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hille B., 1992, IONIC CHANNELS EXCIT; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEUMANSILBERBER, 1984, CELL, V0037; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; PERRIMON N, 1993, CELL, V74, P219, DOI 10.1016/0092-8674(93)90412-J; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STEWART BA, 1994, J COMP PHYSIOL A, V175, P179, DOI 10.1007/BF00215114; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; YATANI A, 1991, CELL, V61, P769; ZHAO ML, 1995, J NEUROSCI, V15, P1406; ZHONG Y, 1993, J NEUROGENET, V9, P15, DOI 10.3109/01677069309167273; ZHONG Y, 1995, NEURON, V14, P527, DOI 10.1016/0896-6273(95)90309-7; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	30	97	98	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					588	592		10.1038/375588a0	http://dx.doi.org/10.1038/375588a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791875				2022-12-28	WOS:A1995RD28700051
J	IGLEHART, JK				IGLEHART, JK			RAPID CHANGES FOR ACADEMIC MEDICAL-CENTERS .2.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CARE											ANDERS G, 1994, WALL STREET J   1221, P1; ANDERSON G, 1989, PROVIDING HOSPITAL S; BLUMENTHAL D, 1993, NEW ENGL J MED, V329, P1812, DOI 10.1056/NEJM199312093292413; COHEN JJ, 1994, EMERGING HLTH SERVIC; COHEN JJ, 1994, 105TH ANN M ASS AM M; ECKHOLM E, 1994, NY TIMES        1218, P34; FOX PD, 1993, HEALTH AFFAIR, V12, P85, DOI 10.1377/hlthaff.12.1.85; FREUDENHEIM M, 1995, NY TIMES        1117, P1; GOLD M, FINANCING ACADEMIC M, V1; GOLDSMITH JC, 1994, HEALTHCARE FORUM SEP, P26; HILZENRATH DS, 1994, WASH POST       0712, pA1; IGLEHART JK, 1993, NEW ENGL J MED, V329, P1052, DOI 10.1056/NEJM199309303291428; IGLEHART JK, 1994, NEW ENGL J MED, V331, P1391, DOI 10.1056/NEJM199411173312025; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1370, DOI 10.1056/NEJM199411173312010; ROGERS MC, 1994, NEW ENGL J MED, V331, P1374, DOI 10.1056/NEJM199411173312013; Schimpff S C, 1992, Md Med J, V41, P595; WINKENWERDER W, 1994, PRIMARY CARE SPECIAL	17	80	80	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 9	1995	332	6					407	411		10.1056/NEJM199502093320624	http://dx.doi.org/10.1056/NEJM199502093320624			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF300	7824014				2022-12-28	WOS:A1995QF30000028
J	AUGER, J; KUNSTMANN, JM; CZYGLIK, F; JOUANNET, P				AUGER, J; KUNSTMANN, JM; CZYGLIK, F; JOUANNET, P			DECLINE IN SEMEN QUALITY AMONG FERTILE MEN IN PARIS DURING THE PAST 20 YEARS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SPERM COUNTS; REPRODUCTIVE-TRACT; HUMAN TESTIS; DIETHYLSTILBESTROL	Background. Several studies have suggested a population-wide decline in the quality of semen over the past 50 years, but clear evidence of decreasing semen quality in recent decades is lacking. Methods. From 1973 through 1992 we measured the volume of seminal fluid, the sperm concentration, and the percentages of motile and morphologically normal spermatozoa in 1351 healthy fertile men. The data on the semen samples were collected at one sperm bank in Paris. The data in each calendar year were analyzed as a function of the year of donation, the age of each patient, the year of birth, and the duration of sexual abstinence before semen collection. Results. There was no change in semen volume during the study period, The mean concentration of sperm decreased by 2.1 percent per year, from 89x10(6) per milliliter in 1973 to 60x10(6) per milliliter in 1992 (P<0.001). During the same period the percentages of motile and normal spermatozoa decreased by 0.6 percent and 0.5 percent per year, respectively (both P<0.001). After adjustment in multiple regression analyses for age and the duration of sexual abstinence, each successive calendar year of birth accounted for 2.6 percent of the yearly decline in the sperm concentration and for 0.3 percent and 0.7 percent, respectively, of the yearly declines in the percentages of motile and normal spermatozoa (all P<0.001). Conclusions. During the past 20 years, there has been a decline in the concentration and motility of sperm and in the percentage of morphologically normal spermatozoa in fertile men that is independent of the age of the men.	UNIV PARIS SUD,CTR HOSP,CTR ETUD & CONSERVAT OEUFS & SPERME HUMAINS,F-94275 LE KREMLIN BICETR,FRANCE	UDICE-French Research Universities; Universite Paris Saclay			Auger, Jacques/AAA-1375-2019	Auger, Jacques/0000-0002-4521-3363				BENDVOLD E, 1989, INT J FERTIL, V34, P401; BOSTOFTE E, 1983, INT J FERTIL, V28, P91; BOYLE P, 1987, EUR J CANCER CLIN ON, V23, P827, DOI 10.1016/0277-5379(87)90286-0; BROMWICH P, 1994, BRIT MED J, V309, P19, DOI 10.1136/bmj.309.6946.19; CANLORBE P, 1966, ANN PEDIATR-PARIS, V42, P969; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; COLEMAN MP, 1993, IARC SCI PUBL, V121, P521; COOPER TG, 1992, FERTIL STERIL, V58, P172; David G., 1975, J GYN OBST BIOL R S1, V1, P17; DIXON WJ, 1988, BMDP STATISTICAL SOF; FARROW S, 1994, BRIT MED J, V309, P1; GINSBURG J, 1994, LANCET, V343, P230, DOI 10.1016/S0140-6736(94)91012-X; GIWERCMAN A, 1992, INT J ANDROL, V15, P373, DOI 10.1111/j.1365-2605.1992.tb01351.x; GIWERCMAN A, 1993, ENVIRON HEALTH PERSP, V101, P65, DOI 10.2307/3431378; IRVINE DS, 1994, BRIT MED J, V309, P476, DOI 10.1136/bmj.309.6952.476; JACKSON MB, 1988, HORM RES, V30, P153, DOI 10.1159/000181052; JAMES WH, 1980, ANDROLOGIA, V12, P381; JARDIN A, 1992, Journal of Urology, V147, p386A; JOHNSON L, 1986, J ANDROL, V7, P331; JOUANNET P, 1977, ANDROLOGIA, V9, P36; JOUANNET P, 1981, INT J ANDROL, V4, P440, DOI 10.1111/j.1365-2605.1981.tb00728.x; MIEUSSET R, 1989, J CLIN ENDOCR METAB, V68, P419, DOI 10.1210/jcem-68-2-419; MIEUSSET R, 1991, TEMPERATURE ENV EFFE, P233; SCHWARTZ D, 1983, FERTIL STERIL, V39, P530; SHARPE RM, 1993, J ENDOCRINOL, V136, P357, DOI 10.1677/joe.0.1360357; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SPIRA A, 1983, REV EPIDEMIOL SANTE, V31, P249; STILLMAN RJ, 1982, AM J OBSTET GYNECOL, V142, P905, DOI 10.1016/S0002-9378(16)32540-6; 1992, WHO LABORATORY MANUA	29	835	883	1	46	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 2	1995	332	5					281	285		10.1056/NEJM199502023320501	http://dx.doi.org/10.1056/NEJM199502023320501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD396	7816062				2022-12-28	WOS:A1995QD39600001
J	CHEN, C; NAGY, Z; RADIC, MZ; HARDY, RR; HUSZAR, D; CAMPER, SA; WEIGERT, M				CHEN, C; NAGY, Z; RADIC, MZ; HARDY, RR; HUSZAR, D; CAMPER, SA; WEIGERT, M			THE SITE AND STAGE OF ANTI-DNA B-CELL DELETION	NATURE			English	Article							REACTIVE LYMPHOCYTES-B; SOMATIC MUTATION; ESCAPE TOLERANCE; AUTOIMMUNE MICE; CLONAL DELETION; BONE-MARROW; MOUSE; ANTIBODIES; AUTOANTIBODIES; ELIMINATION	ANTIBODIES to DNA and nucleoproteins are found in sera of individuals with systemic autoimmune disease. In the population (and in the autoimmune mouse strain MRL/lpr) there is a great variety of such antinuclear antibodies, but individuals with systemic lupus erythematosus or single MRL mice express a subset only of the antinuclear specificities found in the population. These observations have been interpreted to mean that these antibodies arise by immunization(1) The oligoclonal nature of the autoantibody response and the evidence of selection acting on somatically mutated autoantibodies favour this interpretation(2,3). Specific activation of autoantibodies in disease implies either that autoantibodies are regulated in non-diseased individuals or that autoantigen availability is variable. The former has been demonstrated in anti-DNA transgenic mice. In normal mice, transgene-encoded antibodies against double-stranded (ds) DNA are not expressed in serum or on B cells(4-6). Here we describe modified anti-dsDNA transgenic mice which allow us to study the site and developmental stage at which such B-cell regulation occurs. This model shows that in normal mice B cells expressing anti-DNA specificity are deleted in the bone marrow at a pre-B to immature B transitional stage.	MED COLL PENN,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19129; FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111; GENPHARM INT INC,MT VIEW,CA 94043; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109	Drexel University; Fox Chase Cancer Center; University of Michigan System; University of Michigan	CHEN, C (corresponding author), PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.			Camper, Sally/0000-0001-8556-3379; Radic, Marko/0000-0002-8004-282X				ALLMAN DM, 1993, J IMMUNOL, V151, P4431; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; CHEN C, 1994, J IMMUNOL, V152, P1970; CHEN JZ, 1993, INT IMMUNOL, V5, P647, DOI 10.1093/intimm/5.6.647; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; EILAT D, 1988, J IMMUNOL, V141, P1745; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HARDIN JA, 1986, ARTHRITIS RHEUM, V29, P457, DOI 10.1002/art.1780290401; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; MARION TN, 1990, J IMMUNOL, V145, P2322; NEMAZEE D, 1991, IMMUNOL REV, V122, P117, DOI 10.1111/j.1600-065X.1991.tb00600.x; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; RADIC MZ, 1991, J IMMUNOL, V146, P176; RADIC MZ, 1993, J IMMUNOL, V150, P4966; RADIC MZ, 1993, J EXP MED, V177, P1165, DOI 10.1084/jem.177.4.1165; RADIC MZ, 1994, REV IMMUNOL, V12, P487; SHLOMCHIK M, 1990, J EXP MED, V171, P265, DOI 10.1084/jem.171.1.265; SHLOMCHIK MJ, 1987, NATURE, V328, P805, DOI 10.1038/328805a0; SHLOMCHIK MJ, 1987, P NATL ACAD SCI USA, V84, P9150, DOI 10.1073/pnas.84.24.9150; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009	24	261	264	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					252	255		10.1038/373252a0	http://dx.doi.org/10.1038/373252a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816141	Green Submitted			2022-12-28	WOS:A1995QC27800066
J	JONES, PH; HARPER, S; WATT, FM				JONES, PH; HARPER, S; WATT, FM			STEM-CELL PATTERNING AND FATE IN HUMAN EPIDERMIS	CELL			English	Article							INTEGRINS ALPHA-3-BETA-1; FIBRONECTIN RECEPTOR; MESSENGER-RNA; ADHESION; EXPRESSION; KERATINOCYTES; MIGRATION; CYTOSKELETAL; ANTIGEN; ROLES	Within human epidermis there are two types of proliferating keratinocyte: stem cells, which have high proliferative potential, and transit-amplifying cells, which are destined to undergo terminal differentiation after a few rounds of division. We show that, in vivo, stem cells express higher levels of the alpha(2) beta(1) and alpha(3) beta(1) integrins than transit-amplifying cells and that this can be used both to determine the location of stem cells within the epidermis and to isolate them directly from the tissue. The distribution of stem cells and transit-amplifying cells is not random: patches of integrin-bright and integrin-dull cells have a specific location with respect to the epidermal-dermal junction that varies between body sites and that correlates with the distribution of S phase cells. Stem cell patterning can be recreated in culture, in the absence of dermis, and appears to be subject to autoregulation.	IMPERIAL CANC RES FUND, KERATINOCYTE LAB, LONDON WC2A 3PX, ENGLAND; LEICESTER GEN HOSP, DEPT NEPHROL, LEICESTER LE5 4PW, LEICS, ENGLAND	Cancer Research UK; University Hospitals of Leicester NHS Trust; Leicester General Hospital			Jones, Philip/D-2464-2009; Watt, Fiona/AHB-0226-2022	Jones, Philip/0000-0002-5904-795X; Watt, Fiona/0000-0001-9151-5154	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS JC, 1991, J CELL BIOL, V115, P829, DOI 10.1083/jcb.115.3.829; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BARRANDON Y, 1988, J INVEST DERMATOL, V91, P315, DOI 10.1111/1523-1747.ep12475646; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; CHEN FA, 1991, J EXP MED, V173, P1111, DOI 10.1084/jem.173.5.1111; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; DESTROOPER B, 1988, CELL BIOL INT REP, V12, P9, DOI 10.1016/0309-1651(88)90106-3; GERMAIN L, 1993, BURNS, V19, P99, DOI 10.1016/0305-4179(93)90028-7; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HALL PA, 1989, DEVELOPMENT, V106, P619; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRIS ME, 1991, MOL CELL BIOL, V11, P2416, DOI 10.1128/MCB.11.5.2416; HERTLE MD, 1991, DEVELOPMENT, V112, P193; HODIVALA KJ, 1994, J CELL BIOL, V124, P589, DOI 10.1083/jcb.124.4.589; Holbrook K.A., 1991, PHYSL BIOCH MOL BIOL, P63; HOTCHIN NA, 1993, J CELL SCI, V106, P1131; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; LANE EB, 1991, ANN NY ACAD SCI, V642, P197; LAVKER RM, 1983, J INVEST DERMATOL, V81, pS121, DOI 10.1111/1523-1747.ep12540880; OFARRELL PH, 1994, NATURE, V368, P188, DOI 10.1038/368188a0; POTTEN CS, 1988, J CELL SCI, P45; POTTEN CS, 1974, CELL TISSUE KINET, V7, P77, DOI 10.1111/j.1365-2184.1974.tb00401.x; PRINGLE JH, 1990, J PATHOL, V162, P197, DOI 10.1002/path.1711620305; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; ROCHAT A, 1994, INT J DEV BIOL, V76, P1063; SYMINGTON BE, 1993, J CELL BIOL, V120, P523, DOI 10.1083/jcb.120.2.523; TENCHINI ML, 1993, CELL ADHES COMMUN, V1, P55, DOI 10.3109/15419069309095681; UCHIDA N, 1993, CURR OPIN IMMUNOL, V5, P177, DOI 10.1016/0952-7915(93)90002-A; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; WATT FM, 1993, J CELL SCI, V106, P175; WATT FM, 1984, J CELL BIOL, V98, P16, DOI 10.1083/jcb.98.1.16; YANG JS, 1993, J INVEST DERMATOL, V101, P652, DOI 10.1111/1523-1747.ep12371671; ZHONG R, 1983, NUCLEIC ACIDS RES, V11, P7409, DOI 10.1093/nar/11.21.7409	37	675	733	0	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 13	1995	80	1					83	93		10.1016/0092-8674(95)90453-0	http://dx.doi.org/10.1016/0092-8674(95)90453-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813021	Bronze			2022-12-28	WOS:A1995QB91000012
J	POMERANTZ, JL; SHARP, PA; PABO, CO				POMERANTZ, JL; SHARP, PA; PABO, CO			STRUCTURE-BASED DESIGN OF TRANSCRIPTION FACTORS	SCIENCE			English	Article							DNA-BINDING SPECIFICITY; POU-DOMAIN; PROTEIN; REPRESSOR; SEQUENCE	Computer modeling suggested that transcription factors with novel sequence specificities could be designed by combining known DNA binding domains. This structure-based strategy was tested by construction of a fusion protein, ZFHD1,that contained zinc fingers 1 and 2 from Zif268, a short polypeptide linker, and the homeodomain from Oct-1. The fusion protein bound optimally to a sequence containing adjacent homeodomain (TA-ATTA) and zinc finger (NGGGNG) subsites. When fused to an activation domain, ZFHD1 regulated promoter activity in vivo in a sequence-specific manner. Analysis of known protein-DNA complexes suggests that many other DNA binding proteins could be designed in a similar fashion.	MIT,HARVARD DIV HLTH SCI & TECHNOL,CAMBRIDGE,MA 02139; MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	POMERANTZ, JL (corresponding author), MIT,CTR CANC RES,DEPT BIOL,CAMBRIDGE,MA 02139, USA.			Pomerantz, Joel L./0000-0002-5030-1018	NATIONAL CANCER INSTITUTE [P01CA042063, P30CA014051] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA42063, P30-CA14051] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; PAVIETICH NP, 1991, SCIENCE, V252, P809; PELLETT PE, 1985, P NATL ACAD SCI USA, V82, P5870, DOI 10.1073/pnas.82.17.5870; POMERANTZ JL, 1994, BIOCHEMISTRY-US, V33, P10851, DOI 10.1021/bi00202a001; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; POMERANTZ JL, UNPUB; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SUCKOW M, 1994, NUCLEIC ACIDS RES, V22, P2198, DOI 10.1093/nar/22.12.2198; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x; WHARTON RP, 1985, NATURE, V316, P601, DOI 10.1038/316601a0; YOUDERIAN P, 1983, CELL, V35, P777, DOI 10.1016/0092-8674(83)90110-1	20	121	179	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 6	1995	267	5194					93	96		10.1126/science.7809612	http://dx.doi.org/10.1126/science.7809612			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA235	7809612				2022-12-28	WOS:A1995QA23500037
J	ANGELINI, GD; IZZAT, MB; BRYAN, AJ; WEST, RR				ANGELINI, GD; IZZAT, MB; BRYAN, AJ; WEST, RR			HOW SENSITIVE ARE CARDIAC-SURGEONS FINGERS	BRITISH MEDICAL JOURNAL			English	Article									UNIV WALES COLL MED, CTR PUBL HLTH STUDIES, CARDIFF CF4 4XN, S GLAM, WALES	Cardiff University	ANGELINI, GD (corresponding author), UNIV BRISTOL, DEPT CARDIAC SURG, BRISTOL BS2 8HW, AVON, ENGLAND.		Izzat, Mohammad Bashar/I-1987-2019	Izzat, Mohammad Bashar/0000-0001-6758-8716; angelini, gianni/0000-0002-1753-3730				BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; LOWE CR, 1962, LANCET, V1, P1086; PAUCA AL, 1989, ANESTHESIOLOGY, V70, P935, DOI 10.1097/00000542-198906000-00009; URZUA J, 1990, ANESTHESIOLOGY, V73, P191, DOI 10.1097/00000542-199007000-00035	4	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1685	1686		10.1136/bmj.309.6970.1685	http://dx.doi.org/10.1136/bmj.309.6970.1685			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819985	Green Published			2022-12-28	WOS:A1994PY71700009
J	CREED, F				CREED, F			IRRITABLE BOWEL OR IRRITABLE MIND - PSYCHOLOGICAL TREATMENT IS ESSENTIAL FOR SOME	BRITISH MEDICAL JOURNAL			English	Article							CONTROLLED TRIAL; HYPNOTHERAPY				CREED, F (corresponding author), MANCHESTER ROYAL INFIRM,DEPT PSYCHIAT,RAWNSLEY BLDG,MANCHESTER M13 9WL,LANCS,ENGLAND.							CHAUDHARY NA, 1962, Q J MED, V31, P307; CREED F, 1988, GUT, V29, P235, DOI 10.1136/gut.29.2.235; CREED F, 1992, MED SYMPTOMS EXPLAIN, P9; DROSSMAN DA, 1988, GASTROENTEROLOGY, V95, P701, DOI 10.1016/S0016-5085(88)80017-9; DROSSMAN DA, 1992, ANN INTERN MED, V116, P1009, DOI 10.7326/0003-4819-116-12-1009; GORARD SA, 1994, GUT, V35, P203; GUTHRIE E, 1987, BRIT MED J, V295, P577, DOI 10.1136/bmj.295.6598.577; GUTHRIE E, 1991, GASTROENTEROLOGY, V100, P450, DOI 10.1016/0016-5085(91)90215-7; Heaton KW, 1992, MED SYMPTOMS NOT EXP, P1; LATIMER P, 1981, GASTROENTEROLOGY, V80, P893; PRIOR A, 1990, GUT, V31, P896, DOI 10.1136/gut.31.8.896; RUMSEY N, 1991, CONFIDENT MANAGEMENT, P33; SVEDLUND J, 1983, ACTA PSYCHIAT SCAND, V67, P1, DOI 10.1111/j.1600-0447.1983.tb03707.x; WHITEHEAD WE, 1988, GASTROENTEROLOGY, V95, P709, DOI 10.1016/S0016-5085(88)80018-0; WHORWELL PJ, 1984, LANCET, V2, P1232, DOI 10.1016/S0140-6736(84)92793-4	15	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1647	1648		10.1136/bmj.309.6969.1647	http://dx.doi.org/10.1136/bmj.309.6969.1647			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PY220	7819953	Green Published			2022-12-28	WOS:A1994PY22000040
J	RIORDAN, JF; SIMPSON, J				RIORDAN, JF; SIMPSON, J			MANAGEMENT FOR DOCTORS - GETTING STARTED AS A MEDICAL MANAGER .2.	BRITISH MEDICAL JOURNAL			English	Article									BARNES HOSP,BRITISH ASSOC MED MANAGERS,CHEADLE SK8 2NY,CHESHIRE,ENGLAND		RIORDAN, JF (corresponding author), CENT MIDDLESEX NHS TRUST HOSP,LONDON NW10 7NS,ENGLAND.								0	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 10	1994	309	6968					1563	1565		10.1136/bmj.309.6968.1563	http://dx.doi.org/10.1136/bmj.309.6968.1563			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX564	7819901	Green Published			2022-12-28	WOS:A1994PX56400027
J	HUNDLEY, VA; CRUICKSHANK, FM; LANG, GD; GLAZENER, CMA; MILNE, JM; TURNER, M; BLYTH, D; MOLLISON, J; DONALDSON, C				HUNDLEY, VA; CRUICKSHANK, FM; LANG, GD; GLAZENER, CMA; MILNE, JM; TURNER, M; BLYTH, D; MOLLISON, J; DONALDSON, C			MIDWIFE MANAGED DELIVERY UNIT - A RANDOMIZED CONTROLLED COMPARISON WITH CONSULTANT LED CARE	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONER OBSTETRICS; LOW-RISK; CONTROLLED TRIAL; 2 SYSTEMS; WOMEN; LABOR; BIRTH	Objective-To examine whether intrapartum care and delivery of low risk women in a midwife managed delivery unit differs from that in a consultant led labour ward. Design-Pragmatic randomised controlled trial. Subjects were randomised in a 2:1 ratio between the midwives unit and the labour ward. Setting-Aberdeen Maternity Hospital, Grampian. Subjects-2844 low risk women, as defined by existing booking criteria for general practitioner units in Grampian. 1900 women were randomised to the midwives unit and 944 to the labour ward. Main outcome measures-Maternal and perinatal morbidity. Results-Of the women randomised to the midwives unit, 647 (34%) were transferred to the labour ward antepartum, 303 (16%) were transferred intrapartum, and 80 (4%) were lost to follow up. 870 women (46%) were delivered in the midwives unit. Primigravid women (255/596, 43%) were significantly more likely to be transferred intrapartum than multigravid women (48/577, 8%). Significant differences between the midwives unit and labour ward were found in monitoring, fetal distress, analgesia, mobility, and use of episiotomy. There were no significant differences in mode of delivery or fetal outcome. Conclusions-Midwife managed intrapartum care for low risk women results in more mobility and less intervention with no increase in neonatal morbidity. However, the high rate of transfer shows that antenatal criteria are unable to determine who will remain at low risk throughout pregnancy and labour.	ABERDEEN ROYAL HOSP NHS TRUST,ABERDEEN AB9 2ZA,SCOTLAND; UNIV ABERDEEN,HLTH SERV RES UNIT,ABERDEEN AB9 2ZD,SCOTLAND; UNIV ABERDEEN,DEPT PUBL HLTH,HLTH ECON RES UNIT,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen; University of Aberdeen	HUNDLEY, VA (corresponding author), UNIV ABERDEEN,ABERDEEN MATERN HOSP,DEPT OBSTET & GYNAECOL,ABERDEEN AB9 2ZA,SCOTLAND.			Hundley, Vanora/0000-0003-3578-4135; Donaldson, Cam/0000-0003-4670-5340				[Anonymous], 1990, SPSS REFERENCE GUIDE; Casagrande J. T., 1978, APPLIED STATISTICS, V27, P176; CHAPMAN MG, 1986, BRIT J OBSTET GYNAEC, V93, P182, DOI 10.1111/j.1471-0528.1986.tb07884.x; ENKIN MW, 1993, PREGNANCY CHILDBIRTH; FELDMAN E, 1987, BIRTH-ISS PERINAT C, V14, P18, DOI 10.1111/j.1523-536X.1987.tb01444.x; FLYNN AM, 1978, BRIT MED J, V2, P591, DOI 10.1136/bmj.2.6137.591; KLEIN M, 1983, BRIT J OBSTET GYNAEC, V90, P118, DOI 10.1111/j.1471-0528.1983.tb08894.x; KLEIN M, 1983, BRIT J OBSTET GYNAEC, V90, P123, DOI 10.1111/j.1471-0528.1983.tb08895.x; LEVENO KJ, 1986, NEW ENGL J MED, V315, P615, DOI 10.1056/NEJM198609043151004; LOWE SW, 1987, J R COLL GEN PRACT, V137, P484; MACDONALD D, 1985, AM J OBSTET GYNECOL, V152, P524, DOI 10.1016/0002-9378(85)90619-2; MACVICAR J, 1993, BRIT J OBSTET GYNAEC, V100, P316, DOI 10.1111/j.1471-0528.1993.tb12972.x; NEWELL DJ, 1992, INT J EPIDEMIOL, V21, P837, DOI 10.1093/ije/21.5.837; REID AJ, 1989, CAN MED ASSOC J, V140, P625; REYNOLDS JL, 1988, J ROY COLL GEN PRACT, V38, P307; TAYLOR GW, 1980, LANCET, V2, P1287; TEW M, 1985, J ROY COLL GEN PRACT, V35, P390; WALSH D, 1989, MIDWIVES CHRONIC AUG, P270; 1993, CHANGING CHILDBIRTH; 1992, HCP29 HOUS COMM HLTH; 1959, REPORT MATERNITY SER; [No title captured]; 1956, CMND9663; 1980, HC663 HOUS COMM SOC; 1993, PROVISION MATERNITY; 1970, DOMICILIARY MIDWIFER	26	114	115	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1994	309	6966					1400	1404		10.1136/bmj.309.6966.1400	http://dx.doi.org/10.1136/bmj.309.6966.1400			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7819846	Green Published			2022-12-28	WOS:A1994PU76400018
J	KOHLENBERGER, C; SPRUNG, CL; DANIS, M; ARMSTRONG, C; BAILY, MA; CHALFIN, DB; DAGI, TF; DAVILA, F; DEVITA, M; ENGELHARDT, HT; GRENVIK, A; HOFMANN, PB; HOYT, JW; JAMETON, A; KOFKE, WA; LYNN, J; MARSHALL, MF; MCCARTNEY, JJ; NELSON, RM; NINOS, N; RAPHAELY, RC; REARDON, F; RIE, MA; ROSENBAUM, SH; SILVERMAN, H; SOTTILE, FD; SPANIER, A; STEINBERG, A; TENDLER, MD; TERES, D; TRUOG, RD; WALLACE, TE; WLODY, G; YEH, TS				KOHLENBERGER, C; SPRUNG, CL; DANIS, M; ARMSTRONG, C; BAILY, MA; CHALFIN, DB; DAGI, TF; DAVILA, F; DEVITA, M; ENGELHARDT, HT; GRENVIK, A; HOFMANN, PB; HOYT, JW; JAMETON, A; KOFKE, WA; LYNN, J; MARSHALL, MF; MCCARTNEY, JJ; NELSON, RM; NINOS, N; RAPHAELY, RC; REARDON, F; RIE, MA; ROSENBAUM, SH; SILVERMAN, H; SOTTILE, FD; SPANIER, A; STEINBERG, A; TENDLER, MD; TERES, D; TRUOG, RD; WALLACE, TE; WLODY, G; YEH, TS			CONSENSUS STATEMENT ON THE TRIAGE OF CRITICALLY ILL PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE TECHNOLOGY; RESOURCE-ALLOCATION; RATIONING DECISIONS; INEVITABILITY; FUTILITY; UNITS	The demand for medical services such as critical care is likely to often exceed supply. In the setting of these constraining conditions, institutions and individual providers of critical care must use some moral framework for distributing the available resources efficiently and equitably. Guidelines are therefore provided for triage of criticalLy ill patients. There are several general principLes that should guide decision making: providers should advocate for patients; members of the provider team should collaborate; care must be restricted in an equitable system; decisions to give care should be based on expected benefit; mechanisms for alternative care should be planned; explicit policies should be written; prior public notification is necessary. Patients who are not expected to benefit from intensive care, such as those with imminently fatal illnesses or permanent unconsciousness, should not be placed in the intensive care unit. Hospitals should assign individuals the responsibility of intensive care triage, and a committee should oversee the performance of this responsibility to facilitate the most efficient and equitable use of intensive care.	SOC CRIT CARE MED, ETH COMM, 8101 E KAISER BLVD, ANAHEIM, CA 92808 USA; HEBREW UNIV JERUSALEM, HADASSAH MED SCH, IL-91010 JERUSALEM, ISRAEL; UNIV N CAROLINA, CHAPEL HILL, NC 27514 USA; UNIV TENNESSEE CTR HLTH SCI, MEMPHIS, TN 38163 USA; MASSACHUSETTS APPEALS COURT, BOSTON, MA USA; GEORGE WASHINGTON UNIV, WASHINGTON, DC 20052 USA; WINTHROP UNIV HOSP, MINEOLA, NY USA; GEORGETOWN UNIV, KENNEDY INST, WASHINGTON, DC 20057 USA; TEXAS A&M UNIV, COLL MED, TEMPLE, TX USA; UNIV PITTSBURGH, SCH MED, PITTSBURGH, PA 15261 USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA; UNIV KENTUCKY, COLL MED, LEXINGTON, KY 40506 USA; ST VINCENTS HOSP, WORCESTER, MA USA; SIR MORTIMER B DAVIS JEWISH HOSP, MONTREAL H3T 1E2, QUEBEC, CANADA; YESHIVA UNIV, NEW YORK, NY 10033 USA; BAYSTATE MED CTR, SPRINGFIELD, MA 01107 USA; CHILDRENS HOSP OAKLAND, OAKLAND, CA USA; STANFORD UNIV, CTR BIOMED ETH, STANFORD, CA 94305 USA; ST FRANCIS MED CTR, PITTSBURGH, PA USA; UNIV NEBRASKA, MED CTR, OMAHA, NE 68105 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, HANOVER, NH 03756 USA; MED UNIV S CAROLINA, CHARLESTON, SC 29425 USA; VILLANOVA UNIV, VILLANOVA, PA 19085 USA; MED COLL WISCONSIN, MILWAUKEE, WI 53226 USA; USA MED CORPS, PALM SPRINGS, CA USA; CHILDRENS HOSP PHILADELPHIA, PHILADELPHIA, PA USA; HASSAN AND REARDON, BOSTON, MA USA; UNIV CALIF LOS ANGELES, SCH COUNSELING, LOS ANGELES, CA 90024 USA; YALE UNIV, SCH MED, NEW HAVEN, CT 06510 USA; UNIV MARYLAND, SCH MED, BALTIMORE, MD 21201 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Hebrew University of Jerusalem; University of North Carolina; University of North Carolina Chapel Hill; University of Tennessee System; University of Tennessee Health Science Center; George Washington University; Winthrop University Hospital; Georgetown University; Texas A&M University System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Baylor College of Medicine; University of Kentucky; McGill University; Yeshiva University; Baystate Medical Center; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Stanford University; University of Nebraska System; University of Nebraska Medical Center; Dartmouth College; Medical University of South Carolina; Villanova University; Medical College of Wisconsin; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of California System; University of California Los Angeles; Yale University; University System of Maryland; University of Maryland Baltimore; Harvard University; Harvard Medical School			Embrett, Mark G./H-4466-2014	Embrett, Mark G./0000-0002-3969-0219				AARON HJ, 1984, PAINFUL PRESCRIPTION; [Anonymous], 1988, Crit Care Med, V16, P807; BAKER R, 1992, Kennedy Institute of Ethics Journal, V2, P103; BERENSON RA, 1984, OTAHCS28 US C OFF TE; Churchill L. R, 1987, RATIONING HLTH CARE; DANIS M, 1991, HASTINGS CENT REP, V21, P25, DOI 10.2307/3563343; ENGELHARDT HT, 1986, JAMA-J AM MED ASSOC, V255, P1159, DOI 10.1001/jama.255.9.1159; EVANS RW, 1983, JAMA-J AM MED ASSOC, V249, P2208, DOI 10.1001/jama.249.16.2208; EVANS RW, 1983, JAMA-J AM MED ASSOC, V249, P2047; FUCHS VR, 1984, NEW ENGL J MED, V311, P1572, DOI 10.1056/NEJM198412133112411; HIATT HH, 1987, AM HLTH BALANCE CHOI; KALB PE, 1989, JAMA-J AM MED ASSOC, V261, P2389, DOI 10.1001/jama.261.16.2389; LANTOS JD, 1989, AM J MED, V87, P81; Olick R S, 1991, Kennedy Inst Ethics J, V1, P275; REAGAN MD, 1984, NEW ENGL J MED, V311, P1572; RUND DA, 1981, TRIAGE; SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2335, DOI 10.1001/jama.263.17.2335; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; STRAUSS MJ, 1986, JAMA-J AM MED ASSOC, V6, P255; TERES D, 1993, CRIT CARE MED, V21, P598, DOI 10.1097/00003246-199304000-00022; THUROW LC, 1984, NEW ENGL J MED, V311, P1569, DOI 10.1056/NEJM198412133112410; TRUOG RD, 1992, NEW ENGL J MED, V326, P1560, DOI 10.1056/NEJM199206043262310; Winslow GR, 1982, TRIAGE JUSTICE; 1983, JAMA-J AM MED ASSOC, V250, P798; 1983, DECIDING FOREGO LIFE, P3	25	181	187	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 20	1994	271	15					1200	1203						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF207	7818629				2022-12-28	WOS:A1994NF20700030
J	HOWELL, A; ROBERTSON, J				HOWELL, A; ROBERTSON, J			RESPONSE TO A SPECIFIC ANTIESTROGEN (ICI-182780) IN TAMOXIFEN-RESISTANT BREAST-CANCER	LANCET			English	Letter									CITY HOSP, DEPT SURG, NOTTINGHAM, ENGLAND	University of Nottingham	HOWELL, A (corresponding author), UNIV MANCHESTER, CHRISTIE HOSP NHS TRUST, CRC, DEPT MED ONCOL, MANCHESTER M20 4BX, LANCS, ENGLAND.			Howell, Anthony/0000-0002-6233-719X				DOWSETT, 1995, LANCET          0225, P525; HOWELL A, 1988, EUR J CANCER CLIN ON, V24, P1567, DOI 10.1016/0277-5379(88)90046-6; HOWELL A, 1995, LANCET, V345, P29, DOI 10.1016/S0140-6736(95)91156-1; HOWELL A, 1993, REV ENDOCR REL CANCE, V43, P1	4	291	305	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 15	1995	345	8955					989	990		10.1016/S0140-6736(95)91156-1	http://dx.doi.org/10.1016/S0140-6736(95)91156-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7799704				2022-12-28	WOS:A1995QT91900051
J	HOWELL, A; DEFRIEND, D; ROBERTSON, J; BLAMEY, R; WALTON, P				HOWELL, A; DEFRIEND, D; ROBERTSON, J; BLAMEY, R; WALTON, P			RESPONSE TO A SPECIFIC ANTIESTROGEN (ICI-182780) IN TAMOXIFEN-RESISTANT BREAST-CANCER	LANCET			English	Note							PURE ANTIESTROGEN; ESTROGEN-RECEPTOR; BINDING	We treated 19 patients with advanced breast cancer resistant to tamoxifen with a new specific antioestrogen (ICI 182780) which, in animal studies, has no agonist activity. 13 (69%) patients responded (7 had partial responses and 6 showed no change) to monthly intramuscular injections of ICI 182780 after progression on tamoxifen, for a median duration of 18 months with minimum side effects. Preliminary evidence suggests that the agent is without effects on the liver or the hypothalamic-pituitary axis. ICI 182780 appears to be a promising new agent for treatment of advanced and early breast cancer.	UNIV S MANCHESTER HOSP,DEPT SURG,MANCHESTER M20 8LR,LANCS,ENGLAND; CITY HOSP,DEPT SURG,NOTTINGHAM NG5 1PB,ENGLAND; ZENECA PHARMACEUT,MACCLESFIELD,CHESHIRE,ENGLAND	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of Nottingham	HOWELL, A (corresponding author), UNIV MANCHESTER,CHRISTIE HOSP,CRC,DEPT MED ONCOL,MANCHESTER M20 9BX,LANCS,ENGLAND.			Howell, Anthony/0000-0002-6233-719X				BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; DEFRIEND DJ, 1994, BRIT J CANCER, V70, P204, DOI 10.1038/bjc.1994.281; FAWELL SE, 1990, P NATL ACAD SCI USA, V87, P6883, DOI 10.1073/pnas.87.17.6883; HOWELL A, 1988, EUR J CANCER CLIN ON, V24, P1567, DOI 10.1016/0277-5379(88)90046-6; HOWELL A, 1992, ANN ONCOL, V3, P611, DOI 10.1093/oxfordjournals.annonc.a058286; OSBORNE CK, 1991, J NATL CANCER I, V83, P1477, DOI 10.1093/jnci/83.20.1477; PAVLIK EJ, 1992, CANCER RES, V52, P4106; THOMAS EJ, 1994, IN PRESS HUM REPROD, V9; VOGEL CL, 1993, J CLIN ONCOL, V11, P345, DOI 10.1200/JCO.1993.11.2.345; WAKELING AE, 1991, CANCER RES, V51, P3867	10	291	305	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					29	30		10.1016/S0140-6736(95)91156-1	http://dx.doi.org/10.1016/S0140-6736(95)91156-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799704				2022-12-28	WOS:A1995QA29000014
